# Lumenis > Lumenis ### Pages #### About WHO WE ARE BeautyTech for Life SEE MANAGEMENT TEAM Lumenis is a global leader in developing and commercializing energy-based solutions for the Aesthetic and Vision markets. We have a rich history of defying technological boundaries, redefining standards, and transforming people’s lives – both inside and out. BeautyTech for Life Strong brand The Lumenis name and brand are associated with high quality among healthcare professionals. Innovative technology Over 330 registered patents and numerous FDA clearances. Partnership with key opinion leaders (KOL’s) Strong KOL support and commitment to research and development. Global reach Active installed base of more than 80,000 systems and presence in over 100 countries. ABOUT US Lumenis gives people new reasons to feel good about themselves, empowers them to live life to the fullest, and promotes genuine well-being by broadening the horizons of health. Lumenis is a portfolio company of Baring Private Equity Asia. Headquartered in Israel and with offices on four continents, Lumenis is a truly international organization with a solid global footprint in developed and emerging markets around the world and sales in over 100 countries. The unique set of values and key behaviors below drive us as a company and aspire to connect our team of nearly 1,500 professionals worldwide. What We Do: At Lumenis, we empower people and innovate relentlessly Why We Do It: Our purpose is to make a meaningful impact How We Do It: We take ownership, we evolve and stay ahead, and we aim high Close OUR PRODUCTS Learn more about our innovative Aesthetics and Vision solutions FoLix triLift Stellar M22™ OptiLIGHT OptiPLUS SPLENDOR X Digital Duet UltraPulse Alpha Legend Pro™ LightSheer® QUATTRO NuEra™ Tight FoLix triLift Stellar M22™ OptiLIGHT OptiLIFT OptiPLUS SPLENDOR X Digital Duet UltraPulse Alpha Legend Pro™ LightSheer® QUATTRO NuEra™ Tight AESTHETICS HAIR REMOVAL Hair removal, permanent hair reduction, PFB. BODY Cellulite Reduction & Skin Smoothing SKIN TREATMENTS resurfacing (e.g. wrinkles), burns and scars, leg veins, pigmented & vascular lesions and tattoo removal TATTOO REMOVAL Unwanted pigmentation, Skin irregularities, Sun Damage, Tattoo removal. WOMEN’S HEALTH Vaginal abscess, Genital warts, Labial reduction, Lichen sclerosis VISION DRY EYE GLAUCOMA RETINA #### Accessibility Statement  Accessibility Statement #### Austria WEEE Information for Lumenis Customers and Recyclers Collection and Recycling Arrangements in Austria Lumenis products are sold in Austria by distributors. The distributors act as the importer of the equipment into Austria. Thus the distributors have the legal responsibility to: Register as the WEEE producer in Austria. Provide arrangements for collection and recycling of WEEE arising from Lumenis products that the distributor sells in Austria. Please contact the distributor in Austria below to understand what arrangements he has made for collection and recycling of WEEE arising from Lumenis products: Werner Duschek Products:Ophthalmic, Aesthetic Street Address: Laxenburger Strasse 218, A – 1230 Wien Country: AUSTRIA Phone: 43 (1) 888 31 12 Fax: 43 (1) 888 31 1240 Main Contact: Werner Duschek Regional Manager: Reiner Schmidt #### Baring Private Equity Asia Agrees to Acquire Lumenis Baring Private Equity Asia Agrees to Acquire Lumenis November 18, 2019 – Hong Kong Baring Private Equity Asia today announced that its affiliated private equity funds (“BPEA”) have agreed to acquire Lumenis, a leading provider of specialty energy-based medical devices across the fields of aesthetics, urology, ophthalmology, ENT and gynecology from XIO. The transaction values Lumenis at an enterprise value of over $1 billion. Lumenis is a global leader in the field of minimally-invasive clinical solutions for the Aesthetic, Surgical, and Ophthalmology specialties. For over 50 years, Lumenis’ ground-breaking products have redefined medical treatments and have set numerous gold-standards. The company has a presence in over 100 countries and close to 1,500 employees worldwide. The Asia Pacific region is its largest market, together with a strong presence in North America and EMEA. “BPEA’s investment is a tremendous vote of confidence in Lumenis and in the achievements of our entire global organization. In recent years, we have developed and introduced multiple groundbreaking technological solutions that have redefined our industry and opened entirely new market segments. I would like to thank the entire Lumenis team, I am truly proud of all we have accomplished and honored to lead a company on the cutting edge of healthcare innovation, committed to improving the lives of people across the world. We look forward to partnering with the team at BPEA to continue developing and delivering to the world better technology for better patient care”, said Tzipi Ozer-Armon, CEO of Lumenis. Yan Jiao, Managing Director at BPEA commented: “Lumenis has built a market-leading position by creating some of the most innovative technologies in the industry. It is a clear leader worldwide, especially in Asia which recently emerged as the largest market for medical and aesthetics treatments.  We look forward to working with the CEO and management team to support their global growth aspirations.” The transaction remains subject to the customary regulatory approval process and is expected to be completed in early 2020. #### Baring Private Equity Asia Announces Agreement to Sell Lumenis’ Surgical Business to Boston Scientific for $1.07 bln Baring Private Equity Asia Announces Agreement to Sell Lumenis’ Surgical Business to Boston Scientific for $1.07 bln Innovative Surgical portfolio and business to join BSC in milestone transaction Baring Private Equity Asia retains ownership of fast-growing Aesthetics and Vision businesses, to reinvest part of deal proceeds to accelerate growth #### Belgium WEEE Information for Lumenis Customers and Recyclers Collection and Recycling Arrangements in Belgium Lumenis products are sold in Belgium by distributors. The distributors act as the importer of the equipment into Belgium. Thus the distributors have the legal responsibility to: Register as the WEEE producer in Belgium. Provide arrangements for collection and recycling of WEEE arising from Lumenis products that the distributor sells in Belgium. Please contact the distributor in Belgium below to understand what arrangements he has made for the collection and recycling of WEEE arising from Lumenis products: De Ceunynck Medical Products:Ophthalmic, Aesthetic Street Address: Kontichsesteenweg 36, B-2630 Aartselaar Country: BELGIUM Phone: 32 3 870 37 63 Fax: 32 3 877 27 06 Main Contact: Jean Pierre Kinet Contact 2: Ralph van den Eynden Regional Manager: Remco Schmitz #### Bulgaria WEEE Information for Lumenis Customers and Recyclers Collection and Recycling Arrangements in Bulgaria Lumenis products are sold in Bulgaria by distributors. The distributors act as the importer of the equipment into Bulgaria. Thus the distributors have the legal responsibility to: Register as the WEEE producer in Bulgaria. Provide arrangements for collection and recycling of WEEE arising from Lumenis products that the distributor sells in Bulgaria. Please contact the distributor in Bulgaria below to understand what arrangements he has made for collection and recycling of WEEE arising from Lumenis products: Kindy Products:Ophthalmic, Aesthetic Street Address: Kishinev St. 16A/2, 1407 Sofia Country: BULGARIA Phone: 359 (0)2 862-44-65 / 359 (0)2 862-31-00 Fax: 359 (0)2 862-46-86 Main Contact: Nikolai Djunakov #### Careers WELCOME TO LUMENIS CAREER PAGE WHAT WE DO Lumenis develops life-changing, minimally invasive solutions for the Aesthetic and Vision markets. We create and commercialize innovative energy-based technologies that enable a variety of skin, body, and eye care treatments. Headquartered in Israel and with offices on four continents, Lumenis is an international organization with sales in over 100 countries and a team of nearly 1,500 professionals worldwide. Working at Lumenis is a unique experience, shaped by a set of values and key behaviors that drive us as a company. WE INVITE YOU TO APPLY TO JOIN US! OPEN POSITIONS WE EMPOWER PEOPLE We are passionate about our people. We are a diverse, talented group who care about their work and strive to make a difference.
We are committed to creating a work environment that fosters learning and improvement.
When we grow, we grow together. LOVE WHAT
YOU DO. PURPOSE-DRIVEN WORK. COLLABORATIVE SUCCESS. PERSONAL & GLOBAL IMPACT. UNIQUELY LUMENIS WHEN LEGACY MEETS INNOVATION: LET’S BUILD THE FUTURE FACE OF BEAUTY TOGETHER! JOIN. GROW. SHINE. WHERE SOLID FOUNDATION UNLEASHES BOLD INNOVATION. Open Positions EXPLORE OUR LATEST JOB OPENINGS Business Development Business Development Manager EMEA · Full-time · Senior Business Development Manager United Kingdom · Full-time · Senior Business Development Manager Italy · Full-time · Senior Business Development Manager Germany · Full-time · Senior Clinical Clinical Manager Lumenis HQ - Yokneam · Full-time · Senior Clinical Trainer – UK & Europe United Kingdom · Full-time · Intermediate EMEA Regional Sales Manager EU EMEA · Full-time Engineering Project Engineer Lumenis HQ - Yokneam · Full-time Technical Project Engineer Lumenis HQ - Yokneam · Full-time Finance Assistant Controller- EMEA Lumenis HQ - Yokneam · Full-time · Intermediate Procurement Operations Sub-Contractor Manager Lumenis HQ - Yokneam · Full-time Research & Development NPI Engineer Lumenis HQ - Yokneam · Full-time · Senior Service Office Manager Germany · Full-time · Intermediate By submitting my CV for a position in Lumenis, I agree for my personal data to be processed by Lumenis to determine my suitability for the position, and for future communication, internal record-keeping and other purposes outlined in the Job Applicant Privacy Notice available HERE. PB-00094670 #### Contact CONTACT US Physicians & Providers WE’RE HERE TO HELP Enter your details and we’ll be in touch shortly. SHAPE THE FUTURE CAREER PAGE FIND A PRACTICE NEAR YOU PATIENTS SECTION HAVING PRODUCT ISSUES? SERVICE REQUEST Lumenis is committed to providing quality customer service PRODUCT SERVICE REQUEST If you have an urgent request, you can find your local service center telephone number in Lumenis service locations. LUMENIS SUBSIDIARIES Headquarters Lumenis Be Ltd. Yokneam Industrial Park Hakidma 9 P.O.B. # 426 Yokneam 2069236 Israel Tel: +972-77-9599000  Fax: +972-77-9599001 Americas Lumenis Be, Inc. - USA 1735 Technology Dr, Suite 850 San Jose, CA 95110 Tel: 877-Lumenis (877-586-3647) Fax: 408-764-3999 E-Mail: USService@lumenis.com Lumenis Be Canada, Ltd Tel: 877-Lumenis (877-586-3647) Fax: 408-764-3999 E-Mail: CanadaService@lumenis.com Europe Lumenis Be (UK) Limited 15 The Valley Centre Gordon Road High Wycombe, HP13 6EQ United Kingdom Contact Lumenis Aesthetics: Email: customercareuk@lumenis.com Tel: +44 20 4536 5418 Fax: +44(0)- 2087364119 Contact Lumenis Vision: Email: emea.vision@lumenis.com Lumenis (Germany) GmbH Hanauer Landstraße 291A D-60314 Frankfurt am Main Germany Tel: +49 (0)6103-8335-0 Fax: +49 (0)6103-8335-300 Lumenis Be (Italy) S.r.l Via Delle Macere 20 00060 - Formello Italy Tel: +39 06 90 75 230 Fax: +39 06 90 75 269 Lumenis Be (France) SAS Espace Nouvel’R - SPACES 143 Bd René Cassin Bâtiment B, 06200 Nice Email: lumenis.france@lumenis.com Tel: +33 (4) 89 39 83 42 Tel: +33 (4) 89 39 83 41 China Lumenis Be Laser Technology Co., Ltd Beijing Office 6th Floor, South Tower, CP Center No.20 Jinhe East Road, Chaoyang District Beijing 100020 China Tel: +86 010-57376677 Fax: +86 010-57376767 Shanghai Office Room 904-906, Central Plaza, No. 227 North Huangpi Road, Shanghai, 200003,China Tel: +86 021-63759335 Fax: +86 021-63759334 Guangzhou Office Room 2701,GIE Tower, 403 Huanshi Dong Road,Guangzhou, 510095 China Tel: +86 020-37589791/37589153 Fax: +86 020-37589152 Chengdu Office No.6 Renmindong road, SAC Tower,room 1003, Jinjiang district,Chengdu Sichuan 610016, China Tel: +86 028-86767712/86767721 Fax: +86 028-86767207 Xi’an Office Room 1304, E Block, Chang’an Metropolis Center, 88 Nanguan zheng Street, Xi’an. 710001 China Tel: +86 029-87206121 Fax: +86 029-87206159 Wuhan Office Room1307, Oceanwide city squeare office building, No.198 Yuncai Road, Jianghan District, Wuhan City, HuBei Province, China Tel：+86 027-85781586、85757712 Fax：+86 027-85748889 Shen Yang Office Room 2103, Tower C, President Building No. 69 Heping North Ave. Heping Dist. Shenyang P.R. China Tel:+86 024-22815105 Fax:+86 024-22815995 Japan Lumenis Be Japan Co., Ltd Tokyo office Roppongi Hills Mori Tower 17th floor 6-10-1 Roppongi, Minato-ku, Tokyo, Japan Zip: 106-6117 Tel: +81-3-4535-1466 Fax: +81-3-4535-1465 Osaka Office Hiranomachi Chuo Bldg 6th floor 3-2-13 Hiranomachi, Osaka-shi Chuo-ku, Osaka, Japan Zip: 541-0046 Tel: +81-6-6231-1210 Fax: +81-6-6231-1220 Nagoya Office R Bldg 303 4-7 Kawanami-cho, Nagoya-shi Atsuta-ku, Aichi, Japan Zip: 456-0072 Tel: +81-52-681-0605 Fukuoka Office Office Parea Nakahata III-1 1-35-19 Nakahata, Ohnojo-shi, Fukuoka, Japan Zip: 816-0921 Tel: +81-92-593-2286 Operation Center MGL Katsushima Warehouse No. 18, 6F 1-5-21, Katsushima, Shinagawa-Ku Zip: 140-0012 Tel: +81-3-4535-1467 Fax: +81-3-4535-1468 Asia-Pacific Lumenis Be ANZ Pty Ltd. Level 8 | Tower A, The Zenith 821 Pacific Highway Chatswood NSW 2067 AUS: 1800 586 364 | NZ: 0800 239 015 Lumenis Be (India) Private Limited Unit 505-507, 5th Floor, Suncity Business Tower, Sector-54, Golf Course Road, Gurgaon-122002 Haryana , India Tel: 0124-4854900 Lumenis Be (HK) Limited 16/F, The Cameron, 33 Cameron Road, Tsimshatsui, Kowloon, Hong Kong Tel: +852 2174-2800 Fax: +852 2722-5151 Lumenis Be (HK) Limited, Taiwan Branch 7F-3, No 1, SongGao Rd, Xinyi District, Taipei city 110, Taiwan (R.O.C.) Tel: 886 2 7758 8079 Fax: 886 2 7758 8159 Lumenis Be (Korea) Ltd. 34 floor, IFC Seoul Tower 3 10 Gukjegeumyung-ro, Yeongdeungpo-gu, Seoul 07326 South Korea Office : +82 2 6137 9220 Fax : +82 2 6137 9231 FIND A DISTRIBUTOR[put_wpgm id=”2″] #### Cyprus WEEE Information for Lumenis Customers and Recyclers Collection and Recycling Arrangements in Cyprus Lumenis products are sold in Cyprus by distributors. The distributors act as the importer of the equipment into Cyprus. Thus the distributors have the legal responsibility to: Register as the WEEE producer in Cyprus. Provide arrangements for collection and recycling of WEEE arising from Lumenis products that the distributor sells in Cyprus. Please contact the distributor in Cyprus below to understand what arrangements he has made for collection and recycling of WEEE arising from Lumenis products: Scientronics Street Address: 7 Megalou Alexandrou Ave.2233 Latsia, Nicosia Country: Cyprus Phone: +357 95505203 (Mob.) / +357 22467880 (Tel) Fax: +357 22764614 Website: www.scientronics.com #### Czech Republic WEEE Information for Lumenis Customers and Recyclers Collection and Recycling Arrangements in the Czech Republic Lumenis products are sold in the Czech Republic by distributors. The distributors act as the importer of the equipment into the Czech Republic. Thus the distributors have the legal responsibility to: Register as the WEEE producer in the Czech Republic. Provide arrangements for collection and recycling of WEEE arising from Lumenis products that the distributor sells in the Czech Republic. Please contact the distributor in the Czech Republic below to understand what arrangements he has made for collection and recycling of WEEE arising from Lumenis products: Beneficium Euro Ltd. Products:Ophthalmic, Aesthetic Street Address: VANCUROVA STREET 1548, CZ-27201 KLADNO Country: CZECH REPUBLIC Phone: 420 602 643241 Fax: 420 312 269041 Main Contact: Tomas Hadrbolec Regional Manager: Gus Griffin #### Denmark WEEE Information for Lumenis Customers and Recyclers Collection and Recycling Arrangements in Denmark Lumenis does not have a sales office or approved distributor based in Denmark. Instead, Lumenis products are sold directly to business end-users in Denmark from distributors in other Member States. Selling products directly to an end-user in another Member State is known as ‘distance selling’. The WEEE Directive and Danish WEEE Regulations state that neither Lumenis nor its distributor is responsible for WEEE arising from distance sales of business products directly to the business end-user in other Member States. Instead, it is the business end-user’s responsibility to ensure that products which they buy through distance selling arrangements are managed in an environmentally responsible manner at end of life. #### Estonia WEEE Information for Lumenis Customers and Recyclers Collection and Recycling Arrangements in Estonia Lumenis does not have a sales office or approved distributor based in Estonia. Instead, Lumenis products are sold directly to business end-users in Estonia from distributors in other Member States. Selling products directly to an end-user in another Member State is known as ‘distance selling’. The WEEE Directive and Estonian WEEE Regulations state that neither Lumenis nor its distributor is responsible for WEEE arising from distance sales of business products directly to the business end-user in other Member States. Instead, it is the business end-user’s responsibility to ensure that products which they buy through distance selling arrangements are managed in an environmentally responsible manner at end of life. #### Finland WEEE Information for Lumenis Customers and Recyclers Collection and Recycling Arrangements in Finland Lumenis products are sold in Finland by distributors. The distributors act as the importer of the equipment into Finland. Thus the distributors have the legal responsibility to: Register as the WEEE producer in Finland. Provide arrangements for collection and recycling of WEEE arising from Lumenis products that the distributor sells in Finland. Please contact the distributor in Finland below to understand what arrangements he has made for collection and recycling of WEEE arising from Lumenis products: Finlaser Oy Products:Ophthalmic, Aesthetic Street Address: Mkituvantie 9, 01510 Vantaa Country: Finland Phone: 358 10 425 1700 Fax: 358 10 425 1710 Main Contact: Juha Vuojolainen Regional Manager: Remco Schmitz (UNITED KINGDOM) #### France WEEE Information for Lumenis Customers and Recyclers Collection and Recycling Arrangements in France Lumenis products are sold in France by distributors. The distributors act as the importer of the equipment into France. Thus the distributors have the legal responsibility to: Register as the WEEE producer in France. Provide arrangements for collection and recycling of WEEE arising from Lumenis products that the distributor sells in France. Please contact the distributor in France below to understand what arrangements he has made for collection and recycling of WEEE arising from Lumenis products: EBCmedica Products:Ophthalmic Street Address: 8 Rue Joly de Bammeville, Parc de la Fontaine de Jouvence 92460, MARCOUSSIS FRANCE Country: FRANCE Phone: 33 160 196614 Fax: 33 160 196629 Website: http://www.ebcmedical.com Main Contact: Geoffrey Petit Contact 2: Guillaume Chauvin Regional Manager: Nicola Fuccia Mediform Products:Aesthetic Street Address: 77 rue Marcel Dassault, 92100 Boulogne Billancourt Country: FRANCE Phone: 33 (0) 1 46 94 80 39 Fax: 33 (0) 1 46 20 56 47 Website: http://www.mediform.com Main Contact: Information@mediform.fr Regional Manager:Shlomo Alkalay #### Germany WEEE Information for Lumenis Customers and Recyclers Collection and Recycling Arrangements in Germany Under the Germany Act Governing the Sale, Return and Environmentally Sound Disposal of Electrical and Electronic Equipment (ElektroG) which came into force on August 13th 2005, the financing of collection and recycling of any waste electrical and electronic equipment (WEEE) arising from equipment bought before March 24th 2006 is the customer’s responsibility. This is regardless of whether the old equipment is being replaced by a new item of equipment purchased from Lumenis. Waste arising from equipment purchased before March 24th 2006 is referred to as Historic WEEE. Under the ElektroG Act, Lumenis are required to provide arrangements for the collection, treatment, recycling and recovery of any new electrical and electronic equipment that you buy from them after March 24th 2006, when that new equipment eventually becomes waste. This is referred to as New WEEE. Lumenis products are very competitively priced. Any new increase in operating costs for manufacturers such as Lumenis is normally reflected in a price increase in the product. However, instead of increasing the prices of our products, Lumenis has decided to share these new environmental costs directly with our customers. We believe in being transparent with you on any new environmental costs that our products need to address. Our approach to sharing these new environmental costs is: Lumenis pays for the costs of treatment, recycling and recovery of the WEEE to meet the targets set by ElektroG. Lumenis pays for the costs of data management and reporting to the Federal Environmental Agency (UBA) to demonstrate compliance with all administrative requirements of ElektroG. you pay for transportation of your WEEE to Lumenis’s appointed recycler in Germany. Lumenis has established a recycling contract with the European Advanced Recycling Network (EARN) and will cover any costs of treatment, recycling and recovery of the equipment on arrival at the EARN recycling facility in Germany. All New WEEE that arises from the purchase of Lumenis products is classed as non-hazardous waste. It is your responsibility to arrange and pay for costs of collection and transportation to the recycler. Under German waste management regulations, you are free to use any carrier you wish to collect and transport non-hazardous WEEE to the EARN recycler. For larger quantities of waste, you may want to contact the recycler directly to arrange and pay for alternative collection methods. The EARN recycling facility in Germany is: Recycler Electrocycling Telephone Number: +49 (0)5321 336724 Website: http://www.electrocycling.de/kontakt In order to enable EARN to identify Lumenis equipment upon arrival at the recycler’s address, please download the Recycling Label for German Customers. Complete the label with your company details and attach it to a suitable box for transport to EARN. Recycling Label for German Customers WEEE Reporting Recycling Data for Lumenis Equipment in Germany Under Part 2, Section 13 of ElektroG, Lumenis must provide annual information on the quantities and categories of electrical and electronic equipment put on the market, reused, recycled and recovered within Germany. The first WEEE recycling report will cover the period March 2009 to February 2010. #### Get Updates Keep Me Updated #### Greece WEEE Information for Lumenis Customers and Recyclers Collection and Recycling Arrangements in Greece Lumenis products are sold in Greece by distributors. The distributors act as the importer of the equipment into Greece. Thus the distributors have the legal responsibility to: Register as the WEEE producer in Greece. Provide arrangements for collection and recycling of WEEE arising from Lumenis products that the distributor sells in Greece. Please contact the distributor in Greece below to understand what arrangements he has made for collection and recycling of WEEE arising from Lumenis products: Amtec Hellas s.a. Products:Aesthetic Street Address: 160 Spaton Ave Pallini, Athens 1015351 Country: Greece Phone: 30 211 6000 400 Fax: 30 211 6000 581 Main Contact: Takis Kaliniotis, PM Contact 2: Serge Mordoh, MD Pharmex SA Products:Ophthalmic Street Address: 156 Avlonos str., 104 43 Athens Country: Greece Phone: 30 210 5199 200 Fax: 30 210 5144 279 Website: http://www.pharmex.gr Contact 2: Christos Koborozos Regional Manager: Nicola Fuccia (393454735831) #### Homepage Watch Full Video AESTHETIC TREATMENTS triLift SKIN HAIRREMOVAL BODY HAIRLOSS VISION TREATMENTS DRY EYE GLAUCOMA RETINA WHY LUMENIS Over 60 years of industry leadership and innovation Lumenis develops life-changing, minimally invasive solutions for the Aesthetic and Vision markets. We create and commercialize innovative energy-based technologies that enable a variety of skin, body, and eye care treatments. Lumenis has successfully introduced solutions for previously untreatable conditions and designed advanced technologies that have revolutionized existing treatment methods. We are BeautyTech pioneers, empowering people by broadening the horizons of health and celebrating beauty that matters. 88+ COUNTRIES WORLDWIDE 90k+ DEVICES Installed Worldwide 60+ YEARS of industry leadership & innovation 500+ CLINICAL PUBLICATIONS 88+ COUNTRIES WORLDWIDE 90k+ DEVICES Installed Worldwide 500+ CLINICAL PUBLICATIONS 50+ YEARS of industry leadership & innovation OUR PRODUCTS FoLix triLift Stellar M22™ OptiLIGHT OptiLIFT OptiPLUS SPLENDOR X Digital Duet UltraPulse Alpha Legend Pro™ LightSheer® QUATTRO NuEra™ Tight NuEra™ Tight YOUR SUCCESS IS OUR MISSION Every decision and device at Lumenis centres on you and your ability to change people’s lives. Day in and day out, we’re committed to #CelebratingYou and the difference you make. INDUSTRY BEST We are pioneers and leaders within the aesthetics and vision industries, bringing the most expansive expertise in energy-based treatments to the field. As a Lumenis partner, you are equipped with the confidence that you are providing the very best that technology has to offer. PIONEERING INNOVATION For over 60 years, Lumenis has revolutionized the Aesthetic and Vision domains by developing innovative energy-based solutions, including Laser, Intense Pulsed Light (IPL) and Radio Frequency (RF). We are passionate innovators, empowering our customers and patients worldwide. Resources Visit our Aesthetic and Vision resource hubs for expert on-demand education brought to you by our global leaders FoLixHair LossNewsResource HubTreatmentsFoLixHair LossNewsResource HubTreatmentsFoLix Named Best Laser Treatment for Hair Loss Two Years RunningREAD MOREDry EyeNewsPeriorbital Muscle StimulationTreatment TypeVision Resource HubDry EyeNewsPeriorbital Muscle StimulationTreatment TypeVision Resource HubLumenis OptiLIFT Dynamic Muscle Stimulation Device receives Health Canada Approval for Reducing Signs and Symptoms of Evaporative Dry Eye DiseaseREAD MOREClinical StudiesDry EyePeriorbital Muscle StimulationTreatment TypeVision Resource HubClinical StudiesDry EyePeriorbital Muscle StimulationTreatment TypeVision Resource HubThe Potential Benefits of Periorbital Transcutaneous Electrical Stimulation for the Management of Dry Eye DiseaseREAD MOREDry EyePeriorbital Muscle StimulationPress PublicationsTreatment TypeVision Resource HubDry EyePeriorbital Muscle StimulationPress PublicationsTreatment TypeVision Resource HubSisters Grow Practice Into Medical Hub for Dry Eye TreatmentREAD MOREBlog PostsGlaucomaTreatment TypeVision Resource HubBlog PostsGlaucomaTreatment TypeVision Resource HubDigital Duet 2.0 with Dr. JaiREAD MOREDry EyePeriorbital Muscle StimulationPress PublicationsVision Resource HubDry EyePeriorbital Muscle StimulationPress PublicationsVision Resource HubDoubling Down on Innovation: Why Dr. Nikki Iravani Invested in Two OptiLIFT SystemsREAD MOREBlog PostsDry EyeTreatment TypeVision Resource HubBlog PostsDry EyeTreatment TypeVision Resource HubRedefining Dry Eye Care: A Boutique Practice Case StudyREAD MOREBlog PostsHair LossResource HubBlog PostsHair LossResource HubNew Growth for Hair Loss Solutions: First West Coast Provider Shares Insights on FoLix by LumenisREAD MOREFoLixHair LossNewsResource HubTreatmentsFoLixHair LossNewsResource HubTreatmentsFoLix™ by Lumenis Wins Innovation Award in Hair Loss Technology at the 2025 Medical Device Network Excellence AwardsREAD MORE WE’RE HERE TO HELP WITH ANY QUESTIONS Please fill out our form, and we’ll get in touch shortly. Close #### Hungary WEEE Information for Lumenis Customers and Recyclers Collection and Recycling Arrangements in Hungary Lumenis products are sold in Hungary by distributors. The distributors act as the importer of the equipment into Hungary. Thus the distributors have the legal responsibility to: Register as the WEEE producer in Hungary. Provide arrangements for collection and recycling of WEEE arising from Lumenis products that the distributor sells in Hungary. Please contact the distributor in Hungary below to understand what arrangements he has made for collection and recycling of WEEE arising from Lumenis products: Dragon Holding ZRT Products:Aesthetic Street Address: Gdllő, Hunyadi u. 3., 2100 Country: HUNGARY Phone: 36-28-526600 Fax: 36-28-512620 Main Contact: George Juhasz Contact 2: Meryem Omer Regional Manager: Gus Griffin Medicontur Products:Ophthalmic Street Address: Csorsz Str. 13, 1123 Budapest Country: HUNGARY Phone: 36 1 214 2032 / 36 1 214 2033 Fax: 36 1 214 2026 Main Contact: Laszlo Kontur Contact 2: Peter Datan Regional Manager: Gus Griffin (Germany) #### Ireland WEEE Information for Lumenis Customers and Recyclers Collection and Recycling Arrangements in Ireland Lumenis products are sold in Ireland by distributors. The distributors act as the importer of the equipment into Ireland. Thus the distributors have the legal responsibility to: Register as the WEEE producer in Ireland. Provide arrangements for collection and recycling of WEEE arising from Lumenis products that the distributor sells in Ireland. Please contact the distributor in Ireland below to understand what arrangements he has made for collection and recycling of WEEE arising from Lumenis products: LaserTec Address: 66 Ballymoney Road, Holywood BT18 0JJ, Ireland Phone: +44 28 9146 2891 Email: mark@lasertecmedical.com Selling products directly to an end-user in another Member State is known as ‘distance selling’. The WEEE Directive and Irish WEEE Regulations state that neither Lumenis nor its distributor is responsible for WEEE arising from distance sales of business products directly to the business end-user in other Member States. Instead, it is the business end-user’s responsibility to ensure that products which they buy through distance selling arrangements are managed in an environmentally responsible manner at end of life. #### Italy WEEE Information for Lumenis Customers and Recyclers Collection and Recycling Arrangements in Italy Under the Italian Decree to implement 2002/96/EC Waste Electrical and Electronic Equipment (WEEE) Directive which came into force on August 13th 2005, for equipment that you buy from Lumenis after December 31st 2009, Lumenis is required to provide arrangements for the collection, treatment, recycling and recovery of WEEE that your new purchase replaces, on a one-for-one, like-for-like basis. This is providing the weight of the old equipment is less than double that of the new purchase. The old equipment that your new purchase from Lumenis replaces is referred to as Historic WEEE. Under the Italian Decree, this take-back system will be established at end of 2009. Under the Decree, Lumenis is also required to provide arrangements for the collection, treatment, recycling and recovery of any new electrical and electronic equipment that you buy from Lumenis after December 31st 2009, when that new equipment eventually becomes waste. This is referred to as New WEEE. Lumenis products are very competitively priced. Any new increase in operating costs for manufacturers such as Lumenis is normally reflected in a price increase in the product. However, instead of increasing the prices of our products, Lumenis has decided to share these new environmental costs directly with our customers. We believe in being transparent with you on any new environmental costs that our products need to address. Our approach to sharing these new environmental costs is: Lumenis pays for the costs of treatment, recycling and recovery of the WEEE to meet the targets set by the Decree. Lumenis pays for the costs of data management and reporting to the Ministry of Environment to demonstrate compliance with all administrative requirements of the Decree. you pay for transportation of your WEEE to Lumenis’s appointed recycler in Italy. Lumenis has established a recycling contract with the European Advanced Recycling Network (EARN) and will cover any costs of treatment, recycling and recovery of the equipment on arrival at the EARN recycling facility in Italy. All New WEEE that arises from the purchase of Lumenis products is classed as non-hazardous waste. It is your responsibility to arrange and pay for costs of collection and transportation to the recycler. In order to meet Italian regulations for waste disposal, you should use one of the following carriers (which hold a valid Waste Carriers licence): ach to sharing these new environmental costs is: Lumenis pays for the costs of treatment, recycling and recovery of the WEEE to meet the targets set by the WEEE Regulations; Lumenis pays for the costs of data management and reporting to the Environment Agency to demonstrate compliance with all administrative requirements of the WEEE Regulations; you pay for transportation of your WEEE to Lumenis’s appointed recycler in the UK. Lumenis has established a recycling contract with the European Advanced Recycling Network (EARN) and will cover any costs of treatment, recycling and recovery of the equipment on arrival at the EARN recycling facility in the UK. All New WEEE that arises from the purchase of Lumenis products is classed as non-hazardous waste. It is your responsibility to arrange and pay for costs of collection and transportation to the recycler. In order to meet UK Duty of Care Regulations for waste disposal, you should use one of the following carriers (which hold a valid Waste Carriers licence): Waste Carrier Kuehne+Nagel on behalf of S.Eco Servizi Ecologici Telephone Number: 045 8204880 Email: venditeol@tecser.it For larger quantities of waste you may wish to contact the recycler directly in order to arrange and pay for an alternative collection method. The EARN recycling facility in Italy is: Recycler Stena Technoworld S.r.l. Website: www.stenametall.com Telephone: +39 0267373030 To comply with Italian Waste Transport Regulations all WEEE must be accompanied by suitable documentation when transported to the recycler. In order to comply with this regulation and to enable EARN to identify Lumenis equipment upon arrival at the recycler’s address, please download the Recycling Label for Italian Customers. Complete the labelwith your company details and attach it to a suitable box for transport to EARN. Recycling Label for Italian Customers WEEE Reporting Recycling Data for Lumenis Equipment in Italy Under Article 13 of the Decree, Lumenis must provide annual information on the quantities and categories of electrical and electronic equipment put on the market, reused, recycled and recovered within Italy. The first WEEE recycling report will cover the period 2010. EARN will prepare the recycling data report for Lumenis. #### Latvia WEEE Information for Lumenis Customers and Recyclers Collection and Recycling Arrangements in Latvia Lumenis does not have a sales office or approved distributor based in Latvia. Instead, Lumenis products are sold directly to business end-users in Latvia from distributors in other Member States. Selling products directly to an end-user in another Member State is known as ‘distance selling’. The WEEE Directive and Latvian WEEE Regulations state that neither Lumenis nor its distributor is responsible for WEEE arising from distance sales of business products directly to the business end-user in other Member States. Instead, it is the business end-user’s responsibility to ensure that products which they buy through distance selling arrangements are managed in an environmentally responsible manner at end of life. #### Lithuania WEEE Information for Lumenis Customers and Recyclers Collection and Recycling Arrangements in Lithuania Lumenis does not have a sales office or approved distributor based in Lithuania. Instead, Lumenis products are sold directly to business end-users in Lithuania from distributors in other Member States. Selling products directly to an end-user in another Member State is known as ‘distance selling’. The WEEE Directive and Lithuanian WEEE Regulations state that neither Lumenis nor its distributor is responsible for WEEE arising from distance sales of business products directly to the business end-user in other Member States. Instead, it is the business end-user’s responsibility to ensure that products which they buy through distance selling arrangements are managed in an environmentally responsible manner at end of life. #### Lumenis and Baring Private Equity Asia to Accelerate Investment in Aesthetics and Vision Verticals Following the Strategic Sale of Lumenis Surgical for $1.07B Lumenis and Baring Private Equity Asia to Accelerate Investment in Aesthetics and Vision Verticals Following the Strategic Sale of Lumenis Surgical for $1.07B Strong investment in R&D, new business, global sales, and employees “Exciting move toward a bright future” for a leader in dual market domains September 1st, 2021 – Israel and Hong Kong – Lumenis, a global leader in energy-based medical devices for minimally invasive aesthetic and vision applications, announced today the completion of the sale of its Surgical business to Boston Scientific Corporation, a leading global medical device manufacturer, in a transaction valued at $1.07B. Lumenis will refocus and accelerate planned investments to support the development of its fast-growing Aesthetic and Vision businesses, emphasizing R&D, global sales and marketing channels, and business development activities. “After the strategic sale of Lumenis Surgical, we now have a mission to move Lumenis forward in the Aesthetics and Vision markets through strong investment in Lumenis’ gold-standard technologies, innovation and employees,” said BPEA Managing Director Yan Jiao. “BPEA is looking ahead not only to expanding Lumenis’ existing capabilities but also to pursuing new strategic growth opportunities.” “Completion of this deal and transfer of the Surgical business to Boston Scientific – including its robust product portfolio, global team, and the Israeli surgical laser center of excellence – represents a major milestone and a testament to the outstanding work of the Surgical team. Today signals an exciting move toward a bright future for everyone here at Lumenis,” commented Lumenis CEO Tzipi Ozer-Armon. “We have developed and introduced multiple groundbreaking technological solutions for Aesthetics and Vision that have redefined our industry and opened entirely new market segments. We now look towards building on this success by accelerating the expansion of our Aesthetics and Vision businesses. We will also be investing in and growing our exceptional global teams, who have made innovation and market leadership our company’s defining traits.” Added Ozer-Armon, “Lumenis remains as committed as ever to the premium level of quality, service, and excellence that our Aesthetics and Vision customers, partners, and patients have come to expect. In the months and years to come, we plan to significantly increase our investment in these domains and build upon our gold-standard portfolio of solutions through the introduction of new and innovative products, services, and digital capabilities.” With a legacy spanning over 50 years in the Aesthetic and Vision domains, Lumenis is an undisputed leader. Lumenis, now more than ever, has a vast portfolio of products that offer exceptional solutions to address multiple evolving needs of physicians and patients. To learn more about Lumenis and explore careers, visit www.lumenis.com. About Lumenis www.lumenis.com Lumenis is a premier global inventor and manufacturer of energy-based medical devices for minimally invasive aesthetic and vision applications. Regarded as a world-renowned expert in developing and commercializing innovative energy-based technologies, including intense pulsed light (IPL), Lumenis has introduced groundbreaking products, redefined medical treatments and set numerous technological and clinical gold standards for nearly 50 years. Lumenis has created solutions for previously untreatable conditions, as well as designed advanced technologies that revolutionized existing treatment methods. #### Lumenis App LUMENIS APP Elevate your business For over 50 years, Lumenis has been empowering professionals like you to build successful businesses. Now, we’re putting that expertise in the palm of your hand!Experience a new standard of ongoing support, available exclusively to Lumenis’ US Aesthetic device owners. Sign up here Or scan the QR code to sign up on your smartphone​ SIGN UP TODAY TO ACCESS: SIGN UP TODAY WHAT’S ON THE LUMENIS APP: ONBOARDING JOURNEY Receive scheduling updates, marketing starter kits and training resources. BUSINESS ANALYTICS Optimize your marketing, pricing, and operations with data-driven insights. GAIN A CLINICAL EDGE Stay up-to-date with the latest treatment offerings and clinical protocols, and watch tutorials and demos. MARKETING RESOURCES Download and share fresh, ready-to-use marketing assets and campaigns. ONLINE STORE Earn Lumenis+ Points on every online purchase! Order consumables for your Lumenis device and and track shipping 24/7 MULTICHANNEL SUPPORT Troubleshoot with personalized self-help resources, call or write for technical and clinical support, and get device status updates. Already own a Lumenis device? Sign up here or scan the QR code to sign up on your smartphone​ SIGN UP HERE You will be asked to enter your device’s serial number for data protection The Lumenis App is accessible only to Lumenis’ Aesthetic customers in the United States. Any Questions? Contact Us Already own a Lumenis device? Sign up here #### Lumenis Leadership Lumenis Leadership Our multidisciplinary leadership team of prominent experts here at Lumenis are the legacy to our success. Learn more about our passionate leaders below. Tzipi Ozer-Armon Chief Executive Officer (CEO) Shy Basson Chief Financial Officer (CFO) Stacey Winter Vice President and Regional President, North America Qiying Zhai Senior Vice President & Regional President, APAC & Japan Roy Ramati Senior Vice President, EMEA & Business Development Hadas Padan Senior Vice President, Head of Aesthetics and Vision Business Group Ezi Hayon Vice President, Operations Itay Mayer Chief Commercial Officer AyeletBarneah-Alsheich Vice President, Aesthetics Business Unit Assaf Preiss VP Aesthetics R&D and CTO Daniel Shemesh Vice President, Data & Digital Karen Smith Vice President, Regulatory Affairs & Quality Ido Warshavski Vice President, General Counsel & Corporate Secretary #### Lumenis to Be Acquired for Approximately $510 Million, $14.00 per Share, in Cash Lumenis to Be Acquired for Approximately $510 Million, $14.00 per Share, in Cash June 18, 2015 – יוקנעם עילית, ישראל Lumenis Ltd. (NASDAQ: LMNS), the world’s largest energy-based medical company for surgical, ophthalmology and aesthetic applications, announced today that it has signed a definitive agreement to be acquired by XIO Group for $14.00 per share in cash, for an aggregate purchase price of approximately $510 million. “This acquisition is a strong recognition and vote of confidence in Lumenis’ achievements and its employees, and I am excited about the future prospects of Lumenis” said Tzipi Ozer-Armon, Chief Executive Officer. “Over the past 3 years we have managed to transform Lumenis into a strong, growing and profitable company. We have refocused our strategy, introduced new products, and tripled our EBITDA. Furthermore, we have created a very bright and promising future for Lumenis by building a robust pipeline of innovative products, a strong sales team in each region, and by enhancing our global brand recognition. I am confident that we will continue to thrive and reach new heights together with XIO Group.” “We are excited about the announced transaction and the value created for Lumenis’ shareholders”, said Harel Beit-On, Chairman of the Board of Directors. “Over the last years, we had an opportunity to lead Lumenis through a strategic transformation into a valuable growing business with global appeal. We respect and appreciate the efforts of Lumenis management and employees and wish the company continued success.” The prospective transaction is subject to customary closing conditions, including approval by Lumenis’ shareholders and receipt of certain regulatory approvals, and is expected to close in September 2015. The Board of Directors of each of Lumenis and XIO Group has approved the transaction. The two largest shareholders of Lumenis, Viola Group and XT Hi-Tech Investments (1992) Ltd., which collectively own approximately 59% of the shares of Lumenis, have entered into a customary voting agreement with XIO Group. Goldman Sachs acted as the exclusive financial advisor to Lumenis in respect of this transaction. Morgan Stanley acted as the exclusive financial advisor to XIO Group. About XIO Group XIO Group is a global multi-billion dollar alternative investments firm with offices in London, Hong Kong and Shanghai. The company has a significant amount of committed capital in place for global transactions. The Group seeks to leverage its unique global network to provide growth for portfolio companies. About Lumenis Lumenis (Nasdaq:LMNS) is a global leader in the field of minimally-invasive clinical solutions for the Surgical, Ophthalmology and Aesthetic markets, and is a world-renowned expert in developing and commercializing innovative energy-based technologies, including Laser, Intense Pulsed Light (IPL) and Radio-Frequency (RF). For nearly 50 years, Lumenis’ ground-breaking products have redefined medical treatments and have set numerous technological and clinical gold-standards. Lumenis has successfully created solutions for previously untreatable conditions, as well as designed advanced technologies that have revolutionized existing treatment methods in each and every one of the verticals we operate in. For more information visit: www.lumenis.com. Forward-Looking Statements Information provided in this press release may contain statements relating to current expectations, estimates, forecasts and projections about future events that are “forward-looking statements” as defined in the Private Securities Litigation Reform Act of 1995. These forward-looking statements may include but are not limited to statements about the expected completion of the proposed transaction with the XIO Group and the timing thereof, the satisfaction or waiver of any conditions to the proposed transaction, anticipated benefits, growth opportunities and other events relating to the proposed transaction, the Company’s plans, objectives and expectations for future operations, including its projected results of operations. Forward-looking statements are often characterized by the use of forward-looking terminology such as “may,” “will,” “expect,” “anticipate,” “estimate,” “continue,” “believe,” “should,” “intend,” “plan,” “project” or other similar words, but are not the only way these statements are identified. These forward-looking statements are based upon our management’s current estimates and projections of future results or trends. Factors that could cause actual events, results, performance, circumstances or achievements to differ from such forward-looking statements include, but are not limited to, the following: (1) the Company may not be able to satisfy all of the conditions to the closing of the proposed transaction; (2) the proposed transaction may involve unexpected costs, liabilities or delays; (3) the Company’s business may suffer as a result of uncertainty surrounding the proposed transaction and diversion of management attention on transaction related matters; (4) the outcome of any legal proceedings related to the proposed transaction; (5) the Company may be adversely affected by other economic, business, and/or competitive factors; (6) the occurrence of any event, change or other circumstances that could give rise to the termination of the merger agreement; (7) difficulties in recognizing benefits of the proposed transaction; (8) the proposed transaction may disrupt current plans and operations and raise difficulties for employee retention; (9) impact of the transaction on relationships with customers, distributors and suppliers and (10) other risks to consummation of the transaction, including the risk that the transaction will not be consummated within the expected time period or at all. Actual results may differ materially from those projected as a result of certain risks and uncertainties, including those risks discussed under the heading “Risk Factors” in our most recent Annual Report on Form 20-F filed with the U.S. Securities and Exchange Commission. These forward-looking statements are made only as of the date hereof, and the Company undertakes no obligation to update or revise the forward-looking statements, whether as a result of new information, future events or otherwise. For Investor Inquiries, please contact: Michael Piccinino, CFA Westwicke Partners, LLC. 443.213.0500 Lumenis@westwicke.com  ADDITIONAL INFORMATION In connection with the proposed transaction, the Company intends to mail a notice, proxy statement and proxy card to its shareholders and furnish a copy of those materials to the SEC in a report on Form 6-K. Shareholders of the Company are urged to read the proxy statement and the other materials when they become available because they will contain important information about the proposed transaction and related matters. Shareholders are also urged to carefully read the proxy statement and other materials before making any voting or investment decision with respect to the proposed transaction. The proxy statement (when available) may be obtained for free at the SEC’s website at www.sec.gov. In addition, the proxy statement will be available, without charge, at the Company’s website at www.lumenis.com  #### Luxembourg WEEE Information for Lumenis Customers and Recyclers Collection and Recycling Arrangements in Luxembourg Lumenis does not have a sales office or approved distributor based in Luxembourg. Instead, Lumenis products are sold directly to business end-users in Luxembourg from distributors in other Member States. Selling products directly to an end-user in another Member State is known as ‘distance selling’. The WEEE Directive and Luxembourg WEEE Regulations state that neither Lumenis nor its distributor is responsible for WEEE arising from distance sales of business products directly to the business end-user in other Member States. Instead, it is the business end-user’s responsibility to ensure that products which they buy through distance selling arrangements are managed in an environmentally responsible manner at end of life. #### Malta WEEE Information for Lumenis Customers and Recyclers Collection and Recycling Arrangements in Malta Lumenis products are sold in Malta by distributors. The distributors act as the importer of the equipment into Malta. Thus the distributors have the legal responsibility to: Register as the WEEE producer in Malta. Provide arrangements for collection and recycling of WEEE arising from Lumenis products that the distributor sells in Malta. Please contact the distributor in Malta below to understand what arrangements he has made for collection and recycling of WEEE arising from Lumenis products: Technoline Ltd. Products:Ophthalmic, Aesthetic Street Address: Regional House, 51 Edgar Bernard Street, Gzira, GZR 06 Country: MALTA Phone: 381-11-3615955 / 356-21-344-149 Fax: 356-21-343-952 Main Contact: Ivan Vassallo Contact 2: admin@technoline-mt.com #### Netherlands WEEE Information for Lumenis Customers and Recyclers Collection and Recycling Arrangements in the Netherlands Lumenis products are sold in the Netherlands by distributors. The distributors act as the importer of the equipment into the Netherlands. Thus the distributors have the legal responsibility to: Register as the WEEE producer in the Netherlands. Provide arrangements for collection and recycling of WEEE arising from Lumenis products that the distributor sells in the Netherlands. Please contact the distributor in the Netherlands below to understand what arrangements he has made for collection and recycling of WEEE arising from Lumenis products: LASERVISION Instruments BV Products:Ophthalmic, Aesthetic Street Address: De Grift 20, 7711 EJ Nieuwleusen, The Netherlands Country: NETHERLANDS Phone: 31-529-428000 Fax: 31-529-428001 Main Contact: Jos Helthuis Contact 2: Jos van Gemst Regional Manager: Remco Schmitz #### News Corporate News September 1, 2021Lumenis and Baring Private Equity Asia to Accelerate Investment in Aesthetics and Vision Verticals Following the Strategic Sale of Lumenis Surgical for $1.07BLumenis will refocus and accelerate planned investments to support the development of its fast-growing Aesthetic and Vision businesses, emphasizing R&D,...March 3, 2021Baring Private Equity Asia Announces Agreement to Sell Lumenis’ Surgical Business to Boston Scientific for $1.07 blnBaring Private Equity Asia (BPEA) and Lumenis announced today that they have entered into a definitive agreement to sell the...November 18, 2019Baring Private Equity Asia Agrees to Acquire Lumenis“Baring Private Equity Asia today announced that its affiliated private equity funds (“BPEA”) have agreed to acquire Lumenis”June 18, 2015Lumenis to Be Acquired for Approximately $510 Million, $14.00 per Share, in CashLumenis Ltd. (NASDAQ: LMNS), the world’s largest energy-based medical company for surgical, ophthalmology and aesthetic applications, announced today that it has... #### Patents Lumenis Be Ltd Patents #### Patients Patient Information Lumenis Laser Treatments Looking for the best treatment solution for you or your loved ones? Visit our patient websites to learn more about the specific treatment that’s right for you. If you can’t find what you are looking for contact us through the “GET MORE INFO” form below. FIND A PROVIDER Hair Loss TreatmentUnlock your hair’s potential with FoLix, the New FDA-cleared laser treatment for hair loss.Use our locator to easily find a specialist near you.VISIT OUR SITESmoothGlo™SmoothGlo™ sets a new bar for aesthetic outcomes.Say goodbye to the uneven skin tone that gives away your age.VISIT OUR SITEOptiLIGHT Dry Eye Practice LocatorLooking for a doctor in your area?Use the practice locator to easily find the specialist closest to you.VISIT OUR SITESkin Treatments and Hair RemovalAesthetipedia.com is an online resource about a range of skin concerns and the relevant Lumenis energy-based treatments available.VISIT OUR SITELaser Hair RemovalLightsheer.com is your go-to-source for all things on Laser Hair Removal.VISIT OUR SITEScars TreatmentHopeForScars.com is an online resource with information about scars and the relevant Lumenis energy-based treatments available.VISIT OUR SITEWomen’s HealthFemTouch.eu is an online resource for women’s health. Learn about the treatment and find a treatment provider in your area.VISIT OUR SITE Lumenis is an equipment manufacturer and does not provide professional medical or aesthetic services to patients. This application is intended for the convenience of patients interested in locating practitioners and clinics that use Lumenis’ equipment for treatments, without recommendation or solicitation on the part of Lumenis with respect to the services of such practitioners or clinics. GET MORE INFO × #### Poland WEEE Information for Lumenis Customers and Recyclers Collection and Recycling Arrangements in Poland Lumenis products are sold in Poland by distributors. The distributors act as the importer of the equipment into Poland. Thus the distributors have the legal responsibility to: Register as the WEEE producer in Poland. Provide arrangements for collection and recycling of WEEE arising from Lumenis products that the distributor sells in Poland. Please contact the distributor in Poland below to understand what arrangements he has made for collection and recycling of WEEE arising from Lumenis products: ITP SA. Products: Ophthalmic, Aesthetic Street Address: Ul. Domaniewska 37 02-672 Warszawa Country: Poland Phone: +48 722 008 002 Main Contact: itp@itpsa.pl Contact 2: marketing@itpsa.pl ABJ Vision Products: Ophthalmic Street Address: ul. Główna 76, 95-041 Gałkow Duży Country: Poland Phone: +48 509 151 584 Phone: +48 42 2920732 Fax: +48 42 2920738 Website: https://abj-vision.pl/ Main Contact: biuro@abj-vision.pl #### Portugal WEEE Information for Lumenis Customers and Recyclers Collection and Recycling Arrangements in Portugal Lumenis products are sold in Portugal by distributors. The distributors act as the importer of the equipment into Portugal. Thus the distributors have the legal responsibility to: Register as the WEEE producer in Portugal. Provide arrangements for collection and recycling of WEEE arising from Lumenis products that the distributor sells in Portugal. Please contact the distributor in Portugal below to understand what arrangements he has made for collection and recycling of WEEE arising from Lumenis products: Jose Cotta – Equipamentos Medicos e Servicos, S.A. Products:Ophthalmic Street Address: Rua Prof. Correia Araujo No. 723, Apartado 2114, 4200 – 205 Porto Country: PORTUGAL Phone: 351-22-550-5855 / 351-22-550-5857 Fax: 351-22-550-5873 Main Contact: Antonio Cotta Regional Manager: Mario Annesi Mediform Portugal Products:Aesthetic Street Address: Rua Embaxaidor Martins Janeira n 9A, 1769-0089 Lisbon Country: PORTUGAL Phone: 351 21 754.15.82/3 Fax: 351 21 758.00.73 Main Contact: Joao P. Valle Contact 2: informacao@mediform.com Contact 3: Lidia Fornells Regional Manager: Mario Annesi (SPAIN) #### Privacy Statement Privacy Statement #### Recycling WEEE Information for Lumenis Customers and Recyclers Under the Waste Electrical and Electronic Equipment (WEEE) Directive and implementing regulations, when customers buy new electrical and electronic equipment from Lumenis they are entitled to: Send old equipment for recycling on a one-for-one, like-for-like basis (this varies depending on the country) Send the new equipment back for recycling when this ultimately becomes waste Instructions to both customers and recycle/treatment facilities wishing to obtain dis-assembly information are provided by following the links below. Recycling and Take Back Services Product Take-Back and Recycle Program Lumenis is an environmentally conscious company committed to continuous improvement and using development and manufacturing processes that do not adversely affect the environment, that minimize waste and prevent pollution, and that minimize health and safety risks of our customers and employees. The European Union (EU) has developed the WEEE (Waste Electrical and Electronic Equipment) directive to ensure that systems for collection, treatment and recycling of electronic waste will be in place throughout the European Union In support of our environmental goals, effective January 2010, Lumenis have launched a formal product Take-Back and Recycle Program in Europe that complies with the European Union Directive 2012-19-EU on waste electrical and electronic equipment (“WEEE Directive”). This program will provide self-service instructions for ease of use product take-back and recycling. Equipment that is returned through this program will be handled in an environmentally safe manner using processes that comply with the WEEE Directive requirements. This program is for Lumenis customers who have Lumenis products that have reached the end-of-life and are ready for disposal. While the WEEE Directive applies to most of Lumenis’ products, it does not apply to parts, assemblies or consumables such as filters or fibers. WEEE Information Are you a recycler / treatment facility wanting information on how to disassemble and recycle a Lumenis product? Recyclers Click Here Contact Service: Online Form or Phone US 877-LUMENIS ( 877-586-3647 ) #### Recycling Locations WEEE Information – Locations Please click to select: Austria Czech Republic France Ireland  Luxembourg Poland Slovenia United Kingdom Belgium Denmark Germany Italy Malta Portugal Spain Bulgaria Estonia Greece Latvia Sweden Cyprus Finland Hungary Lithuania Netherlands  Slovakia Romania #### Romania WEEE Information for Lumenis Customers and Recyclers Collection and Recycling Arrangements in Romania Lumenis products are sold in Romania by distributors. The distributors act as the importer of the equipment into Romania. Thus the distributors have the legal responsibility to: Register as the WEEE producer in Romania. Provide arrangements for collection and recycling of WEEE arising from Lumenis products that the distributor sells in Romania. Please contact the distributor in Romania below to understand what arrangements he has made for collection and recycling of WEEE arising from Lumenis products: Wilhelm Romco CO. Products:Ophthalmic, Aesthetic Street Address: RO-71512, Sos. Nordului Nr. 58, Bucharest 014104 Country: ROMANIA Phone: 40-21-2320090 Fax: 40-21-2322284 Main Contact: Florin Serbanescu Contact 2: Mircea Aninoiu #### Safety Information Safety Information #### Service SERVICE Manufacturer Certified Service For Medical Equipment Repair And Maintenance At Lumenis we are committed to providing the highest quality and the most comprehensive service in the industry for medical equipment repair and maintenance. Lumenis Service provides you with peace of mind, so you can focus on patient care, not the equipment. Lumenis service is provided only by manufacturer-certified Service Engineers Lumenis Service Engineers are certified, trained and constantly updated on all recent procedures and updates required by the manufacturer Only original equipment manufacturer (OEM) replacement parts are used to ensure optimal performance of Lumenis systems Maximized operational uptime with Preventative Maintenance and timely response Lumenis has more than 40 years of experience providing service solutions to our customers with the largest multidisciplinary service organization in the laser industry Highly experienced and dedicated team of Service Medical Laser Engineers with an average tenure of 14 years Service Plans What is included in Lumenis service contracts? Lumenis provides you with the most comprehensive service and maintenance plans in the industry for medical laser repair and maintenance. Variety of Service Plans were tailored to meet your individual needs and provide you with unsurpassed quality, timely, and cost-effective service. Comprehensive, all inclusive coverage; includes all manufacturer-certified parts, wear and tear, labor and travel1 Preventative Maintenance included in all plans to ensure safety and compliance with the latest Federal, State, CMS, The Joint Commission and ANSI regulations Priority response and resolution Loaner system for extended repair scenarios2 Access to refurbished parts2 Periodic software updates required by a manufacturer to ensure reliability and optimal performance of the Lumenis system User and bio-medical technical in-service laser training available on all Lumenis Service Plans3 Variety of solutions to accommodate our customers’ various financial and risk management priorities The unique benefits of Lumenis service plans contract Maximized Uptime for Your System As the manufacturer, only Lumenis has the ability to perform post-market surveillance of tens of thousands of Lumenis systems all over the world to identify any potential risks and safety issues and act proactively to prevent them by installing software updates, performing calibrations, and ensuring a Lumenis system performs at its optimal level. By doing so we are able to minimize unnecessary downtime of your Lumenis system and reduce your corrective service expenses. Regulatory Compliance Lumenis Service partners with our customers to ensure safety and compliance with the latest CMS and The Joint Commission requirements, the highest quality standards in the industry. According to the updated CMS4 and The Joint Commission5 requirements, Medical Laser devices’ maintenance should be performed according to the manufacturer’s specifications and is not eligible to be managed via an Alternate Equipment Management (AEM) program. These regulations intend to limit potential for injury and inadvertent light exposure during service of the Medical Laser devices. In order to comply with the highest regulatory standards Lumenis Service provides you with: Service by Lumenis Certified Service Engineers, who embrace the highest degree of training, state of-the-art tools, superior process and up-to-date procedures in place to comply with FDA 21CFR820, ANSI Z136.3, ISO 13485, CMS and The Joint Commission requirements Comprehensive compliance and quality management system based on FDA 21CFR820, ANSI Z136.3, ISO 13485, CMS and The Joint Commission’s latest requirements. Lumenis Service promotes user and patient safety with a complete safety check during every Preventative Maintenance Service in accordance with the manufacturer’s specifications Readily available validation and up-to-date computerized individual equipment history records to support The Joint Commission requirements. Lumenis Service is performed only by manufacturer trained and certified Service Engineers who use only original equipment manufacturer (OEM) parts A range of offerings to accommodate our customers’ various financial and risk management priorities Reduced Risk, Predictable and Cost Effective Solutions After manufacturer’s warranty expires, medical equipment service repair and replacement costs become a customer’s responsibility. Lumenis Service offers predictable and cost effective solutions for all types of accounts and budgets that can save our customers thousands of dollars over the lifetime of a Lumenis System. Comprehensive, all-inclusive Lumenis Service Plans can help you save substantial money and lower the lifetime cost of ownership by covering all parts, accessories, labor and travel, and performing regular Preventative Maintenance check-ups. All these eliminate exposure to unpredictable substantial expenses and prevent many problems from ever occurring, while extending the life of the laser and optimizing its performance. Click here to find your local service center for LightSheer, M22, AcuPulse , UltraPulse, Holmium, Ophthalmic and some other Lumenis laser system repair and maintenance services or fill in the contact form and our regional service expert will contact you shortly. WHAT OUR CLIENTS SAY Testimonials “The impeccable service delivered by the Lumenis team has allowed us to minimize our downtime preventing patient inconvenience and lost revenue. In the rare instance that one of our three Lumenis lasers had needed service, the turnaround was brief and issues resolved to complete satisfaction.” Jason Bacharach, M.D. Medical Director, North Bay Eye Assoc. Sonoma County, CA “I have had 6 Lumenis laser devices over the past 14 years and highly recommend purchasing an official service plan through Lumenis. When a machine needs repair, I know with confidence that the service provided by great people like Will and Brian is second to none. Trust your machine to no one else.” Ramsey Markus, M.D. Associate Professor of Dermatology & Director of Laser Surgery Department of Dermatology Baylor College of Medicine Houston, TX “Lumenis service provides me with peace of mind, knowing that I can always count on their certified service professionals and great staff. They keep our lasers in compliance with the latest regulations, including all the latest manufacturer required updates, software and whatever it takes to keep our lasers in the best operational status. You can rest assured you are in good hands when you purchase a Lumenis Service Agreement.” Susan Lossing, CME Permanent Choice, MN “Being under a Lumenis Service Contract has been great for Fauquier Hospital in every way. Lumenis Service does a great job! Timely performed semiannual Preventative Maintenance check-ups were provided as part of the service contract benefits provided by Lumenis. Whenever we get audited by The Joint Commission, thanks to the service for our lasers provided by the manufacturer, we are able to pass the audit and accreditation verification with flying colors. Once we present documentation of Lumenis’ equipment service performed by Original Equipment Manufacturer, then we easily pass the audit with no additional questions asked. On the rare occasion our lasers needed corrective maintenance, all needed repairs were always provided in a timely fashion and any issues were resolved in one visit and to our highest satisfaction. The Lumenis Service Engineer is always competent, patient, dependable, reliable, on time and able to provide the highest level of service to us.” Laura Nicely Clinical Engineering Manager Fauquier Hospital Warrenton, VA. “Enrolling in a Lumenis Service Agreement was one of the best decisions I have made for my practice. Lumenis takes care of everything so that I can spend less time worrying about the equipment and more time focusing on my patients. Our system operates optimally thanks to the included Preventative Maintenance, and the few issues we’ve had in the past 8 years were resolved promptly and efficiently. The Service Agreement proved to be cost effective, and over time it actually lowered our cost of ownership. The certified Lumenis Engineer that services our laser is exceptional, and I am highly satisfied with the quality of his service. On a scale from one to ten, I give Wes a twelve!” Rekha Singh, M.D. Atlanta Laser Clinic Suwanee, GA. “Having the Lumenis Service Agreement has been extremely beneficial to Greenbrier Valley Medical Center. We have the Preventative Maintenance scheduled every six months. Our laser PMs are always completed on-time resulting in me always meeting compliance for The Joint Commission requirements.The field service engineer, Eric, is very knowledgeable and performs a great service for us. When I rarely have a machine down I can callservice and shortly after speaking with the service department Eric is returning my call with an estimated time of arrival. He is very friendly, always wearing a smile, courteous and highly professional.” Saundra Zermeno, BSEET / BMET III Biomedical Services Greenbrier Valley Medical “As one of the very first hair removal practices opened in Wisconsin, I always turned to Lumenis for service and customer support issues. I am thrilled with the expertise and courtesy of the Service Engineer that Lumenis has for our area for all of the 14 years. Not only did Wayne provide very informative answers to all our questions, but he also suggested best ways to maintain the equipment in the most efficient manner. The service contract that we purchased from Lumenis was the best decision for our business. Not only was it wise as a cost-saving option, but, most importantly, it provided us with the worry-free confidence that our equipment will be maintained and serviced by manufacturer-certified experts.” Nancy Neusen, RE Clinic of Medical Electrolysis Fond Du Lac, WI. SERVICE CONTACT REQUEST LUMENIS SERVICE LOCATION Lumenis Global Service Organization includes service centers in key locations in Europe, North America, Latin America, India, Australia, China, Japan and Israel. Click here to find your local service center or fill in your details on our online contact form and our regional service experts will get in touch with you shortly. [put_wpgm id=9] SERVICE AT 360 DEGREES References: Under Premium Protection Plan, Total Protection Plan,and Enhanced Protection Plan. For more details please see the description of each plan. Subject to availability. Following training will be provided to a biomedical/clinical engineering personnel available at the time of installation and/or PM visits: basic theory of operation, user maintenance & cleaning, recognition & resolution of user error messages, training of user replaceable parts, general training on connection and maintenance of accessories. CMS Hospital Equipment Maintenance requirements, December 20, 2013: http://www.cms.gov/Medicare/Provider-Enrollment-and-Certification/SurveyCertificationGenInfo/Downloads/ Survey-and-Cert-Letter-14-07.pdf. Accepted: New Hospital Requirements to Maintain Alignment with CMS. Joint Commission Perspectives (May, 2014). 34(5). http:// www.jointcommission.org/assets/1/6/JCP0514_New_Hospital_Req_CMS.pdf #### Service LightSheer Handpieces Lumenis Service for LightSheer® Handpieces Thousands of satisfied customers are benefiting from the Gold Standard performance of LightSheer® diode laser technology, that has been validated in numerous clinical studies and peer reviewed articles. The Gold Standard  Lumenis Service for LightSheer handpieces provides you with an unrivaled value for your investment in terms of quality of the original spare parts, warranty provided, service and price. Purchase the original LightSheer heads and benefit from: Refurbished handpieces with an all new diode laser array Original LightSheer spare parts manufactured and tested by qualified, certified engineers Unparalleled warranty terms Minimized system downtime: delivery of refurbished handpiece before receipt of the returned one Headrooms equal to Lumenis’ new handpieces specifications Don’t compromise for anything less than the original LightSheer spare parts and tips. Fill in the contact form in this page or contact your local service representative for the latest handpiece promotion. Contact Service #### Service Locations LUMENIS SERVICE LOCATIONS Lumenis Global Service Organization includes service centers in key locations in Europe, North America, Latin America, India, Australia, China, Japan and Israel. Click here to find your local service center or fill in your details on our online contact form and our regional service experts will get in touch with you shortly. Lumenis Service Worldwide Locations [put_wpgm id=6] CONTACT SERVICE SUBSIDIARIES Headquarters Lumenis Be Ltd. Yokneam Industrial Park Hakidma 9 P.O.B. # 426 Yokneam 2069236 Israel eMail: servicecorp@lumenis.com Tel: +972-77-9599000 Fax: +972-77-9599001 Americas Lumenis Be, Inc. – USA 1735 Technology Dr, Suite 850 San Jose, CA 95110 Tel: 877-Lumenis (877-586-3647) Fax: 408-764-3999 E-Mail: USService@lumenis.com Lumenis Be Canada, Ltd Tel: 877-Lumenis (877-586-3647) Fax: 408-764-3999 E-Mail: CanadaService@lumenis.com Europe Lumenis Be (UK) Limited Address: 15 The Valley Centre Gordon Road High Wycombe United Kingdom Email: enquiresuk@lumenis.com Tel: 0208 736 4110 (Option 1) Lumenis (Germany) GmbH Address: Heinrich-Hertz-Strasse 3 63303 Dreieich, Germany Email: service.germany@lumenis.com Tel: +49 06103 83350 Fax: +49 (0)6103-8335-300 China Lumenis Be Laser Technology Co., Ltd Tel: 800-820-5188 (Option 1) Tel: 400-820-5188 (Option 2) Address: 6th Floor, South Tower CP Center No.20 Jinhe East Road Chaoyang District Beijing 100020 China Japan Lumenis Be Japan Co., Ltd Customer Call Center Address: Nippon Express Shinsuna Warehouse No. 6, 3rd floor 2-3-15 Shinsuna, Koto-ku Tokyo, Japan eMail: info.japan@Lumenis.com Asia-Pacific Lumenis Be (HK) Limited Tel: +852 3520 2100 Email: 35202100@lumenis.com Address: 16/F, The Cameron, 33 Cameron Road, TST, Kowloon, Hong Kong Lumenis Be ANZ Pty Ltd. Level 8 | Tower A, The Zenith 821 Pacific Highway Chatswood NSW 2067 AUS: 1800 586 364 | NZ: 0800 239 015 Email: servicemax.au@lumenis.com Lumenis Be (Korea) Ltd. Tel: 1522-8773 Email: service.kr@lumenis.com 34 floor, IFC Seoul Tower 3 10 Gukjegeumyung-ro, Yeongdeungpo-gu, Seoul 07326 South Korea Lumenis Be (HK) Limited, Taiwan Branch Tel: 0800-090-866 Email: Info.TW@lumenis.com Address: 7F-3, No 1, SongGao Rd, Xinyi Dist., Taipei City 110, Taiwan (R.O.C.) Lumenis Be (India) Private Limited Tel: 0124-4854900 Email: customercareindia@lumenis.com Address: Unit 505-507, 5th Floor, Suncity Business Tower, Sector-54, Golf course road, Gurgaon-122002, Haryana, India #### Slovakia WEEE Information for Lumenis Customers and Recyclers Collection and Recycling Arrangements in Slovakia Lumenis does not have a sales office or approved distributor based in Slovakia. Instead, Lumenis products are sold directly to business end-users in Sovakia from distributors in other Member States. Selling products directly to an end-user in another Member State is known as ‘distance selling’. The WEEE Directive and Slovak WEEE Regulations state that neither Lumenis nor its distributor is responsible for WEEE arising from distance sales of business products directly to the business end-user in other Member States. Instead, it is the business end-user’s responsibility to ensure that products which they buy through distance selling arrangements are managed in an environmentally responsible manner at end of life. #### Slovenia WEEE Information for Lumenis Customers and Recyclers Collection and Recycling Arrangements in Slovenia Lumenis products are sold in Slovenia by distributors. The distributors act as the importer of the equipment into Slovenia. Thus the distributors have the legal responsibility to: Register as the WEEE producer in Slovenia. Provide arrangements for collection and recycling of WEEE arising from Lumenis products that the distributor sells in Slovenia. Please contact the distributor in Slovenia below to understand what arrangements he has made for collection and recycling of WEEE arising from Lumenis products: Angiomedic d.o.o. Products: Ophthalmic, Aesthetic Street Address: Zemljemerska ulica 12, SI-1000 Ljubljana Country: SLOVENIA Phone: +386 1230 94 60 Fax: +386 1230 94 70 Main Contact: Miha Matjasic #### Social Responsibility Corporate Social Responsibility Bringing the Light of Life to Those in Need The name Lumenis originates in Latin and means Light of Life.  As the world-renowned expert in developing and commercializing innovative energy-based technologies, light is central to our technological innovations, but also a symbol of our mission to improve the lives of people with medical and cosmetic conditions. Lumenis is committed to supporting medical community leaders as they reach out to patients in need – no matter where they live – to bring them the life-changing benefits of minimally invasive procedures.  In just the past year, Lumenis has provided technology and resources to help undeserved and underprivileged populations across the globe. Welcome to the Lumenis Cares Foundation Our mission is to support projects dedicated to supporting independence, physical and environmental well-being in various fields including healthcare, education, employment, equal opportunities through charitable sponsorship and activities. Launched in November 2019, the Lumenis Cares Foundation is aiming to raise awareness and support for meaningful causes affecting the everyday working world, including but not limited to Global Healthcare and Education.  To continually connect people with worthy causes, which support education and quality of life.  Helping those who aim to help others, in fostering an environmentally friendly, and healthy world in which to live and work. The Lumenis Cares Foundation are proud to support the charity Street Child. Street Child support children in some of the world’s poorest and most vulnerable communities. Areas where sanitation, PPE and other vital resources to battle COVID-19 are very scarce. Members of the Lumenis Cares Foundation are taking on a 30KM walk on 2nd August 2020 to raise money for this great cause. 35€ could provide a hand-washing station enabling 150 people to access water to wash their hands and reduce the risk of infection. 55€ could provide vital supplies of disinfectant, masks, soap and sanitiser to a community of 250 people enabling them to protect themselves and help prevent the spread of the virus. 120€ could pay for a trained COVID-19 worker to support three communities for one month, communicating urgent life-saving messages about prevention and protection as well as providing psychological first aid for children and adolescents affected by the pandemic. The Lumenis Cares foundation are aiming to raise funds to support this charity, and any donation, however large or small, will go a long way towards helping Street Child to SAVE LIVES. https://www.justgiving.com/fundraising/lumenis-cares-foundation Throughout July 2020 Street Child continued to respond to the COVID-19 pandemic across its 14 countries of operation by intensifying its interventions that focus on child education and protection and livelihoods, while continuing to carry out essential coronavirus awareness-raising activities. With schools having been shut for up to five months, it is fundamental that efforts are scaled up to support children back into learning, be it remotely or through supporting schools to become COVID-safe environments, to prevent education drop-out. Without access to the safe space that schools provide, children are also increasingly vulnerable and facing heightened protection risks, and, as such, Street Child’s protection work is now more necessary than ever, with our teams working hard to implement innovative, remote approaches to provide children with much-needed services. Additionally, economic recovery is central to empowering communities and safeguarding their futures, and Street Child has thus escalated its efforts to support the livelihoods of the vulnerable people it serves. Afghanistan Street Child’s COVID-19 protection response continued to expand across Balkh, Badakhshan, Herat and Kunduz provinces, with interventions including psychosocial support services, case management services for unaccompanied and separated children, and specialised services such as interim care and family tracing and reunification for children at severe risk of exposure to exploitation and violence. The charity also continued to provide protection services in the Balkh and Kabul prisons and pivoted to providing remote learning for 3,500 children in Uruzgan. Cameroon In collaboration with its local partners, Street Child is continuing to grow and diversify its response work to reflect the need as restrictions are lifted. With schools reopening to allow students to sit exams, the charity distributed COVID-19 kits including thermometers, soap, handwashing stations, face masks and hand sanitiser to 30 densely populated schools to ensure the safety of their pupils. Street Child also supported 22 women with training and basic income-generating starter packs to combat the economic impact COVID-19 has had on their livelihoods. Democratic Republic of the Congo Ebenezer Ministry International (EMI), Street Child’s core partner in DRC, supported 648 children by distributing government-designed paper-based learning booklets to support the content being taught by teachers in small group teaching sessions. Efforts to break the chain of COVID-19 transmission also continued, with 30 handwashing stations being installed and 2,000 posters with key prevention information being distributed in areas affected by the Uvira floods. Around the globe In Haiti, Lumenis is supporting the efforts of the St. Luke Foundation for Haiti and Dr. Mitchell Humphreys of the Mayo Clinic to provide relief and prevent potentially life-threatening complications in Benign Prostatic Hyperplasia (BPH) patients using the VersaPulse PowerSuite family of Holmium and Dual Wavelength lasers. In Russia, China and Vietnam, Lumenis worked with acclaimed Dr. Rox Anderson  of Harvard Medical School to treat children suffering from burn injuries. Children at the Pediatric Hospital No. 9 in Moscow were treated using Lumenis’ UltraPulse SCAAR FX CO2 laser.  Lumenis donated the laser system to the hospital and Dr. Anderson trained the local doctors so that more children could be helped in the future.  Similar missions with Dr. Anderson were carried out in China and Vietnam where over 300 children were healed. Read More In St. Lucia, where glaucoma affects nearly 9% of the population over the age of 30, Lumenis worked with Dr. Tony Realini of West Virginia University to help reduce preventable blindness using the Selecta II SLT laser.  Lumenis has also collaborated with the Wills Eye Institute to provide SLT procedures to undeserved patients in Philadelphia. In the United States and Israel, the Lumenis HOPE campaign is helping wounded soldiers gain access to advanced burn treatment with the UltraPulse SCAAR FX CO2 laser.  The Company is committed to doing its part to ensure that Veterans wounded in battle receive the best medical care possible, regardless of their ability to pay. In India, Lumenis and Aravind Eye Care System, a social organisation committed to the goal of elimination of needless blindness, are collaborating to evaluate the effect of Selective Laser Trabeculoplasty, a painless laser application, in minimizing glaucoma progression in India. In Africa, Lumenis has collaborated with Right-to-Sight – a non-profit organization registered at the Royal College of Surgeons in Ireland, to Join fight to eliminate preventable blindness in Africa.  “Glaucoma is responsible for up to 20% of the preventable blindness cases in Africa, yet there is less than one ophthalmic surgeon per one million inhabitants across the continent,” said Dr. Kate Coleman, ophthalmic surgeon and founder of Right-to-Sight. “Furthermore, standard medical treatments such as prostaglandin-analogues are largely unavailable, difficult to store at correct temperatures, and often cost more than a local monthly wage. Right to Sight, together with Lumenis, believes that glaucoma in Africa must be addressed as a matter of urgency in view of the recent statistics from the IOVS survey, and in order to alleviate the plight of the millions of individuals in Africa who unnecessarily lose their eyesight to glaucoma,” added Dr. Coleman. In Armenia, Lumenis supported a successful mission to treat children with burn injuries.  The mission, led by R. Rox Anderson, MD, Director of the Wellman Center for Photomedicine and Professor of Dermatology at Harvard Medical School, was designed to provide immediate access to treatment for patients in need, but also to help local medical leaders establish a sustainable burn injury care network in Armenia. The Lumenis UltraPulse®, the most powerful CO2 laser system for scar evision procedures, with the unique SCAARFX mode, was used in the mission. It has also been used in similar humanitarian initiatives in Russia, China and Vietnam, and is considered the standard of care for treating soldiers injured in battle, for example in the VA hospitals in the USA. Read More In Haiti, Lumenis is supporting the efforts of the St. Luke Foundation for Haiti and Dr. Mitchell Humphreys of the Mayo Clinic Dr. Rox Anderson treats children suffering from burn injuries with Lumenis’ UltraPulse SCAAR FX laser system R. Rox Anderson “Unfortunately, sometimes the most effective and innovative healthcare technologies don’t get to the patients who need them most.  We’re determined to change that.Children with burn injuries – whether they live in the suburbs of New York City or a small village in Vietnam – should have access to treatments like SCAAR FX.” R. Rox Anderson, MD, Professor of Dermatology, Harvard Medical School Tzipi Ozer-Armon “Lumenis is proud to support these important initiatives, and on a parallel track we are establishing programs that provide training to empower local doctors and nurses in these communities to offer our life-changing treatments to their patients. We look forward to working with leaders of the medical community to help ensure that these efforts are sustainable.” Tzipi Ozer-Armon, Chief Executive Officer, Lumenis Learn More Wellman Center for Photomedicine Katie Piper Foundation Wills Eye Institute St.Luke Foundation for Haiti Wounded Warriors Project #### Spain WEEE Information for Lumenis Customers and Recyclers Collection and Recycling Arrangements in Spain Lumenis products are sold in Spain by distributors. The distributors act as the importer of the equipment into Spain. Thus the distributors have the legal responsibility to: Register as the WEEE producer in Spain. Provide arrangements for collection and recycling of WEEE arising from Lumenis products that the distributor sells in Spain. Please contact the distributor in Spain below to understand what arrangements he has made for collection and recycling of WEEE arising from Lumenis products: Oftalmica Bonet Products:Ophthalmic Street Address: General Zabala, 4 – 28002 Madrid Country: SPAIN Phone: 91 564 59 00 Fax: 91 564 28 65 Website: http://www.oftalmicabonet.com Main Contact: Jos Bonet Contact 2: Jos Antonio Prez Regional Manager: Nicola Fuccia Mediform Products:Aesthetic Street Address: c/o Doctor Trueta, 46, Bxos, 08005 Barcelona Country: SPAIN Phone: 34 93 225 6500 / 34 93 225 6502 Fax: 34 93 225 6510 Main Contact: Dr. Alejandro Urrea Contact 2: Lidia Fornells Regional Manager: Nicola Fuccia Druco S.L. Products:Aesthetic Street Address: Paseo Arroyas, 10 Urb. Los Berrocalles, 28860 Paracuellos Del Jarama, Madrid Country: SPAIN Phone: 34 91 675-0509 Fax: 34 91 676- 4769 Main Contact: Hugo Druille Regional Manager: Nicola Fuccia #### Sweden WEEE Information for Lumenis Customers and Recyclers Collection and Recycling Arrangements in Sweden Lumenis products are sold in Sweden by distributors. The distributors act as the importer of the equipment into Sweden. Thus the distributors have the legal responsibility to: Register as the WEEE producer in Sweden. Provide arrangements for collection and recycling of WEEE arising from Lumenis products that the distributor sells in Sweden. Please contact the distributor in Sweden below to understand what arrangements he has made for collection and recycling of WEEE arising from Lumenis products: Medicolle AB Products:Ophthalmic Street Address: Tre Liljor 4, SE-113 44 Stockholm Country: SWEDEN Phone: 46 (0)8 654 66 15 Fax: 46 (0)8 654 83 73 Website: http://www.medicolle.se Main Contact: Jan Somp Contact 2: Jan-Christer Isaksson Regional Manager: Remco Schmitz MikronMed Products: Aesthetic Street Address: Bjorkhemsvagen 19, S-291 54 Kristianstad Country: SWEDEN Phone: 46 44 21 2126 Fax: 46 44 21 2179 Main Contact: Christer Persson Contact 2: Lisa anderson Regional Manager: Remco Schmitz (UNITED KINGDOM) #### Terms of Use Terms of Use #### United Kingdom WEEE Information for Lumenis Customers and Recyclers Collection and Recycling Arrangements in the United Kingdom Under the UK Waste Electrical and Electronic Equipment (WEEE) Regulations, for old equipment that you have bought before August 2005 which is being replaced on a one-for-one, like-for-like basis by the purchase of new Lumenis equipment, Lumenis is required to provide arrangements for the collection, treatment, recycling and recovery of the old equipment. The old equipment that your new purchase from Lumenis replaces is referred to as Historic WEEE. Under the UK WEEE Regulations, Lumenis is also required to provide arrangements for the collection, treatment, recycling and recovery of any new electrical and electronic equipment that you buy from Lumenis after August 2005, when that new equipment eventually becomes waste. This is referred to as New WEEE. Lumenis is required to provide these arrangements starting from 1 July 2007. Lumenis products are very competitively priced. Any new increase in operating costs for manufacturers such as Lumenis is normally reflected in a price increase in the product. However, instead of increasing the prices of our products, Lumenis has decided to share these new environmental costs directly with our customers. We believe in being transparent with you on any new environmental costs that our products need to address. Our approach to sharing these new environmental costs is: Lumenis pays for the costs of treatment, recycling and recovery of the WEEE to meet the targets set by the WEEE Regulations; Lumenis pays for the costs of data management and reporting to the Environment Agency to demonstrate compliance with all administrative requirements of the WEEE Regulations; you pay for transportation of your WEEE to Lumenis’s appointed recycler in the UK. Lumenis has established a recycling contract with the European Advanced Recycling Network (EARN) and will cover any costs of treatment, recycling and recovery of the equipment on arrival at the EARN recycling facility in the UK. All New WEEE that arises from the purchase of Lumenis products is classed as non-hazardous waste. It is your responsibility to arrange and pay for costs of collection and transportation to the recycler. In order to meet UK Duty of Care Regulations for waste disposal, you should use one of the following carriers (which hold a valid Waste Carriers licence): Waste Carriers TNT UK Ltd Telephone Number: +44 (0)800 100600 Website: www.tnt.co.uk DHL International (UK) Ltd Telephone Number: +44 (0)8701 100300 Website: www.dhl.co.uk Christian Salvesen PLC Telephone Number: +44 (0)870 3655714 Website: www.salvesen.com For larger quantities of waste, you may want to contact the recycler directly to arrange and pay for alternative collection methods. The EARN recycling facility in the United Kingdom is: Recycler MDJ Light Bros Ltd Telephone Number: +44 (0)1273 486848 Website: www.lightbros.co.uk To comply with the UK Duty of Care Regulations the transport of your waste to the recycler must be accompanied by suitable documentation. You must also keep a signed copy of this documentation for two years. In order to meet this requirement and to enable EARN to identify Lumenis equipment upon arrival at the recycler’s address, please download the Recycling Label for British Customers. Complete the label with your company details and attach it to a suitable box for transport to EARN. Recycling Label for British Customers WEEE Reporting Recycling Data for Lumenis Equipment in the United Kingdom Under Section 27 of of the WEEE Regulations, information on the quantities and categories of Lumenis electrical and electronic equipment put on the market, reused, recycled and recovered within the UK must be reported by the end of each compliance period. The first WEEE recycling report will cover the period January 2009 to December 2009. EARN will prepare the recycling data report for Lumenis. ### Aesthetic Pages #### $500 per hour with SPLENDOR X $500 per hour with SPLENDOR X Publish Date: Aug 13, 2020 Maximizing ROI is at the forefront of every provider’s mind when it comes to investing in new technology. For the Still Waters Day & Medical Spa in Pensacola, Florida, laser hair removal is in high demand. Using the SPLENDOR X as their go-to hair removal machine, they have built a business model thatkeeps their treatment rooms booked and their revenue soaring, averaging $500/hour with their device. PB-00019950 Rev A #### 2025 NewBeauty Award Winner Lumenis Expands FoLix™ Global Footprint with Canadian Launch 2025 NewBeauty Award Winner Lumenis Expands FoLix™ Global Footprint with Canadian Launch FoLix’s expansion into Canada marks a significant milestone for patients and providers, increasing access to the first and only FDA-cleared fractional laser for hair loss, now also cleared by Health Canada FoLix named as the ‘Best Laser Treatment for Hair Loss‘ on NewBeauty’s 15th Annual Beauty Awards YOKNE’AM ILLIT, Israel, March 28, 2025 /PRNewswire/ — Lumenis Be. Ltd., a leading energy-based medical device company, is proud to announce the expansion of FoLix™, the first and only FDA-cleared fractional laser for hair loss, to Canada. Following its success in the United States since its debut in June 2024, Lumenis is marking a significant milestone in its international expansion with the launch of FoLix into the Canadian market to help both men and women to look and feel their best by offering an effective and safe hair loss solution. Earlier this week, FoLix was named the “Best Laser Treatment for Hair Loss” on NewBeauty’s 2025 Beauty Awards list, highlighting the treatment’s effectiveness powered by its groundbreaking approach. FoLix’s novel technology harnesses non-ablative fractional laser (NAFL), and proprietary technology tailored for scalp hair to stimulate hair follicles. FoLix delivers precise pulses of laser that leverage the body’s natural healing processes to stimulate hair follicles, enhance blood flow and promote tissue regeneration. FoLix can produce results in only four to six monthly sessions with no chemicals, needles, anesthesia, surgery or downtime. Expanding availability of FoLix is a meaningful step in improving patient care, as more than 85% of men and 50% of women1 experience some form of hair loss in their lifetime, which can deeply affect self-esteem and overall quality of life. “With FoLix, we’re not just offering a treatment—we’re empowering people to reclaim their confidence and feel like their best selves,” said Tzipi Ozer-Armon, CEO of Lumenis. “Today’s expansion into Canada marks a pivotal milestone in our mission to transform the hair loss space with a solution that is science-backed, safe, and clinically proven. This momentum—reinforced by our NewBeauty award—fuels our commitment to accelerate access to FoLix worldwide.” NewBeauty’s 15th Annual Beauty Awards recognizes the very best beauty products and treatments, highlighting award-winning and cutting-edge technology solutions, presented by the aesthetic experts of NewBeauty. Being recognized with such a prestigious award underscores the advantages of FoLix’s groundbreaking approach and demonstrates Lumenis’ dedication to developing novel, energy-based devices to address some of the most pressing aesthetic-related concerns. FoLix’s ability to easily fit into a wide range of practice groups’ preexisting offerings showcases how the treatment has achieved such rapid expansion into various international markets within its first year since launch. With patients’ growing interest in non-surgical solutions with minimal discomfort that fit easily into their lifestyle – FoLix stands out as the premier choice for hair loss treatment. For more information about FoLix please visit Lumenis.com/FoLix About Lumenis Lumenis is a global leader in the medical aesthetic market and is a world-renowned expert in developing and commercializing innovative energy-based technologies, including Laser, Intense Pulsed Light (IPL) and Radiofrequency (RF). For more than 50 years, Lumenis’ ground-breaking products have redefined medical treatments and set technological and clinical gold-standards, revolutionizing existing treatment methods, and creating solutions for previously untreatable conditions. Lumenis is a portfolio company of EQT Private Capital Asia. For more information regarding Lumenis’ range of clinical solutions, please visit: www.lumenis.com. About FoLix™ FoLix™ is a non-ablative fractional laser device indicated for improving the appearance of scalp hair in adult males and females with Fitzpatrick skin types I to IV, who are seeking treatment for hair loss. FoLix™ treatment could cause redness, swelling, scarring, damage to natural skin texture (e.g. blisters), fragile skin, burns, hair shedding, itching, and pigmentation change. The use of FoLix is contraindicated for patients with any concurrent cancer or history of skin cancer, or pre-cancerous lesions at the treatment area, active infection, chronic fungal or bacterial diseases or chronic dermatological condition of the scalp. See the system user manual for a complete list of contraindications and risks. About NewBeauty Founded in 2005, NewBeauty stands as the definitive authority on beauty, delivering in-depth insights on the latest products, cutting-edge innovations and breakthrough technologies. Each issue offers readers a comprehensive look at the beauty industry, empowering them with knowledge to make informed beauty decisions. Known for its commitment to quality and innovation, NewBeauty remains at the forefront of beauty trends, setting the standard for beauty news and information. 1 Men’s Hair Loss. American Hair Loss Association- https://www.americanhairloss.org/mens-hair-loss/ and Hair Loss in Women. Cleveland Clinic- https://my.clevelandclinic.org/health/diseases/16921-hair-loss-in-women Media Contact Erick Edwing, erick.edwing@havasred.com SOURCE Lumenis Be. Ltd. DOWNLOAD FoLix BROCHURE PB-00088270 Rev A #### 8 Ways To Prevent & Heal Summer Breakouts 8 Ways To Prevent & Heal Summer Breakouts Bustle June 15, 2017 View More #### A new collaboration with the Harrods Wellness Clinic in London, establishing a partnership of excellence A new collaboration with the Harrods Wellness Clinic in London, establishing a partnership of excellence May 5, 2021 – Yokne'am Illit, Israel Lumenis Ltd., the world’s largest energy-based medical device company for aesthetic, surgical and ophthalmic applications, is proud to announce a new partnership with the prestigious Harrods Wellness Clinic, London, UK. Harrods will equip its aesthetic clinic with the Stellar M22™. This powerful multi-application modular platform that combines IPL and lasers technologies will first be installed in the consulting room of renowned Doctor Marwa Ali. Educated at St George’s University of London, holder of a post-graduate diploma in clinical dermatology at Queen Mary University of London and Member of the British Cosmetic Dermatology Group, Dr. Marwa Ali practises advanced aesthetic procedures and is renowned for her supremely natural-looking results. “We’re very proud to offer one of the newest and most innovative treatments available on the market and are therefore thrilled to be adding the Lumenis’ Stellar M22™ to our menu. I’m very excited by the capabilities of this system as some of the conditions it combats have previously been deemed untreatable. I can’t wait to introduce my clients to the Stellar M22™ and to use it to its full potential”, said Dr. Ali. It is no less than 4 innovative technologies that Harrods Wellness Clinic will now offer to their patients: – A versatile IPL™ applicator to treat more than 20 skin conditions, including Acne, Rosacea, Pigmented and Vascular Lesions, reduction of age spots and hair removal. – A Multi-Spot™ Nd:YAG to deliver precise treatment of vascular and leg vein lesions on all skin types. – A Q-Switched Nd:YAG for the treatment of pigmented lesions and Dark Tattoos removal. – A ResurFX™, the only fractional laser with non-ablative scanner for a high-end treatment of stretch marks, scars and skin rejuvenation. “It was only a matter of time before these two institutions met. Harrods Wellness Clinic is one of the world’s most renowned institutions in the field of aesthetic medicine and Lumenis, in addition to having invented the Intensive Pulsed Light (IPL) and its applications, is a pioneering company in the medical use of laser and energy based devices. This is not just an agreement. It’s the perfect match.” stated Claire Dubowski, Vice-President EMEA, at Lumenis. Starting at the end of January, patients seeking extremely natural results in addition to state-of-the-art technology will be able to take full advantage of the treatments offered by the Stellar M22™ at the Harrods Wellness Clinic. If you would like to learn more about this new partnership or about the Stellar M22™ please contact Mateo Bettinger, Brand Manager for Skin at Lumenis: mateo.bettinger@lumenis.com. #### Ablative Lasers CO2 CO2 ABLATIVE LASER Ablative CO2 laser skin resurfacing lasers generate beams of coherent light that are absorbed by the body’s tissue as energy. About The LaserHow Does It Work?NumbersTreatmentsClinicaly ValidatedTestimonials This energy is delivered through a narrow range of wavelengths, elevating the temperature in the targeted area, resulting in tissue evaporation or ablation. Ablative lasers effectively treat a broad range of skin conditions by removing all or only parts of the skin in a fractional manner. The body’s natural healing processes then drive the production of new elastin and collagen fibers, which help replace damaged skin with new and healthy tissue. Although several types of ablative lasers exist, differing mainly by wavelength, CO2 ablative lasers have long been considered the industry’s “Gold Standard” for delivering an exceptional ratio between ablation and coagulation (heating tissue without evaporating it). This standard is backed by more than 30 years of extensive research. SEE MORE RESULTS HOW DOES A CO2 LASER WORK? Exceptional Ablation/Coagulation Ratio CO2 lasers produce light at a 10,600nm wavelength, which is absorbed by water molecules in the tissue. The laser energy heats up the water until it reaches a boiling point, causing the evaporation of the affected tissue. Some of the heat is absorbed by the tissue adjacent to the ablated target area, causing tissue coagulation which induces hemostasis (the cessation of bleeding) as well as thermal stimulation of deep skin layers, which induces fibroblast stimulation and neocollagenesis (the formation of new collagen). The laser beam can also be transmitted through a scanner which is a device used to further control the delivery of energy. The scanner regulates the configuration of energy delivered onto the skin, which can range from covering the entire treatment area or just a fraction of it, leaving some areas of untreated skin that drive faster recovery (“fractional ablation”). The overall effect of ablation and coagulation, either full or fractional, is the removal of damaged skin and the stimulation of the body to replace it with newer, younger, and vibrant skin. FULL RANGE OF ADVANCED CONTINUOUS CAPABILITIES Lumenis CO2 utilized three types of pulse technology UltraPulseTM UltraPulse® technology delivers high peak power in a short pulse duration for deep penetration with ideal ablation and coagulation ratio – penetrating up to 4mm in a single pulse. Highest Peak Power Deepest Impact Narrow, Controlled Thermal Zone ULTRApulse® Alpha SCAARFX™ Mode Spot Size: 120µm Energy: 150mJ Density: 3% Not indicative of clinical results Up to 4mm in a single pulse SuperPulseTM SuperPulse delivers High peak power in a short pulse duration for Deep penetration with ideal ablation and coagulation ratio. Highest Peak Power Deepest Impact Narrow, Controlled Thermal Zone AcuPulseTM DeepTM Mode Spot Size: 120µm Energy: 20mJ Density: 15% Penetration Depth: 700µm Not indicative of clinical results Up to 1mm in a single pulse Superficial and CW Delivers Low peak power for superficial impact and wider coagulation zone, used for full ablation and fractional treatments. Low Peak Power Superficial Impact Wider Thermal Zone AcuPulseTM SuperficialTM Mode Spot Size: 1.3mm Energy: 170mJ Density: 60% Penetration Depth: 150-200µm Not indicative of clinical results Up to 1mm in a single pulse ~1-2 WEEKS RECOVERY 89% REALSELF WORTH IT RATING LEARN MORE 30+ MEDICAL INDICATIONS CAN BE TREATED USING LUMENIS’ ABLATIVE CO2 LASERS CO2 LASER TREATMENTS DEEP WRINKLES Lumenis’ CO2 ablative technologies enable a high rate of improvement for skin damage and skin tone with minimal downtime. This is due to their unique pulse technologies and tailored treatment modes. SCAR REVISION Lumenis’ CO2 devices allow advanced treatment of a variety of severely damaged skin lesions which require synergistic coagulation and ablation for advanced resurfacing. CLICK TO DOWNLOAD ACNE SCARS Syringomas are benign tumors, typically found clustered on eyelids, although they may also be found in other body parts. These can be treated by CO2 laser in a safe, and nonscarring method. BLEPHAROPLASTY Lumenis offers a complete laser blepharoplasty solution that combines an incisional solution with complementary eyelid resurfacing. With laser assisted incisions, bleeding during the procedure as well as post-surgery bruising are reduced. Providers may also consider resurfacing the eyelids as an alternative to surgical treatment. FRACTIONAL ABLATIVE RESURFACING #### Acne Scars Acne Scars Laser Treatment Persistent and untreated inflammatory acne lesions may cause various degrees of permanent scarring. Laser resurfacing is one of the most effective ways of reducing and clearing acne scars. Available laser treatments include ablative and non-ablative skin resurfacing. The choice of treatment depends on the type of scar (box, rolling, or icepick) and on the patient’s preferences and expectations in terms of number of treatments and downtime. › Ablative resurfacing: ideal for patients seeking an amazing improvement in a single session. › Non-ablative resurfacing: ideal for patients who prefer a milder treatment approach that requires several treatments but has less downtime. The Lumenis Solution Lumenis® offers a range of ablative and non-ablative resurfacing solutions tailored to each practice and each patient’s needs and preferences. Lumenis® CO2 ablative resurfacing: Lumenis’ ablative technologies dramatically decrease scars, even very deep ones, as well as repair damaged skin and improve skin tone. Treatment is free of complications and requires minimized downtime due to the unique pulse technologies and tailored treatment modes. The ablative technologies are available in the UltraPulse® and AcuPulse™ products. Advantages For Physicians Optimal results and treatment control with Lumenis’ UltraPulse® and AcuPulse™ unique short pulse technologies that allows for an exceptional ablation/coagulation ratio. Unique ability to reach the desired treatment depth quickly and in a single pulse with minimal collateral thermal damage. Advanced scanner technology offers a wide choice of energy, density, scanning shape and size options, facilitating customized treatment parameters for the optimal treatment of each patient condition. Clinical Evidence Lumenis® CO2 compendium of peer reviewed articles Related Products The ablative technology is available in the UltraPulse® and AcuPulse™ products. For the Lumenis non-ablative solutions please see Non-ablative resurfacing. UltraPulse® The most powerful CO2 laser in aesthetic medicine AcuPulse™ MultiModeTM SuperPulseTM CO2 Laser Learn More Bibliography of studies & peer reviewed papers PB-1004602 Rev A × GET MORE INFO #### AcuPulse AcuPulse™ MultiMode™ SuperPulse™ CO2 Laser AcuPulse™ is a complete ablative laser resurfacing workstation, featuring state of the art technology for all aesthetic resurfacing needs. Request Demo Visit the Aesthetics Resource Hub for professional insights GO! POWERFUL. VERSATILE. SIMPLE. SuperPulse™ Technology Exceptional ablation/coagulation ratio Reach the desired treatment depth with a single pulse 11 Built-in Treatment Modes Maximum versatility with only two scanners Full parameter control for advanced users Short Pulse Duration Enhanced patient comfort Lower chance of side effects Intuitive User Interface Easy setup and quick treatments User presets for single-click treatments Treatments & Indications Scar Revision The AcuPulse allows for advanced treatment of a variety of severely damaged skin lesions which require synergistic coagulation and ablation for advanced resurfacing. Acne Scars Lumenis CO2 ablative technologies dramatically decrease scars, even very deep ones, as well as repair damaged skin and improve skin tone. Syringomas Syringomas are benign tumors, typically found clustered on eyelids, although they may also be found in other body parts. These can be treated by CO2 laser in a safe, and nonscarring method. Blepharoplasty Lumenis offers a complete laser blepharoplasty solution that combines an incisional solution with complementary eyelid resurfacing. With laser assisted incisions, bleeding during the procedure as well as post-surgery bruising are reduced. Women's Health The women’s health on AcuPulse™ offers a range of minimally invasive solutions for women coping with gynecologic conditions that affect their well-being, confidence and intimacy. Fractional ablative resurfacing Ablative skin resurfacing procedures use lasers to reduce the signs of aging, improve skin texture, laxity and tone, and reduce scars and stretch marks. Ablative resurfacing is ideal for patients seeking a dramatic improvement in a single session. Rhinophyma Rhinophyma is a disorder causing development of a large, bulbous nose associated with granulomatous infiltration, commonly due to untreated rosacea. This can be treated with CO2 laser as a surgical tool. Deep Wrinkles The Lumenis™ CO2 ablative technologies enable a high rate of improvement for skin damage and skin tone with minimal downtime. This is due to their unique pulse technologies and tailored treatment modes. AcuPulse patients experience Patients tell about their experience with AcuPulse treatment Request Demo Full Range of Advanced Continuous Capabilities AcuPulse utilized two types of pulse technology: SuperPulse™ SuperPulse delivers high peak power in a short pulse duration for deep penetration with ideal ablation and coagulation ratio. AcuPulse™ Deep™ Mode Spot Size: 120µm Energy: 20mJ Density: 15% Penetration Depth: 700µm Not indicative of clinical results Up to 1mm in a single pulse Continuous Wave (CW) delivers low peak power for superficial impact and a wider coagulation zone used for full ablation and fractional treatments. AcuPulse™ Superficial™ Mode Spot Size: 1.3mm Energy: 170mJ Density: 60% Penetration Depth: 150-200µm Not indicative of clinical results Up to 1mm in a single pulse 11 Treatment Modes For Maximum Versatility AcuScan120™ fractional scanner Superficial™ For uneven pigmentation, fine lines, uneven texture, dyschromia, actinic keratosis and more. Combo™ Deep and Superficial combined together for uneven pigmentation, acne scars, wrinkles and more. Deep™ For deeper lines and wrinkles, acne scars, uneven texture, dyschromia and more. StretchTouch™ For skin furrows and textural irregularities. SurgiTouch™ advanced scanner FeatherTouch™ For gentle, single scan treatments. ToeTouch™ SilkTouch™ For more vigorous, double scan treatments. Paint™ For skin furrows and textural irregularities. FineTouch™ For precise ablation of irregular pigmented lesions at various depths. 125mm™ incisional handpiece Bleph™ For precise, clean incisions with minimal bleeding. Women’s Health Women’s Health Accessory Standard focus tip (28mm) enables stretching of the treated area for optimal scanning and is suitable for most patients. Fine (21 mm) designed for cases in which the Standard tip is not applicable Technology Unique SuperPulse Technology AcuPulse™ features a unique SuperPulse™ mode for extraordinarily safe deep impact, as well as a full range of advanced continuous wave capabilities for precision work. Exceptional Ablation/Coagulation Ratio When ablation depth is equal, more energy means more excess heat in the tissue. SuperPulse™ technology enables the deepest penetration with the lowest energy.  This reduces patient discomfort, downtime and thermal damages. AcuPulse™ also enables shorter pulses, further enhancing patient safety. Read more Clinical Research 2012 – Clinical Evaluation of the Safety and Efficacy of a Novel Superficial and Deep Carbon Dioxide Fractional System in the Treatment of Patients With Skin of Color Michael H.Gold, MD Read More 2013 Treatment of Cosmetic Tattoos Using Carbon Dioxide Ablative Fractional Resurfacing in an Animal Model: A Novel Method Confirmed Histopathologically Chia-Chen Wang, MD ,Chuen-Lin Huang, PhD, Yuh-Mou Sue, MD5, Shao-Chen Lee, PhD2,Fur-Jiang Leu, MD, PhD Read More 2012 Combined superficial & deep fractional skin treatment for photodamaged skin – a prospective clinical trial Michael H. Gold & Julie A. Biron Read More 2012 – A new multi-modal fractional ablative CO2 laser for wrinkle reduction and skin resurfacing Matteo Tretti Clementoni,Rosalia Lavagno, Girish ,Munavalli Read More Hear From Our Doctors Dr. Michael Gold on AcuPulse Dr. Gilly Munavalli on AcuPulse Dr. Daniel Friedmann on AcuPulse Learn more about AcuPulse Get our Clinical Casebook. A collection of Before & After images from around the world E-Book Brochure PB-00025440 Rev A GET MORE INFO × Close Close Close #### AcuPulse for Women’s Health Women’s Health Help your patients live their life to the fullest Address a wide range of women’s health issues with a non-surgical, virtually painless, non-hormonal treatment. Women at any age can enjoy the benefits and feel improvement in just a few short sessions. EXPLORE OUR PRODUCTS Women’s Health on AcuPulse 360° of women’s health solution The women’s health on AcuPulse™ offers a range of minimally invasive solutions for women coping with gynecologic conditions that affect their well-being, confidence and intimacy. Gynecological Treatment When operating on delicate anatomy, the aim is, first and foremost, to avoid thermal damage. That’s why the AcuPulse CO2 laser technology is a treatment of choice, suitable for use with a variety of approaches and applications. Vaginal approach Vaginal abscess Genital warts Labial reduction Lichen sclerosis Colposcopy approach Cervical Intraepithelial Neoplasia (CIN) Leukoplakia Condyloma Benign & malignant tumors Laparoscopy approach Endometriosis Adhesions Myomas Cysts Hysterectomy Related Products   FemTouch™ The women’s health on AcuPulse™ offers a range of minimally invasive solutions for women coping with gynecologic conditions that affect their well-being, confidence and intimacy. PB-1004645 Rev A   GET MORE INFO × #### Advanced intelligent skincare with the Stellar M22 Advanced intelligent skincare with the Stellar M22 Publish Date: Feb 24, 2021 Length: 63 Minutes In this webinar Dr. E. Victor Ross introduces the new Stellar M22 from Lumenis with a powerful modular multi-application platform. With four technologies in one platform Stellar M22 enables you to treat more patients and expand your business. Discover the infinite possibilities available with the Stellar M22. Dr. Victor Ross E. Victor Ross, MD ,Dermatologic Surgeon, board-certified in Dermatology, Director of Laser and Cosmetic Dermatology Scripps Clinic, CA, US PB-00016580 Rev A #### Aesthetic Treatment Demand Statistics Post-Shutdown Report Aesthetic Treatment Demand Statistics Post-Shutdown Report Publish Date: July 1 2020 The purpose of this whitepaper is to give aesthetic providers insight into what treatments other providers around the country are recommending currently, as well as the most in-demand treatments. PB-00016360 A #### All Your Most Embarrassing Butt Questions, Answered All Your Most Embarrassing Butt Questions, Answered Refinery29 May 31, 2017 View More #### Are Injection-Free Treatments the Future of Anti-Aging? Are Injection-Free Treatments the Future of Anti-Aging? August 25, 2024 This next level no-downtime treatment that Dr. Amy B Lewis says creates muscle memory, leading to improved lifting and tightening effects, similar to a facelift Read Full Article PB-00074820 Rev A #### Ask Clinical LightSheer Webinar Ask Clinical LightSheer Webinar Publish Date: Nov 25, 2020 Length: 46 Minutes With LightSheer QUATTRO you can customize patient treatments according to each individual’s hair type, skin type (including tanned and dark skin) and therefore access a larger demographic. This clinically-proven diode laser treatment featuring two wavelengths 805nm and 1060nm as well as two unique laser delivery technologies: High Speed vacuum assisted technology and ChillTip™ integrated contact cooling technology. In this webinar three leading Lumenis laser hair removal experts discuss what makes LightSheer unique and review the technology in detail. Learn more on the benefits of each handpiece and its unique features. Sandra Woods Experienced Clinical Director with a demonstrated history of working in the hospital & health care industry. La Toya Boyd Clinical Application Specialist, Lumenis Linda Buj Clinical Applications Specialist, Lumenis PB-00016500 A #### Attracting Male Laser Hair Removal Patients Attracting Male Laser Hair Removal Patients Publish Date: July 1 2020 Meeting the demands of aesthetic patients requires top-tier technology. While this applies to all patients, it is especially true for males. Fill out our form to download and learn more today. PB-00000000 Rev A #### Attracting Male Patients with Radio Frequency Technology Attracting Male Patients with Radio Frequency Technology Publish Date: July 1 2020 Increase Revenues with Male Patients. Download Our eBook to Learn the Most Effective Strategies for Attracting Male Patients Now and In the Future. Fill out the form to download our ebook. PB-00000000 Rev A #### Australian Skin Clinics Choose Lumenis and Splendor X as Preferred Supplier URL: https://lumenis.com/aesthetics/resource-hub/australian-skin-clinics-choose-lumenis-and-splendor-x-as-preferred-supplier/ #### Baring Private Equity Asia Agrees to Acquire Lumenis Baring Private Equity Asia Agrees to Acquire Lumenis November 18, 2019 – Tel Aviv-Yafo, Israel Baring Private Equity Asia today announced that its affiliated private equity funds (“BPEA”) have agreed to acquire Lumenis, a leading provider of specialty energy-based medical devices across the fields of aesthetics, urology, ophthalmology, ENT and gynecology from XIO. The transaction values Lumenis at an enterprise value of over $1 billion. Lumenis is a global leader in the field of minimally-invasive clinical solutions for the Aesthetic, Surgical, and Ophthalmology specialties. For over 50 years, Lumenis’ ground-breaking products have redefined medical treatments and have set numerous gold-standards. The company has a presence in over 100 countries and close to 1,500 employees worldwide. The Asia Pacific region is its largest market, together with a strong presence in North America and EMEA. “BPEA’s investment is a tremendous vote of confidence in Lumenis and in the achievements of our entire global organization. In recent years, we have developed and introduced multiple groundbreaking technological solutions that have redefined our industry and opened entirely new market segments. I would like to thank the entire Lumenis team, I am truly proud of all we have accomplished and honored to lead a company on the cutting edge of healthcare innovation, committed to improving the lives of people across the world. We look forward to partnering with the team at BPEA to continue developing and delivering to the world better technology for better patient care”, said Tzipi Ozer-Armon, CEO of Lumenis. Yan Jiao, Managing Director at BPEA commented: “Lumenis has built a market-leading position by creating some of the most innovative technologies in the industry. It is a clear leader worldwide, especially in Asia which recently emerged as the largest market for medical and aesthetics treatments.  We look forward to working with the CEO and management team to support their global growth aspirations.” The transaction remains subject to the customary regulatory approval process and is expected to be completed in early 2020. #### Best Skincare Regimen for Your 20s, 30s, 40s, and Beyond Best Skincare Regimen for Your 20s, 30s, 40s, and Beyond BRIT+CO September 4, 2017 View More #### Between Medicine & Beauty: Cosmetic Dermatology Between Medicine & Beauty: Cosmetic Dermatology August 26, 2024 The science behind maintaining a youthful appearance with triLift’s standout technology, and how traditional dermatologists are now embracing aesthetic medicine. Read Full Article PB-00074830 Rev A #### BLEND X® Alex YAG BLEND X®: Latest Hair Removal Technology Binary laser emission of Nd:YAG (1064nm) and Alexandrite (755nm) wavelengths What is BLEND X Technology? Most laser hair removal technologies on the market use one of two wavelengths to target the hair follicle: The Alexandrite wavelength at 755 nm, which is ideal for treating skin tones 1, 2 and 3 (fair and light skin tones). It is highly absorbed in melanin and is therefore not safe for use on darker skin tones. The Nd:YAG wavelength at 1064 nm, which is ideal for treating skin tones 4, 5 and 6 (4 being tanned skin and 5 and 6 darker skin tones) as the absorption by melanin is much lower than with the Alexandrite wavelength. This wavelength is highly absorbed in oxyhemoglobin, which affects the blood supply to the hair follicle. When using these technologies, treatment providers often need to use high settings of each wavelength to effectively remove hair. This can result in more painful treatments and temporary complications. BLEND X Technology Synchronizes Both Wavelengths* In order to solve these challenges, Lumenis introduced BLEND X technology. This unique technology is the first of its kind to synchronize Alexandrite (755nm) and Nd:YAG (1064nm) wavelengths to fire with adjustable proportions. With this technology, each pulse can be BLEND Xed when fired with varying proportions to tailor treatment, and customized to fit the patient’s specific skin type, hair color and thickness for the most effective treatment. BLEND X technology is used to power the SPLENDOR X solid-state laser device. With this powerful, fast and versatile device, treatment providers can synchronize Alexandrite and Nd:YAG wavelengths to customize treatment options for patients with different skin and hair type combinations. BLEND X technology targets the hair Note: In the US the lasers are binary operated. Fluence: 20 J/cm2 Configuration Square spot size Repetition rate Alexandrite &Nd:YAG 20x20mm24x24mm 3Hz1Hz * In the US the lasers are binary operated. Related Products SPLENDOR X Laser hair removal workstation powered by BLEND X technology PB-2012234 Rev A   GET MORE INFO × #### Blepharoplasty About Blepharoplasty Blepharoplasty is an aesthetic surgical procedure that corrects/modifies defects, deformities or disfiguration of the eyelids. It involves excision, removal and/or repositioning of excess tissue and reinforcement of the muscle and tendon tissues. Patients undergo blepharoplasty procedures in order to restore functionality of the eyelids and improve the appearance of the eye-region of the face. The Lumenis Solution Lumenis® offers a complete laser blepharoplasty solution that combines an incisional solution with complementary eyelid resurfacing. The AcuPulse™ as well as the UltraPulse® systems have an incisional handpiece that provides excellent surgical precision during treatment. With laser assisted incisions, bleeding during the procedure as well as post-surgery bruising are reduced. The systems are also equipped with fractional ablative skin resurfacing modes that offer excellent skin rejuvenation results in the surrounding periorbital areas. Advantages For Physicians Ultimate versatility in one system, allowing both the required incisional mode as well as the complementary eyelid rejuvenation using fractional ablative skin resurfacing. Optimal results and treatment control with Lumenis’ unique short pulse technologies UltraPulse® and SuperPulse™ allowing the best ablation/coagulation ratio. Clinical Evidence Lumenis® CO2 compendium of peer reviewed articles Related Products The ablative technology is available in the UltraPulse® and AcuPulse™ products. For the Lumenis non-ablative solutions please see Non-ablative resurfacing. PB-1004605 Rev A × GET MORE INFO #### Body Body Cellulite Reduction & Skin Smoothing Personalized non-invasive body treatments from head to toe, targeting the specific needs and desires of each patient for natural-looking results with no downtime. EXPLORE OUR PRODUCTS Cellulite Cellulite, also known as orange-peel skin, is a condition in which the skin has a dimpled, lumpy presence. It occurs when fat deposits push through the connective tissue beneath the skin and usually affects the thighs and buttocks (yet can also occur in other areas). Almost all women (and some men) have cellulite, stemming from genetic predisposition, hormonal changes and weight gain. As Social Media drives us to appear picture perfect (at any cost), individuals turn to exercise and strict diets in a struggle to pursue their ideal body image. Unfortunately, sometimes, a change in lifestyle is just not enough, and stubborn fat or loose skin just won’t budge. According to the American Society for Aesthetic Plastic Surgery, one of the most promising ways to combat cellulite is laser treatment, causing the body shaping and skin tightening market to gradually grow by 16.3% through 2020. The Lumenis Solution There are many solutions on the market, yet unlike the invasiveness of surgery and the harshness of chemicals, NuEra Tight harnesses the power of science naturally heating the skin, inducing collagen contraction and creation, kicking the body’s own healing mechanism, and generating natural, long lasting looking results, with no downtime. This non-invasive skin smoothing platform is suitable for a wide range of body types and areas, treating a wide range of conditions in one, impactful tailored-made session, all while focusing on simplicity of treatment and providing exceptional ROI. There are many solutions on the market, yet unlike the invasiveness of surgery and the harshness of chemicals, NuEra tight harnesses the power of science naturally heating the skin, inducing collagen contraction and creation, kicking the body’s own healing mechanism, and generating natural, long lasting looking results, with no downtime. This non-invasive skin smoothing platform is suitable for a wide range of body types and areas, treating a wide range of conditions in one, impactful tailored-made session, all while focusing on simplicity of treatment and providing exceptional ROI. Advantages For Physicians All-In-One, total body platform Impressive results & customer satisfaction Patient safety & comfort Simplicity Reliable technology Advantages for Patients Natural looking and long-lasting results “Hot stone” massage feel Comfortable, over lunch Treatment with no downtime Clinical Evidence – Before and After Related Products   NuEra™ Tight High Power, Temperature-Controlled Top to Toe RF Skin Laxity and Cellulite Treatment. NuEra™ Tight NuEra tight is a temperature-controlled radio frequency (RF) skin smoothing system with the power to redefine the future. The power to target and revive, to uplift and to perfect all over. PB-2012317 Rev A GET MORE INFO × #### Bosley and Lumenis Partner to Introduce Breakthrough Hair Loss Solution, FoLix™, to the U.S. Bosley and Lumenis Partner to Introduce Breakthrough Hair Loss Solution, FoLix™, to the U.S. Lumenis’ first-in-class, proprietary and FDA-cleared fractional laser technology for hair loss treatment has the power to transform the lives of millions of hair loss sufferers in the U.S. SAN JOSE, Calif., Sept. 24, 2024 /PRNewswire/ — Lumenis Be. Ltd., a leading energy-based medical device company for aesthetic and eye care solutions, announced a new partnership with Bosley, the largest hair restoration practice in the United States and a recognized leader in the industry. Bosley becomes the first national hair restoration medical practice in the United States to offer FoLix™, the first and only FDA-cleared fractional laser for hair loss treatment. Recently cleared by the FDA, FoLix becomes the first and only fractional laser for safe, effective, and natural hair loss treatment for women and men in the United States. Bosley will initially offer FoLix at its Beverly Hills location beginning September 2024 and plans to roll out the service at its other locations across the country over time. This partnership initiates a new era in hair loss treatment by introducing the first FDA-cleared fractional laser solution for hair loss to U.S. customers for the first time, potentially benefiting more than 80 million people affected by hair loss across the country1. The partnership also highlights Bosley’s dedication to supporting customers in their fight against hair loss, reinforcing its position as one of the world’s most trusted and experienced hair restoration experts. “Staying at the forefront of innovations and excellence, we are always looking for the latest and most effective advancements to support our customers in their hair restoration journey,” said Rob Spurrell, CEO and President of Bosley. “FoLix is a strong and perfect fit for our expanding range of solutions, as it offers a non-surgical, in-office approach with minimal discomfort, showing promising results in several monthly sessions.” “At Bosley, we understand the profound impact that hair loss can have on our patients’ lives. We have been helping patients with hair loss, surgically and non-surgically, with emerging technology for 50 years, and we are excited to introduce the Lumenis FoLix treatment, an innovative treatment designed to help our patients restore their hair and confidence,” said Ken Washenik, MD PhD, Chief Medical Officer at Bosley. Following the FDA clearance granted earlier this year, Lumenis launched FoLix, a groundbreaking innovation in hair loss treatment and the first of its kind. Developed with Lumenis’ proprietary technology, FoLix offers a non-invasive, effective, simple, and safe solution that uses a unique approach to deliver precise pulses of laser light that leverage the body’s natural processes to stimulate hair follicles. FoLix is anticipated to attract considerable interest from people impacted by hair loss, as it offers results through 4-6 monthly sessions with no chemicals, needles, anesthesia, or downtime. Lumenis and Bosley are both committed to raising awareness and educating about the causes, prevention, and treatment of hair loss. Hair loss is a common condition that could appear in various stages of life, with 2 in 3 men facing hair loss by age 352 and 1 in 2 women facing hair loss by age 503. The introduction of FoLix meets this strong clinical need and can have a significant impact on people’s self-esteem, confidence, and quality of life. “With proven results from Lumenis’ pre-clinical and clinical studies, FoLix represents a significant leap forward in the world of hair restoration for both patients and providers,” said Brad Oliver, President of Lumenis Americas. “Our partnership with Bosley is an exciting first step in bringing FoLix to the U.S. market, and we are confident that this revolutionary technology will make a meaningful difference in the lives of millions of people who suffer from hair loss, empowering them to take control and grow more confident in their everyday experiences.” For more information about FoLix™, please visit Lumenis.com/FoLix About Lumenis Lumenis is a global leader in the medical aesthetic market and is a world-renowned expert in developing and commercializing innovative energy-based technologies, including Laser, Intense Pulsed Light (IPL) and Radiofrequency (RF). For more than 50 years, Lumenis’ ground-breaking products have redefined medical treatments and set technological and clinical gold-standards, revolutionizing existing treatment methods, and creating solutions for previously untreatable conditions. Lumenis is a portfolio company of EQT Private Capital Asia. For more information regarding Lumenis’ range of clinical solutions, please visit: www.lumenis.com. About Bosley Founded in 1974, Bosley is the largest hair restoration practice in the United States. For more than 50 years, Bosley physicians have focused on the art and science of hair restoration for both men and women, utilizing innovative, artistic and scientific techniques. With more than 500,000 hair restoration procedures performed (with patients from all 50 states and 60 other countries), Bosley has helped hundreds of thousands of patients find a permanent solution for their hair loss. For more information, please visit www.bosley.com. About FoLix™ FoLix™ is a non-ablative fractional laser device indicated for improving the appearance of scalp hair in adult males and females with Fitzpatrick skin types I to IV, who are seeking treatment for hair loss. FoLix™ treatment could cause redness, swelling, scarring, and pigmentation change. The use of FoLix is contraindicated for patients with any concurrent cancer or history of skin cancer, active infection, fungal or bacterial diseases. See the system user manual for a complete list of contraindications and risks. Media Contact Andrew Spivak, andrews@bosley.com. Courtney Myers, courtney.myers@havasred.com. According to the American Academy of Dermatology Association. According to the American Academy of Dermatology Association. According to MedlinePlus by NIH. DOWNLOAD FoLix BROCHURE PB-00081710 Rev A #### Brand New triLift Muscle Stimulation Treatment Brand New triLift Muscle Stimulation Treatment August 25, 2024 Trending aesthetic technology offers a facelift like effect – Minus the scalpel Read Full Article PB-00074810 Rev A #### Candela and Lumenis Announce Settlement of Patent Infringement Lawsuit Candela and Lumenis Announce Settlement of Patent Infringement Lawsuit Mutual settlement agreement and sublicense ending the patent disputes between the companies. July 16, 2019 – Yokne'am Illit, Israel WAYLAND, Massachusetts and YOKNEAM, Israel, July 16, 2019 /PRNewswire/ — Candela Corporation, a leading global aesthetic device company and the exclusive licensee of certain patents of General Hospital Corporation, d/b/a Massachusetts General Hospital,  Lumenis Ltd., a global leader in the field of minimally-invasive clinical solutions for the aesthetic, surgical, and ophthalmic markets, and its subsidiary, Pollogen Ltd., announce that they have entered into a mutual settlement agreement and sublicense ending the patent disputes between the companies. While terms of the settlement and sublicense agreements are confidential, Lumenis and Pollogen will continue to actively market and develop their fractional RF micro-needle product line, including the Legend and Divine family of products.   #### Case study – Dr. Gilbert Case study – Dr. Gilbert Publish Date: Apr 19, 2021 Dr. Dore Gilbert required a device that was not only effective and safe, but that offered an excellent return on investment. Find out why he chose M22 as an investment, and how it proved worthwhile by delivering an impressive ROI. PB-00002930 Rev A #### Clinical Innovation In Laser Hair Removal Webinar Clinical Innovation In Laser Hair Removal Webinar Publish Date: Jul 1, 2020 Length: 53 Minutes Learn more on the clinical side of SPLENDOR X laser hair removal Sachi Norman, MD Senior Medical Director at Lumenis PB-00016360 A #### Clinical Results Lightsheer DESIRE Overview The Technology How It Works Patients Benefit Practice Benefits Clinical Results White Papers Desirable Clinical Results The LightSheer technology by Lumenis has been validated in numerous clinical studies and peer reviewed articles. Our customers benefit from the LightSheer DESIRE features and enjoy high patient satisfaction. Physician Testimonials “With the High Speed Technology I can treat large body areas in record time. Using the 22×35 handpiece I can complete treatment on backs and legs in less than 10 minutes and the treatment is very effective. My customers love the results and recommend it to their friends. My business turnover has in-creased.” Mary Lupo, M.D “I chose the LightSheer for my practice because it uses an 805 and I am very pleased with my choice. The results are outstanding and the treatment is most comfortable for the patients. With the combination of three handpieces utilizing two different technologies,I can give the best treatment to every patient that comes to my office ” Adele Quintana, M.D. “The LightSheer is a fast and easy to use device. It is perfect for treating large body areas as well as small and precise ones due to the combination of the High-Speed and the ChillTip, ET & XC, handpieces. Both the vaccum of the High-Speed and the cooling of the ChillTip combine effective treatments with novel ways to minimize discomfort. It is a device that both my staff and patients can count on…” Omar A. Ibrahimi, M.D., Ph.D. PB-00005680 Rev A × GET MORE INFO #### Configurations LightSheer DUET Overview Treatment & Testimonials Configurations Patients Benefit Practice Benefits Take the High Speed Challenge Configurations Versatile platform for those focused on practice growth, enables a customized approach across the broadest range of patients and treatment areas Vacuum Assisted High-Speed Integrated Technology A large 22×35 mm spot size enables the use of low-fluence and with a unique mechanism for pain reduction provides effective, fast and comfortable treatment. ChillTip™ Technology – Integrated contact cooling provides epidermal protection for treatment areas requiring precision and higher fluence Indications For Use Hair removal, permanent hair reduction, and the treatment for Pseudofolliculitis Barbae(PFB). Treatment of vascular lesions, including angiomas, hemangiomas, telangiectasia, leg veins and other benign vascular lesions. Treatment of benign pigmented lesions.  Specifications: Platform LightSheer DUET HandPiece ET HS Technical Specifications: Laser Type AIGaAs Diode Arrays AIGaAs Diode Arrays Wavelength 805 nm (nominal) 805 nm (nominal) Spot Size 9 mm X 9 mm 22 mm X 35 mm Repetition Rate Up to 3 Hz Up to 3 Hz Pulse repetition 1 Pulse 1-3 Pulse Fluence 10-100 J/cm2 4.5-12 J/cm2 Pulse Width(OptiPulse) 5-400 ms 30-400ms Peak Power 1600 W 2300 W Comfort Management Chilltip contact cooling (5°C) Vacuum assist (up to 18 in Hg) Preset Parameters Yes Yes Warranty 1 Year 1 Year On-Site Service Yes; Replaceable handpiece Yes; Replaceable handpiece Platform Specifications : Electrical 100-240 VAC, 15 A max. | 50/60 Hz. | Single-phase grounded outlet Weight 48 kg(105 lbs) Dimensions (WxDxH) 44 x 50 x 112 cm; (17.4 x 19.7 x 44 in) Learn More LightSheer DUET Patient BrochureLightSheer DUET Physician Brochure PB-1049670 Rev C GET MORE INFO × #### Diode Lasers Diode Laser Technology for Hair Reduction A diode laser uses semiconductor technology that produces coherent projection of light in the visible to infrared range. It uses a light beam with a narrow spectrum to target specific chromophores in the skin. Compared to other laser systems such as the Ruby and Alexandrite, the 800nm diode laser wavelength offers the deepest penetration levels and superior melanin absorption. These unique characteristics make the diode laser the most suitable technology for laser hair removal, enabling safe and effective treatment of all skin and hair types, in all body areas. How Does A Diode Laser Work? Diode lasers use the principle of selective photothermolysis (abbreviated SPTL) to target specific chromophores in the skin, usually melanin or blood.  The lasers damage the chromophores by selectively heating them while leaving surrounding tissue unharmed.  When treating unwanted hair, for example, the melanin in the hair follicles is targeted and damaged which results in the disruption of hair growth and regeneration.  A diode laser can be complemented by cooling technology, or other pain reducing methods which improve treatment efficacy and patient comfort. The Lumenis Diode Laser Solution Lumenis’ LightSheer diode technology by Lumenis has been validated in numerous clinical studies and peer reviewed articles. Our customers benefit from the LightSheer DESIRE features and enjoy high patient satisfaction. The LightSheer uses high-power diode technology that can deliver high fluence. This is combined with user-select pulse duration, effective contact cooling and compression for high-performance. The LightSheer also offers a 22 x 35 mm spot size which allows for greater depth of penetration and significantly faster treatment. Related Products LightSheer® QUATTRO™ Feel the confidence that comes with LightSheer. GET MORE INFO × #### Dr. Lori Aliksanian Highlights Trilift – the One and Only Device Fighting All Signs of Aging Dr. Lori Aliksanian Highlights Trilift – the One and Only Device Fighting All Signs of Aging August 7, 2024 Dr. Lori of MedBeauty LA, Downtown L.A.’s Premier Med Spa, showed her patients triLift by Lumenis, a noninvasive and safe way to generate a face lift-like effect without downtime at a reasonable price point. Read Full Article PB-00070120 Rev A #### Dr. Saras & Co. Aesthetic Clinic Future-proofed Her Practice With Trilift Dr. Saras & Co. Aesthetic Clinic Future-proofed Her Practice With Trilift August 15, 2024 Helping her patients to achieve impressive anti-aging results without surgery, Dr. Cosmetic Physician Dr. Saras Sundrum introduced triLift at her three Sydney, AU-based clinics, improving her practice beyond expectations! Read Full Article PB-00070210 Rev A #### Early triLift Adopter Dr. James Chelnis now is a Thriving triLift Success Story Early triLift Adopter Dr. James Chelnis now is a Thriving triLift Success Story August 26, 2024 Renowned Aesthetic Surgeon Dr. Chelnis “counts on Lumenis to keep delivering safe, effective, cutting-edge technology”, and strives to maintain advanced technological innovations in aesthetic medicine such as triLift Read Full Article PB-00070220 Rev A #### EPIC Miami EPIC Miami AKA Brickhell Hotel 1395 Brickell Ave, Miami, FL 33131 Register Now – Make Your Aesthetic Business EPIC – Join us and discover how the latest in BeautyTech Empowers practices and Inspires customers with life changing aesthetic outcomes. Experience EPIC Panels on: IPL Secrets, Skin & SmoothGlo Discover NEW frontiers, pioneers & triLift CO2 & You – From Novice to Master Breakthrough Laser Hair Loss Treatment Serve ALL skin types Providers, Patients, & PAIN, the TRUTH about Marketing BeautyTech Showcase And More! #### EPIC Scottsdale EPIC Scottsdale W Scottsdale Hotel 7277 E Camelback Rd, Scottsdale, AZ 85251 Register Now – Make Your Aesthetic Business EPIC – Join us and discover how the latest in BeautyTech Empowers practices and Inspires customers with life changing aesthetic outcomes. Experience EPIC Panels on: IPL Secrets, Skin & SmoothGlo Discover NEW frontiers, pioneers & triLift CO2 & You – From Novice to Master Breakthrough Laser Hair Loss Treatment Serve ALL skin types Providers, Patients, & PAIN, the TRUTH about Marketing BeautyTech Showcase And More! #### EPIC Scottsdale EPIC Scottsdale W Scottsdale Hotel 7277 E Camelback Rd, Scottsdale, AZ 85251 Register Now – Make Your Aesthetic Business EPIC – Join us and discover how the latest in BeautyTech Empowers practices and Inspires customers with life changing aesthetic outcomes. Experience EPIC Panels on: IPL Secrets, Skin & SmoothGlo Discover NEW frontiers, pioneers & triLift CO2 & You – From Novice to Master Breakthrough Laser Hair Loss Treatment Serve ALL skin types Providers, Patients, & PAIN, the TRUTH about Marketing BeautyTech Showcase And More! #### EPIC: Scottsdale EPIC Scottsdale W Scottsdale Hotel 7277 E Camelback Rd, Scottsdale, AZ 85251 Register Now – Make Your Aesthetic Business EPIC – Join us and discover how the latest in BeautyTech Empowers practices and Inspires customers with life changing aesthetic outcomes. Experience EPIC Panels on: IPL Secrets, Skin & SmoothGlo Discover NEW frontiers, pioneers & triLift CO2 & You – From Novice to Master Breakthrough Laser Hair Loss Treatment Serve ALL skin types Providers, Patients, & PAIN, the TRUTH about Marketing BeautyTech Showcase And More! #### Events Aesthetics Events OWNER’S SUMMIT 2026 – ChicagoAugust 28, 2026Transform your practice at the Owners Summit, where you and your staff will master next-level revenue strategies from proven Lumenis...READ MORE You're Invited! Please accept our invitation to join Lumenis at any of our seminars and presentations, where you and your staff can learn more about the groundbreaking technology behind our laser and light-based treatment systems—and the opportunities they offer for your practice. Lumenis will be in attendance at numerous conferences sponsored by professional organizations around the globe. In partnership with its local distributors, Lumenis also offers workshops that give physicians the chance to familiarize themselves with state-of-the-art laser and light-based technologies during hands-on demonstrations. × GET MORE INFO #### FemTouch FemTouch™ A REVOLUTIONARY SOLUTION FOR WOMEN’S HEALTH FemTouch is an out-patient, non-invasive, and non-hormonal treatment for improved vaginal health, restoring patient confidence and wellbeing. FemTouch positions you at the forefront of women’s health technology, while expanding your practice offer SCHEDULE A DEMO DOWNLOAD BROCHUREAbout FemTouchResultsTestimonialsTechnology UNIQUE TECHNOLOGY WITH COMBINATION OF UNSURPASSED ADVANTAGES FAST The procedure only takes a couple of minutes SIMPLE No anesthesia nor special post procedure care are required EFFECTIVE Noticeable results from the first treatment Read Research> PRECISE Full control of ablation and coagulation depth LET’S TALK RESULTS LONG LASTING RESULTS Read Research > PATIENT SATISFACTION Read Research > HEAR FROM FemTouch PATIENT AND CUSTOMERS I didn’t even know that I really needed this procedure and now my husband and I are like ‘wow’! This has been great. I have told all of my friends about it! Angela & Tim’s Story Courtesy of Matteo Tretti Clementoni, MD LUMENIS TECHNOLOGY FemTouch is powered by the Lumenis CO2 laser. This innovative CO2 laser technology enables precise and controlled fractional laser microbeams to be applied to the vaginal lining. READ MORE LEARN MORE ABOUT FemTouch Download the FemTouch Info Kit Brochure, Clinical Casebook and More Close #### FoLix BREAKTHROUGH LASER FOR HAIR LOSS TREATMENT DOWNLOAD BROCHURE CONTACT US WHAT IS FoLix? FoLix is a revolutionary non-ablative fractional laser system using hair stimulation technology, providing effective, safe, and simple treatment for women and men. FIRST FDA-CLEARED The first FDA-cleared fractional laser for hair loss treatment PROVEN RESULTS Clinical studies show increase in hair count and improvement in scalp hair appearance* NATURAL AND SAFE Leveraging the body’s own processes for hair stimulation without chemicals SIMPLE 30 MIN PROCEDURE Simple to use, easy to learn, quick to treat. Without anesthesia, needles or downtime SYSTEM TECHNOLOGY TREATMENT SYSTEM FoLix™ Laser Technology Unique algorithm ensure optimal irradiance and area coverage, to maximize operational efficiency, patient comfort, and clinical outcomes. FoliCool™ Tip(Patent Pending) Enhances safety and comfort  with constant cooling. Designed  to separate the hair for smooth  treatment. Intuitive User Interface Incorporating FDA-cleared settings ensuring efficient, consistent treatments. DOWNLOAD BROCHURE TECHNOLOGY FoLix Technology Ensures optimal irradiance and area coverage by homogenous placement of the laser’s micro-beams onto the tissue. This promises patients’ safety and minimal discomfort while allowing to reach the required settings to achieve results. Customized Settings Ensuring productivity due to customized settings based on the type of area treated and patient tolerability Unlock Nature with Science FoLix uses targeted laser energy for dermal coagulation, activating natural healing processes. This boosts blood flow, cytokine activity, and hair follicle stimulation. DOWNLOAD BROCHURE TREATMENT The Power of Laser Meet your patients’ preferences with no chemicals, no needles, no anesthesia, no surgery and no after-care. Optimized Treatment Protocol 4-6 sessions every four weeks, plus maintenance 2-3 times a year to sustain and enhance the results. Quick Treatment & Outstanding Results Offer your patients superior outcomes and satisfaction in a 30-minute treatment with minimal discomfort and no downtime. DOWNLOAD BROCHURE TRUST SCIENCE, TRUST FoLix Proven results in prospective and retrospective studies, with over 120 participating patients, led by industry experts. Clinical studies show an increase in hair count, an increase in the number of follicular units per cm2 and noticeable improvement in scalp hair appearance* DOWNLOAD BROCHURE CONTACT US Courtesy of LaserMed clinic Courtesy of LaserMed clinic Courtesy of LaserMed clinic Courtesy of LaserMed clinic Courtesy of LaserMed clinic Courtesy of LaserMed clinic Courtesy of LaserMed clinic Courtesy of LaserMed clinic HEAR FROM THE EXPERTS Dr. Marc Avram, Harvard-trained, board-certified dermatologist who specializes in hair loss and hair transplantation in private practice in New York City. Clinical professor of dermatology at Cornell Medical Center. Dr. Neil Sadick, a leading recognized dermatologist involved in the research of advanced technologies and treatments for hair loss. Clinical Professor of Dermatology at Cornell Medical College, and Adjunct Professor, Department of Dermatology at the University of Minnesota. DOWNLOAD FoLix BROCHURE FoLix availability varies by region and is subject to local regulatory approvals in each jurisdiction. Indication for use: Improving the appearance of scalp hair in adult males and females with Fitzpatrick skin types I to IV, who are seeking treatment for hair loss. Contraindication and Risks: The use of FoLix is not suitable for everyone, contraindicated for certain patients and carries some risks. FoLix treatment is not suitable for patients with any concurrent cancer or history of skin cancer, or pre-cancerous lesions at the treatment area, active infection, chronic fungal or bacterial diseases or chronic dermatological condition of the scalp. Treatment may cause redness, swelling, scarring, damage to natural skin texture (e.g. blisters), fragile skin, burns, hair shedding, itching, and pigmentation change. Be sure to consult with us before choosing this treatment. *Measured in 1-month and 3-months follow ups following last treatment session, compared to baseline. Data on file. **Avram, M.R., Queen, D., Shapiro, J. and Munavalli, G. (2025), Improvement in Scalp Hair Appearance Following Treatment With a Non-Ablative Fractional Laser: A Retrospective Observational Study. Lasers in Surgery and Medicine, 57: 590-597. https://doi.org/10.1002/lsm.70044. Testimonial represents a specific experience of a paid spokesperson. Experience of others may vary. The presenter in FoLix’s marketing materials isn’t a licensed practitioner. The footage is a demonstration, treatment must be done by licensed practitioners wearing protective eyewear. PB-00076340 Rev B Close GET MORE INFO #### FoLix Named Best Laser Treatment for Hair Loss Two Years Running FoLix Named Best Laser Treatment for Hair Loss Two Years Running NewBeauty’s 16th Annual Beauty Awards recognize FoLix by Lumenis for the second consecutive year, cementing its place as the leading in-office solution for hair loss. NewBeauty has once again named FoLix by Lumenis the “Best Laser Treatment for Hair Loss” in its 16th Annual Beauty Awards — honoring 395 products and treatments that, in the editors’ words, “will do what they claim and earn your stamp of approval like they have ours.” For FoLix, this marks back-to-back recognition: the same award, the same category, the second year in a row. Tatiana Bido, NewBeauty’s director of aesthetic content, called FoLix “a thoughtful in-office option for patients concerned about thinning hair.” And that’s a growing market. Around 85% of men1 and 50% of women2 will face hair loss. Hair thinning is a tangible experience, often undermining one’s confidence and sense of self, and many are desperate for it to stop, often turning to industry staples like minoxidil, LLLT, PRP, stem-cell serums, and more. While it can be overwhelming for medical providers and patients to identify the most optimal solutions in such a crowded market, NewBeauty highlighted what sets FoLix apart: It harnesses FDA-cleared fractional laser energy to stimulate hair follicles without pills, injections, or invasive procedures. It’s a meaningful step forward for patients who want clinical results without the complexity. NewBeauty’s selection process goes well beyond surface-level testing. Editors track launches and innovations year-round, reading white papers, analyzing clinical data, and interviewing experts. They also survey 150 board-certified dermatologists and plastic surgeons on the in-office treatments they consider most effective, from microneedling to fillers and beyond. What makes FoLix a category leader? Launched in the U.S. in September 2024, FoLix is built on non-ablative fractional laser (NAFL) technology and a suite of proprietary advancements tailored specifically for treating hair loss. Rather than a one-size-fits-all approach, FoLix delivers precise laser pulses that work with the body’s own healing processes, stimulating dormant follicles, improving blood flow, and encouraging tissue regeneration at the scalp level. Results in just 4 to 6 monthly sessions, with no chemicals, needles, anesthesia, surgery, or downtime Homogeneous micro-beam placement ensures optimal irradiance and consistent area coverage session after session Intuitive interface with FDA-cleared treatment settings for efficient, repeatable outcomes Patent-pending FoliCool™ tip actively cools the scalp during treatment, enhancing comfort and enabling faster, smoother application The clinical evidence FoLix’s performance is backed by a growing body of clinical research. Prospective studies* demonstrate measurable, statistically meaningful improvements in hair density following treatment, including a 10–18% increase in hair count and 13–16% increase in follicular units per cm². A retrospective analysis** of 98 patients showed consistent improvement in scalp hair appearance after 4 to 6 laser treatments, with no adverse events reported. Three U.S. board-certified dermatologists reviewed the results, correctly identifying before-and-after images in 96.9% of cases. Behind FoLix is the full weight of Lumenis’ decades of expertise in energy-based medical technology. This recognition reflects not just a single product, but a commitment to meaningful innovation. We develop solutions that genuinely improve the lives of the millions of people worldwide living with hair loss, giving both patients and providers the tools to move forward with confidence. DOWNLOAD FoLix BROCHURE FoLix availability varies by region and is subject to local regulatory approvals in each jurisdiction. Indication for use: Improving the appearance of scalp hair in adult males and females with Fitzpatrick skin types I to IV, who are seeking treatment for hair loss. Contraindications and Risks: The use of FoLix is not suitable for everyone, contraindicated for certain patients and carries some risks. FoLix treatment is not suitable for patients with any concurrent cancer or history of skin cancer, or pre-cancerous lesions at the treatment area, active infection, chronic fungal or bacterial diseases, or chronic dermatological condition of the scalp. Treatment may cause redness, swelling, scarring, damage to natural skin texture (e.g., blisters), fragile skin, burns, hair shedding, itching, and pigmentation change. Be sure to consult with us before choosing this treatment. *Measured in 1-month and 3-month follow-ups following last treatment session, compared to baseline. Data on file. **Avram, M.R., Queen, D., Shapiro, J. and Munavalli, G. (2025), Improvement in Scalp Hair Appearance Following Treatment With a Non-Ablative Fractional Laser: A Retrospective Observational Study. Lasers in Surgery and Medicine, 57: 590-597. https://doi.org/10.1002/lsm.70044. A testimonial represents a specific experience of a paid spokesperson. Experience and results of others may vary. The presenter in FoLix’s marketing materials isn’t a licensed practitioner. The footage is a demonstration, treatment must be done by licensed practitioners wearing protective eyewear. References: https://www.americanhairloss.org/mens-hair-loss/ https://my.clevelandclinic.org/health/diseases/16921-hair-loss-in-women PB-00092332 Rev A #### FoLix™ by Lumenis Wins Innovation Award in Hair Loss Technology at the 2025 Medical Device Network Excellence Awards FoLix™ by Lumenis Wins Innovation Award in Hair Loss Technology at the 2025 Medical Device Network Excellence Awards Lumenis is thrilled to announce that FoLix™, our groundbreaking hair loss treatment device, has been named a winner in the 2025 Medical Device Network Excellence Awards, receiving recognition with the Hair Loss Technology Innovation Award. The Medical Device Network Excellence Awards honor the most significant achievements and innovations in the medical devices industry. Powered by GlobalData’s business intelligence, the Awards recognize the people and companies leading positive change and shaping the future of the industry. “We understand that experiencing hair loss can have a profound impact on patients. We’re honored that FoLix, the first FDA-cleared non-ablative fractional laser for hair loss, has been recognized as the premier treatment choice for restoring confidence and helping people feel like their best selves.” — Tzipi Ozer-Armon, CEO of Lumenis The New Standard in Hair Loss Treatment Hair loss affects more than 80 million people in the U.S., with significant emotional and psychological consequences. Despite its prevalence, many existing treatments fall short—whether due to limited efficacy, side effects, or the invasiveness of surgical procedures. FoLix offers a non-invasive, clinically validated alternative that is safe, effective, and accessible to both men and women. As the first and only FDA-cleared non-ablative fractional laser (NAFL) for hair loss, FoLix uses Lumenis’ proprietary NAFL technology to stimulate hair follicles by activating the body’s natural healing processes. The treatment protocol requires just four to six monthly sessions, plus maintenance 2-3 times a year to sustain and enhance the results. Each session is quick and comfortable, with no downtime. This innovation is underpinned by a unique mechanism of action: the creation of microscopic thermal zones (MTZs) in the skin, which triggers a regenerative response without damaging surrounding tissue. The technology’s specificity and safety profile are further validated by its FDA clearance, a milestone that sets a new industry standard for device-based hair loss treatment. By leveraging decades of expertise in energy-based medical devices, Lumenis has established a new category of treatment that is both effective and accessible. Clinically Proven, Patient-Centric Innovation FoLix’s effectiveness is backed by rigorous clinical validation*. Preclinical studies have demonstrated that NAFL treatment induces a natural inflammatory response that stimulates hair follicle transition into a growth state. For example, in controlled studies on mice, NAFL treatment led to significant overexpression of key hair growth markers such as Sonic Hedgehog (SHH) and activation of the Wnt/B-catenin pathway, both of which are critical for hair follicle development and regeneration. Histological analysis confirmed positive tissue repair and hair follicle regeneration post-inflammatory response. In clinical settings, retrospective studies involving human subjects have reinforced these findings. In a review of 98 patients aged 21-66, who underwent three to six FoLix treatments, independent board-certified dermatologists were able to correctly identify before-and-after images in 96.9% of cases. Both male and female subgroups demonstrated high rates of improvement, with no adverse events reported during or after treatment. Prospective studies further provided quantitative results that demonstrate an increase in hair count per square centimeter and an increase in the number of follicular units per square centimeter. The high safety profile and the statistically significant improvements in scalp hair appearance underscore the reliability of the technology for a broad patient population. Driving Global Impact Through Strategic Partnerships FoLix’s rapid growth has been fueled by partnerships with leading dermatologists and hair restoration experts, including the NYU Dermatology Department, Bauman Medical, and Dr. Ronda Farah. Lumenis’ collaboration with Bosley, the largest hair restoration chain in the U.S., has accelerated clinical adoption and patient access. Within its first year, FoLix established a presence across North America, the Middle East, and the Asia-Pacific region, with continued global expansion driven by strong demand from physicians and patients worldwide**. Looking Ahead As we continue to invest in digital health, remote connectivity, and smart device ecosystems, Lumenis is shaping the future of energy-based medical devices. Our vision includes real-time adaptive treatments, remote troubleshooting, and personalized care that enhances both clinical outcomes and operational efficiency. FoLix is just the beginning. We’re exploring new technologies and indications to further expand our impact—driven by innovation, validated by science, and inspired by the patients and providers we serve. DOWNLOAD FoLix BROCHURE * Avram, M.R., Queen, D., Shapiro, J. and Munavalli, G. (2025), Improvement in Scalp Hair Appearance Following Treatment With a Non-Ablative Fractional Laser: A Retrospective Observational Study. Lasers in Surgery and Medicine, 57: 590-597. https://doi.org/10.1002/lsm.70044. ** FoLix availability varies by region and is subject to local regulatory approvals in each jurisdiction. PB-00095090 Rev A #### FoLix™ Recognized for Dermatology Innovation in 2025 MedTech Breakthrough Awards Program FoLix™ Recognized for Dermatology Innovation in 2025 MedTech Breakthrough Awards Program Lumenis is proud to announce that FoLix™, the innovative hair loss treatment by Lumenis, has been honored with the “Best New Dermatology Technology Solution” award at the 2025 MedTech Breakthrough Awards. This groundbreaking solution is the first FDA-cleared non-ablative fractional laser for hair loss, delivering results in just 4-6 monthly sessions with minimal discomfort and no downtime. The awards’ judging panel selected FoLix as the winner of this competitive category due to its combination of scientific innovation, patient-centric design and measurable clinical impact. According to MedTech, FoLix fills a critical gap in the dermatology space and also offers a truly novel, non-invasive option for patients seeking meaningful results – making FoLix a standout among this year’s dermatology technology innovations. The judges were particularly impressed by FoLix’s ability to apply the regenerative power of fractional laser technology to a new frontier: hair follicle stimulation. The award underscores Lumenis’ significant contribution to the fields of dermatology and technological innovation. Tzipi Ozer-Armon, CEO of Lumenis, stated that FoLix represents a significant advancement in hair treatment, addressing lifestyle needs while enhancing confidence and beauty. The MedTech Breakthrough Awards program celebrates excellence and innovation across medical technology sectors, showcasing transformative solutions like FoLix. The MedTech Breakthrough Awards program celebrates excellence and innovation in the health and medical technology industry, recognizing the companies, products, and solutions driving meaningful progress and improving patient care. For more information about FoLix please visit Lumenis.com/FoLix About FoLix™ FoLix™ is a non-ablative fractional laser device to improve the appearance of scalp hair in adult males and females with Fitzpatrick skin types I to IV, who are seeking treatment for hair loss. FoLix treatment could cause redness, swelling, scarring, damage to natural skin texture (e.g. blisters), fragile skin, burns, hair shedding, itching, and pigmentation change. The use of FoLix is contraindicated for patients with any concurrent cancer or history of skin cancer, or pre-cancerous lesions at the treatment area, active infection, chronic fungal or bacterial diseases or chronic dermatological condition of the scalp. See the system user manual for a complete list of contraindications and risks. DOWNLOAD FoLix BROCHURE PB-00088280 Rev A #### Fractional Non Ablative What Are Non Ablative Lasers? A non-ablative laser generates beams of coherent light using a very narrow range of wavelengths.The light beams selectively target and heat the water chromophore in the skin. As a result the temperature of the tissue rises which stimulates neocollagenesis. There are various forms of non-ablative lasers and they typically have a good water absorption mechanism that impacts the water chromophores but does not cause ablation. Fiber lasers are commonly used for non-ablative treatments. A fiber laser is an optical fiber that is “doped” with elements designed to generate a laser beam at the desired wavelength. Erbium Glass is a typical fiber laser used for this purpose. How Does A Non Ablative Laser Work? The non-ablative laser uses a wavelength that does not cause the water in the tissue to evaporate (ablate) but rather the laser energy heats the tissue in a controlled manner.  The rise in temperature stimulates neocollagenesis, a process in which new collagen is produced by the body.  Collagen is a fibrous protein that is responsible for giving the skin its elasticity and suppleness. By producing new collagen the skin regains is youthful appearance. Since the treatment does not involve tissue evaporation or ablation, treatment downtime is significantly reduced, which is also why it is preferred over ablative treatments by many patients. The Lumenis Non Ablative Solution The ResurFX™™ laser is the only true fractional non- ablative technology. Unlike other fractional technologies, ResurFX™ only needs one pass to be effective, saving time and protecting the patient’s skin. ResurFX™ uses a 1565nm fiber laser and an advanced scanner, which enables the user to choose from more than 600 combinations of shape, size and density options, for optimal treatment results. The ResurFX™ has state-of-the-art CoolScan™ scanner for non-sequential scanning. The CoolScan™ scanner uses a proprietary algorithm that controls the placement of each fractional spot. This protects the tissue from heat accumulation and overheating. Moreover, the ResurFX™ handpiece is equipped with continuous contact cooling to increase patient comfort during treatment. Related Products Stellar M22™ Intelligent skincare platform for the treatment of over 30 skin conditions and hair removal. M22™ with ResurFX™ For Fractional Non-Ablative Skin Resurfacing. PB-1004647 Rev A GET MORE INFO × #### Get Rid of That Nasty Scab Get Rid of That Nasty Scab Readers Digest February 1, 2017 View More #### Getting Back to Business, a Ten Step Plan Getting Back to Business, a Ten Step Plan Publish Date: June 15, 2020 Length: 63 Minutes Your reopening marketing plan and the new normal. Get a tactical recovery marketing plan with 10 easy steps that will enable you to get back fast and successfully. Lori Werner Chief Marketing Whiz & Co-Founder #### Getting Started With Telehealth Getting Started With Telehealth Publish Date: July 1 2020 Dr. Alissa Lamoureux covers everything from types of telehealth to platforms to choose. Read about how telehealth can change your practice and most importantly, your patient relationships. Types of telehealth (there’s more than just video conferencing) Billing and revenue Laws, regulations, and compliance Choosing a telehealth platform and integrating it into your workflow How consultations help patients make informed decisions And more! Fill out the form to download your free eBook. PB-00000000 Rev A #### Glamour Facial Muscles – What, Where and How Glamour Facial Muscles – What, Where and How Publish Date: May 16, 2024 Length: 58 Minutes What are the Glamour Facial Muscles and how treating them results in a toned lifted look. Targeting saggy jowls, droopy cheeks, and loose facial skin. Addressing the high demand for naturally lifted looks. Learn from the best! Discover how James Chelnis, M.D. took his practice to the next level with triLift’s Facial Muscle Stimulation treatment. James Chelnis James Chelnis, MD is an award-winning aesthetic surgeon and internationally renowned speaker and educator in aesthetics and plastic surgery. He’s been recognized as a Top 10 Best Plastic Surgeon by Super Doctors Rising Stars, Top Doctors, and several national plastic surgery societies. PB-00078680 Rev A #### Grazia investigates the hottest contouring and lifting treatments coming to a clinic near you Grazia investigates the hottest contouring and lifting treatments coming to a clinic near you GRAZIA November 20, 2017 View More #### Groundbreaking Minimally-Invasive Laser Solutions from Lumenis Groundbreaking Minimally-Invasive Laser Solutions from Lumenis Latest Share News March 29, 2017 View More #### Hair Loss LASER HAIR LOSS TREATMENT Hair Loss is More Common Than You Think. Hair thinning is a concern shared by millions, often prompting individuals to seek expert solutions. Offering effective guidance starts with understanding the underlying causes and the full range of treatment pathways. Integrating trusted solutions into your offering empowers you to address patient needs with confidence and elevate the level of care you provide. LEARN MORE ABOUT HAIR LOSS SOLUTION HAIR LOSS IN NUMBERS 80M Americans are effected by Hair loss (50M men & 30M women). 50% OF WOMEN of women experience hair loss by the age of 50. 85% OF MEN Will experience hair loss in their lifetime. 87% Agree that the condition of their hair greatly influences their confidence. WHAT IS HAIR LOSS? Experiencing hair loss is more common than you think. More than 50% of Americans experience hair loss at some point in their lives. The causes of hair loss can vary, including genetics, hormonal changes, stress, certain medications, and aging. There are several different types of hair loss: Androgenetic Alopecia (AGA) Natural, gradual, common hair loss as a result of changes in androgen levels that usually come with age. Alopecia Areata (AA) Autoimmune disease where the immune system mistakenly attacks the hair follicles. Telogen Effluvium A form of hair loss that is triggered by physical trauma, psychological stress or other types of unexpected change. Courtesy of LaserMed clinic Courtesy of LaserMed clinic Courtesy of LaserMed clinic Courtesy of LaserMed clinic Courtesy of LaserMed clinic Courtesy of LaserMed clinic Courtesy of LaserMed clinic Courtesy of LaserMed clinic THE HAIR GROWTH CYCLE Throughout life, hair follicles undergo cyclic degeneration and regeneration-between 10 and up to 30 cycles for each hair follicle. STAGE 1 ANAGEN (GROWTH) The longest phase, lasting 2-8 years, where the follicle actively produces the hair shaft. Hair length potential is determined by this phase’s duration, which naturally shortens with age. STAGE 2 CATAGEN (TRANSITION) A brief 2-week phase where the follicle detaches from the dermal papilla and regresses. The dermal papilla must reach the follicle bulge during this time, or the hair will be shed. STAGE 3 TELOGEN (RESTING) A 2-3 month period where growth stops and new hair begins forming at the follicle base. Typically, 10-15% of scalp hairs are in this phase at any time. STAGE 4 EXOGEN (SHEDDING) The final phase where hair is naturally shed unless the follicle re-enters the anagen phase. Normal daily hair loss ranges from 50-100 strands. THE LUMENIS SOLUTION FOR HAIR LOSS FoLix represents a groundbreaking advancement in laser hair loss treatments. This revolutionary system leverages proprietary fractional laser technology to naturally stimulate hair follicles through enhanced blood flow and growth factor activation. The new FDA-cleared treatment for hair loss, FoLix offers a safe, non-invasive, chemical-free alternative to traditional hair loss solutions, delivering proven results through 4-6 monthly sessions. FoLix Technology FoLix uses fractional laser energy delivery for dermal coagulation, activating natural healing processes. FoLix uses laser technology to harness the body’s natural processes. The laser’s interaction with the tissue promotes enhanced blood circulation, cytokine activity, and stimulates hair follicles. NO DOWNTIME Patients can resume normal activities immediately after their laser treatment for hair loss. QUICK TREATMENTS Monthly sessions last about 30 minutes, fitting easily within your busy day. NO CHEMICALS Avoids external substances and harnesses your body’s natural processes. MINIMAL DISCOMFORT No surgery or injections required. LEARN MORE ON FOLIX FAQ’s WHAT IS FOLIX BY LUMENIS? FoLix is the first and only FDA-cleared non-ablative fractional laser for hair loss, providing effective, safe, simple and non-surgical hair loss treatment for women and men. HOW LONG DOES A FOLIX TREATMENT SESSION TAKE? Each FoLix treatment session lasts approximately 30 minutes, making it easy to fit into a busy schedule. HOW MANY SESSIONS WILL I NEED? Typically, patients need between 4 to 6 sessions, spaced about four weeks apart to achieve optimal results. WILL THE TREATMENT BE PAINFUL? Patients generally report minimal discomfort during FoLix sessions, often describing the experience as a warm prickling sensation. WHEN WILL I START SEEING RESULTS? The hair growth cycle is long, so when it comes to treating hair loss, patience is key. Initial signs of improvement, such as reduced shedding and the appearance of baby hairs, can be noticed throughout the treatment series. WHAT IS THE RECOMMENDED TREATMENT PROTOCOL FOR FOLIX? The optimized protocol consists of 4-6 sessions conducted every four weeks, followed by 2-3 yearly maintenance treatments to sustain and enhance results. Each treatment session takes approximately 30 minutes. WHICH PATIENTS ARE SUITABLE CANDIDATES FOR FOLIX TREATMENT? FoLix is indicated for adult males and females with Fitzpatrick skin types I to IV who are seeking treatment for hair loss. Early to mid-stages of hair loss are expected to show the utmost results. However, it is contraindicated for some diseases- see warning and risks for full information. HOW DOES FOLIX TECHNOLOGY WORK TO STIMULATE HAIR GROWTH? FoLix uses targeted laser energy for dermal coagulation, which activates natural healing processes. This mechanism enhances blood flow and cytokine activity, leading to hair follicle stimulation. WHAT SAFETY MEASURES AND SIDE EFFECTS SHOULD CLINICIANS BE AWARE OF? While FoLix is designed with patient safety in mind, the system incorporates FDA-cleared settings and the FoLiCool™ tip for enhanced safety and comfort. The intuitive user interface ensures consistent, efficient treatments. Potential side effects may include redness, swelling, scarring, burns and pigmentation changes – see warning and risks for full information. FoLix availability varies by region and is subject to local regulatory approvals in each jurisdiction. Indication for use: Improving the appearance of scalp hair in adult males and females with Fitzpatrick skin types I to IV, who are seeking treatment for hair loss. Contraindication and Risks: The use of FoLix is not suitable for everyone, contraindicated for certain patients and carries some risks. FoLix treatment is not suitable for patients with any concurrent cancer or history of skin cancer, or pre-cancerous lesions at the treatment area, active infection, chronic fungal or bacterial diseases or chronic dermatological condition of the scalp. Treatment may cause redness, swelling, scarring, damage to natural skin texture (e.g. blisters), fragile skin, burns, hair shedding, itching, and pigmentation change. Be sure to consult with us before choosing this treatment. *Measured in 1-month and 3-months follow ups following last treatment session, compared to baseline. Data on file. **Avram, M.R., Queen, D., Shapiro, J. and Munavalli, G. (2025), Improvement in Scalp Hair Appearance Following Treatment With a Non-Ablative Fractional Laser: A Retrospective Observational Study. Lasers in Surgery and Medicine, 57: 590-597. https://doi.org/10.1002/lsm.70044. A testimonial represents a specific experience of a paid spokesperson. Experience and results of others may vary. The presenter in FoLix’s marketing materials isn’t a licensed practitioner. The footage is a demonstration, treatment must be done by licensed practitioners wearing protective eyewear. References: American Academy of Dermatology. Hair Loss Resource Center Cleveland Clinic. Hair Loss American Hair Loss Association U.S. National Library of Medicine Lumenis survey 2025, 802 patients experiencing hair loss (51% male, 48% female, and 0.3% other) PB-00085300 Rev A #### Hair Removal Laser Hair Removal Customize hair removal across a wide range of skin tones like never before Laser hair removal is one of the most popular aesthetic procedures globally and has become a standard of care for both women and men alike. Discover the strength of the most researched hair removal brands that offer fast effective and comfortable method for permanent hair reduction (including tanned and dark skin). EXPLORE OUR PRODUCTS Laser Hair Removal Treatment Based on the principle of selective photothermolysis, laser hair removal targets the entire hair structure, from the hair shaft down to the follicle. Light energy with a specific wavelength is absorbed by the endogenous chromosphere melanin, resulting in the rapid heating and subsequent local thermal necrosis of the follicles’ regenerative structures. To achieve permanent hair reduction, the laser system must be able to effectively treat all skin types, while providing maximum skin protection. Lighter skin types are mainly treated with 755nm (Alexandrite) or 805 nm (diodes laser) while darker skin types are mainly treated with 1060/1064 nm, which is available on both diode and solid state lasers. The laser’s wavelength, fluence, pulse duration and spot size determine the effectiveness of the treatment and also influence the depth of penetration and treatment speed. Laser Hair Removal Market Laser hair removal is still one of the most popular aesthetic procedures. The treatment has gained acceptance globally and has become the standard for both women and men of all ages from early teens upward. Due to technological advances, laser hair removal is now even quicker, more convenient and more affordable than ever before – enabling the fast treatment of larger areas with minimal discomfort and no downtime. As a result the hair removal market is growing at a rapid pace, and it is expected to rise to $1.35B by the end of 2022.2 In addition, its popularity makes it an excellent way get patients through the door. It gives treatment providers the opportunity to expand their patient base, penetrate new demographics and increase the opportunities of upselling additional treatments and strengthening other revenue streams. Hair Removal Solutions by Lumenis Lumenis is a pioneer in the field of aesthetic medicine and laser hair removal, and has led the LHR market for over 20 years with clinically-proven solutions that are synonymous with effective and reliable laser hair removal. With Lumenis hair removal solutions, treatment providers can give their patients all the confidence they need! Lumenis offers two powerful and versatile laser hair removal solutions for aesthetic treatment providers: The LightSheer® Product Line – uses clinically-proven 805 nm and 1060 nm diode laser technology to permanently1 remove unwanted hair quickly, comfortably and effectively. SPLENDOR X – the first solid-state, synchronized laser emission Alexandrite (755nm) and Nd: YAG (1064mm) system to use BLEND X™ technology.LightSheer® Product LineSPLENDOR X™ with BLEND X TechnologyLightSheer® Product Line LightSheer® Product Line   The LightSheer® systems use clinically-proven 805 nm and 1060 nm diode laser technology to permanently remove unwanted hair quickly, comfortably and effectively. 3,4,5 These systems feature two unique technologies: a High Speed vacuum assisted technology for large treatment areas and ChillTip™ integrated cooling technology for smaller areas and where precision treatment is required. Treatment providers can customize treatments according to each patient’s hair type, skin type (including tanned and dark skin) and lifestyle – and therefore access a larger demographic. The system range includes: The QUATTRO™ – a scalable and upgradable head-to-toe laser hair removal workstation. The DUET™ – with two fixed hand-pieces for high volume clinics and chains. Although primarily used for laser hair removal, LightSheer is also cleared for treating benign pigmented lesions, vascular lesions and wrinkle reduction. SPLENDOR X™ with BLEND X Technology SPLENDOR X™ with BLEND X Technology   SPLENDOR X by Lumenis is the first solid-state, synchronized laser emission Alexandrite and Nd: YAG system to be powered by . It is also the first fiber-delivered laser featuring a patented square spot for uniform skin coverage; and an integrated plume (smoke) evacuator and HEPA filter for a smoke-free working environment. The patient experience is enhanced even more with the integrated DCS (Dual Cooling System), which eliminates the need for numbing cream to make the procedure even faster. Powerful, fast and versatile, SPLENDOR X is generally suitable for all skin tones (even dark or tanned skin) and for all body areas and types of hair. In addition to permanent hair reduction5, it can also be used to treat (PFB) Pseudofolliculitis Barbae, wrinkles, warts, pigmentation, and more. 1 Permanent hair reduction is defined as the long-term, stable reduction in the number of hairs re-growing when measured at 6, 9 and 12 months after the completion of a treatment regime. Fitzpatrick skin types I – VI, including tanned skin. 2 Transparency Market Research (TMR), Oct 2017. 3 Ibrahimi OA, Kilmer SL. Long-term clinical evaluation of a 800-nm long-pulsed diode laser with a large spot size and vacuum-assisted suction for hair removal. Dermatol Surg. 2012. 4 Xia Y, Moore R, Cho S, Ross EV. Evaluation of the vacuum-assisted handpiece compared with the sapphire-cooled handpiece of the 800-nm diode laser system for the use of hair removal and reduction. J Cosmet Laser Ther. 2010; 12: 264-268. 5 Permanent hair reduction is defined as the long-term, stable reduction in the number of hairs re-growing when measured at 6, 9 and 12 months after completing a treatment regime. Related Products   LightSheer® DUET™ Rethink the Business of Hair Removal LightSheer® QUATTRO™ Feel the confidence that comes with LightSheer SPLENDOR X Laser hair removal workstation powered by BLEND X technology PB-2012310 Rev A   GET MORE INFO × #### Here’s What You Should Know About Loose-Skin Surgery Here’s What You Should Know About Loose-Skin Surgery BYRDIE August 18, 2017 View More #### Here’s How to Properly Clean Your Lady Parts Here’s How to Properly Clean Your Lady Parts Yahoo Beauty May 24, 2017 View More #### Homepage AESTHETICS Uniquely designed for you TRILIFT SKINTREATMENTS SMOOTHGLO HAIRREMOVAL BODY ~88 Countries 40K+ Systems Installed Worldwide 60+ Years of industry leadership & innovation ~400 Clinical Publication INDUSTRY BEST We are the pioneers and leaders of the aesthetics industry. We have the longest, deepest and most expansive expertise in energy-based aesthetics treatments. As a Lumenis partner, you are equipped with the confidence to provide the very best technology has to offer. PIONEERING INNOVATION For over 60 years, Lumenis has redefined and revolutionized aesthetic medical treatments by developing innovative energy-based technologies, including Laser, Intense Pulsed Light (IPL) and Radio Frequency (RF). We are passionate innovators, empowering our customers and patients worldwide with the latest and most advanced technologies for superior results. YOUR SUCCESS IS OUR MISSION Every decision and device at Lumenis centres on you and your ability to change people’s lives. Day in and day out, we’re committed to #CelebratingYou and the difference you make. 360° AESTHETICS SOLUTIONS Laser Hair Removal Body Shaping Skin Solutions Facial Muscle Stimulation Women’s Health Beauty LASER HAIR REMOVAL One of the most sought-after, non-invasive aesthetic treatments for women and men alike, laser hair removal is a cornerstone offering for aesthetic practices looking to expand their patient base and create a substantial revenue stream. Lumenis’ diverse product portfolio and advanced technology empowers practices of all sizes with proven, comprehensive solutions. LEARN MORE SPLENDOR X Alexandrite & Nd:YAG laser hair removal workstation Powered by BLEND X technology. High fluence, built-in smoke evacuator large square spot size and rapid repetition rate. Read More LightSheer® Diode Laser Hair Removal system for all skin types, offering both 805nm and 1060nm wavelengths. High fluence, large spot size and rapid repetition rate. Read More BODY SHAPING Patients around the world are increasingly turning to body shaping to get the smooth skin or contoured figure they’ve always dreamed of, without the invasiveness or recovery time of surgery. Our advanced body shaping solutions put your business ahead and help you give patients the care and results they seek. LEARN MORE NuEra Tight® Personalized non-invasive body sculpting solution featuring FocalRF technology to control the treatment depth for Fat Reduction, Skin Tightening, Wrinkle and Cellulite Reduction. For a treatment as unique as your patients. Read More NuEra Tight® Personalized non-invasive body solution featuring FocalRF technology to dial-in the depth of energy penetration from muscle to skin to account for clinical indications and specific body areas. For a treatment as unique as your patients. Read More SKIN SOLUTIONS Empower your patients to love the skin they’re in with non-invasive skin rejuvenation solutions that treat a broad range of skin concerns from texture, tone, vascular lesions and even scar revision. Our advanced solutions offer maximum efficacy and clinically proven results for all your patients accounting for different skin tones, age or lifestyles. LEARN MORE Legend Pro+ Advanced radio frequency skin treatment platform with unique RF microneedling and TriPollar® for skin resurfacing, inducing renewal, as well as wrinkle reduction. Read More Legend Pro Advanced radio frequency skin treatment platform with unique RF microneedling, TriPollar®, and Dynmaic Muscle Stimulation technology for skin resurfacing, inducing renewal, as well as wrinkle reduction. Read More Stellar M22™ An innovative multi-application platform, treating 30 skin conditions and hair removal. It fully upgradeable, so as your business grows, the Stellar M22 can adapt and grow with it. Read More ULTRApulse® Alpha The best CO2 laser technology in aesthetics has been perfected, providing WOW results in just one treatment, while maintaining patient comfort and safety with minimal downtime. ULTRApulse Alpha is the next step in growing your practice. Read More AcuPulse™ A complete ablative CO2 laser resurfacing workstation, featuring state of the art technology for all aesthetic resurfacing needs. Read More Facial Muscle Stimulation The new facial stimulation treatment to combine Dynamic Muscle Stimulation (DMSt) with triPollar RF and triFX microneedling to achieve a face lift-like effect. LEARN MORE TriLift A new category in facial stimulation aesthetics, triLift is an innovative, non-invasive treatment that combines three technologies in one single device to produce the natural face lift-like effect that patients desire. Read More WOMEN’S HEALTH Help women of any age overcome gynecological conditions with treatments that are non-surgical, non-hormonal, and virtually painless. Our solutions address a variety of conditions, boosting wellbeing, confidence and intimacy in just a few short and minimally invasive sessions. LEARN MORE FemTouch FemTouch addresses vaginal health related conditions by promoting the remodeling of the vaginal mucous epithelium layer.  Fractional CO2 laser is applied along the vaginal wall, resulting in gently controlled ablation and coagulation of the vaginal lining. Read More Women's Health AcuPulseW is a complete ablative and resurfacing platform featuring state of the art technology for aesthetic resurfacing and women’s health needs. Read More PROFESSIONAL BEAUTY Pollogen’s ground-breaking Intelligent Biology solutions are built on decades of clinical expertise and harness the body’s ability to heal, awaken, and renew itself. Our professional beauty products cover a complete range of face and body treatments that help patients reveal the essence of their beauty. LEARN MORE Pollogen The ultimate facial treatment platform for achieving younger, fresher and natural-looking skin. it is the only device in the market offering unique technologies, oxygeneo and ultrasound. your beauty comes from within. Read More Laser Hair Removal LASER HAIR REMOVAL One of the most sought-after, non-invasive aesthetic treatments for women and men alike, laser hair removal is a cornerstone offering for aesthetic practices looking to expand their patient base and create a substantial revenue stream. Lumenis’ diverse product portfolio and advanced technology empowers practices of all sizes with proven, comprehensive solutions. LEARN MORE SPLENDOR X Alexandrite & Nd:YAG laser hair removal workstation Powered by BLEND X technology. High fluence, built-in smoke evacuator large square spot size and rapid repetition rate. Read More LightSheer® Diode Laser Hair Removal system for all skin types, offering both 805nm and 1060nm wavelengths. High fluence, large spot size and rapid repetition rate. Read More Body Shaping BODY SHAPING Patients around the world are increasingly turning to body shaping to get the smooth skin or contoured figure they’ve always dreamed of, without the invasiveness or recovery time of surgery. Our advanced body shaping solutions put your business ahead and help you give patients the care and results they seek. LEARN MORE NuEra Tight® Personalized non-invasive body sculpting solution featuring FocalRF technology to control the treatment depth for Fat Reduction, Skin Tightening, Wrinkle and Cellulite Reduction. For a treatment as unique as your patients. Read More NuEra Tight® Personalized non-invasive body solution featuring FocalRF technology to dial-in the depth of energy penetration from muscle to skin to account for clinical indications and specific body areas. For a treatment as unique as your patients. Read More Skin Solutions SKIN SOLUTIONS Empower your patients to love the skin they’re in with non-invasive skin rejuvenation solutions that treat a broad range of skin concerns from texture, tone, vascular lesions and even scar revision. Our advanced solutions offer maximum efficacy and clinically proven results for all your patients accounting for different skin tones, age or lifestyles. LEARN MORE Legend Pro+ Advanced radio frequency skin treatment platform with unique RF microneedling and TriPollar® for skin resurfacing, inducing renewal, as well as wrinkle reduction. Read More Legend Pro Advanced radio frequency skin treatment platform with unique RF microneedling, TriPollar®, and Dynmaic Muscle Stimulation technology for skin resurfacing, inducing renewal, as well as wrinkle reduction. Read More Stellar M22™ An innovative multi-application platform, treating 30 skin conditions and hair removal. It fully upgradeable, so as your business grows, the Stellar M22 can adapt and grow with it. Read More ULTRApulse® Alpha The best CO2 laser technology in aesthetics has been perfected, providing WOW results in just one treatment, while maintaining patient comfort and safety with minimal downtime. ULTRApulse Alpha is the next step in growing your practice. Read More AcuPulse™ A complete ablative CO2 laser resurfacing workstation, featuring state of the art technology for all aesthetic resurfacing needs. Read More Facial Muscle Stimulation Facial Muscle Stimulation The new facial stimulation treatment to combine Dynamic Muscle Stimulation (DMSt) with triPollar RF and triFX microneedling to achieve a face lift-like effect. LEARN MORE TriLift A new category in facial stimulation aesthetics, triLift is an innovative, non-invasive treatment that combines three technologies in one single device to produce the natural face lift-like effect that patients desire. Read More Women’s Health WOMEN’S HEALTH Help women of any age overcome gynecological conditions with treatments that are non-surgical, non-hormonal, and virtually painless. Our solutions address a variety of conditions, boosting wellbeing, confidence and intimacy in just a few short and minimally invasive sessions. LEARN MORE FemTouch FemTouch addresses vaginal health related conditions by promoting the remodeling of the vaginal mucous epithelium layer.  Fractional CO2 laser is applied along the vaginal wall, resulting in gently controlled ablation and coagulation of the vaginal lining. Read More Women's Health AcuPulseW is a complete ablative and resurfacing platform featuring state of the art technology for aesthetic resurfacing and women’s health needs. Read More Beauty PROFESSIONAL BEAUTY Pollogen’s ground-breaking Intelligent Biology solutions are built on decades of clinical expertise and harness the body’s ability to heal, awaken, and renew itself. Our professional beauty products cover a complete range of face and body treatments that help patients reveal the essence of their beauty. LEARN MORE Pollogen The ultimate facial treatment platform for achieving younger, fresher and natural-looking skin. it is the only device in the market offering unique technologies, oxygeneo and ultrasound. your beauty comes from within. Read More PARTNER WITH LUMENIS Grow your business with Lumenis Choosing a Lumenis product is just the beginning of our journey together. From clinical training to marketing support and professional service programs, by partnering with Lumenis you become part of a complete ecosystem that sets you up for the highest patient satisfaction and ongoing success. LUMENIS PRACTICE LOCATOR Over 50,000 patients search for treatment providers on our directory every month. Our social media campaigns, viral videos, and collaborations with influencers introduce even more people to our products and treatments. LUMENIS ONLINE Patients have many questions about aesthetic treatments. Lumenis’ customer-facing digital resources give them the information they need to make educated decisions and move forward with confidence. TEAM TRAINING Every device comes with comprehensive training by our clinical experts to set you and your staff up for confidence and success; from assessing skin types and conditions, explaining system settings to creating the perfect treatment plan for each patient. YOUR MOST VALUABLE RESOURCE When you partner with us, you become part of the Lumenis family. Your dedicated representatives are just an email, text, or phone call away. BRAND YOUR CLINIC As a Lumenis partner, you gain exclusive access to the Lumenis Partner Zone, where you’ll find marketing materials such as brochures and posters, as well as a wealth of clinical and product information. EXTENSIVE SERVICE NETWORK We are committed to providing high-quality, comprehensive service for medical equipment repair and maintenance year-round. Our professional service gives you peace of mind that your practice is operating smoothly, so you can focus on what is important to you. WHY LUMENIS Over 60 years of industry leadership and innovation Lumenis is a global leader in the medical aesthetic market and is a world-renowned expert in developing and commercializing innovative energy-based technologies, including Laser, Intense Pulsed Light (IPL) and Radio-Frequency (RF). For over 60 years, Lumenis’ ground-breaking products have redefined medical treatments and set technological and clinical gold-standards, revolutionizing existing treatment methods and creating solutions for previous untreatable conditions. Lumenis is a portfolio company of Baring Private Equity Asia. AESTHETIC RESOURCE HUB Professional Insights SEE MORE EBOOKS WEBINARS NEWS TUTORIALS THE LATEST FROM LUMENIS Stay up to date on new Lumenis developments and the latest trends in the medical and aesthetics industries PB-00029820 Rev B GET MORE INFO × #### How aesthetic providers can address the needs of Wounded Warriors How aesthetic providers can address the needs of Wounded Warriors Publish Date: Aug 15, 2020 Learn how combination therapy, including laser hair removal and neuromodulators help improve the overall quality of life for veterans. PB-00019960 Rev B #### How does it work LightSheer DUET Overview Treatment & Testimonials Configurations Patients Benefit Practice Benefits Take the High Speed Challenge How Does It Work LightSheer DUET includes two wavelength 805 nm diode hair removal technologies on one versatile platform Advantages Of High-Speed Vacuum Assisted Technology Efficacy: reduction in competing chromophores enables delivery of laser energy more efficiently. Safety*: less energy is absorbed by the epidermis and lower fluence is required since the target is closer to the energy source. Decreased pain*: The unique vacuum mechanism activates tactile and pressure skin receptors to inhibit the transmission of pain sensation. Advantages Of ChillTip™ Technology Safety: superior epidermal protection is achieved through ChillTip contact cooling Patient comfort**: by continuously cooling the skin, pain and discomfort are significantly reduced. Efficacy: Compression of the skin rotates follicle closer to the surface, blenches blood vessels and reduces competing chromophores. High fluence enables treatment of areas requiring precision and thin, light hair. How ChillTip™ Works Skin is cooled before and during treatment. Skin is compressed. Laser beam applied to skin and target is damaged How Vacuum Assisted Technology Works Vacuum gently draws skin into the handpiece, skin is stretched thin and target is pulled closer to the energy source. Energy is applied to target in which melanocytes are spread apart and blood flow is constricted. Target is damaged and skin is released. How Does It Work Clinical Results *Ibrahimi OA, Kilmer SL. Long-term clinical evaluation of a 800-nm long-pulsed diode laser with a large spot size and vacuum-assisted suction for hair removal. Dermatol Surg. 2012 **Xia Y, Moore R, Cho S, Ross EV. Evaluation of the vacuum-assisted handpiece compared with the sapphire-cooled handpiece of the 800-nm diode laser system for the use of hair removal and reduction. J Cosmet Laser Ther. 2010; 12: 264-268. Learn More LightSheer DUET Patient BrochureLightSheer DUET Physician Brochure PB-1049670 Rev C | PB-1003139 Rev G GET MORE INFO × #### How Dr. Elizabeth Grieshaber recouped her Legend Pro investment in 3 months How Dr. Elizabeth Grieshaber recouped her Legend Pro investment in 3 months Publish Date: Aug 15, 2020 Find out how Dr. Elizabeth Grieshaber paid off her Legend Pro investment in three months, why she chose Legend Pro as an investment, and how it proved worthwhile by delivering an impressive ROI. PB-00017480 #### How I Built my triLift™ Practice How I Built my triLift™ Practice Rondalph Taylor, MD, combines traditional and nontraditional medicine with cutting-edge technologies to meet or exceed his patients’ treatment goals. Every day, he serves a diverse patient group from his multi-location practice in New York. Dr. Taylor and his team recently added triLift from Lumenis to their offering. This case study explores the business reasons behind the decision, implementation, and the benefits to his business. Read Full Study PB-00052140 Rev A #### How it works Lightsheer DESIRE Overview The Technology How It Works Patients Benefit Practice Benefits Clinical Results White Papers How Vacuum Assisted Technology Works Vacuum gently draws skin into the handpiece, skin is stretched thin and target is pulled closer to the energy source. Energy is applied to target in which melanocytes are spread apart and blood flow is constricted. Target is damaged and skin is released. Advantages Of High-Speed Vacuum Assisted Technology Efficacy: reduction in competing chromophores enables delivery of laser energy more efficiently. Safety*: less energy is absorbed by the epidermis and lower fluence is required since the target is closer to the energy source. Decreased pain*: The unique vacuum mechanism activates tactile and pressure skin receptors to inhibit the transmission of pain sensation. How ChillTip™ Works Skin is cooled before and during treatment. Skin is compressed. Laser beam applied to skin and target is damaged Advantages Of ChillTip™ Technology Safety: superior epidermal protection is achieved through ChillTip contact cooling Patient comfort**: by continuously cooling the skin, pain and discomfort are significantly reduced. Efficacy: Compression of the skin rotates follicle closer to the surface, blenches blood vessels and reduces competing chromophores. High fluence enables treatment of areas requiring precision and thin, light hair. *Ibrahimi OA, Kilmer SL. Long-term clinical evaluation of a 800-nm long-pulsed diode laser with a large spot size and vacuum-assisted suction for hair removal. Dermatol Surg. 2012 **Xia Y, Moore R, Cho S, Ross EV. Evaluation of the vacuum-assisted handpiece compared with the sapphire-cooled handpiece of the 800-nm diode laser system for the use of hair removal and reduction. J Cosmet Laser Ther. 2010; 12: 264-268. Learn More LightSheer DESIRE Brochure PB-00005650 Rev A × GET MORE INFO #### How to Bring your Clinic Back to Life How to Bring your Clinic Back to Life Publish Date: July 1 2020 This summer your patients will be eager to get back to their social lives and spend as much time possible outside. They’ll be looking for beauty treatments that help them feel good — fast. To help you meet their unique needs, we’ve put together some tips from our and aesthetic thought leaders’ insights around the globe. Learn about the benefits of combined treatments and give your patients the most in-demand face and body treatments. PB-00016750 #### How to increase ROI & patient intake with laser hair removal treatment How to increase ROI & patient intake with laser hair removal treatment Publish Date: Feb 11, 2020 Length: 58 Minutes Dr. Cartier and Petrina Nugawela discuss: Laser Hair Removal market trends Laser parameters that affect results LightSheer technology and handpieces Treatment results Petrina Nugawela Director at MBA Ltd, Dr Hugues Cartier, Dermatologist and IMCAS Global Course Co-ordinator Dr Hugues Cartier Dermatologist, phlebologist and derm laserist at the Clinic Saint-Jean, Arras, France. He is also the chief of wound care in the dermatology department of Arras Hospital. PB-00004600 REV A #### How Trilift’s Facial Stimulation Technology Will Elevate Your Practice How Trilift’s Facial Stimulation Technology Will Elevate Your Practice August 8, 2024 Due to triLift’s game-changing Dynamic Muscle Stimulation technology (DMSt), its inclusivity for everyone regardless of age, complexion, or skin type, immediate results for patients, and a user-friendly system with seamless integration, implementation, and a strong return on investment, you will not regret adding this product to your own practice. Read Full Article PB-00070170 Rev A #### How will your patients benefit Lightsheer DESIRE Overview The Technology How It Works Patients Benefit Practice Benefits Clinical Results White Papers How Will Your Patients Benefit? Short Treatment Time Comfortable Treatment Long lasting results Short Treatment Time High-Speed Integrated Vacuum Assisted Technology reduces treatment time by using a large 22x35mm spot size. Back or legs can be treated in 10 minutes or less. In addition, there is no prep time and no cooling or anesthetics required. Comfortable Treatment High-Speed Integrated Vacuum Assisted Technology uses a unique vacuum mechanism that activates the skin’s tactile and pressure receptors to inhibit the transmission of pain. ChillTip™ Technology improves patient comfort by cooling the skin prior to treatment and continuously cooling it throughout the treatment. Long Lasting Results The LightSheer technology by Lumenis has been validated in numerous clinical studies and peer reviewed articles. Our customers benefit from the LightSheer DESIRE features and enjoy high patient satisfaction. Learn More LightSheer DESIRE Brochure PB-00005660 Rev A × GET MORE INFO #### How will your patients benefit? LightSheer DESIRE Light Overview The Technology Behind the DESIRE Light How Will Your Patients Benefit Practice Benefits How Will Your Patients Benefit? Patient Benefits: Faster Treatment Time Ultimate Patient Comfort Clinically Validated Efficacy Ultimate Patient Comfort ChillTip™ Technology improves patient comfort by cooling the skin prior to treatment and continuously cooling it throughout the treatment. Clinically Validated Efficacy Numerous clinical studies and peer review articles have validated the safety and efficacy of the technologies powering the LightSheer® DESIRE™ Light. Thousands of satisfied customers have been and are still benefiting from the gold standard performance and patient satisfaction. In addition to clinically proven hair removal and permanent hair reduction capabilities, the LightSheer DESIRE Light is also FDA cleared for the treatment of Pseudo Folliculitis Barbae (PFB), benign pigmented lesions, and leg veins, providing the operator with multi-application capabilities and versatility. Learn More LightSheer DESIRE Light Brochure PB-2002616 REV C GET MORE INFO × #### HRH Prince Harry The Duke of Sussex visits The Queen Elizabeth Hospital in Birmingham Scar Center HRH Prince Harry The Duke of Sussex visits The Queen Elizabeth Hospital in Birmingham Scar Center HRH Prince Harry found out more about the Scar Free World Centre’s work piloting March 12, 2019 – Birmingham, UK This week the Duke of Sussex HRH Prince Harry found out more about the Scar Free World Centre’s work piloting tailored psychological treatments to help seriously injured armed forces personnel cope with life with an altered, scarred appearance. #### I WANT WHAT SHE HAD! I WANT WHAT SHE HAD! An Aesthetic Transformation Without A Single Incision June 23, 2019 View More #### Inclusive Aesthetic Treatment triLift by Lumenis Safe for ALL Skin Types Inclusive Aesthetic Treatment triLift by Lumenis Safe for ALL Skin Types August 26, 2024 Dr. Elaine Kung, MD, FAAD discusses advancements in energy-based devices and how triLift can raise the standard of care for patients with skin of color Read Full Article PB-00070240 Rev A #### Introducing the NEW Stellar M22 IPL technology Introducing the NEW Stellar M22 IPL technology Publish Date: Feb 24, 2021 Length: 63 Minutes Stellar M22 IPL enables you to treat a wide range of conditions with a single, ergonomic handpiece IPL handpiece. Join world renown plastic surgeon Dr. Matteo Tretti Clementoni who shares how he utilizes the Stellar IPL technology and why it is one of the most advanced and intelligent skincare innovations of our time. Dr. Matteo Tretti Clementoni Matteo Tretti Clementoni, MD, board-certified Plastic Surgeon, Consultant at ENERMEDICA SRL, Milan Area, Italy PB-00018820 Rev A #### IPL (Intense Pulsed Light) What Is IPL? Intense Pulsed Light (abbreviated IPL) describes the use of intense pulses of non-coherent light distributed over a range of wavelengths; from 400nm to 1200nm. The technology utilizes specific wavelength ranges to target various chromophores in the skin. This enables effective treatment of a broad spectrum of conditions, including vascular and pigmented lesions, skin photoaging treatments and hair removal. How Does IPL Works? Broad spectrum pulsed light is transmitted through a continuously cooled applicator, gently placed over the skin. Cut-off filters in the handpiece change the range of wavelengths, optimizing it for different applications and skin types. The light penetrates the tissue and is absorbed by either the relevant chromophores and damages them (blood chromophores when treating vascular lesions and melanin chromophores when treating pigmented lesions).  The body’s natural processes then clear the lesion debris, giving the skin a more even and youthful appearance. The Lumenis IPL Solution Lumenis offers a unique IPL solution with optimal efficacy, safety and ease of use. Optimal Pulse Technology (OPT™) gives users the ability to control the pulse shape. It provides reproducible results as well as gentler, more comfortable treatments. Universal handpiece with nine Expert Filters, enables treatment of a myriad of conditions with a single, versatile and cost effective handpiece Related Products Stellar M22™ Intelligent skincare platform for the treatment of over 30 skin conditions and hair removal. M22™ with IPL Laser For Fractional Non-Ablative Skin Resurfacing. PB-1004668 Rev A GET MORE INFO × #### Jenny Garth Says “WOW!” To The Toning And Tightening Trilift Treatment Jenny Garth Says “WOW!” To The Toning And Tightening Trilift Treatment August 25, 2024 Actress and celebrity Jenny Garth had her first triLift treatment with Nurse Jamie to tone her face and tighten her skin, which she disclosed as one of her anti-aging secrets for success. Read Full Article PB-00074800 Rev A #### Latest trends in Body treatments Latest trends in Body treatments Publish Date: Nov 10, 2020 Length: 52 Minutes In this webinar Dr Gout discusses Nuera Tight, RF (Radio Frequency) and body treatments, that have seen a huge amount of growth over the past few years. Committed to spreading the latest knowledge and raising standards to both colleagues and patients alike, she explains why she has recently tanned her interest towards the arena of energy based devices and particularly NuEra Tight. Learn more about her story and how she came to decide on the latest trend, RF and NuEra Tight. Discover what are the statistics that caused her to change her business strategy and why embrace body as the new face. Dr Uliana Gout Dr Gout is world renowned as a global Key Opinion Leader in Aesthetic Medicine, a Scientific Director of leading global conferences, a published author in the field, and President of the British College of Aesthetic Medicine. PB-00016440 #### Legend M2 Legend M²™ During the aging process, collagen produces at a slower rate relative to the rate of old collagen being broken down. The amount of hyaluronic acid declines, as do the elastic properties of elastin. Skin sags and wrinkles and rhytides appear. Radio frequency is effective for dermatological procedures requiring skin ablation and skin resurfacing, and for the non-invasive treatment of mild to moderate facial wrinkles and rhytides. It activates the body’s natural healing processes to encourage the production of new collagen, elastin and hyaluronic acid and generate new and healthy skin. Contracted fibers create an immediately noticeable tightened and rejuvenated effect on skin. The Lumenis Solution Legend M²™ treatment defeats the signs of aging by combining macro volumetric heating of the tissue with TriPollar® RF and precise micro heating of focal points with VoluDerm™ RF-assisted ultra-thin electrodes. Preheating with the TriPollar® technology lowers the tissue impedance and increases vasodilatation. During Legend M²™ treatment, the fibroblasts undergo two different triggers: minimally invasive and non-invasive. This dual effect creates a synergetic result. The suggested number of treatments may vary for each individual and their treatment areas. A typical course involves 3-5 treatments with touch-up treatments approximately every 3-6 months if needed, according to the individual’s needs. Advantages For Physicians Two treatments in one session, one system No need for numbing pre-treatment Low downtime and no need for post-treatment care Fast treatment. PB-2012180 Rev A × GET MORE INFO #### Legend Pro Legend Pro™ Skin treatments platform with unique RF assist ultra-thin electrodes and TriPollar® RF Imagine a treatment with immediate results, long term efficacy, minimal pain and downtime, and no need for numbing… Sounds too good to be true? Legend Pro is all that, and more. Patients Benefits Technology Results Patients benefits Offer your patients Legend Pro’s synergetic technologies, providing endless options for personalized treatment plans, targeted at answering the specific needs and desires of each patient. By encouraging and enhancing the natural healing processes in the skin, Legend Pro unveils the best in each patient. From resurfacing of the upper layers of the skin to promoting the regeneration of collagen and elastin fibers in the deeper dermis, Legend Pro offers a complete toolkit for creating tailor-made treatments and personalized results for your patients. Clinically proven RF thermal skin regeneration technology Legend Pro’s clinically proven technologies work in synergy to achieve the results you and your patients seek. TriPollar® RF Applicators Triggering regeneration of collagen and elastin fibers, by delivering focused RF energy in a safe and effective manner, inducing controlled heating of the deep dermis VoluDerm™ Activating the body’s natural healing processes by applying RF-assisted ultra-thin electrodes to thermally ablate the epidermis, creating micro channels to induce controlled micro wounds, thus encouraging the generation of new and healthy skin. TriFractional™ Applying contact RF and pin point ablation with controlled volumetric heating to achieve skin resurfacing and regeneration via wound healing process, resulting in skin texture improvement and refinement. Legend Pro™ – Legend M² ™ treatment Legend M²™ unique synergized treatment combines the macro volumetric heating of tissue with TriPollar® RF and the precise micro heating of focal points with VoluDerm™ RF assisted ultra-thin electrodes. Treatments with Legend M²™ reaches multiple layers of the skin introducing a wide range of solutions for skin resurfacing and inducing regeneration as well as wrinkle reduction. Thanks to the unique technologies behind Legend Pro, patients experience minimal pain and downtime during and after treatment, without the need of numbing cream before the treatment. The desired results are promptly visible. Indications include: skin resurfacing and treatment of mild to moderate wrinkles and rhytids. PB-2010179 Rev A GET MORE INFO × #### Legend Pro+ Legend Pro+™ 3 in 1 platform Personalized aesthetic solutions that meet your patients’ expectations and more Multi application RF-based platform with TriPollar® RF, and ultra-thin electrodes for skin resurfacing, skin tightening, cellulite and circumference reduction treatments. Request Demo Treating three layers of tissue with one platform VoluDerm RF Microneedling With Minimum Pain And Downtime RF microneedling, thanking the thermal ablation mode of penetration, and the ultra-thin needles Validated Combination Treatment Protocols With great market experience, feedback and validated technologies, several combination treatment protocols were developed, combining the different modalities of the Legend Pro+ with other Lumenis Be technologies. Immediate Results And Long-Term Results Focused RF and dense electrical fields provide immediate visible results, and also long-lasting results, by triggering fibroblasts to increase their metabolism and produce new elastin collagen and hyaluronic acid. Applicators and their technology TriPollar® RF 3 or more electrodes inducing focused RF heating for facial wrinkle reduction, cellulite treatment, skin tightening and noninvasive body contouring. High energy density – Immediate results visible from the 1st treatment and clinically proven long-lasting results 6-8 months * before touch up and maintenance treatments. Patients report a very pleasant experience. Frequency of 1 MHz: safe and effective for collagen remodeling and treatment of wrinkles. Dermal thickness increased by 49% on average. Kaplan H, Gat A. Clinical and Histopathological results following TriPollar™ radiofrequency skin treatments. Journal of Cosmetic and Laser Therapy 2009; 11: 78–84 VoluDerm ™ Significant increase in natural hyaluronic acid content in the skin No bleeding & minimal sensation Smooth RF assist ablation of ultra-thin electrodes Emission of RF energy to the tissue too, causing a thermal effect which leads to a wound healing process for skin resurfacing and regeneration. Suitable for all skin types. TriFractional™ Wrinkle Reduction Applying RF Electrode Ablation With Controlled Volumetric Heating Both ‘blinded’ evaluators in this study revealed improvement in the majority of subjects. Their evaluation of subject’s Fitzpatrick Wrinkle Scores revealed reduction from an average baseline score of 4.8 to 3.4 at three months follow up evaluation Source Gold MH, Adelglass J. Evaluation of Safety and Efficacy of the TriFractional RF technology for treatment of facial wrinkles. Journal of Cosmetic and laser Therapy. 2013 Vol. 16, No. 1 , Pages 2-7 Legend Pro+ treatment protocols Legend M2 TM Legend M²’S Unique Synergistic Treatment Combines Macro Volumetric Heating Of Tissue With Tripollar® Rf And Precise Micro Heating Of Voluderm Rf-Assisted Ultra-Thin Electrodes To Turn Your Patients’ Wishes Into Reality. Legend M² treatment confirmed by clinical experience, as published in the article by Steven D. Shapiro * Treatment with Legend M² reaches multiple layers of the skin and offers a wide range of solutions for skin renewal and regeneration as well as wrinkle reduction. Legend Pyramid Face Lift The Synergy Of Different Rf Modalities Creates A Three-Dimensional Effect With TriPollar dermal focused hating, VoluDerm micro wounds and TriFractional resurfacing the sensation may be controlled with topical numbing creams, and the downtime may be as long as 48 hours before the appearance of scabs SmoothGlo Stellar/M22 Ipl And Voluderm ™ Sequential Treatment. For enhanced clinical outcome on ageing skin, an ideal treatment targeting “reds and browns”, texture and skin volume, targets: melanin, haemoglobin, water PB-2012036 Rev A Close GET MORE INFO × #### LightSheer DESIRE Legacy Lightsheer DESIRE Overview The Technology How It Works Patients Benefit Practice Benefits Clinical Results White Papers LightSheer® DESIRE™ Laser System Portable Laser Solution for Skin Treatment More and more people desire to have permanent hair reduction. They want a treatment that is effective, fast and comfortable. To meet these needs, Lumenis, a leader in laser and energy based technologies, developed the LightSheer DESIRE, the new generation of laser hair reduction system from the LightSheer Family of products, so you can grow your business by offering your patients what they DESIRE Performance Unique features: Versatile 805nm diode laser. 3 handpieces with various spot sizes. 2 advanced technologies. Upgradable features: add capabilities as your practice grows. 3 Handpieces for Treating All Body Areas The HS has a HIT 22x35mm spot size enabling use of low-fluence and a unique mechanism of pain reduction, providing, fast and comfortable treatment. The XC has a Sapphire ChillTip spot size of 12x12mm, providing a solution for large and small areas requiring higher fluence levels. The ET has a Sapphire ChillTip spot size of 9x9mm designed to treat small areas that require maximum precision and higher fluence. Product Video Related products LightSheer® DESIRE™Light Offer your patients the permanent hair reduction solution they desire. By using our hair removal lasers your patients will enjoy a treatment that is effective and comfortable. LightSheer® DUET™ With two handpieces supporting two technologies LightSheer DUET enables you to treat legs or back comfortably in 15 minutes or less, making hair removal profitable without anesthetics and gels. Learn More LightSheer DESIRE Brochure PB-00024250 Rev A × GET MORE INFO #### LightSheer DESIRE Light LightSheer DESIRE Light Overview The Technology Behind the DESIRE Light How Will Your Patients Benefit Practice Benefits LightSheer® DESIRE™Light Laser Hair Removal Device The starting point to your success Offer your patients the permanent hair reduction solution they desire with LightSheer® DESIRE™ Light. By using our hair removal lasers your patients will enjoy a treatment that is effective and comfortable, using 805nm diode laser with advanced ChillTip technology. Grow your business by providing your patients laser hair removal treatments and benefit from rapid return on investment. Performance Features: 805nm diode laser ChillTip™ integrated contact cooling for epidermal protection A choice of 2 handpieces: 9×9 mm or 12×12 mm Light weight design for maximal ease of use No consumables or disposables Versatile treatment: hair removal, vascular lesions and pigmented lesions Product Video Multi-Application Capability In addition to documentation of clinical efficacy with hair removal and permanent hair reduction, the LightSheer is also FDA cleared for the treatment of pseudo folliculitis barbae (PFB), benign pigmented lesions, and leg veins, providing the operator with multi-application capabilities and versatility.In addition to Leg Veins – Approximately 50% to 60% of men and women have unsightly leg veins. While sclerotherapy is still considered the treatment of choice for the removal of superficial leg veins, many vessels may be too small to inject or patients may have an aversion to this invasive procedure. The LightSheer diode laser system can provide an alternative method of treatment that requires no painful injections. Benign Pigmented Lesions – The LightSheer diode laser system can successfully treat a wide range of cosmetically undesirable benign pigmented lesions. Pseudofolliculitis Barbae (PFB) – PFB, or razor bumps, is a common condition in which the regrowing hair, after shaving, curves back towards and pierces the skin resulting in a pustule or papule. PFB is very prevalent in populations with curly hair, affecting nearly 85% of men of African descent and a growing number of women. The LightSheer’s excellent safety profile for all skin types including the darkest skin, makes it a safe, effective and revolutionary alternative for the treatment of pseudofolliculitis Barbae. Learn More LightSheer DESIRE Light Brochure PB-2002616 REV C GET MORE INFO × #### LightSheer DUET LightSheer DUET Overview Treatment & Testimonials Configurations Patients Benefit Practice Benefits Take the High Speed Challenge LightSheer® DUET™ Rethink the Business of Hair Removal With two handpieces supporting two technologies LightSheer DUET enables you to treat legs or back comfortably in 15 minutes or less, making hair removal profitable without anesthetics and gels. No topical anesthetic required Reduce prep time Short treatment time Differentiate your practice Grow your patient base Grow your profits Product Video Depth Of Penetration Larger spot size enables greater depth of penetration, for improved absorption of energy at the target follicle.1 The only laser with unique and dedicated technology for pain reduction, enhanced efficacy, safety. Versatile The LightSheer DUET includes two optimal wavelength 800 nm diode hair removal systems on one versatile platform. The LightSheer’s dual heads enables permanent hair reduction from all areas of the body. Its advanced technology reduces pain while increasing efficacy, enabling fast and comfortable treatments for patients and practitioners. LightSheer ET 9 x 9 mm spot size Fluence up to 100 J/cm2 ChillTip™ continuous contact cooling Pulse widths up to 400 ms LightSheer HS 22 x 35 mm spot size Largest spot size of any diode Integrated vacuum-assist technology Pulse widths up to 400 ms No cooling or anesthetics required Intuitive touchscreens Fluence up to 100 J/cm2 Customizable treatment presets Simple and intuitive operation of the device due to recommended treatment settings and customizable treatment presets. Differentiate Your Practice Treat with 1/10 the pulses–save time and effort Make large-area treatments affordable for your patients Estimated Pulses per Treated Site: ET XC* HS Treatment Site Est.Area(cm2) Spotsize: 9X9 mm 12X12 mm 22X35 mm Bikini Area 125 154 87 16 Under Arm(2) 190 235 132 25 Man's back 2750 3395 1910 357 Full Legs(2) 8100 10000 5695 1052 *12X12 mm spotsize available on LightSheer DESIRE platform only. Klavuhn KG. Illumination Geometry: The Importance of Laser Beam Spatial Characteristics. Lumenis, 2001. FDA cleared for hair removal and permanent reduction in all skin types (Fitzpatrick I-VI) and tanned skin; PFB (pseudofolliculitus barbae); superficial leg veins; benign pigmented lesions. What Do Physicians Say? [ytp_video source=”Sl6MnkjT8OI,x4wGvXu_ZJw”] Learn More LightSheer DUET Patient BrochureLightSheer DUET Physician Brochure PB-1049670 Rev C GET MORE INFO × #### LightSheer QUATTRO LightSheer® QUATTRO™ Laser Hair Removal Device for All Skin Types LightSheer® QUATTRO™ is a diode laser workstation that is a perfect fit for any practice. Powered by two advanced technologies and featuring 805nm and 1060nm wavelengths, LightSheer QUATTRO can treat all hair types and skin tones. Watch Video Schedule a Demo Close Visit the Aesthetics Resource Hub for professional insights GO! Satisfying patients, growing business Treat Any Skin Type including dark and tanned skin, with the 805nm and 1060nm wavelengths. Portable with a compact footprint to fit every practice. Upgradeable and scalable enabling you to expand your practice offering. Treatment versatility Hair removal, wrinkle reduction, benign pigmented & vascular lesions We don’t just build technology, we build confidence High speed vacuum assisted Technology High Speed handpiece 22x35mm Offers a unique pain reduction mechanism and works without gel. Ideal for treating larger body areas, quickly and comfortably. Efficacy2 drawing skin into the handpiece reduces competing chromophores and pulls the target closer to the laser source which delivers energy efficiently. Decreased pain1 Unique vacuum mechanism reduces pain during treatment. Safety2 Lower fluence is required per pulse. Treatment time1,2 Rapid coverage rate without gel or anesthesia. ChillTip Integrated Contact Cooling Technology XC 12x12mm Providing a solution for both large and small areas requiring higher fluence levels. ET 9x9mm Designed to treat small areas that require maximum precision. Efficacy2,3 Compression of the skin reduces competing chromophores Safety3 Epidermal protection through continuous sapphire contact cooling Patient comfort3 Continuously cooling significantly increases comfort. 1. Ibrahimi OA, Kilmer SL. Long-term clinical evaluation of an 800-nm long-pulsed diode laser with a large spot size and vacuum-assisted suction for hair removal. Dermatol Surg. 2012 2. Xia Y, Moore R, Cho S, Ross EV. Evaluation of the vacuum-assisted handpiece compared with the sapphire cooled handpiece of the 800-nm diode laser system for the use of hair removal and reduction. J Cosmet Laser Ther. 2010; 12: 264-268. 3. Campos, V. B., Dierickx, C. C., Farinelli, W. A., Lin, T. Y. D., Manuskiatti, W., & Anderson, R. R. (2000). Hair removal with an 800-nm pulsed diode laser. Journal of the American Academy of Dermatology, 43(3), 442–447. LightSheer Globally renown laser hair removal treatment 0+ Devices Installed worldwide 0+ Clinical Papers Proving efficacy 0+ #LightSheer Posts in Instagram We’re confident in our results, so you can be too. “What I liked best about the LightSheer is the science of the vacuum assisted technology. As the skin is gently suctioned into the handpiece, the melanocyte density is reduced. Those hair follicles are closer to the energy source. Heat is going to go into the hair follicle, and destroy it” Panta Rouhani Schaffer MD, PHD, MPH “Time is money – for me and my patients. When you offer patients a solution that will have great results and doesn’t have downtime or require a lot of their personal time, they are absolutely ready to sign up.” Monica Bonakdar M.D., of the Bonakdar Aesthetics, Newport Beach, CA Hear real life stories from LightSheer users on how laser hair removal made a difference in their patient’s lives. Download Casebook You can be confident in our technology Built-in confidence – Two cutting-edge technologies for permanent hair reduction*, for all skin types. LightSheer® uses a state-of-the-art diode laser technology with a wavelength of either 805nm or 1060nm. A precise laser pulse targets the hair follicle while leaving the skin unharmed. Today, diode laser is the most commonly used technology for hair removal, enabling safe and effective treatment of all skin and hair types. LightSheer® Technologies *Permanent hair reduction is defined as the long-term, stable reduction in the number of hairs re-growing when measured at 6, 9 and 12 months after the completion of a treatment regime. Clinical Evidence Long-Term Clinical Evaluation of Hair Clearance in Darkly Pigmented Individuals Using a Novel Diode 1060 nm Wavelength with Multiple Treatment Handpieces : A Prospective Analysis With Modeling and Histological Findings Ross, E. V, Ibrahimi, Ã. O. A., Kilmer, S., Clinic, S., & Diego, S., Lasers Surg Med. 2018 May 30 Read More Evaluation of the Safety and Efficacy of a 1060-nm Large Spot Size, Vacuum-Assisted Hair Removal Diode Laser System in Asian/Pacific Fitzpatrick’s Skin Types IV-V Patients Tahiliani, S. T., & Tahiliani, H. S., J Drugs Dermatol. 2016 Nov 1;15(11):1427-1434 Read More Long-term clinical evaluation of a 800-nm long-pulsed diode laser with a large spot size and vacuum-assisted suction for hair removal Ibrahimi, O. A., & Kilmer, S. L., (2012). Dermatologic Surgery, 38(6), 912–917 Read More Laser Diode 800nm and Hirsutism in Darker Skinned Patients: Our Experience on 552 Women Scilletta, A., & Pompili, G., JAPSR (September 2008), 1–4. Read More Hair Removal with an 800 nm Pulsed Diode Laser Campos VB, Dierickx CC, Farinelli WA, Lin TY, Manuskiatti W, A. R. J., Am Acad Dermatol. 2000 Sep;43(3):442-7 Read More Learn more about LightSheer® QUATTRO™ Download the product brochure or an eBook offering tactics that can help you grow your hair removal business E-Book Brochure PB-00025330 Rev A GET MORE INFO × Close Close Close #### Long Pulsed Nd:YAG What Is A Long Pulsed Nd:YAG Laser? An Nd:YAG laser is a solid state laser capable of producing a near-infrared wavelength that penetrates deep into the skin and is readily absorbed by hemoglobin and melanin chromophores. The lasing medium of Nd:YAG (Neodymium-doped Yttrium Aluminum Garnet) is a man-made crystal (solid state) that is pumped by a high intensity lamp and placed into a resonator (a cavity capable of amplifying the power of the laser). By creating a variable long pulse duration and an appropriate spot size, it is possible to significantly heat deep skin tissues, such as large blood vessels and vascular lesions. How Does A Long Pulsed Nd:YAG Laser Work? Nd:YAG laser energy is selectively absorbed by the deeper levels of the dermis and allows for treatment of deeper vascular lesions such as telangiectasias, hemangiomas and leg veins. The laser energy is delivered using long pulses which are converted into heat in the tissue. The heat impacts the vasculature of the lesions. In addition, the Nd:YAG Laser can treat at a more superficial level; by heating the subcutaneous skin (in a non-ablative manner) it stimulates neocollagenesis which improves the appearance of facial wrinkles. The Lumenis Long Pulsed Nd:YAG Solution Lumenis’ long pulsed Nd:YAG laser is available as part of the M22™ multi-application platform. By utilizing the same power supply for both the IPL and the Nd:YAG laser, Lumenis is able to provide more treatment versatility in a single platform.Multiple Sequential Pulsing (MSP™) is available in both the Nd:YAG and the IPL modules on the M22™ platform. MSP™ allows for cooling between a sequence of pulses which protects the epidermis and allows for safe use of higher fluence. The MSP™ offers safe treatment of all skin types, including dark skin, and significantly reduces side-effects in treatment of vascular lesions. Related Products Stellar M22™ Intelligent skincare platform for the treatment of over 30 skin conditions and hair removal. M22™ with Nd: YAG laser For Fractional Non-Ablative Skin Resurfacing. PB-1004646 Rev A GET MORE INFO × #### Lumenis Announces a Breakthrough in Aesthetic Medical Devices: NuEra® Tight with FocalRF® Technology Lumenis Announces a Breakthrough in Aesthetic Medical Devices: NuEra® Tight with FocalRF® Technology, a New Era in Personalized Body Treatments August 17, 2020 – יוקנעם עילית, ישראל Lumenis Ltd., the world’s largest energy-based medical device company for aesthetic, surgical and ophthalmic applications, is proud to announce its latest innovation, the NuEra Tight with FocalRF technology. The platform introduces a breakthrough in personalized non-invasive RF body treatments to match the unique needs of every patient. NuEra Tight with FocalRF technology was developed to provide tailored body treatments to a patient’s distinctive needs. The new technology gives practitioners advanced tools for today’s aesthetic patients, accounting for clinical indications and specific body areas, all in one device. “Radio Frequency treatments are among the most requested aesthetic therapies today,” said Macrene Alexiades-Armenakas, MD, PhD, FAAD, Clinical Dermatologist, Laser Surgeon and Researcher Dermatologist, New York. “NuEra Tight with FocalRF technology is highly customizable with a wide selection of frequencies and handpieces that deliver fast, comfortable and non-invasive treatments. This results in my patients’ achieving their desired improved appearance, while ensuring safety and efficacy. This device is painless yet effective in body contouring, a game-changer for my patients.” The system’s easy to use interface features NuAPIC™ (Automatic Personalized Intelligent Control) which ensures the therapeutic temperature throughout the procedure, as well as the innovative NuLogic™ advanced protocol customization tool, that enhances further personalization for optimal treatment. “One size doesn’t fit all. That’s why we revolutionized the NuEra Tight,” said Tzipi Ozer-Armon, CEO of Lumenis. “We recognized the need for the next level solution in non-invasive body treatments, which led us to create a device that tailors a treatment specifically for a particular condition and body area. We developed FocalRF to accurately target various skin conditions throughout the procedure, resulting in a treatment that is as unique as your patients.” NuEra Tight will be available worldwide starting with the United States in August 2020 and Europe, the Middle East and Asia later this year. Please visit lumenis.com for more information about the Lumenis family of products. About Lumenis Lumenis is a global leader in the field of minimally-invasive clinical solutions for the Surgical, Ophthalmology, and Aesthetic markets, and is a world-renowned expert in developing and commercializing innovative energy-based technologies, including Laser, Intense Pulsed Light (IPL) and Radio-Frequency (RF). For over 50 years, Lumenis’ ground-breaking products have redefined medical treatments and have set numerous technological and clinical gold-standards. Lumenis has successfully created solutions for previously untreatable conditions, as well as designed advanced technologies that have revolutionized existing treatment methods. Lumenis is a portfolio company of Baring Private Equity Asia. For further information, contact 5W Public Relations at Lumenis@5wpr.com. #### Lumenis Celebrates 50 Years of Changing Lives Through Innovation at the American Academy of Dermatology (AAD) Lumenis Celebrates 50 Years of Changing Lives Through Innovation at the American Academy of Dermatology (AAD) American Academy of Dermatology (AAD) Annual Meeting in Orlando, FL from March 3rd – 7th, 2017. March 1, 2017 – Orlando, FL, USA Lumenis Ltd., the world’s largest energy-based medical device company for surgical, aesthetic, and ophthalmic applications, proudly announces its 50th anniversary, which will be celebrated at the American Academy of Dermatology (AAD) Annual Meeting in Orlando, FL from March 3rd – 7th, 2017. As an international leader in the development and commercialization of innovative aesthetic energy-based technologies, Lumenis has invented Intense Pulsed Light (IPL™) for skin treatments, LightSheer® – diode laser for hair removal and the UltraPulse® – the most powerful CO2 laser in aesthetic medicine, among many others. Lumenis has redefined medical treatments and set numerous technological and clinical gold standards. The company has successfully created solutions for previously untreatable conditions, as well as designed advanced technologies that have revolutionized existing treatment methods. “When we were the first to develop the IPL in the 1990s, it was not clearly understood how a pulsed broadband non-laser energy source could treat specific chromophore targets, but through the years it has proven to be one of the most versatile technologies on the market. The invention of these laser and light-based approaches for dermatology- opened up my practice for a whole new set of aesthetic indications [that] I never had a good solution for. Now I can’t do [it] without them,” said Dr. Mitchel P. Goldman, from Cosmetic Laser Dermatology, San Diego, Medical Director for West Dermatology and a former Medical Director at Lumenis.  Dr. Goldman is a guest speaker at the AAD. Lumenis’ vision is to provide better technology for better patient care through innovative energy-based solutions. With a ground-breaking technological legacy of five decades, the company is committed to enhancing patient health and quality of life, addressing new and growing needs of the aging population, and continuing to offer medical professionals innovative solutions to meet the developing and dynamic healthcare environment of the 21st century. “Lumenis is proud to provide advanced noninvasive solutions from the most common to the most severe skin concerns,” said Tzipi Ozer-Armon, CEO of Lumenis. “As we have for the past 50 years, Lumenis is committed to continue supporting medical community leaders advancing the use of medical laser technologies and providing innovative, life-changing treatment benefits.” In an effort to serve underprivileged and underserved populations, Lumenis has partnered with a number of foundations, hospitals, and healthcare professionals internationally, with countries including Haiti, Russia, St. Lucia, India, Africa, and Armenia, to provide the latest energy-based treatments to patients suffering from conditions such as BPH, burn injuries, and glaucoma. Lumenis lasers are used in humanitarian missions around the world to treat wounded warriors, war survivors, and severe scar patients, including Kim Phuc, a survivor of the Vietnam War bombing who is recognized as “The Girl in the Picture.” Lumenis lasers improve the quality of life of many patients around the world, such as cancer survivor, Angela Wissel, who is also speaking at the AAD.   “The FemTouch procedure was absolutely life changing. I couldn’t believe the difference in just a short amount of time, and we had our life back – literally. It was amazing,” said Wissel. “The treatments are quick, they are painless, they’re easy, and I wish I had known about this instead of suffering for years waiting for a solution.” Lumenis will honor its 50th anniversary and decades of innovation at this year’s AAD with a champagne celebration. Please visit lumenis.com for a detailed agenda of activities at the conference.  For more information about the Lumenis family of products, please visit the Lumenis booth (#2541), where attendees can win prizes for answering fun quiz questions about laser history. About Lumenis Lumenis is a global leader in the field of minimally-invasive clinical solutions for the Surgical, Ophthalmology, and Aesthetic markets, and is a world-renowned expert in developing and commercializing innovative energy-based technologies, including Laser, Intense Pulsed Light (IPL) and Radio-Frequency (RF). For 50 years, Lumenis’ ground-breaking products have redefined medical treatments and have set numerous technological and clinical gold-standards. Lumenis has successfully created solutions for previously untreatable conditions, as well as designed advanced technologies that have revolutionized existing treatment methods. For more information visit: www.lumenis.com Forward-Looking Statements Information provided in this press release may contain statements relating to current expectations, estimates, forecasts and projections about future events that are forward-looking statements. These forward-looking statements may include but are not limited to the Company’s plans, objectives and expectations for future operations, including its projected results of operations. Forward-looking statements are often characterized by the use of forward-looking terminology such as “may,” “will,” “expect,” “anticipate,” “estimate,” “continue,” “believe,” “should,” “intend,” “plan,” “project” or other similar words, but are not the only way these statements are identified. These forward-looking statements are based upon our management’s current estimates and projections of future results or trends. Actual results may differ materially from those projected as a result of certain risks and uncertainties These forward-looking statements are made only as of the date hereof, and the Company undertakes no obligation to update or revise the forward-looking statements, whether a result of new information, future events or otherwise. For further information, contact 5W Public Relations at Lumenis@5wpr.com. #### Lumenis Disrupts the Energy-Based Treatment Category with a New Facial Stimulation Treatment, triLift™ Lumenis Disrupts the Energy-Based Treatment Category with a New Facial Stimulation Treatment, triLift™, at the 2022 American Academy of Dermatology (AAD) March 23, 2022 – Boston, MA, USA Lumenis Be, Ltd., a leading energy-based medical device company for aesthetic and eye care applications, is proud to announce the launch of triLift, a facial stimulation device targeting the three aging elements: structure, contour, and texture, by treating the three tissue layers – the muscles, the dermal layer and the epidermal layer. Lumenis is proud to unveil this new device exclusively at the 2022 AAD Annual Meeting’s show floor from March 25th – March 27th. The patent pending triLift is the first treatment in the market to use Dynamic Muscle Stimulation (DMStTM) in sequence with two other modalities to tone healthy muscles, reduce facial wrinkles, and smooth and resurface the skin, achieving an effect similar to a face lift, noninvasively. Unlike traditional electrical muscle stimulation and magnetic muscle stimulation, DMSt technology allows in-motion muscle stimulation, covering small to large areas. TriPollar RF and triFX Radiofrequency Microneedling then tighten the skin, smoothen its texture and plump it by regenerating collagen and elastin. According to studies1,2,3, triLift can increase skin smoothness by 80%, reduce the appearance of wrinkles by 30%, and triple the natural production of Hyaluronic Acid compared to baseline. “Aging is part of life and happens to all of us, but what many people do not realize is that aging is more than wrinkles on the skin surface, it starts and continues with the muscles, bones and soft tissues below our skin” said Dr. Steven Dayan, facial plastic surgeon and director of Denova research in Chicago. “I am enthused by triLift’s innovative technology, an advancement in treating the multilayer influences of aging, including the muscles, the dermal and the epidermal layers”. He continued, “triLift is an option for anyone who wants to firm up the appearance of their face with a noninvasive, no downtime approach.  Patients can expect a visible lift and glow that is pleasant, quick, and seems to improve with every additional treatment.” “At Lumenis we are always pioneering new technological and clinical frontiers, bringing to market innovative, efficacious and safe energy-based aesthetic solutions,” said Tzipi Ozer-Armon, CEO of Lumenis. “With the launch of triLift, a new facial stimulation category leveraging our DMSt technology, we have done just that – providing providers and patients another first-of-its-kind aesthetic solution.  We look forward to partnering with providers across the globe in the months and years to come to further expand the impact and reach of this revolutionary technology.” Lumenis will unveil triLift at the  AAD Annual Meeting’s show floor, booth #2817, on March 25, 2022, at 3pm EDT. References: Kaplan H., Gat A., Journal of Cosmetic and Laser Therapy Potekaev N, Zhukova O., Journal of Cosmetics, Dermatological Sciences and Applications Boisnic S, Branchet MC., Eur J Dermatol   About Lumenis Lumenis is a global leader in the medical aesthetic market and is a world-renowned expert in developing and commercializing innovative energy-based technologies, including Laser, Intense Pulsed Light (IPL) and Radio-Frequency (RF). For over 50 years, Lumenis’ ground-breaking products have redefined medical treatments and set technological and clinical gold-standards, revolutionizing existing treatment methods and creating solutions for previous untreatable conditions. Lumenis is a portfolio company of Baring Private Equity Asia. #### Lumenis Exhibits Innovative Energy-based Technologies and the Launch of PiQo4 at 37th Annual Conference of the American Society for Laser Medicine and Surgery Lumenis Exhibits Innovative Energy-based Technologies and the Launch of PiQo4 at 37th Annual Conference of the American Society for Laser Medicine and Surgery The most powerful advanced laser technology for tattoo removal and pigmentation. April 4, 2017 – San Diego, CA, USA Lumenis Ltd., the world’s largest energy-based medical device company for surgical, aesthetic, and ophthalmic applications, proudly announces its newest launch, PiQo4 – the most powerful advanced laser technology for tattoo removal and pigmentation. The technology will be showcased at the 37th annual American Society for Laser Medicine and Surgery (ASLMS) conference in San Diego, CA from April 5th – 9th, 2017. The Lumenis PiQo4 provides versatile tattoo removal that yields truly remarkable results as it treats a wide range of pigment colors, and has an adaptable energy matrix to ensure effective shattering of pigment deposits. PiQo4 offers dual Nano + Pico technology, a combination of energy types offering the user versatility and the ability to optimize treatment parameters to maximize results. PiQo4 features a unique combination of high power output, four wavelength to target nine of the most common ink colors and the largest spot size on the market, allowing it to effectively reach deep pigments in both new and old tattoos. The introduction of the system signifies an important advancement in tattoo removal technology, enabling the physicians to remove multicolor tattoos in a couple of short treatments. “I’m excited to be able to treat my patients with the new Lumenis PiQo4,” said Dr. E. Victor Ross. “Its high power and large spot size is making a significant difference in faster tattoo clearances, and in treating resistant inks – even the deepest pigmented, older tattoos.” PiQo4 treats a wide variety of skin conditions in addition to tattoo removal including treatment of pigmented lesions, lentiginous, cafe-au-lait birthmarks and vascular lesions. The PiQo4 offers a non-thermal option to skin resurfacing and discoloration and with 72% of consumers seeking to correct skin texture and/or discoloration (according to the ASAPS), this latest innovation allows physicians to offer an effective solution to the growing demand in the market. “As the pioneer of laser technology, Lumenis is proud to lead the way with a new solution in the field of tattoo removal,” said Tzipi Ozer-Armon, CEO of Lumenis. “With independent control of spot size, pulse and energy for maximum versatility, PiQo4 yields truly remarkable results and allows us to continue helping clinicians improve the well-being and lifestyle of their patients.” Introducing this latest technology aligns with Lumenis’ vision to provide better technology for better patient care through innovative energy-based solutions. In an effort to help scar patients around the world, Lumenis is introducing HopeForScars.com, an online resource intended to provide patients and healthcare professionals with comprehensive information about scars and treatment options available, including the Lumenis UltraPulse®, which is quickly becoming the standard of care for scar patients around the world. One of the patients who benefitted from the UltraPulse treatment for scars is Kim Phuc, an iconic survivor of the Vietnam War Napalm bombing. Kim was treated by her physician, Dr. Jill Waibel, with the Lumenis® UltraPulse®. On Friday, April 7th, Kim Phuc will be the keynote speaker at “The Kim Phuc Story & The Road to Healing Through the UltraPulse® Scar Revision,” a plenary session held in Hall F from 10:30 AM – 12PM. In addition to her session, Kim and Dr. Waibel will also be available for discussion and interviews throughout the conference. For more information about the Lumenis family of products, please visit the Lumenis booth (#417). About Lumenis Lumenis is a global leader in the field of minimally-invasive clinical solutions for the Surgical, Ophthalmology, and Aesthetic markets, and is a world-renowned expert in developing and commercializing innovative energy-based technologies, including Laser, Intense Pulsed Light (IPL) and Radio-Frequency (RF). For 50 years, Lumenis’ ground-breaking products have redefined medical treatments and have set numerous technological and clinical gold-standards. Lumenis has successfully created solutions for previously untreatable conditions, as well as designed advanced technologies that have revolutionized existing treatment methods. For more information visit: www.lumenis.com Forward-Looking Statements Information provided in this press release may contain statements relating to current expectations, estimates, forecasts and projections about future events that are forward-looking statements. These forward-looking statements may include but are not limited to the Company’s plans, objectives and expectations for future operations, including its projected results of operations. Forward-looking statements are often characterized by the use of forward-looking terminology such as “may,” “will,” “expect,” “anticipate,” “estimate,” “continue,” “believe,” “should,” “intend,” “plan,” “project” or other similar words, but are not the only way these statements are identified. These forward-looking statements are based upon our management’s current estimates and projections of future results or trends. Actual results may differ materially from those projected as a result of certain risks and uncertainties these forward-looking statements are made only as of the date hereof, and the Company undertakes no obligation to update or revise the forward-looking statements, whether a result of new information, future events or otherwise. For further information, contact 5W Public Relations at Lumenis@5wpr.com. #### Lumenis Features Acoustics & Heat Experience and Introduces PicoFractional™ Technology at the American Academy of Dermatology Annual Meeting (AAD) Lumenis Features Acoustics & Heat Experience and Introduces PicoFractional™ Technology at the American Academy of Dermatology Annual Meeting (AAD) New photoacoustic fractional laser, at the American Academy of Dermatology (AAD). February 13, 2018 – San Diego, CA, USA Lumenis Ltd., the world’s largest energy-based medical device company for aesthetic, surgical, and ophthalmic applications, is thrilled to unveil Pico Fractional™, a new photoacoustic fractional laser, at the American Academy of Dermatology (AAD) Annual Meeting in San Diego, CA from February 16th-18th, 2018. Pico Fractional, is a new PiQo4™ hand-piece, which introduces a fractional laser beam based on photoacoustics. As opposed to traditional laser treatments, which use thermal energy, PicoFractional creates thousands of microscopic treatment zones within the skin, and utilizes the shattering effect of sound waves to create tiny holes deep within the dermis, known as Laser Induced Optical Breakdown (LIOB). The photoacoustic beam creates pressure waves that initiate an enhanced inflammatory healing response, resulting in an increased production of collagen and elastin. “Lumenis is thrilled to introduce this innovative new technology and all of its advantages to our customers and consumers. The PiQo4 platform has reached a new level of versatility, offering truly acoustic skin resurfacing leading to neocollogenesis and minimum-downtime,” said Tzipi Ozer-Armon, Lumenis CEO. “This unique combination of high efficacy with minimized recovery time further emphasizes our continued commitment to delivering better technology for better patient care.” With Lumenis featuring groundbreaking photoacoustic and photothermal technologies this year, the brand’s theme will be “Acoustics and Heat,” which will be represented with a unique 3D adventure highlighting the power that both have in transforming the aesthetics industry. The wide range of Lumenis products allows physicians to work using a combination of technologies, such as IPL and PiQo4. With a hologram 3D journey through astounding dermatological results, this year’s booth will be an exciting look into the future of aesthetics. “This is a great combination, [acoustics and heat are] great dance partners. You have the acoustic effect of the fractional mode of PiQo4 that is very synergistic with the thermal mode of the AcuPulse system. So now you have a nice, deeper penetrating laser, but it is painless,” said Dr. Vic Ross, who uses AcuPulse and PiQo4 at his practice. For more information about the Lumenis family of products, please visit the Lumenis booth (#2229) or lumenis.com for a detailed agenda of activities at the conference. About Lumenis Lumenis is a global leader in the field of minimally-invasive clinical solutions for the aesthetic, surgical, and ophthalmic markets, and is a world-renowned expert in developing and commercializing innovative energy-based technologies, including Laser, Intense Pulsed Light (IPL) and Radio-Frequency (RF). For over 50 years, Lumenis’ ground-breaking products have redefined medical treatments and have set numerous technological and clinical gold-standards. Lumenis has successfully created solutions for previously untreatable conditions, as well as designed advanced technologies that have revolutionized existing treatment methods. For more information visit:  www.lumenis.com Forward-Looking Statements Information provided in this press release may contain statements relating to current expectations, estimates, forecasts and projections about future events that are forward-looking statements. These forward-looking statements may include but are not limited to the Company’s plans, objectives and expectations for future operations, including its projected results of operations. Forward-looking statements are often characterized by the use of forward-looking terminology such as “may,” “will,” “expect,” “anticipate,” “estimate,” “continue,” “believe,” “should,” “intend,” “plan,” “project” or other similar words, but are not the only way these statements are identified. These forward-looking statements are based upon our management’s current estimates and projections of future results or trends. Actual results may differ materially from those projected as a result of certain risks and uncertainties. These forward-looking statements are made only as of the date hereof, and the Company undertakes no obligation to update or revise the forward-looking statements, whether a result of new information, future events or otherwise. For further information, contact 5W Public Relations at Lumenis@5wpr.com. #### Lumenis Introduced PiQo4 Technology in NYC. An intimate Night of Conversation and Live Demos for Top-tier Editors was hosted by Dr. Marmur Lumenis Introduced PiQo4 Technology in NYC. An intimate Night of Conversation and Live Demos for Top-tier Editors was hosted by Dr. Marmur Lumenis PiQo4 Launch Event December 5, 2017 – New York, NY, USA To celebrate and introduce the launch of the PiQo4 technology, Lumenis organized an intimate night of conversation and live demos for top-tier editors in NYC. The event took place at Dr. Marmur’s office, a leading dermatologist in NYC. Dr. Marmur shared details on Lumenis as the leader in non-invasive laser treatments, followed by her presentation of the PiQo4 technology and its benefits. Following, editors were escorted to Dr. Marmur’s treatment room to watch a live demo of the technology. The Lumenis team was excited to meet with the editors and hear their positive feedback on the PiQo technology. Here is a live update from Bridal Guide, Kayla Hayes! #### Lumenis Introduces a New Skin Rejuvenating Technology, Legend Pro+™, at the 17th Aesthetic & Anti-Aging Medicine World Congress Lumenis Introduces a New Skin Rejuvenating Technology, Legend Pro+™, at the 17th Aesthetic & Anti-Aging Medicine World Congress Lumenis announces the launch of its newest platform, the Legend Pro+™, a unique multi-application platform powered by four clinically-proven, complimentary technologies. April 4, 2019 – Monte Carlo, 98000 Monaco #### Lumenis Introduces an Advanced, Intelligent Skincare Innovation, Stellar M22™ Lumenis Introduces an Advanced, Intelligent Skincare Innovation, Stellar M22™ March 9, 2020 – יוקנעם עילית, ישראל Lumenis Ltd., the world’s largest energy-based medical device company for aesthetic, surgical and ophthalmic applications, announces the launch of its newest, innovative platform, the Stellar M22™. This versatile multi-application platform builds on the heritage of the iconic M22 and is set to lead the category. #### Lumenis introduces FoLix™, the first FDA-cleared proprietary fractional laser for hair loss treatment Lumenis introduces FoLix™, the first FDA-cleared proprietary fractional laser for hair loss treatment June 5, 2024 – Yokne'am Illit, Israel Lumenis Be. Ltd., a leading energy-based medical device company for aesthetic and eye care solutions, is proud to announce the launch of its breakthrough laser system designed to combat hair loss. Recently cleared by the Food and Drug Administration (FDA), FoLix becomes the first and only fractional laser choice for safe, effective, and natural hair loss treatment for women and men in the United States1. Affecting more than 85% of men and 50% of women2, hair loss remains a persistent, widespread challenge. FoLix’s groundbreaking approach utilizes fractional laser and Lumenis’ proprietary technology tailored for hair. This is a revolution for hair loss patients, offering results in 4-6 monthly sessions with no chemicals, needles, anesthesia, surgery, or downtime. FoLix’s unique technology delivers precise pulses of laser that leverage the body’s natural processes to stimulate hair follicles. Lumenis’ pre-clinical and clinical studies measuring the laser’s effect showed a positive impact on hair growth, with noticeable improvements in scalp hair appearance and an increase in hair count3. “Fractional lasers have been shown to have remarkable effects on the skin and now, finally, Lumenis has been able to harness that power and bring an innovative solution for hair stimulation.” Said Dr. Marc Avram, a renowned hair transplant specialist and Clinical Professor of Dermatology at Weill Cornell Medical College (WCMC). “With hair loss becoming a growing concern, FoLix emerges as a pivotal innovation for both patients and providers” adds Dr. Neil Sadick, a world-leading dermatologist and researcher, and Clinical Professor of Dermatology at WCMC. “FoLix offers a unique opportunity to help those suffering from hair loss through short monthly sessions and with minimal discomfort and no downtime.” “At Lumenis, we’re committed to transforming lives through science and innovation.  FoLix is about more than just hair; it’s about having the self-confidence to live life to the fullest,” said Lumenis CEO Tzipi Ozer-Armon.  “We are eager to collaborate with providers across the US to extend the influence and accessibility of this groundbreaking solution.” For more information about FoLix please visit Lumenis.com/FoLix. About Lumenis Lumenis is a global leader in the medical aesthetic market and is a world-renowned expert in developing and commercializing innovative energy-based technologies, including Laser, Intense Pulsed Light (IPL) and Radiofrequency (RF). For more than 50 years, Lumenis’ ground-breaking products have redefined medical treatments and set technological and clinical gold-standards, revolutionizing existing treatment methods, and creating solutions for previously untreatable conditions. Lumenis is a portfolio company of EQT Private Capital Asia. For more information regarding Lumenis’ range of clinical solutions, please visit: www.lumenis.com About FoLix FoLix is a non-ablative fractional laser device to improve the appearance of scalp hair in adult males and females with Fitzpatrick skin types I to IV, who are seeking treatment for hair loss. FoLix treatment could cause redness, swelling, scarring, and pigmentation change. The use of FoLix is contraindicated for patients with any concurrent cancer or history of skin cancer, active infection, fungal or bacterial diseases. See the system user manual for a complete list of contraindications and risks. *The physicians’ testimonials represent a specific experience of a paid spokesperson. Experience of others may vary. 1 See the “About FoLix” section for the indication of use and relevant skin types. 2 Men’s Hair Loss. American Hair Loss Association- https://www.americanhairloss.org/mens-hair-loss/ and Hair Loss in Women. Cleveland Clinic- https://my.clevelandclinic.org/health/diseases/16921-hair-loss-in-women 3 As measured in 1-month and 3-month follow-ups following the last treatment session, compared to baseline. ​Data on file. DOWNLOAD FoLix BROCHURE PB-00079380, Rev A #### Lumenis Introduces New Laser Hair Removal Solution, SPLENDOR X, at the 2018 American Society of Dermatological Surgery (ASDS) Lumenis Introduces New Laser Hair Removal Solution, SPLENDOR X, at the 2018 American Society of Dermatological Surgery (ASDS) SPLENDOR X— the first solid state laser system equipped with the unique BLEND X technology for fast and effective hair removal and skin solutions October 11, 2018 – Phoenix, AZ, USA Lumenis Ltd., the world’s largest energy-based medical device company for aesthetic, surgical and ophthalmic applications, excitedly announces its newest launch, SPLENDOR X— the first solid state laser system equipped with the unique BLEND X technology for fast and effective hair removal and skin solutions. The technology will be showcased for the first time at the 2018 American Society of Dermatological Surgery – ASDS in Phoenix from October 11th-October 14th, 2018. SPLENDOR X treats a wide range of hair removal procedures, with BLEND X, Binary laser emission of Nd: YAG (1064nm) and Alexandrite (755nm) wavelengths, synchronized to fire with adjustable proportions. At 250W output power, SPLENDOR X provides rapid coverage rate combining high fluency, large spot size and high repetition rate. The unique square spot shape eliminates overlap and hot spots, guaranteeing uniform skin coverage. Furthermore, a built-in plume evacuator ensures a smoke free and safer environment. “The SPLENDOR X technology not only allows the use of the laser on all other skin tones, but due to its unique BLEND X technology, I’m able to create customized treatment options for patients of all skin types and hair types” said Dr. Suzanne L. Kilmer of Laser and Skin Surgery Center in Northern California. “The two adjustable wavelengths, Nd: YAG and Alexandrite allow me to use the machine to fit treatment requirements to each individual.” Lumenis will be showcasing SPLENDOR X, the newest addition to its laser hair removal portfolio, through Lumenis’ Hot Topic Symposium at ASDS. Dr. Mary Lupo will introduce the SPLENDOR X on October 11th at 7pm-9pm in a lecture titled The Splendor of Hair Removal with NEW Synchronized Emissions & Square Spot + Body. The device’s innovations will be highlighted, such as its ability to provide deeper penetration giving uniform coverage of the treatment area quickly and safely on all skin types including tanned and darker skin tones all year round. The SPLENDOR X the next generation in hair removal and truly expands our offering in this category,” said Tzipi Ozer-Armon, CEO of Lumenis. “As with all our products, and this one specifically, we look not only to build technology, but also to create, design and inspire confidence for our customers.“ In addition to launching the latest in their laser hair removal portfolio, Lumenis will offer live demonstrations of the NuEra tight, an all-in-one radiofrequency device for the body and GeneO+, a 3-in-1 super facial device. Lumenis will be hosting a booth (#316) that will showcase all of Lumenis’ latest innovations in light based technologies. Please visit lumenis.com for more information about the Lumenis family of products. Lumenis is a global leader in the field of minimally-invasive clinical solutions for the Surgical, Ophthalmology, and Aesthetic markets, and is a world-renowned expert in developing and commercializing innovative energy-based technologies, including Laser, Intense Pulsed Light (IPL) and Radio-Frequency (RF). For 50 years, Lumenis’ ground-breaking products have redefined medical treatments and have set numerous technological and clinical gold-standards. Lumenis has successfully created solutions for previously untreatable conditions, as well as designed advanced technologies that have revolutionized existing treatment methods. Lumenis is a portfolio company of XIO Group, a global alternative investments firm headquartered in London and led by its four founders; Athene Li, Joseph Pacini, Murphy Qiao and Carsten Geyer. For more information visit:  www.lumenis.com Forward-Looking Statements Information provided in this press release may contain statements relating to current expectations, estimates, forecasts and projections about future events that are forward-looking statements. These forward-looking statements may include but are not limited to the Company’s plans, objectives and expectations for future operations, including its projected results of operations. Forward-looking statements are often characterized by the use of forward-looking terminology such as “may,” “will,” “expect,” “anticipate,” “estimate,” “continue,” “believe,” “should,” “intend,” “plan,” “project” or other similar words, but are not the only way these statements are identified. These forward-looking statements are based upon our management’s current estimates and projections of future results or trends. Actual results may differ materially from those projected as a result of certain risks and uncertainties these forward-looking statements are made only as of the date hereof, and the Company undertakes no obligation to update or revise the forward-looking statements, whether a result of new information, future events or otherwise. For further information, contact 5W Public Relations at Lumenis@5wpr.com.  #### Lumenis is Proud to Support Scars II, the Second International Scar Treatment Conference in Israel Lumenis is Proud to Support Scars II, the Second International Scar Treatment Conference in Israel International Scar Treatment Conference in Israel March 19, 2018 – Yokne'am Moshava, Israel Lumeni Ltd., the world’s largest energy-based medical device company for surgical, aesthetic, and ophthalmic applications, announced that it will again be supporting the International Scar Treatment Conference in Israel, which will be held for the second time in Tel Aviv, on March 21st-22nd, 2018. Last year, at the very first Scar Treatment Conference, the international event allowed key opinion leaders from the USA, Europe and Israel to gather and share important new studies and patient care protocols. Among them were Dr. Jill Waibel, Dr. Peter Shumaker, Dr. Mateo Tretti Clementoni and other leading experts, who spoke about the unique Lumenis UltraPulse® SCAARFX™ solution for severe scar treatment. “Treatment of scars is my passion and last year’s 2017 International Scars Conference was one of the most informative meetings regarding this topic,” said Dr. Matteo Tretti Clementoni. “Lumenis produces a variety of devices including the UltraPluse CO2, the ResurFX™ (1565 nm non-ablative fractional), and the IPL with OPT™, that allow me to treat most of the scars I see during my everyday activity. Using their devices along or in combination we are not only able to change the features of a scar but also to really improve the quality of life of the patients.” Under the direction of The Tel Aviv Medical Center, Ichilov, with the Israel Society of Dermatology and Venereology, the Israeli Society for Dermatologic Surgery and the Israeli Society of Plastic and Aesthetic Surgery, the conference will bring together experts from the plastic surgery, aesthetic, and dermatology community worldwide to explore the newest, cutting-edge practices in scar treatment and aesthetics. “Lumenis is proud to support the second International Scar Treatment Conference in Israel,” said Tzipi Ozer-Armon, CEO of Lumenis. “We take great pride in our meaningful solutions for scar treatments, which not only impact the visibility of scars, but the quality of life of patients who suffer from them.” Lectures will be held on a diverse range of topics, including scar mitigation and healing, surgery and trauma, therapies for medical management, laser and light therapy, and acne scarring and striae to name just a few. In addition to the presentations, and a live scar treatment workshop, an extensive, professional exhibition will be held to showcase the latest breakthrough innovations in medical equipment and the pharmaceutical industry worldwide, including a section featuring Lumenis breakthroughs, such as the UltraPulse® SCAARFX™, M22™ – multi application platform, and AcuPulse™. On Wednesday, March 21st and Thursday, March 22nd the Lumenis UltraPulse® SCAARFX™, M22™ – multi application platform, and AcuPulse™ complete aesthetic workstation will be the focus of over 20 lectures at the Scars II Conference. Highlights include, live scar treatments workshop by world renowned experts, “Ameliorating pain and itch”, by Dr. William Norbury, “Algorithm for laser scar treatment”, by Dr. Matteo Tretti Clementoni, and more. Please visit lumenis.com for a detailed agenda. About Lumenis Lumenis is a global leader in the field of minimally-invasive clinical solutions for the Surgical, Ophthalmology, and Aesthetic markets, and is a world-renowned expert in developing and commercializing innovative energy-based technologies, including Laser, Intense Pulsed Light (IPL) and Radio-Frequency (RF). For 50 years, Lumenis’ ground-breaking products have redefined medical treatments and have set numerous technological and clinical gold-standards. Lumenis has successfully created solutions for previously untreatable conditions, as well as designed advanced technologies that have revolutionized existing treatment methods. For more information visit:  www.lumenis.com Forward-Looking Statements Information provided in this press release may contain statements relating to current expectations, estimates, forecasts and projections about future events that are forward-looking statements. These forward-looking statements may include but are not limited to the Company’s plans, objectives and expectations for future operations, including its projected results of operations. Forward-looking statements are often characterized by the use of forward-looking terminology such as “may,” “will,” “expect,” “anticipate,” “estimate,” “continue,” “believe,” “should,” “intend,” “plan,” “project” or other similar words, but are not the only way these statements are identified. These forward-looking statements are based upon our management’s current estimates and projections of future results or trends. Actual results may differ materially from those projected as a result of certain risks and uncertainties these forward-looking statements are made only as of the date hereof, and the Company undertakes no obligation to update or revise the forward-looking statements, whether a result of new information, future events or otherwise. For further information, contact 5W Public Relations at Lumenis@5wpr.com. PB-2010161 Rev A #### Lumenis is Proud to Support the First International Scar Treatment Conference in Israel Lumenis is Proud to Support the First International Scar Treatment Conference in Israel Lumenis Ltd., the world’s largest energy-based medical device company for surgical, aesthetic, and ophthalmic applications, announced that it will be supporting the first International Scar Treatment Conference in Israel. February 22, 2017 – Yokne'am Moshava, Israel Lumenis Ltd., the world’s largest energy-based medical device company for surgical, aesthetic, and ophthalmic applications, announced that it will be supporting the first International Scar Treatment Conference in Israel, which will be held in Tel Aviv, on February 22nd, 2017. The primary focus of the conference is an interdisciplinary approach for successful management of scars, and it will feature many key scar experts from around the world, including Dr. Peter Shumaker (US), Dr. Jill Waibel (US), Dr. Matteo Tretti Clementoni (Italy), Dr. Gerd Gauglitz (Germany), Dr. Ofir Artzi (Israel) and more. “The management and treatment of cutaneous scars is a major burden in healthcare,” said Dr. Ofir Artzi, MD, Head of the Center for Aesthetic Dermatology at Tel Aviv Sourasky Medical Center and one of the conference organizers. “It is estimated that approximately 100 million people develop scars after trauma and elective surgery every year – 15% of them will require certain intervention for their scars due to aesthetic considerations or functional impairment. I am very proud to be the chairman of this first international scar treatment conference.” Many of the panelists and attending physicians who regularly use the Lumenis® UltraPulse® in their practice for the treatment of scars, will be featuring the technology for scar revision during the conference. Quickly becoming the standard of care for scar patients around the world, the Lumenis® UltraPulse® has multiple options for maximum versatility, speed, and efficacy. The Lumenis® UltraPulse® SCAAR FX™ has the deepest impact per pulse for treating thick, complex lesions, helping to change the quality of care and life of these severe scar patients. “I’ve been using the Lumenis® UltraPulse® SCAAR FX on my scar patients, including well-known patients such as Tanya St-Arnaud, an acid attack survivor, and Kim Phuc, a survivor of the Vietnam War bombing who is recognized as ‘The Girl in the Picture,’” said Dr. Jill Waibel. “It has truly changed their lives. Helping these patients heal and improve their quality of life is the most rewarding gift.” International Scar Treatment Conference attendees are invited to attend sessions and workshops featuring a variety of Lumenis systems for skin and scars treatment including UltraPulse®, the most powerful CO2 laser in the aesthetic medicine, AcuPulse™ -MultiMode™ SuperPulse™ CO2 Laser and M22™ – modular multi-application system for the treatment of over 30 skin conditions. The full agenda can be found here. “Our treatment, utilizing the unique UltraPulse technology, yields truly remarkable results for burn scars”, said Tzipi Ozer-Armon, CEO of Lumenis. “As a company, we are honored to lead and advance medical solutions of this nature to benefit veterans around the world and the population at large. Lumenis is proud to support the first International Scar Treatment Conference in Israel, and looks forward to continuing to support these incredible doctors and their efforts.” For more information about the Lumenis family of fractional ablative laser resurfacing products and its portfolio of innovative scar treatment solutions, please visit the Lumenis booth # 6-7 at the conference, presented in cooperation with Alphamedix, the Lumenis distributor in Israel. About Lumenis Lumenis is a global leader in the field of minimally-invasive clinical solutions for the Surgical, Ophthalmology, and Aesthetic markets, and is a world-renowned expert in developing and commercializing innovative energy-based technologies, including Laser, Intense Pulsed Light (IPL) and Radio-Frequency (RF). For 50 years, Lumenis’ ground-breaking products have redefined medical treatments and have set numerous technological and clinical gold-standards. Lumenis has successfully created solutions for previously untreatable conditions, as well as designed advanced technologies that have revolutionized existing treatment methods. For more information visit: www.lumenis.com Forward-Looking Statements Information provided in this press release may contain statements relating to current expectations, estimates, forecasts and projections about future events that are forward-looking statements. These forward-looking statements may include but are not limited to the Company’s plans, objectives and expectations for future operations, including its projected results of operations. Forward-looking statements are often characterized by the use of forward-looking terminology such as “may,” “will,” “expect,” “anticipate,” “estimate,” “continue,” “believe,” “should,” “intend,” “plan,” “project” or other similar words, but are not the only way these statements are identified. These forward-looking statements are based upon our management’s current estimates and projections of future results or trends. Actual results may differ materially from those projected as a result of certain risks and uncertainties These forward-looking statements are made only as of the date hereof, and the Company undertakes no obligation to update or revise the forward-looking statements, whether a result of new information, future events or otherwise. For further information, contact 5W Public Relations at Lumenis@5wpr.com. #### Lumenis Proudly Showcases a Wide Range of Technologies for Multiple Skin & Body Applications at the 24th World Congress of Dermatology (WCD) 2019 Lumenis Proudly Showcases a Wide Range of Technologies for Multiple Skin & Body Applications at the 24th World Congress of Dermatology (WCD) 2019 Lumenis showcasing a wide range of novel technologies for skin, hair, body and women’s health applications at this year’s WCD, 11th – 14th June. June 10, 2019 – Milan, Metropolitan City of Milan, Italy Lumenis Ltd, the world’s largest energy-based medical device company for aesthetic, surgical, and ophthalmic applications, is proud to be showcasing a wide range of novel technologies for skin, hair, body and women’s health applications at this year’s WCD, 11th – 14th June.   The newest of the range is Legend Pro+™, a 4-in-1 Radio Frequency platform, for muscle toning of both the face (SMAS) and body, as well as resurfacing the epidermal layer from inside out with its unique RF ablation. Also on display will be NuEra tight™, the brand’s new state-of-the-art dual body and face solution. Its non-invasive, intelligent temperature-controlled RF technology can be used for both superficial and deep heating, treating a variety of conditions such as skin laxity and the appearance of cellulite. Lumenis will also present SPLENDOR X™, the world’s first square spot laser for hair removal. Equipped with the unique BLEND X™ technology, the system provides a rapid coverage rate combining high fluence and repetition rate. Attendees are invited to meet another leading addition – PiQo4™, the ultimate pigment superstation for all skin complexions, which uses Pico and Nano technologies to remove unwanted tattoos and pigmented lesions on all skin types. Lumenis world-renowned M22™, LightSheer™ and UltraPulse® technologies will also be presented at the booth.  Rounding out the highlighted technologies is the Geneo™ facial treatment platform by Pollogen™, offering a unique treatments of Tripollar™ RF, Oxygeneo and Ultrasound technologies, empowered by the novel Active OxyPods. “Lumenis has always provided a wide range of treatments for Dermatologists like myself,” said Dr. Mary Lupo, of New Orleans, Louisiana.” A few years ago, I began my relationship with Lumenis and their M22 and UltraPulse devices. Since then these devices has serviced hundreds of my patients with multiple skin concerns. Now with the brand’s new technologies, such as SPLENDOR X, I can expand successful results to additional patients with additional needs. SPLENDOR X is a quantum leap in laser hair removal technology above all other platforms in the space.” As part of Lumenis’ commitment to success, the brand is organizing multiple educational activities at its booth #A86. Here attendees will have access to expert presentations and one-on-one meetings with leading experts including, Dr. Michael Gold and Dr. Ines Verner (Legend Pro+), Dr. Mary Lupo, (SPLENDOR X), Dr. Franco Vercesi (PiQo4), Dr. Jennifer Browning (FemTouch) as well as  additional expert meetings featuring the NuEra tight™ and LightSheer technologies. During these sessions, guests will have the opportunity to connect and gain new insights as the experts share unique techniques on how to best utilize these devices to optimize patient results. “We are excited to present our powerful portfolio of premium technologies and solutions,” said Tzipi Ozer-Armon, CEO of Lumenis. “As always, Lumenis is committed to providing our customers a broad range of innovative solutions to shape and build their practices, and to our clinical promise of better technology for better patient care!” Lumenis will be providing booth attendees complimentary professional headshots and hosting an exclusive VIP Champagne toast at its booth on Tuesday, June 11th at 3PM. For more information, please visit Lumenis.com or booth #A86. Lumenis is a global leader in the field of minimally-invasive clinical solutions for the Surgical, Ophthalmology, and Aesthetic, Surgical, and Ophthalmology markets, and is a world-renowned expert in developing and commercializing innovative energy-based technologies, including Laser, Intense Pulsed Light (IPL) and Radio-Frequency (RF). For 50 years, Lumenis’ ground-breaking products have redefined medical treatments and have set numerous technological and clinical gold-standards. Lumenis has successfully created solutions for previously untreatable conditions, as well as designed advanced technologies that have revolutionized existing treatment methods. Lumenis is a portfolio company of XIO Group, a global alternative investments firm headquartered in London. For more information visit:  www.lumenis.com For further information, contact 5W Public Relations at Lumenis@5wpr.com. PB-2012627 Rev A #### Lumenis solutions featured in New Beauty article: “LASERS: The New Anti-Aging Revolution” Lumenis solutions featured in New Beauty article: “LASERS: The New Anti-Aging Revolution” NewBeauty May 1, 2018 View More #### Lumenis Unveils a Wide Range of Innovative Technologies for Multiple Skin and Body Applications at the 2019 American Academy of Dermatology (AAD) Conference Lumenis Unveils a Wide Range of Innovative Technologies for Multiple Skin and Body Applications at the 2019 American Academy of Dermatology (AAD) Conference The innovative NuEra Tight will be Lumenis’ showcase platform on display during the AAD. March 1, 2019 – Washington, DC, USA Lumenis Ltd., the world’s largest energy-based medical device company for aesthetic, surgical, and ophthalmic applications, will unveil a wide range of new solutions at this year’s AAD. Launching on the show floor March 1st – March 3rd will be updates to brand-favorite technologies such as the new LightSheer™ QUATTRO and SPLENDOR X in the hair-removal category, PiQo4 for tattoo removal, pigmentation and skin resurfacing, and rounding out the range of new launches will be the exciting new NuEra Tight™. #### Lumenis Unveils Enhanced SPLENDOR XTM Laser Hair Removal Solution with New Clinical Data at the Annual American Society for Laser Medicine and Surgery (ASLMS) Conference Lumenis Unveils Enhanced SPLENDOR XTM Laser Hair Removal Solution with New Clinical Data at the Annual American Society for Laser Medicine and Surgery (ASLMS) Conference New data demonstrates effectiveness of SPLENDOR X™’s dual-wavelength simultaneous laser emission technology for improved hair removal results The newest edition of SPLENDOR X™ systems is now available in the US and Canadian Markets* *Indications for use and select features are country specific and may vary between countries. Yokne’am Illit, Israel – 4/21— Lumenis Be. Ltd., a leading energy-based medical device company, today unveiled the newest edition of its breakthrough dual-wavelength laser hair removal solution, SPLENDOR XTM. The newest edition builds upon the proven advantages of BLEND X® and patented square-fiber technologies, and features a brand new, user-centric design as well as advanced digital capabilities. SPLENDOR XTM is powered by Lumenis’ proprietary BLEND X® technology, the only FDA-cleared simultaneous dual laser emission of Alexandrite (755nm) and Nd:YAG (1064nm), enabling providers to customize an optimal blend for each patient needs across a wide range of skin tones and hair types. The advantages of the BLEND X® technology were researched in a prospective, multi-center 12-month clinical trial and the positive outcomes of the study will be presented at the upcoming American Society for Laser Medicine and Surgery (ASLMS) Conference taking place in Orlando from April 24 – 26, 2025. “Laser hair removal consistently remains a top-demand procedure and as a provider, I’m looking for a solution that can cater to a diverse patient population and still achieve optimal results,” said Dr. Anne Chapas, M.D., board-certified dermatologist, founder and medical director of Union Square Laser Dermatology. “As one of the clinical sites in the BLEND X® study, we’ve already experienced the benefits of this technology in terms of superior hair reduction as well as the ability to tailor the parameters for each patient’s needs.” The new edition of the SPLENDOR XTM solution is now available in both the US and Canada, featuring new, innovative patient- and provider-centric features such as preset parameters for laser hair removal and vascular treatments. The U.S. edition also offers new digital capabilities enabling improved system uptime and advanced data services for large accounts. Tzipi Ozer-Armon, CEO of Lumenis added, “Lumenis is a pioneer in the laser hair removal industry, and with this launch we are thrilled to deliver on our promise to continuously innovate and elevate hair removal treatment to a whole new level. The clinical evidence confirms that our unique simultaneous, dual wavelength BLEND X® technology, the first and only FDA-cleared one of its kind, offers improved results, empowering providers and patients alike with the knowledge that these safe, comfortable, and effective treatments will enable patients to exude confidence and look radiant.” Presentation details below: Date & Time: Thursday April 24, 2025, from 2:20 PM – 2:24 PM EST Session Title: Use of Simultaneous Emission of ND: YAG and Alexandrite Lasers in Blend Mode for Hair Removal and Permanent Hair Reduction Presenting Author: Nkemjika Ugonabo, MD, MPH To learn more about SPLENDOR XTM and BLEND X®, visit www.lumenis.com/splendorx About Lumenis Lumenis is a global leader in the medical aesthetics and eye care markets and is a world-renowned expert in developing and commercializing innovative energy-based technologies, including Laser, Intense Pulsed Light (IPL) and Radiofrequency (RF). For more than 50 years, Lumenis’ ground-breaking products have redefined medical treatments and set technological and clinical gold-standards, revolutionizing existing treatment methods, and creating solutions for previously untreatable conditions. Lumenis is a portfolio company of EQT Private Capital Asia. For more information regarding Lumenis’ range of clinical solutions, please visit: www.lumenis.com. About SPLENDOR XTM SPLENDOR XTM is unlike any other Alexandrite and Nd:YAG system for laser hair removal (LHR), benign dermatological vascular lesions, and more. Introduced by LUMENIS, a global leader in laser and energy-based technologies, it is the only Alexandrite and Nd:YAG laser system powered by BLEND X® technology for unprecedented power, speed, efficacy and versatility. SPLENDOR XTM lets you customize and tailor laser hair removal and other treatments across a wide range of skin tones, like never before. It is an innovative square fiber-delivered laser system featuring optimal skin coverage by large, square spots, providing safe, efficient treatments thanks to unique energy management, together with an integrated plume evacuator and supporting an optimal patient experience by a Dual Cooling System (DCS). *For safety information and Instructions for Use, please refer to the User Manual and Treatment Guidelines provided with your SPLENDOR XTM device. The User Manual includes warning and cautions that are important to ensure your safety and the safety of your patients.   Media Contact Erick Edwing, erick.edwing@havasred.com PB-00089560 Rev A #### Lumenis Unveils NuEra™ tight, Its High Power, Temperature-Controlled Top to Toe Radio Frequency Skin Laxity and Cellulite Treatment, at the 2018 Aesthetic Show Lumenis Unveils NuEra™ tight, Its High Power, Temperature-Controlled Top to Toe Radio Frequency Skin Laxity and Cellulite Treatment, at the 2018 Aesthetic Show A non-invasive, intelligent temperature-controlled technology for both superficial and deep heating that treats a variety of conditions such as skin laxity and the appearance of cellulite. July 2, 2018 – Las Vegas, NV, USA Lumenis Ltd., the world’s largest energy-based medical device company for surgical, aesthetic, and ophthalmic applications, is excited to announce its newest launch, NuEra tight– a non-invasive, intelligent temperature-controlled technology for both superficial and deep heating that treats a variety of conditions such as skin laxity and the appearance of cellulite. Lumenis will be showcasing the newest addition to their portfolio, NuEra tight, through multiple activities at the 2018 Aesthetic Show in Las Vegas from July 6th – 8th, 2018. The FDA cleared, high-power device will be highlighted at two separate booths. Guests will be able to learn about the technology’s ability to target problematic areas around the abdomen, flanks, buttocks, inner and outer thighs, upper arms, elbows, knees, bra and back fat as well as around the eyes, mouth, cheeks and neck thanks to the device’s powerful, temperature-controlled RF technology. “Lumenis is rounding out their repertoire of aesthetic solutions with the addition of the NuEra tight,” said E. M. Zimmerman, MD, Cosmetic Surgeon, Nevada.  “With a significant percentage of adult women being affected by some grade of cellulite, this fast, comfortable, non-invasive treatment provides my patients with the desired improved appearance, while ensuring safety thanks to the APIC temperature-control technology.” NuEra tight uses Automatic Power and Impedance Control (APIC), the next generation of temperature-control technology, to ensure safety and efficacy. The APIC automatically increases the RF power to the target temperature, delivering precise heating to the skin’s surface with predictable results. This powerful RF technology emits at 470kHz and high 250W power to deliver the required amount of heat – precisely and deeply – for optimally effective, comfortable treatment with consistently successful results. “We are proud to welcome a new era of fast, effective and versatile treatments for body and face with the NuEra tight,” said Tzipi Ozer-Armon, CEO of Lumenis. “The Lumenis family is always looking for ways to further our expertise in RF technologies so we are excited to provide a treatment that is able to address all areas quickly, safely, and efficiently in a soothing experience that patients will enjoy.” NuEra tight uses Automatic Power and Impedance Control (APIC), the next generation of temperature-control technology, to ensure safety and efficacy. The APIC automatically increases the RF power to the target temperature, delivering precise heating to the skin’s surface with predictable results. This powerful RF technology emits at 470kHz and high 250W power to deliver the required amount of heat – precisely and deeply – for optimally effective, comfortable treatment with consistently successful results. “We are proud to welcome a new era of fast, effective and versatile treatments for body and face with the NuEra tight,” said Tzipi Ozer-Armon, CEO of Lumenis. “The Lumenis family is always looking for ways to further our expertise in RF technologies so we are excited to provide a treatment that is able to address all areas quickly, safely, and efficiently in a soothing experience that patients will enjoy.” During the weekend, Lumenis will have a grand presence at this year’s Aesthetic Show, hosting a symposium where physicians will give an in-depth look at the latest innovations in RF waves. Key topics of focus will include monopolar, bipolar and TriPollar technologies as well as live demonstrations of the NuEra tight and Lumenis’ innovative Legend Pro device. In addition to the RF-Focused symposium, Lumenis will also be hosting two booths on the show floor. The primary booth (#609), will showcase all of Lumenis’ offerings and allow attendees to experience their “3 in 1” super OxyGeneO facials firsthand. The second booth (#628), will spotlight the RF technologies in their portfolio, NuEra tight and Legend Pro. About Lumenis Lumenis is a global leader in the field of minimally-invasive clinical solutions for the Surgical, Ophthalmology, and Aesthetic markets, and is a world-renowned expert in developing and commercializing innovative energy-based technologies, including Laser, Intense Pulsed Light (IPL) and Radio-Frequency (RF). For 50 years, Lumenis’ ground-breaking products have redefined medical treatments and have set numerous technological and clinical gold-standards. Lumenis has successfully created solutions for previously untreatable conditions, as well as designed advanced technologies that have revolutionized existing treatment methods. For more information visit:  www.lumenis.com Forward-Looking Statements Information provided in this press release may contain statements relating to current expectations, estimates, forecasts and projections about future events that are forward-looking statements. These forward-looking statements may include but are not limited to the Company’s plans, objectives and expectations for future operations, including its projected results of operations. Forward-looking statements are often characterized by the use of forward-looking terminology such as “may,” “will,” “expect,” “anticipate,” “estimate,” “continue,” “believe,” “should,” “intend,” “plan,” “project” or other similar words, but are not the only way these statements are identified. These forward-looking statements are based upon our management’s current estimates and projections of future results or trends. Actual results may differ materially from those projected as a result of certain risks and uncertainties these forward-looking statements are made only as of the date hereof, and the Company undertakes no obligation to update or revise the forward-looking statements, whether a result of new information, future events or otherwise. For further information, contact 5W Public Relations at Lumenis@5wpr.com. PB-2010843 Rev A #### Lumenis’ triLift™ Honored in Two Categories on the MedEsthetics 2025 Readers’ Choice Awards Lumenis’ triLift™ Honored in Two Categories on the MedEsthetics 2025 Readers’ Choice Awards triLift™ honored as the “Best Non-Invasive Facelifting Device” and the “Best Light & Energy-Based Device” categories for its breakthrough technology in facial muscle stimulation Renowned awards program celebrates excellence in aesthetics as chosen by industry professionals and readers. SAN JOSE, CALIFORNIA, Nov. 24/25, 2025– Lumenis Be. Ltd., a leading energy-based medical device company, proudly announces that triLift™, its groundbreaking facial muscle stimulation treatment, has been named on the MedEsthetics Readers’ Choice Awards in two different categories, being recognized as the “Best Non-Invasive Facelifting Device” and the “Best Light & Energy-Based Device” of 2025. This prestigious recognition highlights triLift’s position as a category-defining innovation that delivers a toned and lifted look without surgery, injectables or downtime by dynamically addressing the muscle. According to a 2025 American Society for Dermatologic Surgery (ASDS) survey, 73% of consumers now consider lines, wrinkles and folds in the mid-face a top concern. This demonstrates a growing demand for treatments like triLift that restore and tone the underlying facial muscles to address common concerns like facial sagging, jawline smiles, eye bags, and more. As the inventor of Dynamic Muscle Stimulation (DMSt™) technology, triLift uniquely strengthens facial muscles to combat sagging, delivering a well-defined, lifted look. In addition to its proprietary DMSt, triLift incorporates TriPollar® Radiofrequency (RF) to stimulate collagen regeneration1 and increase dermal thickness. It also utilizes triFX™ technology, which improves skin smoothness2 and significantly boosts hyaluronic acid production3. Together, these technologies work synergistically to revitalize the skin and restore a natural, youthful appearance from within. triLift works safely on all skin types and tones, pairs effortlessly with other aesthetic treatments, and is simple to perform—making it a smart, high-value offering to any practice or medical spa. The new frontier of facial dynamic muscle stimulation is the ability to deliver a toned and lifting effect, all without any surgery or injections involved. triLift delivers on that promise, by providing visibly lifted look by repositioning your own tissue to where it belongs, rather than relying on invasive measures. My patients love how quickly they notice improved definition and skin quality, making it an integral tool in my practice,” said Dr. James Chelnis, MD, FACS, of Manhattan Face and Eye. Since its launch in 2022, triLift has been adopted by leading dermatologists, plastic surgeons and aesthetic physicians worldwide for its ability to adapt to varying patients’ needs and enable individual facial anatomy. This recognition from MedEsthetics stands as a compelling testament from both providers and consumers, underscoring Lumenis’ ongoing commitment to advancing care through proven, safe and effective medical-grade technology. Itay Mayer, Chief Commercial Officer of Lumenis, added, “We are honored to be recognized by MedEsthetics readers. triLift reflects our commitment to advancing aesthetic care through the integration of science, innovation and artistry. Driven by cutting-edge Dynamic Muscle Stimulation (DMSt™) technology, triLift empowers providers to naturally tone muscles, enabling patients to look and feel their best.” The annual MedEsthetics Readers’ Choice Awards celebrates the most revolutionary and trusted professional products in medical aesthetics, as voted by practitioners and experts across North America. To learn more about triLift and find a provider near you, visit https://trilift.me/ About Lumenis Lumenis is a global leader in the medical aesthetic and eye care markets and is a world-renowned expert in developing and commercializing innovative energy-based technologies, including Laser, Intense Pulsed Light (IPL) and Radiofrequency (RF). For more than 50 years, Lumenis’ ground-breaking products have redefined medical treatments and set technological and clinical gold-standards, revolutionizing existing treatment methods, and creating solutions for previously untreatable conditions. Lumenis is a portfolio company of EQT Private Capital Asia. For more information regarding Lumenis’ range of clinical solutions, please visit: www.lumenis.com. About triLift™ The triLift System and its accessories are intended for dermatological procedures requiring ablation and resurfacing of the skin when using VoluDerm Energy (Applicator VO). It is also intended for use in dermatologic and general surgical procedures for the noninvasive treatment of mild to moderate facial wrinkles and rhytides when using TriPollar RF Energy and for muscle conditioning to stimulate healthy muscles (Applicators 1-3). triLift System is not intended to be used in conjunction with therapy or treatment of medical diseases or medical conditions of any kind. The triLift System is intended to be operated by a trained professional who is present to monitor treatment. For more information regarding triLift, visit: https://trilift.me/. About MedEsthetics MedEsthetics is a leading publication dedicated to medical aesthetics professionals, providing in-depth coverage of the latest technologies, trends, clinical studies, regulatory issues and business insights. Its annual Readers’ Choice Awards recognize industry excellence by honoring professional products, devices and treatments that deliver superior outcomes and innovation. Media Contact Jacqueline Wickwire, Jacqueline.wickwire@havasred.com [1] Haim Kaplan, Andrea Gat, Clinical and histopathological results following TriPollar™ radiofrequency skin treatments Journal of Cosmetic and Laser Therapy 2009; 11: 78–84 DOI: 10.1080/14764170902846227 [2] Ibid. [3] Boisnic S, Branchet MC. Ex-vivo study of hybrid energy technology using a human skin model. Eur J Dermatol 2014; 24(1): 46-52 oi:10.1684/ejd.2013.2233 PB-00096018 #### M22 M22 Overview Universal IPL Multi-Spot Nd:YAG ResurFX Q-Switched Nd:YAG M22™ Modular Aesthetic Laser Multi-Application Platform M22™ is a modular multi-application platform for the treatment of over 30 skin conditions and hair removal. Used by physicians around the world, M22™ enables you to treat a vast variety of patients and conditions with excellent outcomes. SCHEDULE A DEMO 4 Multiple Technologies in One Modular System M22™ grows with your practice Expands to your treatment needs and adapts to future applications as they emerge. Universal IPL  Optimal Pulse Technology (OPT™) Single handpiece with changeable filters and lightguides For IPL skin treatments using photorejuvenation ResurFX™ The only True fractional non-ablative, with CoolScan™ scanner No disposables For skin resurfacing Multi-Spot™ Nd:YAG  With Multiple Sequential Pulsing (MSP™) 2 sized lightguides, changeable in seconds For treatment of leg veins and vascular lesions Q-Switched Nd:YAG Homogenous beam profile for enhanced treatment safety and efficacy For skin toning by treatment of pigmented lesions and dark tattoos removal A premium M22 version with AOPT is now available in China! The M22™ Universal IPL is now coupled with AOPT, enabling full control to advanced users, making it simple to individually tailor the settings for each patient and each condition. Make the best use of each pulse and easily provide consistent and solid clinical results for your patients! With the golden line design, Lumenis proudly presents a premium M22 version, with precise, safe, and effective light & laser based treatments to the aesthetic medical market. Product Video What Do Doctors Say About the M22? [ytp_video source=”ZY4pYRJnimE,PdvUXB5Fe7c,itvNPB3NmMU”] M22™ Before & After Gallery DOWNLOAD BROCHURE PB-2000761 Rev B Close Close GET MORE INFO × #### Melasma: What You Don’t Expect When You’re Expecting Melasma: What You Don’t Expect When You’re Expecting Publish Date: July 1 2020 Melasma may not be what you expect when you’re expecting, and it’s not something to celebrate, but it’s not serious, and it can be treated. This guide will tell you everything you need to know about melasma, from what it is and why it happens when you’re pregnant, to what you can do to remedy it. PB-00002320 Rev A #### Multi-Spot Nd:YAG M22 Overview Universal IPL Multi-Spot Nd:YAG ResurFX Q-Switched Nd:YAG Nd:YAG Laser With Multiple Sequential Pulsing Technology Multiple-Sequential Pulsing The Nd:YAG module of M22™ offers treatments for telangiectasias, hemangiomas, leg veins and facial wrinkles. Precise and comfortable treatment with 4 cooled and easily changed lightguides. Multiple Sequential Pulsing, which is available in both the Nd:YAG and IPL modules on M22™, enables cooling between a sequence of pulses, to protect the epidermis while allowing the safe use of higher fluences. This enables treatment on all skin types, including darker skin, and reduces the chance of unwanted side effects in vascular lesion treatments. SCHEDULE A DEMO Multiple-Sequential Pulsing How it Works: Light energy is delivered during the pulses, and the tissue cools during the delays. More energy is safely delivered to the target. What It Does: Multiple-Sequential Pulsing allows for cooling between pulses to safely remove hair on all skin types including darker skin and reduces the chance of skin damage in vascular lesion treatments. Lumenis Leg Veins Treatment Video Typical Clinical Results DOWNLOAD BROCHURE PB-1003629 Rev D Close Close GET MORE INFO × #### My triLift™ Story: Pura Vida Body & Mind Spa My triLift™ Story: Pura Vida Body & Mind Spa Julie Davis is the visionary founder of Pura Vida Body & Mind Spa, a one-of-a-kind medical spa in Fleming, Florida. Pura Vida (a Costa Rican term which means being thankful for what you have and not dwelling on the negative) serves patients using a holistic, results-centric philosophy that combines medical treatments with non-medical services to both restore youthfulness and reenergize the mind. Julie Davis knew that integrating triLift by Lumenis into her offering would help her clinic soar! Find out how she reached this decision and how implementing triLift elevated Pura Viida Body & Mind Spa. Read Full Study PB-00052140 Rev A #### New Distributor Announcement – DELEO New Distributor Announcement – DELEO #### New Innovation in Laser Hair Removal New Innovation in Laser Hair Removal Publish Date: Jun 30, 2020 Length: 34 Minutes In this webinar Dr. Mary Lupo shares her experience with SPLENDOR X and how she has come to love it. She discusses the unique features of SPLENDOR X and the business aspect of laser hair removal in her practice Mary Lupo MD, FAAD Board Certified Dermatologist and Owner at Lupo Center for Aesthetic and General Dermatology PB-00015570 A #### New LightSheer QUATTRO Lumenis Launches the New LightSheer QUATTRO, Laser Hair Removal Platform, at 22nd International Master Course on Aging Science (IMCAS) January 30, 2020 – Paris, France Lumenis Ltd., the world’s largest energy-based medical device company for aesthetic, surgical and ophthalmic applications, announces the launch of its newest platform, the LightSheer Quattro. Following a successful US launch in 2019 the platform will be showcased at the 22nd International Master Course on Aging Science (IMCAS) conference in Paris, France from 30th January – 1st February 2020. LightSheer Quattro is the newest addition to the premium Lumenis LightSheer family positioning it ahead of the market, as a flagship solution in the diode laser hair removal industry. The system offers clinically proved laser hair removal treatments for all skin types with either 805nm or 1060nm wavelengths with no down time as well as treatment of pigmented and vascular lesions. The newest addition to the LightSheer family allows practitioners to deliver excellent clinical results by combining High Speed Vacuum assisted technology with ChillTip™ Integrated Contact cooling technology, providing patients with comfortable, effective, fast and safe treatments. The compact and portable LightSheer Quattro system is upgradeable and a great addition to a MedSpa or a Medical office, whether experienced or just starting out in the industry. “The LightSheer Quattro allows me to customize treatments with confidence, treat all skin types and achieve optimal results for every patient”, says Dr. Marco Lucrezio from Ugento (LE) – Italy. “My patients enjoy short and comfortable treatments with long lasting results,” added Dr. Lucrezio. “Lumenis is excited to introduce our newest addition to the LightSheer product line, a solution for all those seeking a tried and true, versatile laser hair removal system,” said Tzipi Ozer-Armon, CEO of Lumenis. “The LightSheer technology and brand have been industry benchmarks for over 20 years, driven by well-established, proven clinical benefits.” Lumenis will introduce the LightSheer Quattro™ during the IMCAS conference in January.  At the event Lumenis will also showcase additional leading systems including: Legend Pro+ (RF-assisted ultra-thin electrodes treatment combined with direct current, TriPollar® RF, DMA™ muscle stimulation and TriFractional™) , SPLENDOR X (Alexandrite and Nd:Yag powered by BLENDX technology) and NuEra tight  (temperature-controlled RF technology for skin tightening, Cellulite & skin laxity treatment). For more information about the Lumenis family of products, please visit the Lumenis booth (N242). #### News Aesthetics News November 18, 2019Baring Private Equity Asia Agrees to Acquire LumenisBaring Private Equity Asia Agrees to Acquire LumenisJuly 16, 2019Candela and Lumenis Announce Settlement of Patent Infringement LawsuitCandela and Lumenis Announce Settlement of Patent Infringement LawsuitJune 23, 2019I WANT WHAT SHE HAD!An Aesthetic Transformation Without A Single IncisionJune 10, 2019Lumenis Proudly Showcases a Wide Range of Technologies for Multiple Skin & Body Applications at the 24th World Congress of Dermatology (WCD) 2019Lumenis showcasing a wide range of novel technologies for skin, hair, body and women’s health applications at this year’s WCD,...June 3, 2019New Distributor Announcement – DELEODELEO will be our exclusive distributor for France and French part of Switzerland.April 4, 2019NuEra tight was awarded the Editor’s Choice in the April 2019 issue of Aesthetic MedicineApril 4, 2019 – Yokne’am Illit, IsraelApril 4, 2019Lumenis Introduces a New Skin Rejuvenating Technology, Legend Pro+™, at the 17th Aesthetic & Anti-Aging Medicine World CongressHRH The Duke of Sussex visits The Queen Elizabeth Hospital in Birmingham Scar CenterMarch 12, 2019HRH Prince Harry The Duke of Sussex visits The Queen Elizabeth Hospital in Birmingham Scar CenterHRH The Duke of Sussex visits The Queen Elizabeth Hospital in Birmingham Scar CenterMarch 1, 2019Lumenis Unveils a Wide Range of Innovative Technologies for Multiple Skin and Body Applications at the 2019 American Academy of Dermatology (AAD) ConferenceLumenis Unveils a Wide Range of Innovative Technologies for Multiple Skin and Body Applications at the 2019 American Academy of...October 11, 2018Lumenis Introduces New Laser Hair Removal Solution, SPLENDOR X, at the 2018 American Society of Dermatological Surgery (ASDS)Lumenis Ltd., the world’s largest energy-based medical device company for aesthetic, surgical and ophthalmic applications, excitedly announces its newest launch,...July 2, 2018Lumenis Unveils NuEra™ tight, Its High Power, Temperature-Controlled Top to Toe Radio Frequency Skin Laxity and Cellulite Treatment, at the 2018 Aesthetic ShowLumenis Ltd., the world’s largest energy-based medical device company for surgical, aesthetic, and ophthalmic applications, is excited to announce its...June 1, 2018This New Laser Offers a Faster and Safer Way to Eliminate Dark SpotsThis New Laser Offers a Faster and Safer Way to Eliminate Dark Spots #### Non-Ablative Skin Resurfacing About Non-Ablative Skin Resurfacing Skin resurfacing procedures use lasers to reduce the signs of aging and improve skin texture, laxity and tone. They are also used for scar and stretch mark reduction as well as for treatment of a variety of other cosmetic concerns. Skin resurfacing can be achieved with either ablative or non-ablative lasers (see Ablative Skin Resurfacing). Non-ablative resurfacing keeps the skin intact, stimulates collagen growth and tightens the underlying skin. It is ideal for patients who prefer a milder treatment approach with less downtime and no risk of skin infection. The Lumenis Solution The Lumenis ResurFX™ is the only true Fractional Non-Ablative solution on the market. It uses an advanced scanner technology called CoolScan™. CoolScan™ uses a sophisticated, patent-pending algorithm for non-sequential scanning which ensures that the energy delivery is precise and homogenous, so the required coverage is achieved in only one pass. The ResurFX™ module is available as part of the M22™ multi-application platform. Advantages For Physicians Effective and safe results in a single pass with a state-of-the-art CoolScan™ scanner that enables precise and homogenous energy delivery. Ability to tailor treatment parameters perfectly for each patient and condition using the CoolScan™ scanner, which allows a choice of over 600 combinations of shape, size, density and energy settings. Preset treatment parameters for a wide range of clinical indications ensure ease of use and a fast learning curve. Integrated contact cooling for enhanced patient comfort. Cost effective with no required disposables. Clinical Evidence Related Products The ResurFX™ is available in the M22™ Multi-Application platform PB-1004607 Rev A × GET MORE INFO #### NuEra Tight NuEra® Tight with FocalRF® Technology Personalized, Non-invasive, Radio Frequency body sculpting treatment treating Fat Reduction, Skin Tightening, Wrinkle and Cellulite Reduction. Watch Video Schedule a Demo Close Visit the Aesthetics Resource Hub for professional insights GO! Body Sculpting Takes on a New Meaning Personalized Body Sculpting No two patients are exactly alike This is why a one-size-fits-all treatment plan is no longer suitable. Now, you can leave all limitations behind and discover an unparalleled level of personalization, A treatment as unique as your patients FocalRF Technology Utilize multiple RF frequencies to dial-in the depth of energy penetration accounting for different indications, tissue thickness variations between body areas and patients. No Downtime This non-invasive treatment delivers natural looking results that last longer and feels like a comfortable hot stone massage Highly Customizable Lumenis developed NuEra Tight with state-of-the-art features in an easy-to-use device with an intuitive graphical user interface. Selecting proper treatment parameters is only a touch away. Fat Reduction A truly personalized body contouring experience starts with FocalRF technology treating subcutaneous fat on any region of the body easily and effectively. Choose 2MHz to remove/target stubborn fat cells or lower frequencies up to 470kHz for deeper heating. Cellulite Reduction Powered by FocalRF technology NuEra Tight applies multiple frequencies, two treatment modes and effective mechanical massage for connective tissue manipulation, to remodel cellulite and improve the appearance of bumps and dimpling Wrinkle Reduction With high frequencies and precise temperature control, NuEra Tight is able to stimulate the activity of fibroblasts and enhance blood flow, creating an immediate smoothing effect that will continue to improve as the body’s healing mechanism generates new collagen production. Skin Tightening NuEra Tight automatically elevates and regulates the temperature in the skin tissue to the required degree stimulating collagen, improving signs of sagging skin and wrinkles. From larger areas of the body to a smaller facial area, FocalRF technology targets the energy penetration to the dermis layer, ensuring safe and effective treatments. Control the Depth, Control the Results More and more of my patients are looking to eliminate fat in stubborn areas and tighten their skin to sculpt their body and address skin texture issues such as cellulite and wrinkles.” said Freeda Tannous M.D., Dermatologist, Amman, Jordan. “Thanks to FocalRF technology I am now able to tailor the treatment specifically for each patient needs achieving the desired improved appearance. Dr. Freeda Tannous is a Specialist Dermatology and both the co-founder of Dermaline Cosmetic Skin and Laser Center and the Medical Director. Radio Frequency treatments are among the most requested aesthetic therapies today. NuEra Tight with ForcalRF technology is highly customizable with a wide selection of frequencies and handpieces that deliver fast, comfortable, and non-invasive treatments. This results in my patients’ achieving their desired improved appearance while ensuring safety and efficacy thanks to the NuAPIC temperature-control feature. Macrene Alexiades-Armenakas, MD, PhD, FAAD, Clinical Dermatologist, Laser Surgeon and Researcher Dermatologist, New York. Skin Tightening Request Demo Speaks your body language The key parameter that determines the success of your treatment is the ability to target the treatment to the right tissue depth – and this can vary between people, and between different areas of the body. NuEra Tight’s groundbreaking technology offers unparalleled treatment depth control: it targets tissue at the exact depth which yields the best results, so the results last longer and look more natural. Advanced Tools for Today’s Aesthetic Patient Lumenis developed NuEra Tight with state-of-the-art features in an easy-to-use device with an intuitive graphical user interface. NuAPIC Automatic Personalized Temperature Control ensuring therapeutic temperature throughout the procedure. Adapting the power to meet the patient’s unique features. NuLogic Advanced Protocol for Expert Users. A new level of customization applying multiple treatment protocols automatically in one treatment session. Set multiple values for frequency, temperature, time and electrode size. Multiple Accessories to Treat Any Body Area Multiple Accessories to Treat Any Body Area Eight electrodes to perfectly match any patient from head to toe, ranging from 20mm to 100 mm. A unique design with Coated Capacitive Energy Transfer (CCET) for improved comfort & uniform heating distribution across the treatment area. Ergonomic Handpieces Three light-weight handpieces to obtain consistently e­ffective: Body, Face and Bipolar. FocalRF Technology Experience a new level of control with NuEra Tight powered by FocalRF technology. Utilize 5 different frequencies to dial-in the depth of energy penetration heating specific skin and tissue layers achieving Fat Reduction, Skin Tightening, Cellulite and Wrinkle Reduction. 470kHz – Deep heating 1 and 2MHz – Medium deep heating 4 and 6MHz – Superficial heating and penetration Learn more about NuEra Tight Get the NuEra Tight brochure for additional details or download our Clinical Casebook, a collection of B&A images from around the world E-Book Brochure PB-00023210 Rev A GET MORE INFO × Close Close Close #### NuEra Tight US NuEra® Tight with FocalRF® Technology Non-invasive, Radio Frequency body treatments, with an unparalleled level of personalization, all in one device. Watch Video Schedule a Demo Close Visit the Aesthetics Resource Hub for professional insights GO! A New Era of Personalized Body Treatments Personalized Treatments No two patients are exactly alike This is why a one-size-fits-all treatment plan is no longer suitable. Now, you can leave all limitations behind and discover an unparalleled level of personalization, A treatment as unique as your patients FocalRF Technology Utilize multiple RF frequencies to dial-in the depth of energy penetration accounting for different indications, tissue thickness variations between body areas and patients. No Downtime This non-invasive treatment delivers natural looking results that last longer and feels like a comfortable hot stone massage Highly Customizable Lumenis developed NuEra Tight with state-of-the-art features in an easy-to-use device with an intuitive graphical user interface. Selecting proper treatment parameters is only a touch away. Control the Depth, Control the Results Radio Frequency treatments are among the most requested aesthetic therapies today. NuEra Tight with ForcalRF technology is highly customizable with a wide selection of frequencies and handpieces that deliver fast, comfortable, and non-invasive treatments. This results in my patients’ achieving their desired improved appearance while ensuring safety and efficacy thanks to the NuAPIC temperature-control feature. Macrene Alexiades-Armenakas, MD, PhD, FAAD, Clinical Dermatologist, Laser Surgeon and Researcher Dermatologist, New York Skin Tightening Request Demo Speaks your body language The key parameter that determines the success of your treatment is the ability to target the treatment to the right tissue depth – and this can vary between people, and between different areas of the body. NuEra Tight’s groundbreaking technology offers unparalleled treatment depth control: it targets tissue at the exact depth which yields the best results, so the results last longer and look more natural. Advanced Tools for Today’s Aesthetic Patient Lumenis developed NuEra Tight with state-of-the-art features in an easy-to-use device with an intuitive graphical user interface. NuAPIC Automatic Personalized Temperature Control ensuring therapeutic temperature throughout the procedure. Adapting the power to meet the patient’s unique features. NuLogic Advanced Protocol for Expert Users. A new level of customization applying multiple treatment protocols automatically in one treatment session. Set multiple values for frequency, temperature, time and electrode size. Multiple Accessories to Treat Any Body Area Multiple Accessories to Treat Any Body Area Eight electrodes to perfectly match any patient from head to toe, ranging from 20mm to 100 mm. A unique design with Coated Capacitive Energy Transfer (CCET) for improved comfort & uniform heating distribution across the treatment area. Ergonomic Handpieces Three light-weight handpieces to obtain consistently e­ffective: Body, Face and Bipolar. FocalRF Technology Experience a new level of control with NuEra tight powerd by FocalRF technology. Utilize multiple RF frequencies to dial-in the depth of energy penetration accounting for tissue thickness variations between body areas. 470kHz – Deep heating 1 and 2MHz – Medium deep heating 4 and 6MHz – Superficial heating and penetration Learn more about NuEra Tight Get the NuEra Tight brochure for additional details or download our Clinical Casebook, a collection of B&A images from around the world E-Book Brochure PB-00023210 Rev A GET MORE INFO × Close Close Close #### NuEra tight was awarded the Editor’s Choice in the April 2019 issue of Aesthetic Medicine NuEra tight was awarded the Editor’s Choice in the April 2019 issue of Aesthetic Medicine Vicky Eldridge tries out the new NuEra Tight treatment from Lumenis with Renne Lapino April 4, 2019 – Yokne'am Illit, Israel Cellulite. Like most women I have it and it’s only got worse with age. I recently turned 40 and while I’m fitter and in better shape than I ever have been, the backs of my thighs and buttocks have cellulite on them. It’s not that bad but if I could get rid of it and without suffering to do so, then great! So I headed off to Renne Lapino’s amazing new clinic in Kensington to try out the latest device from Lumenis – NuEra Tight – that aside from its many other indications, promises to be a pain-free solution for reducing cellulite. NuEra Tight is an FDA-cleared, temperature-controlled radiofrequency skin smoothing system. From skin tightening, wrinkle reduction, body sculpting, and lymphatic drainage to the temporary reduction in the appearance of cellulite, NuEra Tight is ideal for those who want to look and feel good, without having to go under the knife or suffer downtime. The system emits powerful RF waves at 470kHz with high 250W power, to heat the skin’s surface superficially and to target tissue at a deeper level. By using the precise frequency and depth of heat, NuEra can treat a variety of conditions with levels of severity on the abdomen, flanks, buttocks, inner and outer thighs, upper arms, bra and back fat, as well as around the eyes, mouth, cheeks, and neck. The treatment works with one resistive bipolar handpiece and two unipolar handpieces with Coated Capacitive Energy Transfer (CCET) electrodes in a wide variety of capacitor head sizes – from small to very large. Lapino says, “The speed and ease of treatment is unparalleled and the results are nearly instantaneous. There are no hot spots or spikes in temperature, making the patient experience not only comfortable but also pleasurable. And she’s not wrong. The treatment is relaxing and comfortable and as soon as you feel the heat beginning to build too much, there’s a noticeable shift as the machine adjusts to avoid creating painful hotspots. I have experienced these in the past and I’m always on edge during treatments because of this. One of the best things about the treatment is that you do see results after only one session, which encourages you to come back for more. Lapino adds, “After one treatment the face is noticeably contoured, and the body feels smoother and tighter, with an obvious softening of cellulite tissue. As with all radiofrequency, a course of treatment is recommended, but because of the depth of treatment (with the exception of cellulite) sessions need only be carried out every two weeks. “The results in the weekly cellulite sessions are astounding. So much so that as a busy clinic owner I have already booked a course in for myself which I am photographing and publically documenting. It’s a remarkable device, and I strongly feel this technology has the ability to change the face of the radiofrequency market globally.” I was definitely sold. I almost fell asleep during my treatment, which was a marked difference from when I once tried Acoustic Wave Therapy for cellulite and only managed to cope with one thigh being done.   #### Patients Benefits LightSheer DUET Overview Treatment & Testimonials Configurations Patients Benefit Practice Benefits Take the High Speed Challenge Exciting Treatment Speed & Comfort Laser hair removal, a popular solution for unwanted body hair, has been limited by the patient’s need to invest valuable time and accept treatment discomfort to achieve desired results. These limitations can be significant when treating larger body areas such as shoulders and backs, chests or legs. How Will Your Patients Benefit? With LightSheer Duet features High-Speed and ChillTip technologies which can offer the following benefits: Faster treatments with the High Speed handpiece saving time Comfortable treatments encourage treatment completion Completed treatment cycle improves results increasing patient satisfaction Christine Dierickx, MD (Dermatologist, Belgium) “Patients will love it. Nurses will too.  I recently treated a large gentleman’s back and in the 20 minutes it took to treat him, he was practically falling asleep –  the treatment was that comfortable.” Data source: Beth Haney, NP;  Learn More LightSheer DUET Patient BrochureLightSheer DUET Physician Brochure PB-1049670 Rev C GET MORE INFO × #### Photofabulous For radiant skin that lets you shine Healthy, clear-looking skin is always on-trend. But as we age, our texture and tone can change. Meet Photofabulous- an optimally tailored treatment that addresses the early signs of aging and provides noticeable results for pigmentation, age or sun spots, fine lines, and overall skin appearance. Request Demo Visit the Aesthetics Resource Hub for professional insights Go! Reduce redness and pigmentation all in one treatment By using both the Stellar M22™ IPL and ResurFX™ technologies sequentially in the same treatment session, both skin pigmentation and texture can be treated, simultaneously. Stellar M22 IPL removes both unwanted pigmentation and vascular lesions from the skin, while the ResurFX™ fractional laser stimulates the production of new collagen and elastin fibers in the deeper layers of the skin. Initiating new collagen production is the key to having more radiant, youthful-looking skin. Makeup isn’t long lasting, but Photofabulous skin is. Photofabulous skin is always camera ready There’s no need to feel unconfident in your own skin. With Photofabulous, you can say goodbye to uneven skin tone and say hello to radiant skin that lets you shine. The Stellar M22 Photofabulous treatment is a complete skin rejuvenation solution that empowers physicians to offer remarkable results to address a wide range of aging skin concerns like age and sun spots, fine lines, acne scars, and uneven texture and skin tone in one treatment session. Our unique rejuvenation treatment utilizes two technologies sequentially- IPL (Intense Pulsed Light) and ResurFX non-ablative skin resurfacing so that both skin tone and texture can be treated. Photofabulous Treatment Benefits Collagen Naturally stimulates new collagen production and elastic fibers Vascular Lesions Remove Unwanted vascular lesions Texture Improves texture and tone Pigmentation Remove Unwanted pigmentation Redness Decrease Redness 18.9 Billion Global value of non-invasive aesthetic treatment market Source: https://www.visionresearchreports.com/non-invasive-aesthetic-treatment-market-size-share-trends-growth-production-consumption-revenue-company-analysis-and-forecast-2021-2028/36887 13.8% Compound annual growth rate of non-invasive treatments from 2021-2028 Source: https://www.grandviewresearch.com/industry-analysis/non-invasive-aesthetic-treatment-market 280,815 Non-surgical skin treatments performed with IPL & combination lasers in the United States in 2020 Source: https://cdn.theaestheticsociety.org/media/statistics/aestheticplasticsurgerynationaldatabank-2020stats.pdf 86.4% Over 100 Dermatologists surveyed noted their patients citing video-conferencing calls as a reason to seek cosmetic treatments Source: https://www.sciencedirect.com/science/article/pii/S2352647521000137 Two is greater than one Better Patient Outcomes Stellar M22 Photofabulous is a gold standard treatment that addresses the early signs of aging that provides noticeable results for pigmentation, age/sun spots, fine lines, and overall skin appearance.* Satisfy Consumer Demand Demand has increased for consumers seeking treatments that address multiple skin conditions in one session** Efficient Multiple skin conditions treated in one session Increase Revenue Your clinic benefits from providing a sequential treatment that delivers visible results with minimal pain or downtime *Typically, about 3 sessions are needed to have visible improvement in the skin texture and fine lines. Optimal results are achieved after 3-5 sessions in 2–6-week intervals. Let’s Talk Results! Courtesy of Jennifer Deaver-Peterson, MD Courtesy of Matteo Tretti Clementoni, MD Courtesy of Matteo Tretti Clementoni, MD In-House Clinic In-House Clinic Courtesy of Diana Demidion, MD Courtesy of Matthew Knight, MD Courtesy of Matthew Knight, MD Courtesy of Gerd Kautz, MD What our Doctors Have to Say “The treatment allows in one treatment, to address signs of the aging skin” Sabrina G. Fabi, MD “The treatment downtime is very limited…in most cases, 1-2 days of downtime” Melanie D. Palm, MD “Downtime with the Photofabulous is minimal and results are visible and similar to those of more aggressive techniques. My patients appreciate the Photofabulous a lot!” Patricia Ortiz Garcia, MD “We see great results with IPL, but with Photofabulous we improve pigmentation, skin texture, redness, blood vessels, pigments, and pores in only one combined session. Patients have a treatment on Friday and they go to work on Monday.” Gerd Kautz, MD “I favour the Photofabulous , because with this combination patients make only a single visit and they get double results.” Gerd Gaugliz, MD “With ResurFX, the settings work well and the risks are low. It’s a great system to start with. In addition, combined with Stellar M22/ M22’s IPL in Photofabulous treatment, the results are even greater and patients are extremely satisfied.” Prof. Alina Fratila, MD Technology Stellar M22™ Lumenis’s Stellar M22 is a powerful modular, multi-application platform that addresses over 30 skin conditions, including hair removal. Trusted by doctors around the globe, Stellar M22 delivers excellent patient outcomes and empowers practitioners’ to safely and effectively treat different indications in all skin types, ages and gender. -Photofabulous treatment demonstrates two technologies sequentially: IPL (Intense Pulsed Light) and ResurFX™ non-ablative. -IPL is still considered the gold standard for photofacial™ treatments because of its optimal combination of efficacy, safety and versatility in wavelengths that can treat the largest variety of indications. Stellar’s IPL handpiece has 9 Expert Filters and 3 SapphireCool™ lightguides, enabling 27 different combinations to treat 23 clinical indications. – ResurFX™ it’s a fractional non-ablative skin resurfacing, with a technology of 1565 nm Er: Glass fiber laser- a true fractional non-ablative skin resurfacing for treating dyschromia, scars, striae, and wrinkles. With the ResurFX, High precision micro-beams create narrow, deep columns of tissue coagulation in the epidermis and dermis, stimulating a natural healing response. It’s extremely versatile- choose from over 600 combinations of area shape, size and density for optimal treatment, whether a single lesion or the whole face- with a state of the art CoolScan™ technology and contact cooling for increased patient comfort. Stellar M22™ How Does it Work? Photofabulous technology By sequentially administering both the IPL and ResurFX technologies in the same treatment session, skin pigmentation and texture can be addressed. Stellar M22 IPL technology removes unwanted pigmentation and vascular lesions from the skin, while the ResurFX fractional laser stimulates the production of new collagen and elastin fibers in the deeper layers of the skin. Stimulating new collagen production is the key to a more radiant, youthful-looking skin. Laser microbeams heat the deeper layers of the skin to stimulate collagen and elastin fibers, and intense pulses of light address unwanted pigmentation and vascular lesions The treatment To ensure utmost comfort, your physician will typically apply a topical numbing cream before treatment and/or use air cooling during treatment. Depending on your specific concern, you can expect the session to last 15-30 minutes. You may experience a warm or prickling sensation as the laser is applied to the skin. But the treatment is gentle and you should not feel uncomfortable. The advanced scanner delivers the laser beams in a precise manner with integrated cooling to ensure maximum comfort Related Products Stellar M22™ Intelligent skincare platform for the treatment of over 30 skin conditions and hair removal. **Sources based on the stat above about IPL and combination treatments being in demand https://www.coherentmarketinsights.com/market-insight/combination-treatment-in-aesthetics-market-2066 PB-00044270 Rev A GET MORE INFO × Close #### Photorejuvenation About Photorejuvenation Photorejuvenation refers to the use of Intense Pulsed Light (IPL) to treat conditions related to sun-induced skin damage. IPL uses a broad spectrum of light which is primarily absorbed by melanin and oxyhemoglobin and is effective in reducing the appearance of sun spots, capillaries, elastosis and fine lines. The Lumenis Solution As a pioneer in aesthetic medicine, Lumenis developed the first IPL technology and the first Photorejuvenation platform. The Company has established itself as long-standing leader in the field due to its vast knowledge and expertise in the market.The Lumenis IPL with OPT™ is considered the ‘Gold Standard’ in photorejuvenation treatments and its efficacy has been proven in over 80 peer reviewed papers (Bibliography of studies & peer reviewed papers). Advantages For Physicians Optimal treatment safety and efficacy using Optimal Pulse Technology (OPT™) and Multiple Sequential Pulsing (MSP™) which facilitate achieving the desired clinical results with enhanced patient comfort. The Universal IPL handpiece allows for filters and spot sizes to be changed in seconds during treatment, reducing treatment time and eliminating the need for additional hand pieces. Preset treatment parameters for a wide range of clinical indications ensure ease of use and a fast learning curve. Clinical Evidence Related Products The Lumenis IPL with OPT™  is available on the M22™ Multi-Application platform PB-1004608 Rev A × GET MORE INFO #### Pigmentation Pigmentation Sun spots, age spots and redness are common skin conditions They are usually a cosmetic concern and vary in size, shape, and depth. Successfully treat pigmentation on both facial and body areas, regardless of skin type, achieving brighter, more uniform looking skin minimal downtime. EXPLORE OUR PRODUCTS About Pigmentation Pigmented lesions are hypermelanocytic areas typically induced by sun exposure, the natural aging process or congenital factors. Pigmented lesions vary widely in size, shape and depth. They can be either raised or flat and are usually a cosmetic rather than a medical concern. Intense Pulsed Light (IPL) which targets the melanin is effective in treating benign lesions and clearing them. The Lumenis Solution The Lumenis IPL with OPT™ is considered the ‘Gold Standard’ in photorejuvenation treatments and its efficacy has been proven in over 80 peer reviewed papers (IPL bibliography of studies and peer reviewed articles). As a pioneer in aesthetic medicine, Lumenis developed the first IPL technology and the first Photorejuvenation platform. The Company has established itself as long-standing leader in the field due to its vast knowledge and expertise in the market. The versatility of Lumenis’ IPL enables effective and comprehensive treatment of a wide range of pigmented lesions. Advantages For Physicians Optimal treatment safety and efficacy using Optimal Pulse Technology (OPT™) and Multiple Sequential Pulsing (MSP™) which facilitate achieving the desired clinical results with enhanced patient comfort. The Universal IPL handpiece allows for filters and spot sizes to be changed in seconds during treatment, reducing treatment time and eliminating the need for additional hand pieces. Preset treatment parameters for a wide range of clinical indications ensure ease of use and a fast learning curve. Clinical Evidence Related Products   M22™ with IPL Laser For Fractional Non-Ablative Skin Resurfacing. Learn More Bibliography of studies & peer reviewed papers PB-1004609 Rev A GET MORE INFO × #### Pollogen Pollogen – Innovation and Excellence in Aesthetics Pollogen offers professional and home-based customers the best products based on top-notch technologies like TriPollar® RF and Oxygeneo. With years of field experience and clinical expertise, combined with the agility and personal touch as well as a ’start up-spirit’, Pollogen directs its innovation towards these customers’ needs and desires. Encouraging Intelligent Biology Pollogen presents a way to encourage your body to reveal the essence of your personal beauty. It’s called Intelligent Biology ; ‘Your body is the most intricate organism that nature created. A multitude of processes, elements and interactions complement each other in fascinating accuracy that makes YOU. Your body is wise. Your body knows best. Given the right stimulation, it knows how to heal and renew, how to awaken the secrets of its cells, how to reveal the essence of beauty from within.’ Fine Lines and Wrinkle Reduction Oxygenation Skin & Face Rejuvenation Acne Scars Treatment Skin Tightening Cellulite Reduction Fat and Circumference Reduction To Read More About Our Treatments Geneo The three-in-one facial treatment platform for achieving a younger, fresher, replenished and naturally better-looking skin. Divine pro The ultimate facial treatment platform, offering a comprehensive toolkit for effective facial rejuvenation that can be personalized to the customer’s needs Maximus The complete platform for full body contouring and tightening, combining best-in-class technologies for circumference reduction, treating cellulite and reducing fat. Pollogen technologies Pollogen offers its users a full range of non-invasive, safe and effective products that are based on its proprietary technologies, all under the umbrella concept of Intelligent Biology, i.e., encouraging and enhancing the natural processes of rejuvenation. OxyGeneo Refreshing and improving skin texture and tone, by attracting the natural oxygen from the bloodstream to the skin surface, gently exfoliating the skin, preparing it for the infusion of active ingredients. Ultrasound Absorption of active ingredients by applying ultrasound waves below the surface of the skin, to increase the permeability of the stratum corneum and improve the cellular metabolism Trifractional Contact RF ablation for skin resurfacing, pinpoint ablations and controlled volumetric heating, inducing the wound healing process for skin regeneration Voluderm RF-assisted micro-needling thermal penetration and non-thermal ablation, creating microchannels to induce controlled micro-wounds, thus encouraging the generation of new and healthy skin. TriPollar RF Triggering regeneration of collagen and elastin fibers, by delivering focused RF energy in a safe and effective manner, inducing controlled heating of the deep dermis. PB-00020060 Rev B #### Popping Your Pimple Isn’t the Only Cause of Acne Scarring Popping Your Pimple Isn’t the Only Cause of Acne Scarring InStyle June 21, 2017 View More #### Practice Benefits Lightsheer DESIRE Overview The Technology How It Works Patients Benefit Practice Benefits Clinical Results White Papers How Will Your Practice Benefit? Satisfied Patients: Treatments are cost effective and large areas can be treated in less than 10 minutes, so you can see more satisfied patients. Faster Learning Curve: The system is simple to operate and has a friendly Graphic User Interface (GUI) and preset programs- For a faster learning curve and easy treatment delegation. Treatment Versatility: The handpieces have been ergonomically designed and can be switched using a simple ‘Plug and Play’ method-To allow versatility in treatment options and improved system handling. Multi-Location-Usage: The system is light and portable and can easily be transported from one place to another- To enable multi-location use. Upgrade: The system is up-gradable so it can grow with your business-To fit your needs in any given time and match your practice requirements so you can maximize revenues. PB-00005670 Rev A   × GET MORE INFO #### Practice Benefits LightSheer DESIRE Light Overview The Technology Behind the DESIRE Light How Will Your Patients Benefit Practice Benefits Grow Your Business With LightSheer® DESIRE™ Light Rapid return on investment Increase your patient satisfaction Grow your business Benefit from a short return on investment, expand your practice’s offering with laser hair removal  technology and attract new customers seeking fast, comfortable & affordable laser hair removal treatments. How Will Your Practice Benefit? Satisfied Patients: Long lasting results with a comfortable treatment suitable for all skin types. Faster Learning Curve: The system is simple to operate and has a friendly Graphic User Interface (GUI) and preset programs- For a faster learning curve and easy treatment delegation. Treatment Versatility: The handpieces have been ergonomically designed and can be switched using a simple ‘Plug and Play’ method-To allow versatility in treatment options and improved system handling. Multi-Location-Usage: The system is light and portable and can easily be transported between locationsLearn More LightSheer DESIRE Light BrochureGET MORE INFO × #### Practice Benefits LightSheer DUET Overview Treatment & Testimonials Configurations Patients Benefit Practice Benefits Take the High Speed Challenge How Will Your Practice Benefit? Improve Patient Flow & Revenue Potential Pratice Benefits Treat More | Attract More | Convert More | Make More High Speed LightSheer Duet will also change your staff’s perception of laser hair removal and significantly improve patient flow. Using this technology enables you to:  Shorten treatment time using the High Speed handpiece Attract more patients due to treatment speed, comfort, affordability Enjoy a higher rate of prospect conversion and positive referrals Grow your patient base and increase your practice revenue potential Differentiate your practice to better compete in today’s marketplace ROI Scenario 1: Optimize Your Procedure Volume & Revenue Potential Assumption BEFORE High Speed LightSheer WITH High Speed LightSheer Backs or Legs $450 per procedure $450 per procedure Max. Daiy Volume 6-9 procedures per day 18 total per day Max.Volume Logic 9 hour day 60-90 min per session (longer w/topical anesthetic) 9 hour day 30 min per session (no topical needed) Estimated Revenue Potent al $2,700 - 4,050 $8,100 Note : Hypothetical assumption based on LightSheer Duet treatment speed and regional pricing “Larger treatment areas like the back and legs tend to be the most profitable, but are also considered the most tedious. Before, nurses didn’t like to do these procedures and in some cases resisted them altogether – typically citing wrist fatigue, sore shoulders and lower back aches. Now with the High Speed LightSheer the procedure is much faster and requires less effort by the hair removal nurse. The vacuum assist technology does more of the work and improves patient comfort as well. Easier on the nurse and the patient…it’s terrific!”   Beth Haney, NP (CNP & Clinical Trainer, California)  ROI Scenario 2: Differentiate Your Practice & Gain Competitive Advantage LightSheer Duet also enables you to lower your costs, providing you an excellent opportunity to pass on savings to your current and prospective laser hair removal clients – as well as a distinct competitive advantage in some markets. “Not having to apply a topical anesthetic is a huge advantage, because neither the patient nor the practice has to incur that cost…and no treatment gel is used with the high speed handpiece.  Due to the shorter treatment times, we don’t have to charge as much. Practices offering  laser hair removal can now compete more effectively with spas. We were able to reduce our prices by 50%, which makes the procedure more affordable…” Dore Gilbert, MD, (Dermatologist, California) Learn More LightSheer DUET Patient BrochureLightSheer DUET Physician Brochure PB-1049670 Rev C GET MORE INFO × #### Products Aesthetics Product Portfolio triLiftA new category in facial stimulation aesthetics, triLift is an innovative, non-invasive treatment that combines three technologies in one single device to produce the natural face lift-like effect that patients desire.MORE INFOLeading Treatments Facial Muscle Stimulation Stellar M22™All-in-one, multi-application platform expanding your aesthetic offering with over 30 best-selling IPL & laser skin treatments.MORE INFOLeading Treatments Skin Resurfacing & Rejuvenation Benign Pigmented Lesions Benign Vascular Lesions Hair Removal SPLENDOR XAlexandrite & Nd:YAG laser hair removal workstation Powered by BLEND X technology. High fluence, built-in smoke evacuator large square spot size and rapid repetition rate.MORE INFOLeading Treatments Hair Removal Benign Vascular Lesions Wrinkle Reduction Benign Pigmented Lesions ULTRApulse® AlphaThe best CO2 laser technology in aesthetics has been perfected, providing WOW results in just one treatment, while maintaining patient comfort and safety with minimal downtime. ULTRApulse Alpha is the next step in growing your practice.MORE INFOLeading Treatments Scar Revision Skin Resurfacing Blepharoplasty Acne Scars Legend Pro+™Advanced radio frequency skin treatment platform with unique RF microneedling and TriPollar® for skin resurfacing, inducing renewal, as well as wrinkle reduction.MORE INFOLeading Treatments RF Microneedling Skin Tightening smoothGlo LightSheer® QUATTRO™Diode Laser Hair Removal system for all skin types, offering both 805nm and 1060nm wavelengths. High fluence, large spot size and rapid repetition rate.MORE INFOLeading Treatments Hair Removal Benign Vascular Lesions Wrinkle Reduction Benign Pigmented Lesions NuEra® TightPersonalized non-invasive body sculpting solution featuring FocalRF technology to control the treatment depth for Fat Reduction, Skin Tightening, Wrinkle and Cellulite Reduction. For a treatment as unique as your patients.MORE INFOLeading Treatments Fat Reduction Wrinkle Reduction Cellulite Reduction Skin Tightening AcuPulse™A complete ablative CO2 laser resurfacing workstation, featuring state of the art technology for all aesthetic resurfacing needs.MORE INFOLeading Treatments Skin Resurfacing Acne Scars Pigmentation Dyschromia FemTouchFemTouch addresses vaginal health related conditions by promoting the remodeling of the vaginal mucous epithelium layer.  Fractional CO2 laser is applied along the vaginal wall, resulting in gently controlled ablation and coagulation of the vaginal lining.MORE INFOLeading Treatments Vulvar & Vaginal Atrophy triLiftA new category in facial stimulation aesthetics, triLift is an innovative, non-invasive treatment that combines three technologies in one single device to produce the natural face lift-like effect that patients desire.MORE INFOLeading Treatments Facial Muscle Stimulation Legend Pro™Advanced radio frequency skin treatment platform with unique RF microneedling and TriPollar® technology for skin resurfacing, inducing renewal, as well as wrinkle reduction.MORE INFOLeading Treatments RF Microneedling Wrinkle Reduction Skin smoothGlo Stellar M22™All-in-one, multi-application platform expanding your aesthetic offering with over 30 best-selling IPL & laser skin treatments.MORE INFOLeading Treatments Skin Resurfacing & Rejuvenation Benign Pigmented Lesions Benign Vascular Lesions Hair Removal SPLENDOR XAlexandrite & Nd:YAG laser hair removal workstation Powered by BLEND X technology. High fluence, built-in smoke evacuator large square spot size and rapid repetition rate.MORE INFOLeading Treatments Hair Removal Benign Vascular Lesions Wrinkle Reduction Benign Pigmented Lesions ULTRApulse® AlphaThe best CO2 laser technology in aesthetics has been perfected, providing WOW results in just one treatment, while maintaining patient comfort and safety with minimal downtime. ULTRApulse Alpha is the next step in growing your practice.MORE INFOLeading Treatments Scar Revision Skin Resurfacing Blepharoplasty Acne Scars LightSheer® QUATTRO™Diode Laser Hair Removal system for all skin types, offering both 805nm and 1060nm wavelengths. High fluence, large spot size and rapid repetition rate.MORE INFOLeading Treatments Hair Removal Benign Vascular Lesions Wrinkle Reduction Benign Pigmented Lesions NuEra® TightPersonalized non-invasive body solution featuring FocalRF technology to dial-in the depth of energy penetration from muscle to skin to account for clinical indications and specific body areas. For a treatment as unique as your patients.MORE INFOLeading Treatments Cellulite Reduction Skin Smoothing AcuPulse™A complete ablative CO2 laser resurfacing workstation, featuring state of the art technology for all aesthetic resurfacing needs.MORE INFOLeading Treatments Skin Resurfacing Acne Scars Pigmentation Dyschromia AcuPulseWAcuPulseW is a complete ablative and resurfacing platform featuring state of the art technology for aesthetic resurfacing and women's health needs.MORE INFOLeading Treatments Women's Health PB-00027540 Rev A GET MORE INFO × #### Q-Switched Nd:YAG M22 Overview Universal IPL Multi-Spot Nd:YAG ResurFX Q-Switched Nd:YAG Q-Switched Nd:YAG For skin toning by treatment of pigmented lesions and dark tattoo removal Single Head for All Q-Switched Applications Easy to use; no need to change treatment heads when changing applications. 7 spot sizes for customized treatments, 4 of which are available also as disposable tips: SCHEDULE A DEMO “Top-Hat” Beam Profile Advantages Enhanced treatment safety and efficacy by homogeneous distribution of energy Top-hat beam profile minimizes epidermal damage, tissue textural changes and the occurrence of scarring A lack of an homogenizer might result in hot spots within the beam and increased risk of scarring Beam profile side view without an homogenizer Beam profile side view with an homogenizer for a top-hat beam M22 Q-Switched Procedural Videos [ytp_video source=”bO89NGLbVzA,OfmyghdoBik,I12F2XBNX5g,OaKzt33BZJo,_QPDiy3X44c,IK2rbT7YqNY”] Typical Clinical Results DOWNLOAD BROCHURE PB-1003630 Rev D Close Close GET MORE INFO × #### Radio-Frequency (RF) Aesthetic RadioFrequency Technology TriPollar® RF Technology Radio Frequency (RF) energy, in the form of radiating waves or electrical currents, used in medical treatments for over 75 years, generally for minimally invasive surgeries using radiofrequency ablation. Radio Frequencies at non-ablation energy levels commonly used as a part of aesthetic treatments that can tighten skin, reduce fat by lipolysis and apoptosis, or promote healing. How Does Radio Frequency (RF) Work? Radio Frequency energy is a form of electromagnetic energy. Radio Frequency current through tissue will generate heat in the tissue. This source of heat has extensively used in surgery for hemostasis and tissue ablation (electro-surgery), but more recently it has been applied as a means of shrinking redundant or lax connective tissues through the mechanism of collagen denaturation. Collagen molecules are produced by fibroblasts. Heated fibroblasts are also implicated in new collagen formation and subsequent tissue remodeling which can also contribute to the final clinical result. The precise heat-induced behavior of connective tissues is dependent on several factors which include the maximum temperature reached, exposure time, tissue hydration and tissue age. The Lumenis solution: TriPollar® RF TriPollar® technology, available in the Legend Pro™ skin treatments’ platform, is a unique third generation RF technology that builds on the advantages of its predecessors to result in an improved and more refined version. RF runs through three or more electrodes, that change their polarity during treatment for more homogeneous coverage and improved thermal effect. The polarity ratio is always two to one: two positive and one negative, and vice versa. This rotating polarity means more homogeneous heating of the tissue from within, keeping the epidermis safe. Thanks to this RF modality the risk of burns and blisters is minimized. On the Legend Pro™ platform, applicators no1 and 2 are equipped with an Infra-Red (IR) sensor for real-time, in-motion milliseconds temperature reading precision that ensures treatment endpoint and efficacy. There is no need for skin cooling and treatment is easy to perform. TriPollar® treats facial wrinkles and rhytids. Results are immediately visible from the first treatment and may last for several months before touch up and maintenance treatments are required. A combination protocol: Legend M²™ TriPollar® RF is ideally combined with VoluDerm™ precise micro heating through Legend M² ™combination therapy. The two technologies target different skin layers individually and synergistically in a single procedure. TriPollar RF VoluDerm Related Products Legend Pro+ Skin treatments platform with unique RF assist ultra-thin electrodes and TriPollar® RF Legend Pro Skin treatments platform with unique RF assist ultra-thin electrodes and TriPollar® RF PB-2012180 Rev A GET MORE INFO × #### Recreating the Patient BUZZ Recreating the Patient BUZZ Publish Date: Feb 11, 2020 Length: 66 Minutes Recreating the patient BUZZ. Learn various PR tactics and how to optimize your media assets in Post Corona times. Taylor Naples Vice President (Beauty) at 5W Public Relations #### Resource Hub WELCOME TO THE AESTHETICS RESOURCE HUB FoLixHair LossNewsResource HubTreatmentsFoLixHair LossNewsResource HubTreatmentsFoLix Named Best Laser Treatment for Hair Loss Two Years RunningREAD MOREBlog PostsHair LossResource HubBlog PostsHair LossResource HubNew Growth for Hair Loss Solutions: First West Coast Provider Shares Insights on FoLix by LumenisREAD MOREFoLixHair LossNewsResource HubTreatmentsFoLixHair LossNewsResource HubTreatmentsFoLix™ by Lumenis Wins Innovation Award in Hair Loss Technology at the 2025 Medical Device Network Excellence AwardsREAD MOREFacial Muscle StimulationNewsResource HubTreatmentstriLiftFacial Muscle StimulationNewsResource HubTreatmentstriLiftLumenis’ triLift™ Honored in Two Categories on the MedEsthetics 2025 Readers’ Choice AwardsREAD MOREFoLixHair LossNewsResource HubTreatmentsFoLixHair LossNewsResource HubTreatmentsFoLix™ Recognized for Dermatology Innovation in 2025 MedTech Breakthrough Awards ProgramREAD MOREHair RemovalNewsProductsProductsResource HubSplendor XTreatmentsHair RemovalNewsProductsProductsResource HubSplendor XTreatmentsLumenis Unveils Enhanced SPLENDOR XTM Laser Hair Removal Solution with New Clinical Data at the Annual American Society for Laser Medicine and Surgery (ASLMS) ConferenceREAD MOREFoLixHair LossNewsProductsResource HubFoLixHair LossNewsProductsResource Hub2025 NewBeauty Award Winner Lumenis Expands FoLix™ Global Footprint with Canadian LaunchREAD MOREFoLixHair LossNewsProductsResource HubFoLixHair LossNewsProductsResource HubBosley and Lumenis Partner to Introduce Breakthrough Hair Loss Solution, FoLix™, to the U.S.READ MOREFacial Muscle StimulationNewsProductsResource HubtriLiftFacial Muscle StimulationNewsProductsResource HubtriLiftInclusive Aesthetic Treatment triLift by Lumenis Safe for ALL Skin TypesREAD MOREFacial Muscle StimulationNewsProductsResource HubtriLiftFacial Muscle StimulationNewsProductsResource HubtriLiftEarly triLift Adopter Dr. James Chelnis now is a Thriving triLift Success StoryREAD MOREFacial Muscle StimulationNewsProductsResource HubtriLiftFacial Muscle StimulationNewsProductsResource HubtriLiftBetween Medicine & Beauty: Cosmetic DermatologyREAD MOREFacial Muscle StimulationNewsProductsResource HubtriLiftFacial Muscle StimulationNewsProductsResource HubtriLiftAre Injection-Free Treatments the Future of Anti-Aging?READ MORE GET MORE INFO × #### ResurFX M22 Overview Universal IPL Multi-Spot Nd:YAG ResurFX Q-Switched Nd:YAG ResurFX™ The ResurFX™ module of M22™ is the only true fractional non-ablative technology. One pass is all it takes. Unlike other fractional technologies, ResurFX™ needs only one pass to be effective, saving you time and protecting the patient’s skin. ResurFX™ uses a 1565 nm fiber laser and a very advanced scanner, which enables you to choose from more than 600 combinations of shape, size and density for optimal treatment. SCHEDULE A DEMO ResurFX™ With CoolScan™ For Optimal Treatment The ResurFX™ module has a state-of-the-art CoolScan™ scanner for non-sequential scanning. The patent pending algorithm places each fractional spot in a controlled manner to protect the tissue from heat accumulation and overheating. This ability is unique to the ResurFX™ 1565nm fiber laser. The ResurFX™ handpiece is equipped with continuous contact cooling, to increase patient comfort during treatment. Clinical Results Histologies taken immediately after treatment* *Taken on Porcine tissue. Not indicative of clinical results. Before and After Images: DOWNLOAD BROCHURE PB-1000139US Rev D   Close Close GET MORE INFO × #### RF Micro-Needling Fractional RF Microneedling Benefits of RF Microneedling Micro-needling (also known as collagen induction therapy) is a minimally invasive treatment that has been used for decades to rejuvenate the skin. A device with fine needles or pins creates tiny punctures in the top layer of the skin, which triggers the body to create new collagen and elastin. Results can include improved texture and firmness, as well as skin resurfacing. RF micro-needling adds the element of radiofrequency energy to the traditional micro-needling procedure. The RF energy is delivered via small needles into the dermis. In addition to the benefits seen with the micro-injury provided by the traditional microneedles, RF micro-needling also delivers RF energy deep into the dermis further enhancing skin tightening and scar reduction. How Does RF Micro-Needling Work? The RF energy heats the underlying layers of skin, causing constriction and tightening of the skin, as well as the stimulation of collagen and elastin production. Because the RF energy is delivered so deeply, it can produce faster results that are more dramatic. The Lumenis solution: VoluDerm™ Unlike the rest of the technologies in the market, VoluDerm™ does not use needles to puncture the skin and deliver RF energy into the dermis after the needles fully inserted. Instead, VoluDerm™ uses an array of ultra-thin electrodes that thermally ablate the outer surface of the skin to reach the deep dermis. The ultra-thin electrodes create micro-channels via RF ablation to induce controlled micro wounds and thermal damage. This ablation leads to a wound healing process that regenerates younger and smoother looking skin. Using the thinnest electrodes in the market (ø 0.15 mm), this smooth RF-assisted ablation leads to reduced pain and downtime. While there is no bleeding, and minimal to no pain with VoluDerm, patients obtain visible results from its proprietary technology that delivers RF energy from the skin surface through to the deep dermis. The unique smart tip design enables even distribution of RF energy between the electrodes and the tip’s surface. This design reduces the risk of arcing and undesired side effects while at the same time creating areas of ablative and thermal damage. Several disposable tip configurations are available, differing in length, width and density, to ensure flexibility for creating the desired clinical effect. Treatment is suitable for all skin types in dermatological procedures requiring ablation and skin resurfacing. TriFractional™ Available with the VoluDerm™ applicator, the TriFractional™ is using RF electrodes pins for superficial skin resurfacing, via pinpoint ablation with controlled volumetric heating. Unlike the VoluDerm™, this treatment is more superficial for texture and is associated with some downtime and higher sensation then the VoluDerm™. The treatment achieves skin resurfacing and regeneration of tissue via wound healing process, resulting in skin texture improvement and refinement. A combination protocol: Legend M²™ VoluDerm™ is ideally combined with TriPollar® RF macro-volumetric tissue heating through Legend M2™ combination therapy. The two technologies target different skin layers individually and synergistically in a single treatment. Related Products   Legend Pro™ Skin treatments platform with unique RF assist micro-needling and TriPollar® RF Legend Pro+™ Skin treatments platform with unique RF assist micro-needling and TriPollar® RF PB-2012180 Rev B GET MORE INFO × #### Rosacea About Rosacea Rosacea is a chronic skin condition which expresses itself in redness on the face and sometimes on the neck and chest. The exact cause of Rosacea is yet unknown and many who are affected by it are unaware of their condition. Rosacea can be effectively treated using Intense Pulsed Light (IPL). IPL uses controlled light in specific wavelengths to alleviate the inflammation, redness, pimples and uneven skin tones caused by the condition. IPL offers a gentle, long-lasting solution for those suffering from Rosacea by providing a gradual and natural improvement to the skin’s appearance. The Lumenis Solution The Lumenis IPL with OPT™ is considered the industry’s ‘Gold Standard’ for treatment of vascular lesions and its efficacy has been proven in over 80 peer reviewed papers (IPL bibliography of studies and peer reviewed articles). The IPL procedure removes facial superficial vessels and as a result dramatically decreases or completely eliminates facial redness. The vascular components of Rosacea can vary from flushing to telangiectasia and can have different densities and depths. With a choice of multiple vascular cut-off filters and unique pulse sequencing, Lumenis’ IPL with OPT™ can coagulate each sub-type of capillaries, reducing the redness and simultaneously triggering neocollagenesis which limits the reccurrence of the condition. Advantages For Physicians Optimal treatment safety and efficacy using Optimal Pulse Technology (OPT™) and Multiple Sequential Pulsing (MSP™) which facilitate achieving the desired clinical results with enhanced patient comfort. types. The Universal IPL handpiece allows for filters and spot sizes to be changed in seconds during treatment, reducing treatment time and eliminating the need for additional hand pieces. Preset treatment parameters for a wide range of clinical indications ensure ease of use and a fast learning curve. Clinical Evidence Related Products The Lumenis IPL with OPT™ is available in the M22™ Multi-Application platform Learn More Bibliography of studies & peer reviewed papers PB-1004610 Rev A × GET MORE INFO #### Roundtable – UltraPulse with Dr. Duplechain Roundtable – UltraPulse with Dr. Duplechain Publish Date: Feb 15, 2020 Length: 57 Minutes Interested in learning today’s leading practices in fractional CO2 laser therapy? Watch this intriguing webinar with Kevin Duplechain, MD, FACS, a leading expert in UltraPulse CO2 for a roundtable discussion on best practices and techniques. This peer-to-peer session features reviews of real cases and explores how your practice can benefit from the Lumenis UltraPulse CO2. Dr. Duplechain J. Kevin Duplechain, MD, FACS cosmetic surgeon and president at the Aesthetic Medicine Center, Louisiana, US PB-00025890 Rev A #### Scar Revision Scars Atrophic, hypertrophic, keloid, and acne scars treatments Self confidence is a reflection of how we perceive our outer appearance. Our state of the art, powerful laser technologies treat a wide range of scars improving skin texture, pigment and functional aspects. EXPLORE OUR PRODUCTS About Scar Revision Scars result from a chaotic wound healing response leaving behind fibrotic tissue due to irregular collagen formation. There are different types of scar including atrophic, hypertrophic, contracture and keloid scars. Available scar revision therapies depend on the type of scar, and range from topical creams for mild scarring, to grafting in the case of large, traumatic scars. Laser scar revision is an effective method for treating a wide range of scars that improves skin texture and pigment as well as functional aspects. For acne and some surgical scars (see also Acne Scars Treatment), fractional skin resurfacing can effectively treat textural and pigment concerns. IPL can also be used to decrease pigmentation and vascular effects. Scars caused by burns and other traumatic injuries are more complicated in nature and can negatively affect the quality of life due to disfigurement, pain, bleeding, pruritis (itching) and restricted range of motion. Fractional ablative laser resurfacing has been proven to effectively treat such scars and provide consistent and significant functional improvement as well as measurable cosmetic benefits. The Lumenis Solution Lumenis offers a range of ablative and non-ablative fractional resurfacing solutions to treat different degrees of scar. the SCAAR FX™ mode available as part of the UltraPulse® system, allows for advanced treatment of a variety of severely damaged skin lesions which require synergistic coagulation and ablation for advanced resurfacing (SCAAR).  By delivering more powerful pulses than any other laser in its category, the UltraPulse reaches an unparalleled depth of 4mm in a single pulse, enabling physicians to treat and rehabilitate scars more effectively. With the smallest beam diameter and shortest pulse width in the industry, the UltraPulse delivers bursts of high energy at low densities that are ideal for a wide range of scar treatments. SCAAR FX uses a unique ablation/coagulation ratio to substantially improve the structure of deep contracted lesions by restoring more normal collagen deposition. This maximizes results, minimizes thermal damage and reduces treatment time. Advantages For Physicians The SCAAR FX™ mode penetrates up to 4 mm for effective treatment of complex and deep contracted lesions. Small beam diameter and exceptional ablation/coagulation ratio ensures effective results with minimal risk of thermal damage. Ability to perfectly tailor treatment to each scar type using advanced scanner technology that provides a wide choice of energy, shape, size and density. Lumenis also offers fractional ablative skin resurfacing for a range of scar types in the AcuPulse product, as well as fractional non-ablative skin resurfacing that is available with ResurFX™. Clinical Evidence Related Products   M22™ For Fractional Non-Ablative Skin Resurfacing. AcuPulse™ AcuPulse™ is a complete ablative laser resurfacing workstation, featuring state of the art technology for all aesthetic resurfacing needs. UltraPulse® UltraPulse® can penetrate deeper than any aesthetic ablative CO2 laser. This makes UltraPulse® perfect for both everyday procedures and the thick and complex lesions. ResurFX™ The only non ablative fractional laser system with CoolScan™ scanner, customizable treatment parameters, and no disposables. PB-1004611 Rev A GET MORE INFO × #### Scar Wars – UltraPulse Expert Panel Scar Wars – UltraPulse Expert Panel Publish Date: Nov 10, 2020 Length: 105 Minutes For far too long, little could be done for patients with heavy scars left from trauma. Patients were left with permanent disfigurement that impacted their self-esteem and lifestyle. Furthermore, many patients had to live with the debilitating lack of mobility that accompanies tough scar tissue. Now, technological innovations are giving trauma survivors with scars a new hope and a better future. Expert providers are harnessing the capabilities of state-of-the-art laser technology to improve the appearance of scars, decrease pain and itching and dramatically increase the patient’s mobility. For patients, this means a dramatic boost to self-image and physical recovery. In this encore roundtable presentation, you can learn more about the extraordinary evolution of scar treatment from six of the world’s experts. These seasoned providers share their perspectives based on hands-on, real-world experience helping patients reclaim their mobility and take tangible steps toward recovery and wellbeing. Each expert speaker shares unique and inspiring real-world case stories as examples of the treatments and technology in use. Additionally, these diligent professionals provide an in-depth exploration of the technology, treatment timeline, and precise, but minimally invasive techniques that make these treatments possible. Complete the web form to watch now. Chad Hivnor, MD, FAAD Chief of Dermatology South Texas Veterans Health Care System. Peter Shumaker, MD Board-certified Dermatologist in San Diego, CA. Matthias B. Donelan, MD Board-certified plastic surgeon, Chief of Staff, Emeritus, Shriners-Boston Nathan Uebelhoer, MD Board-certified dermatologist in Poway, CA Andrew Krakowski, MD Chief of Dermatology at St. Luke’s University Health Network, Bethlehem PA. Thomas Beachkofsky, MD Board-certified dermatologist, Tampa FL PB – 00016790 #### Science Meets Demand Science Meets Demand Publish Date: Feb 21, 2021 Your technology must meet market demands. More importantly, your technology must provide great results time-after-time while maximizing patient safety and minimizing risk. This guide explores the science behind the industry’s leading technology solutions and highlights the studies that validate their claims. Download Science Meets Demand to stay up-to-date on the latest clinically-proven aesthetic trends. PB-00026490 Rev A #### Skin Skin Wide variety of skin rejuvenation solutions to treat skin damage, texture and tone Whether texture, vascularity or tone, our wide range of advanced solutions uniquely tailored to your patient’s lifestyle and skin concerns, provide maximum efficacy, with clinically proven results. Empower your patients to love how their skin looks and feels by unleashing their true beauty. EXPLORE OUR PRODUCTS Skin rejuvenation opportunities Confidence-boosting aesthetic treatments are now in high demand by women and men who want to look better, feel good about themselves and age gracefully. As the medical aesthetic market continues to grow, laser and energy device treatments are emerging as a key driver with facial lasers being one of four key trends shaping the market* and 70% of patients looking for skin rejuvenation treatments**. Skin rejuvenation solutions As pioneers in energy-based technologies, backed by scientific evidence, Lumenis leads the way in expertise and innovation. Lumenis offers an extensive variety of skin rejuvenation solutions to improve skin damage, texture and tone. These range from non-ablative procedures with minimal downtime to ablative technologies with maximum efficacy. Find out more about our cutting-edge technologies below – and discover how you can tailor treatment to suit each patient’s needs precisely. PhotorejuvenationNon-ablative skin resurfacingAblative skin resurfacingRF skin rejuvenationBlepharoplastyPhotorejuvenation Photorejuvenation Photorejuvenation refers to the use of Intense Pulsed Light (IPL) to treat conditions related to sun-induced skin damage and vascularity issues. IPL uses a broad spectrum of light which is primarily absorbed by melanin and oxyhemoglobin and effectively reduces the appearance of sun spots, capillaries, and elastosis, and builds collagen. IPL was invented by Lumenis and is still considered the gold standard for photorejuvenation treatments. Available through our technologically advanced and highly versatile M22™ platform, Lumenis IPL with Optimal Pulse Technology (OPT™) enables delivery of high peak power with shorter pulses, ensuring homogeneous fluence delivery along the pulse duration. The efficacy of IPL with OPT™ has been proven in over 80 peer reviewed papers. More about Photorejuvenation treatment Non-ablative skin resurfacing Non-ablative skin resurfacing   Non-ablative skin resurfacing keeps skin intact, stimulates collagen growth and tightens underlying skin. It is ideal for patients who prefer a milder treatment approach with less downtime and no risk of skin infection. The ResurFX™ module of M22™ is the only true fractional non-ablative technology on the market for skin resurfacing. It uses an advanced scanner technology, CoolScan™, to ensure that energy delivery is precise and homogenous. Unlike other fractional technologies, ResurFX™ needs only one pass to be effective, saving the practitioner time and protecting the patient’s skin. More about Non-ablative skin resurfacing treatment Ablative skin resurfacing Ablative skin resurfacing   Ablative skin resurfacing procedures use lasers to reduce the signs of aging, improve skin texture, laxity and tone, and reduce scars and stretch marks. Ablative resurfacing is ideal for patients seeking a dramatic improvement in a single session. Superficial resurfacing creates micro-wounds which trigger the body’s natural healing ability to rejuvenate skin and improve texture. The treatment ensures significantly reduced downtime and minimal discomfort. Lumenis offers two powerful state-of-the-art CO2 laser devices with tailored treatment modes: UltraPulse® and AcuPulse™. Both use high-power short duration pulse technologies to maximize treatment and patient comfort, as well as minimize downtime. More about Ablative skin resurfacing RF skin rejuvenation RF skin rejuvenation   Radio frequency (RF) energy has been used in medical treatments for over 75 years. This form of radiating waves or electrical currents alone is used for non-invasive skin rejuvenation treatments but can be combined with minimally invasive treatment for greater effect. TriPollar® RF non-invasive technology, available on our Legend Pro+™ platform, treats mild to moderate facial wrinkles and rhytids. Results are immediately visible and may last for several months before a maintenance treatment is required. TriFractional™ RF is minimally invasive treatment on our Legend Pro+™ platform, which resurfaces and regenerates skin through the wound healing process to improve and refine skin texture by applying contact RF at pin point ablation with controlled volumetric heating. VoluDerm™ technology, also minimally invasive and on Legend Pro+™, encourages the generation of new and healthy skin. RF-assisted ultra-thin electrodes are applied creating controlled micro wounds, trigger the production of new collagen, elastin and hyaluronic acid. TriPollar® RF is ideally combined with VoluDerm™ in our unique synergized Legend M²™ treatment for face and body on Legend Pro+™. Legend M²™ combines the macro volumetric heating of tissue with TriPollar® RF and the precise micro heating of focal points with VoluDerm™ to target different skin layers individually in a single procedure. Fibroblasts undergo non-invasive and minimally invasive triggers for a synergetic result. The treatment activates the body’s natural healing processes to generate new and healthy skin for an immediately noticeable tightened and rejuvenated effect. More about RF skin rejuvenation Blepharoplasty Blepharoplasty   Blepharoplasty is an aesthetic surgical procedure that corrects/modifies defects, deformities or disfiguration of the eyelids. It involves the excision, removal and/or repositioning of excess tissue and reinforcement of the muscle and tendon tissues. Lumenis offers a complete laser blepharoplasty solution through our innovative UltraPulse® and AcuPulse™ technologies for maximum precision and high-end performance. This incisional solution is combined with complementary eyelid rejuvenation using fractional ablative skin resurfacing for optimal results. More about Blepharoplasty treatment *Realself U.S. Laser & Energy report. Consumer insights & trend July 2018 **Society for Dermatologic Surgery (ASDS) 2017 Consumer Survey on Cosmetic Dermatologic Procedures. Related Products   M22™ For Fractional Non-Ablative Skin Resurfacing. Legend Pro™ Skin treatments platform with unique RF assist micro-needling and TriPollar® RF Legend Pro+™ Skin treatments platform with unique RF assist micro-needling and TriPollar® RF UltraPulse® UltraPulse® can penetrate deeper than any aesthetic ablative CO2 laser. This makes UltraPulse® perfect for both everyday procedures and the thick and complex lesions. AcuPulse™ AcuPulse™ is a complete ablative laser resurfacing workstation, featuring state of the art technology for all aesthetic resurfacing needs. ResurFX™ The only non ablative fractional laser system with CoolScan™ scanner, customizable treatment parameters, and no disposables. PB-00025470 Rev B GET MORE INFO × #### Skin by Sarah Hudson Adopts Non-invasive Aesthetic Treatment Skin by Sarah Hudson Adopts Non-invasive Aesthetic Treatment August 11, 2024 Sarah Hudson of Australia-based skin-clinic enjoys using triLift in her practice because it provides a more long-term and holistic alternative to injectables by stimulating underlying facial muscles. Read Full Article PB-00070180 Rev A #### Skin Toning About Skin Toning Skin toning refers to the use of Q-Switched lasers for non ablative skin rejuvenation. This term is more common in Asian countries. In skin toning, multiple passes of low-dose  Q-Switched Nd:YAG are delivered through a large spot size to induce sublethal injury to melanosomes causing fragmentation and rupture of melanin granules into the cytoplasm. This effect is highly selective for melanosomes and leads to overall skin brightness. Moreover, the subthreshold injury to the surrounding dermis stimulates the formation of collagen that results in tighter skin. The Lumenis Solution The Lumenis Q-Switched Nd:YAG was developed to enable skin toning, by treatment of pigmented lesions, using a large and non-disposable tip of 6mm. Using a top-hat beam profile ensures control of homogeneous energy delivery and maximum safety without hot-spots nor any risk of side effects or complication for the patient. Advantages For Physicians Optimal treatment safety and efficacy using Top-Hat beam profile, which ensures homogeneous distribution of energy. The affordable upgrade of the Q-Switched Nd:YAG handpiece for the M22™ Multi-Application Platform, enables adding more versatility and advanced combination treatment options. Preset treatment parameters ensure ease of use and a fast learning curve. Related Products The Lumenis Q-Switched Nd:YAG systems, is available in the M22™ Multi-Application platform PB-2007298 × GET MORE INFO #### SmoothGlo SmoothGlo™ The Synergy Of Energy SmoothGlo is an innovative sequential skin treatment that utilizes two proven technologies delivered one following the other in one session that results in visibly fuller, brighter, firmer, and more youthful looking skin. Schedule a Demo Two clinically-proven technologies that deliver synergistic results In response to consumers seeking skin treatments that address multiple signs of aging in one session, we created SmoothGlo, a sequential treatment protocol that delivers smooth, glowing skin naturally. This innovative treatment incorporates two proven technologies that deliver immediate and accumulative results with minimal discomfort and downtime. It’s The “Glo” Standard By leveraging the capabilities of StellarM22™ IPL and Legend Pro™ VoluDerm™ technologies, SmoothGlo™ improves skin tone, texture and volume in a sequential treatment that sets a new standard for aesthetic results. The magic is in the sequence. The first portion of the treatment is with the StellarM22™ IPL, which removes both brown and red lesions improving overall tone, while increasing the water content in the skin. It’s the increase in the skin’s water content that amplifies the clinical effects of the second part of the treatment with the Legend Pro™ VoluDerm™ RF microneedling, which exposes the elevated moisture in the skin to an electrical charge that improves the texture, contour, and volume of the skin. SmoothGlo reverses the signs of aging by delivering both immediate and accumulative results with full results achieved in 3-4 visits with little to no downtime. All you need is SmoothGlo™. SmoothGlo™ Treatment Benefits Skin Tone Stellar IPL treats “reds and browns” including stubborn lentigos and improves overall skin tone Texture Legend Pro™ VoluDerm™ RF microneedling smoothes wrinkles and improves skin texture Volume Legend Pro™ VoluDerm™ RF microneedling improves the natural production of hyaluronic acid resulting in improved volume 4.6 Bilion Global value of non-invasive aesthetic treatment market Read More 13.9 % Compound annual growth rate of non-invasive treatments from 2021-2028 Read More 18.9 Bilion Global value of non-invasive aesthetic treatment market Read More ≈290 K Non-surgical skin treatments performed with IPL & combination lasers in the United States in 2020 Read More Treatment review SmoothGlo Stellar IPL Legend Pro™ VoluDerm™ SmoothGlo SmoothGlo is a brand new skin treatment protocol that utilizes two proven technologies delivered sequentially in one session that results in visibly fuller, brighter, firmer, and more youthful looking skin. Stellar IPL The first portion of the sequential SmoothGlo treatment is with the Stellar IPL, which removes both brown and red lesions improving overall tone, while increasing the water content in the skin. The elevated moisture levels in the skin amplifies the benefits of the second portion of the treatment. Legend Pro™ VoluDerm™ The second part of the sequential SmoothGlo treatment is with Legend Pro™ VoluDerm™, which exposes the increased water in the skin to an electrical charge that improves skin texture, contour, and volume. SmoothGlo SmoothGlo SmoothGlo is a brand new skin treatment protocol that utilizes two proven technologies delivered sequentially in one session that results in visibly fuller, brighter, firmer, and more youthful looking skin. Stellar IPL Stellar IPL The first portion of the sequential SmoothGlo treatment is with the Stellar IPL, which removes both brown and red lesions improving overall tone, while increasing the water content in the skin. The elevated moisture levels in the skin amplifies the benefits of the second portion of the treatment. Legend Pro™ VoluDerm™ Legend Pro™ VoluDerm™ The second part of the sequential SmoothGlo treatment is with Legend Pro™ VoluDerm™, which exposes the increased water in the skin to an electrical charge that improves skin texture, contour, and volume. Before and After SmoothGlo™ reverses the signs of aging by improving skin tone* and texture. It immediately gives you visibly fuller, tighter, more youthful skin, with just 3-4 treatments and continued improvement in the following months. * Skin tone improvement through treatment of pigmented lesions Courtesy of Dr Bahar Gul, Turkey Courtesy of Dr Bahar Gul, Turkey Courtesy of Dr Bahar Gul, Turkey Courtesy of the garden med spa Courtesy of Dr. Michael Mirmanesh Courtesy of Dr. Michael Mirmanesh Courtesy of Dr. Michael Mirmanesh Courtesy of Dr. Michael Mirmanesh Efficient Multiple skin conditions treated in one session Capture More Patients Demand has increased for consumers seeking treatments that address multiple skin conditions in one session Increase Revenue ​Your clinic benefits from providing more treatments that deliver visible results with minimal discomfort and downtime​ Testimonials SmoothGlo™ has become a significant revenue generator in my practice. Combining Lumenis Stellar M22 with the Legend Pro, I am able to provide my patients a treatment affecting both pigment and texture, without compromising on downtime. Results are astonishing, bringing in more patients asking about it. Dr. Matteo Tretti Clementoni, Italy SmoothGlo™ fits perfectly into my current offering filling a gap in my ability to get my clients most efficiently to full correction of their concerns. It allows me to use the devices and technologies that I already own and trust in a revolutionary new way to achieve better, more complete results than ever before. I love the ability to maximize the results that can be obtained while minimizing the time to the practice and the cost to the patient by performing two treatments back-to-back in the same visit! Dr. Lori King TX, USA Some treatments sell themselves and SmoothGlo™ is one of them. Patients request IPL every day. They’re looking for a great result and expectations can be higher than what the tech can deliver. This is the answer to that problem. SmoothGlo™ gives them the outcomes they want and adds very little downtime to get there. Patients love their results and feel like they got more than their money’s worth. That’s exactly what good providers want their patients to say. Dr. Michael Mirmanesh NJ, USA Technology Legend Pro™ VoluDerm™ Legend Pro™ Voluderm™ delivers a smooth fractional ablative treatment that puts a premium on patient comfort without compromising the results. Using the thinnest RF-assisted thermal electrodes in the market, Voluderm™ encourages the renewal of healthy skin from within by creating controlled micro-wounds that trigger the production of new collagen, elastin, and hyaluronic acid. Read More Read More Stellar IPL The Stellar™ IPL is one of the most advanced, intelligent skincare innovations in the world. With one applicator, 9 filters, and 3 lightguides, Stellar™ IPL can treat over 20 skin conditions including acne, rosacea, pigmented and vascular lesions, and reducing hyperpigmentation through photorejuvenation. Read More Related Products Legend Pro Skin treatments platform with unique RF assist ultra-thin electrodes and TriPollar® RF Legend Pro + Skin treatments platform with unique RF assist ultra-thin electrodes and TriPollar® RF Stellar M22™ Intelligent skincare platform for the treatment of over 30 skin conditions and hair removal. Close PB-00026650 Rev A GET MORE INFO × #### SPLENDOR X Elevating Laser Hair Removal with the power of Blend X® : The ideal blend of Alexandrite & Nd:YAG technologies DOWNLOAD BROCHURE WATCH VIDEOAbout SPLENDOR XLaser Hair Removal SolutionBefore & AfterTreatmentsTechnology The ideal blend of practice success and patient satisfaction SUPERIOR HAIR REDUCTION RESULTS1 Effective across a wide range of skin tones with BLEND X technology UNMATCHED SPEED2 The only solution with patented square-fiber technology enabling the largest spot size and optimal coverage ENHANCED PATIENT COMFORT Dual cooling and integrated plume evacuation OPTIMIZED CLINIC EFFICIENCY Clinically validated presets and smart system analytics VASCULAR OFFERING Dedicated vascular kit and presets as well as other indications Next Generation Hair Removal The SPLENDOR X device allows for customizable laser hair removal and skin treatments across various skin tones, including dark or tanned skin.3 Suitable for both men and women, it effectively treats a wide range of hair removal needs and skin concerns, such as wrinkle reduction, vascular lesions, and pigmented lesions. DOWNLOAD CLINICAL EVIDENCE Blend X Technology The only FDA cleared simultaneous dual laser emission of Alexandrite (755nm) and Nd:YAG (1064nm) wavelengths, can be adjusted and synchronized, enabling tailored treatments. Dual Cooling System (DCS) Minimal pain and burn prevention with Cryo-Touch and Cryo-Air, delivering cold air precisely over the laser treatment area to remove heat from target tissues. patented square spot technology 37% larger coverage vs leading competitors5, optimal treatment coverage with no overlaps or missed spots and largest spot size powered by patented Square-fiber with Variety of sizes (up to 27x27mm). Integrated Plume Evacuator Built–in plume (smoke4) evacuator and HEPA filter provide a safer environment with less smoke and smell to ensure the well-being of both the patient and treatment provider. Energy Check Port5 Consistent energy delivery at all times for optimal patient satisfaction and system uptime. Operational Efficiency5 WiZ connected technology for business, clinical and operational optimization, including remote service and upgrades. Next Generation Hair Removal Solution The SPLENDOR X device allows for customizable laser hair removal and skin treatments across various skin tones, including dark or tanned skin.3 Suitable for both men and women, it effectively treats a wide range of hair removal needs and skin concerns, such as wrinkle reduction, vascular lesions, and pigmented lesions. DOWNLOAD CLINICAL EVIDENCE Blend X Technology The only FDA cleared simultaneous dual laser emission of Alexandrite (755nm) and Nd:YAG (1064nm) wavelengths, can be adjusted and synchronized, enabling tailored treatments. Dual Cooling System (DCS) Minimal pain and burn prevention with Cryo-Touch and Cryo-Air, delivering cold air precisely over the laser treatment area to remove heat from target tissues. patented square spot technology 37% larger coverage vs leading competitors5, optimal treatment coverage with no overlaps or missed spots and largest spot size powered by patented Square-fiber with Variety of sizes (up to 27x27mm). Integrated Plume Evacuator Built–in plume (smoke4) evacuator and HEPA filter provide a safer environment with less smoke and smell to ensure the well-being of both the patient and treatment provider. Energy Check Port5 Consistent energy delivery at all times for optimal patient satisfaction and system uptime. Operational Efficiency5 connected technology for business, clinical and operational optimization, including remote service and upgrades. UNMATCHED RESULTS Laser Hair Removal and Vascular treatments before & after gallery Lumenis In-House Clinic – Left Leg Lumenis In-House Clinic – Leg Courtesy of Prof. Leonardo Marini – Under Nose Lumenis In-House Clinic – Axillae Treatment Lumenis In-House Clinic – Leg Treatment Lumenis In-House Clinic – Chest Treatment Lumenis In-House Clinic – Back Treatment Lumenis In-House Clinic – Chest Treatment Lumenis In-House Clinic – Back Treatment DOWNLOAD BROCHURE Treatments Treatments with The Nd:YAG 1064 and Alexandrite 755 Lasers: Expertly guided with easy-to-use device presets Laser Hair removal Removal of unwanted hair, for stable long term or permanent hair reduction6 and for treatment of Pseudofolliculitis Barbae (PFB). The lasers are indicated on all skin types, such as Fitzpatrick I-VI, including tanned skin. Benign pigmented lesions Treatment of benign pigmented lesions such as, but not limited to, lentigos (age spots), solar lentigos, tattoos and plaques. The laser is indicated for benign pigmented lesions to reduce lesion size, for patients with benign lesions that would potentially benefit from aggressive treatment, and for patients with benign lesions that have not responded to other laser treatments. onychomycosis, warts and podiatric applications Onychomycosis and warts are specific foot-related conditions that can affect the nails and skin of the feet. Dermatological vascular lesions Photocoagulation and hemostasis of benign pigmented and vascular lesions such as, but not limited to, port-wine stains, hemangioma, warts, telangiectasia, rosacea, venus lake, leg veins and spider veins. Coagulation and hemostasis of soft tissue The processes by which lasers are used to stop bleeding and promote tissue repair by precisely targeting blood vessels and tissues during medical or surgical procedures. Lasers are highly effective in achieving hemostasis due to their ability to simultaneously cut and coagulate tissue with minimal damage to surrounding areas. GOLD STANDARD TECHNOLOGY BLEND X TECHNOLOGY Powered by BLEND X technology, SPLENDOR X delivers unmatched hair reduction results for all skin tones and hair types. With dual synchronized wavelengths, it tailors treatments for maximum safety, speed, and effectiveness. Offering superior outcomes and higher patient satisfaction, SPLENDOR X redefines laser hair removal with no compromises. SQUARE SPOT TECHNOLOGY SPLENDOR X sets a new standard with its unique square-shaped laser spot, ensuring precise, consistent coverage without missed areas or overlap risks. Its patented Square-Fiber technology offers unmatched speed and safety, treating large areas 37% faster than competitors with the largest 27mm spot size—saving time and enhancing results for both practitioners and patients. Ultimate Precision & Comfort Experience smooth, fast, and safe treatments with a lightweight ergonomic handpiece, dual cooling for unmatched patient comfort, and a built-in plume evacuator for a safer environment. Interchangeable tips and advanced features ensure versatile, comfortable treatments for both practitioners and patients. DOWNLOAD CLINICAL EVIDENCE LESS TIME. MORE PATIENTS. HIGHER CUSTOMER SATISFACTION “Laser hair removal is what brings most of the patients into the clinic. In my 14-year career I’ve used many different laser machines and for me SPLENDOR X is good because it blends the Alex and the YAG together…which cuts the treatment times, and clinic visits”. Shonda Chase, FNP, MedWeight, Lasers & Wellness Centers, Irvine CA “What I like about the SPLENDOR X is the speed, you don’t have to overlap nearly as much, you avoid hot spots, you avoid having to retreat an area… We are able to treat any skin types from I-VI and patients who are tanned…” Alma, RN, MedWeight, Lasers & Wellness Centers, Irvine CA Close Close Close GET IN TOUCH Have a question? Contact a representative 1 Lumenis data on file (Doc: 1019230) 2 When treating average back compared to the leading competitors (26mm round spot) 3 Not deep suntan, recent suntan, sunburn or artificially tanned skin. 4 J. A. de Boer A, Fransen F, R. Bloemen P, A. Meesters A, A. de Rie M, Wolkerstorfer A. Ultrafine particle concentrations during laser hair removal: Effectiveness of smoke evacuators. Lasers Surg Med. 2021;1–7. https://doi.org/10.1002/lsm.23465 5 Features availability depends on regional regulations. 6 Permanent hair reduction is defined as the long-term, stable reduction in the number of hairs regrowing when measured at 6, 9, and 12 months after the completion of a treatment regime. For safety information and instruction for use, please refer to the User Manual and Treatment Guidelines provided with your SPLENDOR X device. PB-00087550 Rev A #### SPLENDOR X Clinical Webinar SPLENDOR X Clinical Webinar Publish Date: Jul 2, 2020 Length: 43 Minutes Don’t take our word for it! Learn from the experts what makes SPLENDOR X laser hair removal a game changer. Tammy Haddad Experienced Senior Sales Manager with a demonstrated history of working in the medical device industry. Sandra Woods Experienced Clinical Director with a demonstrated history of working in the hospital & health care industry. PB-00016470 A #### SPLENDOR X Introduces BLEND-X Technology SPLENDOR X Introduces BLEND-X Technology Publish Date: Jul 8, 2020 Length: 60 Minutes In this webinar Dr. Chapas and Dr. Kim discuss how to best use SPLENDOR X and its differentiating BLEND-X technology Anne Chapas, MD Medical Director, Union Square Laser Dermatology David Kim, MD M.S. Dr. David Kim is a double board-certified, Harvard-trained pain management physician and anesthesiologist. PB-00017940 A #### Stellar M22 THE EXPERT TOOL TO ELEVATE YOUR PRACTICE Featuring XPL technology developed by the inventors of IPL DOWNLOAD BROCHURE AI-generated video for illustrative purposes Close DOWNLOAD BROCHUREAbout Stellar M22TreatmentsTechnologiesClinical EvidenceDownload Brochure ONE PLATFORM FOR YOUR PATIENTS’ NEEDS From the company that invented the original IPL system, the Stellar M22™ is the latest in multi-platform innovations. Unleash your practice’s X-Factor with breakthrough features to deliver patients natural-looking and visible results in just one treatment. CLINICALLY VALIDATED, GLOBALLY TRUSTED Proven by 150+ clinical studies and 30,000 systems sold worldwide. OFFER MORE TREATMENTS TO MORE PATIENTS Treat 30+ indications with four different laser and light-based technologies all in one compact system. BUILT-IN PROTOCOLS, DESIGNED BY EXPERTS 850+ science-based presets for safe, consistent results and confident delegation MADE BY LUMENIS, A BRAND YOU CAN TRUST 60 years of expertise delivering clinical optimization and superior utility ADVANCED INSIGHTS FOR COMPETITIVE EDGE Built-in connectivity boosts efficiency, and simplifies service with remote support DISCOVER THE STELLAR M22 SKIN TREATMENTS The Stellar M22 machine enables you to treat more patients and is designed to treat the most in-demand energy-based treatments. Discover the infinite possibilities with the Stellar M22 Skin Rejuvenation Stimulates new collagen and elastin fibers for visible skin rejuvenation, improving texture, tone, and the appearance of fine lines Acne Scars Smooths and resurfaces skin to reduce scar appearance by stimulation creation of collagen and elastin fibers Stretch Marks Improves skin texture and elasticity in affected areas by stimulation creation of collagen and elastin fibers Photofractional Combines XPL + ResurFX for both pigment and texture correction Pigmented Lesions Breaks down pigment safely across all skin types Sun Damage/ Pigmentation Breaks down excess melanin by heating it to fade sunspots and even skin tone Rosacea Targets blood vessels to reduce redness and visible capillaries by targeting the hemoglobin in the blood vessels Age Spots Lightens brown spots caused by aging & sun exposure by absorption of the melanin pigment at the dermis & epidermis until it's fragmented & clears Acne Reduces inflammation and bacteria to clear active acne while ``shrinking`` the sebaceous glands and reduces forming acne Hair removal Targets hair follicles to reduce unwanted hair growth Skin Toning Evens out skin tone and boosts radiance by combining reducing of the pigmentation and improving the vascularity of the skin Dark Tattoo Removal Breaks down dark tattoo ink for gradual fading by the Q-Switch's photo-acoustic effect Deep Vascular Lesions Collapses deeper blood vessels to reduce discoloration Leg Veins Treats visible spider veins and small varicose veins on the legs DOWNLOAD BROCHURE *Refer to user manual for region-specific approved applications FOUR TECHNOLOGIES IN ONE DEVICE XPL – Expert pulse light One versatile handpiece with 8 expert filters and 3 lightguides treats multiple conditions and skin types. Sub-Pulsing technology (MSP™) delivers optimized energy in rapid micropulses for safer, more comfortable treatments across all skin types. The new Glide Mode enables high-speed treatment with up to 4Hz repetition for efficient coverage of larger areas. LEARN MORE Courtesy of Melanie D. Palm, MD Courtesy of Gilly Munavalli, MD Courtesy of Matteo Tretti Clementoni, MD Courtesy of Bill Chehao Hsu, MD LEARN MORE ResurFX® Reverse Aging Without Breaking the Surface Dermis-level fractional resurfacing for transformative collagen renewal, smoother skin, and lasting results, with minimal downtime. Patented CoolScan™ algorithm distributes micro-beams in non-sequential patterns to enhance results, speed recovery, and reduce discomfort. LEARN MORE Courtesy of Olga Yarish, MD Courtesy of Matteo Tretti Clementoni, MD Courtesy of Matteo Tretti Clementoni, MD Courtesy of Olga Yarish, MD LEARN MORE MULTI-SPOT™ ND:YAG Treat the Full Vascular Range on All Skin Types With One Platform Confidently target deeper, larger lesions, complementing XPL’s superficial coverage. Sub-pulsing technology for gradual, uniform vessel heating with inter-pulse cooling. LEARN MORE In House Clinic In House Clinic Courtesy of Jose Miguel Montero Garcia, MD In House Clinic LEARN MORE Q-SWITCHED ND:YAG Pigment Clearing and Tattoo Removal For
All Skin Types Clear deep and superficial pigments and dark tattoos with nanosecond photo-acoustic precision, high peak power, and proven epidermal safety. LEARN MORE In House Clinic In House Clinic In House Clinic Courtesy of Panta Rouhani Schaffer, MD LEARN MORE CLINICAL EVIDENCE The Stellar M22 is supported by 150+ clinical studies and trusted by 30,000+ installations worldwide. Our commitment to evidence-based medicine ensures reliable, reproducible results. Efficacy and safety of Intense Pulsed Light in the treatment of inflammatory acne vulgaris with a novel filter. By: Sunyi Chen; Yan Wang; Jie Ren; Baishuang Yue; Guanyin Lai; Juan Du Intense pulsed light (IPL) has become a well-recognized method in treating acne vulgaris, one of the most common skin conditions. One month after treatment, 75% of the participants showed excellent or good results from IPL treatments. Inflammatory lesions dramatically decreased, and the severity improved significantly. The IPL filter offers effective treatment with minimal reversible
side effects. LEARN MORE Facial telangiectasias: Our experience in treatment with IPL By: Matteo Tretti Clementoni; Patrizia Gilardino; Gabriele F Muti; Massimo Signorini; Antonio Pistorale; Paolo G Morselli; Carlo Cavina This study examined the treatment of vascular lesions (Facial teleangectasias) using the intense pulsed light (IPL) source. IPL was found to be an effective alternative or supplement to existing laser devices to treat this condition. Eighty-seven percent of patients presented 75% to 100% clearance of the lesions. LEARN MORE Hair removal using a new intense pulsed light source in Chinese patients By: Yu-Miao Feng; Zhan-Chao Zhou; Michael H Gold This study found that IPL has short-term efficacy for removing unwanted hair without significant complications. Using Lumenis One IPL in Chinese women reduced unwanted upper lip hair by 49.9% after one session, 79.3% after three sessions, and 83.3% after four sessions. LEARN MORE Clinical analysis of port wine stains treated by intense pulsed light By: Guang Li, Tong Lin, Qiuju Wu, Zhanchao Zhou, Michael H Gold Port wine stains (PWS) are formed by dilation and malformation of dermal capillaries without endothelium proliferation. Despite the improvements in lasers and light therapy for PWS therapy in the past 10 years, the ‘cure’ rate is only about 10%. In this study, 72 patients with PWS were treated with an IPL with synchronous cooling. Most of the PWS lesions faded significantly and the response rate in this series was 76.4%. Patients resistant to other forms of therapy also showed good clinical results. LEARN MORE Sequential facial skin rejuvenation with intense pulsed light and non-ablative fractionated laser resurfacing in Fitzpatrick skin type II-IV patients: A prospective multicenter analysis By: J Matthew Knight; Gerd Kautz This study undertook a non-conventional treatment approach to skin aging combining non-ablative fractionated laser (NAFL) with intense pulsed light (IPL) therapies to improve skin tone and collagen deposition. This study evaluated the combined effect of same-day, sequential IPL-NAFL treatment and found gradual improvement on wrinkles over the treatment period, with about 90% of treated patients exhibiting improved appearance after 6 months. LEARN MORE Treatment of facial photodamage and rhytides using a novel 1,565 nm non-ablative fractional erbium-doped fiber laser By: Daniel P Friedmann; Julia E Tzu; Arielle N B Kauvar; Mitchel P Goldman Non-ablative fractional lasers (NAFL) generate microscopic non-contiguous columns of thermal injury in the dermis to remodel collagen. After receiving three treatments at 4- or 5-week intervals, patients showed a statistically significant decrease in Fitzpatrick-Goldman Wrinkle and Elastosis Score (FGWES) after both 3 and 6 months. Most patients were satisfied after 3 months and did not report adverse events. LEARN MORE Evaluation of a non-ablative, fractional 1565 nm laser for the improvement of striae distensae albae Telangiectasias and Reticular Veins (Brief Communication/ Case Report) By: A Guertler; M Reinholz; S Steckmeier; G G Gauglitz Striae distensae (SD) represent therapeutically challenging forms of dermal atrophic scarring. Treatments include topical ointments, medical needling and various energy-based devices.The use of a fractional non-ablative 1565 nm laser represents a safe way to treat SD albae by significantly reducing atrophic lesions and skin irregularities. Six months after the treatment, patients reported 68% improvement as measured by Dermatology Life Quality Index (DLQI). LEARN MORE Long-term results with a multiple synchronized-pulse 1064 nm Nd:YAG laser for the treatment of leg venulectasias and reticular veins By: N S Sadick The long-pulsed Nd:YAG (1064 nm) laser has been shown to be effective in the treatment of blue venulectasias and reticular veins, with 64% of patients achieving 75% or more clearing of vessels after 3 sessions and feeling satisfied with the results. LEARN MORE Treatment of venous infraorbital dark circles using a long-pulsed 1,064-nm neodymium-doped yttrium aluminum garnet laser By: Gang Ma; Xiao-Xi Lin; Xiao-Jie Hu; Yun-Bo Jin; Hui Chen Infraorbital dark circles are a common cosmetic problem with multiple causative factors and limited treatment options. This study used a long-pulsed 1064 nm Nd:YAG laser therapy to reduce the appearance of the veins. Patients reported complete clearance and satisfaction after 12 months. The treatment was found to be effective and safe in removing visible prominent veins. LEARN MORE A novel 1565 nm non-ablative fractional device for stretch marks: A preliminary report By: Matteo Tretti Clementoni; Rosalia Lavagno Striae Distensae (SD) is a very common dermatologic condition that causes stretch marks. Using a novel non-ablative fractional 1565 nm laser showed improvements in pigmentation, volume, and texture appearance in all patients tested; notably, 91% reported improvement in the depressions and 83% said coloring improved. Patients shared that the pain was tolerable and were satisfied with the treatment. LEARN MORE EXPAND YOUR PRACTICE WITH STELLAR M22 AI-generated image for illustrative purposes PB-00012290 Rev c #### Stellar M22 Optimized Design Optimized Success Stellar M22 Optimized Design Optimized Success Publish Date: March 01, 2021 Length: 7 Minutes Want to learn how the Stellar M22 can drive your practice forward? With four technologies in one platform, Stellar M22 can treat over 30 skin conditions and hair removal. In this webinar leading experts share their experience with the new ergonomic IPL handpiece, specially designed with practitioners in mind, and elaborate on the Stellar M22’s new design and simplicity of use. DR. E. Victor Ross DR. Ross: E. Victor Ross, MD ,Dermatologic Surgeon, board-certified in Dermatology, Director of Laser and Cosmetic Dermatology Scripps Clinic, CA, US Dr. Mitchel P. Goldman DR.Goldman: Mitchel P. Goldman – MD, dermatologic surgeon, Diplomate of the American Board of Cosmetic Surgery, founder and Medical Director of Cosmetic Laser Dermatology, CA, US PB-00018820 Rev A #### Take the High Speed Challenge LightSheer DUET Overview Treatment & Testimonials Configurations Patients Benefit Practice Benefits Take the High Speed Challenge High Speed Lightsheer Duet vs 755nm Alexandrite Take The High Speed Challenge – Videos Videos below: LightSheer DUET – Comparison on a man’s back LightSheer DUET – Comparison on a woman’s legs Duet comparison woman’s lower legs, axilla Take The High Speed Challenge [ytp_video source=”aFD0ZCAYSls,foBAaxYYLfk,SQ5U0OXLrpo”] Learn More LightSheer DUET Patient BrochureLightSheer DUET Physician Brochure PB-1049670 Rev C GET MORE INFO × #### Tattoo Removal About Tattoo Removal Tattoo inks are made of solid colored particles, which can be targeted and eliminated by dedicated lasers in the similar manner as pigmented lesions. Different tattoos might require different types of laser in order to remove them, depending on the type of ink, the color, and the depth of the tattoo. Q-Switch lasers release high-powered pulses of extremely short duration. The intense and rapid heating induced by light absorption leads to a photo-thermal effect. As the chromophore is heated, it undergoes sudden thermal expansion generating shock waves audible as a popping sound with each laser pulse. This photo-acoustic effect generates forces that allow fragmenting tattoo pigment particles. The pigment treated this way gradually becomes shallower over time until it fades away. The peripheral tissues remain unaltered making the treatment selective and safe. The Lumenis Solution The Lumenis Q-Switched Nd:YAG is very effective for the removal of dark tattoos and the safest for skin of color. Using a top-hat beam profile ensures control of homogeneous energy delivery and maximum safety without hot-spots nor any risk of side effects or complication for the patient. The versatility of 5 spot sizes allows to use the ideal parameters for the clearance of dark tattoos. Advantages For Physicians Optimal treatment safety and efficacy using Top-Hat beam profile, which ensures homogeneous distribution of energy. The affordable upgrade of the Q-Switched Nd:YAG handpiece for the M22™ Multi-Application Platform, enables adding more versatility and advanced combination treatment options. Preset treatment parameters ensure ease of use and a fast learning curve. Related Products The Lumenis Q-Switched Nd:YAG systems, is available in the M22™ Multi-Application platform M22™ For Fractional Non-Ablative Skin Resurfacing. PB-2007297   GET MORE INFO × #### Technology Better Technology For Better Patient Care Lumenis® is a global leader in medical lasers and light-based technologies and continuously develops state-of-the-art products that redefine treatment performance. The primary principal behind lasers and light based technologies is selective photothermolysis (abbreviated SPTL) which is the ability to target specific chromophores (light-reactive elements) such as blood, melanin, or water using a specific wavelength or color of laser or light source.  In hair removal treatments, for example, the laser targets the hair follicle (melanin chromophore) while leaving the surrounding skin (water chromophore) and blood vessels (hemoglobin chromophore) unharmed. Technology IPL (Intense Pulsed Light) Lumenis offers a unique IPL solution with optimal efficacy, safety and ease of use. Optimal Pulse Technology (OPT™) gives users the ability to control the pulse shape. It provides reproducible results as well as gentler, more comfortable treatments. Universal handpiece with nine ExpertFilters™, enables treatment of a myriad of conditions with a single, versatile and cost effective handpiece. Ablative Lasers (CO2) Lumenis® offers two state-of-the-art CO2 laser devices: the UltraPulse® and the AcuPulse™. Both use high-power-short duration pulse technologies that maximize the treatment and patient comfort, as well as minimize downtime. Lumenis’ CO2 laser devices optimally treat a broad range of conditions from gentle superficial treatments to deep contracted scar revision. Click to View Diode Lasers Lumenis’ LightSheer diode technology efficacy has been proven in extensive clinical trials and long-term clinical practice. The LightSheer uses high-power diodes that delivers high fluence in two wavelengths (805nm and 1060nm). This is combined with user-select pulse duration, effective contact cooling or vacuum assisted technology. Click to View Long Pulsed Nd:YAG Lumenis® long pulsed Nd:YAG laser is available as part of the M22™ multi-application platform. By utilizing the same power supply for both the IPL and the Nd:YAG laser, Lumenis is able to provide more treatment versatility in a single platform. Multiple Sequential Pulsing (MSP™) is available in both the Nd:YAG and the IPL modules on the M22™ platform. MSP™ allows for cooling between a sequence of pulses which protects the epidermis and allows for safe use of higher fluence. The MSP™ offers safe treatment of all skin types, including dark skin, and significantly reduces side-effects in treatment of vascular lesions. Click to View Non-Ablative Lasers The ResurFX™ laser is the only true fractional non- ablative technology. Unlike other fractional technologies, ResurFX™ only needs one pass to be effective, saving time and protecting the patient’s skin. ResurFX™ uses a 1565nm fiber laser and an advanced scanner, which enables the user to choose from more than 600 combinations of shape, size and density options, for optimal treatment results. The ResurFX™ has state-of-the-art CoolScan™ scanner for non-sequential scanning. The CoolScan™ scanner uses a proprietary algorithm that controls the placement of each fractional spot. This protects the tissue from heat accumulation and overheating. Moreover, the ResurFX™ handpiece is equipped with continuous contact cooling to increase patient comfort during treatment. Click to View RF MICRO-NEEDLING Lumenis offers precise Micro-heating of focal points with VoluDerm™ RF-assisted thermal ultra-thin electrodes for skin regeneration. Using the thinnest electrodes in the market (ø 0.15 mm), this smooth RF-assisted ablation means reduced downtime – without compromising efficacy. Suitable for all skin types. Efficacy is improved when combined with TriPollar® RF technology in Lumenis’ clinically proven and tested combination therapy for the face: Legend M2TM. Click to View RADIO-FREQUENCY Lumenis offers TriPollar® RF: it safely delivers focused RF energy for collagen remodeling and wrinkle treatment by using low 1MHz frequency. Its controlled high density energy field forces the electrical current deep into the skin, with effective heating due to the electrode configuration and rotating polarity algorithm. Click to View PB-1004643 GET MORE INFO × #### Telehealth The New Normal Telehealth The New Normal Publish Date: Jun 15, 2020 Length: 58 Minutes Learn more on the latest trend, Telehealth, and how it has affected clinics worldwide since the COVID-19 pandemic. Alissa Lamoureux President at Skin Dermatology Company #### Ten Ways to Market Your New Aesthetic Offering Ten Ways to Market Your New Aesthetic Offering Publish Date: Feb 14, 2021 Meet the demand of the ever changing digital marketing place and grow your practice by implementing a few simple tactics that make all the difference. PB-00023260 Rev A #### The Aesthetic Provider’s Reopening Checklist The Aesthetic Provider’s Reopening Checklist Publish Date: July 1 2020 Post COVID19 your reopening strategy must acknowledge patient’s varying concerns and strive to minimize them. Every aspect of your strategy must assure patients that it’s safe to visit you for treatment. This guide is intended to help you increase client confidence and get back to doing what you do best – treating patients. PB-00000000 Rev A #### The Lumenis M22 laser was featured as the “best dark spot remover”on SheFinds.com The Lumenis M22 laser was featured as the “best dark spot remover”on SheFinds.com SheFinds June 1, 2018 View More #### The Million Dollar Hair Removal business The Million Dollar Hair Removal business Publish Date: July 1 2020 This ebook focuses on one of the most accepted and sought-after treatments in the non-surgical category – laser hair removal. It offers marketing tactics that can help you grow your hair removal business to unprecedented levels. PB-00004830 Rev A #### The Nonsurgical Procedure Your Friends Are Getting, but Aren’t Telling You The Nonsurgical Procedure Your Friends Are Getting, but Aren’t Telling You NewBeauty June 12, 2017 View More #### The technology behind the DESIRE Lightsheer DESIRE Overview The Technology How It Works Patients Benefit Practice Benefits Clinical Results White Papers The Technology Behind The DESIRE Great clinical results begin with the LightSheer DESIRE 805 nm diode laser empowered by two advanced technologies Vacuum Assisted High-Speed Integrated Technology A large 22×35 mm spot size enables the use of low-fluence and with a unique mechanism for pain reduction provides effective, fast and comfortable treatment. ChillTip™ Technology – Integrated contact cooling provides epidermal protection for treatment areas requiring precision and higher fluence. 3 Handpieces For Treating All Body Areas The HS has a HIT 22x35mm spot size enabling use of low-fluence and a unique mechanism of pain reduction, providing, fast and comfortable treatment. The XC has a Sapphire ChillTip spot size of 12x12mm, providing a solution for large and small areas requiring higher fluence levels The ET has a Sapphire ChillTip spot size of 9x9mm designed to treat small areas that require maximum precision and higher fluence. Cutting Edge Technologies Advanced Graphical User InterfaceIndications For UseTechnical SpecificationsAdvanced Graphical User Interface Advanced Graphical User Interface Intuitive presets for fast learning curve and easy treatment delegation. Indications For Use Hair removal, permanent hair reduction, and the treatment for Pseudo Folliculitis Barbae (PFB). Treatment of vascular lesions, including angiomas, hemangiomas, telangiectasia, leg veins and other benign vascular lesions. Treatment of benign pigmented lesions. Technical Specifications Platform LightSheer DESIRE HandPiece HS XC ET Technical Specifications: Laser Type AIGaAs Diode Arrays AIGaAs Diode Arrays AIGaAs Diode Arrays Wavelength 805 nm (nominal) 805 nm (nominal) 805 nm (nominal) Spot Size 22 mm X 35 mm 12 mm X 15 mm 9 mm X 9 mm Repetition Rate Up to 3 Hz Up to 3 Hz Up to 3 Hz Pulse repetition 1-3 Pulse 1 Pulse 1 Pulse Fluence 4.5-12 J/cm2 10-40 J/cm2 10-100 J/cm2 Pulse Width(OptiPulse) 30-400ms 5-400 ms 5-400 ms Peak Power 2310 W 1920 W 1620 W Comfort Management Vacuum assist (up to 18 in Hg) Chilltip contact cooling (5°C) Preset Parameters Yes Yes Platform Specifications : Electrical 100-240 VAC +/- 10% , 12 A max. | 50/60 Hz. | Single-phase grounded outlet Weight 32 kg(70.5 lbs.) Dimensions (WxDxH) 51 x 60 x 42 cm; (20.1 x 23.6 x 16.55 in) PB-00005640 Rev A × GET MORE INFO #### The Technology Behind the DESIRE Light LightSheer DESIRE Light Overview The Technology Behind the DESIRE Light How Will Your Patients Benefit Practice Benefits The Technology Behind The LightSheer DESIRE Light LightSheer® DESIRE™ Light uses a 805nm diode wavelength, an industry standard for permanent hair reduction for all skin types. The high fluence ChillTip™ technology, a cooled sapphire that chills the skin before and during treatment, offers treatment efficacy and patient comfort. Advanced Graphical User Interface Intuitive presets for fast learning curve and easy treatment delegation. Indications For Use Hair removal, permanent hair reduction, and the treatment for Pseudofolliculitis Barbae (PFB). Treatment of vascular lesions, including angiomas, hemangiomas, telangiectasia, leg veins and other benign vascular lesions. Treatment of benign pigmented lesions. How ChillTip™ Works Skin is cooled before and during treatment. Skin is compressed. Laser beam applied to skin and target is damaged Advantages Of ChillTip™ Technology Safety: epidermal protection is achieved through ChillTip contact cooling Comfort: by continuously cooling the skin, pain and discomfort are significantly reduced. Efficacy: Compression of the skin rotates follicle closer to the surface, blenches blood vessels and reduces competing chromophores. High fluence enables treatment of areas requiring precision as well as thin, light hair. Technical Specifications Platform LightSheer@ DESIRETM Light Handpiece XC ET Technical Specifications: Laser Type AIGaAs Diode Arrays AIGaAs Diode Arrays Wavelength 805 nm (nominal) 805 nm (nominal) Spot Size 12 mm X 12 mm 9 mm X 9 mm Repetition Rate Up to 3 Hz Up to 3 Hz Pulse repetition 1 Pulse 1 Pulse Fluence 10-40 J/cm2 10-100 J/cm2 Pulse Width 5-400ms 5-400ms Peak Power 1920 W 1620 W Comfort Management ChillTip contact cooling (5oC) Preset Parameters Yes On-Site Service Yes; Replaceable handpiece Platform Specifications : Electrical 100-240 VAC +/- 10%, 12 A max.| 50160 Hz. | Single-phase grounded outlet Dimensions (WxDxH) 51 x 60 x 42 cm; (20.1 x 23.6 x 16.55 in) Learn More LightSheer DESIRE Light Brochure PB-2002616 REV C GET MORE INFO × #### This New Laser Offers a Faster and Safer Way to Eliminate Dark Spots This New Laser Offers a Faster and Safer Way to Eliminate Dark Spots NEWBEAUTY June 1, 2018 View More #### Treating Rosacea with M22 Treating Rosacea with M22 Publish Date: Dec 15, 2019 Length: 24 Minutes In this webinar Dr. Jennifer Deaver Peterson discusses: The main features and advantages of M22 What is Rosacea The duration of Rosacea treatments Dr. Jennifer Deaver Peterson Cosmetic Dermatologist at The Pearl Dermatology PB-2012388 Rev A #### Treatment & Testimonials LightSheer DUET Overview Treatment & Testimonials Configurations Patients Benefit Practice Benefits Take the High Speed Challenge A Collection Of Testimonials Lightsheer Duet video – DR Daniel Friedman from Lumenis on Vimeo. Testimonials “The fact that new technologies often choose LightSheer as the basis for comparison emphasizes that it’s such a trusted and popular device.” Shlomit Halachmi, M.D., Ph.D. “I had my back treated with the new High Speed system in 15 minutes. Normally, this would take about an hour to do, so the time savings alone is significant. … i think it’s a winner.” Mitch Goldman, MD “Patients will love it. Nurses will love it…I recently treated a large gentleman’s back and in the 20 minutes it took to threat him, he was practically falling asleep – the treatment was that comfortable.” Christine Dierickx, MD “I’ve used several laser hair removal devices in my practice…LightSheer remains the ‘gold standard’ because it is the most effective for targeting unwanted hair. Effectiveness, long lasting results, satisfied patients…all add up to repeat business and positive referrals.” Beth Haney, NP “The new LightSheer DUET is extremely well tolerated by patients. My hair removal nurse likes the single pulsing for treatment speed and patient comfort. My expectation is the LightSher diode will perform better as it penetrates deeper…This system is definitely worth pursuing.” Girsh Munavalli, MD “The science behind the HS handpiece allows for successful treatment at a lower fluence, thereby conferring hair removal efficacy similar to that of other lasers, but with much lower levels of discomfort during treatment.” Omar A. Ibrahimi, M.D., Ph.D. Videos PB-1049670 Rev C GET MORE INFO × #### Treatments AESTHETIC TREATMENTS Ablative Skin Resurfacing With Lumenis’ CO2 ablative technologies skin damage and tone are significantly improved with minimal downtime. This is due to their unique pulse technologies and tailored treatment modes. The Lumenis™ CO2 ablative technologies enable a high rate of improvement for skin damage and skin tone with minimal downtime. This is due to their unique pulse technologies and tailored treatment modes. The ablative technologies are available in the UltraPulse® and AcuPulse™ products. More about Ablative Skin Resurfacing The Treatment is available with: AcuPulse   UltraPulse  Acne Scar Treatment The Lumenis Solution Lumenis offers a range of ablative and non-ablative resurfacing solutions tailored to each practice and each patient’s needs and preferences. Lumenis CO2 ablative resurfacing: Lumenis’ ablative technologies dramatically decrease scars, even very deep ones, as well as repair damaged skin and improve skin tone. Treatment is free of complications and requires minimized downtime due to the unique pulse technologies and tailored treatment modes. The ablative technologies are available in the UltraPulse® and AcuPulse™ products. More about Acne Scar Treatment The Treatment is available with: AcuPulse   UltraPulse  Skin Toning The Lumenis Q-Switched Nd:YAG was developed to enable skin toning, by treatment of pigmented lesions, using a large  and non-disposable tip of 6mm. Using a top-hat beam profile ensures control of homogeneous energy delivery and maximum safety without hot-spots nor any risk of side effects or complication for the patient. More about Skin Toning Blepharoplasty Lumenis offers a complete laser blepharoplasty solution that combines an incisional solution with complementary eyelid resurfacing. The AcuPulse™ as well as the UltraPulse® systems have an incisional handpiece that provides excellent surgical precision during treatment.  With laser assisted incisions, bleeding during the procedure as well as post-surgery bruising are reduced.  The systems are also equipped with fractional ablative skin resurfacing modes that offer excellent skin rejuvenation results in the surrounding periorbital areas. More about Blepharoplasty Tattoo Removal The Lumenis Q-Switched Nd:YAG is very effective for the removal of dark tattoos and the safest for skin of color. Using a top-hat beam profile ensures control of homogeneous energy delivery and maximum safety without hot-spots nor any risk of side effects or complication for the patient. The versatility of 5 spot sizes allows to use the ideal parameters for the clearance of dark tattoos. More about Tattoo Removal Vascular & Leg Vein Treatment The Lumenis IPL with OPT™ (Optimal Pulse Technology) is designed to treat vascular lesions up to 1.5 mm deep and up to 1 mm in diameter. The Multi-Spot Nd:YAG with Multiple Sequential Pulsing (MSP) effectively treats vascular lesions up to 4.5 mm deep and with a diameter of up to 4 mm,  such as leg veins. The Multi-Spot Nd:YAG treats all skin types safely and effectively. More about Vascular & Leg Vein Treatment Laser Hair Removal The Lumenis’ LightSheer® systems ( QUATTRO™, and DUET™ ) uses 805nm diode laser technology that has become the well-established method for permanent hair reduction.  The LightSheer technology by Lumenis has been validated in numerous clinical studies and peer reviewed articles. Our customers benefit from the LightSheer features and enjoy high patient satisfaction. More about Laser Hair Removal This Treatment is available with: QUATTRO™   DUET™ Non-Ablative Skin Resurfacing The Lumenis ResurFX™ is the only true Fractional Non-Ablative solution on the market.  It uses an advanced scanner technology called CoolScan™. CoolScan uses a sophisticated, patent-pending algorithm for non-sequential scanning which ensures that the energy delivery is precise and homogenous, so the required coverage is achieved in only one pass. The ResurFX™ module is available as part of the M22 multi-application platform. More about Non-Ablative Skin Resurfacing Pigmentation Pigmented lesions are hypermelanocytic areas typically induced by sun exposure, the natural aging process or congenital factors. Pigmented lesions vary widely in size, shape and depth. They can be either raised or flat and are usually a cosmetic rather than a medical concern. Intense Pulsed Light (IPL) which targets the melanin is effective in treating benign lesions and clearing them. More about Pigmentation  Rosacea The Lumenis IPL with OPT™ is considered the industry’s ‘Gold Standard’ for treatment of vascular lesions and its efficacy has been proven in over 80 peer reviewed papers (IPL bibliography of studies and peer reviewed articles). The IPL procedure removes facial superficial vessels and as a result dramatically decreases or completely eliminates facial redness. The vascular components of Rosacea can vary from flushing to telangiectasia and can have different densities and depths. With a choice of multiple vascular cut-off filters and unique pulse sequencing, Lumenis’ IPL with OPT can coagulate each sub-type of capillaries, reducing the redness and simultaneously triggering neocollagenesis which limits the reccurrence of the condition. More about Rosacea Scar Revision Lumenis offers a range of ablative and non-ablative fractional resurfacing solutions to treat different degrees of scar. The SCAAR FX™ mode available as part of the UltraPulse® system, allows for advanced treatment of a variety of severely damaged skin lesions which require synergistic coagulation and ablation for advanced resurfacing (SCAAR). By delivering more powerful pulses than any other laser in its category, the UltraPulse reaches an unparalleled depth of 4mm in a single pulse, enabling physicians to treat and rehabilitate scars more effectively. With a small beam diameter and shortest pulse width in the industry, the UltraPulse delivers bursts of high energy at low densities that are ideal for a wide range of scar treatments. SCAAR FX uses a unique ablation/coagulation ratio to substantially improve the structure of deep contracted lesions by restoring more normal collagen deposition. This maximizes results, minimizes thermal damage and reduces treatment time More about Scar Revision Photorejuvenation As a pioneer in aesthetic medicine, Lumenis developed the first IPL technology and the first Photorejuvenation platform. The Company has established itself as long-standing leader in the field due to its vast knowledge and expertise in the market. The Lumenis IPL with OPT™ is considered the ‘Gold Standard’ in photorejuvenation treatments and its efficacy has been proven in over 80 peer reviewed papers (IPL bibliography of studies and peer reviewed articles). More about Photorejuvenation Legend M2TM Lumenis Legend M2TM is a clinically proven and tested combination therapy for ablation and skin resurfacing and to treat wrinkles and rhytides. It is a combination treatment for greater efficacy, with TriPollar® RF and VoluDerm™ technologies targeting different skin layers individually. More about skin aging treatment LEARN MORE ABOUT OUR AESTHETIC TREATMENTS GO! RELATED PRODUCTS Stellar M22™ SPLENDOR X NuEra™ Tight LightSheer® QUATTRO Legend Pro + TriLift Stellar M22™ UltraPulse Alpha SPLENDOR X NuEra™ Tight LightSheer® QUATTRO Legend Pro™ GET MORE INFO × #### Treatments to make you look like a supermodel Treatments to make you look like a supermodel TATLER March 26, 2018 View More #### triLift FIGHT THE SAG, LOSE THE BAGS TONE YOUR GLAMOUR FACIAL MUSCLES DOWNLOAD KIT Glamour Facial Muscles What is triLift? Technology Before & After Celebrity Endorsements How it Works? Clinically Validated Providers Say Media GLAMOUR FACIAL MUSCLESTHE KEY TO A TONED AND LIFTED LOOK Glamour Facial Muscles refer to the muscle groups responsible for our toned and defined look. Using Dynamic Muscle Stimulation technology, triLift tones the cheek, jowl line and under-eye areas to enhance the underlying facial structure. With this customizable aesthetic treatment your patients will enjoy a naturally lifted look. WHAT IS ? THE NEW FACIAL MUSCLE STIMULATION TREATMENT TONE THE GLAMOUR FACIAL MUSCLES Address the underlying structure of the face by toning the Glamour Facial Muscles, and offer your patients a naturally, lifted look NATURALLY LIFTED LOOK, NO INJECTIONS OR SURGERY Achieve naturally lifted look, without surgery or injections, by activating the triple elements – facial muscles, skin, and structure. SEIZE THE BUSINESS OPPORTUNITY Untapped market. Set yourself apart with the new facial muscle stimulation treatment, with the 3-in-1 device to reach both the muscles and the skin. EASILY INTEGRATED INTO YOUR PRACTICE WORKFLOW Highly delegable and can be operated by various practitioners in your clinic ADDRESS ALL 3 ELEMENTS IN ONE TREATMENT Address the Glamour Facial Muscles, skin and volume in one treatment DMSt Dynamic Muscle Stimulation technology works by activating different facial muscles with electrical stimulation for a well-defined, toned, and lifted look. TriPollar® RF Focused RF Thickens and strengthens the dermal layer to treat facial wrinkles, Regenerates collagen and elastin with clinically proven long-lasting results. RFMN Smooth RF assisted Microneedling increases the natural volume, tightens, and smoothes the skin texture while causes 3x more natural production of Hyaluronic Acid1 DOWNLOAD KIT WHAT THE PROVIDERS ARE SAYING Dr. James Chelnis Ophthalmic Plastic & Reconstructive Surgeon, triLift Provider Manhattan Face & Eye, New York, NY triLift helps me tend to patients who are interested in natural approaches to aesthetics. Dr. Amy Lewis Dermatologist and Owner Lewis Dermatology New York, US triLift’s technology works beyond skin deep to tone the muscles for a more defined, youthful appearance. Dr. Michael Mirmanesh The Garden medical Spa, triLift Provider This noninvasive, no downtime treatment is a GAME-CHANGER! Julie Davis Hunter Owner, Fleming Island, FL Pura Vida Body & Mind Spa, Inc. In just 5 short weeks we sold 72 packages, nearly paying off our device! Dr. Randolph Taylor Medical Director Rescu Wellness, triLift provider Rescu Wellness, Scarsdale, NY With triLift we are ahead of our competition and definitely see increase in demand. Dr. Elaine Kung Dermatologist and Owner Future Bright Dermatology New York, US We’re proud to be offering a natural solution for a face lift-like effect LIFT THAT SMILE NO INJECTIONS, OR SURGERY triLift naturally tones the facial muscles for a lifted, youthful look. With only a 20-30 minute treatment protocol, triLift has no downtime or pain, and an immediately long-lasting* visible results that improves with each additional treatment session. UN-BELIEVABLE RESULTS JAWLINE CHEEKBONES NASAL-FOLDS LOWER-EYE-LID Courtesy of Lewis Dermatology Courtesy of Travis J. Laverne, PA-C In House Collection In House Collection Courtesy of Pura Vida Body & Mind Spa Courtesy of Rescu Wellness Courtesy of Travis J. Laverne, PA-C Courtesy of Travis J. Laverne, PA-C Courtesy of Pura Vida Body & Mind Spa In House Collection Courtesy of Travis J. Laverne, PA-C In House Collection Courtesy of Pura Vida Body & Mind Spa Courtesy of Lewis Dermatology In House Collection JAWLINE Courtesy of Lewis Dermatology Courtesy of Travis J. Laverne, PA-C In House Collection In House Collection CHEEKBONES Courtesy of Pura Vida Body & Mind Spa Courtesy of Rescu Wellness Courtesy of Travis J. Laverne, PA-C Courtesy of Travis J. Laverne, PA-C NASAL-FOLDS Courtesy of Pura Vida Body & Mind Spa In House Collection Courtesy of Travis J. Laverne, PA-C In House Collection LOWER-EYE-LID Courtesy of Pura Vida Body & Mind Spa Courtesy of Lewis Dermatology In House Collection DOWNLOAD KIT HEAR FROM OUR GLAMOUROUS Christina Hendricks Actress triLift™ Patient triLift targets the Glamour Facial Muscles in your face to give you a lifted look Alyssa Milano Actress, Charmed triLift™ Patient triLift goes beyond just the skin, targeting the root cause of facial aging – it’s all about the muscles! Jennie Garth Actress and Television Personality triLift™ Patient Do you see this face? So toned! My favorite part: No injections or downtime, and the results have already been incredible Colton Underwood Actor and Television Personality triLift™ Patient I just got a triLift treatment; there is no pain. It was very tolerable; I feel good. It felt like I was working my face out and you can tell that my muscles were contracting, and you could almost feel like my face is getting stronger. Teresa Guidice Dancer and Television Personality triLift™ Patient I definitely see my face (is) more lifted. I see my cheekbones are more contoured. I love the way I look and I’m so happy with the results! Peta Murgatroyd Dancer and Television Personality triLift™ Patient I would absolutely recommend triLift to my friends and family. It’s all natural – you’re not sticking things into your face. It’s you and it’s a more youthful you Teddi Mellencamp Television Personality triLift™ Patient Do you see this face? So toned! My favorite part: No injections or downtime, and the results have already been incredible Ashley Iaconnetti Television Personality triLift™ Patient Those instantaneous results are amazing! I was seriously so snatched and so contoured afterwards… my cheek bones feel higher! Jared Haibon Television Personality triLift™ Patient I would say, “no pain, no gain”, but with [triLift], there is no pain. And I will be getting all the gains. Maksim Chmerkovskiy Dancer and Television Personality triLift™ Patient If you want to present a healthy well-rounded persona and if you’re like me and don’t want any invasive procedures, triLift by Lumenis is the only option that I know exists right now Kerri Lee Walsh Jennings American professional beach volleyball player, Three-time Olympic gold medalist & a one-time Olympic bronze medalist triLift™ Patient It truly feels like I just had a workout for my face, in a good way. I know they say it takes a couple of treatments to get the best efficacy but I see immediate results WHAT A TYPICAL TREATMENT LOOKS LIKE: STEP 1 TONE THE FACIAL GLAMOUR MUSCLES Tone facial muscles with DMSt and RF technologies STEP 2 WOW! See lifted look & selfie time STEP 3 SMOOTH AND VOLUME Volumize and smooth the skin with triFX microneedling CLINICALLY VALIDATED Muscle stimulation for the face, a paradigm shift in facial rejuvenation By: Dr. Michael Mirmanesh, MD Plastic & Reconstructive Surgery Specialist Medical director of The Garden Medical Spa “Muscle toning is achieved by targeting different layers of muscles using directly applied electrical current, which allows intervals of stimulation and relaxation for effectively augmenting muscle workload” LEARN MORE IN THE MEDIA Close Close Close Close Close LEARN HOW YOU CAN YOUR PRACTICE Download triLift Info Kit The triLift release is per regional regulatory approval in the relevant jurisdiction. The approved jurisdictions are: United States, Canada, and Australia. * A course of 4-6 weekly treatments is recommended ** The testimonials of the triLift believers and the providers represent specific experience of a paid spokesperson. The experience of other people may vary. *** This is a testimonial that represents a specific experience. The Experience of others may vary. 1 compared to home use EMS / TENS devices *compared to baseline levels, for natural volume in a laboratory study Boisnic S, Branchet MC.Ex-vivo study of hybrid energy technology using a human skin model. Eur J Dermatol 2014; 24(1): 46-52 oi:10.1684/ejd.2013.2233. Ex vivo study results may not translate into actual clinical results. **compared to baseline levels Indication For Use: The triLift™ system is intended for dermatological procedures requiring ablation and resurfacing of the skin when using triFX™ Energy (Applicator VO), as well as intended for use in dermatologic and general surgical procedures for the non-invasive treatment of mild to moderate facial wrinkles and rhytides when using TriPollar® RF Energy (Applicators 1-3). The triLift with the DMSt™ mode is intended for muscle conditioning to stimulate healthy muscles. triLift with the DMSt™ mode is not intended to be used in conjunction with therapy or treatment of medical diseases or medical conditions of any kind. triLift is intended to be operated by a trained professional who is present to monitor treatment. The following possible side effects can occur following triLift treatment: Side effects may appear either at the time of treatment or shortly after. Side effects may include any of the following: prolonged or significant pain damage to natural skin texture (blister, burn), excessive skin redness (erythema), excessive swelling (edema), fragile skin bruising, excessive itching, change of pigmentation (hyper-pigmentation or hypopigmentation), scarring, transient skin break-out such as acne and pimples. For complete list of contraindications, please refer to the User Manual. Contraindications: triLift is contraindicated for patients with pacemaker, defibrillator, or any implanted electronic device, metal implants in the treatment area PB-00065680 Rev A #### Trilift Combines Three Innovative and Emerging Technologies in 1 Trilift Combines Three Innovative and Emerging Technologies in 1 August 15, 2024 Award-winning plastic surgeon, Michael D. Mirmanesh, discusses triLift’s different technologies that for the first time, treats the muscles, the dermal, and the epidermal layers in a safe, painless, and noninvasive way that can still give a face-lift-like effect without the downtime of surgery. Read Full Article PB-00070190 Rev A #### UltraPulse UltraPulse® The most powerful CO2 laser in aesthetic medicine UltraPulse can penetrate deeper than any aesthetic CO2 laser Exceptional ablation/coagulation ratio Highly Advanced Scanners For Maximum Versatility, Speed and Efficacy Watch Video Request a Demo Close Visit the Aesthetics Resource Hub for professional insights GO! Stretching the limits of performance DeepFX™ | ActiveFX™ Fractional Modes Great versatility and precision for all your resurfacing needs CoolScan™ technology for enhanced patient comfort Exceptional Ablation/Coagulation Ratio Optimal clinical outcomes with minimal excess heating Proven efficacy in dozens of clinical studies and peer reviewed publications Deepest Impact with SCAAR FX™ Mode Up to 3.5mm in a single pulse Ideal mode for treating deep, thick lesions Shortest Pulse Duration Faster than the tissue relaxation time Minimizing thermal damage Indications & Treatments Scar Revision The SCAAR FX™ mode available as part of the UltraPulse® system, allows for advanced treatment of a variety of severely damaged skin lesions which require synergistic coagulation and ablation for advanced resurfacing (SCAAR). Acne Scars Lumenis CO2 ablative technologies dramatically decrease scars, even very deep ones, as well as repair damaged skin and improve skin tone. Syringomas Syringomas are benign tumors, typically found clustered on eyelids, although they may also be found in other body parts. These can be treated by CO2 laser in a safe, and nonscarring method. Blepharoplasty Lumenis offers a complete laser blepharoplasty solution that combines an incisional solution with complementary eyelid resurfacing. With laser assisted incisions, bleeding during the procedure as well as post-surgery bruising are reduced. Fractional ablative resurfacing Ablative skin resurfacing procedures use lasers to reduce the signs of aging, improve skin texture, laxity and tone, and reduce scars and stretch marks. Ablative resurfacing is ideal for patients seeking a dramatic improvement in a single session. Rhynopyhma Rhinophyma is a disorder causing development of a large, bulbous nose associated with granulomatous infiltration, commonly due to untreated rosacea. This can be treated with CO2 laser as a surgical tool. Skin resurfacing The Lumenis™ CO2 ablative technologies enable a high rate of improvement for skin damage and skin tone with minimal downtime. This is due to their unique pulse technologies and tailored treatment modes. Scar revision results Emily Mitchel has suffered from a burn accident leaving scars all over her neck. Her confidence went down, while she felt sad about her appearance. Emily had her life turned around by Lumenis UltraPulse CO2 laser treatments, the freed her from a lifelong struggle with her scars. Emily Mitchell “Elizabeth Perez’s life came to a halt due to a severe burn, covering almost the entire surface of her skin. Thanks to Dr. Chad Hivnor’s treatments with Lumenis’ UltraPulse CO2 laser, Elizabeth has been given new hope.” Elizabeth Perez Wounded warrior Pat Wilkinson was injured in Iraq in 2008, losing his right leg and suffering severe burns on his limbs. Thanks to Lumenis’ UltraPulse CO2 laser, the pain from his surgical scars and burn scars, as well as his range of motion improved significantly, even after the first treatment. Pat Wilkinson The Berns triplets suffered 3rd degree burn injuries when a house fire took a life of their mother 20 years ago. The sisters have undergone multiple surgeries through the years to heal their wounds, but the scars remained. They’ve reached to Dr. Waibel who together with Lumenis agreed to provide them the UltraPulse CO2 laser treatment for their scars free of charge. Dr. Waibel with the Berns Triplets on the Today Show Request Demo UltraPulse. Optimal verastility ActiveFX™ Treat fine lines, texture & dyschroma DeepFX™ Treat wrinkles & acne scars TotalFX™ Combine superficial & deep fractional effects SCAAR FX™ Treat deep, conspicuous and complex lesions Adjustable Healing Zone Volume Spot Size 1.3mm 0.12mm 1.3mm & 0.12mm 0.12mm Depth Scanner ActiveFX (CPG) DeepFX ActiveFX (CPG) & DeepFX DeepFX Clinical Evidence Ultrapulse Carbon Dioxide Laser Ablation of Xanthelasma Palpebrarum: A Case Series Vikas Pathania, Manas Chatterjee Read More (2012) Lesion Dimensions Following Ablative Fractional Laser Treatment in Non-Melanoma Skin Cancer and Premalignant Lesions Katrine Togsverdbo & Uwe Paasch & Christina S. Haak & Merete Haederstal Read More (2014) Laser treatment of traumatic scars with an emphasis on ablative fractional laser resurfacing: consensus report Anderson RR, Donelan MB, Hivnor C, Greeson E, Ross EV, Shumaker PR, Uebelhoer NS, Waibel JS Read More (2014) Ablative fractional laser resurfacing helps treat restrictive pediatric scar contractures Krakowski AC, Goldenberg, Eichenfield LF, Murray JP, Shumaker PR Read More Hear from our Doctors UltraPulse Speed and UltraPulse Dr.Ross on UltraPulse Speed and Power Contact Us Doctors talks about restoring hope to their patients with the UltraPulse. Dr. Jill S. Waibel, Dr. Rox Anderson, Dr. E. Victor Ross, Dr. Nathan S. Uebelhoer, Dr. Tina Alster, Dr. Matthias B. Donelan, and Dr. Peter R. Shumaker Contact Us Dr. Daniel Friedmann on UltraPulse Dr. Daniel Friedmann explains why he loves UltraPulse Above and Beyond for anything from skin care to scar treatment. Dr. Daniel Friedmann Contact Us Dr. Hivnor Treating Wounded Warrirors Watch Dr. Hivnor as he zaps the scars of wars using the UltraPulse. Dr. Hivnor Contact Us Highly Advanced Scanners For Maximum Versatility, Speed And Efficacy UltraPulse© Configuration Treatment Mode Description Spot size & distribution DeepFX™ DeepFX™ Deep impact for treating wrinkles, acne scars and other deep cosmetic lesions SCAAR FX™ Deepest impact for treating thick, complex lesions 0.12 mm ActiveFX™ PigmentFX™ Low, sub-ablative fluency for mild treatment of dyschromia ActiveFX™ /MaxFX™ Wide range of settings, including the CO2 Lite™, ActiveFX Gentel™ , ActiveFX™ and MaxFX™ modes, for full and fractional treatment of texture and pigment inconsistencies 1.3 mm TotalFX All the above A full range of treatment possibilities, from mildest to the most aggressive – all in one 0.12 mm and 1.3 mm Any PrecieseFX™ Collimated 2.0mm handpiece for fact and precise tissue ablation and coagulation with consistent fluency 2.0 mm Any IncisionFX™ 0.2mm focused handpiece for clean, precise incisions 0.2 mm Technology  UltraPulse® – State Of The Art Technology The UltraPulse® laser boasts the Gold Standard UltraPulse® technology, enabling the deepest and safest impact, as well as a full range of advanced capabilities for fractional and full resurfacing, at an unparalleled range of depths. Read more Learn more about UltraPulse Get our Clinical Casebook. A collection of Before & After images from around the world E-Book Brochure PB-00025430 Rev A GET MORE INFO × Close Close Close #### ULTRApulse Alpha WOW Results in Just One Treatment ULTRApulse® Alpha is the Alpha of skin care lasers. Created by the experts who introduced CO2 lasers to aesthetics, ULTRApulse Alpha is reliable, simple to use by experts and beginners alike, and will set your practice apart. WATCH VIDEO REQUEST DEMO AI-generated image for illustrative purposes Elevate Your PracticeCO₂ Made SimpleScanners Made PerfectWOW ResultsMedia STRETCHING THE LIMITS OF PERFORMANCE Multiple Fractional Modes Great versatility and precision for all your resurfacing needs CoolScan™ technology for enhanced patient comfort BrushFX™ proprietary scanning Exceptional Ablation/Coagulation Ratio WOW results in just one treatment Optimal clinical outcomes with minimal excess heating Proven efficacy in dozens of clinical studies and peer reviewed publications Deepest Impact with SCAAR FX™ Mode Up to 4mm in a single pulse Ideal mode for treating deep, thick lesions Shortest Pulse Duration Faster than the tissue relaxation time Minimizing thermal damage Minimal patient discomfort and quicker healing time An all-user-friendly interface with embedded presets making treatments simple and intuitive ULTRApulse® Alpha allows experts and beginners alike to reach WOW results effectively with maximal patient satisfaction. The most advanced CO2 laser device perfected for decades by Lumenis’® experts, is made simple using a versatile interface with numerous presets and automations. DOWNLOAD INFO KITDOWNLOAD INFO KIT 1. Select treatment type 2. Insert patient specifications and desired treatment area 3. Select your handpiece 4. Settings made easier with embedded presets and clinical protocol guidelines 5. All set to reach ULTRAwow results HIGHLY ADVANCED SCANNERS FOR MAXIMUM VERSATILITY, SPEED AND EFFICACY DeepFX™ DeepFX™ Impactful mode for treating fine lines, wrinkles, acne scars and other cosmetic lesions DeepFX™ High Deep impact, designated to treat deep wrinkles, severe acne scars and other deep lesions SCAAR FX™ Deepest impact in a single pulse tor treating thick, complex lesions ActiveFX™  LiteFX™ Low, sub-ablative fluence for mild treatment of dyschromia and wrinkles GentleFX™ ActiveFX™ Wide range of settings for ablative treatments, for full or fractional treatment of texture and pigment inconsistence MaxFX™ TrueSpot™  PreciseFX™ Collimated 2.0mm handpiece for fast and precise tissue ablation and coagulation with consistent fluence Incisional Focused IncisionFX™ 0.2mm & 1.0mm focused for clean, precise incisions CLINICAL EVIDENCE Laser Treatment of Traumatic Scars and Contractures: 2020 International Consensus Recommendations Meghan Seago, Peter R Shumaker, Leah K Spring, Murad Alam, Firas Al-Niaimi, R Rox Anderson, Ofir Artzi, Ardeshir Bayat, Daniel Cassuto, Henry Hl Chan, Christine Dierickx, Matthias Donelan, Gerd G Gauglitz, Boncheol Leo Goo, Greg J Goodman, Geoffrey Gurtner, Merete Haedersdal, Andrew C Krakowski, Woraphong Manuskiatti, William B Norbury, Rei Ogawa, David M Ozog, Uwe Paasch, E Victor Ross, Matteo Tretti Clementoni, Jill Waibel READ MORE Ultrapulse Carbon Dioxide Laser Ablation of Xanthelasma Palpebrarum: A Case Series Vikas Pathania, Manas Chatterjee READ MORE (2012) Lesion Dimensions Following Ablative Fractional Laser Treatment in Non-Melanoma Skin Cancer and Premalignant Lesions Katrine Togsverdbo & Uwe Paasch & Christina S. Haak & Merete Haederstal READ MORE (2014) Laser treatment of traumatic scars with an emphasis on ablative fractional laser resurfacing: consensus report Anderson RR, Donelan MB, Hivnor C, Greeson E, Ross EV, Shumaker PR, Uebelhoer NS, Waibel JS READ MORE (2014) Ablative fractional laser resurfacing helps treat restrictive pediatric scar contractures Krakowski AC, Goldenberg, Eichenfield LF, Murray JP, Shumaker PR READ MORE (2022) Efficacy and adverse reactions of fractional CO 2 laser for atrophic acne scars and related clinical factors: A retrospective study on 121 patients Bingyan Li, Kehui Ren, Xufeng Yin, Huihui She, Houfang Liu, Bingrong Zhou READ MORE DOWNLOAD INFO KIT AI-generated image for illustrative purposes NOT ALL CO2 LASERS ARE CREATED EQUAL Exceptional Ablation/Coagulation Ratio When ablation depth is equal, more energy means more excess heat in the tissue. ULTRApulse Alpha’s technology enables the deepest penetration of the skin with the lowest energy, and with the shortest pulses per energy. These reduce patient discomfort, downtime and thermal damage, and promotes quicker healing. UltraPulse® Alpha DeepFX/SCAARFX mode: Left image: Energy 60mJ; Penetration depth ~2,200 µm Middle image: Energy 100mJ; Penetration depth ~3,470 µm Right image: Energy 150mJ; Penetration depth ~3,900 ULTRApulse Alpha CO2 Laser Treatments Skin resurfacing ULTRApulse Alpha allows you to reach amazing results in just one treatment. ULTRApulse Alpha equipped with technology perfected by experts for years, the device enables a high rate of improvement for skin damage and skin tone with minimal downtime and maximal patient comfort - with no invasive treatment or injectables. Scar Revision The SCAAR FX™ mode available in ULTRApulse Alpha allows for advanced treatment of a variety of severely damaged skin lesions which require synergistic coagulation and ablation for advanced resurfacing (SCAAR), without the need for surgery. Acne Scars ULTRApulse Alpha dramatically decrease acne scars, even very deep and old ones, as well as repair damaged skin and improve skin tone. Syringomas Syringomas are benign tumors, typically found clustered on eyelids, although they may also be found in other body parts. These can be treated by ULTRApulse Alpha in a safe, and nonscarring method. Blepharoplasty ULTRApulse Alpha offers a complete laser blepharoplasty solution that combines an incisional solution with complementary eyelid resurfacing. With laser assisted incisions, bleeding during the procedure as well as post-surgery bruising are reduced. Fractional ablative resurfacing Ablative skin resurfacing procedures use lasers to reduce the signs of aging, improve skin texture, flexibility and tone and reduce scars and stretch marks.Ablative resurfacing is ideal for patients seeking a dramatic improvement in a single session. Rhinophyma Rhinophyma is a disorder causing development of a large, bulbous nose associated with granulomatous infiltration, commonly due to untreated rosacea. ULTRApulse Alpha can treat this indication effectively when used as a precise surgical tool, reducing treatment bleeding and post treatment recovery time. Dyschromia No need to get used to the effects of time or sun exposure – ULTRApulse Alpha allows effective treatment of skin dyschromia and tone changes, with WOW results showing after just one treatment. AI-generated image for illustrative purposes VIDEOS [et_parent tab_style=”underline” tab_to_mobile=”inherit” color_tab_bg=”#F3F3F3″ color_content_bg=”” color_content_txt=”#000000″ title_font_size=”18px”][et_single icon=”” color_tab_txt=”#000000″ color_tab_bg=”#D690FF” tab_title=”VIDEO 1″ tab_id=”1765462255307-4-10″] The remarkable journey of Kim Phuc, known as the “Napalm Girl” – and see how Dr. Jill Waibel transformed her life through ULTRApulse Alpha technology. [/et_single][et_single icon=”” color_tab_txt=”#000000″ color_tab_bg=”#D690FF” tab_title=”VIDEO 2″ tab_id=”1763040665536-3-9″] After sustaining burns over 80% of the body, Karina experienced significant improvement in appearance and mobility following ULTRApulse Alpha treatment. [/et_single][et_single icon=”” color_tab_txt=”#000000″ color_tab_bg=”#D690FF” tab_title=”VIDEO 3″ tab_id=”1761048546235-2-9″] “What I love about this, is the fact that it changes lives…” | Dr. Thomas M. Beachkofsky on ULTRApulse Alpha [/et_single][et_single icon=”” color_tab_txt=”#000000″ color_tab_bg=”#D690FF” tab_title=”VIDEO 4″ tab_id=”1735735091361-6″] ULTRApulse Alpha – Do you have what it takes to be above all? [/et_single][et_single icon=”” color_tab_txt=”#000000″ color_tab_bg=”#D690FF” tab_title=”VIDEO 5″ tab_id=”1735741100362-2-4″] Dr. Jill S. Waibel and Dr. Ofir Artzi discuss ULTRApulse Alpha – reaching WOW results in one treatment, while enjoying the intuitive interface making provider’s lives much easier [/et_single][/et_parent] WOW RESULTS WITH ULTRApulse Alpha TECHNOLOGY ULTRApulse® Alpha Before and After DOWNLOAD INFO KIT VISIBLE RESULTS THAT LAST Courtesy of Suznne L. Kilmer, MD Courtesy of Clayton Moliver, MD Courtesy of Girish Munavalli, MD Courtesy of Ofir Artzi, MD Courtesy of J. Kevin Duplechain, MD Treatment by Jill S. Waibel, MD Courtesy of Ofir Artzi, MD Courtesy of Max Murison, MD Courtesy of Jill S. Waibel, MD Courtesy of Matteo Tretti Clementoni, MD Courtesy of Alina Fratila, MD Courtesy of Clayton Moliver, MD DOWNLOAD INFO KIT Technology ULTRApulse® Alpha – Why not all lasers were created equal ULTRApulse® Alpha is the alpha of the skin care lasers pack, and for all the right reasons. The best CO2 Laser technology in aesthetics has been perfected, and now operated with an all-user-friendly interface with embedded presets and automation – making CO2 easy to use by both beginners and experts. See what makes the ULTRApulse Alpha so unique. READ MORE WOW RESULTS IN JUST ONE TREATMENT WITH Download ULTRApulseAlpha Info Kit Get our Clinical Casebook. A collection of Before & After images from around the world Close Close Close #### UltraPulse Clinical Webinar UltraPulse Clinical Webinar Publish Date: Nov 8, 2020 Length: 39 Minutes Changing People’s Lives with UltraPulse and AcuPulse Ablative CO2 Lasers Join Tammy Haddad and Sandra Woods to hear their experience with the UltraPulse device, quoted the gold standard of CO2 laser treatments, and the most powerful CO2 laser in aesthetic medicine. In addition, we look at the benefits of the AcuPulse device, which provides CO2 laser treatments with a slightly smaller footprint in the clinic. Together we explore the clinical practice guidelines of the highly versatile UltraPulse device, offering 34 FDA-cleared dermatology and plastic surgery indications, and over 100 additional surgical indications. With its ActiveFX™ fractional mode, the UltraPulse offers outstanding cosmetic laser solutions, treating fine lines, skin texture and even pigmentation. The DeepFX™ fractional mode provides an in-depth treatment of wrinkles and scars by encouraging the regeneration of collagen and elastin within the tissues. The combined effect of these two modes – the TotalFX™ mode – offers the benefits of both superficial and deep fractional CO2 treatments. This webinar also discusses the most frequent and effective uses for CO2 lasers in the clinic, like scar removal and skin resurfacing, especially the improvement of mobility and quality of life for patients with burn scars or acne scars. It touches on the potential combination of these devices with additional aesthetic devices, expanding treatment options for a wide range of skin types, indications, and age groups. Finally, we also discuss the devices’ business potential, with it’s high revenue stream and quick ROI. Tammy Haddad Experienced Senior Sales Manager with a demonstrated history of working in the medical device industry Sandra Woods Experienced Clinical Director with a demonstrated history of working in the hospital & health care industry. PB-000016700_A #### Universal IPL M22 Overview Universal IPL Multi-Spot Nd:YAG ResurFX Q-Switched Nd:YAG IPL Laser Machine with Optimal Pulse Technology M22™ Universal IPL module enables you to treat a myriad of conditions with a single, versatile handpiece. The Universal IPL handpiece is designed with 9 ExpertFilters™ tailored to the condition being treated and computer-enabled filter recognition for enhanced safety and ease-of use. With the Universal IPL handpiece change ExpertFilters™ in seconds instead of attaching a whole new handpiece. The Universal IPL handpiece saves not only treatment time and storage space, but is also extremely cost efficient because there is no need to purchase multiple IPL handpieces. Three SapphireCool™ lightguides, for large and small areas, maximize patient comfort with continuous contact cooling. SCHEDULE A DEMO One Applicator for ALL IPL Indications 9 Filters and 3 Lightguides changeable in seconds IPL With Optimal Pulse Technology (OPT™) The Optimal Way To Broaden A Patient Base, Comfortably  The Lumenis OPT™ advantages:  Control pulse shape by equalizing energy distribution over the entire pulse or sequential pulses Gentler, more comfortable, patient-friendly procedures, with lower effective fluences High peak power, shorter pulses – optimal for IPL skin treatments using photorejuvenation and treatment of benign pigmented lesions Advanced OPT™ will also allow determining the specific fluence per sub-pulse when using multiple sequential pulsing, for fine-tuned treatment settings Typical Clinical Results DOWNLOAD BROCHURE PB-1003628 Rev D Close Close GET MORE INFO × #### Vascular & Leg Vein Vascular Lesions Treat superficial and deep vascular lesions on the face and body. Leg veins, spider veins, telangiectasia, rosacea and other visible benign vascular issues are common aesthetic conditions for which patients seek treatment. Now you can outshine all others. Help your patients be vein-free and carefree. EXPLORE OUR PRODUCTS About Vascular & Leg Vein Leg veins, spider veins and other visible benign vascular lesions are common aesthetic conditions for which patients seek treatment for both medical and cosmetic reasons. Lasers and other light based technologies enable effective treatment of leg veins and vascular lesions by inducing vessel collapse through coagulation with minimal damage to adjacent structures. The Lumenis Solution The Lumenis IPL with OPT™ (Optimal Pulse Technology) is designed to treat vascular lesions up to 1.5 mm deep and up to 1 mm in diameter. The Multi-Spot Nd:YAGwith Multiple Sequential Pulsing (MSP™) effectively treats vascular lesions up to 4.5 mm deep and with a diameter of up to 4 mm, such as leg veins. The Multi-Spot Nd:YAG treats all skin types safely and effectively. Advantages For Physicians Optimal treatment safety and efficacy using Optimal Pulse Technology (OPT™) and Multiple Sequential Pulsing (MSP™) which facilitate achieving the desired clinical results with enhanced patient comfort. Preset treatment parameters for a wide range of clinical indications ensure ease of use and a fast learning curve. Clinical Evidence Related Products   M22™ For Fractional Non-Ablative Skin Resurfacing. GET MORE INFO × #### White Papers – LightSheer DESIRE Lightsheer DESIRE Overview The Technology How It Works Patients Benefit Practice Benefits Clinical Results White Papers White Papers – LightSheer DESIRE Doris Day, MD “Optimizing Earnings with LightSheer® Laser Hair Removal” Lumenis, 2013, PB-2007281 Rev B Munavalli Girish, MD “Laser Hair Removal: Efficiency, Efficacy, and Comfort Are Key” Supplement to Practical Dermatology and Modern Aesthetics, Spring 2013. Campos B. Valeria, MD, Anderson R. Rox, MD, Diereckx C. Christine, MD “Use of an 800 nm High-Power Diode Laser for the Treatment of Leg Vein Telangiectasia”. Lumenis, 2002. Kilmer Suzanne, MD, B, Chotzen A. Vera, McClaren Marla, MD “Use of LightSheer Diode Laser for the Treatment of Benign Pigmented Lesions.”. Lumenis, 2000. PB-00005690 Rev A × GET MORE INFO ### Vision Pages #### 6 Tips for Implementing Optima IPL in Your OD Practice 6 Tips for Implementing Optima IPL in Your OD Practice July 9, 2020 When I saw Optima IPL at a conference in 2018, it was love at first sight. By treating peri-ocular rosacea, and thus the underlying inflammation that causes meibomian gland dysfunction (MGD) and dry eye, Optima IPL would fulfill a key unmet need and take a central place in my dry eye clinic*. Over the next 18 months or so, as I waited for IPL to gain approval within our scope in Illinois, I researched the best ways to bring it into my practice. I prepared protocols and pricing and built anticipation in my dry eye patients. And when I was finally able to purchase my system in January 2020 and have in-clinic training, I performed five procedures the next day. Here are some tips to get you started: • Train and treat the team – Our in-clinic training was a “spa day” for our team. They were so happy with the results. Now they’re passionate about sharing their experiences with patients, which has helped build excitement. • Change your treatment model – Now Optima IPL has completely changed how we treat patients. When I diagnose MGD at the first dry eye consult, I immediately recommend Optima IPL and start educating patients about it. They watch a video and receive the paperwork. We can start Optima IPL the same day. If a patient declines, we start another treatment and recommend having Optima IPL in the future. • Schedule IPL between other appointments – Patients start Optima IPL with four or five treatment sessions, scheduled every 3 to 4 weeks, followed by one maintenance session every 6 to 12 months. Each session takes about 5 to 10 minutes. After the first consultation, IPL visits fit nicely between longer appointments. I schedule 4 or 5 a day. • Track revenues – Prior to purchasing Optima IPL, we calculated the break-even number to be approximately 40 patients, or 1 or 2 patients per day, 5 days per week, for 1 month. We met that goal very easily, and we are now adding patients every week. • Collect patient responses – Patients love Optima IPL, and providing care to happy patients who can’t wait to get in to see us definitely adds more joy to our day. Their excitement can be contagious, so we are starting to note people’s comments. It’s common to hear feedback such as, “I’d tried everything for my eyes, but they were still dry, gritty and red all day long. After IPL, I was so much more comfortable that I actually forgot about the problem.” • Adapt to challenges in the practice – When coronavirus restrictions closed our office for about 30 days and limited our patient volume after reopening, Optima IPL helped strengthen our bottom line. Patients who had begun treatment called all the time during shutdown asking when they could resume. Some of them were in tears because they didn’t want their symptoms to return. Those patients rushed back to the practice as we reopened. And with lower patient volumes overall, the fact that Optima IPL increases our revenue per patient means it is helping us survive and thrive. As we’ve implemented Optima IPL in our practice, one benefit has come as a pleasant surprise. Although my practice embraces the medical side of optometry, we often need to refer patients for treatments and surgeries after diagnosis. Optima IPL allows us to diagnose peri-ocular rosacea, keep those patients in our practice, and treat the symptoms and signs ourselves. That’s a good feeling and another good reason to implement Optima IPL in your OD practice.   *Untreated inflammatory skin conditions such as Rosacea can lead to Meibomian Gland Dysfunction. As such, 80% of Rosacea patients are suffering from Meibomian Gland Dysfunction. Optima IPL is used to treat Rosacea, which allows to break the inflammatory process that may lead to Meibomian Gland Dysfunction and Dry Eye. Explore Other Resources Dry EyeNewsPeriorbital Muscle StimulationTreatment TypeVision Resource HubDry EyeNewsPeriorbital Muscle StimulationTreatment TypeVision Resource HubLumenis OptiLIFT Dynamic Muscle Stimulation Device receives Health Canada Approval for Reducing Signs and Symptoms of Evaporative Dry Eye DiseaseREAD MOREClinical StudiesDry EyePeriorbital Muscle StimulationTreatment TypeVision Resource HubClinical StudiesDry EyePeriorbital Muscle StimulationTreatment TypeVision Resource HubThe Potential Benefits of Periorbital Transcutaneous Electrical Stimulation for the Management of Dry Eye DiseaseREAD MOREDry EyePeriorbital Muscle StimulationPress PublicationsTreatment TypeVision Resource HubDry EyePeriorbital Muscle StimulationPress PublicationsTreatment TypeVision Resource HubSisters Grow Practice Into Medical Hub for Dry Eye TreatmentREAD MORE PB-00019240 Rev A #### A New Dawn for Dry Eye: Lumenis OptiLight™ A New Dawn for Dry Eye: Lumenis OptiLight™ Eyes on Eyecare gathers insights from patients and practitioners on the first and only FDA-approved IPL for dry eye management: OptiLight by Lumenis. READ FULL ARTICLE Explore Other Resources Dry EyeNewsPeriorbital Muscle StimulationTreatment TypeVision Resource HubDry EyeNewsPeriorbital Muscle StimulationTreatment TypeVision Resource HubLumenis OptiLIFT Dynamic Muscle Stimulation Device receives Health Canada Approval for Reducing Signs and Symptoms of Evaporative Dry Eye DiseaseREAD MOREClinical StudiesDry EyePeriorbital Muscle StimulationTreatment TypeVision Resource HubClinical StudiesDry EyePeriorbital Muscle StimulationTreatment TypeVision Resource HubThe Potential Benefits of Periorbital Transcutaneous Electrical Stimulation for the Management of Dry Eye DiseaseREAD MOREDry EyePeriorbital Muscle StimulationPress PublicationsTreatment TypeVision Resource HubDry EyePeriorbital Muscle StimulationPress PublicationsTreatment TypeVision Resource HubSisters Grow Practice Into Medical Hub for Dry Eye TreatmentREAD MORE PB-00041440 Rev A #### After OptiLIGHT, Patients Shoulder Smaller Burden of Traditional Home Care Blog PostsDry Eye After OptiLIGHT, Patients Shoulder Smaller Burden of Traditional Home Care August 17, 2023 Donald J. Higgins, OD Dr. Donald J. Higgins is an optometrist, dry eye expert, and owner of Higgins Brothers’ Vision Care, Plainville, Connecticut In our referral practice, where it’s common to see 10 new referrals a week for dry eye disease (DED), patients’ top priority is to lighten the burden of DED. This chronic, progressive condition affects their quality of life and forces them to think about their eyes all the time. Many of them have seen multiple doctors and tried medications, artificial tears, warm compresses, punctal plugs and other therapies. For the vast majority of these patients, I choose OptiLIGHT as the cornerstone of therapy—a solution that quells inflammation, restores the meibomian glands, and diminishes demodex. After we complete the standard series of four treatments with OptiLIGHT, my patients need little maintenance therapy. That means not only do patients get the improvement in DED that they desperately need, but they also reduce the inconvenience and expense of at-home care. Incorporating OptiLIGHT into my practice has made a real difference in patients with meibomian gland dysfunction (MGD) and evaporative dry eye. Lumenis light therapy is the first and only that is FDA-approved for DED, and that is a strong affirmation of safety and efficacy for doctors who are considering implementing OptiLIGHT in their practice as well. I have seen significant increases in the TBUT for each of the patients I’ve treated, going from a 0- to 1-second TBUT, to an average of 14 to 15 seconds in patients who have completed all four treatments. I have never seen patients improve this much with conventional treatment methods, and this demonstrates that we can address the evaporative component in a way we just couldn’t before. Post-OptiLIGHT Home Maintenance When we get our patients’ meibomian glands functioning again with OptiLIGHT, we notice that the need for adjunct therapies drops precipitously, evidenced in follow-up exams and patient feedback. My standard advice after OptiLIGHT is to eat well, stay hydrated, and take a 2000-3000mg high-quality daily Omega 3 supplement. I find it amazing that I rarely need to prescribe immunomodulator drops after OptiLIGHT treatment, which makes patients very happy. I still prescribe immunomodulators and do punctal occlusion (after quelling inflammation) for patients with mixed MGD and aqueous deficient DED, including most patients with Sjogren’s or other autoimmune disorders. My DED patients who also suffer from demodex blepharitis need extra maintenance as well. After OptiLIGHT treatment diminishes demodex, I follow up with in-office cleaning and recommend lid hygiene therapy and sometimes ivermectin treatment at home. I have gotten away from recommending long-term use of warm compresses after OptiLIGHT because they’re unnecessary and may trigger inflammation, but I occasionally recommend that some patients with very thick meibum use warm compresses short-term during the course of OptiLIGHT treatments to clear the glands. OptiLIGHT Maintenance Treatments After the initial series for four OptiLIGHT treatments, we perform maintenance treatments based on a patient’s status. I tell all my patients, “We will get the glands back in healthy shape with OptiLIGHT, but DED is a chronic condition. You’ll always need some maintenance treatments to keep functioning at your best.” To my surprise, once patients have experienced the results of four OptiLIGHT treatments, some of them actually request maintenance treatment months or years later when they want to regain those benefits. I see patients back 1 month after OptiLIGHT to check their results and do follow-up testing, and then we schedule visits based on the severity of their DED before OptiLIGHT (in 3, 4 or 6 months). Over time, we determine if a patient needs maintenance treatment with OptiLIGHT by checking if there is significant change from their post-treatment SPEED questionnaire score, tear meniscus height, redness scale, TBUT and meibography. Patients who suffer from DED are so happy to finally experience a change after OptiLIGHT, as well as to do a lot less home maintenance. With OptiLIGHT, we’re able to make this chronic disease less of an everyday concern and burden for our patients. Discover new possibilities Download OptiLIGHT and OptiPLUS info kit Explore Other Resources Dry EyeNewsPeriorbital Muscle StimulationTreatment TypeVision Resource HubDry EyeNewsPeriorbital Muscle StimulationTreatment TypeVision Resource HubLumenis OptiLIFT Dynamic Muscle Stimulation Device receives Health Canada Approval for Reducing Signs and Symptoms of Evaporative Dry Eye DiseaseREAD MOREClinical StudiesDry EyePeriorbital Muscle StimulationTreatment TypeVision Resource HubClinical StudiesDry EyePeriorbital Muscle StimulationTreatment TypeVision Resource HubThe Potential Benefits of Periorbital Transcutaneous Electrical Stimulation for the Management of Dry Eye DiseaseREAD MOREDry EyePeriorbital Muscle StimulationPress PublicationsTreatment TypeVision Resource HubDry EyePeriorbital Muscle StimulationPress PublicationsTreatment TypeVision Resource HubSisters Grow Practice Into Medical Hub for Dry Eye TreatmentREAD MORE Donald J. Higgins, OD, is the founder of Higgins Brothers Vision Care in Plainville, Connecticut. *OptiLIGHT is intended to be used by licensed practitioners, according to local rules and regulations Indication for Use: In EU: Evaporative Dry Eye Disease (DED), also known as dry eye syndrome or lipid tear deficiency, due to Meibomian Gland Dysfunction (MGD). This indication is intended for Fitzpatrick skin types I-V. In US: Improvement of signs of Dry Eye Disease (DED) due to Meibomian Gland Dysfunction (MGD), also known as evaporative dry eye or lipid deficiency dry eye, in patients 22 years of age and older with moderate to severe signs and symptoms of DED due to MGD and with Fitzpatrick skin types I-IV. IPL is to be applied only to skin on the malar region of the face, from tragus to tragus including the nose (eyes should be fully covered by protective eyewear). IPL is intended to be applied as an adjunct to other modalities, such as meibomian gland expression, artificial tear lubricants and warm compresses. The indications are only relevant where they were approved by the Regulatory Authorities. Treatment with OptiLIGHT is contraindicated for patients with the following conditions in the treatment area: Ocular surgery or eyelid surgery or Neuro-paralysis within 6 months prior to the first treatment; Uncontrolled eye disorders affecting the ocular surface; Pre-cancerous lesions, skin cancer or pigmented lesions; Uncontrolled infections or uncontrolled immunosuppressive diseases; Recent Ocular infections; History of cold sores or rashes in the perioral area, including: Herpes simplex 1 & 2, Systemic Lupus erythematosus and porphyria; Use of photosensitive medication and/or herbs that may cause sensitivity within 3 months prior to the first IPL session; Recent radiation therapy to the head or neck or planned radiation therapy; Recent treatment with chemotherapeutic agent or planned chemotherapy; History of migraines, seizures or epilepsy. Patients’ eyes must be completely occluded during the treatment. Please refer to the operator manual for a complete list of intended use, contraindications and risks. The following possible side effects can occur following IPL treatments: Pain/discomfort, damage to natural skin texture, change of pigmentation, scarring, excessive edema, fragile skin, bruising, burns, pruritus and xerosis. Please refer to the user manual or ask your doctor for a complete list of intended use, contraindications and risks. PB-00067370, Rev A PB-00072970 Rev B #### Alternative Treatments for Apprehensive DED Patients Alternative Treatments for Apprehensive DED Patients November 20, 2023 With patient apprehension from OTC eye drop recalls, James Deom, OD, leads with education first, followed by safe and proven in-office treatments. Read Full Article Explore Other Resources Dry EyeNewsPeriorbital Muscle StimulationTreatment TypeVision Resource HubDry EyeNewsPeriorbital Muscle StimulationTreatment TypeVision Resource HubLumenis OptiLIFT Dynamic Muscle Stimulation Device receives Health Canada Approval for Reducing Signs and Symptoms of Evaporative Dry Eye DiseaseREAD MOREClinical StudiesDry EyePeriorbital Muscle StimulationTreatment TypeVision Resource HubClinical StudiesDry EyePeriorbital Muscle StimulationTreatment TypeVision Resource HubThe Potential Benefits of Periorbital Transcutaneous Electrical Stimulation for the Management of Dry Eye DiseaseREAD MOREDry EyePeriorbital Muscle StimulationPress PublicationsTreatment TypeVision Resource HubDry EyePeriorbital Muscle StimulationPress PublicationsTreatment TypeVision Resource HubSisters Grow Practice Into Medical Hub for Dry Eye TreatmentREAD MORE LEARN HOW YOU CAN ELEVATE YOUR PRACTICE DOWNLOAD OPTILIGHT INFO KIT Learn about the first and only IPL FDA approved for dry eye management PB-00043680 Rev C #### Arita et al. (2019): Therapeutic efficacy of intense pulsed light in patients with refractory meibomian gland dsyfunction Arita et al. (2019): Therapeutic efficacy of intense pulsed light in patients with refractory meibomian gland dsyfunction The results of a prospective, random control trial show the combination of Lumenis IPL with OPTTM and Meibomian Gland Expression (MGX) improves tear film homeostasis and ameliorates ocular symptoms in patients with refractory Meibomian Gland Dysfunction (MGD). READ FULL STUDY Indication for Use: Improvement of signs of Dry Eye Disease (DED) due to Meibomian Gland Dysfunction (MGD), also known as evaporative dry eye or lipid deficiency dry eye, in patients 22 years of age and older with moderate to severe signs and symptoms of DED due to MGD and with Fitzpatrick skin types I-IV. IPL is to be applied only to skin on the malar region of the face, from tragus to tragus including the nose (eyes should be fully covered by protective eyewear). IPL is intended to be applied as an adjunct to other modalities, such as meibomian gland expression, artificial tear lubricants and warm compresses Treatment with M22 or OptiLight is contraindicated for patients with the following conditions in the treatment area: Ocular surgery or eyelid surgery or Neuro-paralysis within 6 months prior to the first treatment; Uncontrolled eye disorders affecting the ocular surface; Pre-cancerous lesions, skin cancer or pigmented lesions in the planned treatment area; Uncontrolled infections or uncontrolled immunosuppressive diseases; Recent Ocular infections; Prior history of cold sores or rashes in the perioral area, including: Herpes simplex 1 & 2, Systemic Lupus erythematosus and porphyria; Use of photosensitive medication and/or herbs that may cause sensitivity within 3 months prior to the first IPL session; Recent radiation therapy to the head or neck or planned radiation therapy; Recent treatment with chemotherapeutic agent or planned chemotherapy; History of migraines, seizures or epilepsy. Patients eyes must be completely occluded during the treatment. Please refer to the operator manual for a complete list of intended use, contraindications and risks. Please consult your physician as to whether this procedure is suitable for you. The following possible side effects can occur following IPL treatments: Pain/discomfort, damage to natural skin texture, change of pigmentation, scarring, excessive edema, fragile skin, bruising, burns, pruritus and xerosis. Please refer to the user manual or ask your doctor for a complete list of intended use, contraindications and risks. Lumenis has an interest in the study device (M22 system). All uses of the M22 system described in the information were approved by the FDA, except the following: – The number of IPL sessions was 8, instead of 4 approved by the FDA. – The study concluded that symptoms of DED were improved by the use of IPL, whereas FDA cleared only improvement of signs Dr. Arita was a consultant of Lumenis. No person known to Lumenis has provided funding for the study. The publication doesn’t discuss any unapproved uses of the device. Explore Other Resources Dry EyeNewsPeriorbital Muscle StimulationTreatment TypeVision Resource HubDry EyeNewsPeriorbital Muscle StimulationTreatment TypeVision Resource HubLumenis OptiLIFT Dynamic Muscle Stimulation Device receives Health Canada Approval for Reducing Signs and Symptoms of Evaporative Dry Eye DiseaseREAD MOREClinical StudiesDry EyePeriorbital Muscle StimulationTreatment TypeVision Resource HubClinical StudiesDry EyePeriorbital Muscle StimulationTreatment TypeVision Resource HubThe Potential Benefits of Periorbital Transcutaneous Electrical Stimulation for the Management of Dry Eye DiseaseREAD MOREDry EyePeriorbital Muscle StimulationPress PublicationsTreatment TypeVision Resource HubDry EyePeriorbital Muscle StimulationPress PublicationsTreatment TypeVision Resource HubSisters Grow Practice Into Medical Hub for Dry Eye TreatmentREAD MORE PB-00038930 Rev A #### Array Pattern Scanning Array LaserLinkTM Pattern Scanning Laser Technology Lumenis introduces ArrayTM LaserLinkTM a technologically advanced delivery system that significantly enhances standard laser treatment by providing new pattern scanning capabilities to photocoagulation lasers and considerably reducing treatment time.  Array offers a range of laser spot sizes from 50µm to 1000µm in single spot mode, 100µm to 500µm in pattern scanning mode. Examples of Scan Pattern Shapes The ArrayTM LaserLinkTM Features The Following Benefits: CompatibilityVersatilitySendibilityCompatibility Compatibility Links with Lumenis lasers: Vision One Novus Spectra And attaches to most popular slit lamps: Lumenis 980 Lumenis 990* Zeiss SL130 Zeiss 30SL Haag Streit 900 BQ*Versatility Versatility With Lumenis multi-wavelength technology, Array delivers any of-following wavelengths: Green: 532 nm Yellow: 577 nm Red: 659 nm Array treatment options: Single spot Pulse mode Various pattern Array offers a range of laser spot sizes from 50µm to 1000µm in single spot mode, 100µm to 500µm in pattern scanning mode. *May have a later release Sendibility Sendibility Intuitive touchscreen presents logical workflow Custom Touchpad is easily moved for use with right or left hand and provides Eyes Forward Control Heads Up Display seen as text on the retina, shows confirmation of important parameter changes Frame Mode displays a precise outline of the area in which the pattern will be administered Titrate Mode is used to establish appropriate pattern laser parameters with a single spot Contact lens menu lists commonly used lenses for calculation of laser spot size on the retina Spot size on retina tells doctor actual parameter of treatment The ArrayTM LaserLinkTM is compatible with Lumenis Vision One and Novus Spectra. And, attaches to most popular slit lamps: Lumenis 980 Lumenis 990* Zeiss SL130 Zeiss 30SL Haag Streit 900 BQ* The ArrayTM LaserLinkTM is versatile. With Lumenis multi-wavelength technology. Array delivers any of the following wavelengths: Green: 532 nm Yellow: 577 nm Red: 659 nm Customized Treatment to Meet the Patient and Physician Needs Continuously Variable Spot Size Single spot from 50µm to 1000µm Pattern mode from 100µm to 500µm For customized treatment for the particular disease state and tissue response Selectable Spot Spacing From 0 to 3 times the spot diameter within a circle From 0.25 to 3 times the spot diameter in other patterns Variety of Adjustable Patterns includes single spot and 6 shapes Square: 2 to 5 spots per side Line: 2 spots in one line up to 4 spots in each of 5 lines Triangle: 6 or 15 spots Circle: Single adjustable ring Quarter of a circle: 1 or 3 adjustable arcs Half of a circle: 1 or 3 adjustable arcs Up to 5 Preset Protocols Retain favorite settings in memory Include settings such as fundus lens selection, laser power, spot size, spot spacing, number of spots and duration New Generation Clearview Filters Utilize photopic balanced coating to eliminate color distortion Utilize photopic balanced coating to eliminate color distortion Patented SureSpotTM Optics Ensures that the focal point of the laser beam is maintained on the retina Minimizes power density on the cornea and lens for increased safety Eyes Forward Control Eyes Forward Control Control and verify treatment parameters without moving from the slit lamp oculars or losing sight of the target retina Unique Array 3D Micromanipulator  Controls laser parameters and micromanipulation Adjustable for left or right hand use Heads Up Display Confirms changes to treatment parameters Displays text on the retina Modified parameters are projected as text onto the retina Intuitive Touchscreen Fully adjustable monitor Is easily reached and visualized for treatment set up and procedure Learn More Product VideoBrochureProduct Video Brochure Lumenis Ophthalmology Devices Digital Duet The first and only all-in-one digital platform for Glaucoma and PCO therapies Digital Trio 3 in 1 digital platform for Glaucoma and Retina care OptiLIGHT A bright solution for dry eyes ArrayTM LaserLinkTM Pattern Scanning Laser Technology Vision One Modular Multi-Wave Photocoagulator Selecta Duet SLT Technology and a Yag Photodisruptor in One Platform Selecta Trio Retinal, Cataract and Glaucoma Therapy in One Platform Novus SpectraTM High-Powered Photocoagulator LumeProbeTM Endo-Photocoagulation Laser Probes PB-2006798 Rev A × GET MORE INFO #### Ashley Tisdale Found an Effective Solution for DED with OptiLIGHT by Lumenis’ Light-Based Therapy! Ashley Tisdale Found an Effective Solution for DED with OptiLIGHT by Lumenis’ Light-Based Therapy! January 4, 2024 Share   Just as she refuses to settle for dry, damaged hair, Ashley Tisdale discovers that she doesn’t have to live with dry eyes either. With OptiLIGHT by Lumenis light therapy for dry eyes, Ashley finds the solution she’s been searching for! Watch more videos Colton Underwood shares his experience with DED and his care journey using OptiLIGHT and OptiLIFTMay 25, 2025WATCH NOWKerri Walsh Jennings Shares the Impact of OptiLIGHT Treatment on Her Dry Eye Disease!May 2, 2024WATCH NOWKerri Has Been Experiencing Dry, Itchy Eyes On And Off The Court For Years. Her Solution: OptiLIGHT!April 28, 2024WATCH NOW PB-00076100, Rev A #### Behind OptiLIFT’s Lid Laxity Innovation Press PublicationsDry EyePeriorbital Muscle Stimulation Behind OptiLIFT’s Lid Laxity Innovation June 16, 2025 Inna Lazar, OD Inna Lazar, OD, has been focused on dry eye treatment since she opened Greenwich Eye Care in Greenwich, Connecticut, in 2017. Her journey into this specialized field is deeply personal; she has experienced the discomfort of nocturnal lagophthalmos. “I used to tape my eyelids shut at night, especially during the winter months,” she says. When she heard that Lumenis was introducing OptiLIFT to address impaired blinking and lid laxity, she got on board and made herself her first patient. “After incorporating OptiLIFT into my regimen, I noticed an immediate improvement.” OptiLIFT, a new innovation from Lumenis, uses Dynamic Muscle Stimulation technology (DMSt™) to non-invasively addresses lower lid laxity. It enhances blink quality and tear distribution while also delivering aesthetic benefits such as reduced puffiness and a naturally lifted appearance. Get firsthand insights from dry eye specialist Dr. Inna Lazar, who also experienced the benefits of OptiLIFT as a patient. Read Full Article *OptiLIGHT and OptiPLUS are intended to be used by licensed practitioners, according to local rules and regulations. DOWNLOAD INFO KIT Discover how OptiLIFT can transform your practice. Contact us for a free demo or to learn more! Close Explore Other Resources Dry EyeNewsPeriorbital Muscle StimulationTreatment TypeVision Resource HubDry EyeNewsPeriorbital Muscle StimulationTreatment TypeVision Resource HubLumenis OptiLIFT Dynamic Muscle Stimulation Device receives Health Canada Approval for Reducing Signs and Symptoms of Evaporative Dry Eye DiseaseREAD MOREClinical StudiesDry EyePeriorbital Muscle StimulationTreatment TypeVision Resource HubClinical StudiesDry EyePeriorbital Muscle StimulationTreatment TypeVision Resource HubThe Potential Benefits of Periorbital Transcutaneous Electrical Stimulation for the Management of Dry Eye DiseaseREAD MOREDry EyePeriorbital Muscle StimulationPress PublicationsTreatment TypeVision Resource HubDry EyePeriorbital Muscle StimulationPress PublicationsTreatment TypeVision Resource HubSisters Grow Practice Into Medical Hub for Dry Eye TreatmentREAD MORE PB-00091010, Rev A #### Celebrating Excellence: Growing Your Dry Eye Practice with Lumenis Technology Blog PostsDry Eye Celebrating Excellence: Growing Your Dry Eye Practice with Lumenis Technology November 5, 2024 Dr. Matthew Jones Owner, Harris Eye Clinic and Family Eye Care, multiple locations in Arkansas. Website Dry eye is the number one disease we see in our eye care practice every day. In the past, we relied on lubrication and other short-term options to remedy the problem. But now, with OptiLIGHT, we can address key contributing factors of dry eye disease (DED) and deliver impactful results to our patients, enabling us to earn their trust while simultaneously growing our practice. In 2019, I helped lead the effort to advance the optometric scope of practice in Arkansas, which led to legislation permitting new procedures. Following the scope expansion, I chose to partner with Lumenis to bring its technology into our practice because I trusted the brand and saw the company’s support of optometry and private practices around the country. At that time, we offered several dry eye treatment options—and still do—but we viewed OptiLIGHT as a major technological advancement we wanted to invest into improving signs of dry eye for patients with MGD for patients with meibomian gland dysfunction (MGD).1,2 Lumenis light therapy is the first and only FDA-approved light therapy for dry eye management, so there wasn’t any question that OptiLIGHT was the right choice for our practice and patients. Offering OptiLIGHT Treatment to Patients When assessing a patient, we ask targeted questions at the start of each eye exam to help determine the best treatment strategies. Many patients don’t realize they have dry eye disease and confuse symptoms like watery eyes with other conditions. When we identify clogged glands and inflammation, we discuss intense pulse light (IPL) therapy as a treatment option.3,4 For established patients who have had persistent dry issues for years, we recommend OptiLIGHT right away. Using the Antares diagnostic tool from Lumenis, we show patients a photo of their meibum, compare it to a healthy example, and explain how IPL treatment can help get them there. Patients receive four treatments, once every two to four weeks, with follow-up maintenance. We offer these OptiLIGHT treatments in a bundle and encourage our patients to invest in that bundle upfront. While some patients can pay per treatment and will feel relief after only one or two sessions, we emphasize that the full course of four will lead to the best results. We also provide an upgradable package that includes aesthetical treatments in addition to the dry eye treatment, as well as individual treatments to remove lesions or sunspots around the eyes. Our patients appreciate the aesthetic benefits of OptiLIGHT, particularly in evening out their complexions and addressing signs of sun damage and photo-aging. Offering combined ocular and aesthetic treatments not only benefits our patients but also enhances the efficiency of our practice’s workflow and boosts our revenue. Patient Growth and Outcomes My practices are in small, rural communities, so we were initially concerned that patients would be hesitant to pay for OptiLIGHT treatment. However, our worries turned out to be unfounded. So many people struggle with dry eye, which significantly affects their daily lives, and they’re willing to do what it takes to improve their quality of life.5 When we describe how OptiLIGHT works, its results, and the relief it can provide, we rarely see any resistance to moving forward with the recommended treatment. Our patients have been thrilled with the results. The majority of our success in marketing OptiLIGHT to patients comes from referrals. I am a big believer in organic growth. While we promote OptiLIGHT on our website, through emails, ads, and social media, word-of-mouth from patients who have experienced the results firsthand goes a long way. Since installing OptiLIGHT, we have seen continuous growth in our number of new patients and our profitability each month, which has led to the addition of more doctors to the practice. Taking the Next Step with OptiPLUS This summer, we plan to take our dry eye treatment protocol one step further by adding OptiPLUS, a complementary treatment to OptiLIGHT and the first dual-frequency RF technology of its kind. We sought an aesthetic-based modality and again found Lumenis to be the best option. When paired with OptiLIGHT, OptiPLUS enhances clinical results by precisely delivering heat across skin tissue layers to target the meibomian glands and boost collagen production.6,7,8 We are currently determining how to package these treatments together, focusing first on our OptiLIGHT patients who believed in the technology early on. We hope they will spread the word to their family, friends, and neighbors once they experience the added benefits of incorporating OptiPLUS into their treatment plan. Final Thoughts Celebrating excellence in a dry eye practice means prioritizing patient care. Our goal is to ensure patients don’t need to travel to a larger city for better treatment. Through our dry eye clinic, they can receive the best possible care right in their hometown. For other dry eye specialists considering an investment for their own practice, my advice is to jump in headfirst. Technologies like OptiLIGHT and OptiPLUS greatly benefit our patients, and if we don’t embrace them, we’re not providing the most advanced care. When a treatment provides life-changing relief for patients, it will not only grow your practice but also boost staff morale, making it a worthwhile investment for all. Matthew Jones, O.D., has been practicing optometry in Arkansas since 2009. He has clinics in Blytheville, Osceola, West Memphis, and Paragould. Dr. Jones is Board-Certified by the American Board of Optometry and was recognized as the American Optometric Association’s “Optometrist of the Year” in 2024. He is active on several committees of the Arkansas Optometric Association, working to effect change through state and national legislation, and helped lead scope expansion efforts in Arkansas. Website: harriseyeclinic.com LinkedIn: https://www.linkedin.com/in/matthew-jones-o-d-748bb18a/ Discover new possibilities Download OptiLIGHT and OptiPLUS info kit Explore Other Resources Dry EyeNewsPeriorbital Muscle StimulationTreatment TypeVision Resource HubDry EyeNewsPeriorbital Muscle StimulationTreatment TypeVision Resource HubLumenis OptiLIFT Dynamic Muscle Stimulation Device receives Health Canada Approval for Reducing Signs and Symptoms of Evaporative Dry Eye DiseaseREAD MOREClinical StudiesDry EyePeriorbital Muscle StimulationTreatment TypeVision Resource HubClinical StudiesDry EyePeriorbital Muscle StimulationTreatment TypeVision Resource HubThe Potential Benefits of Periorbital Transcutaneous Electrical Stimulation for the Management of Dry Eye DiseaseREAD MOREDry EyePeriorbital Muscle StimulationPress PublicationsTreatment TypeVision Resource HubDry EyePeriorbital Muscle StimulationPress PublicationsTreatment TypeVision Resource HubSisters Grow Practice Into Medical Hub for Dry Eye TreatmentREAD MORE 1 Toyos R, Desai NR, Toyos M, Dell SJ. Intense pulsed light improves signs and symptoms of dry eye disease due to meibomian gland dysfunction: A randomized controlled study. PLoS One. 2022;17(6):e0270268. Published 2022 Jun 23. doi:10.1371/journal.pone.0270268 2 Yin Y, Liu N, Gong L, Song N. Changes in the Meibomian Gland After Exposure to Intense Pulsed Light in Meibomian Gland Dysfunction (MGD) Patients. Curr Eye Res. 2018;43(3):308-313. doi:10.1080/02713683.2017.1406525 3 Liu, R., Rong, B., Tu, P., Tang, Y., Song, W., Toyos, R., Toyos, M., & Yan, X. (2017). Analysis of cytokine levels in tears and clinical correlations after intense pulsed light treating meibomian gland dysfunction. American Journal of Ophthalmology, 183, 81-90. https://doi.org/10.1016/j.ajo.2017.08.021 4 Yin Y, Liu N, Gong L, Song N. Changes in the Meibomian Gland After Exposure to Intense Pulsed Light in Meibomian Gland Dysfunction (MGD) Patients. Curr Eye Res. 2018;43(3):308-313. doi:10.1080/02713683.2017.1406525 5 Tutt R, Bradley A, Begley C, Thibos LN. Optical and visual impact of tear break-up in human eyes. Invest Ophthalmol Vis Sci. 2000;41:4117-4123. 6 Javate, R. M., Cruz, R. T. Jr., Khan, J., Trakos, N., & Gordon, R. E. (2011). Nonablative 4-MHz dual radiofrequency wand rejuvenation treatment for periorbital rhytides and midface laxity. Ophthalmic Plastic and Reconstructive Surgery, 27(3), 180-185. doi: 10.1097/IOP.0b013e3181fe8e5a 7 Al-Atif, H. (2022). Collagen supplements for aging and wrinkles: A paradigm shift in the fields of dermatology and cosmetics. Dermatology Practical & Conceptual, 12(1), e2022018. https://doi.org/10.5826/dpc.1201a18 8 Chelnis, J., Garcia, C. N., & Hamza, H. (2023). Multi-frequency RF combined with intense pulsed light improves signs and symptoms of dry eye disease due to meibomian gland dysfunction. Clinical Ophthalmology, 17, 3089-3102. https://doi.org/10.2147/OPTH.S426564 PB-00083760 Rev A #### Celebrity Testimonials INFLUENCER IMPACT Raising Awareness for Dry Eye Disease OUR INFLUENCERS Colton Underwood Former NFL Player,TV producer and host Chari Hawkins USA National Champion Ashley Tisdale Actress & Singer Candice King Actress Jaime Chung Actress Kerri Walsh Jennings Beach Volleyball player Jennie Garth Actress Tomas Nido Professional MLB player Colton Underwood shares his experience with DED and his care journey using OptiLIGHT and OptiLIFTMay 25, 2025WATCH NOWKerri Walsh Jennings Shares the Impact of OptiLIGHT Treatment on Her Dry Eye Disease!May 2, 2024WATCH NOWKerri Has Been Experiencing Dry, Itchy Eyes On And Off The Court For Years. Her Solution: OptiLIGHT!April 28, 2024WATCH NOWOptiLight Dry Eye Solution ft. Candice KingMarch 7, 2024WATCH NOWAshley Tisdale Found an Effective Solution for DED with OptiLIGHT by Lumenis’ Light-Based Therapy!January 4, 2024WATCH NOWHad Enough of Dry, Itchy Eyes? You Don’t Have To Live With That Anymore!January 4, 2024WATCH NOWHad Enough Of Dry, Itchy Eyes? Find A Real Solution With OptiLIGHT’s First And Only Light Therapy!January 4, 2024WATCH NOWTreat The Root Cause of Dry Eye Disease with OptiLIGHT by Lumenis Treatment!January 4, 2024WATCH NOWFind a Real Solution For Dry Eyes with OptiLIGHT”s Light Treatment! | OptiLIGHT by LumenisJanuary 4, 2024WATCH NOWThomas Nido’s OptiLIGHT Treatment Journey Unveiled!December 15, 2023WATCH NOWHear Thomas Nido’s Inspiring Journey with OptiLIGHT’s DED Treatment | OptiLIGHT by LumenisOctober 16, 2023WATCH NOWYou Don’t Have To Live With Dry Eyes Anymore! | OptiLIGHT By LumenisOctober 10, 2023WATCH NOW #### Choi et al (2019): Meibum Expressibility Improvement as a Therapeutic Target of Intense Pulsed Light Treatment in Meibomian Gland Dysfunction and Its Association with Tear Inflammatory Cytokines Choi et al (2019): Meibum Expressibility Improvement as a Therapeutic Target of Intense Pulsed Light Treatment in Meibomian Gland Dysfunction and Its Association with Tear Inflammatory Cytokines In a prospective, single arm study, Lumenis IPL with OPT™ improved signs and symptoms of Dry Eye Disease due to MGD, and decreased tear levels of key inflammation markers. The decrease of two of these markers were correlated with improvement in meibum expressibility. READ FULL STUDY Indication for Use: Improvement of signs of Dry Eye Disease (DED) due to Meibomian Gland Dysfunction (MGD), also known as evaporative dry eye or lipid deficiency dry eye, in patients 22 years of age and older with moderate to severe signs and symptoms of DED due to MGD and with Fitzpatrick skin types I-IV. IPL is to be applied only to skin on the malar region of the face, from tragus to tragus including the nose (eyes should be fully covered by protective eyewear). IPL is intended to be applied as an adjunct to other modalities, such as meibomian gland expression, artificial tear lubricants and warm compresses Treatment with M22 or OptiLight is contraindicated for patients with the following conditions in the treatment area: Ocular surgery or eyelid surgery or Neuro-paralysis within 6 months prior to the first treatment; Uncontrolled eye disorders affecting the ocular surface; Pre-cancerous lesions, skin cancer or pigmented lesions in the planned treatment area; Uncontrolled infections or uncontrolled immunosuppressive diseases; Recent Ocular infections; Prior history of cold sores or rashes in the perioral area, including: Herpes simplex 1 & 2, Systemic Lupus erythematosus and porphyria; Use of photosensitive medication and/or herbs that may cause sensitivity within 3 months prior to the first IPL session; Recent radiation therapy to the head or neck or planned radiation therapy; Recent treatment with chemotherapeutic agent or planned chemotherapy; History of migraines, seizures or epilepsy. Patients eyes must be completely occluded during the treatment. Please refer to the operator manual for a complete list of intended use, contraindications and risks. Please consult your physician as to whether this procedure is suitable for you. The following possible side effects can occur following IPL treatments: Pain/discomfort, damage to natural skin texture, change of pigmentation, scarring, excessive edema, fragile skin, bruising, burns, pruritus and xerosis. Please refer to the user manual or ask your doctor for a complete list of intended use, contraindications and risks. Lumenis has an interest in the study device (M22 system). All uses of the M22 system described in this paper were approved by the FDA, except the following: – The study concluded that both signs and symptoms of DED were improved by the use of IPL, whereas FDA cleared only improvement of signs. None of the authors had financial ties with Lumenis. No person known to Lumenis has provided funding for the study. The publication doesn’t discuss any unapproved uses of the device. Explore Other Resources Dry EyeNewsPeriorbital Muscle StimulationTreatment TypeVision Resource HubDry EyeNewsPeriorbital Muscle StimulationTreatment TypeVision Resource HubLumenis OptiLIFT Dynamic Muscle Stimulation Device receives Health Canada Approval for Reducing Signs and Symptoms of Evaporative Dry Eye DiseaseREAD MOREClinical StudiesDry EyePeriorbital Muscle StimulationTreatment TypeVision Resource HubClinical StudiesDry EyePeriorbital Muscle StimulationTreatment TypeVision Resource HubThe Potential Benefits of Periorbital Transcutaneous Electrical Stimulation for the Management of Dry Eye DiseaseREAD MOREDry EyePeriorbital Muscle StimulationPress PublicationsTreatment TypeVision Resource HubDry EyePeriorbital Muscle StimulationPress PublicationsTreatment TypeVision Resource HubSisters Grow Practice Into Medical Hub for Dry Eye TreatmentREAD MORE PB-00038930 Rev A #### Colton Underwood shares his experience with DED and his care journey using OptiLIGHT and OptiLIFT Colton Underwood shares his experience with DED and his care journey using OptiLIGHT and OptiLIFT May 25, 2025 Share   Colton Underwood shares his experience with DED and his care journey using OptiLIGHT and OptiLIFT. Watch more videos Colton Underwood shares his experience with DED and his care journey using OptiLIGHT and OptiLIFTMay 25, 2025WATCH NOWKerri Walsh Jennings Shares the Impact of OptiLIGHT Treatment on Her Dry Eye Disease!May 2, 2024WATCH NOWKerri Has Been Experiencing Dry, Itchy Eyes On And Off The Court For Years. Her Solution: OptiLIGHT!April 28, 2024WATCH NOW PB-00090620 #### Controversies – Selective Laser Trabeculoplasty vs. Filtration Surgery Controversies – Selective Laser Trabeculoplasty vs. Filtration Surgery Description: Controversies: Selective Laser Trabeculoplasty vs. Filtration Surgery Duration: 62 mins Publish Date: October 21, 2011 Speaker: Dr. Donalid Budenz, Dr. Steven Gedde Explore Other Resources Dry EyeNewsPeriorbital Muscle StimulationTreatment TypeVision Resource HubDry EyeNewsPeriorbital Muscle StimulationTreatment TypeVision Resource HubLumenis OptiLIFT Dynamic Muscle Stimulation Device receives Health Canada Approval for Reducing Signs and Symptoms of Evaporative Dry Eye DiseaseREAD MOREClinical StudiesDry EyePeriorbital Muscle StimulationTreatment TypeVision Resource HubClinical StudiesDry EyePeriorbital Muscle StimulationTreatment TypeVision Resource HubThe Potential Benefits of Periorbital Transcutaneous Electrical Stimulation for the Management of Dry Eye DiseaseREAD MOREDry EyePeriorbital Muscle StimulationPress PublicationsTreatment TypeVision Resource HubDry EyePeriorbital Muscle StimulationPress PublicationsTreatment TypeVision Resource HubSisters Grow Practice Into Medical Hub for Dry Eye TreatmentREAD MORE #### COVID-19 Pandemic: Tips for Staying Connected with Dry Eye Patients COVID-19 Pandemic: Tips for Staying Connected with Dry Eye Patients June 24, 2020 Flying home from a conference on March 7th, absorbing the latest news about COVID-19, I knew I needed to implement a shutdown strategy upon my return. When we closed on March 21st, we were prepared to continue remote services where possible and stay connected with our patients, including a large number receiving comprehensive dry eye management. Here are some tips to help you stay connected and serve your dry eye patients during the COVID-19 pandemic: • Update patients about dry eye procedures and supplies – Before our office closed, we alerted all dry eye patients about the closure date and encouraged them to stock up on the products they would need for the next 3 months. We continued doing scheduled IPL (Optima IPL*, Lumenis) and other procedures until shutdown, even moving up some procedures. I spoke by phone with about a dozen patients who were in the middle of a series of 4 IPL sessions and explained that if the Stay Home – Work Safe order was prolonged, IPL would still be effective, but we might need to add a fifth session. Everyone understood. • Encourage continued home care – Most of our dry eye patients have individual treatment plans that include a daily hygiene routine for lids/lashes, preservative-free artificial tears, prescription medication and nutritional supplements. In our e-newsletter communications with our patient base, we have included a special section for dry eye patients and emphasized that following their plan will help them to feel better throughout lockdown and maintain their ocular surface health. • Offer remote services – Prior to the March 21 – April 30 office closure, we set up secure remote EMR access, arranged online credit card processing, transferred office calls, informed our patient base, and moved administrative operations online. During the closure, team members answered calls and emails Monday through Friday, 9 a.m. to 5 p.m. Our doctors offered telehealth consultations and provided medical eye emergency care at the office while observing strict disinfection and PPE protocols. We arranged either product shipping or scheduled curb-side dispensing for those patients that needed additional dry eye supplies. Our patients have appreciated the fact that they could reach us easily during the closure and their needs were taken care of in a timely and safe manner. • Stay visible and positive in social media feeds – Since everyone is at home staring at their devices, we have posted regularly on our Instagram, Facebook, and Twitter accounts (@visionoptique). In my own Instagram account (@DrBridgitte), my COVID-19 journal with 200+ stories has been viewed tens of thousands of times. Some of our posts remind patients to continue dry eye home care, as well as explain the dry eye services available after we re-open. • Focus on what’s next – Our team is building a brand new website to promote our specialty eye care services, including the Dry Eye Center, and our online store for ocular surface and cosmetics products. It is important that we stay connected with our dry eye patients with clear and compassionate communication throughout the COVID-19 pandemic. When we reopen, the transition will be easier because we have stayed in touch. Now that AOA has confirmed that the CDC’s March 17 nationwide recommendation to postpone routine eye care is no longer in effect, we are re-opening with safety precautions in place on May 1! For the months of May and June, we have adopted procedures to employ principles of social distancing, limiting gatherings, and infection prevention. For example, only one doctor will see patients each day, we will book one patient per 45 minutes and disinfect between patients, we will use PPE, and the practice will run physical and virtual operations concurrently. We look forward to seeing all of our patients again and resuming management of dry eye disease. *inflammatory skin conditions such as Rosacea, untreated, can lead to Meibomian Gland Dysfunction. As such, 80% of Rosacea patients are suffering from Meibomian Gland Dysfunction. Optima IPL is used to treat Rosacea, which allows to break the inflammatory process that may lead to Meibomian Gland Dysfunction. Explore Other Resources Dry EyeNewsPeriorbital Muscle StimulationTreatment TypeVision Resource HubDry EyeNewsPeriorbital Muscle StimulationTreatment TypeVision Resource HubLumenis OptiLIFT Dynamic Muscle Stimulation Device receives Health Canada Approval for Reducing Signs and Symptoms of Evaporative Dry Eye DiseaseREAD MOREClinical StudiesDry EyePeriorbital Muscle StimulationTreatment TypeVision Resource HubClinical StudiesDry EyePeriorbital Muscle StimulationTreatment TypeVision Resource HubThe Potential Benefits of Periorbital Transcutaneous Electrical Stimulation for the Management of Dry Eye DiseaseREAD MOREDry EyePeriorbital Muscle StimulationPress PublicationsTreatment TypeVision Resource HubDry EyePeriorbital Muscle StimulationPress PublicationsTreatment TypeVision Resource HubSisters Grow Practice Into Medical Hub for Dry Eye TreatmentREAD MORE PB-00016680 #### Dell et al. (2017): Prospective evaluation of intense pulsed light and meibomian gland expression efficacy on relieving signs and symptoms of dry eye disease due to meibomian gland dysfunction Dell et al. (2017): Prospective evaluation of intense pulsed light and meibomian gland expression efficacy on relieving signs and symptoms of dry eye disease due to meibomian gland dysfunction In a prospective single arm study, Lumenis IPL with OPT™ combined with MGX reduced the number and severity of symptoms and signs of dry eye disease in subjects with moderate to severe MGD. READ FULL STUDY Steven J Dell et, MD Indication for Use: Improvement of signs of Dry Eye Disease (DED) due to Meibomian Gland Dysfunction (MGD), also known as evaporative dry eye or lipid deficiency dry eye, in patients 22 years of age and older with moderate to severe signs and symptoms of DED due to MGD and with Fitzpatrick skin types I-IV. IPL is to be applied only to skin on the malar region of the face, from tragus to tragus including the nose (eyes should be fully covered by protective eyewear). IPL is intended to be applied as an adjunct to other modalities, such as meibomian gland expression, artificial tear lubricants and warm compresses Treatment with M22 or OptiLight is contraindicated for patients with the following conditions in the treatment area: Ocular surgery or eyelid surgery or Neuro-paralysis within 6 months prior to the first treatment; Uncontrolled eye disorders affecting the ocular surface; Pre-cancerous lesions, skin cancer or pigmented lesions in the planned treatment area; Uncontrolled infections or uncontrolled immunosuppressive diseases; Recent Ocular infections; Prior history of cold sores or rashes in the perioral area, including: Herpes simplex 1 & 2, Systemic Lupus erythematosus and porphyria; Use of photosensitive medication and/or herbs that may cause sensitivity within 3 months prior to the first IPL session; Recent radiation therapy to the head or neck or planned radiation therapy; Recent treatment with chemotherapeutic agent or planned chemotherapy; History of migraines, seizures or epilepsy. Patients eyes must be completely occluded during the treatment. Please refer to the operator manual for a complete list of intended use, contraindications and risks. Please consult your physician as to whether this procedure is suitable for you. The following possible side effects can occur following IPL treatments: Pain/discomfort, damage to natural skin texture, change of pigmentation, scarring, excessive edema, fragile skin, bruising, burns, pruritus and xerosis. Please refer to the user manual or ask your doctor for a complete list of intended use, contraindications and risks. Dr. Gaster was paid a fixed amount per patient who completed the study. Dr. Steven Dell and Dr. Gaster were consultants of Lumenis. Lumenis sponsored the study. No person known to Lumenis has provided funding for the study. Explore Other Resources Dry EyeNewsPeriorbital Muscle StimulationTreatment TypeVision Resource HubDry EyeNewsPeriorbital Muscle StimulationTreatment TypeVision Resource HubLumenis OptiLIFT Dynamic Muscle Stimulation Device receives Health Canada Approval for Reducing Signs and Symptoms of Evaporative Dry Eye DiseaseREAD MOREClinical StudiesDry EyePeriorbital Muscle StimulationTreatment TypeVision Resource HubClinical StudiesDry EyePeriorbital Muscle StimulationTreatment TypeVision Resource HubThe Potential Benefits of Periorbital Transcutaneous Electrical Stimulation for the Management of Dry Eye DiseaseREAD MOREDry EyePeriorbital Muscle StimulationPress PublicationsTreatment TypeVision Resource HubDry EyePeriorbital Muscle StimulationPress PublicationsTreatment TypeVision Resource HubSisters Grow Practice Into Medical Hub for Dry Eye TreatmentREAD MORE PB-00038930 Rev A #### Digital Duet THE DIGITAL SLT AND YAG PLATFORM FROM THE INVENTORS OF SLT. THE FUTURE OF SLT YAG COMBINATION STARTS HERE LASER THERAPY INNOVATION
BEGINS WITH LUMENIS REQUEST DEMO DOWNLOAD THE PRODUCT KIT Close Close SEE YOUR PATIENTS CLEARLY Digital Duet delivers live view and imaging through an integrated HD digital camera, enabling capturing and sharing of high quality images 
and videos. Versatile Applications: from pathology documentation to before-and-after comparisons for treatment evaluation. Advance training and education with powerful visuals for professional learning. A FULLY DIGITAL CLINICAL WORKFLOW The first and only digital SLT/YAG platform, harnessing the power of digitalization to transform ophthalmic workflows. Automatically generate and export clinical treatment reports. Seamless integration with your data & patient management systems (EMR/EHR). DICOM compatible. Full HD & HDMI connectivity to an external screen. 15.6″ Full HD touchscreen with a doctor-focused UI and new clinical presets. HEADS UP DISPLAY. TOTAL FOCUS. Everything you need is inside the binoculars. The heads up display projects real time treatment parameters so you never need to look away. Live projection of laser mode, energy, and pulse data. Real time control without breaking focus. Enhanced procedural flow. OPTIMIZED VISUALIZATION DURING TREATMENT Smart V technology for optimized visualization – enables titratable on axis and off axis illumination during treatment. Increased visualization during capsulotomy and iridotomy. Optimized control on red-reflex. Illumination of vitreous opacities. DESIGNED AROUND THE DOCTOR AND THE PATIENT Digital Duet combines compact design, mobility, and accessibility to support modern ophthalmic practices. Compact all in one SLT and YAG platform, upgradeable to Digital Trio. ADA compliant design – Wheelchair accessible dual-motor tabletop. Premium, precision-engineered optics YAG Anterior & Posterior offset. 15.6″ Full HD touchscreen with a doctor-focused UI. HD digital camera – delivers real-time visualization during procedures. Dedicated button to easily capture images during the treatment. Extremely low optical breakdown <strong>Smart-V</strong><br /> titratable on-axis/off-axis illumination for increased visualization during capsulotomy and iridotomy and illumination of vitreous opacities Dual-motor tabletop, ensuring unobstructed access for wheelchair users. BACKED BY LUMENIS CLINICAL LEADERSHIP With decades of experience in ophthalmic laser innovation and participation in landmark studies such as LiGHT, Lumenis continues to define the standard for SLT/YAG treatment. EXPERIENCE DIGITAL DUET UPGRADE YOUR VISUALIZATION. STREAMLINE YOUR WORKFLOW. DELIVER CONFIDENT LASER FOR GLAUCOMA TREATMENT. REQUEST DEMO DOWNLOAD THE PRODUCT KIT YAG Photodisruptor Mode SLT Mode Wavelength 1064 nm 532 nm Energy 0.3–10 mJ per pulse, up 
to burst of 3 pulses 0.3–2 mJ Pulse Duration 3 nano-seconds 3 nano-seconds Repetition Rate 3 Hz 3 Hz Spot Size 8 µm 400 µm Digital Camera High Definition (HD) Resolution High Definition (HD) Resolution Risk and warnings: Digital Duet/Trio are intended for use by trained physicians. For all indications, use is contraindicated when media opacities interfere with clear visualization. Selective laser Trabeculoplasty is contraindicated for eyes with neovascular or angle-closure glaucoma; risks include iritis and transient IOP rise. Posterior Capsulotomy is contraindicated for eyes with extensive corneal dystrophy and chronically elevated IOP; risks include IOP rise, rupture of the hyaloid face, retinal damage, and uveitis. Iridotomy is contraindicated for eyes without pupillary block; risks include transient elevation of IOP, hyphemia, and damage to the lens/retina/choroid. Inadvertent photocoagulation with Smart532, especially close to the fovea or the optic nerve head, can cause permanent visual loss. Major retinal vessels should be avoided. For a complete list of contraindications and risks, refer to the operator manuals. 0044 PB-00022541 Rev A #### Digital Duet 2.0 with Dr. Jai Blog PostsGlaucoma Digital Duet 2.0 with Dr. Jai February 25, 2026 Dr. Jai Parekh, MD, MBA, FAAO Dr. Jai Parekh is a board-certified anterior segment eye surgeon who specializes in ocular surface disease and advanced dry eye, cornea, cataract, and interventional glaucoma. He is a co-founder of EyeCare Consultants of NJ, bringing over 25 years of expertise to his patients. Dr. Parekh is also a Clinical Associate Professor of Ophthalmology at the New York Eye & Ear Infirmary and Icahn School of Medicine at Mount Sinai. After years of treating glaucoma patients, I’ve seen the field move toward interventional glaucoma—an approach that relies on lasers, drug delivery, and minimally invasive glaucoma surgery (MIGS), and reduces the long-term burden of topical eye drops. In our office and practice, SLT has become a cornerstone of that shift. I’ve seen firsthand how taking a proactive, rather than a reactive, approach to managing glaucoma can improve clinical outcomes, ensure better compliance, and simplify patient care. Because SLT plays such a central role in how I treat glaucoma, the laser I use matters—and Digital Duet 2.0 sets the new gold standard in SLT+YAG technology for glaucoma and posterior capsulotomy treatment. This next-generation platform from Lumenis, the inventor of SLT, combines imaging and connectivity with a user-centric experience that transforms how ophthalmologists operate. It checks all the boxes: safety, efficacy, efficiency, and ease of use. What’s New with Digital Duet 2.0 For me, the upgrade to Digital Duet 2.0 feels like going from an older iPhone straight to an “iPhone 20,” which has yet to even exist. It’s that kind of leap where everything is faster, sharper, and far more intuitive the moment you start using it. Digital Duet 2.0’s tailored design brings advanced high-resolution imaging to the center of ophthalmic care. Its enhanced integrated camera enables live viewing, high-quality image capture, and video recording, supporting diagnosis, documentation, and communication. I can capture angle imagery, monitor disease progression, and even use these recordings as a teaching tool for my staff or to help patients better understand their condition. It also includes adjustable imaging brightness and optimized visualization, further improving precision. Digital Duet 2.0 combines these advanced digital capabilities with Lumenis’s best-in-class SLT+YAG laser technology. The system features the premium optics of Lumenis engineering, a super-Gaussian beam profile, and SmartV titratable on-axis/off-axis illumination, all of which contribute to optimal visualization and energy efficiency. Beyond its glaucoma applications, Digital Duet 2.0 also elevates YAG capsulotomy. As more post-cataract surgery patients expect to avoid glasses, even a thin layer of posterior capsule opacification can affect their vision. With this platform, clearing that Saran Wrap-like tissue takes only seconds. The enhanced interface and precision optics make the procedure smoother for surgeons and more comfortable for patients. Workflow benefits The platform brings meaningful upgrades to clinical workflow. Digital Duet 2.0 integrates network-ready connectivity and automated reporting, connecting directly with EMR/EHR systems to simplify documentation and ensure secure data exchange. Customizable clinical reports are generated automatically to reduce administrative burden for my staff, and the full HD 15.6-inch touchscreen and heads-up display integrate imaging, data, and laser controls into a single, intuitive workspace. With optimized anterior and posterior offset, the system provides more flexibility and offers a premium experience that complements high-performing ophthalmic practices like mine. Ultimately, these workflow improvements give us greater flexibility. In a busy clinic, every minute counts, and the design of Digital Duet 2.0 allows me to move easily between rooms, add patients when needed, and work through a full SLT morning or afternoon without feeling rushed. My scribe can say, “Go to room five,” and I can step in to perform an SLT without disrupting the schedule. When a system can be operated instantly and stays ready throughout the day, we can treat more patients while maintaining a steady, safe pace of care. Backed by the LiGHT trial As we look at what Digital Duet 2.0 brings to SLT, it’s important to consider the strength of the evidence behind this procedure. The multicenter, randomized LiGHT trial compared SLT with topical medications and followed patients for six years, showing that SLT performed exceptionally well as a first-line treatment. A more recent detailed analysis of the data demonstrated that visual field progression was 29% slower in the SLT-first group compared with the drops-first group, confirming earlier findings. The LiGHT trial consistently showed that SLT did a terrific job caring for these patients. For me, it reinforces what we see in practice every day: SLT helps reduce polypharmacy, improves compliance, and gives patients a healthier ocular surface. It’s why so many of us have shifted to using lasers earlier—often first line, or as a replacement for one or even two drops in patients who have struggled with long-term medication use. That’s why the technology delivering SLT matters, and Digital Duet 2.0’s next-generation platform directly supports the level of care the LiGHT trial helped establish. Why it Matters You can’t prevent glaucoma, but you can prevent progression—and the one thing we can control right now is pressure. Digital Duet 2.0 gives us a safe way to treat earlier, reduce drop dependence, and preserve the ocular surface. Nobody wants to lose their sight, and nobody wants a lifetime of medication burden. That’s why having the right platform matters. Digital Duet 2.0 brings together proven laser technology with a doctor-focused design to support where interventional glaucoma is headed—leading to a better experience for both patients and practices. When the laser we use is fast, consistent, and built for how we actually work, it strengthens everything we’re trying to accomplish: safer care, better outcomes, and the ability to meet patients where they are. Explore Other Resources Dry EyeNewsPeriorbital Muscle StimulationTreatment TypeVision Resource HubDry EyeNewsPeriorbital Muscle StimulationTreatment TypeVision Resource HubLumenis OptiLIFT Dynamic Muscle Stimulation Device receives Health Canada Approval for Reducing Signs and Symptoms of Evaporative Dry Eye DiseaseREAD MOREClinical StudiesDry EyePeriorbital Muscle StimulationTreatment TypeVision Resource HubClinical StudiesDry EyePeriorbital Muscle StimulationTreatment TypeVision Resource HubThe Potential Benefits of Periorbital Transcutaneous Electrical Stimulation for the Management of Dry Eye DiseaseREAD MOREDry EyePeriorbital Muscle StimulationPress PublicationsTreatment TypeVision Resource HubDry EyePeriorbital Muscle StimulationPress PublicationsTreatment TypeVision Resource HubSisters Grow Practice Into Medical Hub for Dry Eye TreatmentREAD MORE PB-00094455 #### Digital Duet in Togo: Insights from an Unforgettable Clinical and Professional Journey Digital Duet in Togo: Insights from an Unforgettable Clinical and Professional Journey In Africa, glaucoma presents a uniquely difficult problem, as its high prevalence is compounded by economic barriers to essential medical care. Selective laser trabeculoplasty (SLT) is a potentially transformative modality in this setting, presenting an opportunity for quick, safe, and effective long-term treatment. During a trip to Togo, West Africa, Dr.Shlomo Melamed, MD and his colleagues taught local ophthalmologists to perform SLT using Digital Duet. READ FULL ARTICLE Explore Other Resources Dry EyeNewsPeriorbital Muscle StimulationTreatment TypeVision Resource HubDry EyeNewsPeriorbital Muscle StimulationTreatment TypeVision Resource HubLumenis OptiLIFT Dynamic Muscle Stimulation Device receives Health Canada Approval for Reducing Signs and Symptoms of Evaporative Dry Eye DiseaseREAD MOREClinical StudiesDry EyePeriorbital Muscle StimulationTreatment TypeVision Resource HubClinical StudiesDry EyePeriorbital Muscle StimulationTreatment TypeVision Resource HubThe Potential Benefits of Periorbital Transcutaneous Electrical Stimulation for the Management of Dry Eye DiseaseREAD MOREDry EyePeriorbital Muscle StimulationPress PublicationsTreatment TypeVision Resource HubDry EyePeriorbital Muscle StimulationPress PublicationsTreatment TypeVision Resource HubSisters Grow Practice Into Medical Hub for Dry Eye TreatmentREAD MORE PB-00043680 Rev C #### Digital Trio Laser Therapy Reimagined Taking Glaucoma and Retina treatments to the Next Level The Digital Trio reimagines laser therapy with the first digital dual path SLT-YAG platform on the market. The Digital Trio configuration adds a state-of-the-art retinal care photocoagulator to the digital dual path SLT-YAG system. The platform is a comprehensive digital and imaging solution that streamlines practice efficiency and offers new ways to communicate with patients and peers. Experience laser therapy reimagined with the Digital Duet and Digital Trio. With the revolutionary Digital Trio, Lumenis has completely reimagined the laser platform as a comprehensive solution for digital imaging, treatment and practice efficiency. Diagnosis and decision-making are enhanced with digital image and video capture capabilities, seamlessly saved to the network and the EMR.* The Digital Trio offers the power of three: digital dual path SLT-YAG with an integrated state-of-the-art Smart532 photocoagular with SmartPulse subthreshold capabilities, ensuring maximal efficacy with minimal collateral damage. This ideal all-in-one solution allows physicians to expand retina treatments as well as to further optimize iridotomy. WATCH VIDEO DOWNLOAD KIT Close Bringing Clarity to Your Practice Streamline Workflow Accelerate practice efficiency by seamlessly connecting the EMR, reporting and integrated imagery. Revolutionize Education Capture digital images and videos. Offer live viewing for clear education of patients and students. Smart V Titratable Illumination Optimize visualization during capsulotomy and iridotomy and illuminate vitreous opacities with on-axis/off-axis illumination. The Next Evolution The first and only comprehensive digital laser and imaging platform The Digital Trio opens the door to a new era in laser therapy – one where the seamless integrated connectivity of digital images and video becomes the cornerstone of care. The Digital Trio offers the most technologically advanced SLT-YAG lasers and state-of-the-art Smart532 photocoagular with SmartPulse subthreshold capabilities. Experience how the Digital Trio: Introduces image/video capture capabilities before, during, and after treatment to document pathologies, angle imagery and treatment outcomes – no need for additional imaging device Optimizes workflow through seamless report generation, eliminating the need for laser logs and allowing quicker communication with referring doctors Offers integrated direct, remote support, ensuring minimized downtime and practice efficiency Revolutionizes the educational paradigm by enabling live training for students and images/videos for studies and lectures Extremely low optical breakdown Smart-V</p> <p>titratable on-axis/off-axis illumination for increased visualization during capsulotomy and iridotomy and illumination of vitreous opacities High Definition camera and advanced image optimization Smart532 green photocouagulator with SmartPlus subthreshold technology Dedicated button to take images during the treatment Wheelchair accessible table with convenient control features 12inch touch screen, “smart-phone” experience and export to USB, Network and EMR Vision Resource Hub Here’s the latest inspiring stories, news, insights, and strategies to move your business forward. LEARN MORE Exceptional Precision and Safety Super-Gaussian Beam Profile Superior accuracy and precision combine with the rapid-firing rate of 3 shots per second. Superior Optics with Maximum Accuracy State-of the art optics provide optimal visibility of the trabecular meshwork and anterior segment. WHAT ARE THE EXPERTS SAYING? Reimaging your practice with Digital Trio™ Nathan M. Radcliffe, MD Digital Duet: Reimagining the practice “The Digital Duet is a different paradigm… Your laser is the imaging system.” Dr. Nathan M. Radcliffe explains the revolutionary nature of the Lumenis Digital Duet and the how its imaging and connectivity capabilities are changing his practice. Nathan M. Radcliffe, MD The next level of the gold standart technology Dr. Nathan M. Radcliffe explains how the Digital Duet optimizes clinical capabilities with the patented SmartV titratbale illumination technology, superior optics, Super-Gaussian beam profile, and Digital Trio option for practices expanding into retina procedures. Digital trio™ SPECIFICATIONS YAG Photodisruptor Mode SLT Mode Wavelength 1064nm 532nm Energy 0.3-10 mJ per pulse, up to burst of 3 pulses 0.3-2 mJ Pulse Duration 3 nano-seconds 3 nano-seconds Repetition Rate 3 Hz 3 Hz Spot Size 8 μm 400 μm Digital Camera High Definition (HD) Resolution High Definition (HD) Resolution WANT TO LEARN MORE? Download Digital Trio™ kit Get comprehensive information, detailed brochures and product reviewing videos here DOWNLOAD KIT *Connectivity is through a repository folder with a compatible format between the Digital Duet device and most EMR systems. 1 Gazzard G, Konstantakopoulou E, Garway-Heath D, et. al. Selective laser trabeculoplasty versus eye drops for first-line treatment of ocular hypertension and glaucoma (LiGHT): a multicentre randomised controlled trial. Lancet. 2019;393 (10180):1505-1516. Risk and warnings: Digital Duet/Trio are intended for use by trained physicians. For all indications, use is contraindicated when media opacities interfere with clear visualization. Selective laser Trabeculoplasty is contraindicated for eyes with neovascular or angle-closure glaucoma; risks include iritis and transient IOP rise. Posterior Capsulotomy is contraindicated for eyes with extensive corneal dystrophy and chronically elevated IOP; risks include IOP rise, rupture of the hyaloid face, retinal damage, and uveitis. Iridotomy is contraindicated for eyes without pupillary block; risks include transient elevation of IOP, hyphemia, and damage to the lens/retina/choroid. Inadvertent photocoagulation with Smart532, especially close to the fovea or the optic nerve head, can cause permanent visual loss. Major retinal vessels should be avoided. For a complete list of contraindications and risks, refer to the operator manuals. PB-00022540 Rev A #### Discussing DED treatment cost can help build trust and lead to more same-day procedures Discussing DED treatment cost can help build trust and lead to more same-day procedures November 28, 2023 Cory Lappin, OD shares his strategies for getting comfortable with talking treatment costs to build trust and convert more same-day OptiLIGHT procedures. Read Full Article *OptiLIGHT is intended to be used by licensed practitioners, according to local rules and regulations. Explore Other Resources Dry EyeNewsPeriorbital Muscle StimulationTreatment TypeVision Resource HubDry EyeNewsPeriorbital Muscle StimulationTreatment TypeVision Resource HubLumenis OptiLIFT Dynamic Muscle Stimulation Device receives Health Canada Approval for Reducing Signs and Symptoms of Evaporative Dry Eye DiseaseREAD MOREClinical StudiesDry EyePeriorbital Muscle StimulationTreatment TypeVision Resource HubClinical StudiesDry EyePeriorbital Muscle StimulationTreatment TypeVision Resource HubThe Potential Benefits of Periorbital Transcutaneous Electrical Stimulation for the Management of Dry Eye DiseaseREAD MOREDry EyePeriorbital Muscle StimulationPress PublicationsTreatment TypeVision Resource HubDry EyePeriorbital Muscle StimulationPress PublicationsTreatment TypeVision Resource HubSisters Grow Practice Into Medical Hub for Dry Eye TreatmentREAD MORE LEARN HOW YOU CAN ELEVATE YOUR PRACTICE DOWNLOAD OPTILIGHT INFO KIT Learn about the first and only IPL FDA approved for dry eye management PB-00043680 Rev C #### Diversify Your Practice for Long-term Success Diversify Your Practice for Long-term Success August 31, 2021 Students often ask me, “Will all of this education, training and money be worth it in the long run? Can we have long, viable careers in optometry?” The answer is an emphatic yes, and the key to making it happen is diversification. Rather than worrying about retail competition with online sources for glasses and contact lenses, ODs need to embrace the totality of primary care optometry. Yes, that means offering optical services, but it also means providing full-service eye care, including management of eye diseases. Here are some tips for building a diverse, healthy practice: Immerse yourself in full-service eye care. Optometrists have been free to manage anterior and posterior eye diseases for decades. Now those opportunities are more important than ever to a practice’s financial health. Depending on your preferences, you can offer your patients glasses and contacts as well as treatment for infection, dry eye disease, corneal ulcers, glaucoma, macular degeneration, diabetic macular edema, and more. You can treat diseases using office-based procedures that provide the practice with either reliable reimbursement or the opportunity for cash revenues. Depending on your state, the options for in-office procedures may include popular unreimbursed options such as Optima IPL, which treats periocular inflammation,* and thermal pulsation, which treats the symptoms of meibomian gland dysfunction. You may be able to treat your glaucoma patients with selective laser trabeculoplasty (SLT) (Selecta Duet), an option many doctors are recommending earlier in the disease process to reduce reliance on medications and avoid compliance problems. In some states, optometrists also can perform intralesional injections of steroid for chalazion, YAG capsulotomy and benign lump and bump removal. This diversity of medical options builds optometrists’ full-service profile while growing the practice’s revenues.   Make dry eye management a priority. For optometrists who are just starting to adopt the medical model, dry eye management is a good first step for three reasons. First, the disease is exceedingly common, so screening and treatment are inherent parts of treating most patients. In fact, many doctors who have been in practice for years start out by treating their existing patients. Second, the bar for treating dry eye is very low in terms of additional training or expense, but the rewards are very high for your patients and your practice. Third, dry eye can be treated with a range of effective in-office procedures that provide cash revenue for the practice. You can manage mild to moderate disease with artificial tears and prescription medications, and then acquire the equipment to perform in-office procedures to improve patient care by providing more complete, long-term relief. It’s common to see patients who have suffered for years without diagnosis or adequate treatment at their wit’s end from seeing multiple doctors, but after four Optima IPL sessions, they’re incredibly grateful and enthusiastic. Those patients become vocal advocates for the practice, bringing in more patients to have the procedure. And because dry eye is a chronic, progressive condition, those patients remain in the practice for years of ongoing management. As I tell students: dry eye is one of the “bread and butters” of medical optometry. Embrace eye care’s ever-changing technologies. Optometry is a dynamic field, and there are always new technologies that improve our work. Stay on top of the latest, best advances, whether you’re giving state-of-the-art refractions with an automated phoropter, treating glaucoma patients with SLT, performing cutting-edge dry eye procedures, or using advanced imaging and diagnostic modalities. By doing so, you give patients the best possible care, stay relevant in the community, and maintain the practice’s financial health. By becoming full-service eye care providers, optometrists achieve the diversity that’s required to support a practice for decades. Greet the new possibilities with excitement, as not only will they provide financial security, but they also will ensure that your patients have the best care and you have a stimulating and rewarding career.   *Lumenis M22 Optima IPL is authorized for use to treat Meibomian Gland Dysfunction, the leading type of dry eye disease, in: the European Union (CE), China, Australia, New Zealand, South Korea, Brazil, and Hong Kong. In the US, the device is cleared for treatment of inflammatory skin conditions such as rosacea. Rosacea may lead to ocular surface conditions such as MGD, with 80% of Rosacea patients suffering from MGD. Treatment of Rosacea with the M22 has not been clinically proven to prevent or delay the development of MGD. Explore Other Resources Dry EyeNewsPeriorbital Muscle StimulationTreatment TypeVision Resource HubDry EyeNewsPeriorbital Muscle StimulationTreatment TypeVision Resource HubLumenis OptiLIFT Dynamic Muscle Stimulation Device receives Health Canada Approval for Reducing Signs and Symptoms of Evaporative Dry Eye DiseaseREAD MOREClinical StudiesDry EyePeriorbital Muscle StimulationTreatment TypeVision Resource HubClinical StudiesDry EyePeriorbital Muscle StimulationTreatment TypeVision Resource HubThe Potential Benefits of Periorbital Transcutaneous Electrical Stimulation for the Management of Dry Eye DiseaseREAD MOREDry EyePeriorbital Muscle StimulationPress PublicationsTreatment TypeVision Resource HubDry EyePeriorbital Muscle StimulationPress PublicationsTreatment TypeVision Resource HubSisters Grow Practice Into Medical Hub for Dry Eye TreatmentREAD MORE PB-00020600 Rev A #### Doubling Down on Innovation: Why Dr. Nikki Iravani Invested in Two OptiLIFT Systems Press PublicationsDry EyePeriorbital Muscle Stimulation Doubling Down on Innovation: Why Dr. Nikki Iravani Invested in Two OptiLIFT Systems February 4, 2026 Nikki Iravani, OD Nikki Iravani, OD, founder of eyeXam Optometry in Newport Beach and Santa Clara, focuses on delivering premium, technology-forward patient experience. Her growing interest in wellness and aesthetics led her to add OptiLIFT to both locations. “Patients love how quick and comfortable it is,” she says, noting the immediate refreshed look many experience. Dr. Iravani sees OptiLIFT as a natural extension of her approach to elevating everyday eye care. Dr. Nikki Iravani chose to bring OptiLIFT into both of her eyeXam practices. She highlights strong patient interest, the simplicity of the treatment, and the visible aesthetic improvements it provides. OptiLIFT fits into her broader effort to expand her offerings beyond traditional eye exams into wellness and aesthetics. Read Full Article *OptiLIGHT and OptiPLUS are intended to be used by licensed practitioners, according to local rules and regulations. DOWNLOAD INFO KIT Discover how OptiLIFT can transform your practice. Contact us for a free demo or to learn more! Close Explore Other Resources Dry EyeNewsPeriorbital Muscle StimulationTreatment TypeVision Resource HubDry EyeNewsPeriorbital Muscle StimulationTreatment TypeVision Resource HubLumenis OptiLIFT Dynamic Muscle Stimulation Device receives Health Canada Approval for Reducing Signs and Symptoms of Evaporative Dry Eye DiseaseREAD MOREClinical StudiesDry EyePeriorbital Muscle StimulationTreatment TypeVision Resource HubClinical StudiesDry EyePeriorbital Muscle StimulationTreatment TypeVision Resource HubThe Potential Benefits of Periorbital Transcutaneous Electrical Stimulation for the Management of Dry Eye DiseaseREAD MOREDry EyePeriorbital Muscle StimulationPress PublicationsTreatment TypeVision Resource HubDry EyePeriorbital Muscle StimulationPress PublicationsTreatment TypeVision Resource HubSisters Grow Practice Into Medical Hub for Dry Eye TreatmentREAD MORE PB-00094865 #### Dry eye and Optima™ IPL OPTIMA IPL Treat the root cause: chronic inflammation Optima IPL is a drug free, drop free light-based treatment, which targets the root causes – chronic inflammation. Optima IPL treats periocular inflammatory conditions such as Rosacea and telangiectasia, which may lead to ocular surface conditions such as Dry Eye6,7. 80% of rosacea patients suffer from Meibomian Gland Dysfunction. WATCH VIDEO DOWNLOAD KIT Close STOP THE VICIOUS CYCLE OF INFLAMMATION Reduces inflammatory mediators Decreases the level of pro inflammatory mediators, progressing the inflammation3, 4 Alleviates Abnormal Blood vessels Destroys the abnormal blood vessels that are perpetuating the inflammation1,2 Decreases Demodex Decreases Demodex mites which are stimulating infection leading to inflammation5 ENERGY TO EYE CARE Uniquely designed for the periocular region The Optima IPL is the next-generation IPL technology developed by Lumenis. With every pulse of light, this first-of-its-kind, energy-based therapy works to control the inflammatory process and to stop the vicious cycle of inflammation Reducing the need for medications and providing long-lasting results. Friendly user interface for easy, convenient use Specific presets for treatment of periocular conditions as well as additional skin indications. SapphireCool™ tip for safe and comfortable treatment Expert Filters – tailored to the skin type and condition for optimized results Small and large lightguides for ideal access and coverage Add on cart, for use in multiple locations VISIT LUMENIS VISION BLOG TO LEARN FROM OUR EXPERTS GO! LUMENIS PATENTED TECHNOLOGIES Enables to treat with up to 20 J/cm2, gently and safely for maximum effectiveness Optima IPL with OPT™ SAFETY No spikes in energy The energy you choose is the energy you get EFFICACY Consistent level of energy in every pulse, throughout the pulse Patented water cool tips: perfect fit for eye-care SapphireCool™ chiller tip allows to: 1. Reach higher levels of energy and achieve optimal results 2. Provide safe and comfortable treatment for the patient 3. Small tip for better access to eyelid area ANTARES DRY EYE DISEASE DIAGNOSTICS Advanced, automated DED diagnostic and corneal topographer Quality Accurate, reliable, reproducible and low intra-rater variability Speed Fast examination process and results Comfortable Offers patient comfort as well as physician ease of use Applications Dry eye report, Meibography, Tear Breakup Time, Tear Meniscus, Topographer WHAT ARE THE EXPERTS SAYING? Must have in the ophthalmic toolbox Tal Raviv, MD, Eye Center of New York “The Optima IPL has not just been another addition to our Toolbox, it has become one of the primary workhorses in our practice to achieve outstanding patient outcomes” Neil Desai, MD “Optima IPL has become such a powerful tool in my tool box because it is uniquely and for the first time gives me a method by which I can treat the source of the problem” Practice locator FIND A PRACTICE NEAR YOU FIND A PRACTICE OPTIMA IPL SPECIFICATIONS ExpertFilters 515 nm; 560 nm; 590 nm; 615 nm; 640 nm; 695 nm; 755nm Lightguides 15 x 35 mm; 8 x 15 mm Fluence Up to 35 J/cm2 Cooling Continuous contact cooling OPTIMA IPL FOR DRY EYE* Visit Optima IPL site to learn about Dry eye Disease and how to treat it *Not available in the US. Available in European Union CE, China, Australia, New Zealand, South Korea, Brazil, Hong Kong and Poland only LEARN MORE WANT TO LEARN MORE? Download Optima IPL & Dry Eye Antares kit Get comprehensive information, detailed brochures and product reviewing videos here DOWNLOAD KIT Risk and warning (non-inclusive list): Treatment with M22 Optima IPL is contraindicated for patients with the following conditions in the treatment area: active infections, dysplastic nevi, tattoos, significant concurrent skin inflammation (excluding rosacea or acne), active cold sores, open lacerations, abrasions, and prolonged sun-exposure. Caution is advised for patients with a compromised immune system, coagulation disorders, photosensitivity, hormonal disorders, or a history of Herpes simplex near the treatment area. Patients eyes must be occluded with eye shields during the treatment. 1. Kassir et al. (2011) J Cosmet Laser Ther 13(5):216-22; 2. Papageorgiou et al. (2008) Br J Dermatol 159(3):628-32; 3. Liu et al. (2017) Am J Ophthalmol 183:81-90.; 4. Yin et al. (2018) Curr Eye Res 43(3):308-13; 5. Prieto et al. (2002) Lasers Surg Med 30(2):82-5; 6. De Paiva et al. (2006) Am J Ophthalmol 141(3):438-45; 7. Solomon et al. (2004) Ocul Surf 2(1):34-44; *Antares is manufactured for Lumenis inc. by Costruzione Strumeni Oftalmici PB-00001770 Rev A GET MORE INFO × #### Dry Eye Practices Had enough of Dry Eyes? FIND A dry eye CLINIC NEAR YOU Lumenis is an equipment manufacturer and does not provide professional medical or aesthetic services to patients. This application is intended for the convenience of patients interested in locating practitioners and clinics that use Lumenis’ equipment for treatments, without recommendation or solicitation on the part of Lumenis with respect to the services of such practitioners or clinics. GET MORE INFO × #### Dynamic Muscle Stimulation of the Periorbital Area for Improvement of Blinking in Dry Eye Patients Clinical StudiesDry Eye Dynamic Muscle Stimulation of the Periorbital Area for Improvement of Blinking in Dry Eye Patients April 24, 2025 A newly published study shows OptiLIFT’s Dynamic Muscle Stimulation enhances eyelid function and appearance. We’re proud to share that a clinical study led by Dr. Chelnis, in collaboration with Lumenis, has been officially published. The findings support what practitioners are already seeing in clinics: OptiLIFT’s Dynamic Muscle Stimulation (DMSt) technology is redefining the standard for addressing lower eyelid laxity and impaired blinking. Dynamic Muscle Stimulation of the Periorbital Area for Improvement of Blinking in Dry Eye Patients Read Full Article DOWNLOAD INFO KIT Discover how OptiLIFT can transform your practice. Contact us for a free demo or to learn more! Close Explore Other Resources Dry EyeNewsPeriorbital Muscle StimulationTreatment TypeVision Resource HubDry EyeNewsPeriorbital Muscle StimulationTreatment TypeVision Resource HubLumenis OptiLIFT Dynamic Muscle Stimulation Device receives Health Canada Approval for Reducing Signs and Symptoms of Evaporative Dry Eye DiseaseREAD MOREClinical StudiesDry EyePeriorbital Muscle StimulationTreatment TypeVision Resource HubClinical StudiesDry EyePeriorbital Muscle StimulationTreatment TypeVision Resource HubThe Potential Benefits of Periorbital Transcutaneous Electrical Stimulation for the Management of Dry Eye DiseaseREAD MOREDry EyePeriorbital Muscle StimulationPress PublicationsTreatment TypeVision Resource HubDry EyePeriorbital Muscle StimulationPress PublicationsTreatment TypeVision Resource HubSisters Grow Practice Into Medical Hub for Dry Eye TreatmentREAD MORE PB-00067370, Rev A #### Elevating Patient Care: OptiLight Insights and Case Studies Elevating Patient Care: OptiLight Insights and Case Studies October 3, 2022 Kambiz Silani, OD Kambiz Silani, OD is the found and chief clinical director at Beverly Hills Optometry in Beverly Hills, California. He takes a modern approach towards the treatment of ocular surfaces disease, particularly dry eye. His practice philosophy is patient education and patient empowerment. Kambiz Silani, OD, Chief Clinical Director, Beverly Hills Optometry, Beverly Hills, California Treating dry eye can be challenging, but highly rewarding. In our practice, we’re continually evolving and seeking new therapies, especially evidence-based in-office therapeutics. We proudly offer OptiLight, which has been an amazing foundational treatment providing a multifactorial solution for this multifactorial disease. We’re seeing the benefits of office-based treatments for a variety of stages of dry eye disease. OptiLight is core in dry eye treatment planning As an advanced dry eye center, the majority of our patients (over 75%) see us either for dry eye consultation or treatment. We start off every dry eye patient with a consultation, followed by a dry eye workup that includes meibography. I recommend OptiLight for patients who have meibomian gland dysfunction (MGD) and/or ocular rosacea (telangiectasic vessels along the eyelid margin), or who were given other modalities such as pharmaceutical eye drops from a previous doctor and have not responded. When we manage dry eye, we often use OptiLight as foundation and build on it based on individual needs. For example, in addition to OptiLight, dry eye patients with anterior blepharitis may need lid exfoliation to remove bacterial biofilm buildup on the lash line, while patients with blocked meibomian glands benefit from thermal pulsation to remove unhealthy oils. These therapies work synergistically. Enhanced clinical effectiveness in moderate to severe cases Like any condition, dry eye is best when treated early. When a candidate for OptiLight has moderate signs of dry eye disease, we perform the standard four treatments, spaced about 2-4 weeks apart. For instance, we had a patient fitted with a premium daily contact lens who complained of lens discomfort. After reviewing her images, we diagnosed her with ocular rosacea. The abnormal blood vessels (telangiectasia) were leaking inflammatory mediators and causing dry eye symptoms. We determined that the contact lenses weren’t the problem—the problem was the ocular surface itself. After only four OptiLight treatments, this patient was back to wearing her lenses comfortably. On the more severe side of the scale, a woman in her mid-50s visited our practice. She was driven by her daughter because her dry eye was preventing her from driving. She was wearing sunglasses indoors for two reasons: she was severely light sensitive and her eyes were significantly red. Meibomian gland evaluation with digital pressure showed her glands were clogged with unhealthy, inspissated oils. Her profession requires heavy screen time, which was negatively impacting her dry eye symptoms. It was clear that her dry eye disease had significantly affected her productivity, her quality of vision, and her quality of life. She’d nearly given up hope of returning to normal. After six OptiLight sessions, the patient’s eye redness was significantly reduced, and her tear breakup time was markedly better. Additionally, she had heat therapy and started applying immunomodulator drops. After several months, she was back to work, driving and no longer wearing sunglasses all day. Success evolves by word of mouth from happy OptiLight patients It’s my goal to provide the highest level of care possible within my scope of practice. When we accomplish that for dry eye patients, they become our biggest fans. They drive hours to see us. They get relief not just physically, but also mentally. I tell my dry eye patients, “You’re not alone. In fact, we commonly see patients who are on the severe end of the scale. We’ll be here with you along this journey.” OptiLight is proving to be a cornerstone of that journey. More practitioners are starting to use OptiLight or are aware of this advanced technology. In fact, many colleagues around the country trust our practice and choose to refer patients regularly. Due to our unique, customized protocol, which includes OptiLight, we can help patients achieve significant, lasting results. Explore Other Resources Dry EyeNewsPeriorbital Muscle StimulationTreatment TypeVision Resource HubDry EyeNewsPeriorbital Muscle StimulationTreatment TypeVision Resource HubLumenis OptiLIFT Dynamic Muscle Stimulation Device receives Health Canada Approval for Reducing Signs and Symptoms of Evaporative Dry Eye DiseaseREAD MOREClinical StudiesDry EyePeriorbital Muscle StimulationTreatment TypeVision Resource HubClinical StudiesDry EyePeriorbital Muscle StimulationTreatment TypeVision Resource HubThe Potential Benefits of Periorbital Transcutaneous Electrical Stimulation for the Management of Dry Eye DiseaseREAD MOREDry EyePeriorbital Muscle StimulationPress PublicationsTreatment TypeVision Resource HubDry EyePeriorbital Muscle StimulationPress PublicationsTreatment TypeVision Resource HubSisters Grow Practice Into Medical Hub for Dry Eye TreatmentREAD MORE LEARN HOW YOU CAN ELEVATE YOUR PRACTICE DOWNLOAD OPTILIGHT INFO KIT Learn about the first and only IPL FDA approved for dry eye management PB-00043680 Rev A #### Embrace Emerging Technology for Success in Practice Embrace Emerging Technology for Success in Practice August 22, 2023 Dr. Carly Rose explains how adopting more advanced DED tools like OptiLIGHT in her practice helps her achieve more for her patients, even with less time. READ FULL ARTICLE Explore Other Resources Dry EyeNewsPeriorbital Muscle StimulationTreatment TypeVision Resource HubDry EyeNewsPeriorbital Muscle StimulationTreatment TypeVision Resource HubLumenis OptiLIFT Dynamic Muscle Stimulation Device receives Health Canada Approval for Reducing Signs and Symptoms of Evaporative Dry Eye DiseaseREAD MOREClinical StudiesDry EyePeriorbital Muscle StimulationTreatment TypeVision Resource HubClinical StudiesDry EyePeriorbital Muscle StimulationTreatment TypeVision Resource HubThe Potential Benefits of Periorbital Transcutaneous Electrical Stimulation for the Management of Dry Eye DiseaseREAD MOREDry EyePeriorbital Muscle StimulationPress PublicationsTreatment TypeVision Resource HubDry EyePeriorbital Muscle StimulationPress PublicationsTreatment TypeVision Resource HubSisters Grow Practice Into Medical Hub for Dry Eye TreatmentREAD MORE PB-00043680 Rev C #### Embrace Every Moment, Free from Dry, Itchy Eyes! | OptiLIGHT by Lumenis Embrace Every Moment, Free from Dry, Itchy Eyes! | OptiLIGHT by Lumenis July 15, 2023 Share   Candice King doesn’t let discomfort dim her enjoyment of life. With OptiLIGHT by Lumenis’ innovative light therapy treatment, you can target the signs of dry eyes, allowing a fully immerse in a present and cherish happy moments! Watch more videos Colton Underwood shares his experience with DED and his care journey using OptiLIGHT and OptiLIFTMay 25, 2025WATCH NOWKerri Walsh Jennings Shares the Impact of OptiLIGHT Treatment on Her Dry Eye Disease!May 2, 2024WATCH NOWKerri Has Been Experiencing Dry, Itchy Eyes On And Off The Court For Years. Her Solution: OptiLIGHT!April 28, 2024WATCH NOW PB-00076100, Rev A #### Enhance Patient Care with the Sequential Use of OptiPLUS & OptiLIGHT Blog PostsDry Eye Enhance Patient Care with the Sequential Use of OptiPLUS & OptiLIGHT August 14, 2024 Julie McLaughlin, OD, Diplomate, ABO Lehigh Eye Specialists, Allentown, Pennsylvania Dr. McLaughlin has been practicing at Lehigh Eye Specialists in Allentown, Pennsylvania since 2013. She specializes in the diagnosis and treatment of ocular surface disease and dry eye syndrome. Website While building a dedicated dry eye disease clinic within an MD/OD practice, I’ve made OptiLIGHT the foundation. I chose Lumenis light therapy because it is the first and only option that is FDA-approved for dry eye management. To me, OptiLIGHT’s advanced capabilities make it uniquely suited to this multifactorial disease. It targets the root cause of dry eye while addressing key components, including inflammation, improving the meibomian gland morphology and function, reducing the bacterial burden, and diminishing Demodex.1,2,3,4 Nearly all my patients with moderate to severe dry eye receive OptiLIGHT as part of their treatment plan. When Lumenis introduced OptiPLUS, the first-of-its-kind dual-frequency RF technology, I was eager to bring it into our clinic as a complementary treatment to OptiLIGHT to enhance patient care. OptiPLUS seamlessly integrates into my treatment paradigm and my clinic’s fast-paced, high-volume workflow. My patients love the results of these treatments and the aesthetic effects. A Complement to OptiLIGHT Like OptiLIGHT, OptiPLUS is safe, gentle, and comfortable. It is also FDA-cleared (a prerequisite in my practice) and can be used to treat a wide range of skin types. Patients have four treatment sessions, just like with OptiLIGHT. Although I’ve only had OptiPLUS for a few months, I recommend it to every OptiLIGHT patient as a complementary treatment. With OptiPLUS, we apply innovative dual-frequency RF energy on the skin in the peri-orbital area, reaching every delicate curve. This unique technology delivers heat across skin tissue layers, enhancing blood circulation and collagen production while targeting the meibomian glands.5,6,7 thinning the meibum requires sustained heat, which is difficult to achieve with a mask or compress. By combining dual-frequency RF with IPL technology, we can express meibomian glands more effectively, see clearer meibum, and observe signs improvement.8 One key difference between OptiPLUS and other RF technologies is that it uses a monopolar application rather than a bipolar application. I prefer the monopolar RF method for my patients’ treatment because it mitigates the risk of electrical arcing, offers a more rapid and even heating of deeper eyelid tissue, and features a uniform and rounded device design better suited for delicate areas and efficient gland expression. These factors enhance safety and provide my patients with a more comfortable experience. When I started using OptiLIGHT, I was focused on dry eye and saw any aesthetic benefits as an added bonus. Through OptiLIGHT’s upgradeable configuration, I soon realized the demand for the aesthetic aspects of the treatment among my patients. The addition of OptiPLUS enhances aesthetic results, promoting collagen production and skin rejuvenation.6,7 Thus, these supplementary treatments have opened the door to a new revenue stream. OptiPLUS Packaging and Workflow Implementation started with new packages and a workflow plan. We now offer a total of five packages, three of which contain dual-frequency RF treatment. One package includes four sessions of OptiPLUS + meibomian gland expression (MGX) for patients who fall outside the appropriate Fitzpatrick skin types for OptiLIGHT. Another package includes four OptiLIGHT sessions (dry eye protocol) + OptiPLUS + MGX. Finally, our aesthetics package consists of four sessions of OptiLIGHT (aesthetics protocol) + OptiPLUS + MGX. We were able to seamlessly integrate these packages into our current workflow by establishing protocols and delegating tasks when necessary. My conversation with patients hasn’t changed. After first discussing their dry eye story and test results, I then make a recommendation. For example, I might say, “The exam and tests showed that meibomian gland dysfunction and inflammation are driving your dry eye disease..” By packaging OptiLIGHT and OptiPLUS together from the start, I ensure success for my patients in terms of meeting clinical outcomes, and for my practice in terms of ROI. We had paid off our OptiPLUS device within three months and have continued improving patients’ quality of life. Having a dedicated dual-frequency RF device has significantly improved patients’ symptomatology and meibomian gland function. While costs are out-of-pocket, it is a nice addition to the practice to offer a treatment that not only delivers real results but also elevates the in-office experience. By offering your patients both OptiLIGHT and OptiPLUS sequentially, you can maximize the potential of the technologies. Patient conversion to OptiLIGHT has consistently been high, and I expect this trend to continue when paired with OptiPLUS, which promises potential for future volume growth. Patients love their treatment. I’m happy that we’ve been able to rely so heavily on OptiLIGHT over the years, and now we are able to enhance patient care by complementing it with OptiPLUS. Discover new possibilities Download OptiLIGHT and OptiPLUS info kit Explore Other Resources Dry EyeNewsPeriorbital Muscle StimulationTreatment TypeVision Resource HubDry EyeNewsPeriorbital Muscle StimulationTreatment TypeVision Resource HubLumenis OptiLIFT Dynamic Muscle Stimulation Device receives Health Canada Approval for Reducing Signs and Symptoms of Evaporative Dry Eye DiseaseREAD MOREClinical StudiesDry EyePeriorbital Muscle StimulationTreatment TypeVision Resource HubClinical StudiesDry EyePeriorbital Muscle StimulationTreatment TypeVision Resource HubThe Potential Benefits of Periorbital Transcutaneous Electrical Stimulation for the Management of Dry Eye DiseaseREAD MOREDry EyePeriorbital Muscle StimulationPress PublicationsTreatment TypeVision Resource HubDry EyePeriorbital Muscle StimulationPress PublicationsTreatment TypeVision Resource HubSisters Grow Practice Into Medical Hub for Dry Eye TreatmentREAD MORE [1] Kassir et al. (2011) J Cosmet Laser Ther 13(5):216-22 2 Papageorgiou et al. (2008) Br J Dermatol 159(3):628-32 3 Yin et al. (2018) Curr Eye Res 43(3):308 4 Prieto et al. (2002) Lasers Surg Med 30(2):82-5 5 Rabkin, J. M., & Hunt, T. K. (1987). Local heat increases blood flow and oxygen tension in wounds. Archives of Surgery, 122(2), 221–225. https://doi.org/10.1001/archsurg.1987.01400140103014 6 Javate, R. M., Cruz Jr, R. T., Khan, J., Trakos, N., & Gordon, R. E. (2011). Nonablative 4-MHz dual radiofrequency wand rejuvenation treatment for periorbital rhytides and midface laxity. Ophthalmic Plastic and Reconstructive Surgery, 27(3), 180–185. https://doi.org/10.1097/IOP.0b013e3181fe8e5a 7 Al-Atif, H. (2022). Collagen Supplements for Aging and Wrinkles: A Paradigm Shift in the Fields of Dermatology and Cosmetics. Dermatology Practical & Conceptual, 12(1), e2022018. https://doi.org/10.5826/dpc.1201a18 8 Chelnis, J., Garcia, C. N., & Hamza, H. (2023). Multi-Frequency RF Combined with Intense Pulsed Light Improves Signs and Symptoms of Dry Eye Disease Due to Meibomian Gland Dysfunction. Clinical Ophthalmology, 17, 3089–3102. https://doi.org/10.2147/OPTH.S426564 9 Green, J. B., Dover, J. S., & Kaminer, M. S. (2011). Tolerability of a Monopolar Radiofrequency Facial Skin Tightening Procedure: An Observational Study. https://cdn.mdedge.com/files/s3fs-public/Document/September-2017/024070327.pdf *Per the FDA’s cleared submission, OptiPLUS is not intended to be used within the orbital rim or on the neck. **OptiPLUS is cleared for use in the United States as a standalone device and not as a combination device with other therapies. PB-00081290, Rev A #### FDA approves IPL device to manage dry eye disease FDA approves IPL device to manage dry eye disease Patented Lumenis Optimal Pulse Technology (OPT) becomes the first IPL approved for management of dry eye disease due to MGD, and Lumenis launches OptiLight. READ FULL ARTICLE Explore Other Resources Dry EyeNewsPeriorbital Muscle StimulationTreatment TypeVision Resource HubDry EyeNewsPeriorbital Muscle StimulationTreatment TypeVision Resource HubLumenis OptiLIFT Dynamic Muscle Stimulation Device receives Health Canada Approval for Reducing Signs and Symptoms of Evaporative Dry Eye DiseaseREAD MOREClinical StudiesDry EyePeriorbital Muscle StimulationTreatment TypeVision Resource HubClinical StudiesDry EyePeriorbital Muscle StimulationTreatment TypeVision Resource HubThe Potential Benefits of Periorbital Transcutaneous Electrical Stimulation for the Management of Dry Eye DiseaseREAD MOREDry EyePeriorbital Muscle StimulationPress PublicationsTreatment TypeVision Resource HubDry EyePeriorbital Muscle StimulationPress PublicationsTreatment TypeVision Resource HubSisters Grow Practice Into Medical Hub for Dry Eye TreatmentREAD MORE PB-00038930 Rev A #### Find a Real Solution For Dry Eyes with OptiLIGHT”s Light Treatment! | OptiLIGHT by Lumenis Find a Real Solution For Dry Eyes with OptiLIGHT”s Light Treatment! | OptiLIGHT by Lumenis January 4, 2024 Share   Hear Jaime Chung and James Deom, OD, discussing the unique benefits of OptiLIGHT. Designed to target the root cause of dry eyes, OptiLIGHT by Lumenis stops the dry eye vicious cycle of inflammation. Watch more videos Colton Underwood shares his experience with DED and his care journey using OptiLIGHT and OptiLIFTMay 25, 2025WATCH NOWKerri Walsh Jennings Shares the Impact of OptiLIGHT Treatment on Her Dry Eye Disease!May 2, 2024WATCH NOWKerri Has Been Experiencing Dry, Itchy Eyes On And Off The Court For Years. Her Solution: OptiLIGHT!April 28, 2024WATCH NOW PB-00076100, Rev A #### Fishman et al (2020): Real-Time Video Microscopy of In Vitro Demodex Death by Intense Pulsed Light Fishman et al (2020): Real-Time Video Microscopy of In Vitro Demodex Death by Intense Pulsed Light An in-vitro study demonstrated that, with settings used for treatment of dry eye due to meibomian gland dysfunction (MGD), Lumenis IPL with OPTTM destroyed an isolated Demodex mite. READ FULL ARTICLE Indication for Use: Improvement of signs of Dry Eye Disease (DED) due to Meibomian Gland Dysfunction (MGD), also known as evaporative dry eye or lipid deficiency dry eye, in patients 22 years of age and older with moderate to severe signs and symptoms of DED due to MGD and with Fitzpatrick skin types I-IV. IPL is to be applied only to skin on the malar region of the face, from tragus to tragus including the nose (eyes should be fully covered by protective eyewear). IPL is intended to be applied as an adjunct to other modalities, such as meibomian gland expression, artificial tear lubricants and warm compresses Treatment with M22 or OptiLight is contraindicated for patients with the following conditions in the treatment area: Ocular surgery or eyelid surgery or Neuro-paralysis within 6 months prior to the first treatment; Uncontrolled eye disorders affecting the ocular surface; Pre-cancerous lesions, skin cancer or pigmented lesions in the planned treatment area; Uncontrolled infections or uncontrolled immunosuppressive diseases; Recent Ocular infections; Prior history of cold sores or rashes in the perioral area, including: Herpes simplex 1 & 2, Systemic Lupus erythematosus and porphyria; Use of photosensitive medication and/or herbs that may cause sensitivity within 3 months prior to the first IPL session; Recent radiation therapy to the head or neck or planned radiation therapy; Recent treatment with chemotherapeutic agent or planned chemotherapy; History of migraines, seizures or epilepsy. Patients eyes must be completely occluded during the treatment. Please refer to the operator manual for a complete list of intended use, contraindications and risks. Please consult your physician as to whether this procedure is suitable for you. The following possible side effects can occur following IPL treatments: Pain/discomfort, damage to natural skin texture, change of pigmentation, scarring, excessive edema, fragile skin, bruising, burns, pruritus and xerosis. Please refer to the user manual or ask your doctor for a complete list of intended use, contraindications and risks Lumenis has an interest in the study device (M22 system). FDA clearance of the M22 system is not relevant to this study Two of the authors (Dr. Fishman, and Dr. Periman) were consultants of Lumenis. Neither authors received compensation from Lumenis for the data presented in this paper. No person known to Lumenis has provided funding for the study. No unapproved uses of the M22 system were discussed in this paper. Explore Other Resources Dry EyeNewsPeriorbital Muscle StimulationTreatment TypeVision Resource HubDry EyeNewsPeriorbital Muscle StimulationTreatment TypeVision Resource HubLumenis OptiLIFT Dynamic Muscle Stimulation Device receives Health Canada Approval for Reducing Signs and Symptoms of Evaporative Dry Eye DiseaseREAD MOREClinical StudiesDry EyePeriorbital Muscle StimulationTreatment TypeVision Resource HubClinical StudiesDry EyePeriorbital Muscle StimulationTreatment TypeVision Resource HubThe Potential Benefits of Periorbital Transcutaneous Electrical Stimulation for the Management of Dry Eye DiseaseREAD MOREDry EyePeriorbital Muscle StimulationPress PublicationsTreatment TypeVision Resource HubDry EyePeriorbital Muscle StimulationPress PublicationsTreatment TypeVision Resource HubSisters Grow Practice Into Medical Hub for Dry Eye TreatmentREAD MORE PB-00038930 Rev A #### For Quality Dry Eye Care, Make OptiLight Your First Choice Blog PostsDry Eye For Quality Dry Eye Care, Make OptiLight Your First Choice June 15, 2022 Krystina Lensky-Sipes, OD Kristyna Lensky-Sipes, OD, is the owner of Stanford Ranch Optometry in Rocklin, CA. In most practices, doctors use therapies like medications and punctal plugs all the time, after first-line therapies such as warm compresses and artificial tears have failed. But why not skip the medications and treat patients with OptiLight first, so patients have less work to do at home? Light-based treatment has been proven effective, and the TFOS DEWS II report recommends it as a second-line treatment.1 That means that at the point in therapy when we’re considering prescribing eye drops and doing punctal plugs, it’s also time to consider OptiLight. My colleagues and I purchased OptiLight because we wanted to elevate the quality of dry eye care in our practice. The unique advantage of OptiLight is its ability to treat inflammation, a key contributing factor of dry eye disease. Among the second-line options, OptiLight is often my first choice because it reduces patients’ burden of self-treatment—a benefit that may make it the standard of care in the near future. We are also starting to present OptiLight to our patients as a first-line treatment to get ahead of inflammation and disease progression, with the goal of making dry eye easier to manage as patients age. Our practice benefits from OptiLight just as much as our patients do. In the year since we began treating with OptiLight, it has differentiated our practice in the community, resulting in dry eye patients coming from hours away and ophthalmologists referring patients to us for treatment. We treat about 5-10 patients a week with OptiLight, and that number is growing quickly. Since we brought it into our practice, our gross revenue has increased by more than 10%. In-Office Treatment Makes Life Easier for Patients We know that patients aren’t always compliant with at-home therapies, and we can hardly blame them. They’re told that for the rest of their lives, they need to use multiple eye drops, warm compresses, ointments, gels, and more. When I treat with OptiLight, many of my patients can avoid doing any work at home. For some individuals, I continue to recommend omega supplements or, for patients with incomplete eyelid closure, gel tears before bed. A recent example: I had a patient with ocular rosacea, MGD, and allergies whose condition was very hard to stabilize. On the instruction of previous doctors, she was using prescription eye drops, allergy eye drops, lid scrubs, omega supplements, steroid ointment, lubricating eye drops, warm compresses, hypochloric acid eyelid wash, and an at-home low-light therapy device. Nevertheless, her eyes were constantly irritated, her lids were swollen, and she couldn’t wear makeup. Because her dry eye disease was so severe, we did five OptiLight treatments instead of the standard four. She was thrilled with the results. Now her at-home tasks have decreased by 80%, with just a warm compress, omega supplements, and lubricating and allergy drops when needed. Quality Dry Eye Care Makes Practices Stronger As a second-line treatment, OptiLight is recommended for moderate to severe dry eye disease and mild disease that doesn’t respond to first-line therapies. That’s a lot of patients! In addition, for patients who have tried many therapies without gaining adequate improvement, treatment with OptiLight can make a difference. For example, in my experience, patients with a facial and ocular rosacea component look better and feel better after OptiLight, and patients with obstructive lid disease or inflammation experience significant results. Happy patients tell their friends, so we get a lot of referrals. A set of OptiLight treatments are required for lasting results, so patients schedule the initial four visits 2-4 weeks apart, and then they come back for annual maintenance treatment if needed. Visits only require the time we schedule for a standard exam, so they fit easily into our patient flow. The technology has raised the quality of dry eye care for our patients and reduced their burden, all while strengthening the practice and elevating our reputation in the community. 1. Craig JP, Nelson JD, Azar DT, et al. TFOS DEWS II Report. Ocul Surf. 2017;269-275. Discover new possibilities Download OptiLIGHT and OptiPLUS info kit Explore Other Resources Dry EyeNewsPeriorbital Muscle StimulationTreatment TypeVision Resource HubDry EyeNewsPeriorbital Muscle StimulationTreatment TypeVision Resource HubLumenis OptiLIFT Dynamic Muscle Stimulation Device receives Health Canada Approval for Reducing Signs and Symptoms of Evaporative Dry Eye DiseaseREAD MOREClinical StudiesDry EyePeriorbital Muscle StimulationTreatment TypeVision Resource HubClinical StudiesDry EyePeriorbital Muscle StimulationTreatment TypeVision Resource HubThe Potential Benefits of Periorbital Transcutaneous Electrical Stimulation for the Management of Dry Eye DiseaseREAD MOREDry EyePeriorbital Muscle StimulationPress PublicationsTreatment TypeVision Resource HubDry EyePeriorbital Muscle StimulationPress PublicationsTreatment TypeVision Resource HubSisters Grow Practice Into Medical Hub for Dry Eye TreatmentREAD MORE Indication for Use: Improvement of signs of Dry Eye Disease (DED) due to Meibomian Gland Dysfunction (MGD), also known as evaporative dry eye or lipid deficiency dry eye, in patients 22 years of age and older with moderate to severe signs and symptoms of DED due to MGD and with Fitzpatrick skin types I-IV. IPL is to be applied only to skin on the malar region of the face, from tragus to tragus including the nose (eyes should be fully covered by protective eyewear). IPL is intended to be applied as an adjunct to other modalities, such as meibomian gland expression, artificial tear lubricants and warm compresses Treatment with OptiLight is contraindicated for patients with the following conditions in the treatment area: Ocular surgery or eyelid surgery or Neuro-paralysis within 6 months prior to the first treatment; Uncontrolled eye disorders affecting the ocular surface; Pre-cancerous lesions, skin cancer or pigmented lesions in the planned treatment area; Uncontrolled infections or uncontrolled immunosuppressive diseases; Recent Ocular infections; Prior history of cold sores or rashes in the perioral area, including: Herpes simplex 1 & 2, Systemic Lupus erythematosus and porphyria; Use of photosensitive medication and/or herbs that may cause sensitivity within 3 months prior to the first IPL session; Recent radiation therapy to the head or neck or planned radiation therapy; Recent treatment with chemotherapeutic agent or planned chemotherapy; History of migraines, seizures or epilepsy. Patients eyes must be completely occluded during the treatment. Please refer to the operator manual for a complete list of intended use, contraindications and risks. Please consult your physician as to whether this procedure is suitable for you. The following possible side effects can occur following IPL treatments: Pain/discomfort, damage to natural skin texture, change of pigmentation, scarring, excessive edema, fragile skin, bruising, burns, pruritus and xerosis. Please refer to the user manual or ask your doctor for a complete list of intended use, contraindications and risks PB-00046650 Rev A #### Four Tips for Implementing OptiLight and Optimizing ROI Four Tips for Implementing OptiLight and Optimizing ROI July 20, 2022 Richard A. Adler, MD Dr. Richard Adler is a board certified ophthalmologist, renowned for providing his patients with compassionate care and excellent outcomes. Dr. Adler is an expert in the management of dry eye disease and corneal diseases, as well as vision correction procedures, including LASIK and refractive lens exchange. Light-based therapy has been the standard of care for my dry eye patients for over a decade, with an upgrade to Lumenis technology when it was released in 2015. Nowadays, I’m using OptiLight. By addressing key underlying factors of dry eye with OptiLight, I’ve seen inflammation decline and signs of the disease decrease. With FDA approval of Lumenis light therapy for the management of dry eye disease, I’ve been talking to many colleagues who are new to OptiLight and uncertain about how to implement it in their practices. I explain that OptiLight technology can fit easily into their dry eye toolkit. Simple adjustments at the office can transform good results into great ones. 1. Adjust the practice philosophy toward dry eye disease. Not long ago, we had a limited understanding of dry eye disease and no effective long-term therapies, resulting in reluctance to treat it aggressively or set high expectations for our patients. Today, doctors who excel at managing this condition have a common philosophy: dry eye disease is an opportunity, not an obstacle. We have the tools to help the millions of patients who are already in our practices. There is no single solution that fits every case, but we embrace a technology like OptiLight that serves many patients’ needs. These ideas can’t be the domain of one doctor (a dry eye “champion”). It has to be a whole-practice effort. We want ophthalmologists in all specialties to have a current understanding of dry eye disease, and we train our staff to understand and recognize dry eye and expect to see it in many patients. They also know that light-based therapy is an effective solution. 2. Do not limit OptiLight to the end of your algorithm. Because dry eye disease is so ubiquitous, you need to source your existing patients as OptiLight candidates as well as new patients. Many candidates may benefit from OptiLight, but this treatment’s “lowest-hanging fruits” fall in two places in the treatment algorithm: 1) patients who have tried and failed with traditional therapies such as artificial tears, thermal compresses, and prescription medications, and 2) newly diagnosed patients who don’t want to be dependent on twice-daily use of prescription eye drops. I recommend identifying these two types of patients first. Notice, we don’t need to wait to do OptiLight until after multiple therapies have failed. It is a TFOS DEWS II Step 2 therapy, right alongside common prescription eye drops. OptiLight also fits easily into the practice workflow, with treatment visits that fit into our regular exam slots and very little setup time. 3. Improve communication—say the right thing before, during and after OptiLight. We’re good at setting expectations and defining success for cataract surgery. If you prepare to communicate with patients about OptiLight in the same productive way, you’ll succeed. You have three chances to say the right thing—before, during and after the procedure. I start by explaining dry eye disease, and then I ask if the patient is interested in a “drug-free, drop-free treatment” called OptiLight. I explain that the technology improves the function of the meibomian glands, which contribute to a stable tear film. I describe the risks and benefits, and we discuss payment. During treatment, remind patients why they chose OptiLight. As you adjust the settings, explain your reasons. Afterward, explain the changes you see and how they show goals have been met, such as better gland expressibility, longer TBUT, lower inflammation scores, and improved meibography. 4. Every single dry eye patient is a marketing opportunity. If a practice chooses to pursue external marketing, the message is simple. An email or social media post asking, “Got dry eye? Do you want a drop-free treatment?” goes a long way. You can also connect with your referral partners in optometry and ophthalmology who don’t do OptiLight to encourage referrals, as well as with dermatologists who might do light-based therapies but don’t treat the eyes. Lumenis offers marketing support, including one-on-one consulting and a digital marketing plan. You’ll find that most OptiLight patients, however, are right in your practice. About half of my OptiLight patients come from inside the practice; the other half are referred to me. It’s difficult to think of a disease state with higher prevalence than dry eye disease. It’s one of the most common conditions we see—the patients fill our offices. The opportunity to discuss OptiLight is right there in every patient encounter. Talk about OptiLight with every candidate, and the device will quickly pay for itself. Explore Other Resources Dry EyeNewsPeriorbital Muscle StimulationTreatment TypeVision Resource HubDry EyeNewsPeriorbital Muscle StimulationTreatment TypeVision Resource HubLumenis OptiLIFT Dynamic Muscle Stimulation Device receives Health Canada Approval for Reducing Signs and Symptoms of Evaporative Dry Eye DiseaseREAD MOREClinical StudiesDry EyePeriorbital Muscle StimulationTreatment TypeVision Resource HubClinical StudiesDry EyePeriorbital Muscle StimulationTreatment TypeVision Resource HubThe Potential Benefits of Periorbital Transcutaneous Electrical Stimulation for the Management of Dry Eye DiseaseREAD MOREDry EyePeriorbital Muscle StimulationPress PublicationsTreatment TypeVision Resource HubDry EyePeriorbital Muscle StimulationPress PublicationsTreatment TypeVision Resource HubSisters Grow Practice Into Medical Hub for Dry Eye TreatmentREAD MORE LEARN HOW YOU CAN ELEVATE YOUR PRACTICE DOWNLOAD OPTILIGHT INFO KIT Learn about the first and only IPL FDA approved for dry eye management Indication for Use: Improvement of signs of Dry Eye Disease (DED) due to Meibomian Gland Dysfunction (MGD), also known as evaporative dry eye or lipid deficiency dry eye, in patients 22 years of age and older with moderate to severe signs and symptoms of DED due to MGD and with Fitzpatrick skin types I-IV. IPL is to be applied only to skin on the malar region of the face, from tragus to tragus including the nose (eyes should be fully covered by protective eyewear). IPL is intended to be applied as an adjunct to other modalities, such as meibomian gland expression, artificial tear lubricants and warm compresses Ocular surgery or eyelid surgery or Neuro-paralysis within 6 months prior to the first treatment; Uncontrolled eye disorders affecting the ocular surface; Pre-cancerous lesions, skin cancer or pigmented lesions in the planned treatment area; Uncontrolled infections or uncontrolled immunosuppressive diseases; Recent Ocular infections; Prior history of cold sores or rashes in the perioral area, including: Herpes simplex 1 & 2, Systemic Lupus erythematosus and porphyria; Use of photosensitive medication and/or herbs that may cause sensitivity within 3 months prior to the first IPL session; Recent radiation therapy to the head or neck or planned radiation therapy; Recent treatment with chemotherapeutic agent or planned chemotherapy; History of migraines, seizures or epilepsy. Patients eyes must be completely occluded during the treatment. Please refer to the operator manual for a complete list of intended use, contraindications and risks. Please consult your physician as to whether this procedure is suitable for you. The following possible side effects can occur following IPL treatments: Pain/discomfort, damage to natural skin texture, change of pigmentation, scarring, excessive edema, fragile skin, bruising, burns, pruritus and xerosis. Please refer to the user manual or ask your doctor for a complete list of intended use, contraindications and risks PB-00049260 Rev A PB-00043680 Rev A #### Fundamental Help for Patients: A 6-Month Look at Implementing Optima IPL Fundamental Help for Patients: A 6-Month Look at Implementing Optima IPL February 10, 2021 Carly Rose, OD Carly Rose, OD is the owner of Eyecare on the Square, a primary care center, and Clear Eyes + Aesthetics, a dry eye medical spa, both in Cincinnati, Ohio. Ocular surface disease is persistent and progressive, and it affects vision and quality of life for so many patients. In my practice, the goal is to get ahead of the problem early, when treatment is most effective. When I read all the science behind Optima IPL, I realized that to improve the ocular surface, I needed it to cut off the root cause of the problem: inflammation. It was clear that patients here in Cincinnati deserved IPL, and since no one else had it, I needed to get Optima IPL myself. I started using my new Optima IPL system routinely in June 2020, and it’s been rocking and rolling ever since! The results are great, the demand is amazing, and the ROI is like nothing I expected. Here are some key highlights: Results — We build a management package based on each patient’s individual pathology and lifestyle, so Optima IPL is usually accompanied by medications, products or other procedures. A common combination is Optima IPL with thermal pulsation. Rather than competing against each other, IPL and thermal pulsation complement each other nicely. IPL has dramatically increased my capture rates for thermal pulsation, and the results are much better than thermal pulsation alone. Not only are patients subjectively reporting resolution in symptoms, but my objective clinical signs are decreasing. SPEED scores are decreasing below symptomatic (most of my patients start in the high teens and 20s), inflammatory markers are decreasing, and even objective redness scores are going down. What more could a clinician ask for than happy patients and healthy testing? High demand — With no promotion of Optima IPL, we have averaged five new starts a month. I did not anticipate that high a capture rate in our small practice—it blew me away! With patients having four sessions over the course of a few months, followed by maintenance every year, the volume has snowballed. Patients with tend to do a lot of their own research, so I soon began seeing patients seeking second opinions and asking for IPL by name. Fast ROI — With five new starts each month and the volume compounding through repeat visits and maintenance, ROI for Optima IPL almost immediately surpassed my expectations. It’s wild for me to have over $10,000 worth of sales from the first month, and it has continued consistently. I’m very excited to see what the future holds. Patient love — Patients usually start to feel the results of IPL after about two sessions, and the symptomatic improvement lasts, so they’re very happy. It’s been refreshing. Quite a few patients have asked if they can have Optima IPL more frequently than recommended because it’s a pleasant experience. Patients also notice the aesthetic benefit of IPL, which is a nice bonus. I know a lot of my peers are doing comprehensive screening and understand just how prevalent dry eye disease is in their practices. The next step is to meet each patient’s comprehensive set of needs. Optima IPL is part of that commitment because it allows me to treat periocular inflammation and head off the cascade of problems it causes, including ocular surface disease. If I didn’t use Optima IPL, my patients wouldn’t be getting the complete care they deserve, and they might go elsewhere (cities away) to find it. I’m glad they’re happy with their care and staying with me. * Lumenis M22 Optima IPL and Stellar M22 Optima IPL are authorized for use to treat Meibomian Gland Dysfunction, the leading type of dry eye disease, in: the European Union (CE), China, Australia, New Zealand, South Korea, Brazil, and Hong Kong. In the US, the devices are cleared for treatment of inflammatory skin conditions such as rosacea. Rosacea may lead to ocular surface conditions such as MGD, with 80% of rosacea patients suffering from MGD. Treatment of rosacea with the M22 has not been clinically proven to prevent or delay the development of MGD. Explore Other Resources Dry EyeNewsPeriorbital Muscle StimulationTreatment TypeVision Resource HubDry EyeNewsPeriorbital Muscle StimulationTreatment TypeVision Resource HubLumenis OptiLIFT Dynamic Muscle Stimulation Device receives Health Canada Approval for Reducing Signs and Symptoms of Evaporative Dry Eye DiseaseREAD MOREClinical StudiesDry EyePeriorbital Muscle StimulationTreatment TypeVision Resource HubClinical StudiesDry EyePeriorbital Muscle StimulationTreatment TypeVision Resource HubThe Potential Benefits of Periorbital Transcutaneous Electrical Stimulation for the Management of Dry Eye DiseaseREAD MOREDry EyePeriorbital Muscle StimulationPress PublicationsTreatment TypeVision Resource HubDry EyePeriorbital Muscle StimulationPress PublicationsTreatment TypeVision Resource HubSisters Grow Practice Into Medical Hub for Dry Eye TreatmentREAD MORE Discover new possibilities Download OptiLIGHT and OptiPLUS info kit PB-00026170 Rev A #### Ge et al. (2020): Evaluation of the efficacy of optimal pulsed technology treatment in patients with cataract and Meibomian gland dysfunction in the perioperative period Ge et al. (2020): Evaluation of the efficacy of optimal pulsed technology treatment in patients with cataract and Meibomian gland dysfunction in the perioperative period In a prospective, comparative study, Lumenis IPL with OPT™ improved signs and symptoms of mild to moderate MGD in patients who underwent cataract surgery. READ FULL STUDY Indication for Use: Improvement of signs of Dry Eye Disease (DED) due to Meibomian Gland Dysfunction (MGD), also known as evaporative dry eye or lipid deficiency dry eye, in patients 22 years of age and older with moderate to severe signs and symptoms of DED due to MGD and with Fitzpatrick skin types I-IV. IPL is to be applied only to skin on the malar region of the face, from tragus to tragus including the nose (eyes should be fully covered by protective eyewear). IPL is intended to be applied as an adjunct to other modalities, such as meibomian gland expression, artificial tear lubricants and warm compresses Treatment with M22 or OptiLight is contraindicated for patients with the following conditions in the treatment area: Ocular surgery or eyelid surgery or Neuro-paralysis within 6 months prior to the first treatment; Uncontrolled eye disorders affecting the ocular surface; Pre-cancerous lesions, skin cancer or pigmented lesions in the planned treatment area; Uncontrolled infections or uncontrolled immunosuppressive diseases; Recent Ocular infections; Prior history of cold sores or rashes in the perioral area, including: Herpes simplex 1 & 2, Systemic Lupus erythematosus and porphyria; Use of photosensitive medication and/or herbs that may cause sensitivity within 3 months prior to the first IPL session; Recent radiation therapy to the head or neck or planned radiation therapy; Recent treatment with chemotherapeutic agent or planned chemotherapy; History of migraines, seizures or epilepsy. Patients eyes must be completely occluded during the treatment. Please refer to the operator manual for a complete list of intended use, contraindications and risks. Please consult your physician as to whether this procedure is suitable for you. The following possible side effects can occur following IPL treatments: Pain/discomfort, damage to natural skin texture, change of pigmentation, scarring, excessive edema, fragile skin, bruising, burns, pruritus and xerosis. Please refer to the user manual or ask your doctor for a complete list of intended use, contraindications and risks Lumenis has an interest in the study device (M22 system).  All uses of the M22 system described in this paper were approved by the FDA, except the following: – Patients included in this study had mild to moderate DED, whereas FDA cleared the use of the M22 system for moderate to severe DED. – IPL in this study was not accompanied with MGX, whereas FDA approved IPL followed by MGX. None of the authors had financial ties with Lumenis.  No person known to Lumenis has provided funding for the study. The publication discusses the use of IPL for improving outcomes in patients undergoing cataract surgery. This intended use was not approved by the FDA. Explore Other Resources Dry EyeNewsPeriorbital Muscle StimulationTreatment TypeVision Resource HubDry EyeNewsPeriorbital Muscle StimulationTreatment TypeVision Resource HubLumenis OptiLIFT Dynamic Muscle Stimulation Device receives Health Canada Approval for Reducing Signs and Symptoms of Evaporative Dry Eye DiseaseREAD MOREClinical StudiesDry EyePeriorbital Muscle StimulationTreatment TypeVision Resource HubClinical StudiesDry EyePeriorbital Muscle StimulationTreatment TypeVision Resource HubThe Potential Benefits of Periorbital Transcutaneous Electrical Stimulation for the Management of Dry Eye DiseaseREAD MOREDry EyePeriorbital Muscle StimulationPress PublicationsTreatment TypeVision Resource HubDry EyePeriorbital Muscle StimulationPress PublicationsTreatment TypeVision Resource HubSisters Grow Practice Into Medical Hub for Dry Eye TreatmentREAD MORE PB-00038930 Rev A #### Getting the Very First OptiLight: A Perfect Fit for My Tech-Forward Practice Getting the Very First OptiLight: A Perfect Fit for My Tech-Forward Practice September 23, 2021 Jennifer Tsai, OD Jennifer Tsai, OD is the founder & owner of LINE OF SIGHT in Manhattan. She is passionate about eye health and seeks to provide a concierge level of service to all of her clientele, blending eyecare with holistic wellness in a unique boutique environment. When I opened my own practice in 2020, I knew I wanted to reimagine the traditional eyecare practice and give patients an unparalleled experience that balances a tech-forward philosophy with personalized care and a human touch. That’s why I was the first practitioner to purchase OptiLight. I knew treatment with OptiLight could help me offer the highest quality of care to my patients with dry eye disease, and I quickly found out just how easy it was to start using OptiLight, implement it in my practice and create a new revenue stream. OptiLight Comprehensive Dry Eye Solution Because my practice is still in its first year, every patient that walks through the door is a new patient. As part of a complete exam, everyone has a thorough dry eye evaluation. Once I understand the patient’s condition and lifestyle, I create a personalized treatment plan. I often combine elements such as immunomodulators, thermal treatment for meibomian gland dysfunction, and blepharitis therapies to manage this multifactorial condition. When I read that Lumenis IPL with OPT received FDA approval for management of dry eye disease, I contacted Lumenis and became the first practice to purchase OptiLight. It fit my high standards as a safe, gentle, nonsurgical therapeutic procedure that elevates patient care. And the 10-15 minute sessions with no downtime are convenient for busy patients, so I knew it could propel my practice forward. Easy Implementation—and Great Results OptiLight is so easy to learn that I was able to jump right into doing the procedure. Everything is already set up on the device, including built-in clinically validated treatment protocols and standards. In fact, I felt so comfortable that the patient didn’t even know it was my first—it was that easy. And because the treatments are brief, my staff can schedule them in a typical exam slot. That gives me the flexibility to schedule OptiLight anytime, rather than just in blocks. The results have been amazing. Within a month of acquiring the new OptiLight system, I’ve grown to averaging 3-4 treatments a day and signing up 10 new patients per week. The system is already contributing meaningfully to overall practice profitability. I expect the OptiLight will pay for itself well within 6 months. Most importantly, patients who have been suffering with dry eye love the results. They schedule the full course of four treatments over the course of a few months. OptiLight goes hand in hand with my goals to provide the best care possible, be tech-forward to fit modern needs and expectations, and go beyond the standard of care. Indication for Use: Improvement of signs of Dry Eye Disease (DED) due to Meibomian Gland Dysfunction (MGD), also known as evaporative dry eye or lipid deficiency dry eye, in patients 22 years of age and older with moderate to severe signs and symptoms of DED due to MGD and with Fitzpatrick skin types I-IV. IPL is to be applied only to skin on the malar region of the face, from tragus to tragus including the nose (eyes should be fully covered by protective eyewear). IPL is intended to be applied as an adjunct to other modalities, such as meibomian gland expression, artificial tear lubricants and warm compresses Treatment with OptiLight is contraindicated for patients with the following conditions in the treatment area: Ocular surgery or eyelid surgery or Neuro-paralysis within 6 months prior to the first treatment; Uncontrolled eye disorders affecting the ocular surface; Pre-cancerous lesions, skin cancer or pigmented lesions in the planned treatment area; Uncontrolled infections or uncontrolled immunosuppressive diseases; Recent Ocular infections; Prior history of cold sores or rashes in the perioral area, including: Herpes simplex 1 & 2, Systemic Lupus erythematosus and porphyria; Use of photosensitive medication and/or herbs that may cause sensitivity within 3 months prior to the first IPL session; Recent radiation therapy to the head or neck or planned radiation therapy; Recent treatment with chemotherapeutic agent or planned chemotherapy; History of migraines, seizures or epilepsy. Patients eyes must be completely occluded during the treatment. Please refer to the operator manual for a complete list of intended use, contraindications and risks. Please consult your physician as to whether this procedure is suitable for you. The following possible side effects can occur following IPL treatments: Pain/discomfort, damage to natural skin texture, change of pigmentation, scarring, excessive edema, fragile skin, bruising, burns, pruritus and xerosis. Please refer to the user manual or ask your doctor for a complete list of intended use, contraindications and risks Discover new possibilities Download OptiLIGHT and OptiPLUS info kit PB-00039360 Rev A #### Had Enough Of Dry, Itchy Eyes? Find A Real Solution With OptiLIGHT’s First And Only Light Therapy! Had Enough Of Dry, Itchy Eyes? Find A Real Solution With OptiLIGHT’s First And Only Light Therapy! January 4, 2024 Share   Experience Ashley Tisdale’s journey as she discusses her dry eye concerns with Dr. Kambiz Silani. Dr. Silani provides insights into the causes and symptoms of dry eyes and offers a real solution – OptiLIGHT, designed to target the root cause of DED by MGD. Watch more videos Colton Underwood shares his experience with DED and his care journey using OptiLIGHT and OptiLIFTMay 25, 2025WATCH NOWKerri Walsh Jennings Shares the Impact of OptiLIGHT Treatment on Her Dry Eye Disease!May 2, 2024WATCH NOWKerri Has Been Experiencing Dry, Itchy Eyes On And Off The Court For Years. Her Solution: OptiLIGHT!April 28, 2024WATCH NOW PB-00076100, Rev A #### Had Enough of Dry, Itchy Eyes? You Don’t Have To Live With That Anymore! Had Enough of Dry, Itchy Eyes? You Don’t Have To Live With That Anymore! January 4, 2024 Share   Jaime Chung refuses to live with dry, itchy eyes. With OptiLIGHT, the first and only light therapy FDA-approved for dry eyes, she don’t have to live with it. Watch more videos Colton Underwood shares his experience with DED and his care journey using OptiLIGHT and OptiLIFTMay 25, 2025WATCH NOWKerri Walsh Jennings Shares the Impact of OptiLIGHT Treatment on Her Dry Eye Disease!May 2, 2024WATCH NOWKerri Has Been Experiencing Dry, Itchy Eyes On And Off The Court For Years. Her Solution: OptiLIGHT!April 28, 2024WATCH NOW PB-00076100, Rev A #### Hand in Hand: A Thriving Dry Eye Practice and Boutique Optical Hand in Hand: A Thriving Dry Eye Practice and Boutique Optical December 2, 2021 I started my practice with two things in mind. First, I wanted the practice to reflect the highest standards of achieving optimal ocular health. From day one, I not only provided annual exams and performed routine screenings, but I also managed ocular disease and offered complete care for dry eye disease. Second, because I wanted my patients to see clearly and be passionate about their eyeglasses, I created a unique boutique that offers eyewear my patients feel enthusiastic about wearing every day. A sign on my wall reads, “See better than 20/20 in style.” The results are just what I’d hoped: By treating patients’ conditions and ensuring that they wear their glasses, I am delivering individualized eye care and treating the total patient by improving their quality of life. Dry Eye Practice From the start, it was important to me to offer complete dry eye services because dry eye plays such a huge role in ocular health and clear vision. With increased screen time and the demands placed on the eyes, I inform patients that if they are not actively preventing dry eye, they may be on the road to developing symptoms of dry eye disease. Left untreated, dry eye disease is an inflammatory disease that continually progresses. That is why I prescribe preventive ocular surface wellness with at-home therapy such as lid hygiene (“done daily, like brushing one’s teeth”), heated mask compresses, omega oil supplements, and other measures. For symptomatic patients and for patients showing signs of dry eye disease, I offer in-office treatments, including the standout therapy, OptiLight. OptiLight enables me to treat the root inflammation, breaking the vicious cycle that may lead to ocular surface complications like dry eye disease.* This in-office treatment fits easily into my regular visit schedule, so implementation was quite seamless. My patients are attracted to OptiLight because it’s a safe, light-based procedure. After OptiLight treatments, they’re very happy that there is zero downtime and that they are able to return to the things they want to do immediately after receiving treatment. They also appreciate the aesthetic benefits, such as reduced redness, less noticeable fine lines, and improved skin texture—unique bonuses of this procedure. In fact, OptiLight has been so popular it has significantly added to my practice revenue and offset COVID-related losses. In just 7 months, my dry eye clinic is becoming as robust as the optical boutique. Treating the Total Patient When patients have a healthy ocular surface, I can perform an accurate and precise refraction. We also ensure they receive a personalized eyewear fitting. I explain to my patients that the right eyewear is an extension of their dry eye treatment because visual strain triggers dry eye, particularly during digital device use when the blink rate is reduced. By offering a functioning medical device that’s also a fashion accessory, I am confident my patients are wearing their glasses and optimizing the results achieved by dry eye therapy. Indication for Use: Improvement of signs of Dry Eye Disease (DED) due to Meibomian Gland Dysfunction (MGD), also known as evaporative dry eye or lipid deficiency dry eye, in patients 22 years of age and older with moderate to severe signs and symptoms of DED due to MGD and with Fitzpatrick skin types I-IV. IPL is to be applied only to skin on the malar region of the face, from tragus to tragus including the nose (eyes should be fully covered by protective eyewear). IPL is intended to be applied as an adjunct to other modalities, such as meibomian gland expression, artificial tear lubricants and warm compresses Treatment with OptiLight is contraindicated for patients with the following conditions in the treatment area: Ocular surgery or eyelid surgery or Neuro-paralysis within 6 months prior to the first treatment; Uncontrolled eye disorders affecting the ocular surface; Pre-cancerous lesions, skin cancer or pigmented lesions in the planned treatment area; Uncontrolled infections or uncontrolled immunosuppressive diseases; Recent Ocular infections; Prior history of cold sores or rashes in the perioral area, including: Herpes simplex 1 & 2, Systemic Lupus erythematosus and porphyria; Use of photosensitive medication and/or herbs that may cause sensitivity within 3 months prior to the first IPL session; Recent radiation therapy to the head or neck or planned radiation therapy; Recent treatment with chemotherapeutic agent or planned chemotherapy; History of migraines, seizures or epilepsy. Patients eyes must be completely occluded during the treatment. Please refer to the operator manual for a complete list of intended use, contraindications and risks. Please consult your physician as to whether this procedure is suitable for you. The following possible side effects can occur following IPL treatments: Pain/discomfort, damage to natural skin texture, change of pigmentation, scarring, excessive edema, fragile skin, bruising, burns, pruritus and xerosis. Please refer to the user manual or ask your doctor for a complete list of intended use, contraindications and risks Explore Other Resources Dry EyeNewsPeriorbital Muscle StimulationTreatment TypeVision Resource HubDry EyeNewsPeriorbital Muscle StimulationTreatment TypeVision Resource HubLumenis OptiLIFT Dynamic Muscle Stimulation Device receives Health Canada Approval for Reducing Signs and Symptoms of Evaporative Dry Eye DiseaseREAD MOREClinical StudiesDry EyePeriorbital Muscle StimulationTreatment TypeVision Resource HubClinical StudiesDry EyePeriorbital Muscle StimulationTreatment TypeVision Resource HubThe Potential Benefits of Periorbital Transcutaneous Electrical Stimulation for the Management of Dry Eye DiseaseREAD MOREDry EyePeriorbital Muscle StimulationPress PublicationsTreatment TypeVision Resource HubDry EyePeriorbital Muscle StimulationPress PublicationsTreatment TypeVision Resource HubSisters Grow Practice Into Medical Hub for Dry Eye TreatmentREAD MORE PB-00039370 Rev A #### Hear Thomas Nido’s Inspiring Journey with OptiLIGHT’s DED Treatment | OptiLIGHT by Lumenis Hear Thomas Nido’s Inspiring Journey with OptiLIGHT’s DED Treatment | OptiLIGHT by Lumenis October 16, 2023 Share   Listen to this video as Tomas Nido describes how ever since starting his OptiLIGHT by Lumenis journey, he highlights a notable improvement in his daily routine and emphasizes how OptiLIGHT has made a huge difference on his day-to-day life. OptiLIGHT by Lumenis, a real solution for Dry Eyes! Watch more videos Colton Underwood shares his experience with DED and his care journey using OptiLIGHT and OptiLIFTMay 25, 2025WATCH NOWKerri Walsh Jennings Shares the Impact of OptiLIGHT Treatment on Her Dry Eye Disease!May 2, 2024WATCH NOWKerri Has Been Experiencing Dry, Itchy Eyes On And Off The Court For Years. Her Solution: OptiLIGHT!April 28, 2024WATCH NOW PB-00076100, Rev A #### Homepage VISION The Beauty of Eye Care DRY EYE GLAUCOMA RETINA Experience The Lumenis Difference For over 60 years, Lumenis has been known for developing gold-standard, innovative ophthalmic and optometry equipment. Take the next step in your professional and clinical success with the inventors of IPL for dry eye management and the first digital dual path SLT-YAG platform on the market. Lumenis is your trusted ally in your journey to expertise growth, patient satisfaction and business expansion, while setting the highest standards in eye care for years to come. A BRIGHT SOLUTION
FOR DRY EYES Introducing the first and only light therapy, FDA-approved for management of dry eye disease (DED) due to meibomian gland dysfunction (MGD), the leading cause of DED.1 With clinically proven2,3, patented technologies, the power to manage dry eyes is in the palm of your hand. Get the safe and precise procedure you want, and the comfortable, effective therapy patients need to manage dry eye disease with OptiLIGHT. LEARN MORE A NEW APPROACH TO
LOWER LID LAXITY Introducing OptiLIFT, the non-surgical device designed to tone and stimulate the periorbital muscles, addressing lower lid laxity and impaired blinking. Powered by Lumenis’ proprietary Dynamic Muscle Stimulation (DMSt) and RF technology, OptiLIFT targets natural sagging, restoring tone and enhancing blinking efficiency. LEARN MORE Lightening the Path
to Health The pioneering, comprehensive YAG/SLT ophthalmic laser platform signals a new era in laser therapy. One in which documentation, live viewing, and seamless integrated connectivity become the cornerstones of care. Digital Duet provides effective results and sets a new standard of excellence in Glaucoma treatment. LEARN MORE BREAKTHROUGH DUAL FREQUENCY RF TECHNOLOGY OptiPLUS is breaking new ground with its first-of-its-kind dual-frequency radio frequency (RF) technology. It delivers heat across different skin layers, increasing blood circulation, targeting meibomian glands, and enhancing collagen production to promote medical performance and aesthetic results.4 OptiPLUS offers a complementary treatment to Lumenis’ novel OptiLIGHT technology, which targets the root cause of dry eye disease. LEARN MORE VISION RESOURCE HUB Clinical studies, professional insights, press publications, blog posts and more VIEW ALL RESOURCES Dry EyeNewsPeriorbital Muscle StimulationTreatment TypeVision Resource HubDry EyeNewsPeriorbital Muscle StimulationTreatment TypeVision Resource HubLumenis OptiLIFT Dynamic Muscle Stimulation Device receives Health Canada Approval for Reducing Signs and Symptoms of Evaporative Dry Eye DiseaseREAD MOREClinical StudiesDry EyePeriorbital Muscle StimulationTreatment TypeVision Resource HubClinical StudiesDry EyePeriorbital Muscle StimulationTreatment TypeVision Resource HubThe Potential Benefits of Periorbital Transcutaneous Electrical Stimulation for the Management of Dry Eye DiseaseREAD MOREDry EyePeriorbital Muscle StimulationPress PublicationsTreatment TypeVision Resource HubDry EyePeriorbital Muscle StimulationPress PublicationsTreatment TypeVision Resource HubSisters Grow Practice Into Medical Hub for Dry Eye TreatmentREAD MORE The Doctors’ Experience Lumenisvision We love to see doctors using our OptiPLUS radio frequency treatment! Watch @ocdryeyecenter use OptiPLUS, a quick, painless, in-office procedure that helps unblock the glands that produce oil. Discover the powerful pairing of OptiLIGHT for dry eyes and OptiPLUS’ dual frequency RF technology complementary treatment. Watch the full reel and click the link in our bio to learn more! Lumenisvision Dry eye treatment days are our favorite days too! 🌟 So great to see @eyes_on_westlake using our OptiLIGHT and OptiPLUS treatments and sharing their patient’s positive experience. #DryEyes #DryEyeDisease #OptiPLUS #OptiLIGHT Lumenisvision Another happy doctor using OptiLIGHT! 6 reasons why @woodleyoptometry loves OptiLIGHT for dry eye management👇 ✔️ The first & only IPL, FDA approved for dry eye management! ✔️ Targets inflammation ✔️Decreases bacterial load ✔️Reduces demodex population ✔️2.7 x improvement in tear break up time!3,5 ✔️Gentle & fast, with no downtime! Watch the full reel and follow us to learn more about our OptiLIGHT treatment! #OptiLIGHT #DryEyes #DryEyeManagement Lumenisvision Come along and see @dr.julie_mclaughlin’s dry eye treatment day! We love to see doctors using our OptiLIGHT and OptiPLUS treatments and share their positive experiences. Find a clinic near you via the doctor locator in the link in our bio! #DryEyes #DryEyeDisease #OptiLIGHT FOLLOW LUMENIS VISION References Lemp MA et al. (2012), Cornea 2012;31(5):472-428. Liu et al. (2017), Am J Ophthalmol 181-190. Dell et al. (2017) Clin Ophthalmol 11:817-827. Javate RM. Cruz RT, Khan J, Trakos N, Gordon RE. Nonablative 4-MHZ dual radiofrequency wand rejuvenation treatment for periorbital rhytides and midface laxity. Ophthalmic Plast Reconstr Surg. 2011;27(3):180-185. DOI: 10.1097/IOP.0b013e3181fe8e5a Toyos & Briscoe (2016), J Clin Exp Ophthamol 7:6. PB-00074720, Rev C #### How a Boutique Dry Eye Clinic in an Unexpected Spot Drew $45,000 in the First 9 Months. Press PublicationsDry Eye How a Boutique Dry Eye Clinic in an Unexpected Spot Drew $45,000 in the First 9 Months. March 13, 2024 Marinda Hofacre, OD Marinda Hofacre, OD, is the owner of Hofacre Optometric Corporation & Dry Eye Care, with locations in Chino Hills and San Dimas, California. Marinda Hofacre, OD, explains how she’s created a fast-growing revenue stream for her practice by harnessing the dual power of OptiLIGHT’s dry eye solution and OptiPLUS dual-frequency RF complementary treatment. Read Full Article *OptiLIGHT is intended to be used by licensed practitioners, according to local rules and regulations. Discover new possibilities Download OptiLIGHT and OptiPLUS info kit Explore Other Resources Dry EyeNewsPeriorbital Muscle StimulationTreatment TypeVision Resource HubDry EyeNewsPeriorbital Muscle StimulationTreatment TypeVision Resource HubLumenis OptiLIFT Dynamic Muscle Stimulation Device receives Health Canada Approval for Reducing Signs and Symptoms of Evaporative Dry Eye DiseaseREAD MOREClinical StudiesDry EyePeriorbital Muscle StimulationTreatment TypeVision Resource HubClinical StudiesDry EyePeriorbital Muscle StimulationTreatment TypeVision Resource HubThe Potential Benefits of Periorbital Transcutaneous Electrical Stimulation for the Management of Dry Eye DiseaseREAD MOREDry EyePeriorbital Muscle StimulationPress PublicationsTreatment TypeVision Resource HubDry EyePeriorbital Muscle StimulationPress PublicationsTreatment TypeVision Resource HubSisters Grow Practice Into Medical Hub for Dry Eye TreatmentREAD MORE PB-00043680 Rev C #### How I Tripled My Dry Eye Revenues How I Tripled My Dry Eye Revenues Six months after purchasing OptiLight and focusing his practice on dry eye, Shane Swatts, OD, has tripled revenues, and he’s enjoying his work more than ever. READ FULL ARTICLE Shane Swatts, OD Explore Other Resources Dry EyeNewsPeriorbital Muscle StimulationTreatment TypeVision Resource HubDry EyeNewsPeriorbital Muscle StimulationTreatment TypeVision Resource HubLumenis OptiLIFT Dynamic Muscle Stimulation Device receives Health Canada Approval for Reducing Signs and Symptoms of Evaporative Dry Eye DiseaseREAD MOREClinical StudiesDry EyePeriorbital Muscle StimulationTreatment TypeVision Resource HubClinical StudiesDry EyePeriorbital Muscle StimulationTreatment TypeVision Resource HubThe Potential Benefits of Periorbital Transcutaneous Electrical Stimulation for the Management of Dry Eye DiseaseREAD MOREDry EyePeriorbital Muscle StimulationPress PublicationsTreatment TypeVision Resource HubDry EyePeriorbital Muscle StimulationPress PublicationsTreatment TypeVision Resource HubSisters Grow Practice Into Medical Hub for Dry Eye TreatmentREAD MORE PB-00043680, Rev A #### How OptiLIGHT’s Rapid ROI Is Driving Expansion of My Dry Eye Practice Blog PostsDry Eye How OptiLIGHT’s Rapid ROI Is Driving Expansion of My Dry Eye Practice January 15, 2024 Sabrina Gaan, OD Sabrina Gaan, OD is a primary care optometrist, dry eye expert, and owner of Eyes on Plainville in Plainville, Massachusetts. When I built my dry eye clinic, getting OptiLIGHT was a top priority. In a field where there are lots of remedies with limited effects, I wanted a real, proven, IPL FDA-approved solution to treating dry eye’s underlying inflammation. Through my 10 years working as an associate and then in a solo retail environment, I had referred patients for Lumenis IPL treatment, and the results were amazing! Patients came back happy, telling me their dry eye was significantly better, and I saw the improvements in inflammation, meibomian gland structure, and tear break up time.1 Even my dry eye patients who had tried everything for 10-plus years finally found success with OptiLIGHT. When I bought a local practice to expand my dry eye treatment capabilities, all of this past experience, combined with OptiLIGHT’s industry-leading technology made the purchase an easy decision for me. Although I was excited about OptiLIGHT’s value to my patients, I didn’t know how long it would take to see a return on my investment. I quickly found out: Revenues totaled $120K in the first year. I’m still going strong and reinvesting OptiLIGHT revenues to expand my practice. Keys to OptiLIGHT’s Rapid ROI  When I began using OptiLIGHT, I calculated that I could make my payment every month if I got 2 new OptiLIGHT patients per week. This turned out to be easier than expected. A few influential factors contributed to my fast ROI: I built case volume early – Knowing my OptiLIGHT device was coming soon, I stopped referring patients for treatment and started a waitlist. Within 2 months after it arrived, I was treating 3-4 patients per week, and the numbers continued to increase. I got OptiLIGHT in July 2022; in the first quarter of 2023, revenues were $42K. During winter, I saw 10-20 patients per week, and although treatment volume dips during summer when potential sun exposure reduces demand for light-based therapies, I still did about 7 treatments per week during summer months. Patients continue to return for maintenance treatments if needed 6-12 months after completing 4 sessions. Lumenis’ marketing attracted new patients and referring doctors – Growth in treatment volume has happened organically from Lumenis’ marketing. I started by treating my own growing dry eye patient base with OptiLIGHT. Very soon, I began seeing 3-5 new patients per month through Lumenis’ online directory of OptiLIGHT providers. Some patients searched the directory themselves, and others were referred by doctors who checked it. By delivering new OptiLIGHT patients every month, Lumenis’ strong marketing presence significantly accelerated my ROI. Their name recognition also allowed more patients to find me through internet searches for local OptiLIGHT. These patients and referring doctors never would have found me if I’d chosen to get an inferior, off-label IPL device. As my base of patients happy with their OptiLIGHT results grew, their word-of-mouth referrals continued to grow exponentially as well, ensuring a continual flow of new patients. Revenues are unburdened by pricey disposables – To calculate the potential ROI for OptiLIGHT, consider that its only proprietary disposable is the OptiTips. So, while a thermal device I use in my clinic requires $200 in consumables for each treatment, I only spend a little over $25 on disposables for each OptiLIGHT treatment (OptiTip, a plastic cup for water, a tongue depressor, and gel). The rest is revenue. OptiLIGHT Revenues Are Driving My Practice’s Growth  I started using OptiLIGHT in July, and by October, I needed another doctor, so I hired an associate to share the workload treating dry eye patients. It’s been amazing! We’re generating more revenue, so now I can step back one day a week and enjoy more quality time for myself. I’ve also reinvested the revenues in a new slit lamp with meibography and video capture to enhance the dry eye clinic. The engine behind all of this success is OptiLIGHT, and I couldn’t be happier with the outcome. Discover new possibilities Download OptiLIGHT and OptiPLUS info kit Explore Other Resources Dry EyeNewsPeriorbital Muscle StimulationTreatment TypeVision Resource HubDry EyeNewsPeriorbital Muscle StimulationTreatment TypeVision Resource HubLumenis OptiLIFT Dynamic Muscle Stimulation Device receives Health Canada Approval for Reducing Signs and Symptoms of Evaporative Dry Eye DiseaseREAD MOREClinical StudiesDry EyePeriorbital Muscle StimulationTreatment TypeVision Resource HubClinical StudiesDry EyePeriorbital Muscle StimulationTreatment TypeVision Resource HubThe Potential Benefits of Periorbital Transcutaneous Electrical Stimulation for the Management of Dry Eye DiseaseREAD MOREDry EyePeriorbital Muscle StimulationPress PublicationsTreatment TypeVision Resource HubDry EyePeriorbital Muscle StimulationPress PublicationsTreatment TypeVision Resource HubSisters Grow Practice Into Medical Hub for Dry Eye TreatmentREAD MORE 1. Toyos R, Desai NR, Toyos M, Dell SJ. Intense pulsed light improves signs and symptoms of dry eye disease due to meibomian gland dysfunction: A randomized controlled study. PLoS One. 2022;17(6):e0270268. Published 2022 Jun 23. doi:10.1371/journal.pone.0270268 PB-00043680, Rev C #### Improving Glaucoma Patient Compliance with Selective Laser Trabeculoplasty (SLT) Improving Glaucoma Patient Compliance with Selective Laser Trabeculoplasty (SLT) Description: Topics will include: The value of SLT in a private practice setting SLT as primary or adjunctive therapy Reducing or replacing glaucoma medications The benefits of combining SLT with mono-therapy Detecting non-adherence with glaucoma therapy Helping patients cope with the high cost of medications Duration: 54 mins Publish Date: October 20, 2011 Speaker: Dr. Richard A. Quinones Explore Other Resources Dry EyeNewsPeriorbital Muscle StimulationTreatment TypeVision Resource HubDry EyeNewsPeriorbital Muscle StimulationTreatment TypeVision Resource HubLumenis OptiLIFT Dynamic Muscle Stimulation Device receives Health Canada Approval for Reducing Signs and Symptoms of Evaporative Dry Eye DiseaseREAD MOREClinical StudiesDry EyePeriorbital Muscle StimulationTreatment TypeVision Resource HubClinical StudiesDry EyePeriorbital Muscle StimulationTreatment TypeVision Resource HubThe Potential Benefits of Periorbital Transcutaneous Electrical Stimulation for the Management of Dry Eye DiseaseREAD MOREDry EyePeriorbital Muscle StimulationPress PublicationsTreatment TypeVision Resource HubDry EyePeriorbital Muscle StimulationPress PublicationsTreatment TypeVision Resource HubSisters Grow Practice Into Medical Hub for Dry Eye TreatmentREAD MORE #### Interventional Therapy is a Win for Dry Eye Patients Blog PostsDry Eye Interventional Therapy is a Win for Dry Eye Patients December 25, 2024 Dr. Nate Lighthizer, OD, FAAO Website Dr. Lighthizer is a professor and the dean for the Northeastern State University Oklahoma College of Optometry. He founded and now heads the College’s Dry Eye Clinic. He is also the director of the Continuing Medical Education Program for the College of Optometry. Dr. Lighthizer is a founding member and currently serves as immediate past president of the Intrepid Eye Society, a group of emerging and established thought leaders in optometry. Interventional Therapy is a Win for Dry Eye Patients Nate Lighthizer OD, FAAO Professor and Dean, Northeastern State University Oklahoma College of Optometry Interventional therapy is changing the way we treat dry eye disease (DED), giving eye care professionals a more active role in dry eye management and improving the overall patient experience. Over the last decade or so, patient care has evolved from prescribing the typical at-home treatment options to focusing more on in-office treatments, such as intense pulsed light therapy (IPL) and radiofrequency thermal pulsation (RF). While traditional treatments such as artificial tears and warm compresses may still be helpful, they are no longer the main solution. Dry eye is a progressive, chronic disease, and we need treatments that are disease-modifying, not just symptom-masking. Many treatments only provide temporary relief without addressing underlying issues like meibomian gland dysfunction and inflammation. Compliance also suffers when patients are burdened with doing all the work at home, putting in drops and applying compresses on a day-to-day basis. Instead, offering in-office treatments that we know are effective and safe, such as IPL and RF, leads to better outcomes and long-term patient benefits. The Benefits of IPL Treatment IPL has become a mainstay of dry eye treatment. Five years ago, only a small percentage of doctors were using it, but that has since changed now that we have an FDA-approved IPL for dry eyes. Lumenis IPL is the first and only IPL FDA-approved for the management of dry eye disease due to meibomian gland dysfunction (MGD). OptiLIGHT uses Lumenis’ patented Optimal Pulse Technology (OPT™) to significantly improve tear breakup time, meibum quality, and meibomian gland expressibility. , Inflammation is like a faucet that runs and runs, causing dry eye. If we can turn the faucet off or reduce the flow, it will help. IPL absorbs leaky inflammatory facial vessels, also known as telangiectasia, and helps shut them down, reducing inflammation. This approach is especially important for patients with ocular rosacea, as targeting telangiectasias and MGD dramatically decreases or eliminates facial redness and sets them on the right path for relief. , In my office, we schedule patients for a series of four to six OptiLIGHT treatments spaced two to four weeks apart. With regularly scheduled treatments, we see consistent improvements in dry eye signs, and patients feel better overall. Seeing patients on a regular basis also provides opportunities to educate them on the importance of sticking to the treatment schedule. Those additional touchpoints between the doctor and the patient are critical to reinforcing compliance, the reasons for treatment, and getting buy-in from the patient. Adding RF to IPL Treatment OptiPLUS, a complementary treatment to OptiLIGHT, adds another element to enhance patient care. It is an FDA-cleared dual-frequency radio frequency (RF) device that uses heat to target the meibomian glands and promote collagen production. Since 86% of dry eye cases are linked to MGD, nearly every patient will experience some degree of evaporative dry eye, with the meibomian glands often being the root cause. Heating these glands with radio frequency improves their function and secretion, making it a highly beneficial treatment. We always recommend in-office OptiPLUS treatments over several sessions, which can be done at the same time as OptiLIGHT treatments, to effectively target the meibomian glands. Response to Treatment We have received tremendous feedback from patients regarding their OptiLIGHT and OptiPLUS treatments because they are moving in the right direction. Again, patient education is key. If they expect immediate results from a single IPL treatment, they can be disappointed. I always emphasize that we cannot fix dry eye in a day, a week, or even a month. Treating dry eye is a marathon, not a sprint. It’s about making consistent improvements with every visit. Each time, my goal is to make the patient a little bit better, then a little bit better, and then a little bit better after that. Patients appreciate a doctor who cares, is committed, and uses the latest technology, and they have been very pleased with the results. The future of dry eye management is increasingly shifting toward in-office treatments, much like the evolution we have seen in glaucoma care. Interventional therapies like OptiLIGHT and OptiPLUS are not just about managing signs – they are important for modifying the disease and providing personalized care. By embracing these innovative approaches, you’ll see happier patients will return for follow-ups. It is a win for both your practice and your patients, ultimately leading to better outcomes and long-term results. Discover new possibilities Download OptiLIGHT and OptiPLUS info kit Explore Other Resources Dry EyeNewsPeriorbital Muscle StimulationTreatment TypeVision Resource HubDry EyeNewsPeriorbital Muscle StimulationTreatment TypeVision Resource HubLumenis OptiLIFT Dynamic Muscle Stimulation Device receives Health Canada Approval for Reducing Signs and Symptoms of Evaporative Dry Eye DiseaseREAD MOREClinical StudiesDry EyePeriorbital Muscle StimulationTreatment TypeVision Resource HubClinical StudiesDry EyePeriorbital Muscle StimulationTreatment TypeVision Resource HubThe Potential Benefits of Periorbital Transcutaneous Electrical Stimulation for the Management of Dry Eye DiseaseREAD MOREDry EyePeriorbital Muscle StimulationPress PublicationsTreatment TypeVision Resource HubDry EyePeriorbital Muscle StimulationPress PublicationsTreatment TypeVision Resource HubSisters Grow Practice Into Medical Hub for Dry Eye TreatmentREAD MORE Yin Y, Liu N, Gong L, Song N. Changes in the Meibomian Gland After Exposure to Intense Pulsed Light in Meibomian Gland Dysfunction (MGD) Patients. Curr Eye Res. 2018;43(3):308-313. doi:10.1080/02713683.2017.1406525 Toyos R, Desai NR, Toyos M, Dell SJ. Intense pulsed light improves signs and symptoms of dry eye disease due to meibomian gland dysfunction: A randomized controlled study. PLoS One. 2022;17(6):e0270268. Published 2022 Jun 23. doi:10.1371/journal.pone.0270268 Papageorgiou, P., Clayton, W., Norwood, S., Chopra, S., & Rustin, M. (2008). Treatment of rosacea with intense pulsed light: significant improvement and long-lasting results. British Journal of Dermatology, 159(3), 628-632. https://doi.org/10.1111/j.1365-2133.2008.08702.x Kassir, R., Kolluru, A., & Kassir, M. (2011). Intense pulsed light for the treatment of rosacea and telangiectasias. Journal of Cosmetic and Laser Therapy, 13(5), 216-222. https://doi.org/10.3109/14764172.2011.613480 Chelnis, J., Garcia, C. N., & Hamza, H. (2023). Multi-frequency RF combined with intense pulsed light improves signs and symptoms of dry eye disease due to meibomian gland dysfunction. Clinical Ophthalmology, 17, 3089-3102. https://doi.org/10.2147/OPTH.S426564 Lemp, M. A., Crews, L. A., Bron, A. J., Foulks, G. N., & Sullivan, B. D. (2012). Distribution of aqueous-deficient and evaporative dry eye in a clinic-based patient cohort: A retrospective study. Cornea, 31(5), 472–478. https://doi.org/10.1097/ICO.0b013e318225415a *OptiPLUS is cleared for use in the United States as a standalone device and not as a combination device with other therapies. PB-00085260, Rev A #### IPL for Dry Eye IPL TECHNOLOGY
FOR DRY EYES Explore IPL technology for dry eyes, a cutting-edge, non-invasive solution targeting MGD to improve eye comfort, vision, and quality of life. DOWNLOAD INFO KIT Close AboutPatients BenefitsIPL USE CASEFAQs Close IPL FOR DRY EYES Intense Pulsed Light (IPL) technology is a clinically validated light treatment for dry eye disease caused by Meibomian Gland Dysfunction (MGD). The efficacy of IPL for patients with dry eye due to MGD was first discovered by Dr. Toyos during treatment of facial rosacea, eventually leading to its application in ophthalmology. IPL technology addresses the root cause of Dry Eye Disease (DED) by reducing inflammation in the ocular area. IPL uses a xenon flash lamp to produce a light output of wavelengths between 400 and 1200 nm. The treatment eliminates abnormal blood vessels and stimulates the meibomian glands to restore normal oil production. This process improves gland function, stabilizes tear distribution and enhances overall eye comfort. How IPL technology Works to Treat Dry Eye? Dry Eye Disease is a multifactorial condition affecting hundreds of millions worldwide. While signs of DED can vary from one patient to another, the most common form is evaporative dry eye, primarily caused by MGD1. This condition often leads to tear film instability, which IPL treatment is designed to address. IPL helps stabilize tear film by stimulating the cells responsible for oil production in the meibomian glands, reducing dryness, irritation and discomfort. DOWNLOAD INFO KIT BENEFITS OF IPL FOR DRY EYE PATIENTS REDUCES RELIANCE ON TEMPORARY TREATMENTS IPL technology  provides an effective solution for managing dry eye signs, aiming to decrease patients’ dependencies on eye drops, and other short-term treatments, that only provide temporary relief. NON-INVASIVE AND EFFICIENT PROCEDURE The treatment protocol involves four sessions spaced 2-4 weeks apart with each session lasting 10-15 minutes. The procedure requires no down time, allowing patients to return to their daily activities after treatment.​ IMPROVES VISION AND OVERALL COMFORT Many patients report improvements in vision and reduced discomfort after just 2-3 IPL sessions. Optimal results are often achieved after four treatments, while periodic sessions are recommended for sustained relief. TARGETS INFLAMMATION AND DRYNESS IPL reduces inflammatory markers in the tear film, leading to less dryness and irritation. LEARN MORE INTEGRATING IPL TECHNOLOGY 
INTO YOUR PRACTICE Among the IPL devices available in the United States, OptiLIGHT IPL is the first and only FDA-approved IPL technology for Dry Eye management. It provides clinics with reliable, evidence-based solution for MGD-related dry eye disease. OptiLIGHT is designed to fit seamlessly into practice workflows, providing a potentially quick, effective treatment option with high patient satisfaction and fast ROI. Featuring patented OPT™technology, the device ensures precise and controlled IPL treatment. This precision ensures the treatment is safe and effective for sensitive areas, targeting inflammation without causing discomfort. DOWNLOAD INFO KIT THE BUSINESS CASE FOR IPL Among the IPL devices available in the United States, OptiLIGHT IPL is the first and only FDA-approved IPL technology for Dry Eye management. It provides clinics with reliable, evidence-based solution for MGD-related dry eye disease. OptiLIGHT is designed to fit seamlessly into practice workflows, providing a potentially quick, effective treatment option with high patient satisfaction and fast ROI. Featuring patented OPT™technology, the device ensures precise and controlled IPL treatment. This precision ensures the treatment is safe and effective for sensitive areas, targeting inflammation without causing discomfort. RETURN ON INVESTMENT FOR IPL TECHNOLOGY With its efficient treatment protocols and ability to target a common issue, IPL technology offers an opportunity to a strong return on investment by attracting and retaining patients who suffer from Dry Eye Disease due to MGD. FAQ’s WHAT IS IPL TECHNOLOGY FOR DRY EYES? IPL stimulates meibomian gland cells to secrete oils and regresses dilated blood vessels, reducing inflammation. Additionally, IPL provides antimicrobial benefits, eradicating Demodex mites and lowering microbial burden associated with blepharitis2,3. HOW DOES IPL ADDRESS DRY EYE DISEASE DUE TO MGD? As mentioned above, DED is a multifactorial condition, and inflammation is a key factor contributing to its development. IPL targets this inflammation by addressing several underlying factors, including heating and liquefying meibum, activating fibroblasts and promoting collagen synthesis, which supports tissue health, eradicating Demodex mites, reducing their impact on eyelid and gland health, etc. HOW LONG DOES IPL FOR DRY EYE LAST? The effects of IPL can vary by patient. Most individuals experience significant relief after four initial treatments spaced 2-4 weeks apart. Maintenance sessions every 6-12 months are typically recommended to sustain long-term benefits. Is IPL for Dry Eyes covered by insurance? Insurance generally does not cover IPL treatment for dry eye, however, dry eye clinics may offer flexible payment plans or financing options to make treatment more accessible. It’s always recommended to check with an eye care practitioner for specific coverage details. References: Toyos R, Desai NR, Toyos M, Dell SJ. Intense pulsed light improves signs and symptoms of dry eye disease due to meibomian gland dysfunction: A randomized controlled study. PLoS One. 2022 Jun 23 Prieto V, Sadick N, Lloreta J, Nicholson J, Shea C. Effects of intense pulsed light on sun-damaged human skin, routine, and ultrastructural analysis. Lasers Surg Med. 2002;30(2):82–85. Kirn T. Intense pulsed light eradicates Demodex mites. Skin Allergy News. 2002;33(1):37. PB-00086760 Rev A IPL FOR DRY EYE SOLUTION A BRIGHT SOLUTION
FOR DRY EYES Introducing the first and only light therapy, FDA-approved for management of dry eye disease (DED) due to meibomian gland dysfunction (MGD), the leading cause of DED.1 With clinically proven2,3, patented technologies, the power to manage dry eyes is in the palm of your hand. Get the safe and precise procedure you want, and the comfortable, effective therapy patients need to manage dry eye disease with OptiLIGHT. LEARN MORE #### Itay Mayer, VP and Managing Director of Lumenis Vision, shares exciting product updates about OptiLight 2.0 and insights into Lumenis’ consumer campaign at VEE 2023 VEE 2023: Here what’s new with Lumenis Vision Itay Mayer, Vice President and Managing Director of Lumenis Vision, caught up with Optometry Times® to share an update on the company and its products, which was showcased during the 2023 Vision Expo East meeting in New York, New York. LISTEN TO FULL INTERVIEW Explore Other Resources Dry EyeNewsPeriorbital Muscle StimulationTreatment TypeVision Resource HubDry EyeNewsPeriorbital Muscle StimulationTreatment TypeVision Resource HubLumenis OptiLIFT Dynamic Muscle Stimulation Device receives Health Canada Approval for Reducing Signs and Symptoms of Evaporative Dry Eye DiseaseREAD MOREClinical StudiesDry EyePeriorbital Muscle StimulationTreatment TypeVision Resource HubClinical StudiesDry EyePeriorbital Muscle StimulationTreatment TypeVision Resource HubThe Potential Benefits of Periorbital Transcutaneous Electrical Stimulation for the Management of Dry Eye DiseaseREAD MOREDry EyePeriorbital Muscle StimulationPress PublicationsTreatment TypeVision Resource HubDry EyePeriorbital Muscle StimulationPress PublicationsTreatment TypeVision Resource HubSisters Grow Practice Into Medical Hub for Dry Eye TreatmentREAD MORE PB-00043680, Rev B #### Kerri Has Been Experiencing Dry, Itchy Eyes On And Off The Court For Years. Her Solution: OptiLIGHT! Kerri Has Been Experiencing Dry, Itchy Eyes On And Off The Court For Years. Her Solution: OptiLIGHT! April 28, 2024 Share   Join three-time Olympic gold medalist Kerri Walsh as she shares her experience with OptiLIGHT by Lumenis. Discover how this treatment helped her overcome years of itchy, runny eyes, enhancing her vision and performance both on and off the volleyball court. Watch more videos Colton Underwood shares his experience with DED and his care journey using OptiLIGHT and OptiLIFTMay 25, 2025WATCH NOWKerri Walsh Jennings Shares the Impact of OptiLIGHT Treatment on Her Dry Eye Disease!May 2, 2024WATCH NOWKerri Has Been Experiencing Dry, Itchy Eyes On And Off The Court For Years. Her Solution: OptiLIGHT!April 28, 2024WATCH NOW PB-00077760, Rev A #### Kerri Walsh Jennings Shares the Impact of OptiLIGHT Treatment on Her Dry Eye Disease! Kerri Walsh Jennings Shares the Impact of OptiLIGHT Treatment on Her Dry Eye Disease! May 2, 2024 Share   Kerri Walsh details her experience with OptiLIGHT effective solution! Emphasizing on how it supports her lifestyle as an Olympian, athlete, and mother. Tune in to learn why OptiLIGHT could be the breakthrough you’ve been looking for. Watch more videos Colton Underwood shares his experience with DED and his care journey using OptiLIGHT and OptiLIFTMay 25, 2025WATCH NOWKerri Walsh Jennings Shares the Impact of OptiLIGHT Treatment on Her Dry Eye Disease!May 2, 2024WATCH NOWKerri Has Been Experiencing Dry, Itchy Eyes On And Off The Court For Years. Her Solution: OptiLIGHT!April 28, 2024WATCH NOW PB-00077750, Rev A #### Laser treatment vs drops Laser treatment vs drops Weighing first-line therapies for glaucoma? Dr. Kristin O. Chapman explains how to answer the question: Should you prescribe drops first or start with SLT? READ FULL ARTICLE Kristin O. Chapman, MD Explore Other Resources Dry EyeNewsPeriorbital Muscle StimulationTreatment TypeVision Resource HubDry EyeNewsPeriorbital Muscle StimulationTreatment TypeVision Resource HubLumenis OptiLIFT Dynamic Muscle Stimulation Device receives Health Canada Approval for Reducing Signs and Symptoms of Evaporative Dry Eye DiseaseREAD MOREClinical StudiesDry EyePeriorbital Muscle StimulationTreatment TypeVision Resource HubClinical StudiesDry EyePeriorbital Muscle StimulationTreatment TypeVision Resource HubThe Potential Benefits of Periorbital Transcutaneous Electrical Stimulation for the Management of Dry Eye DiseaseREAD MOREDry EyePeriorbital Muscle StimulationPress PublicationsTreatment TypeVision Resource HubDry EyePeriorbital Muscle StimulationPress PublicationsTreatment TypeVision Resource HubSisters Grow Practice Into Medical Hub for Dry Eye TreatmentREAD MORE PB-00041440 Rev A #### Light After the Storm: A Hopeful Look Ahead for Dry Eye Disease Light After the Storm: A Hopeful Look Ahead for Dry Eye Disease Dr. Laura M. Periman explains the multifactorial complexity of dry eye disease—and how OptiLight is helping the future look bright. READ FULL ARTICLE Laura M. Periman, MD Explore Other Resources Dry EyeNewsPeriorbital Muscle StimulationTreatment TypeVision Resource HubDry EyeNewsPeriorbital Muscle StimulationTreatment TypeVision Resource HubLumenis OptiLIFT Dynamic Muscle Stimulation Device receives Health Canada Approval for Reducing Signs and Symptoms of Evaporative Dry Eye DiseaseREAD MOREClinical StudiesDry EyePeriorbital Muscle StimulationTreatment TypeVision Resource HubClinical StudiesDry EyePeriorbital Muscle StimulationTreatment TypeVision Resource HubThe Potential Benefits of Periorbital Transcutaneous Electrical Stimulation for the Management of Dry Eye DiseaseREAD MOREDry EyePeriorbital Muscle StimulationPress PublicationsTreatment TypeVision Resource HubDry EyePeriorbital Muscle StimulationPress PublicationsTreatment TypeVision Resource HubSisters Grow Practice Into Medical Hub for Dry Eye TreatmentREAD MORE PB-00041440 Rev A #### LIOs Lumenis Smart LIO™ Advanced Laser Indirect Ophthalmoscope Lumenis is proud to present the Smart LIO™, its newest high-end Laser Indirect Ophthalmoscope smart LIO™ offers a new standard of comfort and reliability Duet Trio Selecta II Novus Spectra Novus Spectra (Dual -Port) Aspirating Endo-Ocular Probe X X X Illuminating Endo-Ocular Probe X X X Acculite Endoprobe X X X Laser Indirect Ophthalmoscope (LIO) X X X Laser Link Slit Lamp Adapters X X X X Footswitch X X X X X Physician Eye Safety Filters X X X X X Laser Indirect Ophthalmoscopes Provides superior performance with built-in versatility and maximum safety: Coaxial illumination, aiming and treatment beams guarantee precise delivery and ease of use Integrated three-wavelength eye safety filters maximize your treatment options and physician safety Stereopsis is maximized in all pupil sizes down to 1.2 mm Brochure Lumenis Ophthalmology Devices Digital Duet The first and only all-in-one digital platform for Glaucoma and PCO therapies Digital Trio 3 in 1 digital platform for Glaucoma and Retina care OptiLIGHT A bright solution for dry eyes ArrayTM LaserLinkTM Pattern Scanning Laser Technology Vision One Modular Multi-Wave Photocoagulator Selecta Duet SLT Technology and a Yag Photodisruptor in One Platform Selecta Trio Retinal, Cataract and Glaucoma Therapy in One Platform Novus SpectraTM High-Powered Photocoagulator LumeProbeTM Endo-Photocoagulation Laser Probes PB-00033230 Rev A × GET MORE INFO #### Lumenis is Proud to Introduce OptiPLUS, a First-of-its-Kind Dual Frequency RF Energy Device Lumenis is Proud to Introduce OptiPLUS, a First-of-its-Kind Dual Frequency RF Energy Device Complementing OptiLIGHT, the new OptiPLUS empowers ophthalmologists and optometrists to elevate their practices Yokne’am Illit, Israel, Nov 6, 2023 Lumenis Be., a leading energy-based medical device company for aesthetic and eye care applications, today announced the launch of OptiPLUS, the first dual frequency radiofrequency (RF) device on the market. It delivers heat across different tissue layers, increasing blood circulation to promote medical performance and aesthetic results.1 OptiPLUS is a complementary device to Lumenis’ novel OptiLIGHT technology, which targets the root cause of dry eye disease. While OptiLIGHT relies on a pioneering light-based technology to break the vicious cycle of dry-eye inflammation due to meibomian gland dysfunction, OptiPLUS is a dedicated device that employs a breakthrough RF energy to enhance clinical results. The FDA-cleared dual-frequency RF technology enables energy penetration to different skin depths, heating the superficial layer to promote collagen formation and stimulate peri-orbital skin rejuvenation while also reaching into the deeper tissue to target the meibomian glands.1,2,3 A unique monopolar electrode ensures optimized contact with the delicate contours in the peri-orbital area, enabling OptiPLUS to offer unmatched safety and unrivaled patient comfort.4 Used to treat patients across a range of skin types, OptiPLUS leverages the benefits of state-of-the-art technology with clinically validated, pre-embedded settings and temperature control for better efficacy and safety. “I’m very pleased with the clinical outcomes experienced while using OptiLIGHT to treat dry eye disease, and I’m excited about incorporating OptiPLUS as an essential addition to my armamentarium,” said James Chelnis, MD, FACS, an ophthalmologist at Manhattan Face & Eye. “As the leading investigator in a recently published clinical study, I discovered that the pairing of these two technologies brings remarkable results, significantly improving the number of expressible meibomian glands (over 150% average), meibum clarity (over 70%) and symptoms (over 60%)3. The fact that it also offers aesthetic benefits is just another great advantage.” Itay Mayer, Managing Director of Lumenis Vision said, “Lumenis has a relentless commitment to innovation and eye care advancement. We’ve driven substantial progress in the space with our gold standard OptiLIGHT device and now with our unique dual frequency RF technology, OptiPLUS.” Mayer continued, “Our passion for researching and developing groundbreaking solutions allows eye care practitioners to provide the highest level of care. We are also proud to partner with customers to offer marketing and clinical support that is unparalleled in our industry. In all we do, we focus on what matters the most — making a meaningful impact by transforming people’s lives.” To learn more about how the powerful pairing of OptiLIGHT and OptiPLUS can be used to help build practices by enhancing patient care, please visit https://information.lumenis.com/optilight . References Javate RM. Cruz RT, Khan J, Trakos N, Gordon RE. Nonablative 4-MHZ dual radiofrequency wand rejuvenation treatment for periorbital rhytides and midface laxity. Ophthalmic Plast Reconstr Surg. 2011;27(3):180-185. DOI: 10.1097/IOP.0b013e3181fe8e5a Al-Atif H. Collagen Supplements for Aging and Wrinkles: A Paradigm Shift in the Fields of Dermatology and Cosmetics. Dermatol Pract Concept. Published online Jan. 1, 2022. doi: 10.5826/dpc.1201a18. Chelnis, J. Garcia, Ch. Hamza, H. Multi-frequencyRF combined with intense pulsed light improves signs and symptoms of dry eye disease due to meibomian gland dysfunction. Clinical Ophthalmology. In press. Green JB, Dover JS, Kaminer MS. Tolerability of a Monopolar Radiofrequency Facial Skin Tightening Procedure: An Observational Study. Cosmetic Dermatology. 2011;24(7):327-330. 024070327.pdf (mdedge.com). About Lumenis www.lumenis.com Lumenis develops life-changing, minimally invasive solutions for the Aesthetic and Vision markets. We create and commercialize innovative energy-based technologies that enable a variety of skin, body, and eye care treatments. Lumenis has successfully introduced solutions for previously untreatable conditions and designed advanced technologies that have revolutionized existing treatment methods. We are BeautyTech pioneers, empowering people by broadening the horizons of health and celebrating beauty that matters. Media Contact Colleen Ketchum colleen.ketchum@precisionvh.com Explore Other Resources Dry EyeNewsPeriorbital Muscle StimulationTreatment TypeVision Resource HubDry EyeNewsPeriorbital Muscle StimulationTreatment TypeVision Resource HubLumenis OptiLIFT Dynamic Muscle Stimulation Device receives Health Canada Approval for Reducing Signs and Symptoms of Evaporative Dry Eye DiseaseREAD MOREClinical StudiesDry EyePeriorbital Muscle StimulationTreatment TypeVision Resource HubClinical StudiesDry EyePeriorbital Muscle StimulationTreatment TypeVision Resource HubThe Potential Benefits of Periorbital Transcutaneous Electrical Stimulation for the Management of Dry Eye DiseaseREAD MOREDry EyePeriorbital Muscle StimulationPress PublicationsTreatment TypeVision Resource HubDry EyePeriorbital Muscle StimulationPress PublicationsTreatment TypeVision Resource HubSisters Grow Practice Into Medical Hub for Dry Eye TreatmentREAD MORE BR0009-US.R0 #### Lumenis launches OptiLIFT for toning periorbital muscles NewsPress PublicationsDry EyePeriorbital Muscle Stimulation Lumenis launches OptiLIFT for toning periorbital muscles May 7, 2025 Lumenis has launched OptiLIFT, a new device that tones periorbital muscles to address lower eyelid laxity and impaired blinking. With age, periorbital muscles lose 3-8% of their tone each decade, leading to sagging eyelids. As a result, blinking mechanics become impaired, tear film stability decreases, and ocular conditions may develop. OptiLIFT targets the root cause – weakened periorbital muscles, and clinical data shows significant improvements in tear breakup time, blink quality, and lower lid laxity. Read Full Article *OptiLIGHT and OptiPLUS are intended to be used by licensed practitioners, according to local rules and regulations. DOWNLOAD INFO KIT Discover how OptiLIFT can transform your practice. Contact us for a free demo or to learn more! Close Explore Other Resources Dry EyeNewsPeriorbital Muscle StimulationTreatment TypeVision Resource HubDry EyeNewsPeriorbital Muscle StimulationTreatment TypeVision Resource HubLumenis OptiLIFT Dynamic Muscle Stimulation Device receives Health Canada Approval for Reducing Signs and Symptoms of Evaporative Dry Eye DiseaseREAD MOREClinical StudiesDry EyePeriorbital Muscle StimulationTreatment TypeVision Resource HubClinical StudiesDry EyePeriorbital Muscle StimulationTreatment TypeVision Resource HubThe Potential Benefits of Periorbital Transcutaneous Electrical Stimulation for the Management of Dry Eye DiseaseREAD MOREDry EyePeriorbital Muscle StimulationPress PublicationsTreatment TypeVision Resource HubDry EyePeriorbital Muscle StimulationPress PublicationsTreatment TypeVision Resource HubSisters Grow Practice Into Medical Hub for Dry Eye TreatmentREAD MORE PB-00089800, Rev A #### Lumenis Launches OptiLIFT, a New DMSt Device to Address Lower Lid Laxity and Impaired Blinking. Lumenis Launches OptiLIFT, a New Dynamic Muscle Stimulation Device to Address Lower Lid Laxity and Impaired Blinking. YOKNE’AM ILLIT, Israel, February 6, 2025 – Lumenis Be. Ltd., a leading energy-based medical device company for eye care and aesthetic solutions, announced today the launch of OptiLIFT™, a new, proprietary Dynamic Muscle Stimulation technology (DMSt™) for toning facial muscles to address lower lid laxity and impaired blinking without the need for surgery. OptiLIFT is the latest innovation by Lumenis, the inventor of OptiLIGHT, the first and only intense pulsed light (IPL) device granted authorization by the FDA for dry eye management. OptiLIFT is now available in the United States, with other markets expected to follow. Lower lid laxity is highly prevalent and is associated with the natural aging process, caused in part by the weakening of the orbicularis oculi muscle (OOM).1 Skeletal muscles lose 3-8% mass each decade after age 30.2 Muscle weakening in the periorbital area reduces structural support, which can result in lower lid laxity and incomplete blinking, leading to ocular symptoms and aesthetic concerns.3,4,5 One study revealed that more than 60% of dry eye patients suffer from impaired lid closure.6,7 Until now, options to address lower lid laxity and impaired blinking have been limited. OptiLIFT utilizes Dynamic Muscle Stimulation technology (DMSt™) to restore muscle tone, resulting in improved function of the lower eyelid and blinking quality. In a new clinical study, led by James Chelnis, MD, FACS, an ophthalmic plastic and reconstructive surgeon at Manhattan Face & Eye, Lumenis’s DMSt™ demonstrated a reduction in lid laxity by at least 75%, an improvement in blinking quality by at least 70%, and a significant 286% increase in tear break-up time (TBUT).8 “Lower lid laxity affects a large number of patients and can play a significant role in creating ocular surface symptoms. Despite this, we have had very few options for addressing it effectively. OptiLIFT finally offers us a non-surgical solution that is effective and comfortable for patients, without any downtime,” said Dr. Chelnis. “Our clinical study revealed remarkable outcomes for patients that highlight the true value of OptiLIFT.” Specifically designed for treatment of the periorbital area, OptiLIFT’s Dynamic Muscle Stimulation technology works by activating the facial muscles with electrical impulses, tightening and toning the periorbital muscle. Its radiofrequency (RF) component precisely delivers heat to skin layers to enhance collagen formation.9 OptiLIFT is also available with an optional RF microneedling upgrade, which utilizes ultrathin needles and a double RF mechanism to increase skin smoothness by 80% and triple hyaluronic acid production—offering significant results without downtime or numbing.10 “We are proud to introduce OptiLIFT, a groundbreaking advancement that addresses a significant and unmet need for patients and practices,” said Itay Mayer, Chief Commercial Officer, Lumenis. “OptiLIFT enables providers to address lower lid laxity and impaired blinking non-surgically, delivering meaningful results for patients while offering a unique opportunity for practice differentiation. We look forward to collaborating with providers to close the gap in their practices and bring this new solution to the market and elevate patient care.” Lumenis will exhibit OptiLIFT, at the upcoming Vision Expo East in Orlando, Florida., later this month. To learn more, attendees can visit Lumenis at booth #F1829. For more information about OptiLIFT, please visit https://information.lumenis.com/optilift. *Warnings and risks: The OptiLIFT System is contraindicated for patients with pacemakers, defibrillators, any implanted electronic device, or metal implanted in the treatment area. Side effects may appear either at the time of treatment or shortly after. Side effects may include any of the following: prolonged or significant pain, damage to natural skin texture (blister, burn), excessive skin redness (erythema), excessive swelling (edema), fragile skin bruising, excessive itching, change of pigmentation (hyper-pigmentation or hypopigmentation), scarring transient skin break-out such as acne and pimples. For a complete list of contraindications, please refer to the User Manual. Chhadva, P, AL McClellan, CR Alabiad, WJ Feuer, H Batawi, and A Galor. 2016. “Impact of eyelid laxity on symptoms and signs of dry eye disease.” Cornea 531-535. Volpi E, Nazemi R, Fujita, S. Muscle tissue changes with aging. Current Opinion in Clinical Nutrition and Metabolic Care. 7(4):p 405-410, July 2004. Chhadva, P, AL McClellan, CR Alabiad, WJ Feuer, H Batawi, and A Galor. 2016. Impact of eyelid laxity on symptoms and signs of dry eye disease. Cornea 531-535. Liu, DTS, MA Di Pascuale, J Sawai, YY Gao, and SC Tseng. 2005. Tear film dynamics in floppy eyelid syndrome. Investigative ophthalmology & visual science 46 (4): 1188-1194. Mastrota, KM. 2008. Impact of floppy eyelid syndrome in ocular surface and dry eye disease. Optom Vis Sci 85: 814-816. Korb D, Blackie C, Nau A. Prevalence of compromised lid seal in symptomatic refractory dry eye patients and asymptomatic patients. Invest Ophthalmol Vis Sci. 2017;58:2696 Korb DR, Blackie CA. Treating inadequate lid seal in patients with dry eye using an overnight ointment reduces discomfort upon awakening and overall dry eye symptoms. Invest Ophthalmol Vis Sci. 2016;57(12):6189. Chelnis et al., 2024. Data on file; manuscript under preparation. Haim Kaplan, Andrea Gat, Clinical and histopathological results following TriPollar™ radiofrequency skin treatments Journal of Cosmetic and Laser Therapy 2009; 11: 78–84 DOI: 10.1080/14764170902846227 Potekaev N, Zhukova O. Evaluation of Safety and efficacy of the Maximus System for facial wrinkles. Journal of Cosmetics, Dermatological Sciences and Applications, 2013; Vol. 3: 151-156 About Lumenis Lumenis develops life-changing, minimally invasive solutions for the Aesthetic and Vision markets. We create and commercialize innovative energy-based technologies that enable a variety of skin, body, and eye care treatments. Lumenis has successfully introduced solutions for previously untreatable conditions and designed advanced technologies that have revolutionized existing treatment methods. We are BeautyTech pioneers, empowering people by broadening the horizons of health and celebrating beauty that matters. PB-00087390, Rev A #### Lumenis OptiLIFT Dynamic Muscle Stimulation Device receives Health Canada Approval for Reducing Signs and Symptoms of Evaporative Dry Eye Disease NewsDry EyePeriorbital Muscle Stimulation Lumenis OptiLIFT Dynamic Muscle Stimulation Device receives Health Canada Approval for Reducing Signs and Symptoms of Evaporative Dry Eye Disease YOKNE’AM ILLIT, Israel, May 6, 2026—Lumenis Be. Ltd., a global leader in energy-based medical devices for eye care and aesthetic solutions, today announced that it has received Health Canada authorization to offer OptiLIFT™ and its proprietary Dynamic Muscle Stimulation technology (DMSt) for reducing signs and symptoms of evaporative dry eye disease (DED) and to improve lower lid laxity and blinking mechanism. With this authorization, Lumenis is the first company in Canada to offer a muscle stimulation device cleared for ophthalmic use. OptiLIFT is part of a growing portfolio of innovative technologies from Lumenis, the inventor of OptiLIGHT, its intense pulsed light (IPL) technology authorized by Health Canada for dry eye management. OptiLIFT is also indicated for non-invasive skin tightening and wrinkle treatment, enabling eye care professionals to provide aesthetic services using the device. Lower lid laxity is highly prevalent and is associated with the natural aging process, caused in part by the weakening of the orbicularis oculi muscle (OOM).1 Skeletal muscles lose 3-8% mass each decade after age 30.1 Muscle weakening in the periorbital area reduces structural support, which can result in lower lid laxity and incomplete blinking, leading to ocular symptoms and aesthetic concerns.2,3,4 One study revealed that more than 60% of dry eye patients suffer from impaired lid closure.5,6 Until now, options for managing lower lid laxity and blinking mechanism have been limited to conservative approaches—such as nighttime ointments, taping, and blinking exercises—or in more severe cases, surgery. By utilizing DMSt to strengthen the periorbital muscle, OptiLIFT addresses a key functional aspect associated with evaporative dry eye symptoms, while providing a proactive, non-surgical approach to improve lower lid laxity and blink quality. A clinical study published in Clinical Ophthalmology highlights the effectiveness of Lumenis’s proprietary DMSt technology in patients with lower lid laxity and DED.† Led by James Chelnis, MD, FACS, an ophthalmic plastic and reconstructive surgeon at Manhattan Face & Eye,‡ the study demonstrated a reduction in lower lid laxity by at least 75%, an improvement in blinking quality by at least 70%, and a significant 286% increase in tear break-up time (TBUT).7 Patients also experienced a 53% decrease in Ocular Surface Disease Index over the course of treatment, and saw at least 60% improvement in their eyelid appearance.7 “Dry eye disease is inherently multifactorial, and eyelid dynamics—particularly lower lid laxity and blink dysfunction—are frequently underrecognized contributors to tear film instability and ocular surface disease,” said Laura M. Periman, MD, Director of Dry Eye Services and Clinical Research at Periman Eye Institute in Seattle. “There is growing clinical appreciation that supporting periocular muscle function and eyelid apposition may contribute to improving tear distribution and ocular surface health. By enhancing orbicularis tone and blink efficiency, OptiLIFT represents a non-invasive approach to addressing these root biomechanical drivers in patients seeking alternatives to operative intervention.”§ “OptiLIFT addresses a clear gap in care for patients struggling with lower eyelid laxity and impaired blinking, and we’re proud to bring this advanced technology to patients and practices in Canada,” said Itay Mayer, Chief Commercial Officer, Lumenis. “For 60 years, Lumenis has been at the forefront of innovation, and we continue to partner with eye care professionals to expand what’s possible. By combining patented technology with proven clinical outcomes, OptiLIFT is helping to redefine dry eye treatment and elevate the standard of care.” For more information about OptiLIFT, please visit https://information.lumenis.com/optilift. *This publication describes some uses of medical products that are not approved in certain jurisdictions, including by the US FDA, and the safety and effectiveness of any unapproved use(s) have not been established. # # # † Lumenis Be. Ltd sponsored the clinical study. ‡ The study investigator, Dr. James Chelnis, also serves as a consultant for Lumenis Be. Ltd. § This testimonial represents a specific experience of a paid spokesperson. Experience of others may vary. 1. Volpi E, Nazemi R, Fujita, S. Muscle tissue changes with aging. Current Opinion in Clinical Nutrition and Metabolic Care. 7(4):p 405-410, July 2004. 2. Chhadva, P, AL McClellan, CR Alabiad, WJ Feuer, H Batawi, and A Galor. 2016. Impact of eyelid laxity on symptoms and signs of dry eye disease. Cornea 531-535. 3. Liu, DTS, MA Di Pascuale, J Sawai, YY Gao, and SC Tseng. 2005. Tear film dynamics in floppy eyelid syndrome. Investigative ophthalmology & visual science 46 (4): 1188-1194. 4. Mastrota, KM. 2008. Impact of floppy eyelid syndrome in ocular surface and dry eye disease. Optom Vis Sci 85: 814-816. 5. Korb D, Blackie C, Nau A. Prevalence of compromised lid seal in symptomatic refractory dry eye patients and asymptomatic patients. Invest Ophthalmol Vis Sci. 2017;58:2696. 6. Korb DR, Blackie CA. Treating inadequate lid seal in patients with dry eye using an overnight ointment reduces discomfort upon awakening and overall dry eye symptoms. Invest Ophthalmol Vis Sci. 2016;57(12):6189. 7. Chelnis, James G., and Alexandra Chelnis. “Dynamic Muscle Stimulation of the Periorbital Area for Improvement of Blinking in Dry Eye Patients.” Clinical Ophthalmology, vol. 2025, no. 19, Mar. 26, 2025, pp. 1057–1071. https://doi.org/10.2147/OPTH.S513989 About OptiLIFT OptiLIFT’s Dynamic Muscle Stimulation technology works by activating the facial muscles with electrical impulses, tightening and toning the periorbital muscle. For more information, visit https://information.lumenis.com/optilift. INDICATION FOR USE: The OptiLIFT system is indicated for use for skin ablation, resurfacing, skin tightening and wrinkles reduction, using the Microneedling applicator. The OptiLIFT applicator is intended for non-invasive skin tightening, wrinkles treatments and muscle conditioning to stimulate healthy muscles and to reduce signs and symptoms of evaporative dry eye disease (DED), as well as improvement of lid laxity and blinking mechanism. OptiLIFT System is intended to be operated by a licensed healthcare practitioner who is present to monitor treatment. WARNINGS AND RISKS: The OptiLIFT System is contraindicated for patients with pacemakers, defibrillators, any implanted electronic device, or metal implants in the treatment area. Side effects may appear either at the time of treatment or shortly after. Side effects may include any of the following: prolonged or significant pain, damage to natural skin texture (blister, burn), excessive skin redness (erythema), excessive swelling (edema), fragile skin bruising, excessive itching, change of pigmentation (hyper-pigmentation or hypopigmentation), scarring, transient skin breakouts such as acne and pimples. For a complete list of contraindications, please refer to the User Manual. This information is intended for distribution in Canada only and complies with Canadian regulatory requirements. DOWNLOAD INFO KIT Discover how OptiLIFT can transform your practice. Contact us for a free demo or to learn more! Close Explore Other Resources Clinical StudiesDry EyePeriorbital Muscle StimulationTreatment TypeVision Resource HubClinical StudiesDry EyePeriorbital Muscle StimulationTreatment TypeVision Resource HubThe Potential Benefits of Periorbital Transcutaneous Electrical Stimulation for the Management of Dry Eye DiseaseREAD MOREDry EyePeriorbital Muscle StimulationPress PublicationsTreatment TypeVision Resource HubDry EyePeriorbital Muscle StimulationPress PublicationsTreatment TypeVision Resource HubSisters Grow Practice Into Medical Hub for Dry Eye TreatmentREAD MOREBlog PostsGlaucomaTreatment TypeVision Resource HubBlog PostsGlaucomaTreatment TypeVision Resource HubDigital Duet 2.0 with Dr. JaiREAD MORE PB-00096134 #### Lumenis OptiLight Wins 2022 MedTech Breakthrough Award: Best New Technology Solution for Ophthalmology Lumenis OptiLight Wins 2022 MedTech Breakthrough Award: Best New Technology Solution for Ophthalmology For the third straight year Lumenis wins an award recognizing outstanding medical companies and technologies. May 23, 2022 – Yokne’am Illit, Israel. – Lumenis Be., a leading energy-based medical device company for aesthetic and eye care applications, today announced that OptiLight has received the highly competitive MedTech Breakthrough Award for “Best New Technology Solution for Ophthalmology.” This year, MedTech’s range of health and medical technology categories attracted more than 3,900 nominations from over 15 countries, from which MedTech selected OptiLight for this prestigious recognition. The win follows Lumenis’ MedTech awards for Best Overall Medical Device Company in 2021 and Best New Surgical Technology Solution in 2020. OptiLight is a groundbreaking, light-based treatment. It is the first and only light treatment FDA approved for management of dry eye disease, a very common condition that causes dry, gritty eyes and fluctuating vision for an estimated 49 million Americans.1 Lumenis’ patented, innovative Optimal Pulse Technology (OPT™) offers targeted, uniform, precise, and controlled treatment that safely and effectively breaks the vicious cycle of inflammation associated with dry eye disease. “Dry eye disease is highly prevalent and difficult to manage, and traditional treatments like warm compresses and artificial tears treat the symptoms but not the underlying pathology,” said James Johnson, managing director, MedTech Breakthrough. “OptiLight is leading a revolution in managing dry eye disease with ‘breakthrough’ technology that allows doctors to treat patients quickly, in-office. With broad potential for tens of millions with dry eye disease, OptiLight stands out from the crowd to become our 2022 Best New Technology Solution for Ophthalmology.” Lumenis introduced OptiLight in May 2021 and recently launched a national media campaign featuring singer-songwriter and actress Mandy Moore (This Is Us) to increase awareness for dry eye disease and encourage people who might be suffering from this condition to seek out a physician who offers OptiLight (www.TreatMyDryEye.com). “We’re grateful to MedTech for honoring OptiLight for its innovation and impact in eye care,” said Lumenis CEO Tzipi Ozer-Armon. “Lumenis is committed to raising the bar for patients’ health by providing cutting-edge solutions and treatment innovations. As the only light-based treatment for dry eye disease, OptiLight has the power to elevate dry eye management and improve health and quality of life for millions of people around the world.” 1. Dana R et al. Patient-Reported Burden of Dry Eye Disease in the United States: Results of an Online Cross-Sectional Survey. Am J Ophthalmol. 2020 Aug; 216:7-17. About Lumenis www.lumenis.com Lumenis is a leading energy-based medical device company for aesthetic and ophthalmic applications in the area of minimally invasive clinical solutions. It is regarded as a world-renowned expert in developing and commercializing innovative energy-based technologies, including Laser, Intense Pulsed Light (IPL) and Radio-Frequency (RF). For nearly 50 years, Lumenis’ groundbreaking products have redefined medical treatments and have set numerous technological and clinical gold standards. Lumenis has successfully created solutions for previously untreatable conditions, as well as designed advanced technologies that have revolutionized existing treatment methods. About MedTech Breakthrough Part of Tech Breakthrough, a leading market intelligence and recognition platform for global technology innovation and leadership, the MedTech Breakthrough Awards program is devoted to honoring excellence in medical and health related technology companies, products, services and people. The MedTech Breakthrough Awards provide a platform for public recognition around the achievements of breakthrough health and medical companies and products in categories that include Patient Engagement, mHealth, Health & Fitness, Clinical Administration, Healthcare IoT, Medical Data, Healthcare Cybersecurity and more. For more information visit MedTechBreakthrough.com. Media Contact Colleen Ketchum colleen.ketchum@precisionvh.com PB-00044810 Rev A #### Lumenis Receives FDA Approval for Its IPL Device to Manage Dry Eye Disease and Launches OptiLight™ Lumenis Receives FDA Approval for Its IPL Device to Manage Dry Eye Disease and Launches OptiLight™ April 29, 2021 – Yokne’am Illit, Israel. Lumenis Ltd., the world’s largest energy-based medical device company for ophthalmic, aesthetic and surgical applications and the inventor of intense pulsed light (IPL) technology, today announced that the FDA has granted De Novo authorization for Lumenis’ newest IPL device for improving signs of dry eye disease due to meibomian gland dysfunction (MGD). Dry eye disease is a common disorder that causes dry, gritty, burning, tired eyes and fluctuating vision. About 16 million Americans have been diagnosed,1 and twice as many may be undiagnosed with dry eye. MGD is the leading cause of dry eye disease, accounting for about 86% of cases.2 The Lumenis multi-center, double-blinded, randomized controlled FDA trial showed that Lumenis IPL with patented Optimal Pulse Technology (OPT®) significantly improved tear breakup time, meibum quality, and meibomian gland expressibility.3  The clinical trial joins a long list of studies of Lumenis’ IPL with OPT® that have shown the same results, as well as reduction of inflammatory markers.4-7 Subsequent to the FDA approval, Lumenis is launching OptiLight™, a bright solution for dry eyes. OptiLight™ with Lumenis’ patented OPT® technology is designed for a consistent, precise, and controlled light-based treatment of signs of dry eye disease. “We deal with dry eye every day, but unless we address the underlying inflammation, it’s difficult to meaningfully impact the disease. OptiLight™ helps us to address the inflammation, as shown in Lumenis’ IPL clinical trials, and improves signs of dry eye disease due to MGD, positioning it as a valuable tool in our dry eye toolkit,” said Dr. Steven J. Dell, medical director of Dell Laser Consultants and lead investigator in the Lumenis’ clinical trial submitted to the FDA. “Lumenis has launched many ‘firsts’ in eye care, and we never stop innovating. This is why we are excited that our IPL device with patented OPT® technology is the first and only such device to receive FDA approval for improving signs of dry eye disease. We’re exceptionally proud to elevate dry eye management and to improve the quality of life for millions of patients,” said Lumenis CEO Tzipi Ozer-Armon. “We are proud to launch OptiLight™️, a light-based system that provides doctors with a safe and effective dry eye procedure to add to their toolkit. We look forward to continued collaboration with doctors across the U.S. and globally in elevating dry eye care.” Lumenis will unveil the new OptiLight™ at a formal virtual launch event on May 13, 2021, 7 p.m. EDT. 1. Farrand et al. Am J Ophthalmol 2017;182:90-98. 2. Lemp MA et al. (2012) Cornea May;31(5):472-8. 3. FDA study sponsored by Lumenis: internal reference LUM-VBU-M22-IPL-17-01. 4. Yan et al. (2020), Eye & Contact Lens 2021, 27(1):45-53. 5. Arita et al. (2019) Ocul Surf 17(1):308-13. 6. Gao et al. (2019) Int J Ophthalmol 12(11):1708-1713. 7. Liu et al. (2017) Am J Ophthalmol 183:81-90. About Lumenis www.lumenis.com Lumenis is the world’s largest energy-based medical device company for surgical, aesthetic and ophthalmic applications in the area of minimally invasive clinical solutions. Regarded as a world-renowned expert in developing and commercializing innovative energy-based technologies, including Laser, Intense Pulsed Light (IPL) and Radio-Frequency (RF). For nearly 50 years, Lumenis’ ground-breaking products have redefined medical treatments and have set numerous technological and clinical gold standards. Lumenis has successfully created solutions for previously untreatable conditions, as well as designed advanced technologies that have revolutionized existing treatment methods. About OptiLight OptiLight™ is a new intense pulsed light (IPL) device, with a spectrum of 400-1200 nm, that is indicated for improvement of signs of Dry Eye Disease (DED) due to Meibomian Gland Dysfunction (MGD), also known as evaporative dry eye or lipid deficiency dry eye, in patients 22 years of age and older with moderate to severe signs and symptoms of DED due to MGD and with Fitzpatrick skin types I-IV. IPL is to be applied only to skin on the malar region of the face, from tragus to tragus including the nose (eyes should be fully covered by protective eyewear). IPL is intended to be applied as an adjunct to other modalities, such as meibomian gland expression, artificial tear lubricants and warm compresses. Media Contact Genevieve Britton +1.512.774.0735 (c) genevieve@pascalecommunications.com Explore Other Resources Dry EyeNewsPeriorbital Muscle StimulationTreatment TypeVision Resource HubDry EyeNewsPeriorbital Muscle StimulationTreatment TypeVision Resource HubLumenis OptiLIFT Dynamic Muscle Stimulation Device receives Health Canada Approval for Reducing Signs and Symptoms of Evaporative Dry Eye DiseaseREAD MOREClinical StudiesDry EyePeriorbital Muscle StimulationTreatment TypeVision Resource HubClinical StudiesDry EyePeriorbital Muscle StimulationTreatment TypeVision Resource HubThe Potential Benefits of Periorbital Transcutaneous Electrical Stimulation for the Management of Dry Eye DiseaseREAD MOREDry EyePeriorbital Muscle StimulationPress PublicationsTreatment TypeVision Resource HubDry EyePeriorbital Muscle StimulationPress PublicationsTreatment TypeVision Resource HubSisters Grow Practice Into Medical Hub for Dry Eye TreatmentREAD MORE PB-00029590 Rev A #### Lumenis Vision Is Ready to Partner with Doctors Across the U.S. at 2023 Eyecare Meetings and Brilliance Vision Mastery Events Lumenis Vision Is Ready to Partner with Doctors Across the U.S. at 2023 Eyecare Meetings and Brilliance Vision Mastery Events April 4, 2023 Dr. Shelly Akazany, Director of Global Product Marketing Laarni Cayetano, Director of Marketing, United States At Lumenis, innovation is in our DNA, driving development of the technologies that transform eyecare. But innovation doesn’t happen in isolation. We thrive on personal connections. The doctors who partner with us share their knowledge, enabling Lumenis to maintain the in-depth, up-to-the-minute understanding of changing medical and business landscapes that we need to improve patient care. Continuing our commitment to those personal connections, Lumenis will journey across the United States this year to every major eye care industry meeting, plus host our own mastery events called Brilliance. We’re excited to reunite with our valued partners and spark new relationships, too. We want to hear about your experiences and tell you all about the opportunities offered by our award-winning breakthrough OptiLight technology. Major industry meetings are the perfect chance for you to come see us at our exhibit booth and experience the first and only FDA-approved light therapy for dry eye management. We’re thrilled to show it to you! See for yourself how OptiLight has earned its reputation as the solution of choice for dry eye. During the OptiLight tour across the U.S., we’ll be sharing knowledge, best practices, and success stories. Learn how we’re already helping busy doctors who thrive on cutting-edge technologies differentiate their practices and elevate care for patients with dry eye disease. We’ll even chat about new developments, like how we’ve introduced OptiLight 2.0 next-level workflow and initiated the second phase of our direct-to-consumer celebrity influencer campaign to educate patients with dry eye disease and connect them with OptiLight providers. In the spirit of innovation, we’ve established Brilliance, a vision mastery event powered by Lumenis. Our goal was to take attendees beyond our cutting-edge technology to help them build the essential partnerships that will enable their practices to thrive through the sharing of knowledge, best practices, and success stories. We’d love to invite you to attend these series of unique, personal and exclusive educational gatherings to connect personally with the growing list of doctors using OptiLight. Brilliance events have included educational sessions with esteemed doctors, on-site OptiLight certification, personalized OptiLight dry eye treatment, celebrity guests, advice on marketing and practice growth, and up-to-the-minute best practices. Delivered for professionals, by professionals, attendees can expect topics like dry eye practice marketing bootcamp, successfully broadening your service line, and incorporating cash-pay procedures into your practice. We personally enjoy our Brilliance events very much, and we know you will, too. Whether you’re interested in getting a hands-on experience with OptiLight or you want to build partnerships with the Brilliance educational experience, Lumenis has committed to offering a strong presence in every region. After all, you are our inspiration. We know that through our connections and partnerships with you, we will continue to stay one step ahead, offering the latest and greatest technologies that add value to your practice. Please visit our website for a complete list of events. Explore Other Resources Dry EyeNewsPeriorbital Muscle StimulationTreatment TypeVision Resource HubDry EyeNewsPeriorbital Muscle StimulationTreatment TypeVision Resource HubLumenis OptiLIFT Dynamic Muscle Stimulation Device receives Health Canada Approval for Reducing Signs and Symptoms of Evaporative Dry Eye DiseaseREAD MOREClinical StudiesDry EyePeriorbital Muscle StimulationTreatment TypeVision Resource HubClinical StudiesDry EyePeriorbital Muscle StimulationTreatment TypeVision Resource HubThe Potential Benefits of Periorbital Transcutaneous Electrical Stimulation for the Management of Dry Eye DiseaseREAD MOREDry EyePeriorbital Muscle StimulationPress PublicationsTreatment TypeVision Resource HubDry EyePeriorbital Muscle StimulationPress PublicationsTreatment TypeVision Resource HubSisters Grow Practice Into Medical Hub for Dry Eye TreatmentREAD MORE PB-00043680, Rev B #### Lumenis’s OptiPLUS Delivers Clinically Significant Results for DED Press PublicationsDry Eye Lumenis’s OptiPLUS Delivers Clinically Significant Results for DED September 9, 2024 Dr. Ray Corbin-Simon, OD Ray Corbin-Simon OD is an eye doctor in Piscataway NJ and the owner of In Focus Vision Center Website Ray Corbin-Simon, OD, shares how OptiLIGHT and OptiPLUS have elevated her eye care practice by addressing her patients’ various needs. She highlights that the FDA approval and robust clinical research supporting the efficacy of these devices were key factors in her decision to incorporate the technologies into her practice. Read Full Article *OptiLIGHT and OptiPLUS are intended to be used by licensed practitioners, according to local rules and regulations. Discover new possibilities Download OptiLIGHT and OptiPLUS info kit Explore Other Resources Dry EyeNewsPeriorbital Muscle StimulationTreatment TypeVision Resource HubDry EyeNewsPeriorbital Muscle StimulationTreatment TypeVision Resource HubLumenis OptiLIFT Dynamic Muscle Stimulation Device receives Health Canada Approval for Reducing Signs and Symptoms of Evaporative Dry Eye DiseaseREAD MOREClinical StudiesDry EyePeriorbital Muscle StimulationTreatment TypeVision Resource HubClinical StudiesDry EyePeriorbital Muscle StimulationTreatment TypeVision Resource HubThe Potential Benefits of Periorbital Transcutaneous Electrical Stimulation for the Management of Dry Eye DiseaseREAD MOREDry EyePeriorbital Muscle StimulationPress PublicationsTreatment TypeVision Resource HubDry EyePeriorbital Muscle StimulationPress PublicationsTreatment TypeVision Resource HubSisters Grow Practice Into Medical Hub for Dry Eye TreatmentREAD MORE PB-00076861, Rev A #### Mandy Moore Opens Up About Her Experience With Dry Eyes—’I Figured the Discomfort Was Something I Was Just Going to Have to Live With’ Mandy Moore Opens Up About Her Experience With Dry Eyes—’I Figured the Discomfort Was Something I Was Just Going to Have to Live With’ Ms. Moore has partnered with Lumenis as a brand ambassador for OptiLight to tell her story and empower others. After suffering for years with dry, itchy, burning eyes, Ms. Moore learned her problem was dry eye disease—a condition that affects millions of people. After undergoing treatment with OptiLight, Ms. Moore’s quality of life greatly improved. OptiLight is a revolutionary, patented treatment that is the first and only light-based therapy for dry eye disease. READ FULL ARTICLE Explore Other Resources Dry EyeNewsPeriorbital Muscle StimulationTreatment TypeVision Resource HubDry EyeNewsPeriorbital Muscle StimulationTreatment TypeVision Resource HubLumenis OptiLIFT Dynamic Muscle Stimulation Device receives Health Canada Approval for Reducing Signs and Symptoms of Evaporative Dry Eye DiseaseREAD MOREClinical StudiesDry EyePeriorbital Muscle StimulationTreatment TypeVision Resource HubClinical StudiesDry EyePeriorbital Muscle StimulationTreatment TypeVision Resource HubThe Potential Benefits of Periorbital Transcutaneous Electrical Stimulation for the Management of Dry Eye DiseaseREAD MOREDry EyePeriorbital Muscle StimulationPress PublicationsTreatment TypeVision Resource HubDry EyePeriorbital Muscle StimulationPress PublicationsTreatment TypeVision Resource HubSisters Grow Practice Into Medical Hub for Dry Eye TreatmentREAD MORE PB-00043680, Rev A #### Mandy Moore Partners With Lumenis to Raise Awareness of Dry Eye Disease and OptiLight Treatment Mandy Moore Partners With Lumenis to Raise Awareness of Dry Eye Disease and OptiLight Treatment Ms. Moore has partnered with Lumenis as a brand ambassador for OptiLight to tell her story and empower others. After suffering for years with dry, itchy, burning eyes, Ms. Moore learned her problem was dry eye disease—a condition that affects millions of people. After undergoing treatment with OptiLight, Ms. Moore’s quality of life greatly improved. OptiLight is a revolutionary, patented treatment that is the first and only light-based therapy for dry eye disease. February 8, 2022 – Yokne’am Illit, Israel – Lumenis today announced that it has partnered with singer-songwriter and actress Mandy Moore as a brand ambassador for OptiLight, a bright solution for dry eyes. Ms. Moore suffered from dry eye disease and treatment with OptiLight significantly improved her condition. Now she’s partnering with Lumenis to share her story and empower others. She will star in OptiLight’s new campaign, showing millions of dry eye sufferers that they don’t have to “just live with it”. Before she was diagnosed, Ms. Moore didn’t realize that her dry, itchy, burning eyes were actually signs of a condition called dry eye disease. Dry eye disease is remarkably common, affecting an estimated 49 million Americans, yet only half are diagnosed.1,2 To help dry eye sufferers like Ms. Moore, Lumenis, the world’s largest energy-based medical device company for eye care and aesthetics applications, recently launched OptiLight. This revolutionary, patented treatment is the first and only light-based therapy for dry eye disease. As part of a treatment regimen, OptiLight helps improve dry eye disease with a series of quick, gentle, in-office treatments. “I’m excited to partner with Lumenis and share how OptiLight has made a real impact on my life. For years, I suffered from dry eye disease, but I didn’t know I had it! My eyes felt gritty and tired, and they looked red. I couldn’t wear my contact lenses for long. Eye drops didn’t do much. It was a constant frustration on the set and at home with my family,” said Ms. Moore. “When I learned that I had a medical condition called dry eye disease, I realized I didn’t have to just live with it—I could get a safe, effective treatment with OptiLight. Now, I can focus more time on what’s important to me, rather than battling the constant nuisance and discomfort of dry eye disease, and I want to inspire other people to say, ‘I won’t just live with it.’” The “Not Gonna Live With It Generation” campaign featuring Ms. Moore debuted today with a commercial as well as a digital and print media campaign to encourage people to learn more about dry eye disease and find effective therapy with OptiLight. “Lumenis is thrilled to partner with Mandy Moore for this important campaign, which will raise awareness of dry eye disease and introduce groundbreaking treatment with OptiLight,” said Lumenis CEO Tzipi Ozer-Armon. “OptiLight with patented Optimal Pulse Technology (OPT) is the only light therapy for the management of dry eye disease. For millions of people who share Mandy’s experience with this condition, OptiLight is a perfect fit. Our ability to improve the quality of life for those who suffer from dry eye disease is why we do what we do, so it’s wonderful to see her enthusiasm for OptiLight and the results of her treatment. We hope it will inspire others to get better care for dry eye disease.” To learn more about dry eye disease and OptiLight, visit TreatMyDryEye.com and follow Lumenis on Instagram, Facebook and LinkedIn with #NotGonnaLiveWithIt and #OptiLight. 1. Dana R et al. Patient-Reported Burden of Dry Eye Disease in the United States: Results of an Online Cross-Sectional Survey. Am J Ophthalmol. 2020 Aug; 216:7-17. 2. U.S. Census data. About OptiLight OptiLight™ is a light-based treatment that uses precise, intense broad-spectrum light to improve the signs of dry eye disease due to meibomian gland dysfunction (MGD), also known as evaporative dry eye or lipid deficiency dry eye, in patients 22 years of age and older with moderate to severe signs and symptoms of dry eye disease due to MGD and with Fitzpatrick skin types I-IV. OptiLight is to be applied only to skin on the malar region of the face, from tragus to tragus including the nose (eyes should be fully covered by protective eyewear). OptiLight is intended to be applied as an adjunct to other modalities, such as meibomian gland expression, artificial tear lubricants and warm compresses. The treatment with OptiLight is not indicated for patients with certain medical conditions and carries risks, such as discomfort, damage to natural skin texture and change of skin pigmentation. Please ask your doctor if the OptiLight treatment is right for you. About Lumenis www.lumenis.com Lumenis is a leading energy-based medical device company for aesthetics and eye care applications in the area of minimally invasive clinical solutions. It is regarded as a world-renowned expert in developing and commercializing innovative energy-based technologies, including Laser, Intense Pulsed Light (IPL) and Radio-Frequency (RF). For nearly 50 years, Lumenis’ groundbreaking products have redefined medical treatments and have set numerous technological and clinical gold standards. Lumenis has successfully created solutions for previously untreatable conditions, as well as designed advanced technologies that have revolutionized existing treatment methods. Media Contact Genevieve Britton +1.512.774.0735 (c) Genevieve.Britton@precisionvh.com Explore Other Resources Dry EyeNewsPeriorbital Muscle StimulationTreatment TypeVision Resource HubDry EyeNewsPeriorbital Muscle StimulationTreatment TypeVision Resource HubLumenis OptiLIFT Dynamic Muscle Stimulation Device receives Health Canada Approval for Reducing Signs and Symptoms of Evaporative Dry Eye DiseaseREAD MOREClinical StudiesDry EyePeriorbital Muscle StimulationTreatment TypeVision Resource HubClinical StudiesDry EyePeriorbital Muscle StimulationTreatment TypeVision Resource HubThe Potential Benefits of Periorbital Transcutaneous Electrical Stimulation for the Management of Dry Eye DiseaseREAD MOREDry EyePeriorbital Muscle StimulationPress PublicationsTreatment TypeVision Resource HubDry EyePeriorbital Muscle StimulationPress PublicationsTreatment TypeVision Resource HubSisters Grow Practice Into Medical Hub for Dry Eye TreatmentREAD MORE PB-00042910 Rev A #### Multi Frequency Rf Combined With IPL Improves Signs and Symptoms of DED Due to MGD Clinical StudiesDry Eye Multi Frequency Rf Combined With IPL Improves Signs and Symptoms of DED Due to MGD January 8, 2024 In a prospective, two-centers US-based study, researchers utilized a combination of dual-frequency RF, OPT™ IPL (Intense Pulsed Light), and MGX to effectively treat DED due to MGD. Thirty-one subjects received four treatments at two-week intervals, leading to significant improvements in mMGS, expressible gland count, MGL percentage, and OSDI questionnaire. DOVE MEDICAL PRESS - OPEN ACCESS PUBLISHER OF MEDICAL JOURNALS Read Full Article Discover new possibilities Download OptiLIGHT and OptiPLUS info kit Explore Other Resources Dry EyeNewsPeriorbital Muscle StimulationTreatment TypeVision Resource HubDry EyeNewsPeriorbital Muscle StimulationTreatment TypeVision Resource HubLumenis OptiLIFT Dynamic Muscle Stimulation Device receives Health Canada Approval for Reducing Signs and Symptoms of Evaporative Dry Eye DiseaseREAD MOREClinical StudiesDry EyePeriorbital Muscle StimulationTreatment TypeVision Resource HubClinical StudiesDry EyePeriorbital Muscle StimulationTreatment TypeVision Resource HubThe Potential Benefits of Periorbital Transcutaneous Electrical Stimulation for the Management of Dry Eye DiseaseREAD MOREDry EyePeriorbital Muscle StimulationPress PublicationsTreatment TypeVision Resource HubDry EyePeriorbital Muscle StimulationPress PublicationsTreatment TypeVision Resource HubSisters Grow Practice Into Medical Hub for Dry Eye TreatmentREAD MORE PB-00067370, Rev A #### No Surgery, No Downtime: How OptiLIFT Transforms Lower Lid Laxity Treatment Blog PostsPeriorbital Muscle Stimulation No Surgery, No Downtime: How OptiLIFT Transforms Lower Lid Laxity Treatment March 5, 2025 James Chelnis, MD, FACS Ophthalmologist at Manhattan Face & Eye * This article reflects Dr. Chelnis’s professional experience with OptiLIFT’s technology and its treatment effects. Results may vary. Treating lower lid laxity has often been overlooked in practice because the only real solution has been surgery, and not all patients are candidates. For those with mild to moderate lid laxity, temporary measures like taping lids at night or relying on lubricants are limited in effectiveness since they fail to address the root cause. Now, we can close this gap in care with OptiLIFT™. This non-surgical solution features Lumenis’s proprietary Dynamic Muscle Stimulation (DMSt) technology, which restores muscle tone to address lower lid laxity and impaired blinking. What is Lid Laxity? Our eyelids play a crucial role in maintaining a stable and healthy ocular surface. They are essential to maintaining the tear lake and dispersing meibum to seal the watery layer of the tear film. Without sufficient lid tone to reset and maintain the tear lake with each blink, patients experience symptoms related to the breakdown of the ocular surface. Lower lid laxity is highly prevalent, affecting 78.3% of patients who visit ophthalmology clinics for eyelid-related concerns.1 It’s often associated with aging, as we naturally lose 3-8% of our skeletal muscle mass each decade after age 30.2 This muscle loss increases our vulnerability to gravitational descent and laxity of the lower eyelids as our supports begin to fail. Lid laxity can also be hereditary, so I have encountered younger patients who could also benefit from improved eyelid muscle tone. When lids lose tension, incomplete blinking can occur, which has been closely associated with dry eye disease symptoms, decreased tear breakup time, meibomian gland dropout, and reduced expressibility.3 In fact, more than 60% of dry eye patients struggle with impaired lid closure.4 Eyelid muscles are under constant stress from nonstop blinking throughout life. It makes sense that the muscle tissue starts to gradually degrade over time, and the only way to regain that tone is through treatment. Dynamic Muscle Stimulation (DMSt) as a New, Non-Surgical Treatment Option OptiLIFT’s DMSt technology works by activating the periorbital muscles with gentle electrical impulses to create muscle tone and restore eyelid tightness. It engages the muscles and their networks at their points of origin, increasing their resting tone and supporting the natural structure of the eyelids. Think of it as a barre class for the eyelids. Instead of building bulky, bodybuilder-like muscles, the goal is to tone and strengthen, resulting in a naturally firm muscle at a newly fit baseline. This eyelid “workout” provides long-lasting improvement in tone and tightness without the need for surgery. OptiLIFT treatment protocol includes four sessions, with a one-week interval between them. The treatment involves using a back-and-forth motion with the tip of the handpiece along the inferior orbital rim below the lower eyelids for 14 minutes, seven minutes per side. This non-invasive technology is quick, effective, and easy to incorporate into your workflow—expanding your capabilities while keeping patients in your practice. I’ve seen results in some patients after only one or two OptiLIFT treatments, and there continues to be progressive improvement through treatments three and four. Breakthrough Clinical Study Results I had the opportunity to lead the clinical study on Lumenis’s DMSt technology, which included 30 patients with lower lid laxity and moderate-to-severe dry eye disease due to meibomian gland dysfunction (MGD). We conducted a series of muscle stimulation treatments to determine the optimal treatment schedule and to understand the patients’ progression as they moved through the treatment. We found that Lumenis’s DMSt technology demonstrates a reduction in lid laxity by at least 75% and an improvement in blinking quality by at least 70%, while also significantly improving meibomian gland function and dry eye symptoms.5 The study revealed another promising finding: many of the measured metrics continued to improve throughout the course of treatment without hitting a plateau.5 This suggests that even greater results may be achievable with ongoing DMSt treatment. Unlike in other studies where progress levels off after a certain point, this data shows each treatment building on the previous one, leading not only to increased strength, but also to sustained improvements over time. Patients in the study also experienced no downtime after the procedure, and after weekly treatments for about a month, most showed substantial improvements in tear lake stability, meibum quality, and lower eyelid tone. Overall, the study found a 286% improvement in tear breakup time.5 It’s rare to see such noteworthy differences with the before and after data. A Winning Combination: DMSt with Radio Frequency (RF) In addition to DMSt technology, OptiLIFT utilizes radio frequency (RF). It’s the first device with two modalities that improve the ocular surface, delivered at the same time, through a single handpiece. This combination helps explain why the treatments can be so short yet so effective. Studies have already proven that topical RF—which delivers heat to targeted tissue layers—increases the regeneration and rejuvenation of meibomian glands, improving meibum expression and overall eyelid health.6,7,8 The treatment warms old, stale meibum within the glands, facilitating its natural flow while also promoting collagen production. Together, these technologies improve the overall ocular surface. Final Thoughts OptiLIFT is part of Lumenis’s growing device portfolio, providing practitioners with another tool to help pinpoint the root cause of each patient’s symptoms and deliver solutions to meet their individual needs effectively. While OptiLIGHT and OptiPLUS improve symptoms of dry eye disease due to MGD by reducing inflammation and improving meibum production, OptiLIFT tones the muscles to address lower lid laxity. If a patient’s underlying issue is that their lower lid is lax, the related signs and symptoms will likely continue unless it is addressed directly. A sizeable population of patients can benefit from OptiLIFT, and I am excited to offer them a treatment option that delivers lasting results without surgery or downtime. Dr. James Chelnis is an award-winning aesthetic surgeon and ophthalmologist recognized for his expertise in oculofacial plastic and reconstructive surgery. As the founder and director of Manhattan Face & Eye in New York, Dr. Chelnis is dedicated to helping patients achieve their aesthetic and eye care goals. He specializes in both surgical and non-surgical facial rejuvenation, orbital surgery, and advanced treatments for conditions such as orbital tumors, facial skin cancer, eyelid drooping, tearing issues, and tear duct reconstruction. Website: https://www.manhattanfaceandeye.com/ LinkedIn: https://www.linkedin.com/in/james-chelnis-6b703a71/ DOWNLOAD INFO KIT Discover how OptiLIFT can transform your practice. Contact us for a free demo or to learn more! Close Explore Other Resources Dry EyeNewsPeriorbital Muscle StimulationTreatment TypeVision Resource HubDry EyeNewsPeriorbital Muscle StimulationTreatment TypeVision Resource HubLumenis OptiLIFT Dynamic Muscle Stimulation Device receives Health Canada Approval for Reducing Signs and Symptoms of Evaporative Dry Eye DiseaseREAD MOREClinical StudiesDry EyePeriorbital Muscle StimulationTreatment TypeVision Resource HubClinical StudiesDry EyePeriorbital Muscle StimulationTreatment TypeVision Resource HubThe Potential Benefits of Periorbital Transcutaneous Electrical Stimulation for the Management of Dry Eye DiseaseREAD MOREDry EyePeriorbital Muscle StimulationPress PublicationsTreatment TypeVision Resource HubDry EyePeriorbital Muscle StimulationPress PublicationsTreatment TypeVision Resource HubSisters Grow Practice Into Medical Hub for Dry Eye TreatmentREAD MORE 1 Doan, S., et al. (2020, July 1). Eyelid disorders in ophthalmology practice: Results from a large international epidemiological study in eleven countries. Ophthalmology and Therapy, 9, 597–608. https://doi.org/10.1007/s40123-020-00268-4 2 Volpi, E., et al. (2004, July). Muscle tissue changes with aging. Current Opinion in Clinical Nutrition and Metabolic Care, 7(4), 405–410. https://doi.org/10.1097/01.mco.0000134362.76653.b2 3 Jie Y, Sella R, Feng J, Gomez ML, Afshari NA. Evaluation of incomplete blinking as a measurement of dry eye disease. Ocul Surf. 2019 Jul;17(3):440-446. 4 Lee, H. K., & Madan, M. (2023, March). When is dry eye more than just dry eye? The role of eyelid malposition in ocular surface disease and how to address it. Modern Optometry. https://modernod.com/articles/2023-mar/when-is-dry-eye-more-than-just-dry-eye 5 Chelnis et al., 2024. Data on file; manuscript under preparation. 6 Javate RM. Cruz RT, Khan J, Trakos N, Gordon RE. Nonablative 4-MHZ dual radiofrequency wand rejuvenation treatment for periorbital rhytides and midface laxity. Ophthalmic Plast Reconstr Surg. 2011;27(3):180-185. DOI: 10.1097/IOP.0b013e3181fe8e5a 7 Al-Atif H. Collagen Supplements for Aging and Wrinkles: A Paradigm Shift in the Fields of Dermatology and Cosmetics. Dermatol Pract Concept. Published online Jan. 1, 2022. doi: 10.5826/dpc.1201a18. 8 Chelnis, J., Garcia, C. N., & Hamza, H. (2023). Multi-Frequency RF Combined with Intense Pulsed Light Improves Signs and Symptoms of Dry Eye Disease Due to Meibomian Gland Dysfunction. Clinical Ophthalmology, 17, 3089–3102. https://doi.org/10.2147/OPTH.S426564 PB-00088140, Rev A #### Not All IPL Devices Are Created Equal Blog PostsDry Eye Not All IPL Devices Are Created Equal December 5, 2023 Cory J. Lappin, OD, MS, FAAO Phoenix Eye Care and the Dry Eye Center of Arizona Dr. Cory J. Lappin is in practice at Phoenix Eye Care and the Dry Eye Center of Arizona. He is a member of the American Academy of Optometry, the American Optometric Association, the Arizona Optometric Association, and the Tear Film and Ocular Surface Society (TFOS). Dr. Lappin currently serves on the Board of Directors of the Arizona Optometric Association. When the late Dr. Art Epstein and I first started using Lumenis IPL a few years ago, we were drawn in by the clinical data and the great word-of-mouth we were hearing from other early adopters in the dry eye field. However, nothing prepared us for the amazing results we saw in our first few patients. For the first time, we were treating multiple underlying mechanisms of dry eye disease in a single treatment modality and delivering a whole new level of therapy for our patients. The technology transformed our practice. Soon, between the two of us, we were treating nearly 50 patients per week, and we now have two systems in our practice. Today, we’re seeing some new entrants in the IPL market for dry eye. Many were developed for use in aesthetics, while others are aimed at eye care, however none of these other IPL devices has been FDA approved for this purpose. That’s one of the reasons why we rely on OptiLIGHT by Lumenis, the company that invented IPL technology, when treating our dry eye patients. Only Lumenis’ IPL technology is FDA approved for the management of dry eye disease. While other IPL devices may be FDA approved for aesthetics, Lumenis is the first and only technology to earn FDA approval for the management of dry eye disease due to MGD. That means eye care practitioners can use OptiLIGHT with confidence. I’ve found that my patients are, in fact, curious about FDA approval and ask me directly if the treatment is approved. They are pleased when I respond, “Yes, the IPL technology we’re using is FDA approved for the management of dry eye.” This is a distinct advantage and a huge boost in credibility that is absent with other IPL devices. Safety, efficacy and efficiency are built in. OptiLIGHT’s clinically validated, embedded settings and the Optimal Pulse Technology (OPTTM) allow us to deliver effective treatment with confidence and ease.1 With OptiLIGHT, you don’t have to scour countless clinical studies and guidelines to find the appropriate treatment It’s already loaded with pre-programmed settings based on clinical study results. Just enter the patient’s Fitzpatrick skin type, and you’re ready to go. The settings are also robust and efficient, thanks to the patented OPT TM at the heart of OptiLIGHT, which delivers exceptionally consistent, high-energy, no-spike pulses, making treatment effective, safe and comfortable for the patient.1 The OPT handpiece is made exclusively for delicate eye areas. With OptiLIGHT, we are treating the malar area from tragus to tragus. Other IPL systems rely on the large IPL handpiece traditionally used in aesthetics. OptiLight has both the larger handpiece tip with SapphireCool technology for broad areas and a smaller patented OPT TM handpiece with the OptiTip specifically designed to deliver treatment in tight areas and the fine contours under the lower eyelids. This advanced handpiece is a game-changer that optimizes treatment for the delicate periocular region with exceptional visibility and an intuitive user experience. OptiLIGHT is backed by extensive research-based data Lumenis invented IPL, and its OPT™ technology has been validated for the improvement of dry eye disease in more than 50 studies. I’ve found that’s far above and beyond any other IPL technology marketed for eye care. OptiLIGHT’s technology has been shown to reduce inflammatory markers,2 alleviate telangiectasia,3,4 improve the structure and function of meibomian glands,5 and decrease Demodex burden,6 with each of these benefits being backed by clinical research. These are just a few of the primary reasons I believe OptiLIGHT is in a class by itself. I’ll add that I’ve spoken with a few colleagues who use other IPL devices who aren’t seeing the same results for their patients that I get with OptiLIGHT. I also get some questions about low-level light therapy (LLLT) versus IPL, and I explain that LLLT’s wavelengths are just a subset of those produced by OptiLIGHT, so I don’t find it necessary to use any LLLT-specific devices. When it comes to questions about IPL technology for dry eye, I always recommend that colleagues get hands-on experience with OptiLIGHT to understand the quality of the device, its level of engineering, and the evidence-based pre-embedded settings. Because, for me, all these factors directly translate to the therapeutic advantages of OptiLIGHT that make it a cornerstone treatment for patients in our dry eye clinic. Discover new possibilities Download OptiLIGHT and OptiPLUS info kit Explore Other Resources Dry EyeNewsPeriorbital Muscle StimulationTreatment TypeVision Resource HubDry EyeNewsPeriorbital Muscle StimulationTreatment TypeVision Resource HubLumenis OptiLIFT Dynamic Muscle Stimulation Device receives Health Canada Approval for Reducing Signs and Symptoms of Evaporative Dry Eye DiseaseREAD MOREClinical StudiesDry EyePeriorbital Muscle StimulationTreatment TypeVision Resource HubClinical StudiesDry EyePeriorbital Muscle StimulationTreatment TypeVision Resource HubThe Potential Benefits of Periorbital Transcutaneous Electrical Stimulation for the Management of Dry Eye DiseaseREAD MOREDry EyePeriorbital Muscle StimulationPress PublicationsTreatment TypeVision Resource HubDry EyePeriorbital Muscle StimulationPress PublicationsTreatment TypeVision Resource HubSisters Grow Practice Into Medical Hub for Dry Eye TreatmentREAD MORE 1. Toyos R, Desai NR, Toyos M, Dell SJ. Intense pulsed light improves signs and symptoms of dry eye disease due to meibomian gland dysfunction: A randomized controlled study. PLoS One. 2022;17(6):e0270268. Published 2022 Jun 23. doi:10.1371/journal.pone.0270268 2. Liu R, Rong B, Tu P, et al. Analysis of Cytokine Levels in Tears and Clinical Correlations After Intense Pulsed Light Treating Meibomian Gland Dysfunction. Am J Ophthalmol. 2017;183:81-90. doi:10.1016/j.ajo.2017.08.021 3. Kassir R, Kolluru A, Kassir M. Intense pulsed light for the treatment of rosacea and telangiectasias. J Cosmet Laser Ther. 2011;13(5):216-222. doi:10.3109/14764172.2011.613480 4. Papageorgiou P, Clayton W, Norwood S, Chopra S, Rustin M. Treatment of rosacea with intense pulsed light: significant improvement and long-lasting results. Br J Dermatol. 2008;159(3):628-632. doi:10.1111/j.1365-2133.2008.08702.x 5. Yin Y, Liu N, Gong L, Song N. Changes in the Meibomian Gland After Exposure to Intense Pulsed Light in Meibomian Gland Dysfunction (MGD) Patients. Curr Eye Res. 2018;43(3):308-313. doi:10.1080/02713683.2017.1406525 6. Prieto VG, Sadick NS, Lloreta J, Nicholson J, Shea CR. Effects of intense pulsed light on sun-damaged human skin, routine, and ultrastructural analysis. Lasers Surg Med. 2002;30(2):82-85. doi:10.1002/lsm.10042 PB-00043680 Rev C #### Novus Spectra Novus Spectra is no longer available for Sales We are happy to offer The Smart532 photocoagulator With SmartPulse technology, for our valued customers. LEARN MORE Novus Spectra is no longer available for Sales We are happy to offer The Smart532 photocoagulator With SmartPulse technology, for our valued customers. LEARN MORE Novus Spectra® High-powered photocoagulator Versatile | Portable | Powerful   The Lumenis Novus Spectra® is an innovative photocoagulator with an extensive set of features that deliver power and reliability with proprietary advancements in diode-pumped solid-state  technology. Next-generation DPSS technology drives 2.5 W of power from the compact Novus Spectra system and an active resonator temperature control ensures stable beam output and system reliability. Versatile, efficient and compatible with a wide-array of delivery devices, the Novus Spectra was designed to provide optimal results in the operating room and outpatient clinic. OR Features: Egronomic & Compact OR Cart: with built-in storage for accessories Remote control: conveniently adjust laser parameters PowerEase™ Footswitch: hands-free power adjustment Clinic Features: Compatible with your preferred Slit Lamp Compact, lightweight and space-saving Patented SureSpot Optics Designed for the busy practice with high patient throughput CLINIC FEATURES Ideal Product for the Clinic PowerEase™ footswitch: Provides hands-free power adjustment of the laser by toggling left or right within the footswitch housing. LIO: Choose a Laser Indirect Ophthalmoscope that suits your preferences. Both our Heine™ and Keeler™ models are rugged, lightweight and equipped with the most advanced laser delivery technology in the market. Laser Links: The Lumenis family of LaserLink Slit Lamp adapters will transform most commercially available slit lamps into advanced laser delivery devices with superior optics capabilities. Eye Safety Filters: A selection of automatic and fixed eye safety filters for the Slit Lamp with the Lumenis patented ClearView™ technology. The photopic balanced coating eliminates color distortion of the treatment site while optimizing white light transmission or “brightness” of the physician’s view. OR FEATURES The Ideal Product for the OR Endo Probes: A comprehensive and wide selection of ophthalmic probes to meet every clinical need and indication. These include standard, straight, curved, aspirating, illuminating and stepped in 20, 23 and 25 gauge sizes. Endo Kit: Surgical microscope eye safety with the Lumenis patented ClearView™ technology. The photopic balanced coating eliminates color distortion of the treatment site while optimizing white light transmission or “brightness” of the physician’s view. PowerEase™ Footswitch: The Lumenis *PowerEase™ footswitch provides hands-free power adjustment of the laser by toggling left or right within the footswitch housing. OverviewBrochureSpecificationsSureSpot™ OpticsOverview The Novus Spectra Advantage Superior Optics – Homogeneous laser spot at target tissue Our advanced optics and laser delivery technology features uniform energy distribution across the entire laser spot area for more precise and safer treatment. The result is a homogenous laser spot with evenly distributed power across the full area of the spot, eliminating the potential risk for the formation of “hot spots”. ClearView™ Filters – Optimized view of treatment site The Lumenis ClearView™ filters’ photopic balanced coating eliminates color distortion of the treatment site while optimizing white light transmission or “brightness” of the physician’s view. A proprietary coating protects the filter from environmental changes and scratches. User-Friendly – Control Panel & Remote Keypad A control panel and illuminated remote keypad* put all operations literally at your fingertips. Optional accessories include the PowerEase™ and Smart™ footswitchesBrochure Specifications Laser System Diode-pumped solid-state Wavelength 532 nm Pulse Duration Pulse Duration .01-3.0 seconds Pulse Rate .05-1.0 seconds and single pulse Energy Settings 50 mW to 2500 mW out of an endo-ocular probe Spot Size 50-1000 microns with Laserlink Z-1000,50-500 microns with Converging-Optics Laserlink Aiming Beam Contrasting color,adjustable intensity 635 nm nominal, < 1.0 mW Cooling System Air-cooled Power Requirements 110 VAC,< 6A, 50/60 Hz,Single phase,220 VAC,< 3A, 50/60 Hz,Single phase Dimensions (Console) Single Port 15.2cm (6in.) x 25.4cm {lOin.) x 35.6cm {14in.) Dual Port 15.2cm (6in.) x 25.4cm (lOin.) x 37.5cm (14.5in.) Weight 8 kg or 17.5 lbs Delivery Systems Laserlink Z-1000 Slit Lamp Adaptor (for Zeiss* SL 130,30SL,20SL and 125Sl); Converging Optics Laser link, Keeler* Heine* LIO Comprehensive selection of standard, straight, curved,aspirating,illuminating and stepped endophotocoagulation probes in 20,23 and 25 gauge sizes,among others Physical characteristics Height 15.2 cm (6 in), Width 25.4 cm (10 in),Depth (Single port system) 35.6 cm (14 in), Depth (Dual port system) 37.5 cm (14.5 in), Weight 8 kg (17 lb) SureSpot™ Optics Vision one With SureSpotTM Optics Sharply defined and evenly distributed power on the retina; Safe & low-power density at the cornea and lens Vision One incorporates SureSpotTM Optics Technology in all slit lamp adapters, as with all Lumenis photocoagulators. The unique and patented Lumenis SureSpotTM technology ensures that the focal point of the laser beam is maintained on the retina while power density on the cornea and lens is minimized for increased safety. SureSpotTM optics also creates a 50µ single spot. That capability distinguishes Lumenis technology from other lasers that may have a 100µ minimum spot size and/or project a fuzzy laser spot on the ina. SureSpotTM optics improves treatment efficacy and precision while reducing the potential for damage to anterior-segment tissues. The latter occurrence is especially a concern when using wide-angle lenses that enhance light uptake by the cornea and lens. Lumenis Ophthalmology Devices Digital Duet The first and only all-in-one digital platform for Glaucoma and PCO therapies Digital Trio 3 in 1 digital platform for Glaucoma and Retina care OptiLIGHT A bright solution for dry eyes ArrayTM LaserLinkTM Pattern Scanning Laser Technology Vision One Modular Multi-Wave Photocoagulator Selecta Duet SLT Technology and a Yag Photodisruptor in One Platform Selecta Trio Retinal, Cataract and Glaucoma Therapy in One Platform Novus SpectraTM High-Powered Photocoagulator LumeProbeTM Endo-Photocoagulation Laser Probes Related Links Photocoagulators Caution: Federal (US) law restricts Lumenis devices to sale by or on the order of a licensed practitioner. PB-2006798 Rev A × GET MORE INFO #### OD Brings In Technology To Help Patients Get Off The Hamster Wheel Of Dry Eye Treatments Press PublicationsDry Eye OD Brings In Technology To Help Patients Get Off The Hamster Wheel Of Dry Eye Treatments May 15, 2024 Melanie Denton Dombrowski, OD, MBA, FAAO Melanie Denton Dombrowski, OD, is the owner of Salisbury Eyecare & Eyewear in Salisbury, North Carolina. Dr. Denton, OD sets a new standard of care with Lumenis’ IPL technology and OptiPLUS’ complementary treatment. Paired with Lumenis’ unparalleled support, Dr. Denton saw “stunning transformations” in both her patients and her practice. Read Full Article *OptiLIGHT and OptiPLUS are intended to be used by licensed practitioners, according to local rules and regulations. Discover new possibilities Download OptiLIGHT and OptiPLUS info kit Explore Other Resources Dry EyeNewsPeriorbital Muscle StimulationTreatment TypeVision Resource HubDry EyeNewsPeriorbital Muscle StimulationTreatment TypeVision Resource HubLumenis OptiLIFT Dynamic Muscle Stimulation Device receives Health Canada Approval for Reducing Signs and Symptoms of Evaporative Dry Eye DiseaseREAD MOREClinical StudiesDry EyePeriorbital Muscle StimulationTreatment TypeVision Resource HubClinical StudiesDry EyePeriorbital Muscle StimulationTreatment TypeVision Resource HubThe Potential Benefits of Periorbital Transcutaneous Electrical Stimulation for the Management of Dry Eye DiseaseREAD MOREDry EyePeriorbital Muscle StimulationPress PublicationsTreatment TypeVision Resource HubDry EyePeriorbital Muscle StimulationPress PublicationsTreatment TypeVision Resource HubSisters Grow Practice Into Medical Hub for Dry Eye TreatmentREAD MORE PB-00076860, Rev A #### OPT Shields SAFE TREATMENTS with the world’s only dedicated IPL Ocular Eye Protection Shields OPT™ SHIELDS – Optimal Safety Meets Exceptional Patient Comfort OPT™ ocular IPL eye shields give you the confidence to perform intuitive, gentle IPL treatments around the delicate contours of the eye, on the eyelids, and malar region of the face without the interference of intrusive protective devices. I'M INTERESTED ADVANCED IPL TREATMENTS With Ocular OPT™ Eye Shields ELEVATE YOUR PRACTICE WITH OPT™ SHIELDS Optimal Safety Effective IPL treatments start with the right protection. OPT™ IPL eye Shields feature five layers of pigment that block IPL energy applied near the eyes and on the eyelids while maximizing light reflection externally, providing safety and assurance. Enhanced Treatment Flexibility OPT™ ocular eye Shields enable easy access to the delicate curves and contours around the eyes. They offer IPL eye protection when treating the eyelids areas, for treatment effectiveness. Ease of Use Our soft lenses were designed for intuitive, gentle use by eye care practitioners. 
The procedure involves a simple removal of the disposable OPT™ IPL eye shields from the blister and effortless insertion into the eyes. Patient-Centric Approach Our disposable IPL eye shields are gentle and comfortable to wear. They’re single-use and sterile to ensure optimal hygiene, patient comfort and satisfaction. OPT™ eye shields for IPL treatments Available now for our valued customers at the Lumenis Vision Store ORDER NOW The OPT™ Shields release is per regional regulatory approval in the relevant jurisdiction. OPT™ Shields is currently approved in the United States only. Risks and warnings: Risk of Misuse, Re-sterilization, or Reuse of Device: Use in accordance with provided instructions. Misuse, including re-sterilization and reuse, may result in a range of negative clinical outcomes including contamination, infection requiring medical intervention, serious injury, irreversible patient impairment, including irreversible damage to the eyesight. Do not use the OPT Shield if it is not intact or pass its expiration date, or if you can see debris of pigmentation inside the blister. This product may be used only with IPL systems and with fluence up to 17.6J/cm2. Warnings – Potential Adverse Effects Any serious incident that has occurred in relation to the device should be reported to the manufacturer and the competent authority of the Member State in which the user and/or patient is established. PB-00074060, Rev A #### OptiLIFT CLOSING THE GAP IN YOUR PRACTICE Tone The Muscles To Address Lower Lid Laxity And Impaired Blinking With The New OptiLIFT™ Device REQUEST DEMO AboutTechnologyResultsTestimonials DOWNLOAD KIT DOWNLOAD KIT LIFT UP YOUR PRACTICE WITH LUMENIS’ INNOVATIVE DEVICE Address Lower Lid Laxity and Impaired Blinking By strengthening the muscles in the periorbital area, OptiLIFT addresses the gravitational descent of the lower lids that can result in ineffective blinking Proprietary Dynamic Muscle Stimulation Technology Lumenis’ DMSt uses electrical pulses to trigger nerve signals, activating facial muscles and inducing contractions Ideal Fit For Eye Practice OptiLIFT applicator is specifically designed for the periorbital area, featuring three predefined presets for treating patients’ delicate facial contours Clinically Validated OptiLIFT is easy-to-use, safe and clinically validated to address blinking and lower lid laxity Tone and Tighten the Periorbital Muscles OptiLIFT stimulates the muscles with DMSt technology to tone and tighten the periorbital area, targeting the natural sagging that comes with aging THE POWER OF OPTILIFT TECHNOLOGY Non-Surgical Device to Tone Muscles to Address Droopy Eyelids Aging weakens periorbital muscles, often leading to eyelid laxity, reduced tone and impaired blinking. OptiLIFT’s Dynamic Muscle Stimulation (DMSt) activates muscle contractions, enhances tone, and addresses both the function and appearance of the lower eyelids. <div style='display: flex; text-align: left; gap: 15px;'> <div><img src='/wp-content/uploads/2025/02/optilift-device-tooltip.jpg' /></div> <div style='flex: 1;'><strong style='font-size: 22px;'>Ergonomic Design</strong><br /> The OptiLift industrial design prioritizes comfort with adjustable height options, ensuring it adapts perfectly to any need</div> </div> <p> </p> <div style='text-align: left;'><img style='padding-bottom: 15px; width: 100%;' src='/wp-content/uploads/2025/02/Ergonomic-Handpieces.jpg' /><br /> <strong style='font-size: 22px;'>Ergonomic Handpieces</strong><br /> Featuring three predefined presets, the handpieces are designed for ease of use and compatibility with all skin types</div> <p> </p> <div style='text-align: left;'><img style='padding-bottom: 15px; width: 100%;' src='/wp-content/uploads/2025/02/optilift-device-tooltip-3.jpg' /><br /> <strong style='font-size: 22px;'>Microneedling</strong><br /> An optional upgrade, utilizing RF thermal energy to stimulate wound healing, which helps resurface and regenerate the skin, leading to a tighter, smoother texture</div> <p> </p> <div style='text-align: left;'> <p><img style='padding-bottom: 15px; width: 100%;' src='/wp-content/uploads/2025/02/DMSt.jpg' /><br /> <strong style='font-size: 22px;'>Dynamic Muscle Stimulation (DMSt)</strong><br /> Uses electrical pulses to trigger nerve signals, activating facial muscles</p> <p><strong style='font-size: 22px;'>Radio frequency (RF)</strong><br /> Delivers precise heat to skin layers, promoting collagen production</p> </div> <p> TONE THE MUSCLES BEFORE & AFTER OptiLIFT delivers impressive and visible outcomes in just four easy sessions. It restores the tightness and tone of the muscle and enhances blinking efficiency, offering a gentle, non-invasive approach for a lifted appearance. Courtesy of Dr. Dorina Cheles CLINICALLY PROVEN TO ELEVATE YOUR PRACTICE OptiLIFT is clinically validated1, with Dynamic Muscle Stimulation technology applied below the eyelids delivering results such as: 286% improvement in tear breakup time (TBUT) 70% Improvement in blinking rate and quality Decrease of at least 75% in lower lid laxity Enhanced meibomian gland function, improving signs of DED READ MORE MMGS DECREASED BY 78% FROM 31.2 TO 6.8 TBUT INCREASED BY 286% FROM 2.4 SEC TO 9.1 SEC Tear breakup time % OF PATIENTS WITH NORMAL LLDT TEST INCREASED FROM 3%-80% WHAT DOCTORS ARE SAYING “With Lumenis’ Dynamic Muscle Stimulation technology, we can tone the muscles around the eye, to tighten the lower eyelid and create a lifted look, without surgery” Dr. James Chelnis MD, FACS Manhattan Face and Eye, NewYork “By strengthening the lower lid muscles with Lumenis’ DMSt and RF technologies, I can fight the natural sag that comes from aging” Dr. Laura M. Periman MD Periman Eye Institute Seattle, Washington “The missing link in addressing lower lid laxity. I’m able to keep patients in the practice and address their concerns without an invasive surgical approach” Dr. Julie Mclaughlin OD, ABO Lehigh Eye Sp cialists, Allentown, Pennsylvania “Having Lumenis’ DMSt technology in-office has been a game changer – I’ve seen positive results and steady revenue growth from medical and cosmetic treatments” Dr. Jessica Stone OD, Everett Eye Care Center, Everett, Pennsylvania ** The testimonials of the OptiLIFT believers and the providers represent specific experience of a paid spokesperson. The experience of other people may vary. A PARTNERSHIP YOU CAN TRUST Experience the Lumenis Advantage & Build Your Future. Partner with the pioneers who revolutionized dry eye care. Lumenis is your trusted partner for professional growth, clinical excellence, and expanding your practice—delivering innovative solutions that have been setting the gold standard in eye care for over 60 years. LEARN MORE DOWNLOAD INFO KIT Discover how OptiLIFT can transform your practice. Contact us for a free demo or to learn more! Close 1 Chelnis JG, Chelnis A. Dynamic Muscle Stimulation of the Periorbital Area for Improvement of Blinking in Dry Eye Patients. Clin Ophthalmol. 2025;19:1057-1071 Indication for use: The OptiLIFT System and its accessories are intended for dermatological procedures requiring ablation and resurfacing of the skin when using VoluDerm Energy (Microneedling Applicator). It is also intended for use in dermatologic and general surgical procedures for non-invasive treatment when using RF Energy and for muscle conditioning to stimulate healthy muscles (OptiLIFT Applicator). OptiLIFT System is not intended to be used in conjunction with therapy or treatment of medical diseases or medical conditions of any kind. OptiLIFT System is intended to be operated by a licensed healthcare practitioner who is present to monitor treatment. Warnings and risks: OptiLIFT System is contraindicated for patients with pacemakers, defibrillators, any implanted electronic device, or metal implanted in the treatment area. Side effects may appear either at the time of treatment or shortly after. Side effects may include any of the following: prolonged or significant pain, damage to natural skin texture (blister, burn), excessive skin redness (erythema), excessive swelling (edema), fragile skin bruising, excessive itching, change of pigmentation (hyper-pigmentation or hypopigmentation), scarring transient skin break-out such as acne and pimples. For a complete list of contraindications, please refer to the User Manual. PB-00086860, Rev A #### OptiLIFT in Action: Dr. Julie McLaughlin’s Experience with the New Device Press PublicationsDry EyePeriorbital Muscle Stimulation OptiLIFT in Action: Dr. Julie McLaughlin’s Experience with the New Device April 28, 2025 Julie McLaughlin, OD ABO Diplomate Ocular Surface Disease (Dry Eye Syndrome) Dr. Julie McLaughlin graduated from the University of Virginia with a Bachelor of Arts degree in Sports Medicine and earned her Doctor of Optometry degree from Pennsylvania College of Optometry (now Salus University). She completed a hospital-based residency at the Baltimore VA Medical Center/Johns Hopkins University and has been a diplomate of the American Board of Optometry since 2013. Dr. McLaughlin, a Key Opinion Leader for Lumenis, specializes in ocular surface diseases and dry eye syndrome. #### OptiLIGHT A BRIGHT SOLUTION FOR DRY EYES Videos & ExpertsStopping InflammationUser-centric DesignClinical StudiesInfluencer ImpactDry Eye DiagnosticsInfo KitResource HubFAQ DRY EYE MEDICAL DEVICE Lumenis, the inventor of IPL, presents the first and only IPL FDA-approved for the management of dry eye disease due to MGD. Introducing OptiLIGHT – a bright solution for dry eyes. OptiLIGHT elevates dry eye management with Lumenis’ patented Optimal Pulse Technology (OPT™) and user-centered design. Get the safe, precise, elegant procedure you want and the comfortable, effective therapy your patients need to manage dry eye disease with OptiLIGHT, a dry eye medical device. DOWNLOAD KIT THE FIRST AND ONLY IPL FDA APPROVED FOR DRY EYE MANAGEMENT WATCH OPTILIGHT VIDEO WHAT THE EXPERTS ARE SAYING WATCH OPTILIGHT VIDEO WHAT THE EXPERTS ARE SAYING STOP THE DRY EYE VICIOUS CYCLE OF INFLAMMATION Reduce Inflammatory Mediators Decrease the level of pro-inflammatory mediators to inhibit inflammation.1,2 Improve Tear Breakup Time Significantly boost tear break up time and decrease osmolarity.6,7 Alleviate Abnormal Blood Vessels Destroy the abnormal blood vessels that perpetuate inflammation.3,4 Restore Meibomian Glands Improve meibomian gland morphology and functionality.2 Decrease Demodex Decrease the population of Demodex mites, which stimulate infection and boost the bacterial load on eyelids.5 ELEVATING DRY EYE MANAGMENT Every element designed to provide a precise and comfortable Dry Eye procedure Patented OPT™ Handpiece Each of your patients has individual, delicate facial contours. With the patented OPT™ handpiece, the treatment is easily customized to fit every curve and outline. Ergonomic IPL Handpiece Treat wider areas safely and comfortably using the IPL handpiece with patented SapphireCool™ technology to effectively break dry eye vicious cycle of inflammation. Proven Settings And Protocols Utilize embedded settings based on Lumenis’ clinically validated treatment protocols for safe and effective dry eye treatment. Tailored Experience For Maximum Safety And Comfort Experience optimal energy control with the Opti -Tip, which optimizes light energy for delicate areas, ensuring a safe, hygienic and effective treatment. Optimal Pulse Technology (OPT™) That Transforms Light-Based Therapy Get targeted, precise and controlled treatment with OptiLIGHT’s patented OPT™ technology – optimal energy with no-spike consistency. ELEVATING YOUR DRY EYE PRACTICE Light-based, quick, 15-Minute Procedure Each OptiLIGHT session takes about 15 minutes, so you can easily integrate OptiLIGHT into your practice. With a seamless workflow and just 4 easy-to-perform sessions, OptiLIGHT is an essential tool in your dry eye toolkit. Elevate clinical effectiveness, practice efficiency and business growth with OptiLIGHT, dry eye medical device. Visible results that last Courtesy of Laura M. Periman, MD Visible results that last Courtesy of Laura M. Periman, MD LUMENIS’ BRIGHT SOLUTION: BACKED BY PEER-REVIEWED CLINICAL STUDIES* Effective multifactorial treatment for a multifactorial disease Decrease inflammation Tear film level of IL-17 inflammatory marker is significantly reduced.1 Decrease inflammation Tear film level of IL-6 inflammatory marker is significantly reduced.1 IMPROVE TEAR BREAKUP TIME Treatment nearly doubles the tear breakup time.6 OptiLIGHT’s INFLUENCER IMPACT Raising awareness for dry eye disease VIEW ALL RESOURCES ANTARES DRY EYE DISEASE DIAGNOSTICS Advanced, automated DED diagnostic and corneal topographer Quality Accurate, reliable, reproducible and low intra-rater variability Speed Fast examination process and results Comfortable Offers patient comfort as well as physician ease of use Applications Dry eye report, Meibography, Tear Breakup Time, Tear Meniscus, Topographer LEARN HOW YOU CAN ELEVATE YOUR PRACTICE Meet the first and only FDA-approved IPL for dry eye management. Download OptiLIGHT info kit VISION RESOURCE HUB Clinical studies, professional insights, press publications, blogs posts and more VIEW ALL RESOURCES FAQ What is OptiLIGHT? OptiLIGHT is a light-based treatment that uses precise, intense broad spectrum light to address signs of dry eye disease due to meibomian gland dysfunction (MGD). MGD is the most common cause of dry eye disease, accounting for about 86% of cases8. The treatment addresses inflammation, which is one of the key underlying factors in MGD. OptiLIGHT was specifically developed to reach the delicate contours of the treated area safely, effectively, and gently using the OPT™ technology. It is intended for use in patients who are at least 22 years old, together with other available treatments, such as Meibomian gland expression, artificial tear lubricants, and warm compresses. Is Lumenis light therapy FDA approved? Lumenis light therapy is the first and only IPL FDA approved for Dry Eye management due to Meibomian Glands Dysfunction (MGD). What are the key features of OptiLIGHT? Patented OPTTM handpiece Ergonomic IPL handpiece Personalized experience for safety and comfort Proven setting and protocols Transforming the use of light with OPTTM technology How long does it take to perform a procedure with OptiLIGHT? Each treatment takes about 15 minutes, so you can easily integrate OptiLIGHT into the workflow. Patients achieve results in just 4 comfortable OptiLIGHT treatments. Is there any downtime after a procedure with OptiLIGHT? Immediately following treatment, patients may experience some redness. This will usually disappear within a few hours. Patients can resume their daily activities according to their doctor’s recommendation. What is OPT™ technology? Lumenis’ patented technology OPT™ (Optimal Pulse Technology) transforms the use of light and allows targeted, uniform, precise, and controlled treatment. Specifically designed for the delicate area below the eye, OPT™ safely and effectively breaks the vicious cycle of inflammation associated with dry eye. What is the wavelength of the OptiLIGHT system? The wavelength range of IPL is between 400 and 1200 nm. The OptiLIGHT system limited the wavelength range to of 590-1200 nm obtained with the use of a cut-off filter of 590 nm. OptiLIGHT Specifications ExpertFilters* OptiLIGHT; Acne: (400-600 & 800-1200); Vascular (530-650 & 900-1200); 515 nm, 560 nm; 590 nm; 615 nm; 640 nm; 695 nm; 755nm; Lightguides 15x35mm, 8x15mm, 6.4mm Ø Maximal Fluence** 35 J/cm2 Cooling Continuous contact cooling for IPL handpiece * OptiLIGHT filter is received complementary with the system. Other filters can be purchased separately ** For upgraded IPL aesthetic configuration 1. Liu et al. (2017), Am J Ophthalmol 183-190; 2. Yin et al. (2018), Curr Eye Res 43(3):308-313; 3. Kassir et al. (2011), J Cosmet Laser Ther 13(5):216-322; 4. Papageorgiou et al. (2008), Br J Dermatol 159(3):628-632; 5. Prieto et al. (2002), Lasers Surg Med 30(2):82-85; 6. Dell et al. (2017) Clin Ophthalmol 11:817-827; 7. Toyos & Briscoe (2016), J Clin Exp Ophthamol 7:6. 8. Lemp, et al. Cornea 31.5 (2012): 472-478 * All clinical studies cited here were conducted with Lumenis IPL with OPT technology. OptiLIGHT is intended to be used by licensed practitioners, according to local rules and regulations. Risks and warning (non-inclusive list): In EU: Evaporative Dry Eye Disease (DED), also known as dry eye syndrome or lipid tear deficiency, due to Meibomian Gland Dysfunction (MGD). This indication is intended for Fitzpatrick skin types I-V. In US: Improvement of signs of Dry Eye Disease (DED) due to Meibomian Gland Dysfunction (MGD), also known as evaporative dry eye or lipid deficiency dry eye, in patients 22 years of age and older with moderate to severe signs and symptoms of DED due to MGD and with Fitzpatrick skin types I-IV. IPL is to be applied only to skin on the malar region of the face, from tragus to tragus including the nose (eyes should be fully covered by protective eyewear). IPL is intended to be applied as an adjunct to other modalities, such as meibomian gland expression, artificial tear lubricants and warm compresses. The indications are only relevant where they were approved by the Regulatory Authorities. Treatment with OptiLIGHT is contraindicated for patients with the following conditions in the treatment area: Ocular surgery or eyelid surgery or Neuro-paralysis within 6 months prior to the first treatment; Uncontrolled eye disorders affecting the ocular surface; Pre-cancerous lesions, skin cancer or pigmented lesions; Uncontrolled infections or uncontrolled immunosuppressive diseases; Recent Ocular infections; History of cold sores or rashes in the perioral area, including: Herpes simplex 1 & 2, Systemic Lupus erythematosus and porphyria; Use of photosensitive medication and/or herbs that may cause sensitivity within 3 months prior to the first IPL session; Recent radiation therapy to the head or neck or planned radiation therapy; Recent treatment with chemotherapeutic agent or planned chemotherapy; History of migraines, seizures or epilepsy. Patients eyes must be completely occluded during the treatment. Please refer to the operator manual for a complete list of intended use, contraindications and risks. The following possible side effects can occur following IPL treatments: Pain/discomfort, damage to natural skin texture, change of pigmentation, scarring, excessive edema, fragile skin, bruising, burns, pruritus and xerosis. Please refer to the user manual or ask your doctor for a complete list of intended use, contraindications and risks. PB-00030050 Rev D DOWNLOAD KIT I’M A PATIENT DOWNLOAD KIT I’M A PATIENTGET MORE INFO × #### Optilight by Lumenis – A Bright Solution for Dry Eyes- official launch event Optilight by Lumenis – A Bright Solution for Dry Eyes – official launch event Presenting OptiLight, Lumenis revolutionary new light- based treatment for dry eye disease. Dr. Adler hosts Drs. Toyos, Periman and Epstein, plus OptiLight patients. Richard A. Adler, MD Arthur B. Epstein, OD Rolando Toyos, MD Laura M. Periman, MD Explore Other Resources Dry EyeNewsPeriorbital Muscle StimulationTreatment TypeVision Resource HubDry EyeNewsPeriorbital Muscle StimulationTreatment TypeVision Resource HubLumenis OptiLIFT Dynamic Muscle Stimulation Device receives Health Canada Approval for Reducing Signs and Symptoms of Evaporative Dry Eye DiseaseREAD MOREClinical StudiesDry EyePeriorbital Muscle StimulationTreatment TypeVision Resource HubClinical StudiesDry EyePeriorbital Muscle StimulationTreatment TypeVision Resource HubThe Potential Benefits of Periorbital Transcutaneous Electrical Stimulation for the Management of Dry Eye DiseaseREAD MOREDry EyePeriorbital Muscle StimulationPress PublicationsTreatment TypeVision Resource HubDry EyePeriorbital Muscle StimulationPress PublicationsTreatment TypeVision Resource HubSisters Grow Practice Into Medical Hub for Dry Eye TreatmentREAD MORE PB-00038930 Rev A | PB-00030760 Rev A #### OptiLight Dry Eye Solution ft. Candice King OptiLight Dry Eye Solution ft. Candice King March 7, 2024 Share   Candice King said goodbye to compromising on comfort, whether it’s strutting in six-inch heels or dry, itchy eyes! Hear about OptiLIGHT by Lumenis, a bright solution for dry eyes. Watch more videos Colton Underwood shares his experience with DED and his care journey using OptiLIGHT and OptiLIFTMay 25, 2025WATCH NOWKerri Walsh Jennings Shares the Impact of OptiLIGHT Treatment on Her Dry Eye Disease!May 2, 2024WATCH NOWKerri Has Been Experiencing Dry, Itchy Eyes On And Off The Court For Years. Her Solution: OptiLIGHT!April 28, 2024WATCH NOW PB-00076100, Rev A #### OptiLight First Look: A Difference-Maker for Doctors and Dry Eye Patients OptiLight First Look: A Difference-Maker for Doctors and Dry Eye Patients August 31, 2021 With a major dry eye center in the high desert of Arizona, I need to be on top of new advances in dry eye therapy. It was exciting to see Lumenis, the company that first introduced intense pulsed light (IPL) technology, receive the first and only FDA approval of IPL for management of dry eye disease for Lumenis IPL with Optimal Pulse Technology (OPT™). Approval from the FDA, which has extremely stringent criteria, underscores that the therapy is very well supported by data. When Lumenis introduced OptiLight with OPT™ technology this year, my first impression was that the device is beautifully designed and brilliantly engineered. OPT™ delivers a measured amount of energy in a specific pattern that is clinically proven effective, safe and comfortable for the patient. The design of the OPT™ handpiece makes it easy to precisely treat facial contours, and my patients were very comfortable and pleased with the results. I have found OptiLight to be extremely intuitive. The graphics are beautiful from the clinician’s point of view—all the information you want is right in front of you in an easy-to-understand display. It’s also remarkably easy to implement in the practice because the procedure is relatively quick, and it’s simple for staff to assist with patient setup for treatment. Lumenis is also there to support every step in the implementation process. We were quickly using OptiLight with our patients, and we now treat 20 to 30 patients per week. I anticipate that doctors will find OptiLight very appealing as an in-office procedure for dry eye because it removes some of the complexity of traditional dry eye management and simplifies it in a way that makes it accessible, safe, reproducible, and most importantly, effective. Default settings are based on Lumenis’ clinically proven treatment protocols for dry eye. Error checking is built-in. It’s almost like having an artificial intelligence algorithm looking over your shoulder to double-check every move and make sure you’re using safe and effective settings for your patients. This makes it easier to focus on the primary endpoint, which is improving dry eye signs. And there is still significant latitude to customize treatment if desired. While I see OptiLight as a step forward for ophthalmologists and optometrists alike, I’m particularly intrigued by what I think is a tremendous opportunity for medical management in optometry. We need to move farther away from refractive care and into medical care, and the ubiquity of dry eye makes it an extremely important part of that picture. A device like OptiLight that is sophisticated and aimed specifically at the dry eye patient is a defining addition to the successful dry eye practice. I can attest that effective in-office therapy is well accepted by my patients, so we anticipate a swift return on investment for OptiLight. With the introduction of OptiLight, I see more optometrists expanding to in-office dry eye therapy.* This light-based, nonsurgical, noninvasive therapy is included in the optometrist’s scope of practice in most U.S. states, and it’s so easy to use. I think many of my peers will seize the opportunity to enhance patient care and elevate their practices with the power of OptiLight technology. * The OptiLight system is intended be used by licensed practitioners according to local rules and regulations. Indication for Use: Improvement of signs of Dry Eye Disease (DED) due to Meibomian Gland Dysfunction (MGD), also known as evaporative dry eye or lipid deficiency dry eye, in patients 22 years of age and older with moderate to severe signs and symptoms of DED due to MGD and with Fitzpatrick skin types I-IV. IPL is to be applied only to skin on the malar region of the face, from tragus to tragus including the nose (eyes should be fully covered by protective eyewear). IPL is intended to be applied as an adjunct to other modalities, such as meibomian gland expression, artificial tear lubricants and warm compresses Treatment with OptiLight is contraindicated for patients with the following conditions in the treatment area: Ocular surgery or eyelid surgery or Neuro-paralysis within 6 months prior to the first treatment; Uncontrolled eye disorders affecting the ocular surface; Pre-cancerous lesions, skin cancer or pigmented lesions in the planned treatment area; Uncontrolled infections or uncontrolled immunosuppressive diseases; Recent Ocular infections; Prior history of cold sores or rashes in the perioral area, including: Herpes simplex 1 & 2, Systemic Lupus erythematosus and porphyria; Use of photosensitive medication and/or herbs that may cause sensitivity within 3 months prior to the first IPL session; Recent radiation therapy to the head or neck or planned radiation therapy; Recent treatment with chemotherapeutic agent or planned chemotherapy; History of migraines, seizures or epilepsy. Patients eyes must be completely occluded during the treatment. Please refer to the operator manual for a complete list of intended use, contraindications and risks. Please consult your physician as to whether this procedure is suitable for you. The following possible side effects can occur following IPL treatments: Pain/discomfort, damage to natural skin texture, change of pigmentation, scarring, excessive edema, fragile skin, bruising, burns, pruritus and xerosis. Please refer to the user manual or ask your doctor for a complete list of intended use, contraindications and risks Explore Other Resources Dry EyeNewsPeriorbital Muscle StimulationTreatment TypeVision Resource HubDry EyeNewsPeriorbital Muscle StimulationTreatment TypeVision Resource HubLumenis OptiLIFT Dynamic Muscle Stimulation Device receives Health Canada Approval for Reducing Signs and Symptoms of Evaporative Dry Eye DiseaseREAD MOREClinical StudiesDry EyePeriorbital Muscle StimulationTreatment TypeVision Resource HubClinical StudiesDry EyePeriorbital Muscle StimulationTreatment TypeVision Resource HubThe Potential Benefits of Periorbital Transcutaneous Electrical Stimulation for the Management of Dry Eye DiseaseREAD MOREDry EyePeriorbital Muscle StimulationPress PublicationsTreatment TypeVision Resource HubDry EyePeriorbital Muscle StimulationPress PublicationsTreatment TypeVision Resource HubSisters Grow Practice Into Medical Hub for Dry Eye TreatmentREAD MORE PB-00038110 Rev A #### OptiLIGHT Unlocks Possibilities for Dry Eye Patients and Practices OptiLIGHT Unlocks Possibilities for Dry Eye Patients and Practices September 11, 2023 This white paper highlights how Dr. James Chelnis, MD has benefited from OptiLIGHT‘s ability to transform the way he approaches and treats patients with dry eye disease. As he views the implementation of OptiLIGHT as a huge success, he describes the reasons why OptiLIGHT has become his treatment of choice. READ FULL ARTICLE Explore Other Resources Dry EyeNewsPeriorbital Muscle StimulationTreatment TypeVision Resource HubDry EyeNewsPeriorbital Muscle StimulationTreatment TypeVision Resource HubLumenis OptiLIFT Dynamic Muscle Stimulation Device receives Health Canada Approval for Reducing Signs and Symptoms of Evaporative Dry Eye DiseaseREAD MOREClinical StudiesDry EyePeriorbital Muscle StimulationTreatment TypeVision Resource HubClinical StudiesDry EyePeriorbital Muscle StimulationTreatment TypeVision Resource HubThe Potential Benefits of Periorbital Transcutaneous Electrical Stimulation for the Management of Dry Eye DiseaseREAD MOREDry EyePeriorbital Muscle StimulationPress PublicationsTreatment TypeVision Resource HubDry EyePeriorbital Muscle StimulationPress PublicationsTreatment TypeVision Resource HubSisters Grow Practice Into Medical Hub for Dry Eye TreatmentREAD MORE PB-00043680 Rev C #### Optima IPL Receives CFDA Mark Approval for Treatment of Dry Eye Disease Optima IPL Receives CFDA Mark Approval for Treatment of Dry Eye Disease Now this exciting technology is available to practitioners in China for DED September 10, 2019 – Yokne'am Illit, Israel Lumenis Ltd., happy to announce that it has received CFDA Mark approval for commercial sales in China of its M22 Optima IPL for treatment of Dry Eye Disease using the M22 multi-application platform. Lumenis Optima IPL is a first-of-its-kind, drug free-drop free, light-based treatment that targets chronic inflammation, which is the root cause of dry eye disease. Optima IPL breaks the dry eye vicious cycle in multiple points. It alleviates the abnormal blood vessels1,2 as well as reduces the level of pro-inflammatory mediators3,4 and Demodex5 mites that perpetuate the disease and stimulate this vicious cycle. As such, it effectively restores tear film osmolarity6 and gland morphology7 to normal function, providing long lasting effect. The CFDA is based on a randomized controlled trial of 120 MGD patients, treatment with Optima IPL significantly improved TBUT, symptoms (SPEED), meibum quality and lid margin abnormalities in the study arm compared to control8. This study joins multiple prospective studies, which have demonstrated that the Optima IPL improves both signs and symptoms of dry eye disease due to MGD. As a technological leader in the eye care arena, Lumenis is dedicated to understanding the clinical aspects of the disease and the treatment and continues to invest in Dry Eye studies around the world. China joins a long lists of countries around the world that have already approved the M22 Optima IPL treatment for dry eye disease, including the European Union (CE mark), Australia, New Zealand, South Korea, Brazil, Hong Kong, Poland and Ukraine. References Kassir et al. (2011) J Cosmet Laser Ther 13(5):216-22 Papageorgiou et al. (2008) Br J Dermatol 159(3):628-32 Liu et al. (2017) Am J Ophthalmol 183:81-90 Yin et al. (2018) Curr Eye Res 43(3):308-13 Zhang et al. (2019) Current Eye Research 44:3,250-256. Dell et al. (2017) Clin Ophthalmol 11:817-827 Rong et al. (2018) Photomed Laser Surg 36(6):326-332 The results of this study, are currently in preparation for publication (internal ref: LUM-CHN-M22-16-01) Explore Other Resources Dry EyeNewsPeriorbital Muscle StimulationTreatment TypeVision Resource HubDry EyeNewsPeriorbital Muscle StimulationTreatment TypeVision Resource HubLumenis OptiLIFT Dynamic Muscle Stimulation Device receives Health Canada Approval for Reducing Signs and Symptoms of Evaporative Dry Eye DiseaseREAD MOREClinical StudiesDry EyePeriorbital Muscle StimulationTreatment TypeVision Resource HubClinical StudiesDry EyePeriorbital Muscle StimulationTreatment TypeVision Resource HubThe Potential Benefits of Periorbital Transcutaneous Electrical Stimulation for the Management of Dry Eye DiseaseREAD MOREDry EyePeriorbital Muscle StimulationPress PublicationsTreatment TypeVision Resource HubDry EyePeriorbital Muscle StimulationPress PublicationsTreatment TypeVision Resource HubSisters Grow Practice Into Medical Hub for Dry Eye TreatmentREAD MORE PB-00033230 Rev A × GET MORE INFO #### OptiPLUS REACH DIFFERENT SKIN LAYERS WITH OptiPLUS’ NOVEL DUAL FREQUENCY RF TECHNOLOGY IntroductionIllustrationExpertsBenefitsClinical StudyIn Your PracticeOptiLIGHTLearn MoreSpecifications Embedded treatment presets and automatic electrode detection 2 ergonomic handpieces Electrodes dedicated to
small areas Introducing OptiPLUS Innovative, FDA-cleared, dual frequency RF technology that seamlessly integrates into your workflow. Now, you can precisely reach different skin layers to enhance blood circulation, collagen production and target meibomian glands.1,2 The powerful pairing of OptiLIGHT and OptiPLUS unlocks the potential of two dedicated, innovative devices for advanced expertise, patient comfort and safety, as well as revenue boosting. Complement your treatments, improve meibomian glands function and upgrade aesthetic possibilities to offer your patients the solutions they can trust.6 DOWNLOAD INFO KIT DUAL FREQUENCY RF TECHNOLOGY Precisely deliver heat across several skin layers, improve meibomian glands functionality and enhance collagen production. 1,2,6 1MHz Deep heat delivery 4MHz Enhanced collagen production Actual depth may vary from area to area and according to tissue impedance Actual depth may vary from area to area and according to tissue impedance ELEVATE PATIENT CARE WITH FDA-CLEARED DUAL FREQUENCY RF TECHNOLOGY EMPOWER YOUR PRACTICE WITH THE ADDED BENEFITS OF OptiPLUS Groundbreaking dual frequency RF technology Precisely deliver heat across several skin layers, to both target the meibomian glands and enhance collagen formation. 1,2 Enhanced clinical results Leverage the pairing of dual frequency RF and OPT™ technology to significantly improve the number of expressible meibomian glands, meibum clarity and symptoms.6 Expanded Aesthetic benefits Unlock aesthetic advancement and enhance collagen synthesis for facial skin rejuvenation.1,4 Unique monopolar application Enhance patient safety and comfort with a unique monopolar electrode that ensures optimized contact with every delicate curve in the peri-orbital area.3,5 Revolutionary dedicated RF device Boost productivity, expand your line of treatments and add a new revenue stream with the added expertise of a dedicated device. DRIVEN BY EXCELLENCE, BACKED
BY SCIENCE: PEER-REVIEWED
CLINICAL STUDY RESULTS* Pairing of dual-frequency RF and IPL+MGX improves signs and symptoms of MGD.6 IMPROVES OCULAR SURFACE DISEASE INDEX (OSDI)6 IMPROVES MODIFIED MEIBOMIAN GLAND SCORE (mMGS)6 *The clinical study referred here was conducted with Lumenis IPL with OPTTM and Lumenis dual frequency RF technology. TAILORED SOLUTIONS FOR ADVANCED PATIENT CARE User Friendly Design OptiPLUS delivers ease of use with two handpieces, carefully designed for ergonomic comfort and customized treatment applications. Diverse Skin Type Coverage Leverage the versatility of OptiPLUS and treat a wide range of skin types with confidence, providing significant improvement in eyelid appearance.6   Safe, Effective Treatments Experience enhanced safety and effectiveness with the science of temperature control, and provide targeted treatments with pre-embedded settings based on a clinically validated protocol.6 Quick, Easy Procedures OptiPLUS easily integrates into your workflow with minimal training and set up. Treatments are typically around 6 minutes per side, with noticeable results in just 4 sessions. EXPERIENCE THE LUMENIS DIFFERENCE Take the next step in your professional and clinical success with the innovators who brought you IPL for dry eye. Lumenis is your trusted ally in your journey to professional development, clinical success, and business expansion, while setting the highest standards in eye care for years to come. Meet the first and only FDA-approved light therapy for dry eye management. OptiLIGHT’s patented OPTTM technology targets the root cause of DED and breaks the vicious cycle of inflammation. LEARN MORE DISCOVER NEW POSSIBILITIES With the powerful pairing of OptiLIGHT’s patented OPT™ technology and OptiPLUS’ innovative dual frequency RF technology. OptiPLUS Specifications FocalRF Emission Frequency (±1%) 470 kHz, 1 MHz, 2 MHz, 4 MHz, 6 MHz Maximum Output Power (±10%) 250W Display LCD Touch Screen 15” Operative Mode Automatic treatment presets, NuLogic & Manual Temperature Range From 35°C to 42°C ± 1°C Mains 100-240 Vac; 50/60 Hz; 350W Dimensions 127x55x60 cm (HxWxD) / 49.9 x 21.6 x 23.6″ Weight Weight 44Kg / 97 lbs Safety Class Class I – type BF Capacitive Coated Electrodes* ø10 mm, ø20 mm, ø30 mm, ø40 mm, ø60 mm, ø70 mm, ø80 mm, ø100 mm, ø40 mm with massage *OptiPLUS ø 10mm and ø20mm electrodes are received complementary with the system. Other electrodes can be purchased separately for upgraded aesthetic configuration. References Javate RM, Cruz RT Jr, Khan J, Trakos N, Gordon RE. Nonablative 4-MHz dual radiofrequency wand rejuvenation treatment for periorbital rhytides and midface laxity. Ophthalmic Plast Reconstr Surg. 2011 May-Jun;27(3):180-5. doi: 10.1097/IOP.0b013e3181fe8e5a. PMID: 21283035. Rabkin JM, Hunt TK. Local heat increases blood flow and oxygen tension in wounds. Arch Surg. 1987 Feb;122(2):221-5. doi: 10.1001/archsurg.1987.01400140103014. PMID: 3813871. Malanga GA, Yan N, Stark J. Mechanisms and efficacy of heat and cold therapies for musculoskeletal injury. Postgrad Med. 2015 Jan;127(1):57-65. doi: 10.1080/00325481.2015.992719. Epub 2014 Dec 15. PMID: 25526231. Al-Atif H. Collagen Supplements for Aging and Wrinkles: A Paradigm Shift in the Fields of Dermatology and Cosmetics. Dermatol Pract Concept. 2022 Jan 1;12(1):e2022018. doi: 10.5826/dpc.1201a18. PMID: 35223163; PMCID: PMC8824545. Green JB, Dover JS, Kaminer MS. Tolerability of a monopolar radiofrequency facial skin tightening procedure: An observational study. Cosmetic Dermatology. 2011 July;24(7):327-330 Chelnis J, Garcia CN, Hamza H. Multi-Frequency RF Combined with Intense Pulsed Light Improves Signs and Symptoms of Dry Eye Disease Due to Meibomian Gland Dysfunction. Clin Ophthalmol. 2023;17:3089-3102 The OptiPLUS release is per regional regulatory approval in the relevant jurisdiction. OptiPLUS is currently approved in the United States only. OptiPLUS risks and warning (non-inclusive list) Indication for Use: OptiPLUS is intended to provide topical heating to treat selected medical conditions such as for temporary relief of pain or muscle spasms and to increase local circulation on body and face. The device is also intended to provide, with a massage device, a temporary reduction in the appearance of cellulite. Treatment with OptiPLUS is contraindicated for patients with the following conditions in the treatment area: OptiPLUS is unsuitable for anyone who is pregnant, has an infection or illness, or is heat sensitive. Treatment over cuts, wounds, piercings, and tattoos must be avoided and areas with injectable fillers and toxins left for a month before treatment. Patients with a metal implant or implanted device (e.g pacemaker) must consult with a qualified physician first. If deemed suitable, the return pad must be placed far away from the implant. Local, oral, or systemic anesthetics cannot be used before or during treatment as patients need to provide regular feedback to ensure their continued comfort. Insulate patients from metal objects, especially any in direct contact (e.g. the bed). A full practitioner consultation is always advisable. The device is not intended to be used within the orbital rim or on the neck. The following possible side effects can occur following RF treatments: Moderate burning sensation, burns, erythema, edema, blistering, moderate pain, purpura in exposure area, mild swelling, ear feeling clogged and jaw tightness. Please refer to the operator manual for a complete list of intended use, contraindications, and risks. BR0006-US.R0 #### Patients Education Patient Education Don’t let glaucoma steal your sight, see how SLT therapy can help control your glaucoma Glaucoma is a degenerative eye disease that can cause permanent damage leading to vision loss and blindness without warning or symptoms. You may be visiting this Web site because you or someone you know was diagnosed with glaucoma or may be at risk for developing the eye disease. Selective Laser Trabeculoplasty, or SLT (pioneered by Lumenis), glaucoma therapy, is an effective and convenient laser surgery for glaucoma we have developed in our ongoing effort to prevent glaucoma from “stealing” vision in glaucoma patients. About Glaucoma What is Glaucoma? Glaucoma is an eye disease that can cause blindness without warning or symptoms. Three million Americans have it today but only half know they have it and the others go untreated. Glaucoma vision loss is caused by damage to the optic nerve – the part of the eye that carries images we see to the brain. Definition of Glaucoma Glaucoma eye disease is a degenerative disease that if left untreated can cause permanent damage to the optic nerve resulting in gradual vision loss and eventual blindness. Damage to the optic nerve, due to glaucoma, is usually caused by an elevated intraocular pressure (IOP). Clear fluid, called aqueous humor circulates through the eye providing nourishment to the tissues pressure to help maintain the shape of the eye. Open Angle Glaucoma (OAG), occurs when there is an increase in fluid production or a decrease in fluid drainage. Over time, as the optic nerve fibers are destroyed, peripheral (side) vision is lost. Blocked fluid flow Aqueous humor flows out of the eye through the Trabecular Meshwork (TM), near the edge of the iris. If the TM is blocked, restricting drainage, the pressure inside the eye increases. This elevated eye pressure results in damage to the optic nerve and vision loss occurs. Glaucoma Treatment Options Today, there is no cure for glaucoma. However, there are treatment options combining medication, laser surgery for glaucoma that may prevent further or stop vision loss by controlling the number one risk factor of glaucoma – high levels of IOP. How do you treat Glaucoma? Glaucoma Medicine Up to now, controlling unsafe levels of IOP has been primarily accomplished by using eye drops Laser Surgery for Glaucoma Advances in laser surgery are providing effective alternatives to treat glaucoma. Selective Laser Trabeculoplasty, or SLT, is a highly effective out-patient laser procedure that reduces IOP by stimulating a natural healing response. SLT, a patented low energy laser treatment method, uses a unique combination of minimal energy and short laser pulses. One-time SLT treatment results in eye pressure drop equivalent to the pressure drop experienced from daily use of eye drops. However, SLT is not associated with the systemic side effects, cost issues, and need for daily use. Surgery In surgery a tiny drainage hole is made in the sclera (the white part of the eye). This new hole facilitates fluid outflow which in turn lowers IOP. Another variation of this procedure involves a shunt that is surgically implanted in the eye. The tubes within the shunt decrease IOP by bypassing blocked cellular tissue. Patient Videos [ytp_video source=”fo-5XZ_Ax-c,SczsFiH5I9Y,8VYoJTYMP84,cdnI1gdHsWk,2wTeh6sbPUg,UxNewWzTtfE”] PB-2006798 Rev A × GET MORE INFO #### Perioperative IPL to Prevent and Improve Symptoms of Post Laser Corneal Refractive Surgery Dry Eye Clinical StudiesDry Eye Perioperative IPL to Prevent and Improve Symptoms of Post Laser Corneal Refractive Surgery Dry Eye February 26, 2024 In a randomized controlled study of subjects undergoing corneal laser refractive surgery (SMILE or LASIK), 31 were treated with three sessions of perioperative IPL and 30 were treated with three sessions of placebo (sham IPL). At 3 and 6 months after surgery, signs and symptoms associated with dry eye disease (DED) were significantly better in the IPL group, compared to the control group. These results suggest that perioperative IPL prevents temporary development of DED. ASIA-PACIFIC JOURNAL OF OPHTHALMOLOGY Read Full Article Discover new possibilities Download OptiLIGHT and OptiPLUS info kit Explore Other Resources Dry EyeNewsPeriorbital Muscle StimulationTreatment TypeVision Resource HubDry EyeNewsPeriorbital Muscle StimulationTreatment TypeVision Resource HubLumenis OptiLIFT Dynamic Muscle Stimulation Device receives Health Canada Approval for Reducing Signs and Symptoms of Evaporative Dry Eye DiseaseREAD MOREClinical StudiesDry EyePeriorbital Muscle StimulationTreatment TypeVision Resource HubClinical StudiesDry EyePeriorbital Muscle StimulationTreatment TypeVision Resource HubThe Potential Benefits of Periorbital Transcutaneous Electrical Stimulation for the Management of Dry Eye DiseaseREAD MOREDry EyePeriorbital Muscle StimulationPress PublicationsTreatment TypeVision Resource HubDry EyePeriorbital Muscle StimulationPress PublicationsTreatment TypeVision Resource HubSisters Grow Practice Into Medical Hub for Dry Eye TreatmentREAD MORE PB-00067370, Rev A #### Photocoagulators Retinal Laser Photocoagulation Treatment Retina Laser Photocoagulators Photocoagulators cauterize blood vessels with heat generated by the laser beam. The laser creates tiny, controlled burns that create adhesive forming scar tissue. The Lumenis line of photocoagulation lasers and delivery devices are designed to give ophthalmologists the breadth and depth they need to treat several types of conditions including: Proliferative diabetic retinopathy Retinopathy of prematurity Retinal tears and detachments Branch retinal vein occlusion Choroidal neovascularization Retina Laser Photocoagulators, How it Works Photocoagulators are especially well suited for delicate retinal work. In the case of a retinal tear or hole, the scar tissue helps hold the retina in place. Photocoagulation can seal leaking vessels, as in the case of proliferative diabetic retinopathy, or destroy diseased retinal tissue. Photocoagulation lasers can also be used for choroidal neovascularization. Photocoagulators Smart532™ Green Photocoagulator with SmartPulse™ Sub-Threshold Technology Array™ LaserLink™ Pattern Scanning Laser Technology Smart Selecta Trio SLT + YAG + Smart532™ Your Smart Comprehensive Solution Vision One Multi-Wavelength Photocoagulator Green 532nm, Yellow 577nm and Red 659nm Novus Spectra Green Dual-Port Photocoagulator for the OR and Clinic Brochure Download BrochureRelated Links Photodisruptors Caution: Federal (US) law restricts Lumenis devices to sale by or on the order of a licensed practitioner. PB-02006798 Rev B × GET MORE INFO #### Physician Education Physician Education Learn why Lumenis SLT is good for your patients, your practice and you! Lumenis provides online resources and training events to enable you and your staff to learn more about the technology behind our laser systems – and the opportunities they offer for your practice. Optimizing Glaucoma Therapy For Both Patients And Physicians SLT for OAG – Where are we? Mark A. Latina, MD Massachusetts Eye and Ear Infirmary Watch the Webinar SLT in the Post-Prostaglandin Era Robert Noecker, MD, MBA Ophthalmic Consultants of Connecticut Fairfield, CT Watch the Webinar Repeatability of (SLT) Brian A. Francis, MD, MS Riffenburgh Professor of Glaucoma Doheny Eye Institute Watch the Webinar SLT Physician Testimonials Related Links SLT Lasers Caution: Federal (US) law restricts Lumenis devices to sale by or on the order of a licensed practitioner. PB-2006798 Rev A × GET MORE INFO #### Physician Videos SLT Glaucoma Videos SLT Physician Testimonials [ytp_video source=”I6xPZ0T8Slk,q51gY9Gxt5c,AGWbaRCfli8,A1_xwY7LUyk,r3EaTTnFrPU”] PB-2006798 Rev A × GET MORE INFO #### Preview of the New Digital Duet/Trio, the First Digital SLT+YAG Preview of the New Digital Duet/Trio, the First Digital SLT+YAG November 23, 2020 We recently had the chance to preview the digital capabilities of newly released Lumenis Digital Duet/Trio in our practice. We were familiar with Lumenis’ exceptional SLT+YAG technologies, which offer superior optics and precision for SLT and YAG capsulotomy. Now it’s exciting to see the first digital SLT+YAG device incorporate entirely new capabilities, such as anterior segment images and video and streamlined workflow. The digital data and imaging platform presents a more robust, efficient way of documenting pathology and procedures, gathering more information without slowing users down. The digital platform connects directly with reporting and EMR systems, improving practice efficiency and streamlining the process of how users digitally communicate with referring doctors. That change is exciting to us because we keep referring doctors engaged in their patients’ care by apprising them of what’s happening in our practice every step of the way. We also appreciate that with this system, users do not require an additional slit lamp camera. We believe the platform can help us educate patients about their condition or procedure. Patients are doing more and more learning at home, so they often have very specific questions about their pathology or the procedure we recommend. YAG capsulotomy is an ideal procedure video to show patients because they can clearly see and understand what happens, even without a science background or previous knowledge. In our teaching facility, the Digital Duet/Trio’s ability to allow students to watch live is very enticing as well. Normally, one resident or student can watch the procedure live using the observation tube. A technology that expands the number of people who can watch a procedure in real time presents a good teaching opportunity, particularly with COVID-19 precautions restricting the number of extra personnel in the procedure room. The Digital Duet/Trio offers a lot of functionality in a single platform. We’re looking forward to experiencing the ways that digital integration can enhance our practice. Explore Other Resources Dry EyeNewsPeriorbital Muscle StimulationTreatment TypeVision Resource HubDry EyeNewsPeriorbital Muscle StimulationTreatment TypeVision Resource HubLumenis OptiLIFT Dynamic Muscle Stimulation Device receives Health Canada Approval for Reducing Signs and Symptoms of Evaporative Dry Eye DiseaseREAD MOREClinical StudiesDry EyePeriorbital Muscle StimulationTreatment TypeVision Resource HubClinical StudiesDry EyePeriorbital Muscle StimulationTreatment TypeVision Resource HubThe Potential Benefits of Periorbital Transcutaneous Electrical Stimulation for the Management of Dry Eye DiseaseREAD MOREDry EyePeriorbital Muscle StimulationPress PublicationsTreatment TypeVision Resource HubDry EyePeriorbital Muscle StimulationPress PublicationsTreatment TypeVision Resource HubSisters Grow Practice Into Medical Hub for Dry Eye TreatmentREAD MORE PB-00022540 Rev A #### Products VISION Products Lumenis Vision is recognized for technological breakthroughs In ophthalmology equipment and a long list of industry gold standards in laser eye surgery. Pioneering the first argon laser photocoagulator for ophthalmology; the first approved marketer of Nd:YAG photodisruptor lasers; developed and introduced the breakthrough technology of multicolor photocoagulation along with the world’s first Laser Indirect Ophthalmoscope (LIO); developed the revolutionary SLT technology for managing POAG, and much more. OptiLIGHTA bright solution for dry eyesAntaresAdvanced Corneal Topographer with Comprehensive Dry Eye AnalysisOptiPLUSGroundbreaking dual frequency RF technology complementing OptiLIGHT’s dry eye solutionOptiLIFTNon-Surgical Device to Tone Muscles to Address Droopy EyelidsDigital DuetThe first and only all-in-one digital platform for Glaucoma and PCO therapiesM22 Optima™ IPLThink Outside the Eye, Treat skin and eyelid inflammation.Digital Trio3 in 1 digital platform for Glaucoma and Retina careSmart Selecta DuetSLT + YAG, Your Smart Selection for Glaucoma Care.Smart Selecta TrioSLT + YAG + Smart532™, Your Smart Comprehensive Solution.Smart532™Green Photocoagulator with SmartPulse™ Sub-Threshold TechnologyArray™ LaserLink™Pattern Scanning Laser TechnologyVision OneMulti-Wavelength Photocoagulator Green, Yellow and Red.Novus SpectraGreen Dual-Port Photocoagulator For the OR and ClinicSlit LampsParallel or Convergent Optics Diagnostic Slit LampsLIOsAdvanced Laser Indirect Ophthalmoscopes OptiLIGHTA bright solution for dry eyesOptiPLUSGroundbreaking dual frequency RF technology complementing OptiLIGHT’s dry eye solutionOptiLIFTNon-Surgical Device to Tone Muscles to Address Droopy EyelidsDigital DuetThe first and only all-in-one digital platform for Glaucoma and PCO therapiesDigital Trio3 in 1 digital platform for Glaucoma and Retina careSmart Selecta DuetSLT + YAG, Your Smart Selection for Glaucoma Care.Smart Selecta TrioSLT + YAG + Smart532™, Your Smart Comprehensive Solution.Smart532™Green Photocoagulator with SmartPulse™ Sub-Threshold TechnologyArray™ LaserLink™Pattern Scanning Laser TechnologyVision OneMulti-Wavelength Photocoagulator Green, Yellow and Red.Novus SpectraGreen Dual-Port Photocoagulator For the OR and ClinicSlit LampsParallel or Convergent Optics Diagnostic Slit LampsLIOsAdvanced Laser Indirect OphthalmoscopesLumeProbe™Endo-Photocoagulation Laser Probes INFORMATION Caution: Federal (US) law restricts Lumenis devices to sale by or on the order of a licensed practitioner. PB-2006798 Rev A × GET MORE INFO #### Real Condition, Real Solution! Treat The Root Cause of Dry Eye Disease With OptiLIGHT by Lumenis! Real Condition, Real Solution! Treat The Root Cause of Dry Eye Disease With OptiLIGHT by Lumenis! April 5, 2023 Share   Ashley Tisdale has been overwhelmed by the response to our campaign, hearing stories from people who have been enduring itchiness and irritation in their eyes. Many of them didn’t even realize that what they were experiencing had a name—Dry eyes! But there’s a real solution for that—OptiLIGHT by Lumenis. Watch more videos Colton Underwood shares his experience with DED and his care journey using OptiLIGHT and OptiLIFTMay 25, 2025WATCH NOWKerri Walsh Jennings Shares the Impact of OptiLIGHT Treatment on Her Dry Eye Disease!May 2, 2024WATCH NOWKerri Has Been Experiencing Dry, Itchy Eyes On And Off The Court For Years. Her Solution: OptiLIGHT!April 28, 2024WATCH NOW PB-00076100, Rev A #### Redefining Dry Eye Care: A Boutique Practice Case Study Blog PostsDry Eye Redefining Dry Eye Care: A Boutique Practice Case Study January 5, 2026 Tami Le, OD Le Eye Spa, Las Vegas, Nevada Dr. Tami Le, OD is the founder of Le Eye Spa, a boutique eye care practice in Las Vegas. After more than 13 years in traditional optometry, Dr. Le created Le Eye Spa to reimagine eye care as a patient-centered, spa-like experience focused on dry eye treatment, ocular wellness, and aesthetic care. At her practice, Dr. Le provides personalized care with extended appointment times and performs all treatments herself. She utilizes diagnostic imaging and visual evidence to support diagnosis and track progress throughout treatment. Le Eye Spa incorporates Lumenis OptiLIGHT IPL and OptiPLUS RF as part of its treatment offerings, reflecting Dr. Le’s focus on technologies with medical credibility and FDA-cleared indications for dry eye due to Meibomian Gland Dysfunction This case study tells the story of how Dr. Tami Le established Le Eye Spa in Las Vegas after feeling unfulfilled in traditional optometric practice. Practicing in a desert climate where dry eye symptoms are common, Dr. Le developed a boutique model designed to deliver a different type of patient experience—one centered on comfort, education, and focused specialty care. The study details how Dr. Le selected Lumenis OptiLIGHT IPL and OptiPLUS RF based on their medical credibility, FDA-cleared indications, and relevance to dry eye due to Meibomian Gland Dysfunction. It explores her evidence-based approach to diagnosis and treatment, including the use of imaging, standardized metrics, and consistent follow-up to demonstrate patient progress. Through patient outcomes, referral growth, and personal fulfillment, the case study illustrates how Dr. Le’s focused practice model and use of Lumenis technologies have shaped both her clinical approach and the patient experience at Le Eye Spa. LE EYE SPA: REDEFINING DRY EYE AND AESTHETIC CARE IN LAS VEGAS In the heart of Las Vegas, where the desert climate creates uniquely challenging conditions for eye health, Dr. Tami Le discovered her true calling after nearly walking away from optometry. Feeling unfulfilled by traditional practice, she created Le Eye Spa—a boutique Las Vegas practice that reimagines eye care as a luxurious experience dedicated to dry eye treatment and ocular aesthetics. In a city where residents battle the effects of arid conditions, Dr. Le’s innovative approach has transformed both her patients’ eye health and her own professional passion. Dr. Le’s journey offers valuable insights for eye care professionals looking to differentiate their practices and deliver transformative patient results. Her success with Lumenis technologies, including OptiLIGHT and OptiPLUS, showcases how practices can put themselves on the cutting edge, delivering medical relief and aesthetic benefits that change patients’ lives. FAST FACTS: LE EYE SPA PRACTICE ORIGIN: Cold start with zero inherited patient base founded in Spring 2024 PRACTICE TYPE: 100% cash-only boutique practice in Las Vegas TECHNOLOGY: Lumenis OptiLIGHT IPL & OptiPLUS RF treatments PATIENT EXPERIENCE: 1-2 hour appointments with spa-like amenities TREATMENT PACKAGES: $400 per IPL session, $300 per RF session (with package savings) SPECIALIZATION: Focused exclusively on dry eye, routine ocular wellness, and aesthetic treatments DISCOVERING PURPOSE AFTER NEARLY RETIRING Dr. Le’s path to creating her specialty practice wasn’t straightforward. After 13 years in traditional optometry, she felt that primary eye care no longer excited her professionally. That evolved into a vision for a different kind of eye care experience—one that she herself would want as a patient. “I wanted to create a practice that I would want to go to,” she states, highlighting the patient-centered philosophy that drives her decisions. “I thought I was retiring when I left my last position. And then I got bored. I wanted to come back, but I wanted to do something that I really like—more of a personal project.” THE BOUTIQUE PRACTICE MODEL: CASH-ONLY, SPECIALTY-FOCUSED Le Eye Spa operates on a cash-only model, completely free from insurance constraints. This allows Dr. Le to focus entirely on delivering premium care without being limited by insurance requirements or affected by changes in reimbursement rates. “It’s a cash-only practice where insurance doesn’t influence or dictate treatment choices. It’s a boutique concierge practice,” she explains. This approach has liberated her to create a practice dedicated exclusively to specialty treatments, leaving behind comprehensive exams, contact lens fittings, and glasses dispensing. Her service menu is intentionally focused: lid and lash cleanings or microblepharoexfoliation, OptiLIGHT with IPL, OptiPLUS with RF, low-level light therapy, and a few select additional treatments. This specialization allows her to position herself as an expert in ocular surface disease and aesthetics rather than a generalist. TECHNOLOGY SELECTION: CHOOSING LUMENIS FOR MEDICAL CREDIBILITY When researching treatment technologies, Dr. Le was methodical in her approach. While exploring devices at various price points, she prioritized technology with proper medical credentials and eye care industry support. “I did a lot of research. I wanted that support. And what triggered the decision was that Lumenis had FDA approval for the treatment and management of dry eye due to MGD.” For Dr. Le, Lumenis’ commitment to the eye care space was crucial. “I wanted technology that has proven medical benefits and is eye care forward—not just ‘here’s an aesthetic product that might have some eye health benefits.'” CREATING A PREMIUM PATIENT EXPERIENCE What truly differentiates Le Eye Spa from other practices is the extraordinary attention to patient comfort and experience. Dr. Le has transformed medical treatments into spa-like experiences, allocating 1-2 hours per patient appointment. “We pull out the red carpet for the patients,” she says. “It feels very much like a spa. Smells good. It looks nice. It feels nice, with pillows, blankets, lotions, and more.” This approach contrasted with the efficiency-minded models she observed when conducting competitive research. “I saw that in many practices, it was very medical. The approach was ‘Sit there, close your eyes, and then I’ll see you in two weeks.’ I had the opportunity to do something so different.” BUILDING A REFERRAL NETWORK Dr. Le has implemented creative strategies to build referral relationships with other providers: “When I opened the practice, I had a house party where I invited other doctors, makeup artists, and lash specialists that I thought would be good referral sources.” These networking efforts have yielded significant results, with ophthalmologists and optometrists regularly referring patients to Dr. Le’s practice. Her elite diagnostic technology has become a major referral driver for complex cases requiring specialized testing. Other professionals recognize her advanced equipment produces reliable outcomes their patients need. She also proactively visits practices that don’t have similar technology: “I do marketing at doctors’ offices, ophthalmologists, optometrists, concierge doctors, as well as lash technicians.” EVIDENCE-BASED TREATMENT APPROACH Dr. Le builds patient confidence through comprehensive diagnostics and visual evidence. “First I have to make sure I can show patients something to support their diagnosis, so I always do imaging on every single patient. I show them pictures of their glands. I show them their tear break up time.” This evidence-based approach continues throughout the treatment journey, with consistent metrics tracked at patient visits: “We do tear break up time, tear meniscus height, grading of injection, SPEED score for every patient.” By documenting these metrics, she can demonstrate objective improvement, which is particularly valuable for skeptical patients who have tried multiple treatments without success. BALANCING MEDICAL BENEFITS WITH AESTHETIC OUTCOMES One of Dr. Le’s most effective strategies is presenting the dual benefits of treatments—both medical necessity and aesthetic improvement. This approach resonates with patients who might initially seek help for signs of dry eye but are delighted by the visible improvements in their appearance. “I think that’s the beauty of these treatments—you get both. Patients justify the value, they think, ‘OK, great, I get an aesthetic benefit, but it’s also medical.'” When discussing OptiPLUS RF treatments, she frames the conversation around both aspects: “It’s nice to have tight skin. Proactively tightening skin translates to delaying drooping eyelid skin or dermatochalasis, ectropion, and a number of other medical conditions.” PERSONAL TREATMENT DELIVERY AS A DIFFERENTIATOR Unlike many practices that delegate treatments to technicians, Dr. Le performs all procedures herself. While this limits the number of patients she can see, it has become a significant practice differentiator. “Patients will say, ‘I came here instead of going to another office because you’re doing it yourself,'” she explains. “‘They tell me, I prefer to have the doctor do the treatments instead of a tech.'” This personal touch reinforces the boutique nature of her practice and allows her to maintain direct relationships with every patient throughout their treatment journey. TRANSFORMING LIVES ONE PATIENT AT A TIME Perhaps no patient better illustrates the story of Dr. Le’s practice than a war veteran who had exhausted traditional treatment options. “He had plugs, he tried drops—prescription and nonprescription. He had a history of corneal hypoesthesia, neurotrophic keratitis… and he was defeated.” The patient, referred to Dr. Le by an ophthalmologist, arrived skeptical. “He was just very untrusting. Didn’t want to really be here, to be honest,” she recalls. After beginning treatment with OptiLIGHT IPL, the patient didn’t see immediate improvement. “By the 4th treatment, he said, ‘Oh my gosh, this is life-changing.'” His SPEED score, 24 at his original visit, was at 5 by his final visit. Beyond the medical effects, Dr. Le witnessed a profound transformation in the patient’s demeanor and confidence. “When we took his ‘After’ photo, he was a better-looking person–not just his skin, but his confidence. He held his head up high.” THE PROFESSIONAL REVIVAL THAT CHANGED EVERYTHING Perhaps most remarkably, this new practice has reignited Dr. Le’s passion for her profession. After nearly walking away from optometry, she now works more hours than ever—but with a renewed sense of purpose and satisfaction. “I work way more, but I enjoy it because I’m doing it my way. It took me 14 years in practice to figure out that I needed to do it my way to be truly happy.” Her commitment to success is unwavering: “Failure is just not something that I’m OK with. That’s not an option for me, so I just keep going, and if it doesn’t work, I do it a different way.” THE FUTURE OF EYE CARE Her advice to colleagues considering similar technologies is straightforward: “If you want to be able to offer something that’s groundbreaking in the eye care industry, something other than the eyedrops patients have tried already, this is a game changer.” For patients in Las Vegas seeking relief from dry eye redundant MGD while enjoying aesthetic improvements, Le Eye Spa has become the destination of choice–a testament to Dr. Le’s vision, determination, and commitment to exceptional care. To learn more about Le Eye Spa’s boutique approach to eye care, visit LeEyeSpa.com or follow Dr. Le on Instagram @leeyespa and @dr.tamile. For more information about Lumenis, OptiLIGHT, and OptiPLUS, visit Lumenis.com. Explore Other Resources Dry EyeNewsPeriorbital Muscle StimulationTreatment TypeVision Resource HubDry EyeNewsPeriorbital Muscle StimulationTreatment TypeVision Resource HubLumenis OptiLIFT Dynamic Muscle Stimulation Device receives Health Canada Approval for Reducing Signs and Symptoms of Evaporative Dry Eye DiseaseREAD MOREClinical StudiesDry EyePeriorbital Muscle StimulationTreatment TypeVision Resource HubClinical StudiesDry EyePeriorbital Muscle StimulationTreatment TypeVision Resource HubThe Potential Benefits of Periorbital Transcutaneous Electrical Stimulation for the Management of Dry Eye DiseaseREAD MOREDry EyePeriorbital Muscle StimulationPress PublicationsTreatment TypeVision Resource HubDry EyePeriorbital Muscle StimulationPress PublicationsTreatment TypeVision Resource HubSisters Grow Practice Into Medical Hub for Dry Eye TreatmentREAD MORE PB-00094640 #### Resource Hub WELCOME TO THE VISION RESOURCE HUB Dry EyeNewsPeriorbital Muscle StimulationTreatment TypeVision Resource HubDry EyeNewsPeriorbital Muscle StimulationTreatment TypeVision Resource HubLumenis OptiLIFT Dynamic Muscle Stimulation Device receives Health Canada Approval for Reducing Signs and Symptoms of Evaporative Dry Eye DiseaseREAD MOREClinical StudiesDry EyePeriorbital Muscle StimulationTreatment TypeVision Resource HubClinical StudiesDry EyePeriorbital Muscle StimulationTreatment TypeVision Resource HubThe Potential Benefits of Periorbital Transcutaneous Electrical Stimulation for the Management of Dry Eye DiseaseREAD MOREDry EyePeriorbital Muscle StimulationPress PublicationsTreatment TypeVision Resource HubDry EyePeriorbital Muscle StimulationPress PublicationsTreatment TypeVision Resource HubSisters Grow Practice Into Medical Hub for Dry Eye TreatmentREAD MOREBlog PostsGlaucomaTreatment TypeVision Resource HubBlog PostsGlaucomaTreatment TypeVision Resource HubDigital Duet 2.0 with Dr. JaiREAD MOREDry EyePeriorbital Muscle StimulationPress PublicationsVision Resource HubDry EyePeriorbital Muscle StimulationPress PublicationsVision Resource HubDoubling Down on Innovation: Why Dr. Nikki Iravani Invested in Two OptiLIFT SystemsREAD MOREBlog PostsDry EyeTreatment TypeVision Resource HubBlog PostsDry EyeTreatment TypeVision Resource HubRedefining Dry Eye Care: A Boutique Practice Case StudyREAD MOREBlog PostsDry EyePeriorbital Muscle StimulationBlog PostsDry EyePeriorbital Muscle StimulationTransform Dry Eye Management with the Lumenis PortfolioREAD MOREBlog PostsDry EyePeriorbital Muscle StimulationTopicBlog PostsDry EyePeriorbital Muscle StimulationTopicRetain More Patients in Your Practice with OptiLIFTREAD MOREDry EyePeriorbital Muscle StimulationPress PublicationsPress ReleasesTreatment TypeVision Resource HubDry EyePeriorbital Muscle StimulationPress PublicationsPress ReleasesTreatment TypeVision Resource HubBehind OptiLIFT’s Lid Laxity InnovationREAD MOREDry EyeNewsPeriorbital Muscle StimulationPress PublicationsTreatment TypeVision Resource HubDry EyeNewsPeriorbital Muscle StimulationPress PublicationsTreatment TypeVision Resource HubLumenis launches OptiLIFT for toning periorbital musclesREAD MOREDry EyePeriorbital Muscle StimulationPress PublicationsVision Resource HubDry EyePeriorbital Muscle StimulationPress PublicationsVision Resource HubOptiLIFT in Action: Dr. Julie McLaughlin’s Experience with the New DeviceREAD MOREClinical StudiesDry EyeTopicVision Resource HubClinical StudiesDry EyeTopicVision Resource HubDynamic Muscle Stimulation of the Periorbital Area for Improvement of Blinking in Dry Eye PatientsREAD MORE #### Response of tear cytokines following intense pulsed light combined with meibomian gland expression for treating meibomian gland dysfunction-related dry eye Response of tear cytokines following intense pulsed light combined with meibomian gland expression for treating meibomian gland dysfunction-related dry eye Researchers found that 20 tear cytokines decreased significantly after IPL treatment, illustrating how IPL suppresses DED’s vicious cycle of inflammation. READ FULL STUDY Indication for Use: In EU: Evaporative Dry Eye Disease (DED), also known as dry eye syndrome or lipid tear deficiency, due to Meibomian Gland Dysfunction (MGD). This indication is intended for Fitzpatrick skin types I-V. In US: Improvement of signs of Dry Eye Disease (DED) due to Meibomian Gland Dysfunction (MGD), also known as evaporative dry eye or lipid deficiency dry eye, in patients 22 years of age and older with moderate to severe signs and symptoms of DED due to MGD and with Fitzpatrick skin types I-IV. IPL is to be applied only to skin on the malar region of the face, from tragus to tragus including the nose (eyes should be fully covered by protective eyewear). IPL is intended to be applied as an adjunct to other modalities, such as meibomian gland expression, artificial tear lubricants and warm compresses. The indications are only relevant where they were approved by the Regulatory Authorities. Treatment with OptiLight is contraindicated for patients with the following conditions in the treatment area: Ocular surgery or eyelid surgery or Neuro-paralysis within 6 months prior to the first treatment; Uncontrolled eye disorders affecting the ocular surface; Pre-cancerous lesions, skin cancer or pigmented lesions; Uncontrolled infections or uncontrolled immunosuppressive diseases; Recent Ocular infections; History of cold sores or rashes in the perioral area, including: Herpes simplex 1 & 2, Systemic Lupus erythematosus and porphyria; Use of photosensitive medication and/or herbs that may cause sensitivity within 3 months prior to the first IPL session; Recent radiation therapy to the head or neck or planned radiation therapy; Recent treatment with chemotherapeutic agent or planned chemotherapy; History of migraines, seizures or epilepsy. Patients eyes must be completely occluded during the treatment. Please refer to the operator manual for a complete list of intended use, contraindications and risks. The following possible side effects can occur following IPL treatments: Pain/discomfort, damage to natural skin texture, change of pigmentation, scarring, excessive edema, fragile skin, bruising, burns, pruritus and xerosis. Please refer to the user manual or ask your doctor for a complete list of intended use, contraindications and risks. Explore Other Resources Dry EyeNewsPeriorbital Muscle StimulationTreatment TypeVision Resource HubDry EyeNewsPeriorbital Muscle StimulationTreatment TypeVision Resource HubLumenis OptiLIFT Dynamic Muscle Stimulation Device receives Health Canada Approval for Reducing Signs and Symptoms of Evaporative Dry Eye DiseaseREAD MOREClinical StudiesDry EyePeriorbital Muscle StimulationTreatment TypeVision Resource HubClinical StudiesDry EyePeriorbital Muscle StimulationTreatment TypeVision Resource HubThe Potential Benefits of Periorbital Transcutaneous Electrical Stimulation for the Management of Dry Eye DiseaseREAD MOREDry EyePeriorbital Muscle StimulationPress PublicationsTreatment TypeVision Resource HubDry EyePeriorbital Muscle StimulationPress PublicationsTreatment TypeVision Resource HubSisters Grow Practice Into Medical Hub for Dry Eye TreatmentREAD MORE PB-00043680, Rev A #### Retain More Patients in Your Practice with OptiLIFT Blog PostsDry EyePeriorbital Muscle Stimulation Retain More Patients in Your Practice with OptiLIFT July 7, 2025 Julie McLaughlin, OD ABO Diplomate Ocular Surface Disease (Dry Eye Syndrome) Dr. Julie McLaughlin graduated from the University of Virginia with a Bachelor of Arts degree in Sports Medicine and earned her Doctor of Optometry degree from Pennsylvania College of Optometry (now Salus University). She completed a hospital-based residency at the Baltimore VA Medical Center/Johns Hopkins University and has been a diplomate of the American Board of Optometry since 2013. Dr. McLaughlin, a Key Opinion Leader for Lumenis, specializes in ocular surface diseases and dry eye syndrome. #### Retina Retina Laser Surgery Photocoagulators are especially well suited for delicate retinal work. In the case of a retinal tear or hole, the scar tissue helps hold the retina in place. Photocoagulation can seal up leaking vessels, as in the case of proliferative diabetic retinopathy, or destroy diseased retinal tissue. Photocoagulation can also be used for choroidal neovascularization. Retinal Care Portfolio Smart532™ Green Photocoagulator with SmartPulse™ Sub-Threshold Technology Array™ LaserLink™ Pattern Scanning Laser Technology Smart Selecta Trio SLT + YAG + Smart532™ Your Smart Comprehensive Solution Vision One Multi-Wavelength Photocoagulator Green 532nm, Yellow 577nm and Red 659nm Novus Spectra Green Dual-Port Photocoagulator for the OR and Clinic LIOs Advanced Laser Indirect Ophthalmoscopes LumeProbe™ Endo-Photocoagulation Laser Probes Retinal Indications Overview Photocoagulators cauterize blood vessels with heat generated by the laser beam. The laser creates tiny, controlled burns that create adhesive forming scar tissue. The Lumenis line of photocoagulators and delivery devices are designed to give ophthalmologists the breadth and depth they need to treat several types of conditions including: Proliferative diabetic retinopathy Retinopathy of prematurity Retinal tears and detachments Branch retinal vein occlusion Choroidal neovascularization Meeting the Challenge of Retinal Surgery Lumenis’ line of gold-standard photocoagulators is created for the delicate demands of sophisticated retinal surgery. While diseases of the retina are plentiful, the retina generally responds well to laser treatment. As clinical capabilities within ophthalmology increase, so do your options in selecting a laser. The Lumenis family of retinal lasers offer treatment versatility and optimize therapeutic effect, for today’s most challenging retinal procedures. Key Indications: Proliferative diabetic retinopathy Retinopathy of prematurity Retinal tear and detachment Retinal vein occlusion Age-related macular degeneration (AMD) Download Brochure PB-2006798 Rev A × GET MORE INFO #### Revolutionizing Dry Eye Treatment Press PublicationsDry Eye Revolutionizing Dry Eye Treatment September 10, 2024 Dr. Celesta Ferreira Licensed Therapeutic Optometrist and Dry Eye Specialist. She founded Cypress Optique in Cypress, Texas to fuse her passion for modern technology with handcrafted eyewear. Dr. Ferreira is a recognized Dry Eye Expert and mentors other physicians on treatment protocols and management of Dry Eye Disease. Website Dr. Celesta Ferreira shares how OptiLIGHT and OptiPLUS by Lumenis transformed her dry eye treatment approach, providing patients with lasting relief from meibomian gland dysfunction. This article highlights the advanced technologies behind the treatments, patient success stories, and the significant impact on her practice’s growth and patient care. Read Full Article *OptiLIGHT and OptiPLUS are intended to be used by licensed practitioners, according to local rules and regulations. Discover new possibilities Download OptiLIGHT and OptiPLUS info kit Explore Other Resources Dry EyeNewsPeriorbital Muscle StimulationTreatment TypeVision Resource HubDry EyeNewsPeriorbital Muscle StimulationTreatment TypeVision Resource HubLumenis OptiLIFT Dynamic Muscle Stimulation Device receives Health Canada Approval for Reducing Signs and Symptoms of Evaporative Dry Eye DiseaseREAD MOREClinical StudiesDry EyePeriorbital Muscle StimulationTreatment TypeVision Resource HubClinical StudiesDry EyePeriorbital Muscle StimulationTreatment TypeVision Resource HubThe Potential Benefits of Periorbital Transcutaneous Electrical Stimulation for the Management of Dry Eye DiseaseREAD MOREDry EyePeriorbital Muscle StimulationPress PublicationsTreatment TypeVision Resource HubDry EyePeriorbital Muscle StimulationPress PublicationsTreatment TypeVision Resource HubSisters Grow Practice Into Medical Hub for Dry Eye TreatmentREAD MORE PB-00076871, Rev A #### Significantly Improved Signs of Dry Eye Disease: Key Findings from FDA Study of Lumenis Light Therapy Significantly Improved Signs of Dry Eye Disease: Key Findings from FDA Study of Lumenis Light Therapy November 7, 2022 Steven J. Dell, MD Dr. Steven J. Dell is a board certified ophthalmologist in Austin and the Medical Director of Dell Laser Consultants. An award-winning eye surgeon, Dr. Dell has been a featured presenter at major ophthalmology conferences around the world, where he helps to train other eye surgeons in the latest techniques. As a cataract and refractive surgeon, I see how dry eye disease (DED) is intimately related to the quality of measurements we are able to obtain before surgery and thus the quality of surgical outcomes we can achieve. To ensure my measurements had the accuracy required for very precise outcomes (and happy patients), I began using Lumenis IPL with the patented OPT™ technology for patients with DED. Studies of this technology, which is used in OptiLight, have shown that treatment shrinks telangiectatic vessels, decreases pro-inflammatory markers and demodex population, and improves the accuracy of preoperative measurements.1 – 5 Can Light Therapy Really Treat Dry Eyes? I was pleased to lead the multi-site clinical study of Lumenis light-based treatment with OPT™ technology that resulted in FDA approval for management of dry eye.6 The study team and I had all seen in our own clinical experience that the treatment targets multiple key contributors to inflammation, the underlying cause of dry eye due to meibomian gland dysfunction (MGD), providing a real and effective solution for DED. Patients told us their symptoms improved significantly, even prior to completing the full course of treatments. Many of these patients had suffered from dry eye for years, and we were very pleased to see significant improvement in the clinical signs of DED as part of the study’s results. Light Therapy FDA Study Findings The randomized, controlled, double-blind, multi-center study included 82 patients with DED due to MGD. It showed that Lumenis light-based therapy resulted in significantly pronounced improvements in the treated study group, compared to the baseline. The full results of the study were recently published here, but I’ll share some of the key findings: The number of expressible glands increased almost 7-fold. Tear breakup time was 1.5 times longer. Meibum quality improved more than 3-fold. Patients felt significantly less pain during meibomian gland expression. No adverse events related to light treatment were observed throughout the study. How Does Lumenis Light Treatment Work? With dramatically more expressible glands, longer tear breakup time, and higher quality meibum, the essential pieces are in place for a healthier ocular surface. Based on the significance of the positive clinical outcomes proven in this milestone study, Lumenis light treatment with OPT™ technology for dry eye management earned a de-novo FDA approval – the strongest affirmation of safety and efficacy. The technology is incorporated into OptiLight, which we have been using for some time in our practice. DED improvement is a life-changing result on its own for patients suffering from this condition; in my practice, it also helps us to achieve our preoperative goal to optimize patients’ ocular health for keratometry and topography, resulting in accurate intraocular lens calculations that support precise surgical outcomes. Explore Other Resources Dry EyeNewsPeriorbital Muscle StimulationTreatment TypeVision Resource HubDry EyeNewsPeriorbital Muscle StimulationTreatment TypeVision Resource HubLumenis OptiLIFT Dynamic Muscle Stimulation Device receives Health Canada Approval for Reducing Signs and Symptoms of Evaporative Dry Eye DiseaseREAD MOREClinical StudiesDry EyePeriorbital Muscle StimulationTreatment TypeVision Resource HubClinical StudiesDry EyePeriorbital Muscle StimulationTreatment TypeVision Resource HubThe Potential Benefits of Periorbital Transcutaneous Electrical Stimulation for the Management of Dry Eye DiseaseREAD MOREDry EyePeriorbital Muscle StimulationPress PublicationsTreatment TypeVision Resource HubDry EyePeriorbital Muscle StimulationPress PublicationsTreatment TypeVision Resource HubSisters Grow Practice Into Medical Hub for Dry Eye TreatmentREAD MORE LEARN HOW YOU CAN ELEVATE YOUR PRACTICE DOWNLOAD OPTILIGHT INFO KIT Learn about the first and only IPL FDA approved for dry eye management 1. Kassir et al. (2011) J Cosmet Laser Ther 13(5):216-22. 2. Papageorgiou et al. (2008) Br J Dermatol 159(3):628-32. 3. Liu et al. (2017) Am J Ophthalmol 183:81-90. 4. Yin et al. (2018) Curr Eye Res 43(3):308-13. 5. Prieto et al. (2002) Lasers Surg Med 30(2):82-5. 6. Toyos R, Desai NR, Toyos M, Dell SJ (2022) Intense pulsed light improves signs and symptoms of dry eye disease due to meibomian gland dysfunction: A randomized controlled study. PLoS ONE 17(6): e0270268. PB-00043680, Rev A PB-00054400, Rev A #### Sisters Grow Practice Into Medical Hub for Dry Eye Treatment Press PublicationsDry EyePeriorbital Muscle Stimulation Sisters Grow Practice Into Medical Hub for Dry Eye Treatment May 14, 2026 Sairah Malik, OD, and Sana Malik, OD Sairah Malik, OD, and Sana Malik, OD, are co-owners of Pro-Optix Optometry & Dry Eye Center in Houston. Clinical Director Dr. Sairah Malik is a Texas-licensed optometrist and certified glaucoma specialist. She is board-certified in the treatment and management of ocular disease with a special interest in dry eye, LASIK, cataract co-management, and ocular surface disease. Dr. Sana Malik provides full-scope family eye care with a heavy focus on dry eye. She has additional training in pediatrics, contact lenses, specialty contact lenses, cataracts, glaucoma, and diabetes. Sister duo Sairah Malik, OD, and Sana Malik, OD, share in Women in Optometry how they transformed their practice into a dedicated dry eye center to meet a growing patient need. Their move to a larger space with additional exam lanes and a dedicated spa room supported the addition of technologies like OptiLIGHT and OptiLIFT—part of a broader strategy to address meibomian gland dysfunction, inflammation, and lower lid laxity and incomplete blinking to improve patient outcomes. Read Full Article DOWNLOAD INFO KIT Discover how OptiLIFT can transform your practice. Contact us for a free demo or to learn more! Close Explore Other Resources Dry EyeNewsPeriorbital Muscle StimulationTreatment TypeVision Resource HubDry EyeNewsPeriorbital Muscle StimulationTreatment TypeVision Resource HubLumenis OptiLIFT Dynamic Muscle Stimulation Device receives Health Canada Approval for Reducing Signs and Symptoms of Evaporative Dry Eye DiseaseREAD MOREClinical StudiesDry EyePeriorbital Muscle StimulationTreatment TypeVision Resource HubClinical StudiesDry EyePeriorbital Muscle StimulationTreatment TypeVision Resource HubThe Potential Benefits of Periorbital Transcutaneous Electrical Stimulation for the Management of Dry Eye DiseaseREAD MOREBlog PostsGlaucomaTreatment TypeVision Resource HubBlog PostsGlaucomaTreatment TypeVision Resource HubDigital Duet 2.0 with Dr. JaiREAD MORE PB-00096123 #### Slit Lamps Slit Lamps Lumenis 980 Parallel optics (Zeiss style) diagnostic slit lamp Compatible with Lumenis photocoagulators and pattern scanner: Smart532™, Novus Spectra, Vision One™ and Array™ LaserLink™ 5X magnification changer Table: wheelchair accessible with adjustable height and locking castor wheels Universal 100-240V input power Optional additions: Choice of automatic or fixed eye safety filters LaserLink Z: 50-1000 μm spot size, containing SureSpot™ optics and micromanipulator with finger rest Lumenis 1000 Parallel optics (Zeiss style) fully integrated diagnostic slit lamp 5X magnification changer Compatible with Lumenis photocoagulators: Smart532™, Novus Spectra and Vision One™ Table: wheelchair accessible with adjustable height and locking castor wheels Universal 100-240V input power Built-in micromanipulator Transferable (right or left) elbow rest Built-in three-wavelength automatic eye safety filter (532nm, 577nm, 659nm) LaserLink Z: 50-1000 μm spot size, containing SureSpot™ optics Lumenis 990 Convergent optics (Haag-Streit style) diagnostic slit lamp Available in 2X, 3X and 5X magnification changer Compatible with Lumenis portable SLT and photocoagulators: Selecta II, Smart532™, Novus Spectra and Vision One™ Tonometer mount included Table: wheelchair accessible with adjustable height and locking castor wheels Universal 100-240V input power Optional addition: LaserLink HS: 50-500 μm spot size, containing SureSpot™ optics and fixed eye safety filter SL 130 Original Zeiss, parallel optics, diagnostic slit lamp 5X magnification changer Compatible with Lumenis photocoagulators and pattern scanner: Smart532™, Novus Spectra, Vision One™ and Array™ LaserLink™ Table: wheelchair accessible with adjustable height and locking castor wheels Universal 100-240V input power Required additions: Choice of automatic or fixed eye safety filters LaserLink Z: 50-1000 μm spot size, containing SureSpot™ optics and micromanipulator with finger rest Laserlink Slit Lamp Adapters Laserlink Slit Lamp Adapters Your Favorite Slit Lamp into a Laser Delivery System SureSpot optics deliver a sharp-edged laser spot with even power distribution to the retina and low power density at the cornea High-visibility physician filters provide continuous visualization of the retina, enhanced treatment precision, and full protecti”Slit Lampson for the surgeon during photocoagulation LaserLink HS compatible with most slit lamps: Topcon SL-3E, Topcon SL-7E, Macro III, Mentor SH-12, Nikon NS-1, Nikon FS-3 and more LaserLink Z compatible with the following slit lamps: Zeiss 20 SL, Zeiss 30 SL M, Zeiss 125, Zeiss SL 130Covergent Optics Laser Link The Covergent Optics Laser Link Slit Lamp Adapter expands treatment options by converting an existing an slit lamp into a precise laser delivery system, for details on which slit lamps can be converted contact your local Lumenis representative. Its patented SureSpot Optical Beam design ensures uncompromised laser delivery, while-high visibility physician filters provide an enhanced view of the treatment site with full protection for the surgeon during photocoagulation. Clearview filters to eliminate color distortion of the treatment site while optimizing white light transmission, or “brightness,” of the physician’s view Fixed Eye Safety Filter included True 50 µm-500 µm micron telescope spot size with continuously variable spot-size adjustment for a wide variety of treatment parameters Dichroic mirror to improve access to the far periphery and coaxial visualization LaserLink that rotates out of the way for convenient diagnostic use of the slit lampLaser Link-Z The Laser Link Z Slit Lamp Adapter expands treatment options by converting an existing Zeiss style slit lamp into a precise laser delivery system. Its patented SureSpot Optical Beam design ensures uncompromised laser delivery, while-high visibility physician filters provide an enhanced view of the treatment site with full protection for the surgeon during photocoagulation. SureSpot optics to deliver a sharp, well-defined beam to the retina while assuring minimal power density to the cornea Clearview filters to eliminate color distortion of the treatment site while optimizing white light transmission, or “brightness,” of the physician’s view True 50 µm-1000 µm micron telescope spot size with continuously variable spot-size adjustment for a wide variety of treatment parameters Optional automatic or fixed eye safety filters Self-centering Micromanipulator Learn More SpecificationsBrochureSpecifications   Lumenis 980 Parallel Optics Lumenis 1000 Parallel Optics, Fully Integrated Lumenis 990 Convergent Optics SL 130 Zeiss Original Magnification 5X 5X 2X / 3X / 5X 5X Compatible Devices Smart532™ Novus Spectra Vision One™ Array™ LaserLink™ Smart532™ Novus Spectra Vision One™ Selecta II Smart532™ Novus Spectra Vision One™ Smart532™ Novus Spectra Vision One™ Array™ LaserLink™ LaserLink* LaserLink Z: 50-1000 μm spot size LaserLink Z: 50-1000 μm spot size LaserLink HS: 50-500 μm LaserLink Z: 50-1000 μm spot size Eye Safety Filter (ESF)** Choice of automatic or fixed Built-in automatic Fixed, part of the LaserLink Choice of automatic or fixed SureSpot™ Optics         Table Wheelchair accessible with adjustable height and locking castor wheels Input Power Universal 100-240V Micromanipulator Part of LaserLink Z Part of slit lamp None Part of LaserLink Z Brochure Lumenis Ophthalmology Devices Digital Duet The first and only all-in-one digital platform for Glaucoma and PCO therapies Digital Trio 3 in 1 digital platform for Glaucoma and Retina care OptiLIGHT A bright solution for dry eyes ArrayTM LaserLinkTM Pattern Scanning Laser Technology Vision One Modular Multi-Wave Photocoagulator Selecta Duet SLT Technology and a Yag Photodisruptor in One Platform Selecta Trio Retinal, Cataract and Glaucoma Therapy in One Platform Novus SpectraTM High-Powered Photocoagulator LumeProbeTM Endo-Photocoagulation Laser Probes PB-00033250 Rev A × GET MORE INFO #### SLT – Mechanism of Action SLT – Mechanism of Action Description: Brian Francis, MD – from the University of Southern California of Los Angeles and the Doheny Eye Institute was one of the early adopters of the  Selective Laser Trabeculoplasty (SLT) technology – a micro-incisional glaucoma surgical procedure. Publish Date: January 29, 2017 Speaker: Brian Francis, MD Ophthalmology Devices Learn more about our innovative Vision solutions Digital Duet The first and only all-in-one digital platform for Glaucoma and PCO therapies Digital Trio 3 in 1 digital platform for Glaucoma and Retina care OptiLight A bright solution for dry eyes ArrayTM LaserLinkTM Pattern Scanning Laser Technology Vision One Modular Multi-Wave Photocoagulator Selecta Duet SLT Technology and a Yag Photodisruptor in One Platform Selecta Trio Retinal, Cataract and Glaucoma Therapy in One Platform Novus SpectraTM High-Powered Photocoagulator LumeProbeTM Endo-Photocoagulation Laser Probes Explore Other Resources Dry EyeNewsPeriorbital Muscle StimulationTreatment TypeVision Resource HubDry EyeNewsPeriorbital Muscle StimulationTreatment TypeVision Resource HubLumenis OptiLIFT Dynamic Muscle Stimulation Device receives Health Canada Approval for Reducing Signs and Symptoms of Evaporative Dry Eye DiseaseREAD MOREClinical StudiesDry EyePeriorbital Muscle StimulationTreatment TypeVision Resource HubClinical StudiesDry EyePeriorbital Muscle StimulationTreatment TypeVision Resource HubThe Potential Benefits of Periorbital Transcutaneous Electrical Stimulation for the Management of Dry Eye DiseaseREAD MOREDry EyePeriorbital Muscle StimulationPress PublicationsTreatment TypeVision Resource HubDry EyePeriorbital Muscle StimulationPress PublicationsTreatment TypeVision Resource HubSisters Grow Practice Into Medical Hub for Dry Eye TreatmentREAD MORE PB-1005974 rev B #### SLT + YAG SLT + YAG Lasers For over 60 years Lumenis is known for developing the gold standards innovative devices that change glaucoma, posterior cataract and retina treatment paradigms. From the first SLT laser to the first argon laser photocoagulator to the revolutionary dual-path SLT+YAG laser. We have never stopped moving forward, with Digital Duet / Trio we are continuing a long tradition of offering superior products today and pioneering the next evolution of products for tomorrow. Explore the Lumenis portfolio and learn more. Lumenis Ophthalmology Equipment DIGITAL duet DIGITAL trio DISCOVER DIGITAL SELECTA DUET SELECTA TRIO™ DISCOVER SELECTA DIGITAL duet DIGITAL trio DISCOVER DIGITAL SELECTA DUET SELECTA TRIO™ DISCOVER SELECTA PB-00022540 Rev A #### SLT for Glaucoma SLT for Glaucoma Learn About The Options For Treating Glaucoma We invite you to learn about the eye disease and the importance of regular eye exams, proper diagnosis, and appropriate treatment options in managing glaucoma and preserving vision. SLT treatment advantages: There are a few key reasons why SLT may be deemed beneficial for you: Safe: SLT is not associated with systemic side effects or the compliance and cost issues of medications. Selective: SLT utilizes selective photothermolysis to target only specific cells, leaving the surrounding tissue intact. Smart: SLT stimulates the body’s natural mechanisms to enhance outflow of the fluid in your eye. Sensible: SLT therapy is reimbursed by Medicare and many other insurance providers, which minimizes your out-of-pocket expenses. SLT does not rely on medicines, instead, uses an advanced laser system to target only specific cells of the eye—those containing melanin, a natural pigment. This allows for only these cells to be affected, leaving surrounding tissue intact. As a result, your body’s own healing response helps lower the pressure in your eye. What is SLT ? SLT stands for Selective Laser Trabeculoplasty. This is a non-destructive laser procedure used for glaucoma treatments by reducing the pressure in the eye. How is SLT performed ? SLT is an outpatient procedure. You will sit in a conventional exam chair, where the doctor will use a slit lamp to examine your eye. The same slit lamp contains the SLT laser. During the procedure, the doctor will put anesthetic drops in your eye to numb it, and then place a lens on your eye for better viewing. The laser is applied to the edge of your pupil. The entire procedure only takes a few moments. There is no sensation associated with an SLT procedure. You will require follow up visits with your doctor to monitor the success of the SLT treatment. How often do I need to receive SLT for treating glaucoma ? One application typically lasts for many years. Depending on your individual circumstances and goals, another application may be needed at some point in the future. How does SLT works ? SLT works by using laser light to stimulate the body’s own healing response to lower your eye pressure. Using a special wavelength and energy, the laser affects only pigmented (melanin containing) cells of your eye. SLT improves the flow of fluid in the eye, which in turn lowers your eye pressure. Is SLT right for me ? Only your doctor knows what is best for your individual needs. SLT may be the right glaucoma treatment option for you, simply ask your doctor to find out more. Does SLT work for all types of glaucoma ? There are different types of glaucoma and glaucoma patients. While SLT works on most, it does not work for all. Your doctor will know the appropriate course of action. Will I still need to continue using my eye drops following the SLT treatment ? Maybe. Each individual is different. Although there is a chance you can eliminate or reduce medications, SLT cannot guarantee this. How long will I have to wait to experience the full treatment effect of the SLT laser ? Glaucoma patients can respond as soon as an hour after treatment, or as much as a few months later. Continued monitoring and follow up with determine the response of therapy. How long is the recovery ? The doctor may treat your eye with anti-inflammatory eye drops that will be continued for a few days after the procedure. Glaucoma patients have no limitations after the treatment and are able to drive home. Your doctor will schedule a follow up appointment to evaluate your results. What are the SLT laser side effects ? Though infrequent, possible SLT side effects may include inflammation, temporary increase in eye pressure, eye pain, or inflammation of the conjunctiva, the clear membrane that covers the white part of the eye. Consult your physician regarding contraindications and risks. PB-2006798 Rev A × GET MORE INFO #### SLT for Glaucoma with Dr. Nate Lighthizer SLT for Glaucoma with Dr. Nate Lighthizer In an interactive webinar, Dr. Nate Lighthizer discusses Lumenis SLT’s advantages for glaucoma patients and referral decisions for this trusted laser treatment. Nate Lighthizer, OD Explore Other Resources Dry EyeNewsPeriorbital Muscle StimulationTreatment TypeVision Resource HubDry EyeNewsPeriorbital Muscle StimulationTreatment TypeVision Resource HubLumenis OptiLIFT Dynamic Muscle Stimulation Device receives Health Canada Approval for Reducing Signs and Symptoms of Evaporative Dry Eye DiseaseREAD MOREClinical StudiesDry EyePeriorbital Muscle StimulationTreatment TypeVision Resource HubClinical StudiesDry EyePeriorbital Muscle StimulationTreatment TypeVision Resource HubThe Potential Benefits of Periorbital Transcutaneous Electrical Stimulation for the Management of Dry Eye DiseaseREAD MOREDry EyePeriorbital Muscle StimulationPress PublicationsTreatment TypeVision Resource HubDry EyePeriorbital Muscle StimulationPress PublicationsTreatment TypeVision Resource HubSisters Grow Practice Into Medical Hub for Dry Eye TreatmentREAD MORE PB-00038930 Rev A | PB-00022090 Rev A #### SLT Is my Patients “Insurance Policy” COVID-19 just Proved it SLT Is my Patients “Insurance Policy” COVID-19 just Proved it August 31, 2021 Quarantine and glaucoma do not go together well. To track glaucoma, we have to see patients every few months and measure their IOP. Visits are usually scheduled two or three times a year, but we might see someone with unstable glaucoma as frequently as every 2 weeks. But when the coronavirus hit New York City and someone in our office tested positive, we immediately shut down and saw no patients for a full month. I haven’t been able to see patients as I normally would, but I’m proud to say that by taking a proactive approach to treatment, I’ve given them an added level of safety during this time. By managing glaucoma with SLT, their IOP is controlled without visits and, in many cases, without medication. I certainly did not anticipate that a global pandemic would keep my glaucoma patients away. But on a large scale, it’s entirely predictable that unexpected events like illness, family emergencies or job loss will impair or stop a patient’s compliance with glaucoma management. For example, it’s common to see patients cruising along with well-controlled glaucoma until they break their hip. The rehab facility doesn’t have their glaucoma meds, their pressure gets out of control, and they go blind. With this in mind, rather than putting patients on medication and waiting for glaucoma to get worse before I step up treatment, my approach is very proactive and assertive from the start. To get pressure as low as we can, my first-line treatment is SLT (Lumenis Selecta Duet), plus medication if needed. I tell patients SLT is their “insurance policy” – if they forget to use their medication (and they will), SLT can prevent them from losing their vision. I see the benefits of this approach every day in my patients’ IOP control and quality of life, but when coronavirus sent us all into quarantine and glaucoma visits stopped, I knew this approach was also helping preserve vision for my patients isolating at home. We’d chosen to get ahead of the problem, so they could afford to sit it out for a while. Doctors who decided to sit out the first round of glaucoma treatment, opting for medication and a wait-and-see approach, were headed for difficulty as COVID-19 forced them to sit out the second round. Patients without laser may be at much higher risk during quarantine, just as they would be during any other life event that disrupts medication use and office visits. As restrictions have lifted allowing us to see glaucoma patients again, some patients without SLT have chosen not to come in, even after we explained the risk to their eyesight. Most of these folks are over 80 years old, and they all know people who’ve been diagnosed with COVID-19, so I cannot fault their caution. Nevertheless, a handful of patients who opted not to have SLT will be missing that added layer of security against blindness provided by the laser. As more patients return to the practice over the next year, we will renew our focus on treating them in a way that minimizes visits. Laser is a critical element of that plan. It’s a particularly ideal modality for this situation because appropriate candidates decide in the office, have in-office treatment, and don’t need to return until their regular glaucoma check-up months later. When they see us less often, they can safely stay at home, and we can more easily carry out the new protocols for patient distancing in the office. I’m very proud of reducing patients’ risk of vision loss during the coronavirus pandemic, and when the world eventually moves on, I hope more of us will realize that glaucoma patients always need an insurance policy for whatever life has in store. Explore Other Resources Dry EyeNewsPeriorbital Muscle StimulationTreatment TypeVision Resource HubDry EyeNewsPeriorbital Muscle StimulationTreatment TypeVision Resource HubLumenis OptiLIFT Dynamic Muscle Stimulation Device receives Health Canada Approval for Reducing Signs and Symptoms of Evaporative Dry Eye DiseaseREAD MOREClinical StudiesDry EyePeriorbital Muscle StimulationTreatment TypeVision Resource HubClinical StudiesDry EyePeriorbital Muscle StimulationTreatment TypeVision Resource HubThe Potential Benefits of Periorbital Transcutaneous Electrical Stimulation for the Management of Dry Eye DiseaseREAD MOREDry EyePeriorbital Muscle StimulationPress PublicationsTreatment TypeVision Resource HubDry EyePeriorbital Muscle StimulationPress PublicationsTreatment TypeVision Resource HubSisters Grow Practice Into Medical Hub for Dry Eye TreatmentREAD MORE PB-00018620 #### Smart Selecta Duet Smart Selecta Duet Advanced Platform™ YAG & SLT Combination Smart Selecta® Duet™ represents Lumenis’ most advanced anterior segment laser platform, combining the advantages of YAG photodisruption capabilities along with the innovative Selective Laser Trabeculoplasty (SLT) technology, both developed and brought to market by Lumenis. Now, it’s also available with SmartV, allowing on-axis and off-axis illumination of vitreous opacities. The system’s fully integrated design, enhanced optics and advanced laser cavity make the Duet one of the best performing laser products in its segment. The Duet is also upgradeable – allowing further extension of the system’s capabilities by adding photocoagulation technology at any point in time. Videos Features Brochure Product VideoSLT VideosProduct Video SLT Videos Smart Selecta Duet Features As the company’s flagship multi-modality product, the Selecta represents the next generation of ophthalmic lasers by capitalizing on numerous proprietary features: The Selecta automatically runs internal tests to ensure that every laser pulse meets your exact power requirements An advanced secondary control unit guarantees the power accuracy of each laser shot. A unique temperature-controlled KTP crystal ensures the continuous accuracy and stability of the 532 nm (green) laser beam. Advanced component selection, laser delivery technology and enhanced slit lamp optics provide you with consistently optimal performance from this robust laser platform. Proprietary Advanced Laser Design The Selecta automatically runs internal tests to ensure that every laser pulse meets your exact power requirements An advanced secondary control unit guarantees the power accuracy of each laser shot A unique temperature-controlled KTP crystal ensures the continuous accuracy and stability of the 532 nm (green) laser beam Advanced component selection, laser delivery technology and enhanced slit lamp optics provide you with consistently optimal performance from this robust laser platform Super Gaussian Beam Profile in YAG Mode The Selecta features a highly accurate Super Gaussian beam profile in order to achieve optical breakdown – or photo disruption – with the lowest possible energy levels. This feature enhances the Selecta’s safety profile and allows you to perform capsulotomies on all types of intraocular lenses (IOL) with significantly lower risk of lens pitting or potential adversary effects. With the Selecta, you can achieve more efficient tissue cutting at lower power and with fewer shots. Additional Features Storage Space –  The Selecta table is equipped with built-in compact storage space for lenses or other accessories. Ergonomic Joystick with EZGrip™ Coating – The ergonomically designed joystick includes a convenient integrated laser fire-switch. Advanced Adjustable Offset – The Selecta features 3 posterior defocus positions with an adjustable focal point of up to 350 posterior to the aiming beam. Magnification Changer – The Selecta full Slit Lamp function includes a 6-step magnification changer. Electronic Height Adjustment – The Selecta table height can be easily adjusted using its electronic up/down switch. BrochureSpecificationsBrochure Specifications   YAG Photodisruptor Mode SLT Mode Laser Source Q-Switched Nd:YAG Q-Switched, frequency doubled Nd:YAG Wavelength 1064 nm 532 nm Energy (power) 0.3 - 10 mJ per pulse 0.3 - 2.0 mJ per pulse, continuously variable in 0.1 mJ increments Pulse Duration 3 ns 3 ns Burst Mode 1, 2, or 3 pulses per burst (selectable) Single pulse Spot Size 8 μm 400 μm Cone Angle 16 degrees < 3 degrees Posterior Offset 0 - 350 μm (continuously variable) Not applicable Repetition rate 3 Hz (in single burst) 3 Hz Aiming Beam Red diode, continuously variable with adjustable intensity Red diode, continuously variable with adjustable intensity Cooling Air Cooled Air Cooled Electrical Requirements 100 -240 VAC, 50/60 Hz, 3.15 Amps 100 -240 VAC, 50/60 Hz, 3.15 Amps CDRH Classification FDA IIIb FDA IIIb Lumenis Ophthalmology Devices Digital Duet The first and only all-in-one digital platform for Glaucoma and PCO therapies Digital Trio 3 in 1 digital platform for Glaucoma and Retina care OptiLIGHT A bright solution for dry eyes ArrayTM LaserLinkTM Pattern Scanning Laser Technology Vision One Modular Multi-Wave Photocoagulator Selecta Duet SLT Technology and a Yag Photodisruptor in One Platform Selecta Trio Retinal, Cataract and Glaucoma Therapy in One Platform Novus SpectraTM High-Powered Photocoagulator LumeProbeTM Endo-Photocoagulation Laser Probes Related Links Lumenis SLT Caution: Federal (US) law restricts Lumenis devices to sale by or on the order of a licensed practitioner. PB-2006798 Rev A × GET MORE INFO #### Smart Selecta Trio Selective Laser Trabeculoplasty (SLT) for Glaucoma treatment Laser Procedures for Glaucoma Maximum flexibility; minimum footprint The Lumenis Selecta® Trio™ represents the next generation of multi-modality products, offering retinal, cataract and advanced glaucoma therapies in a single platform. The unit’s integrated design, enhanced optics system and advanced laser cavity make the Trio one of the highest performing laser products in the market – maximum flexibility with minimum footprint. Features Specifications Videos Product Benefits The Selecta Trio has all of the advantages of the Selecta Duet in SLT and YAG modes – along with proprietary advantages in photocoagulation mode Homogeneous Laser Beam Our advanced optics and laser delivery technology features uniform energy distribution across the entire laser spot area for more precise and safer photocoagulation treatment. The result is a homogenous laser spot with evenly distributed power across the full area of the spot, eliminating the potential risk for the formation of “hot spots”. Dual Fiber Port – Instantly switch between delivery devices Changing delivery devices is fast and easy. The Novus Spectra automatically senses the delivery devices connected to it. Laser parameters are adjusted internally to compensate for the chosen delivery device to maintain selected power density on the target tissue. ClearView™ Filters – Optimized view of treatment site The Lumenis ClearView™ filters’ photopic balanced coating eliminates color distortion of the treatment site while optimizing white light transmission or “brightnes optimizing light transmission. The Selecta Duet and or Trio have a built in Physician Eye Safety Filter, that protect the user from both the YAG and Photocoagulation laser wavelengths. AcuGuide™ Micromanipulator Accurate and safe laser beam guidance for fine-tuned laser application on target tissue. Integrated LaserLink Cradle Safely and conveniently stow the laser adapter when not performing photocoagulation. Additional Features Storage Space The Selecta table is equipped with built-in compact storage space for lenses or other accessories. Ergonomic Joystick with EZGrip™ Coating The ergonomically designed joystick includes a convenient integrated laser fire-switch. Advanced Adjustable Offset The Selecta features 3 posterior defocus positions with an adjustable focal point of up to 350 posterior to the aiming beam. Magnification Changer The Selecta full Slit Lamp function includes a 6-step magnification changer. Electronic Height Adjustment The Selecta table height can be easily adjusted using its electronic up/down switch. SpecificationsBrochureFirst Class QualitySpecifications   YAG Photodisruptor Mode SLT Mode Photocoagulator Mode Laser Source Q-Switched Nd:YAG Q-Switched Frequency Doubled Nd:YAG Diode-Pumped Solid State (DPSS) Wavelength 1064nm 532nm 532nm Energy (power) 0.3mJ - 10mJ per pulse 0.3 - 2.0mJ per pulse, continuously variable in 0.1 increments 50 - 2500mW Pulse Duration 3ns (nanoseconds) 3ns (nanoseconds) 0.01 - 3 seconds Burst Mode 1, 2 or 3 pulses per burst (selectable) Single Pulse Not Applicable Spot Size 8 microns 400 microns 50 - 1000 on Z-Link; 5-500 on Convrg-Link Cone Angle 16 degrees < 3 degrees Not Applicable Posterior Offset 0 - 350 microns (continuously variable) Not Applicable Not Applicable Repetition rate 3Hz (in single burst) 3Hz Not Applicable Pulse Rate Not Applicable Not Applicable 0.05 - 1 second & Single Pulse Aiming Beam Red Diode, continuously variable adjustable intensity Red Diode, continuously variable adjustable intensity Red Diode, continuously variable adjustable intensity Cooling Air Cooled Air Cooled Air Cooled, enhanced with TEC Electrical Requirements 100 -240 VAC, 50/60 Hz, 3.15 Amps 100 -240 VAC, 50/60 Hz, 3.15 Amps 100 -240 VAC, 50/60 Hz, 3.15 Amps CDRH Classification FDA IIIb FDA IIIb FDA IIIb Brochure First Class Quality Lumenis First Class Quality Our passion for opthalmic lasers date back more than 40 years! At Lumenis, we truly understand multi-wavelength photo-coagulation-technology; that is after all only one of the privileges reserved for the foremost pioneer in this field. It is also precisely the reason why the decisive majority of general ophthalmologists and retina specialists around the globe have actively chosen to purchase Lumenis multi-color lasers – making Lumenis the global market leader and the company with the largest installed-base of multi-color ophthalmic laser products worldwide. Learn About SLT [ytp_video source=”aR2ehSEnBi4,_7bYDOeiOFs”] Lumenis Ophthalmology Devices Digital Duet The first and only all-in-one digital platform for Glaucoma and PCO therapies Digital Trio 3 in 1 digital platform for Glaucoma and Retina care OptiLIGHT A bright solution for dry eyes ArrayTM LaserLinkTM Pattern Scanning Laser Technology Vision One Modular Multi-Wave Photocoagulator Selecta Duet SLT Technology and a Yag Photodisruptor in One Platform Selecta Trio Retinal, Cataract and Glaucoma Therapy in One Platform Novus SpectraTM High-Powered Photocoagulator LumeProbeTM Endo-Photocoagulation Laser Probes Related Links Photocoagulators Caution: Federal (US) law restricts Lumenis devices to sale by or on the order of a licensed practitioner. PB-2006798 Rev A × GET MORE INFO #### Smart532 Smart532 Laser Photocoagulator 532 nm Photocoagulation Laser with SmartPluse Technology Smart 532™ is the newest photocoagulator by Lumenis, enhanced with the advanced SmartPulse™ technology. Continuous wave and SmartPulse™ sub-threshold technology Superior laser stability due to advanced laser cavity technology 100% Lumenis Technology Exclusive and intuitive user interface Compact and lightweight Dual port designed to best fit the clinic 25 programmable user pre-sets SureSpot™ optics technology ensures sharply defined power on the retina with safe and low density power on the cornea Voice confirmation mode enables the physician to keep eyes on the patient while changing settings during treatment What is SmartPulse™ Technology? SmartPulse™ is a tissue-spearing solution for the treatment of retinal diseases, that allows sub-threshold retinal treatment. Lumenis SmartPulse™ is integrated in the Smart 532™ (532nm green laser) system, to offer maximal efficacy with minimal collateral damage. SmartPulse™ Mode Celebrating 50 years of innovation with the launch of the new retinal care photocoagulator 1970: Lumenis (previously Coherent) introduced the first argon laser photocoagulator in ophthalmology. 2016: Lumenis proudly launches the new retinal care portfolio, starring Smart 532™, the new green photocoagulator with SmartPulse™. Product VideoProduct BrochurePortfolio BrochureProduct Video Product Brochure Portfolio Brochure Risks and warnings: Smart532 is contraindicated when corneal opacities, cataract formation, and vitreous hemorrhage interfere with the physician’s view of the retina. Inadvertent photocoagulation with Smart532, especially close to the fovea or the optic nerve head, can cause permanent visual loss. Major retinal vessels should be avoided. For a complete list of contraindications and risks, refer to the operator manuals. PB-00026290 Rev B × GET MORE INFO #### Stop the Drops: How SLT and IPL Improve Ocular Health and Quality of Life Stop the Drops: How SLT and IPL Improve Ocular Health and Quality of Life September 24, 2020 Glaucoma and ocular surface disease (OSD) are both chronic, progressive conditions that require long-term management, but that doesn’t mean everyone must be burdened with using topical medications for life. When I see patients who rely on medications to alleviate their symptoms, I often recommend interventional treatments that address the root cause of the problem and allow patients to reduce and potentially eliminate the use of eye drops. Selective trabeculoplasty (SLT) with Selecta Duet and intense pulsed light (IPL) treatments with Optima IPL are two effective minimally invasive procedures performed in the office setting that improve my patients’ ocular health and vision, and ultimately improve their quality of life. SLT Minimizes Glaucoma Drops According to the World Health Organization, glaucoma is the leading cause of irreversible blindness worldwide. Medications can control intraocular pressure and prevent vision loss, but as a glaucoma specialist for over 20 years, I can tell you that compliance with medication is a huge problem. When people are diagnosed with glaucoma, their entire quality of life changes dramatically. Patient schedules now revolve around putting in their eye drops at a certain time each day, every day, for life. It’s easy to understand why many of them forget or skip their eye drops and risk losing their vision. Glaucoma drops also can be very difficult to take because they have a toxic effect on the ocular surface. Preservatives such as BAK are known to be a big part of the problem, but the drugs themselves are quite inflammatory as well. Yet patients need to keep using their drops, adding to that inflammation, discomfort, and redness, or risk losing their vision. It’s a bleak process. To help get patients off topical glaucoma medications, I often recommend SLT with Selecta Duet as a first-line therapy. This highly effective in-office procedure allows most patients to reach their target pressure and maintain it more consistently than they did with eye drop medications. Without drops, the ocular surface becomes healthy again, improving vision while eliminating the redness, irritation, burning and foreign body sensation. Patients are so much happier. They feel and see better, they are not chained to that bottle of eye drops every day, and they can feel confident that their glaucoma is controlled, so they are not losing their vision. Optima IPL Controls Inflammation* Many glaucoma patients have concurrent ocular surface disease and must rely on eye drops not only to control their glaucoma, but also to keep their dry eye symptoms at bay. I’ve found Optima IPL treatment to be an outstanding way to treat peri-ocular inflammation, which in turn alleviates symptoms of ocular surface disease*. Patients have less need for topical anti-inflammatory drugs (cyclosporine, lifitegrast, steroids) and artificial tears. For the many patients who have acne rosacea and telangectasias on the lid margin, Optima IPL greatly reduces the skin manifestations of ocular rosacea and often significantly enhances patient quality of vision. Patients love it. It is one of the most effective and powerful procedures that we use to treat peri-ocular inflammation. Optima IPL has been a huge win for our patients, who just love this procedure and happily return for maintenance treatments over time. It has become an integral part of our overall treatment strategy to reduce topical medications and enhance quality of life as much as possible for all of our patients. * Lumenis M22 Optima IPL is authorized for use to treat Meibomian Gland Dysfunction, the leading type of dry eye disease, in: the European Union (CE), China, Australia, New Zealand, South Korea, Brazil, and Hong Kong. In the US, the device is cleared for treatment of inflammatory skin conditions such as rosacea. Rosacea may lead to ocular surface conditions such as MGD, with 80% of rosacea patients suffering from MGD. Treatment of rosacea with the M22 has not been clinically proven to prevent or delay the development of MGD. Explore Other Resources Dry EyeNewsPeriorbital Muscle StimulationTreatment TypeVision Resource HubDry EyeNewsPeriorbital Muscle StimulationTreatment TypeVision Resource HubLumenis OptiLIFT Dynamic Muscle Stimulation Device receives Health Canada Approval for Reducing Signs and Symptoms of Evaporative Dry Eye DiseaseREAD MOREClinical StudiesDry EyePeriorbital Muscle StimulationTreatment TypeVision Resource HubClinical StudiesDry EyePeriorbital Muscle StimulationTreatment TypeVision Resource HubThe Potential Benefits of Periorbital Transcutaneous Electrical Stimulation for the Management of Dry Eye DiseaseREAD MOREDry EyePeriorbital Muscle StimulationPress PublicationsTreatment TypeVision Resource HubDry EyePeriorbital Muscle StimulationPress PublicationsTreatment TypeVision Resource HubSisters Grow Practice Into Medical Hub for Dry Eye TreatmentREAD MORE PB-00021940 Rev A #### Surgical Probes LumeProbe™ Endo-Photocoagulation Laser Probes At Lumenis, we truly understand retinal photocoagulation technology; that is after all only one of the privileges reserved for the company that pioneered the first argon laser photocoagulator for ophthalmology. Our newest line of premium ophthalmic endo-photocoagulation laser probes was designed with the retina specialist in mind. Advanced manufacturing practices, unique fiber polishing techniques and uncompromising quality assurance methodologies deliver product performance & reliability second to none. Furthermore, elements of ergonomics incorporated into the design of the LumeProbe hand-piece provide you with proprietary advantages of comfortable grip and easier guidance towards the treatment site throughout the laser procedure. LumeProbe Benefits & Features Concentric Laser Burns Advanced optics and laser delivery technology, coupled with sophisticated fiber polishing techniques, deliver concentric laser burns and uniform energy distribution across the entire laser spot area, for more precise and safer treatment. The result is a homogenous laser spot with evenly distributed power across the entire spot, eliminating the potential risk for the formation Optimized Energy Transmission Each LumeProbe was designed to be connected directly to a compatible laser port. In light of that, the LumeProbes do not require special adapters when being used with any SMA 905- or 906 connector-based devices, thereby eliminating laser transmission inefficiencies. Connecting the LumeProbe directly into the laser port without the need for an adapter ensures enhanced laser transmission efficiency of more than 8% compared to using a laser probe which requires an adapter. Effect of Connecting Adapter on Transmmission Efficiency Enhanced Safety The ability to connect the LumeProbe directly into the laser console also delivers two key safety elements during each and every procedure: Laser parameters and power calibration remain valid throughout the procedure. Optimized energy transmission ensures the integrity of the probe’s protective polymer coating along with the adhesive bonding between the laser optical fiber and the hand-piece. Reliability & Predictability Advanced laser probes manufacturing techniques and sophisticated quality-assurance methodologies which are based on over 25 years of experience provide you with product reliability and predictability you can count on from case to case. The LumeProbe product family was designed to deliver the results you come to rely on and expect from a premium product in order to achieve optimal clinical outcomes time and again. Meeting your needs The LumeProbe product family consists of comprehensive and wide selection of ophthalmic endophotocoagulation probes to meet every clinical need and indication. These include standard, straight, curved, aspirating, illuminating and stepped in 20, 23 and 25 gauge sizes, among others. Type Features and Benefits Straight (laser probe)    Basic endophotocoagulator for non-peripheral retinal locations    Most efficient delivery of thermal energy    Ease of entry through small gauge cannulas Curved & Stepped (versatile)    Tapered curved for ease of entry through small gauge cannulas    Unique curve for efficient spot placement at far peripheral locations    Versatile for central or peripheral use Illuminated (enhanced visualization and multifunctional)    Provides direct illumination for improved visualization of retinal tears in the far periphery    Allows direct visualization from a single probe during scleral depression Aspirating (multifunctional)    A dual-purpose instrument provides the surgeon with higher efficiency during the procedure    Aspiration capabilities allow the surgeon to manage retinal fluids more efficiently    Both passive or active aspiration capabilities provide the surgeon with more options 23 & 25 gauge Advantage The LumeProbe 23 and 25 gauge selection provides you with the benefits of a less invasive procedure without compromising on the rigidity and stability of the probe during the operation. Based on over 25 years of laser probes manufacturing expertise, the LumeProbe product family was designed to deliver laser energy in the safest and most efficient manner, guaranteeing optimal clinical outcome for all relevant viteroretinal indications. LumeProbe Brochure Lumenis Ophthalmology Devices Digital Duet The first and only all-in-one digital platform for Glaucoma and PCO therapies Digital Trio 3 in 1 digital platform for Glaucoma and Retina care OptiLIGHT A bright solution for dry eyes ArrayTM LaserLinkTM Pattern Scanning Laser Technology Vision One Modular Multi-Wave Photocoagulator Selecta Duet SLT Technology and a Yag Photodisruptor in One Platform Selecta Trio Retinal, Cataract and Glaucoma Therapy in One Platform Novus SpectraTM High-Powered Photocoagulator LumeProbeTM Endo-Photocoagulation Laser Probes Related Links Photocoagulators Retina Caution: Federal (US) law restricts Lumenis devices to sale by or on the order of a licensed practitioner. PB-2006798 Rev A × GET MORE INFO #### Taking Big Leap Forward: The First Six Months with a New Digital Duet Taking Big Leap Forward: The First Six Months with a New Digital Duet November 1, 2021 The decision to purchase the new Digital Duet SLT-YAG system was an easy one. Our practice got our last SLT-YAG laser from Lumenis back in 2003, and it was an excellent instrument that proved very reliable—in 18 years, we only had one service call for a chin rest. When we decided we wanted a new laser, we went straight to Lumenis. Our rep, who had stayed in touch about other Lumenis technologies, told us they were about to release the first digital SLT-YAG laser, which also featured a built-in camera. Lumenis launched the Digital Duet a week later, and we ordered it right away. Now that we’ve been using the Digital Duet for six months, here’s what stands out. Clarity – Since getting the Digital Duet, I’ve done about 60 cases—primarily YAG laser capsulotomy, iridotomy and SLT. The Digital Duet has exceptionally crisp slit lamp optics. I can see the angle, trabecular meshwork and scleral spur very clearly, and it stays in focus, so I don’t have to continuously adjust. Treating the trabecular meshwork is much easier and more efficient. An SLT procedure is only as good as the view of the angle, for which we rely not only on the excellent optics of the Digital Duet but also on using a good gonio laser lens. The Hwang-Latina 5 Bar SLT Gonio Laser lens (Ocular Instruments) included in the Digital Duet purchase is a great lens. Reimbursable imaging – As a bonus, the Digital Duet has created an additional revenue stream for our practice. With the digital camera, we capture external photography of pathology, a billable service. We not only capture images that we used to take with a regular camera, such as eyelid pathologies, but we also get images of corneal pathology using the slit lamp, with the same clear, detailed view we get during SLT. There’s no adaptor or additional expense like most slit lamp cameras—it’s built into the Digital Duet. To date, I’ve done about 30 photos or videos of ocular pathologies for documentation or for follow up: corneal changes from amiodarone, pterygia, band keratopathy, entropion, ectropion, iris heterochromia and corneal lacerations, to name a few. Documentation – The device also automatically records everything I do, including the laser power I select and the number of shots I take, removing a lot of documentation work and saving valuable time and costs. And digital imaging and video capabilities also allow us to document pathologies as well as angle imagery and treatment outcomes. Digital Duet, We print images for our records as well as to share them with referring doctors. If we begin using electronic medical records, Digital Duet data and images will be saved to the system and be shared with referring doctors electronically. Patient and staff education – The images and video are great for educating patients as well as staff. We show patients their pathology, such as an image of the open angle, as well as their treatment, such as video of an SLT procedure. The images and video make education very clear, and patients like it, so it helps us build our relationships and establish the trust we need to move forward with treatment decisions and ensure compliance. Staff better understand pathologies and treatments, which enriches their conversations with patients. A Sound Investment To me, the Digital Duet’s key advantage is the quality of the instrument. We’re getting robust clinical results and excellent imaging, and we expect the device to last for years, just as our old Lumenis SLT-YAG laser did. With its predicted longevity, as well as the increased procedure efficiency and the new revenue stream from imaging, we expect a good return on our investment. And we got the Digital Duet at the perfect time, when SLT volume is on the rise because it is now an accepted first-line therapy.1 I think the Digital Duet will allow us to do a better job with our laser than ever before, and the efficiency now allows me to schedule more patients in my normal clinic hours. 1 Gazzard G, Konstantakopoulou E, Garway-Heath D, et. al. Selective laser trabeculoplasty versus eye drops for first-line treatment of ocular hypertension and glaucoma (LiGHT): a multicentre randomised controlled trial. Lancet. 2019;393 (10180):1505-1516. Risk and warnings: Digital Duet/Trio are intended for use by trained physicians. For all indications, use is contraindicated when media opacities interfere with clear visualization. Selective laser Trabeculoplasty is contraindicated for eyes with neovascular or angle-closure glaucoma; risks include iritis and transient IOP rise. Posterior Capsulotomy is contraindicated for eyes with extensive corneal dystrophy and chronically elevated IOP; risks include IOP rise, rupture of the hyaloid face, retinal damage, and uveitis. Iridotomy is contraindicated for eyes without pupillary block; risks include transient elevation of IOP, hyphemia, and damage to the lens/retina/choroid. Inadvertent photocoagulation with Smart532, especially close to the fovea or the optic nerve head, can cause permanent visual loss. Major retinal vessels should be avoided. For a complete list of contraindications and risks, refer to the operator manuals. Explore Other Resources Dry EyeNewsPeriorbital Muscle StimulationTreatment TypeVision Resource HubDry EyeNewsPeriorbital Muscle StimulationTreatment TypeVision Resource HubLumenis OptiLIFT Dynamic Muscle Stimulation Device receives Health Canada Approval for Reducing Signs and Symptoms of Evaporative Dry Eye DiseaseREAD MOREClinical StudiesDry EyePeriorbital Muscle StimulationTreatment TypeVision Resource HubClinical StudiesDry EyePeriorbital Muscle StimulationTreatment TypeVision Resource HubThe Potential Benefits of Periorbital Transcutaneous Electrical Stimulation for the Management of Dry Eye DiseaseREAD MOREDry EyePeriorbital Muscle StimulationPress PublicationsTreatment TypeVision Resource HubDry EyePeriorbital Muscle StimulationPress PublicationsTreatment TypeVision Resource HubSisters Grow Practice Into Medical Hub for Dry Eye TreatmentREAD MORE PB-00039380 Rev A #### Teaching Peers About Dry Eye Disease Boosts Patients’ Access to Care Press PublicationsDry Eye Teaching Peers About Dry Eye Disease Boosts Patients’ Access to Care May 7, 2024 Pamela E. Theriot, OD, FAAO Dry Eye Relief Center at Lusk Eye Specialists in Shreveport, Louisiana Dr. Pamela E. Theriot is a Clinical Director of the Dry Eye Relief Center at Lusk Eye Specialists in Shreveport, Louisiana. Peer-to-peer education and advanced technology like OptiLIGHT for dry eyes and OptiPLUS complementary treatment are key to clinical success, as Pamela Theriot, OD explains in this article. Read Full Article *OptiLIGHT and OptiPLUS are intended to be used by licensed practitioners, according to local rules and regulations. Discover new possibilities Download OptiLIGHT and OptiPLUS info kit Explore Other Resources Dry EyeNewsPeriorbital Muscle StimulationTreatment TypeVision Resource HubDry EyeNewsPeriorbital Muscle StimulationTreatment TypeVision Resource HubLumenis OptiLIFT Dynamic Muscle Stimulation Device receives Health Canada Approval for Reducing Signs and Symptoms of Evaporative Dry Eye DiseaseREAD MOREClinical StudiesDry EyePeriorbital Muscle StimulationTreatment TypeVision Resource HubClinical StudiesDry EyePeriorbital Muscle StimulationTreatment TypeVision Resource HubThe Potential Benefits of Periorbital Transcutaneous Electrical Stimulation for the Management of Dry Eye DiseaseREAD MOREDry EyePeriorbital Muscle StimulationPress PublicationsTreatment TypeVision Resource HubDry EyePeriorbital Muscle StimulationPress PublicationsTreatment TypeVision Resource HubSisters Grow Practice Into Medical Hub for Dry Eye TreatmentREAD MORE PB-00076860, Rev A #### Telemedicine for Triage: Life-saving Now and Efficient in the Future Telemedicine for Triage: Life-saving Now and Efficient in the Future June 24, 2020 In optometry, where diagnosis often depends on getting a magnified view through the slit lamp with stains and dyes and using point-of-care tests, telemedicine has limited use in terms of billable visits. But the mechanisms of telemedicine have tremendous value as we continue serving our patients under coronavirus restrictions. In my practice, we are using a telemedicine approach to triage patients. Tele-triage is helping us limit nonessential visits while ensuring we do see the patients who need us right away, ensuring they can get the care they need without the risks associated with going to a hospital ER during this pandemic. It’s a process we can continue to use as we reopen. How Tele-Triage Works When patients call and a staff member determines they need to talk to a doctor, I call them back and get as much information as possible about their complaint. For example, it is most important to find out whether there has been a noticeable decline in vision. I have patients isolate one eye and then the other eye and ask if they can see clearly or if they notice a change. If a change has occurred, I want to know how long ago it started. I always want to see patients who have a persistent change in vision. For other patients who have visible problems such as redness or swelling, we jump to FaceTime so I can get a look. Even with FaceTime, the entire tele-triage process only takes about 5 to 10 minutes. We do not charge patients for these triage encounters, choosing instead to only bill for the occasional interaction where we can diagnose a problem and prescribe treatment without seeing the patient in person. Of course, if a visit is necessary, we utilize all screening measures, ensure social distancing from other patients, and have all parties wear masks. All surfaces within the exam room are wiped down with a strong disinfectant following each encounter. Immediate Visits and Other Options During coronavirus restrictions, we have asked a little more than 50% of the tele-triage patients to come into the practice. The most common reason has been decreasing vision accompanied by flashes and floaters, which we suspect may be retinal detachment. We’ve also seen patients for severe red eyes, combined with a history (one or both eyes, duration, pain, discharge, etc.) that does not allow us to rule out bacterial infection or herpes. When patients have called about red eyes, discomfort and transient vision fluctuation that seem to result from allergies or dry eye disease, we’ve explained that they do not need an office visit at this time. We’ve offered palliative measures and suggested over-the-counter drops, and then talked to the patient again in a few days. A full dry eye workup will be done later. Swelling and pain could go in a few directions. In most cases, for a bump on the eyelid, we’ve simply recommended application of warm compresses three or four times a day and checked back in a few days. If the swelling spreads, the patient could have preseptal cellulitis and require an antibiotic. If it is a chronic situation, I might bring in the patient and perform IPL (Optima IPL*, Lumenis). If a patient complained of eye swelling, scalp tenderness and jaw claudication, we would order a lab test for temporal arteritis and follow up with the test results to determine if the patient needs a referral to a vascular surgeon. As we gradually reopen, we will continue to use tele-triage in some capacity, but the percentage of patients we bring into the practice will increase because it will be safe to see them. For example, we will see a surge in cases of ocular irritation and dry eye, including visits for new patients deferred during 6 to 8 weeks of shutdown. For our existing dry eye patient base, we will resume postponed visits and in-office therapies like Optima IPL*, which our patients rely on for management of this chronic, progressive disease. Factoring in Compassion We know the relationship between isolation and mental health, and that has made compassion for our patients more important than ever. I recommend seeing patients who are in a distressed, anxious mental state. As we reopen, patients will no doubt feel comforted as normal access to their doctors is restored. *inflammatory skin conditions such as Rosacea, untreated, can lead to Meibomian Gland Dysfunction. As such, 80% of Rosacea patients are suffering from Meibomian Gland Dysfunction. Optima IPL is used to treat Rosacea, which allows to break the inflammatory process that may lead to Meibomian Gland Dysfunction. Explore Other Resources Dry EyeNewsPeriorbital Muscle StimulationTreatment TypeVision Resource HubDry EyeNewsPeriorbital Muscle StimulationTreatment TypeVision Resource HubLumenis OptiLIFT Dynamic Muscle Stimulation Device receives Health Canada Approval for Reducing Signs and Symptoms of Evaporative Dry Eye DiseaseREAD MOREClinical StudiesDry EyePeriorbital Muscle StimulationTreatment TypeVision Resource HubClinical StudiesDry EyePeriorbital Muscle StimulationTreatment TypeVision Resource HubThe Potential Benefits of Periorbital Transcutaneous Electrical Stimulation for the Management of Dry Eye DiseaseREAD MOREDry EyePeriorbital Muscle StimulationPress PublicationsTreatment TypeVision Resource HubDry EyePeriorbital Muscle StimulationPress PublicationsTreatment TypeVision Resource HubSisters Grow Practice Into Medical Hub for Dry Eye TreatmentREAD MORE PB-00016670 #### The 2024 IPL Report The 2024 IPL Report Discover why OptiLIGHT stands out in the latest 2024 IPL Report! See how over 500 optometrists are using IPL to treat dry eye disease, improve patient outcomes, and overcome treatment challenges. Uncover the benefits, ROI, and why OptiLIGHT is a top choice for Dry Dye Disease management due to MGD! Read Full Article Discover new possibilities Download OptiLIGHT and OptiPLUS info kit Explore Other Resources Dry EyeNewsPeriorbital Muscle StimulationTreatment TypeVision Resource HubDry EyeNewsPeriorbital Muscle StimulationTreatment TypeVision Resource HubLumenis OptiLIFT Dynamic Muscle Stimulation Device receives Health Canada Approval for Reducing Signs and Symptoms of Evaporative Dry Eye DiseaseREAD MOREClinical StudiesDry EyePeriorbital Muscle StimulationTreatment TypeVision Resource HubClinical StudiesDry EyePeriorbital Muscle StimulationTreatment TypeVision Resource HubThe Potential Benefits of Periorbital Transcutaneous Electrical Stimulation for the Management of Dry Eye DiseaseREAD MOREDry EyePeriorbital Muscle StimulationPress PublicationsTreatment TypeVision Resource HubDry EyePeriorbital Muscle StimulationPress PublicationsTreatment TypeVision Resource HubSisters Grow Practice Into Medical Hub for Dry Eye TreatmentREAD MORE PB-00076871, Rev B #### The Business of Dry Eye: 4 Steps to Boosting Practice Profitability with In-Office Treatments The Business of Dry Eye: 4 Steps to Boosting Practice Profitability with In-Office Treatments Dr. Michael Farbowitz explains how offering quintessential, in-office dry eye treatments such as OptiLight can increase your practice’s profitability. READ FULL ARTICLE Indication for Use: In EU: Evaporative Dry Eye Disease (DED), also known as dry eye syndrome or lipid tear deficiency, due to Meibomian Gland Dysfunction (MGD). This indication is intended for Fitzpatrick skin types I-V. In US: Improvement of signs of Dry Eye Disease (DED) due to Meibomian Gland Dysfunction (MGD), also known as evaporative dry eye or lipid deficiency dry eye, in patients 22 years of age and older with moderate to severe signs and symptoms of DED due to MGD and with Fitzpatrick skin types I-IV. IPL is to be applied only to skin on the malar region of the face, from tragus to tragus including the nose (eyes should be fully covered by protective eyewear). IPL is intended to be applied as an adjunct to other modalities, such as meibomian gland expression, artificial tear lubricants and warm compresses. The indications are only relevant where they were approved by the Regulatory Authorities. Treatment with OptiLight is contraindicated for patients with the following conditions in the treatment area: Ocular surgery or eyelid surgery or Neuro-paralysis within 6 months prior to the first treatment; Uncontrolled eye disorders affecting the ocular surface; Pre-cancerous lesions, skin cancer or pigmented lesions; Uncontrolled infections or uncontrolled immunosuppressive diseases; Recent Ocular infections; History of cold sores or rashes in the perioral area, including: Herpes simplex 1 & 2, Systemic Lupus erythematosus and porphyria; Use of photosensitive medication and/or herbs that may cause sensitivity within 3 months prior to the first IPL session; Recent radiation therapy to the head or neck or planned radiation therapy; Recent treatment with chemotherapeutic agent or planned chemotherapy; History of migraines, seizures or epilepsy. Patients eyes must be completely occluded during the treatment. Please refer to the operator manual for a complete list of intended use, contraindications and risks. The following possible side effects can occur following IPL treatments: Pain/discomfort, damage to natural skin texture, change of pigmentation, scarring, excessive edema, fragile skin, bruising, burns, pruritus and xerosis. Please refer to the user manual or ask your doctor for a complete list of intended use, contraindications and risks. Explore Other Resources Dry EyeNewsPeriorbital Muscle StimulationTreatment TypeVision Resource HubDry EyeNewsPeriorbital Muscle StimulationTreatment TypeVision Resource HubLumenis OptiLIFT Dynamic Muscle Stimulation Device receives Health Canada Approval for Reducing Signs and Symptoms of Evaporative Dry Eye DiseaseREAD MOREClinical StudiesDry EyePeriorbital Muscle StimulationTreatment TypeVision Resource HubClinical StudiesDry EyePeriorbital Muscle StimulationTreatment TypeVision Resource HubThe Potential Benefits of Periorbital Transcutaneous Electrical Stimulation for the Management of Dry Eye DiseaseREAD MOREDry EyePeriorbital Muscle StimulationPress PublicationsTreatment TypeVision Resource HubDry EyePeriorbital Muscle StimulationPress PublicationsTreatment TypeVision Resource HubSisters Grow Practice Into Medical Hub for Dry Eye TreatmentREAD MORE PB-00043680, Rev B #### The Potential Benefits of Periorbital Transcutaneous Electrical Stimulation for the Management of Dry Eye Disease Clinical StudiesDry EyePeriorbital Muscle Stimulation The Potential Benefits of Periorbital Transcutaneous Electrical Stimulation for the Management of Dry Eye Disease May 19, 2026 Kendall Donaldson, MD, is the Rodgers Clark Endowed Chair in Ophthalmology and Professor of Clinical Ophthalmology at Bascom Palmer Eye Institute, University of Miami Miller School of Medicine. She also serves as Medical Director of Bascom Palmer Eye Institute in Plantation. A cornea specialist, Dr. Donaldson’s research focuses on advancements in cataract surgery, including laser-assisted techniques, as well as severe ocular surface disease. She has over 20 years of experience in clinical and academic medicine. Kendall Donaldson, MD, reviews the role of transcutaneous electrical stimulation (TCES) in dry eye disease (DED), including Dynamic Muscle Stimulation technology (DMSt) as a targeted approach to improving eyelid function. The paper* highlights blinking and lid mechanics as critical but often overlooked drivers of ocular surface health and explores how DMSt applied in the periocular area may support blink quality, tear film stability, and meibomian gland function in DED patients. Read Full Article Explore Other Resources Dry EyeNewsPeriorbital Muscle StimulationTreatment TypeVision Resource HubDry EyeNewsPeriorbital Muscle StimulationTreatment TypeVision Resource HubLumenis OptiLIFT Dynamic Muscle Stimulation Device receives Health Canada Approval for Reducing Signs and Symptoms of Evaporative Dry Eye DiseaseREAD MOREDry EyePeriorbital Muscle StimulationPress PublicationsTreatment TypeVision Resource HubDry EyePeriorbital Muscle StimulationPress PublicationsTreatment TypeVision Resource HubSisters Grow Practice Into Medical Hub for Dry Eye TreatmentREAD MOREBlog PostsGlaucomaTreatment TypeVision Resource HubBlog PostsGlaucomaTreatment TypeVision Resource HubDigital Duet 2.0 with Dr. JaiREAD MORE *This publication describes some uses of medical products that are not approved in certain jurisdictions, including by the US FDA, and the safety and effectiveness of any unapproved use(s) have not been established. PB-00096122 #### The right fit: Pairing contact lenses and DED therapy deters dropout The right fit: Pairing contact lenses and DED therapy deters dropout November 13, 2023 Dr. Kristyna Lensky Sipes shares her strategies for keeping patients comfortable in their contact lenses by pairing them with the right DED therapy. READ FULL ARTICLE Explore Other Resources Dry EyeNewsPeriorbital Muscle StimulationTreatment TypeVision Resource HubDry EyeNewsPeriorbital Muscle StimulationTreatment TypeVision Resource HubLumenis OptiLIFT Dynamic Muscle Stimulation Device receives Health Canada Approval for Reducing Signs and Symptoms of Evaporative Dry Eye DiseaseREAD MOREClinical StudiesDry EyePeriorbital Muscle StimulationTreatment TypeVision Resource HubClinical StudiesDry EyePeriorbital Muscle StimulationTreatment TypeVision Resource HubThe Potential Benefits of Periorbital Transcutaneous Electrical Stimulation for the Management of Dry Eye DiseaseREAD MOREDry EyePeriorbital Muscle StimulationPress PublicationsTreatment TypeVision Resource HubDry EyePeriorbital Muscle StimulationPress PublicationsTreatment TypeVision Resource HubSisters Grow Practice Into Medical Hub for Dry Eye TreatmentREAD MORE LEARN HOW YOU CAN ELEVATE YOUR PRACTICE DOWNLOAD OPTILIGHT INFO KIT Learn about the first and only IPL FDA approved for dry eye management PB-00043680 Rev C #### The Ultimate Guide to OptiLight for Dry Eye The Ultimate Guide to OptiLight for Dry Eye Hear from two prominent dry eye specialists in the Ultimate Guide to OptiLight for Dry Eye and learn about how they incorporated OptiLight into their practice, access comprehensive information on the history of IPL technology, and gain clear understanding on the unique benefits of OptiLight. The guide includes clinical data on how OptiLight can improve meibomian gland dysfunction through several mechanisms of action, along with pre and post treatment care and quick tips for performing the procedure. This ultimate guide provides scripts for easy ways to talk to patients about OptiLight and valuable recommendations from experts who have leveraged OptiLight to provide a real solution to their patients and elevate their practice success. READ FULL STUDY Explore Other Resources Dry EyeNewsPeriorbital Muscle StimulationTreatment TypeVision Resource HubDry EyeNewsPeriorbital Muscle StimulationTreatment TypeVision Resource HubLumenis OptiLIFT Dynamic Muscle Stimulation Device receives Health Canada Approval for Reducing Signs and Symptoms of Evaporative Dry Eye DiseaseREAD MOREClinical StudiesDry EyePeriorbital Muscle StimulationTreatment TypeVision Resource HubClinical StudiesDry EyePeriorbital Muscle StimulationTreatment TypeVision Resource HubThe Potential Benefits of Periorbital Transcutaneous Electrical Stimulation for the Management of Dry Eye DiseaseREAD MOREDry EyePeriorbital Muscle StimulationPress PublicationsTreatment TypeVision Resource HubDry EyePeriorbital Muscle StimulationPress PublicationsTreatment TypeVision Resource HubSisters Grow Practice Into Medical Hub for Dry Eye TreatmentREAD MORE PB-00043680 Rev A #### The Unequivocal Benefits of Incorporating OptiLIGHT Into Your Dry Eye Practice Blog PostsDry Eye The Unequivocal Benefits of Incorporating OptiLIGHT Into Your Dry Eye Practice August 8, 2023 Kelsi Greider-Sideris, MD Dr. Kelsi Greider-Sideris is a comprehensive ophthalmologist at Greider Eye Associates, San Diego County, California I believe there really is no replacement for incorporating Lumenis’ OptiLIGHT light-based therapy into the management of patients with dry eye disease (DED). Many patients have a very large evaporative component to their DED. These patients have often struggled for years with artificial tears, punctal plugs, and prescription medications, which may help with addressing symptoms associated with tear deficiency but fall short in providing a solution for patients with meibomian gland dysfunction. These patients may find some relief with daily hot compresses and lid hygiene, but compliance might be an issue. Even with perfect compliance though, it rarely leads to a marked increase in tear film stability seen by improved tear breakup time (TBUT). Incorporating OptiLIGHT into my practice has made a real difference in patients with meibomian gland dysfunction (MGD) and evaporative dry eye. Lumenis light therapy is the first and only that is FDA-approved for DED, and that is a strong affirmation of safety and efficacy for doctors who are considering implementing OptiLIGHT in their practice as well. I have seen significant increases in the TBUT for each of the patients I’ve treated, going from a 0- to 1-second TBUT, to an average of 14 to 15 seconds in patients who have completed all four treatments. I have never seen patients improve this much with conventional treatment methods, and this demonstrates that we can address the evaporative component in a way we just couldn’t before. Addressing the Underlying Cause Is the Best Practice I find it essential to address the root cause of meibomian gland dysfunction in my evaporative dry eye patients with OptiLIGHT. In addition to OptiLIGHT, I strongly recommend a good lid hygiene regimen to reduce any overload of bacteria, and Demodex, which contribute to lid and ocular surface inflammation. Additionally, I have them do hot compresses, and use high-quality preservative-free artificial tears while awaiting their OptiLIGHT treatments to keep signs under control. Once a patient has completed four sessions of their OptiLIGHT treatments, daily hot compresses are not really necessary, but I do recommend that they continue lid hygiene and artificial tears to optimize their ocular surface health. OptiLIGHT Easily Integrates Into Your Practice Workflow OptiLIGHT is the first treatment modality we’ve worked with that enables us to address the underlying MGD inflammatory component of DED. Prior in-office therapies targeted to DED due to MGD could improve symptoms, but did not work towards offering a multi- factorial, effective solution to DED. These patients struggle with their dry eye condition for years and are often frustrated by conventional treatments that are burdensome time-wise and provide limited results. Being able to offer OptiLIGHT to these patients at my practice has been one of the most rewarding opportunities of my medical career. When I first started offering OptiLIGHT, I discussed it as an alternative to conventional treatment. After seeing such consistent positive results, my approach has shifted. If I determine that a new patient would benefit from OptiLIGHT, I go ahead and introduce the treatment at the first visit. Many patients will go forward with that treatment plan from the start, knowing that they’re going to get a real solution to their longtime condition. Demodex Count Can Be Reduced With OptiLIGHT Treatment Lately, everyone is talking about Demodex. Personally, I think that the impact of Demodex overgrowth on dry eye and blepharitis has been overlooked, and I am thrilled that dry eye specialists are focusing more on how to reduce Demodex counts. I have observed that patients with underlying MGD and DED are more likely to have signs of Demodex blepharitis on exam, similar to the known correlation of patients with rosacea and Demodex infestation1. It is unclear whether the underlying immune dysregulation in rosacea promotes the overgrowth of Demodex or if Demodex overgrowth causes the immune dysregulation itself. Either way, Demodex overgrowth contributes to the inflammatory cycle in rosacea and blepharitis patients. We know that the OptiLIGHT technology, can decrease the amount of Demodex present in oil glands of the face and eyelids, and is therefore a good approach for management of Demodex- associated blepharitis2. In addition to directly killing Demodex mites, I suspect OptiLIGHT can help prevent regrowth in the future by restoring healthy immune balance to the lids and periocular area. OptiLIGHT May Help to Positively Impact Overall Ocular Health Dry eye management can vary greatly in its impact on a patient’s ocular health. Some patients have a little bit of dry eye with an impact on ocular health that is minimally bothersome. They may have some blepharitis, or MGD, but they’re not too concerned by it. Then there are patients at the other extreme. In addition to having severe DED that might really impact quality of life, patients with severe meibomian gland dysfunction/blepharitis or ocular rosacea can end up with corneal scarring that threatens vision. So, on this end of the spectrum, DED can have a very large impact on a patient’s overall ocular health. We also have patients that come in and have “20/20 unhappy vision,” where they may be able to read the eye chart well but notice blurred vision in most settings due to tear film instability. If your tear film evaporates after 1 to 2 seconds you will never get crisp, quality images. One situation where I see this frequently is in patients who have had cataract surgery with multifocal lenses and coexistent dry eye and are unhappy with their visual outcome. Evaporative dry eye can impact their quality of vision significantly, and these patients may benefit from OptiLIGHT. I also like to discuss OptiLIGHT treatment with DED patients who are considering cataract surgery in the near future. It’s important to optimize the ocular surface prior to cataract surgery, to ensure accurate measurements for more successful outcomes, and to minimize the need to bring patients back to the office multiple times3. In younger patient populations, I notice many cases with evaporative dry eye and blurred vision from increased screen time. As many workers have switched to working remotely throughout the pandemic, this has increased the portion of the day they are in front of computers. These patients are excellent OptiLIGHT candidates. By improving a patient’s DED, it may positively affect their comfort and quality of vision while working from home. OptiLIGHT Enhances Practices At Any Experience Level I’ve only been out of training for three and a half years. I became very passionate about incorporating this procedure into my practice early on, because I had seen so many patients who suffered from meibomian gland dysfunction that could benefit from it. I personally suffered from ocular rosacea, and was antsy to receive the treatment myself! Even though I was very fresh in my career, I brought in OptiLIGHT because I could see it would help elevate patient care. And this really allowed me to establish an “in” for myself within the community. I’ve developed a strong patient following; a lot of new patients come in with referrals from friends and family. I really believe wherever you are in your career, whether early or later on, adding OptiLIGHT to your practice can really help you develop a stream of patients who suffer from DED and are looking for a real solution. Additional Revenue Stream As a mostly medical ophthalmologist, I don’t do cataract surgery. I do minor procedures and lid surgery, but do not spend much time in the operating room. Having OptiLIGHT in my practice serves as a replacement to that cash-pay premium lens revenue source. The same can be true for any ophthalmologists that don’t want to do cataract surgery, whether it’s someone later in their career so they’ve stopped operating and they want to have something to replace this part of the business, or someone earlier on like me that has chosen to spend more time in clinic than the OR. The cataract surgeons in my office always have me in mind if they have a patient with a troublesome ocular surface, either pre- or post-surgery, and will refer those patients to me to clean up the problem. OptiLIGHT has been a true revenue generator for me. Incorporating OptiLIGHT Allows Practices To Expand There are just so many patients with DED, and so many can be benefitted by this treatment modality. This segment of my practice has grown on word of mouth alone. So I’ve taken this passion project, from where I was expecting to have a few patients here and there to add into my schedule, to a point where I have a designated OptiLIGHT afternoon and two additional time slots throughout the week to try to accommodate patients. It’s a very satisfying addition to a practice. The requirements are pretty minimal in terms of space, staffing, and time. When you’re busy, you can bring the patients in and get them out quickly. You can do it out of one room in the clinic, and with minimal tech support required. I have one technician working with me who goes through paperwork, takes photographs, and measures the TBUT before I perform the treatment. The treatment itself takes around 15 minutes, even with cosmetic treatments included. Not only do OptiLIGHT days keep me busy and thus increase office cash flow, but also my patients are happy to be there, and excited for their treatments. Final Thoughts It’s very exciting being on the leading edge of using the OptiLIGHT system, as it becomes more of an emerging technology and more eyecare practitioners are using it. It’s very satisfying to have something to offer to patients, where they didn’t have that access before. It’s a very powerful treatment tool and I see its benefits for eye care in general. I was one of the first clinicians in San Diego to acquire OptiLIGHT some time ago, and as we were waiting to get started there was a waitlist of people who wanted to try it, and were very excited to have access to it. They knew a real solution was finally coming available and were anxious for it. And now patients are reading about this online and seeing video on social media, so they come to me directly asking for it! I’ve found it very satisfying to be involved with the progress and growth of this technology as it has emerged into wider use. Discover new possibilities Download OptiLIGHT and OptiPLUS info kit Explore Other Resources Dry EyeNewsPeriorbital Muscle StimulationTreatment TypeVision Resource HubDry EyeNewsPeriorbital Muscle StimulationTreatment TypeVision Resource HubLumenis OptiLIFT Dynamic Muscle Stimulation Device receives Health Canada Approval for Reducing Signs and Symptoms of Evaporative Dry Eye DiseaseREAD MOREClinical StudiesDry EyePeriorbital Muscle StimulationTreatment TypeVision Resource HubClinical StudiesDry EyePeriorbital Muscle StimulationTreatment TypeVision Resource HubThe Potential Benefits of Periorbital Transcutaneous Electrical Stimulation for the Management of Dry Eye DiseaseREAD MOREDry EyePeriorbital Muscle StimulationPress PublicationsTreatment TypeVision Resource HubDry EyePeriorbital Muscle StimulationPress PublicationsTreatment TypeVision Resource HubSisters Grow Practice Into Medical Hub for Dry Eye TreatmentREAD MORE References 1. Chang YS, Huang YC. Role of Demodex mite infestation in rosa- cea: A systematic review and meta-analysis. J Am Acad Dermatol. 2017 Sep;77(3):441-447.e6. doi: 10.1016/j.jaad.2017.03.040. Epub 2017 Jul 12. PMID: 28711190. https://pubmed.ncbi.nlm. nih.gov/28711190/ 2. Zhang X, Song N, Gong L. Therapeutic Effect of Intense Pulsed Light on Ocular Demodicosis. Curr Eye Res. 2019 Mar;44(3):250- 256. doi: 10.1080/02713683.2018.1536217. Epub 2018 Oct 25. PMID: 30321061. https://pubmed.ncbi.nlm.nih. gov/30321061/ 3. Nibandhe & Donthineni (2023) Seminars in Ophthalmology, 24-30 PB-00043680, Rev B PB-00072970 Rev B #### Thomas Nido’s OptiLIGHT Treatment Journey Unveiled! Thomas Nido’s OptiLIGHT Treatment Journey Unveiled! December 15, 2023 Share   Embark on a remarkable journey with Tomas as he shares his experience with OptiLIGHT treatment for his dry eyes. With each session lasting just 15 minutes with minimal downtime, OptiLIGHT by Lumenis has empowered Tomas to confront his dry eyes head-on. Watch more videos Colton Underwood shares his experience with DED and his care journey using OptiLIGHT and OptiLIFTMay 25, 2025WATCH NOWKerri Walsh Jennings Shares the Impact of OptiLIGHT Treatment on Her Dry Eye Disease!May 2, 2024WATCH NOWKerri Has Been Experiencing Dry, Itchy Eyes On And Off The Court For Years. Her Solution: OptiLIGHT!April 28, 2024WATCH NOW PB-00076100, Rev A #### Three Ways OptiLight Is Changing Dry Eye Management in Our Practice Three Ways OptiLight Is Changing Dry Eye Management in Our Practice November 30, 2022 Rachna Murthy, MD Dr. Rachna Murthy is a London & Cambridge-based Consultant Ophthalmologist, Aesthetic, Oculoplastic & Reconstructive Surgeon. Jonathan Roos, MD Prof. Jonathan Roos is a Cambridge, Harvard & Moorfields-educated consultant eyelid surgeon specialising in cosmetic eyelid surgery, periocular cancer, orbital pathology as well as non-surgical aesthetic facial rejuvenation. The ethos of our practice is to help people be the best version of themselves, by addressing pathology and rejuvenating and restoring appearance. One focus area and subject of our current research is ocular surface and dry eye disease, for which we now offer a whole new level of care with OptiLight, which forms a core part of our OptimEyes™ program. In London, where heredity makes many people likely to suffer with some degree of rosacea, blepharitis, and associated dry eye disease, we are ideally located to research the gold standards treating dry eye. Benefits of OptiLight for Dry Eye Treatment In our effort to provide quality, evidence-based care for our patients, we were motivated to get OptiLight because the technology is supported by over 40 clinical studies, differentiating it from other treatment options. Now, for the first time, we can manage dry eye disease effectively with OptiLight, not just by controlling symptoms, but by targeting the most common cause, meibomian gland dysfunction. OptiLight is already changing our practice in three important ways. Superior engineering translates to better treatment outcomes We see patients who have had six sessions of light-based therapy with other devices, and they weren’t impressed with the results. With Lumenis light therapy, the first to be FDA-approved for dry eye disease, there are major advances in engineering. OptiLight’s OPT™ Technology allows us to control the pulse shape, ensuring that we get the optimal energy, preset for safety and efficacy. Our patients get the results they want in four comfortable 10-15-minute sessions. From the doctor’s perspective, OptiLight’s touchscreen interface makes treatment simple. The gold-standard treatment for dry eye As we mentioned, our research is focused on defining the best treatments for dry eye disease. We’ve found that OptiLight is the emerging gold standard, capable of delivering life-changing results for our patients who suffer from moderate to severe dry eye disease. OptiLight gives us a treatment that is effective on multiple fronts—targeting inflammation, alleviating abnormal blood vessels, lessening the bacterial load, and reducing the demodex population.1-7 Patients have better meibomian gland structure and function, so oil production improves and the tear film stabilizes. In addition, we are currently studying the benefits of OptiLight to improve blepharitis before cataract surgery, optimizing the ocular surface with the added benefit of reducing bacteria. Because inflamed skin delays healing, we think future results in our study of pre- and postoperative analysis may show improved recovery after surgery for patients who have had OptiLight. Expanding beyond dry eye to aesthetics Patients appreciate the aesthetic effects of OptiLight for combined rosacea and dry eye disease, as well as how it delivers significant results from a quick, gentle treatment experience. Physicians who wish to provide more comprehensive patient care can upgrade their system and expand their scope of practice to include aesthetic treatments for skin pigmentation, sun spots, as well as skin resurfacing. Our patients expect to see aesthetic results without downtime or pain. With OptiLight, they can come in on their lunch break and return to work, and they see improvement after a few painless treatments. Proven Results After 9 months with OptiLight, we’re seeing exactly the transformative results that we anticipated for our patients. It is now a cornerstone of dry eye management in our practice, and we will continue to employ it in our research for ocular surface and lid margin disease. Explore Other Resources Dry EyeNewsPeriorbital Muscle StimulationTreatment TypeVision Resource HubDry EyeNewsPeriorbital Muscle StimulationTreatment TypeVision Resource HubLumenis OptiLIFT Dynamic Muscle Stimulation Device receives Health Canada Approval for Reducing Signs and Symptoms of Evaporative Dry Eye DiseaseREAD MOREClinical StudiesDry EyePeriorbital Muscle StimulationTreatment TypeVision Resource HubClinical StudiesDry EyePeriorbital Muscle StimulationTreatment TypeVision Resource HubThe Potential Benefits of Periorbital Transcutaneous Electrical Stimulation for the Management of Dry Eye DiseaseREAD MOREDry EyePeriorbital Muscle StimulationPress PublicationsTreatment TypeVision Resource HubDry EyePeriorbital Muscle StimulationPress PublicationsTreatment TypeVision Resource HubSisters Grow Practice Into Medical Hub for Dry Eye TreatmentREAD MORE Discover new possibilities Download OptiLIGHT and OptiPLUS info kit 1. Liu et al. (2017), Am J Ophthalmol 183-190; 2. Yin et al. (2018), Curr Eye Res 43(3):308-313; 3. Kassir et al. (2011), J Cosmet Laser Ther 13(5):216-322; 4. Papageorgiou et al. (2008), Br J Dermatol 159(3):628-632; 5. Prieto et al. (2002), Lasers Surg Med 30(2):82-85; 6. Dell et al. (2017) Clin Ophthalmol 11:817-827; 7. Toyos & Briscoe (2016), J Clin Exp Ophthamol 7:6. PB-00043680, Rev A PB-00054400, Rev A #### Toyos et al. (2022) Intense pulsed light improves signs and symptoms of dry eye disease due to meibomian gland dysfunction: A randomized controlled study Toyos et al. (2022) Intense pulsed light improves signs and symptoms of dry eye disease due to meibomian gland dysfunction: A randomized controlled study The US FDA approval for Lumenis IPL with OPT™ for management of DED was based on this recent clinical study. In this perspective, multi-center, double-blinded, randomized controlled study, Lumenis IPL with OPT™ combined with MGX significantly improved signs of DED due to MGD in patients with moderate to severe symptoms. READ FULL ARTICLE Indication for Use: Improvement of signs of Dry Eye Disease (DED) due to Meibomian Gland Dysfunction (MGD), also known as evaporative dry eye or lipid deficiency dry eye, in patients 22 years of age and older with moderate to severe signs and symptoms of DED due to MGD and with Fitzpatrick skin types I-IV. IPL is to be applied only to skin on the malar region of the face, from tragus to tragus including the nose (eyes should be fully covered by protective eyewear). IPL is intended to be applied as an adjunct to other modalities, such as meibomian gland expression, artificial tear lubricants and warm compresses Treatment with Lumenis IPL with OPT™ is contraindicated for patients with the following conditions in the treatment area: Ocular surgery or eyelid surgery or Neuro-paralysis within 6 months prior to the first treatment; Uncontrolled eye disorders affecting the ocular surface; Pre-cancerous lesions, skin cancer or pigmented lesions in the planned treatment area; Uncontrolled infections or uncontrolled immunosuppressive diseases; Recent Ocular infections; Prior history of cold sores or rashes in the perioral area, including: Herpes simplex 1 & 2, Systemic Lupus erythematosus and porphyria; Use of photosensitive medication and/or herbs that may cause sensitivity within 3 months prior to the first IPL session; Recent radiation therapy to the head or neck or planned radiation therapy; Recent treatment with chemotherapeutic agent or planned chemotherapy; History of migraines, seizures or epilepsy. Patients eyes must be completely occluded during the treatment. Please refer to the operator manual for a complete list of intended use, contraindications and risks. Please consult your physician as to whether this procedure is suitable for you. The following possible side effects can occur following IPL treatments: Pain/discomfort, damage to natural skin texture, change of pigmentation, scarring, excessive edema, fragile skin, bruising, burns, pruritus and xerosis. Please refer to the user manual or ask your doctor for a complete list of intended use, contraindications and risks Lumenis has an interest in the study device (Lumenis IPL with OPT™) All uses of the Lumenis IPL with OPT™ described in this paper were approved by the FDA, except the following: – The study concluded that both signs and symptoms of DED were improved by the use of IPL, whereas FDA cleared only improvement of signs. Dr. Toyos was a consultant of Lumenis Lumenis sponsored the study The publication doesn’t discuss any unapproved uses of the device. Explore Other Resources Dry EyeNewsPeriorbital Muscle StimulationTreatment TypeVision Resource HubDry EyeNewsPeriorbital Muscle StimulationTreatment TypeVision Resource HubLumenis OptiLIFT Dynamic Muscle Stimulation Device receives Health Canada Approval for Reducing Signs and Symptoms of Evaporative Dry Eye DiseaseREAD MOREClinical StudiesDry EyePeriorbital Muscle StimulationTreatment TypeVision Resource HubClinical StudiesDry EyePeriorbital Muscle StimulationTreatment TypeVision Resource HubThe Potential Benefits of Periorbital Transcutaneous Electrical Stimulation for the Management of Dry Eye DiseaseREAD MOREDry EyePeriorbital Muscle StimulationPress PublicationsTreatment TypeVision Resource HubDry EyePeriorbital Muscle StimulationPress PublicationsTreatment TypeVision Resource HubSisters Grow Practice Into Medical Hub for Dry Eye TreatmentREAD MORE PB-00043680 Rev A #### Transform Dry Eye Management with the Lumenis Portfolio Blog PostsDry EyePeriorbital Muscle Stimulation Transform Dry Eye Management with the Lumenis Portfolio September 4, 2025 Lori Duquette, OD Duquette Family Eye Care, North Smithfield, Rhode Island Dr. Lori Duquette is the clinical director and owner of Duquette Family Eye Care, serving the North Smithfield and Greater Providence, Rhode Island areas. She has been practicing optometry in Rhode Island for over 20 years. Dr. Duquette is a primary care optometrist with a special interest in caring for patients with diabetes, age-related eye disease, dry eyes, and pre- and post-cataract surgery, as well as managing various ocular pathologies. Dry eye shows up in my exam room daily, often in more than half the patients I see. Symptoms vary in severity, and because it’s a multifactorial disease—inflammation, clogged glands, droopy eyelids, and incomplete blinking can all play a role—there is no one-size-fits-all approach to addressing it. Effective management requires targeting the root causes, not just masking symptoms. I’ve had patients who were frustrated by the same cycle of treatments: drops, plugs, and hot compresses—often with minimal results. I’ve invested in advanced in-office technologies from Lumenis—OptiLIGHT, OptiPLUS, and OptiLIFT—that allow me to treat inflammation, restore meibomian gland function, and tighten and tone the lower eyelids when needed. It’s a comprehensive approach that’s helped improve comfort and outcomes for my patients. Why I Chose OptiLIGHT My introduction to Lumenis began with OptiLIGHT—initially for my own dry eye. As a woman going through perimenopause, I’ve experienced firsthand how erratic hormone fluctuations can significantly increase the risk of dry eye and meibomian gland dysfunction (MGD). Over the past several years, as my symptoms worsened, I turned to traditional, over-the-counter treatments, but the relief was minimal and frustratingly short-lived. I’ve always been committed to finding better solutions, both for myself and for my patients, to ease the ongoing burden of managing dry eye. That search led me to intense pulsed light (IPL) therapy. During my extensive research, I kept coming back to OptiLIGHT, the first and only FDA-approved IPL device for the management of dry eye disease (DED) due to meibomian gland dysfunction.1 It targets inflammation—one of the key underlying factors of MGD—and has been proven to improve tear breakup time, meibum quality, and meibomian gland expression.2,3 The combination of FDA approval, peer-reviewed studies, and positive feedback from other doctors gave me confidence in the decision to bring this technology into my practice. Since introducing OptiLIGHT, we’ve seen a reduction in dry eye symptoms for many patients. During exams, I explain that dry eye is an inflammatory condition, and that OptiLIGHT uses light-based therapy to address the underlying cause and help restore meibomian gland morphology and functionality2—not just relieve symptoms. Treatment typically includes four sessions, spaced about a month apart, with an occasional fifth treatment for more severe cases. While we usually fit dry eye patients into our daily schedule, I also reserve a half-day each week just for IPL treatments to ensure consistency and give patients the time they need. I also invested in the photofacial upgrade for OptiLIGHT and offer it as part of a package alongside the dry eye treatment. When we include the facial component, patients not only report relief from dry eye symptoms—they often notice a visible difference in skin appearance as well. Beyond the benefits I’ve seen in my patients, my own experience has reinforced how effective OptiLIGHT can be. After my first session, I felt immediate relief. I now receive maintenance treatments every six months to keep my dry eye symptoms in check. It has made a meaningful difference in my daily life, allowing me to work more efficiently and live more freely without the constant distraction of dry, irritated eyes. Patient Success with OptiLIGHT It’s powerful to see the real impact on patients. One woman came in saying, “I can’t live like this.” She was using drops six to eight times a day, which disrupted her daily life. After four OptiLIGHT sessions and gland expression, she felt dramatically better. She no longer had to think about her eyes constantly—and could finally live her life without discomfort. While OptiLIGHT’s primary purpose is treating dry eye disease, patients often experience broader aesthetic and dermatological benefits—helping expand what we can provide in practice. Another patient had noticeable facial pigmentation from sun exposure, especially on the left side of her face. Dermatology hadn’t helped, so during her consultation, I set realistic expectations and explained how IPL might lighten the pigmentation and improve comfort. By her third OptiLIGHT session, she was so pleased she said she no longer needed as much makeup, which boosted her confidence. We’ve also seen excellent results in patients with rosacea, many of whom had struggled for years with facial redness and the dry eye symptoms that often accompany it. Their success has sparked new word-of-mouth referrals. The results speak for themselves—patients we’ve treated with OptiLIGHT have experienced improvement in their symptoms. Enhancing Results with OptiPLUS I added OptiPLUS radiofrequency (RF) to my practice alongside OptiLIGHT, and it’s been a valuable addition—especially for patients with meibomian gland dysfunction. The dual-frequency RF heats the tissue, making gland expression more effective. Patients often report greater symptom relief when we combine the two technologies. In fact, pairing OptiPLUS dual-frequency RF with OptiLIGHT IPL has been shown to improve the number of expressible meibomian glands, meibum clarity, and symptoms.4 We typically follow a four-session treatment protocol, combining OptiPLUS with OptiLIGHT and adding meibomian gland expression (MGX) after the second or third visit. Each OptiPLUS session adds about six minutes per side and can be used on a wide range of skin types. An added benefit of RF is the stimulation of collagen production, which can enhance skin rejuvenation.5 While aesthetics isn’t the primary focus, many patients are pleasantly surprised by the aesthetic improvements. As we continue to grow awareness and introduce advanced treatments like OptiLIFT, I expect interest in those benefits to increase. Closing the Gap with OptiLIFT OptiLIFT is the latest addition to my practice. We introduced it this spring, first testing it with friends and family, and now offering it more broadly as interest grows. The early response has been exciting—several patients saw noticeable changes after just two or three sessions, even before completing the full series of four sessions. I chose to invest in OptiLIFT because many of my patients show signs of lower eyelid laxity, one of the first visible signs of aging. As we age, natural collagen loss, weakened muscle tone, and fluid retention can contribute to lower eyelid laxity, fine lines, and puffiness.6 This lower eyelid laxity also contributes to dry eye symptoms by impairing tear film distribution and blinking function.7 Historically, options to address lower lid laxity and impaired blinking have been limited. Surgical referrals often take a year or more, and many patients want to avoid invasive procedures. OptiLIFT helps close that gap by providing a noninvasive way to tighten and lift the periorbital muscles—restoring lower lid function and improving comfort.8 It utilizes Lumenis’ Dynamic Muscle Stimulation technology (DMSt) to activate facial muscles with electrical impulses, tightening and toning the periorbital muscle, resulting in improved function of the lower eyelid and blinking quality.8 Because OptiLIFT is still new, I often point out during exams when lower lid laxity is contributing to a patient’s symptoms. Many are relieved to learn there’s now a noninvasive option and are eager to try it. The radiofrequency component also gently heats the skin to stimulate collagen production. Together, RF and DMSt address lid tone, reduce puffiness, and smooth under-eye skin—leaving patients feeling more comfortable and confident. A Full Portfolio Approach Having access to the full Lumenis portfolio has transformed how I manage dry eye. It allows me to tailor treatment plans to each patient’s specific needs and opens the door to proactive conversations about in-office solutions, especially since patients often see results faster than with more traditional methods. As I’ve gained more experience with each device, I’ve begun combining them more intentionally—pairing OptiLIGHT with OptiPLUS for MGD, or integrating OptiLIFT when lower lid laxity is a factor or when patients want aesthetic benefits along with symptom relief. This ability to customize care has led to more effective outcomes and more satisfied patients. From a practice standpoint, it’s been a win-win. Patients feel better, outcomes are stronger, and we’ve seen steady growth in referrals and revenue. Investing in Care that Delivers For doctors still deciding whether to invest in in-office technologies like OptiLIGHT, OptiPLUS, or OptiLIFT, my advice is simple: do your research and do the math. Even if you’re seeing just a few dry eye patients a day, there’s real opportunity—not just to grow your practice, but to offer care that truly makes a difference. I chose Lumenis because I wanted confidence in what I was offering. The published clinical research, FDA approval, and versatility of the devices gave me that. These systems work, and they’ve helped elevate the standard of care I can provide every day.      * OPTILIGHT RISKS AND WARNINGS (NON-INCLUSIVE LIST):  Indication for Use: In EU: Evaporative Dry Eye Disease (DED), also known as dry eye syndrome or lipid tear deficiency, due to Meibomian Gland Dysfunction (MGD). This indication is intended for Fitzpatrick skin types I-V.  In US: Improvement of signs of Dry Eye Disease (DED) due to Meibomian Gland Dysfunction (MGD), also known as evaporative dry eye or lipid deficiency dry eye, in patients 22 years of age and older with moderate to severe signs and symptoms of DED due to MGD and with Fitzpatrick skin types I-IV. IPL is to be applied only to skin on the malar region of the face, from tragus to tragus including the nose (eyes should be fully covered by protective eyewear). IPL is intended to be applied as an adjunct to other modalities, such as meibomian gland expression, artificial tear lubricants and warm compresses. The indications are only relevant where they were approved by the Regulatory Authorities.  Treatment with OptiLIGHT is contraindicated for patients with the following conditions in the Treatment area: Ocular surgery or eyelid surgery or Neuro-paralysis within 6 months prior to the first treatment; Uncontrolled eye disorders affecting the ocular surface; Pre-cancerous lesions, skin cancer or pigmented lesions; Uncontrolled infections or uncontrolled immunosuppressive diseases; Recent Ocular infections; History of cold sores or rashes in the perioral area, including: Herpes simplex 1 & 2, Systemic Lupus erythematosus and porphyria; Use of photosensitive medication and/or herbs that may cause sensitivity within 3 months prior to the first IPL session; Recent radiation therapy to the head or neck or planned radiation therapy; Recent treatment with chemotherapeutic agent or planned chemotherapy; History of migraines, seizures or epilepsy. Patients eyes must be completely occluded during the treatment. Please refer to the operator manual for a complete list of intended use, contraindications and risks.  The following possible side effects can occur following IPL treatments: Pain/discomfort, damage to natural skin texture, change of pigmentation, scarring, excessive edema, fragile skin, bruising, burns, pruritus and xerosis.  Please refer to the user manual or ask your doctor for a complete list of intended use, contraindications and risks.  OPTIPLUS RISKS AND WARNINGS (NON-INCLUSIVE LIST):  Indication for Use: (US) OptiPLUS is intended to provide topical heating to treat selected medical conditions such as for temporary relief of pain or muscle spasms and to increase local circulation on body and face. The device is also intended to provide, with a massage device, a temporary reduction in the appearance of cellulite. (AU) OptiPLUS intended purpose is to develop localized heat to warm the subcutaneous tissue by means of radio frequency energy, delivered through electrodes in contact with the patient body and face. The biological effects of the OptiPLUS are linked to the increase of the local temperature of the tissues, in the different body areas. These effects bring to several clinical effects, the device indications for use are: treatment of edematous-fibrous-sclerous dermopanniculosis, treatment of skin atrophy and elastosis, treatment of microcirculation and venous insufficiency, treatment of hyperplasia and hypertrophy of adipocytes. (Canada) OptiPLUS intended purpose is to develop localized heat to warm the subcutaneous tissue by means of radio frequency energy, delivered through electrodes in contact with the patient body and face. The biological effects of the OptiPLUS are linked to the increase of the local temperature of the tissues, in the different body areas. These effects bring to several clinical effects, the device indications for use are: treatment of edematous-fibrous-sclerous dermopanniculosis, treatment of skin atrophy and elastosis, treatment of microcirculation and venous insufficiency, treatment of hyperplasia and hypertrophy of adipocytes, treatment of signs and symptoms of evaporative dry eye disease (DED), also known as dry eye syndrome or lipid tear deficiency, due to Meibomian Gland Dysfunction (MGD) – only when used in conjunction with Lumenis’ OptiLight (Licence No.: 109995) and meibomian gland expression (MGX).  Treatment with OptiPLUS is contraindicated for patients with the following conditions in the treatment area: OptiPLUS is unsuitable for anyone who is pregnant, has an infection or illness, or is heat sensitive. Treatment over cuts, wounds, piercings, and tattoos must be avoided and areas with injectable fillers and toxins left for a month before treatment. Patients with a metal implant or implanted device (e.g pacemaker) must consult with a qualified physician first. If deemed suitable, the return pad must be placed far away from the implant. Local, oral, or systemic anesthetics cannot be used before or during treatment as patients need to provide regular feedback to ensure their continued comfort. Insulate patients from metal objects, especially any in direct contact (e.g. the bed). A full practitioner consultation is always advisable.  The device is not intended to be used within the orbital rim or on the neck. The following possible side effects can occur following RF treatments: Moderate burning sensation, burns, erythema, edema, blistering, moderate pain, purpura in exposure area, mild swelling, ear feeling clogged and jaw tightness. Please refer to the operator manual for a complete list of intended use, contraindications, and risks.  OptiLIFT RISKS AND WARNINGS (NON-INCLUSIVE LIST):  Indication for use: The OptiLIFT System and its accessories are intended for dermatological procedures requiring ablation and resurfacing of the skin when using VoluDerm Energy (Microneedling Applicator). It is also intended for use in dermatologic and general surgical procedures for non-invasive treatment when using RF Energy and for muscle conditioning to stimulate healthy muscles (OptiLIFT Applicator). OptiLIFT System is not intended to be used in conjunction with therapy or treatment of medical diseases or medical conditions of any kind. OptiLIFT System is intended to be operated by a trained professional who is present to monitor treatment.  Warnings and risks: The OptiLIFT System is contraindicated for patients with pacemakers, defibrillators, any implanted electronic device, or metal implanted in the treatment area. Side effects may include any of the following: prolonged or significant pain, damage to natural skin texture (blister, burn), excessive skin redness (erythema), excessive swelling (edema), fragile skin bruising, excessive itching, change of pigmentation (hyper-pigmentation or hypopigmentation), scarring transient skin break-out such as acne and pimples. For a complete list of contraindications and risks, please refer to the User Manual. **The manufacturer Bios srl disclaims all liability, express or implied, and cannot be held responsible for direct or indirect personal injury and/or property damage, occurring as a result of incorrect procedures linked to the use of the OptiPLUS device combined with other devices that are not manufactured by Bios srl or out of the FDA/TGA approved scope. Any content of the document related to devices manufactured by third parties is not subjected to the review and the approval by Bios DOWNLOAD INFO KIT Discover how OptiLIFT can transform your practice. Contact us for a free demo or to learn more! Close Explore Other Resources Dry EyeNewsPeriorbital Muscle StimulationTreatment TypeVision Resource HubDry EyeNewsPeriorbital Muscle StimulationTreatment TypeVision Resource HubLumenis OptiLIFT Dynamic Muscle Stimulation Device receives Health Canada Approval for Reducing Signs and Symptoms of Evaporative Dry Eye DiseaseREAD MOREClinical StudiesDry EyePeriorbital Muscle StimulationTreatment TypeVision Resource HubClinical StudiesDry EyePeriorbital Muscle StimulationTreatment TypeVision Resource HubThe Potential Benefits of Periorbital Transcutaneous Electrical Stimulation for the Management of Dry Eye DiseaseREAD MOREDry EyePeriorbital Muscle StimulationPress PublicationsTreatment TypeVision Resource HubDry EyePeriorbital Muscle StimulationPress PublicationsTreatment TypeVision Resource HubSisters Grow Practice Into Medical Hub for Dry Eye TreatmentREAD MORE 1 Lumenis receives FDA approval for its IPL device to manage dry eye disease and launches OptiLight. (2021, April 29). Lumenis. Retrieved from https://lumenis.com/vision/resource-hub/lumenis-receives-fda-approval-for-its-ipl-device-to-manage-dry-eye-disease-and-launches-optilight/. 2 Yin et al. (2018) Curr Eye Res 43(3):308. 3 Dell et al. (2017) Clin Ophthalmol 11:817-827 4 Chelnis, James, Chantel N. Garcia, and Haya Hamza. “Multi-frequency RF combined with intense pulsed light improves signs and symptoms of dry eye disease due to Meibomian gland dysfunction.” Clinical Ophthalmology, vol. 17, 2023, pp. 3089–3102. https://doi.org/10.2147/OPTH.S426564. 5 Al-Atif, Hend. “Collagen supplements for aging and wrinkles: A paradigm shift in the fields of dermatology and cosmetics.” Dermatology Practical & Conceptual, vol. 12, no. 1, Jan. 1, 2022, e2022018. https://pmc.ncbi.nlm.nih.gov/articles/PMC8824545/. 6 Volpi E, Nazemi R, Fujita, S. Muscle tissue changes with aging. Current Opinion in Clinical Nutrition and Metabolic Care. 7(4):p 405-410, July 2004. 7 Chhadva, P, AL McClellan, CR Alabiad, WJ Feuer, H Batawi, and A Galor. 2016. Impact of eyelid laxity on symptoms and signs of dry eye disease. Cornea 531-535. 8 Chelnis, James G., and Alexandra Chelnis. “Dynamic Muscle Stimulation of the Periorbital Area for Improvement of Blinking in Dry Eye Patients.” Clinical Ophthalmology, vol. 2025, no. 19, Mar. 26, 2025, pp. 1057–1071. https://doi.org/10.2147/OPTH.S513989. PB-00094890 #### Treat The Root Cause of Dry Eye Disease with OptiLIGHT by Lumenis Treatment! Treat The Root Cause of Dry Eye Disease with OptiLIGHT by Lumenis Treatment! January 4, 2024 Share   It may be tempting to choose quick fixes rather than addressing the root cause. But when dealing with dry eyes, Candice King knows that temporary solutions just won’t suffice! That’s why she recommends OptiLIGHT by Lumenis—a light-based treatment that offers a real, effective solution. Watch more videos Colton Underwood shares his experience with DED and his care journey using OptiLIGHT and OptiLIFTMay 25, 2025WATCH NOWKerri Walsh Jennings Shares the Impact of OptiLIGHT Treatment on Her Dry Eye Disease!May 2, 2024WATCH NOWKerri Has Been Experiencing Dry, Itchy Eyes On And Off The Court For Years. Her Solution: OptiLIGHT!April 28, 2024WATCH NOW PB-00076100, Rev A #### VIDEO: Assign staff member to work with dry eye patients VIDEO: Assign staff member to work with dry eye patients Cases in Dr. Carly Rose’s dry eye clinic have “exploded” when adding OptiLight to her practice. Her secrets: Offer OptiLight early to get a head of inflammation and assign a staff member to be the dry eye “coach”. CONTINUE TO VIDEO Carly Rose, OD Explore Other Resources Dry EyeNewsPeriorbital Muscle StimulationTreatment TypeVision Resource HubDry EyeNewsPeriorbital Muscle StimulationTreatment TypeVision Resource HubLumenis OptiLIFT Dynamic Muscle Stimulation Device receives Health Canada Approval for Reducing Signs and Symptoms of Evaporative Dry Eye DiseaseREAD MOREClinical StudiesDry EyePeriorbital Muscle StimulationTreatment TypeVision Resource HubClinical StudiesDry EyePeriorbital Muscle StimulationTreatment TypeVision Resource HubThe Potential Benefits of Periorbital Transcutaneous Electrical Stimulation for the Management of Dry Eye DiseaseREAD MOREDry EyePeriorbital Muscle StimulationPress PublicationsTreatment TypeVision Resource HubDry EyePeriorbital Muscle StimulationPress PublicationsTreatment TypeVision Resource HubSisters Grow Practice Into Medical Hub for Dry Eye TreatmentREAD MORE PB-00043680 Rev A #### Vision One Vision One – Retinopathy Laser Multi-Wavelength Photocoagulation System Product Highlights Modular and upgradable – Ability to upgrade the system at any time by a adding wavelengths as a scanner User friendly design – Touch screen and remote keypad, Dual Port for efficient setup of alternate delivery devices, advance memory settings SureSpot™ Optics Technology – Sharply defined and evenly distributed power on the retina REDYELLOWGREENRED  Red (659 nm) Red laser light offers excellent penetration through hemoglobin, making it the wavelength of choice in situations where it is necessary to penetrate through preretinal, subretinal or intraretinal hemorrhage. It is also the optimal wavelength for achieving deeper penetration into the choroid to treat choroidal melanomas or other deep pigmented lesions. It is also the preferred wavelength for treating infant eyes with ROP because it penetrates through the tunica vasculosa lentis, the vascular network surrounding the lens. Absorption by those vessels is associated with higher risk for cataract formation. YELLOW   Yellow (577 nm) Yellow Laser light offers the clinician high absorption in hemoglobin and negligible absorption in macular Xanthophyll. In addition to easily penetrating through nuclear sclerotic cataracts, the yellow wavelength is desirable when it is necessary to penetrate through fluid, such as when treating a retinal detachment or tear. It also penetrates mild pigmentary disturbances and so is well suited for conditions where the target lies in a region of previous photocoagulation treatment. One of the main advantages of yellow laser light stems from the fact that it approximates the peak absorption of hemoglobin, xanthophyll in the neurosensory retina. Therefore, it is recommended for focally treating extrafoveal microaneurysms or other vascular lesions in the macular region that may cause macular edema. In addition, yellow laser produces significantly less light scatter, allowing for more efficient treatment and requiring lower energy levels to achieve desirable clinical outcome; this creates significantly less discomfort for the patient during and following the laser procedure. GREEN   Green (532 nm) Green laser light is a clinically-proven wavelength that is excellent at targeting the melanin-containing retinal pigment epithelium (RPE), through clear ocular media. It is well suited for a variety of retinal treatments in which melanin is the target chromophore, such as pan-retinal photocoagulation (PRP). System Benefits Advanced Control Voice Confirmation – The Vision One is equipped with a unique voice confirmation feature, which allows the user to change any of the key parameters, while receiving a vocal confirmation of the dialed choice. This feature allows the operator to adjust parameters also during treatment, without having to shift view from the treatment site to the unit’s control panel. Dependability you can count on CaseSaver Mode – Dependability is of crucial importance in both the OR and Office Setting. The Vision One has laser cavities that work independent of one another. CaseSaver™ Mode: In the unlikely event that one of the laser wavelengths were to become inoperable, the other two* wavelengths will remain operational – allowing you to keep on treating your patients until the unit is promptly serviced by a qualified Lumenis Engineer – part of the largest service network in the industry. *If unit was purchased with more than one wavelength Convenience & Flexibility Dual Fiber Port – Changing delivery devises is fast and easy. The Vision One remembers the settings that were last used with the selected delivery device allowing for a smoother transition. Memory Settings – The Vision One has five programmable memory setting that can be set to remember the most used treatment parameters. Intelligent Smart™ Fiber Technology – The Vision One features Smart fiber technology that allows the laser system to distinguish an LIO from an endoprobe or LaserLink and will automatically adjust power settings to increase safety parameters. The Lumenis Smart fiber technology also alerts the surgeon and staff if the physician eye safety filter, footswitch and delivery devices are not properly attached to the laser console. User-Friendly Touch screen & remote keypad – A color touch screen and illuminated remote keypad put all operations literally at your fingertips. Easily adjust parameters or instantly switch between treatment wavelengths. Conveniently position the remote control on either side of the slit lamp, or in a sterile cover for the operating room. he Lumenis *PowerEase™ footswitch provides hands-free power adjustment of the laser by toggling left or right within the footswitch housing.The Lumenis *Smart™ footswitch contains an integrated proximity sensor which inserts and removes the physician eye safety filter at the moment you slide your foot in and out of the footswitch housing. * Optional accessories ClearView™ Filters Optimized view of treatment site – The Lumenis ClearView™ filters’ photopic balanced coating eliminates color distortion of the treatment site while optimizing white light transmission or “brightness” of the physician’s view. Versatile Compatibility with a wide variety of delivery devices – The Vision One is compatible with a wide variety of accessories and delivery devices – meeting you specific preferences in the outpatient clinic and the OR. Lumenis also developed an integrated laser slit lamp with the retina specialist in mind. Choose a multicolor Laser Indirect Ophthalmoscope that suits your preferences. Both our Heine and Keeler models are rugged, lightweight and equipped with the most advanced laser delivery technology in the market. The Lumenis family of LaserLinks will transform most commercially available slit lamps into advanced laser delivery devices with superior optics capabilities. Product Video Learn More BrochureSpecificationsAccessoriesSureSpot OpticsBrochure Specifications Laser System Optically Pumped Semiconductor Laser (OPSL) Wavelength 532 nm Green.577 nm Yellow.659 nm Red Pulse Duration 0.01 to 3.0 seconds Treatment intervals 0.05 to 1.0 seconds, and single pulse Power 532 nm:50 - 2000 mW | 577 nm:50 - 1500 mW | 659 nm: 50 - 800 mW Spot Size 50 - 1000 µm with LaserLink Z | 50 - 500 µm with H/S LaseLink Aiming beam Contrasting color, adjustable intensity 635 nm nominal, < 1.0 mW Cooing System Air cooled, enhanced with thermoelectric cooling Power Requirements 100-230 VAC +- 10% 50/60 Hz. < 10 Amps, single phase Dimensions (Console) 105cm x 45cm x 63cm | 42" x 18" x 25" ;(H x W x D) Weight 57 kg or 126 lb Delivery Systems Lumenis 1000 | LaserLink HS adapter for compatible convergent optics Lumenis 9900 slit lamp | LaserLink Z adapter for Zeiss SL 130 and Lumenis 9800 Slit lamps | Laser indirect Ophthalmoscope (LIO) | Endoprobe | Array TM LaserLinkTM. Standard Accessories Standard Footswitch. Remote control. Optional Accessories Smart and PowerEase TM Footswitch, Comprehensive selection of standard, straight curved. aspirating, and illuminating endophotocoagulation probes in 20. 23, and 25 gauge sizes. Leica@ and Zeiss@ : moving and fixed safety filters for surgical microscopes.. Accessories Meeting Your Needs The LumeProbe product family consists of comprehensive and wide selection of ophthalmic endophotocoagulation probes to meet every clinical need and indication. These include standard, straight, curved, aspirating, illuminating and stepped in 20, 23 and 25 gauge sizes, among others. Learn More SureSpot Optics Vision one With SureSpotTM Optics Sharply defined and evenly distributed power on the retina; Safe & low-power density at the cornea and lens Vision One incorporates SureSpotTM Optics Technology in all slit lamp adapters, as with all Lumenis photocoagulators. The unique and patented Lumenis SureSpotTM technology ensures that the focal point of the laser beam is maintained on the retina while power density on the cornea and lens is minimized for increased safety. SureSpotTM optics also creates a 50µ single spot. That capability distinguishes Lumenis technology from other lasers that may have a 100µ minimum spot size and/or project a fuzzy laser spot on the ina. SureSpotTM optics improves treatment efficacy and precision while reducing the potential for damage to anterior-segment tissues. The latter occurrence is especially a concern when using wide-angle lenses that enhance light uptake by the cornea and lens. Lumenis Ophthalmology Devices Digital Duet The first and only all-in-one digital platform for Glaucoma and PCO therapies Digital Trio 3 in 1 digital platform for Glaucoma and Retina care OptiLIGHT A bright solution for dry eyes ArrayTM LaserLinkTM Pattern Scanning Laser Technology Vision One Modular Multi-Wave Photocoagulator Selecta Duet SLT Technology and a Yag Photodisruptor in One Platform Selecta Trio Retinal, Cataract and Glaucoma Therapy in One Platform Novus SpectraTM High-Powered Photocoagulator LumeProbeTM Endo-Photocoagulation Laser Probes Related Links Retina Photocoagulators Caution: Federal (US) law restricts Lumenis devices to sale by or on the order of a licensed practitioner. PB-2006798 Rev A × GET MORE INFO #### WesternU College of Optometry Partners With Lumenis for Hands-On Training in Laser Therapy WesternU College of Optometry Partners With Lumenis for Hands-On Training in Laser Therapy Western University of Health Sciences College of Optometry partners with Lumenis to train students in Digital Duet, the first digital SLT-YAG and cutting-edge OptiLight treatments. READ FULL ARTICLE Explore Other Resources Dry EyeNewsPeriorbital Muscle StimulationTreatment TypeVision Resource HubDry EyeNewsPeriorbital Muscle StimulationTreatment TypeVision Resource HubLumenis OptiLIFT Dynamic Muscle Stimulation Device receives Health Canada Approval for Reducing Signs and Symptoms of Evaporative Dry Eye DiseaseREAD MOREClinical StudiesDry EyePeriorbital Muscle StimulationTreatment TypeVision Resource HubClinical StudiesDry EyePeriorbital Muscle StimulationTreatment TypeVision Resource HubThe Potential Benefits of Periorbital Transcutaneous Electrical Stimulation for the Management of Dry Eye DiseaseREAD MOREDry EyePeriorbital Muscle StimulationPress PublicationsTreatment TypeVision Resource HubDry EyePeriorbital Muscle StimulationPress PublicationsTreatment TypeVision Resource HubSisters Grow Practice Into Medical Hub for Dry Eye TreatmentREAD MORE PB-00038930 Rev A #### Yan et al. (2021): The Efficacy of Intense Pulsed Light Combined With Meibomian Gland Expression for the Treatment of Dry Eye Disease Due to Meibomian Gland Dysfunction: A Multicenter, Randomized Controlled Trial Yan et al. (2021): The Efficacy of Intense Pulsed Light Combined With Meibomian Gland Expression for the Treatment of Dry Eye Disease Due to Meibomian Gland Dysfunction: A Multicenter, Randomized Controlled Trial In a prospective, multicenter, randomized control trial, Lumenis IPL with OPT™ combined with MGX significantly improved signs and symptoms of DED due to MGD. READ FULL STUDY Indication for Use: Improvement of signs of Dry Eye Disease (DED) due to Meibomian Gland Dysfunction (MGD), also known as evaporative dry eye or lipid deficiency dry eye, in patients 22 years of age and older with moderate to severe signs and symptoms of DED due to MGD and with Fitzpatrick skin types I-IV. IPL is to be applied only to skin on the malar region of the face, from tragus to tragus including the nose (eyes should be fully covered by protective eyewear). IPL is intended to be applied as an adjunct to other modalities, such as meibomian gland expression, artificial tear lubricants and warm compresses Treatment with M22 or OptiLight is contraindicated for patients with the following conditions in the treatment area: Ocular surgery or eyelid surgery or Neuro-paralysis within 6 months prior to the first treatment; Uncontrolled eye disorders affecting the ocular surface; Pre-cancerous lesions, skin cancer or pigmented lesions in the planned treatment area; Uncontrolled infections or uncontrolled immunosuppressive diseases; Recent Ocular infections; Prior history of cold sores or rashes in the perioral area, including: Herpes simplex 1 & 2, Systemic Lupus erythematosus and porphyria; Use of photosensitive medication and/or herbs that may cause sensitivity within 3 months prior to the first IPL session; Recent radiation therapy to the head or neck or planned radiation therapy; Recent treatment with chemotherapeutic agent or planned chemotherapy; History of migraines, seizures or epilepsy. Patients eyes must be completely occluded during the treatment. Please refer to the operator manual for a complete list of intended use, contraindications and risks. Please consult your physician as to whether this procedure is suitable for you. The following possible side effects can occur following IPL treatments: Pain/discomfort, damage to natural skin texture, change of pigmentation, scarring, excessive edema, fragile skin, bruising, burns, pruritus and xerosis. Please refer to the user manual or ask your doctor for a complete list of intended use, contraindications and risks. Lumenis has an interest in the study device (M22 system). All uses of the M22 system described in this paper were approved by the FDA, except the following: – The study concluded that both signs and symptoms of DED were improved by the use of IPL, whereas FDA cleared only improvement of signs. Dr. Yan was a consultant of Lumenis Lumenis sponsored the study The publication doesn’t discuss any unapproved uses of the device. Explore Other Resources Dry EyeNewsPeriorbital Muscle StimulationTreatment TypeVision Resource HubDry EyeNewsPeriorbital Muscle StimulationTreatment TypeVision Resource HubLumenis OptiLIFT Dynamic Muscle Stimulation Device receives Health Canada Approval for Reducing Signs and Symptoms of Evaporative Dry Eye DiseaseREAD MOREClinical StudiesDry EyePeriorbital Muscle StimulationTreatment TypeVision Resource HubClinical StudiesDry EyePeriorbital Muscle StimulationTreatment TypeVision Resource HubThe Potential Benefits of Periorbital Transcutaneous Electrical Stimulation for the Management of Dry Eye DiseaseREAD MOREDry EyePeriorbital Muscle StimulationPress PublicationsTreatment TypeVision Resource HubDry EyePeriorbital Muscle StimulationPress PublicationsTreatment TypeVision Resource HubSisters Grow Practice Into Medical Hub for Dry Eye TreatmentREAD MORE PB-00038930 Rev A #### Yang et al. (2021): Treatment of contact lens related dry eye with intense pulsed light Yang et al. (2021): Treatment of contact lens related dry eye with intense pulsed light In a prospective paired-eye study of patients wearing contact lenses and experiencing contact lens related dry eye, eyes treated with Lumenis IPL with OPTTM improved in signs and symptoms of dry eye disease (DED). READ FULL STUDY Indication for Use: Improvement of signs of Dry Eye Disease (DED) due to Meibomian Gland Dysfunction (MGD), also known as evaporative dry eye or lipid deficiency dry eye, in patients 22 years of age and older with moderate to severe signs and symptoms of DED due to MGD and with Fitzpatrick skin types I-IV. IPL is to be applied only to skin on the malar region of the face, from tragus to tragus including the nose (eyes should be fully covered by protective eyewear). IPL is intended to be applied as an adjunct to other modalities, such as meibomian gland expression, artificial tear lubricants and warm compresses Treatment with M22 or OptiLight is contraindicated for patients with the following conditions in the treatment area: Ocular surgery or eyelid surgery or Neuro-paralysis within 6 months prior to the first treatment; Uncontrolled eye disorders affecting the ocular surface; Pre-cancerous lesions, skin cancer or pigmented lesions in the planned treatment area; Uncontrolled infections or uncontrolled immunosuppressive diseases; Recent Ocular infections; Prior history of cold sores or rashes in the perioral area, including: Herpes simplex 1 & 2, Systemic Lupus erythematosus and porphyria; Use of photosensitive medication and/or herbs that may cause sensitivity within 3 months prior to the first IPL session; Recent radiation therapy to the head or neck or planned radiation therapy; Recent treatment with chemotherapeutic agent or planned chemotherapy; History of migraines, seizures or epilepsy. Patients eyes must be completely occluded during the treatment. Please refer to the operator manual for a complete list of intended use, contraindications and risks. Please consult your physician as to whether this procedure is suitable for you. The following possible side effects can occur following IPL treatments: Pain/discomfort, damage to natural skin texture, change of pigmentation, scarring, excessive edema, fragile skin, bruising, burns, pruritus and xerosis. Please refer to the user manual or ask your doctor for a complete list of intended use, contraindications and risks. Lumenis has an interest in the study device (M22 system). All uses of the M22 system described in the information were approved by the FDA, except the following: – FDA approved the use of M22 for treatment of DED due to MGD in patients 22 years or older. In the current study, the average age implies that younger patients may have participated. – A cut-off filter of 560 nm was used, instead of the 590 nm filter approved by the FDA. – The number of IPL sessions was at least 2, instead to the 4 IPL sessions approved by the FDA. – The study concluded that symptoms of DED were improved by the use of IPL, whereas FDA cleared only improvement of signs. None of the authors had financial ties with Lumenis. No person known to Lumenis has provided funding for the study. The publication doesn’t discuss any unapproved uses of the device. Explore Other Resources Dry EyeNewsPeriorbital Muscle StimulationTreatment TypeVision Resource HubDry EyeNewsPeriorbital Muscle StimulationTreatment TypeVision Resource HubLumenis OptiLIFT Dynamic Muscle Stimulation Device receives Health Canada Approval for Reducing Signs and Symptoms of Evaporative Dry Eye DiseaseREAD MOREClinical StudiesDry EyePeriorbital Muscle StimulationTreatment TypeVision Resource HubClinical StudiesDry EyePeriorbital Muscle StimulationTreatment TypeVision Resource HubThe Potential Benefits of Periorbital Transcutaneous Electrical Stimulation for the Management of Dry Eye DiseaseREAD MOREDry EyePeriorbital Muscle StimulationPress PublicationsTreatment TypeVision Resource HubDry EyePeriorbital Muscle StimulationPress PublicationsTreatment TypeVision Resource HubSisters Grow Practice Into Medical Hub for Dry Eye TreatmentREAD MORE PB-00038930 Rev A #### You Don’t Have To Live With Dry Eyes Anymore! | OptiLIGHT By Lumenis You Don’t Have To Live With Dry Eyes Anymore! | OptiLIGHT By Lumenis October 10, 2023 Share   Listen to Jaime Chung as she recounts her experience with the transformative benefits of OptiLIGHT and how she addressed the root cause of the inflummetion, ensuring she no longer has to live with it. Watch more videos Colton Underwood shares his experience with DED and his care journey using OptiLIGHT and OptiLIFTMay 25, 2025WATCH NOWKerri Walsh Jennings Shares the Impact of OptiLIGHT Treatment on Her Dry Eye Disease!May 2, 2024WATCH NOWKerri Has Been Experiencing Dry, Itchy Eyes On And Off The Court For Years. Her Solution: OptiLIGHT!April 28, 2024WATCH NOW PB-00076100, Rev A